CPR:2	Binding of  bbbbb1 hydroxyflutamide eeeee1  to m- bbbbb2 AR eeeee2  in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR
CPR:2	Analogous to the antiandrogens,  bbbbb1 bicalutamide eeeee1  and hydroxyflutamide, binding of estramustine phosphate metabolites to the  bbbbb2 androgen receptor eeeee2  was observed
CPR:2	Analogous to the antiandrogens, bicalutamide and  bbbbb1 hydroxyflutamide eeeee1 , binding of estramustine phosphate metabolites to the  bbbbb2 androgen receptor eeeee2  was observed
CPR:2	Analogous to the antiandrogens, bicalutamide and hydroxyflutamide, binding of  bbbbb1 estramustine phosphate eeeee1  metabolites to the  bbbbb2 androgen receptor eeeee2  was observed
CPR:3	Binding of  bbbbb1 hydroxyflutamide eeeee1  to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of  bbbbb2 PSA eeeee2  expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR
CPR:4	Down-regulation of  bbbbb1 prostate-specific antigen eeeee1  (PSA) expression, an AR-target gene, by  bbbbb2 estramustine eeeee2  and bicalutamide was accompanied by the blockade of the mutated androgen receptor
CPR:4	Down-regulation of prostate-specific antigen ( bbbbb1 PSA eeeee1 ) expression, an AR-target gene, by  bbbbb2 estramustine eeeee2  and bicalutamide was accompanied by the blockade of the mutated androgen receptor
CPR:4	Down-regulation of prostate-specific antigen (PSA) expression, an  bbbbb1 AR eeeee1 -target gene, by  bbbbb2 estramustine eeeee2  and bicalutamide was accompanied by the blockade of the mutated androgen receptor
CPR:4	Down-regulation of  bbbbb1 prostate-specific antigen eeeee1  (PSA) expression, an AR-target gene, by estramustine and  bbbbb2 bicalutamide eeeee2  was accompanied by the blockade of the mutated androgen receptor
CPR:4	Down-regulation of prostate-specific antigen ( bbbbb1 PSA eeeee1 ) expression, an AR-target gene, by estramustine and  bbbbb2 bicalutamide eeeee2  was accompanied by the blockade of the mutated androgen receptor
CPR:4	Down-regulation of prostate-specific antigen (PSA) expression, an  bbbbb1 AR eeeee1 -target gene, by estramustine and  bbbbb2 bicalutamide eeeee2  was accompanied by the blockade of the mutated androgen receptor
CPR:4	The levels of  bbbbb1 PSA eeeee1  mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of  bbbbb2 estramustine eeeee2 , respectively (IC50 = 10.97 +/- 1.68 microM)
CPR:4	Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by  bbbbb1 estramustine eeeee1  and bicalutamide was accompanied by the blockade of the mutated  bbbbb2 androgen receptor eeeee2 
CPR:4	Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and  bbbbb1 bicalutamide eeeee1  was accompanied by the blockade of the mutated  bbbbb2 androgen receptor eeeee2 
CPR:4	Exposure of LNCaP cells to  bbbbb1 estramustine eeeee1  for 24 hr caused transcriptional inhibition of  bbbbb2 PSA eeeee2  in a concentration-dependent manner
CPR:5	Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that  bbbbb1 hydroxyflutamide eeeee1  acted as an agonist of the m- bbbbb2 AR eeeee2 
CPR:6	Our data indicate that  bbbbb1 estramustine phosphate eeeee1  metabolites perform as androgen antagonists of  bbbbb2 AR eeeee2 , an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.
CPR:6	Our data indicate that estramustine phosphate metabolites perform as  bbbbb1 androgen eeeee1  antagonists of  bbbbb2 AR eeeee2 , an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.
CPR:6	 bbbbb1 Androgen eeeee1  antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated  bbbbb2 androgen receptor eeeee2 
CPR:6	Androgen antagonistic effect of  bbbbb1 estramustine phosphate eeeee1  (EMP) metabolites on wild-type and mutated  bbbbb2 androgen receptor eeeee2 
CPR:6	Androgen antagonistic effect of estramustine phosphate ( bbbbb1 EMP eeeee1 ) metabolites on wild-type and mutated  bbbbb2 androgen receptor eeeee2 
CPR:4	In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of  bbbbb1 Torpedo californica AChE eeeee1  soaked with the reversible inhibitor  bbbbb2 edrophonium eeeee2 , using a total X-ray exposure time of 24 ms
CPR:4	The current study evaluates the effects of a selective  bbbbb1 COX-2 eeeee1  inhibitor ( bbbbb2 SC-236 eeeee2 ) on renal function in cirrhotic rats with ascites
CPR:4	RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective  bbbbb1 COX-1 eeeee1 /COX-2 inhibitor,  bbbbb2 ketorolac eeeee2 , resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism
CPR:4	RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/ bbbbb1 COX-2 eeeee1  inhibitor,  bbbbb2 ketorolac eeeee2 , resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism
CPR:9	Selective inhibition of  bbbbb1 cyclooxygenase 2 eeeee1  spares renal function and  bbbbb2 prostaglandin eeeee2  synthesis in cirrhotic rats with ascites
CPR:9	RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective  bbbbb1 COX-1 eeeee1 /COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of  bbbbb2 prostaglandins eeeee2 , and glomerular filtration rate and in a significant impairment in renal water metabolism
CPR:9	RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/ bbbbb1 COX-2 eeeee1  inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of  bbbbb2 prostaglandins eeeee2 , and glomerular filtration rate and in a significant impairment in renal water metabolism
CPR:2	By contrast, membrane expression of  bbbbb1 annexin-1 eeeee1 , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M  bbbbb2 FP eeeee2 , and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA)
CPR:2	 bbbbb1 FMLP eeeee1 /CB-stimulated translocation of  bbbbb2 cPLA2 eeeee2  to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP
CPR:2	FMLP/ bbbbb1 CB eeeee1 -stimulated translocation of  bbbbb2 cPLA2 eeeee2  to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M  bbbbb1 FP eeeee1  in the presence of 10 pg/ml  bbbbb2 human recombinant interleukin-5 eeeee2  (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB)
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M  bbbbb1 FP eeeee1  in the presence of 10 pg/ml human recombinant interleukin-5 ( bbbbb2 rhIL-5 eeeee2 ) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB)
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml  bbbbb1 human recombinant interleukin-5 eeeee1  (rhIL-5) and activated with  bbbbb2 formyl-met-leu-phe eeeee2  (FMLP) + cytochalasin B (CB)
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 ( bbbbb1 rhIL-5 eeeee1 ) and activated with  bbbbb2 formyl-met-leu-phe eeeee2  (FMLP) + cytochalasin B (CB)
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml  bbbbb1 human recombinant interleukin-5 eeeee1  (rhIL-5) and activated with formyl-met-leu-phe ( bbbbb2 FMLP eeeee2 ) + cytochalasin B (CB)
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 ( bbbbb1 rhIL-5 eeeee1 ) and activated with formyl-met-leu-phe ( bbbbb2 FMLP eeeee2 ) + cytochalasin B (CB)
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml  bbbbb1 human recombinant interleukin-5 eeeee1  (rhIL-5) and activated with formyl-met-leu-phe (FMLP) +  bbbbb2 cytochalasin B eeeee2  (CB)
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 ( bbbbb1 rhIL-5 eeeee1 ) and activated with formyl-met-leu-phe (FMLP) +  bbbbb2 cytochalasin B eeeee2  (CB)
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml  bbbbb1 human recombinant interleukin-5 eeeee1  (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B ( bbbbb2 CB eeeee2 )
CPR:2	Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 ( bbbbb1 rhIL-5 eeeee1 ) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B ( bbbbb2 CB eeeee2 )
CPR:3	Inhibition of LTC4 synthesis precedes the global cytotoxic effects of  bbbbb1 FP eeeee1  as indicated by the simultaneous upregulation of  bbbbb2 annexin-1 eeeee2  expression
CPR:4	FMLP/CB-stimulated translocation of  bbbbb1 cPLA2 eeeee1  to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by  bbbbb2 FP eeeee2 
CPR:4	Inhibition of  bbbbb1 cPLA2 eeeee1  translocation and leukotriene C4 secretion by  bbbbb2 fluticasone propionate eeeee2  in exogenously activated human eosinophils
CPR:4	We find that  bbbbb1 FP eeeee1  causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by  bbbbb2 phospholipase A2 eeeee2  (PLA2)
CPR:9	We find that FP causes a decrease in stimulated eosinophil secretion of  bbbbb1 LTC4 eeeee1  that is regulated by  bbbbb2 phospholipase A2 eeeee2  (PLA2)
CPR:9	We find that FP causes a decrease in stimulated eosinophil secretion of  bbbbb1 LTC4 eeeee1  that is regulated by phospholipase A2 ( bbbbb2 PLA2 eeeee2 )
CPR:2	Desipramine treatment decreases  bbbbb1 3H-nisoxetine eeeee1  binding and  bbbbb2 norepinephrine transporter eeeee2  mRNA in SK-N-SHSY5Y cells
CPR:4	We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of  bbbbb1 desipramine eeeee1  to downregulate the  bbbbb2 NET eeeee2 .
CPR:4	The antidepressant  bbbbb1 desipramine eeeee1  has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter ( bbbbb2 NET eeeee2 ) in vivo and in vitro, on both an acute and a chronic basis
CPR:4	The antidepressant  bbbbb1 desipramine eeeee1  has been shown to decrease synaptic membrane concentrations of the  bbbbb2 norepinephrine re-uptake transporter eeeee2  (NET) in vivo and in vitro, on both an acute and a chronic basis
CPR:4	 bbbbb1 Desipramine eeeee1  treatment decreases 3H-nisoxetine binding and  bbbbb2 norepinephrine transporter eeeee2  mRNA in SK-N-SHSY5Y cells
CPR:2	These findings suggested affinity for open and/or inactivated channel states. 4 Inactivation was significantly accelerated by cisapride in a concentration-dependent manner and there was a small (-7 mV) shift in the voltage dependence of steady state inactivation. 5 Channel blockade by cisapride was modulated by [K+]o, with a 26% reduction in the potency of channel blockade when [K+]o was increased from 1 to 10 mM. 6 In conclusion,  bbbbb1 HERG eeeee1  channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external  bbbbb2 potassium eeeee2  concentration
CPR:4	nhibition of the  bbbbb1 human ether-a-go-go-related gene (HERG) potassium channel eeeee1  by  bbbbb2 cisapride eeeee2 : affinity for open and inactivated states. 1 Cisapride is a prokinetic agent which has been associated with QT prolongation, torsades de pointes and cardiac arrest
CPR:4	These findings suggested affinity for open and/or inactivated channel states. 4 Inactivation was significantly accelerated by cisapride in a concentration-dependent manner and there was a small (-7 mV) shift in the voltage dependence of steady state inactivation. 5 Channel blockade by cisapride was modulated by [K+]o, with a 26% reduction in the potency of channel blockade when [K+]o was increased from 1 to 10 mM. 6 In conclusion,  bbbbb1 HERG eeeee1  channel inhibition by  bbbbb2 cisapride eeeee2  exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration
CPR:4	The cellular mechanism for these observations is high affinity blockade of IKr (encoded by HERG). 2 In a chronic transfection model using CHO-K1 cells,  bbbbb1 cisapride eeeee1  inhibited  bbbbb2 HERG eeeee2  tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. 4 nM at 20-22 degrees C and 23.6 nM at 37 degrees C). 3 Channel inhibition exhibited time-, voltage- and frequency-dependence
CPR:2	 bbbbb1 Ziprasidone eeeee1  is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to  bbbbb2 5-HT1D eeeee2 , 5-HT2, and D2 sites
CPR:2	 bbbbb1 Ziprasidone eeeee1  is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D,  bbbbb2 5-HT2 eeeee2 , and D2 sites
CPR:2	 bbbbb1 Ziprasidone eeeee1  is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and  bbbbb2 D2 eeeee2  sites
CPR:2	 bbbbb1 Ziprasidone eeeee1  is a novel antipsychotic agent which binds with high affinity to  bbbbb2 5-HT1A receptors eeeee2  (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and D2 sites
CPR:2	The goal of the present study was to examine the  bbbbb1 5-HT1A eeeee1  properties of  bbbbb2 ziprasidone eeeee2  in vivo using as a marker of central 5-HT1A activity the inhibition of firing of serotonin-containing neurons in the dorsal raphe nucleus
CPR:2	Pretreatment with the  bbbbb1 5-HT1A eeeee1  antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the  bbbbb2 ziprasidone eeeee2 -induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine
CPR:2	Pretreatment with the  bbbbb1 5-HT1A eeeee1  antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by  bbbbb2 clozapine eeeee2  and olanzapine
CPR:2	Pretreatment with the  bbbbb1 5-HT1A eeeee1  antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and  bbbbb2 olanzapine eeeee2 
CPR:2	Comparison of the novel antipsychotic  bbbbb1 ziprasidone eeeee1  with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of  bbbbb2 5-HT1A receptor eeeee2  activation
CPR:2	Comparison of the novel antipsychotic ziprasidone with  bbbbb1 clozapine eeeee1  and olanzapine: inhibition of dorsal raphe cell firing and the role of  bbbbb2 5-HT1A receptor eeeee2  activation
CPR:2	Comparison of the novel antipsychotic ziprasidone with clozapine and  bbbbb1 olanzapine eeeee1 : inhibition of dorsal raphe cell firing and the role of  bbbbb2 5-HT1A receptor eeeee2  activation
CPR:5	These profiles suggest a mechanism of action for each agent,  bbbbb1 5-HT1A eeeee1  agonism for  bbbbb2 ziprasidone eeeee2  and alpha 1 antagonism for clozapine and olanzapine
CPR:5	The  bbbbb1 5-HT1A eeeee1  agonist activity reported here clearly distinguishes  bbbbb2 ziprasidone eeeee2  from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.
CPR:5	While it is an antagonist at these latter receptors,  bbbbb1 ziprasidone eeeee1  behaves as a  bbbbb2 5-HT1A eeeee2  agonist in vitro in adenylate cyclase measurements
CPR:6	Pretreatment with the  bbbbb1 5-HT1A eeeee1  antagonist  bbbbb2 WAY-100,635 eeeee2  (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine
CPR:6	Pretreatment with the  bbbbb1 5-HT1A eeeee1  antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of  bbbbb2 WAY-100,635 eeeee2  had little effect on the inhibition produced by clozapine and olanzapine
CPR:4	The nonselective and irreversible  bbbbb1 MAO eeeee1  inhibitors,  bbbbb2 phenelzine eeeee2  (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement
CPR:4	The nonselective and irreversible  bbbbb1 MAO eeeee1  inhibitors, phenelzine (3-10 mg/kg),  bbbbb2 tranylcypromine eeeee2  (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement
CPR:4	The nonselective and irreversible  bbbbb1 MAO eeeee1  inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and  bbbbb2 nialamide eeeee2  (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement
CPR:4	The irreversible  bbbbb1 MAO-B eeeee1  inhibitors,  bbbbb2 pargyline eeeee2  (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice
CPR:4	The reversible  bbbbb1 MAO-A eeeee1  inhibitor,  bbbbb2 befloxatone eeeee2  (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration
CPR:4	The reversible MAO-A inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible  bbbbb1 MAO-A eeeee1  inhibitor,  bbbbb2 clorgyline eeeee2  (10-30 mg/kg), also reduced ethanol self-administration
CPR:4	The irreversible  bbbbb1 MAO-B eeeee1  inhibitors, pargyline (30 mg/kg) and  bbbbb2 l-deprenyl eeeee2  (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice
CPR:4	 bbbbb1 Dicumarol eeeee1 , a potent inhibitor of  bbbbb2 quinone oxidoreductase eeeee2 , at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin
CPR:2	A novel missense mutation,  bbbbb1 G663A eeeee1 , in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) was identified in a Japanese male with  bbbbb2 pyridoxine eeeee2 -responsive sideroblastic anemia
CPR:2	A novel missense mutation, G663A, in exon 5 of the  bbbbb1 erythroid-specific delta-aminolevulinate synthase eeeee1  gene (ALAS2) was identified in a Japanese male with  bbbbb2 pyridoxine eeeee2 -responsive sideroblastic anemia
CPR:2	A novel missense mutation, G663A, in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene ( bbbbb1 ALAS2 eeeee1 ) was identified in a Japanese male with  bbbbb2 pyridoxine eeeee2 -responsive sideroblastic anemia
CPR:2	Activity of the mutant  bbbbb1 delta-aminolevulinate synthase eeeee1  protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of pyridoxal 5'-phosphate, consistent with the clinical response of the patient to  bbbbb2 pyridoxine eeeee2  treatment
CPR:2	A novel mutation of the  bbbbb1 erythroid-specific gamma-Aminolevulinate synthase eeeee1  gene in a patient with non-inherited  bbbbb2 pyridoxine eeeee2 -responsive sideroblastic anemia
CPR:3	Activity of the mutant  bbbbb1 delta-aminolevulinate synthase eeeee1  protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of  bbbbb2 pyridoxal 5'-phosphate eeeee2 , consistent with the clinical response of the patient to pyridoxine treatment
CPR:4	Preferential cerebrospinal fluid  bbbbb1 acetylcholinesterase eeeee1  inhibition by  bbbbb2 rivastigmine eeeee2  in humans
CPR:4	Inhibition of  bbbbb1 AChE eeeee1  in the CSF after  bbbbb2 rivastigmine eeeee2  administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours
CPR:4	Plasma  bbbbb1 BuChE eeeee1  activity was significantly lower after  bbbbb2 rivastigmine eeeee2  than after placebo, but this was not clinically relevant
CPR:4	 bbbbb1 BuChE eeeee1  activity in CSF was significantly lower after  bbbbb2 rivastigmine eeeee2  than after placebo for up to 3.6 hours after dosing, but this difference was not sustained
CPR:4	This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that  bbbbb1 rivastigmine eeeee1  markedly inhibits CSF  bbbbb2 AChE eeeee2  after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.
CPR:4	This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that  bbbbb1 rivastigmine eeeee1  markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central  bbbbb2 AChE eeeee2  is substantially greater than that of peripheral AChE or BuChE.
CPR:4	This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that  bbbbb1 rivastigmine eeeee1  markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral  bbbbb2 AChE eeeee2  or BuChE.
CPR:4	This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that  bbbbb1 rivastigmine eeeee1  markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or  bbbbb2 BuChE eeeee2 .
CPR:1	 bbbbb1 Amino acids eeeee1  between Ile(183) and Val(191) are necessary for proper  bbbbb2 factor IX eeeee2  activation, but additional sequence between Ser(195) and Ile(197) or between Phe(260) and Ser(265) is required for complete restoration of activation.
CPR:1	To identify key  bbbbb1 amino acids eeeee1  involved in  bbbbb2 factor IX eeeee2  activation, recombinant factor XIa proteins containing alanine substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay
CPR:1	To identify key amino acids involved in factor IX activation, recombinant  bbbbb1 factor XIa eeeee1  proteins containing  bbbbb2 alanine eeeee2  substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay
CPR:1	Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the  bbbbb1 N eeeee1  terminus and for Ser(258)-Ser(264) at the C terminus of the  bbbbb2 A3 domain eeeee2  markedly decreased factor XI coagulant activity
CPR:1	Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the N terminus and for Ser(258)-Ser(264) at the  bbbbb1 C eeeee1  terminus of the  bbbbb2 A3 domain eeeee2  markedly decreased factor XI coagulant activity
CPR:1	Identification of  bbbbb1 amino acids eeeee1  in the  bbbbb2 factor XI apple 3 domain eeeee2  required for activation of factor IX
CPR:1	Identification of  bbbbb1 amino acids eeeee1  in the factor XI apple 3 domain required for activation of  bbbbb2 factor IX eeeee2 
CPR:2	 bbbbb1 Yohimbine eeeee1  displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for  bbbbb2 h5-HT(1A) eeeee2 , h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors
CPR:2	 bbbbb1 Yohimbine eeeee1  displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A),  bbbbb2 h5-HT(1B) eeeee2 , h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors
CPR:2	 bbbbb1 Yohimbine eeeee1  displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B),  bbbbb2 h5-HT(1D) eeeee2 , and hD(2) receptors and weak affinity for hD(3) receptors
CPR:2	 bbbbb1 Yohimbine eeeee1  displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and  bbbbb2 hD(2) receptors eeeee2  and weak affinity for hD(3) receptors
CPR:2	 bbbbb1 Yohimbine eeeee1  displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for  bbbbb2 hD(3) receptors eeeee2 
CPR:2	In [ bbbbb1 (35)S eeeee1 ]GTPgammaS binding protocols, yohimbine exerts antagonist actions at  bbbbb2 halpha(2A)-AR eeeee2 , h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites
CPR:2	In [ bbbbb1 (35)S eeeee1 ]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR,  bbbbb2 h5-HT(1B) eeeee2 , h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites
CPR:2	In [ bbbbb1 (35)S eeeee1 ]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B),  bbbbb2 h5-HT(1D) eeeee2 , and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites
CPR:2	In [ bbbbb1 (35)S eeeee1 ]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and  bbbbb2 hD(2) eeeee2  sites, yet partial agonist actions at h5-HT(1A) sites
CPR:2	In [ bbbbb1 (35)S eeeee1 ]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at  bbbbb2 h5-HT(1A) eeeee2  sites
CPR:2	Herein, we evaluate the interaction of the alpha(2)-AR antagonist,  bbbbb1 yohimbine eeeee1 , as compared to fluparoxan, at multiple  bbbbb2 monoaminergic receptors eeeee2  and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats
CPR:2	Herein, we evaluate the interaction of the alpha(2)-AR antagonist, yohimbine, as compared to  bbbbb1 fluparoxan eeeee1 , at multiple  bbbbb2 monoaminergic receptors eeeee2  and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats
CPR:5	However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the  bbbbb1 5-HT(1A) eeeee1  agonist actions of  bbbbb2 yohimbine eeeee2  suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.
CPR:5	In [(35)S]GTPgammaS binding protocols,  bbbbb1 yohimbine eeeee1  exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at  bbbbb2 h5-HT(1A) eeeee2  sites
CPR:5	In vivo, agonist actions of  bbbbb1 yohimbine eeeee1  at  bbbbb2 5-HT(1A) eeeee2  sites are revealed by WAY100,635-reversible induction of hypothermia in the rat
CPR:5	In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the  bbbbb1 5-HT(1B) eeeee1  agonist,  bbbbb2 GR46,611 eeeee2 
CPR:5	In distinction to  bbbbb1 yohimbine eeeee1 , fluparoxan shows only modest partial agonist actions at  bbbbb2 h5-HT(1A) eeeee2  sites versus marked antagonist actions at halpha(2)-ARs
CPR:5	In distinction to yohimbine,  bbbbb1 fluparoxan eeeee1  shows only modest partial agonist actions at  bbbbb2 h5-HT(1A) eeeee2  sites versus marked antagonist actions at halpha(2)-ARs
CPR:5	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at alpha(2)-adrenergic receptors  bbbbb2 (AR)s eeeee2 , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:5	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin  bbbbb2 (5-HT)(1A) eeeee2 , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:5	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  bbbbb2 5-HT(1B) eeeee2 , 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:5	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  bbbbb2 5-HT(1D) eeeee2  and dopamine D(2) and D(3) receptors
CPR:5	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at  bbbbb2 alpha(2)-adrenergic receptors eeeee2  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:5	Agonist and antagonist actions of yohimbine as compared to  bbbbb1 fluparoxan eeeee1  at alpha(2)-adrenergic receptors  bbbbb2 (AR)s eeeee2 , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:5	Agonist and antagonist actions of yohimbine as compared to  bbbbb1 fluparoxan eeeee1  at  bbbbb2 alpha(2)-adrenergic receptors eeeee2  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:6	In conclusion, the  bbbbb1 alpha(2)-AR eeeee1  antagonist properties of  bbbbb2 yohimbine eeeee2  increase DA and NAD levels both alone and in association with fluoxetine
CPR:6	However, in contrast to the selective  bbbbb1 alpha(2)-AR eeeee1  antagonist,  bbbbb2 fluparoxan eeeee2 , the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.
CPR:6	In [(35)S]GTPgammaS binding protocols,  bbbbb1 yohimbine eeeee1  exerts antagonist actions at  bbbbb2 halpha(2A)-AR eeeee2 , h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites
CPR:6	In [(35)S]GTPgammaS binding protocols,  bbbbb1 yohimbine eeeee1  exerts antagonist actions at halpha(2A)-AR,  bbbbb2 h5-HT(1B) eeeee2 , h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites
CPR:6	In [(35)S]GTPgammaS binding protocols,  bbbbb1 yohimbine eeeee1  exerts antagonist actions at halpha(2A)-AR, h5-HT(1B),  bbbbb2 h5-HT(1D) eeeee2 , and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites
CPR:6	In [(35)S]GTPgammaS binding protocols,  bbbbb1 yohimbine eeeee1  exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and  bbbbb2 hD(2) eeeee2  sites, yet partial agonist actions at h5-HT(1A) sites
CPR:6	Herein, we evaluate the interaction of the  bbbbb1 alpha(2)-AR antagonist eeeee1 ,  bbbbb2 yohimbine eeeee2 , as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats
CPR:6	In vivo, agonist actions of yohimbine at  bbbbb1 5-HT(1A) eeeee1  sites are revealed by  bbbbb2 WAY100,635 eeeee2 -reversible induction of hypothermia in the rat
CPR:6	In guinea pigs, antagonist actions of  bbbbb1 yohimbine eeeee1  at  bbbbb2 5-HT(1B) eeeee2  receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611
CPR:6	Herein, we evaluate the interaction of the  bbbbb1 alpha(2)-AR antagonist eeeee1 , yohimbine, as compared to  bbbbb2 fluparoxan eeeee2 , at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats
CPR:6	In distinction to  bbbbb1 yohimbine eeeee1 , fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at  bbbbb2 halpha(2)-ARs eeeee2 
CPR:6	In distinction to yohimbine,  bbbbb1 fluparoxan eeeee1  shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at  bbbbb2 halpha(2)-ARs eeeee2 
CPR:6	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at alpha(2)-adrenergic receptors  bbbbb2 (AR)s eeeee2 , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:6	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin  bbbbb2 (5-HT)(1A) eeeee2 , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:6	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  bbbbb2 5-HT(1B) eeeee2 , 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:6	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  bbbbb2 5-HT(1D) eeeee2  and dopamine D(2) and D(3) receptors
CPR:6	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at  bbbbb2 alpha(2)-adrenergic receptors eeeee2  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:6	Agonist and antagonist actions of yohimbine as compared to  bbbbb1 fluparoxan eeeee1  at alpha(2)-adrenergic receptors  bbbbb2 (AR)s eeeee2 , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:6	Agonist and antagonist actions of yohimbine as compared to  bbbbb1 fluparoxan eeeee1  at  bbbbb2 alpha(2)-adrenergic receptors eeeee2  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CPR:5	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and  bbbbb1 kappa-opioid receptor eeeee1  ( bbbbb2 BRL 52974 eeeee2 ) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CPR:5	The nonselective  bbbbb1 opioid receptor eeeee1  antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of  bbbbb2 codeine eeeee2  or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated
CPR:5	The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of  bbbbb1 codeine eeeee1  or SB 227122, indicating that the antitussive activity of both compounds is  bbbbb2 opioid receptor eeeee2 -mediated
CPR:5	The nonselective  bbbbb1 opioid receptor eeeee1  antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or  bbbbb2 SB 227122 eeeee2 , indicating that the antitussive activity of both compounds is opioid receptor-mediated
CPR:5	The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or  bbbbb1 SB 227122 eeeee1 , indicating that the antitussive activity of both compounds is  bbbbb2 opioid receptor eeeee2 -mediated
CPR:5	The  bbbbb1 delta-receptor eeeee1  antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of  bbbbb2 SB 227122 eeeee2  (20 mg/kg, i.p.)
CPR:5	In this study, the activity of the  bbbbb1 delta-opioid receptor eeeee1  subtype-selective agonist,  bbbbb2 SB 227122 eeeee2 , was investigated in a guinea pig model of citric acid-induced cough
CPR:5	The  bbbbb1 sigma-receptor eeeee1  antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of  bbbbb2 dextromethorphan eeeee2  (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122
CPR:5	These studies provide compelling evidence that the antitussive effects of  bbbbb1 SB 227122 eeeee1  in this guinea pig cough model are mediated by agonist activity at the  bbbbb2 delta-opioid receptor eeeee2 .
CPR:5	Parenteral administration of selective agonists of the  bbbbb1 delta-opioid receptor eeeee1  ( bbbbb2 SB 227122 eeeee2 ), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CPR:5	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122),  bbbbb1 mu-opioid receptor eeeee1  ( bbbbb2 codeine eeeee2  and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CPR:5	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122),  bbbbb1 mu-opioid receptor eeeee1  (codeine and  bbbbb2 hydrocodone eeeee2 ), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CPR:6	The nonselective  bbbbb1 opioid receptor eeeee1  antagonist,  bbbbb2 naloxone eeeee2  (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated
CPR:6	The  bbbbb1 delta-receptor eeeee1  antagonist,  bbbbb2 SB 244525 eeeee2  (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.)
CPR:6	In contrast, combined pretreatment with  bbbbb1 beta-funaltrexamine eeeee1  ( bbbbb2 mu-receptor eeeee2  antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)
CPR:6	In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and  bbbbb1 norbinaltorphimine eeeee1  ( bbbbb2 kappa-receptor eeeee2  antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)
CPR:6	The  bbbbb1 sigma-receptor eeeee1  antagonist  bbbbb2 rimcazole eeeee2  (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122
CPR:4	New modes of therapy have recently been introduced, and data on the  bbbbb1 cyclooxygenase-2 eeeee1  (COX-2)-specific inhibitors  bbbbb2 celecoxib eeeee2  and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.
CPR:4	New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 ( bbbbb1 COX-2 eeeee1 )-specific inhibitors  bbbbb2 celecoxib eeeee2  and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.
CPR:4	New modes of therapy have recently been introduced, and data on the  bbbbb1 cyclooxygenase-2 eeeee1  (COX-2)-specific inhibitors celecoxib and  bbbbb2 rofecoxib eeeee2  suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.
CPR:4	New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 ( bbbbb1 COX-2 eeeee1 )-specific inhibitors celecoxib and  bbbbb2 rofecoxib eeeee2  suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.
CPR:4	 bbbbb1 Dichloroally]-lawsone eeeee1  was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for  bbbbb2 mammalian dihydroorotate dehydrogenases eeeee2 
CPR:4	Another inhibitor,  bbbbb1 brequinar eeeee1  was previously reported to be a slow-binding inhibitor of the  bbbbb2 human dihydroorotate dehydrogenase eeeee2  [W
CPR:4	Loffler, Species-related inhibition of  bbbbb1 human and rat dihyroorotate dehydrogenase eeeee1  by immunosuppressive  bbbbb2 isoxazol eeeee2  and cinchoninic acid derivatives, Biochem
CPR:4	Loffler, Species-related inhibition of  bbbbb1 human and rat dihyroorotate dehydrogenase eeeee1  by immunosuppressive isoxazol and  bbbbb2 cinchoninic acid eeeee2  derivatives, Biochem
CPR:4	With respect to the substrate  bbbbb1 dihydroorotate eeeee1 , atovaquone was an uncompetitive inhibitor of  bbbbb2 human dihydroorotate dehydrogenase eeeee2  (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM). 1.5 mM polyporic acid, a natural quinone from fungi, influenced the activity of the human enzyme only slightly; the activity of the rat enzyme was decreased by 30%
CPR:4	With respect to the substrate dihydroorotate,  bbbbb1 atovaquone eeeee1  was an uncompetitive inhibitor of  bbbbb2 human dihydroorotate dehydrogenase eeeee2  (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM). 1.5 mM polyporic acid, a natural quinone from fungi, influenced the activity of the human enzyme only slightly; the activity of the rat enzyme was decreased by 30%
CPR:4	Kinetics of inhibition of  bbbbb1 human and rat dihydroorotate dehydrogenase eeeee1  by atovaquone, lawsone derivatives,  bbbbb2 brequinar sodium eeeee2  and polyporic acid
CPR:4	Kinetics of inhibition of  bbbbb1 human and rat dihydroorotate dehydrogenase eeeee1  by atovaquone, lawsone derivatives, brequinar sodium and  bbbbb2 polyporic acid eeeee2 
CPR:4	Kinetics of inhibition of  bbbbb1 human and rat dihydroorotate dehydrogenase eeeee1  by  bbbbb2 atovaquone eeeee2 , lawsone derivatives, brequinar sodium and polyporic acid
CPR:4	Kinetics of inhibition of  bbbbb1 human and rat dihydroorotate dehydrogenase eeeee1  by atovaquone,  bbbbb2 lawsone eeeee2  derivatives, brequinar sodium and polyporic acid
CPR:4	With respect to the quinone co-substrate of the dihydroorotate dehydrogenase,  bbbbb1 atovaquone eeeee1  (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of  bbbbb2 human dihydroorotate dehydrogenase eeeee2 
CPR:4	With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and  bbbbb1 dichloroally-lawsone eeeee1  (Kic = 9.8 nM) were shown to be competitive inhibitors of  bbbbb2 human dihydroorotate dehydrogenase eeeee2 
CPR:9	Mitochondrially-bound  bbbbb1 dihydroorotate dehydrogenase eeeee1  (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of  bbbbb2 uridine monophosphate eeeee2 
CPR:9	Mitochondrially-bound dihydroorotate dehydrogenase ( bbbbb1 EC 1.3.99.11 eeeee1 ) catalyzes the fourth sequential step in the de novo synthesis of  bbbbb2 uridine monophosphate eeeee2 
CPR:9	With respect to the  bbbbb1 quinone eeeee1  co-substrate of the  bbbbb2 dihydroorotate dehydrogenase eeeee2 , atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase
CPR:2	METHODS AND RESULTS: The effect of intravenous  bbbbb1 ajmaline eeeee1  (1 mg/kg), procainamide (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a  bbbbb2 SCN5A eeeee2  mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C)
CPR:2	METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg),  bbbbb1 procainamide eeeee1  (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a  bbbbb2 SCN5A eeeee2  mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C)
CPR:2	METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg), procainamide (10 mg/kg), or  bbbbb1 flecainide eeeee1  (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a  bbbbb2 SCN5A eeeee2  mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C)
CPR:2	To further analyze the mechanism governing the  bbbbb1 Ca2+ channel eeeee1 - bbbbb2 Mibefradil eeeee2  interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CPR:2	Therefore, we conclude that the tissue and sub-cellular localization of  bbbbb1 calcium channel eeeee1  subunits as well as their specific associations are essential parameters to understand the in vivo effects of  bbbbb2 Mibefradil eeeee2 .
CPR:4	 bbbbb1 Mibefradil eeeee1  blocked alpha1A and alpha1E with a Kd comparable to that reported for  bbbbb2 T-type channels eeeee2 , but had a lower affinity (approximately 30-fold) for alpha1C
CPR:4	 bbbbb1 Mibefradil eeeee1  (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block  bbbbb2 T-type Ca2+ channels eeeee2 
CPR:4	Determinants of voltage-dependent inactivation affect  bbbbb1 Mibefradil eeeee1  block of  bbbbb2 calcium channels eeeee2 
CPR:4	Mibefradil ( bbbbb1 Ro 40-5967 eeeee1 ) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block  bbbbb2 T-type Ca2+ channels eeeee2 
CPR:4	Postoperative concentrations of  bbbbb1 plasminogen eeeee1  were decreased significantly in the  bbbbb2 tranexamic acid eeeee2  group (P < 0.001)
CPR:5	Iontophoresis of  bbbbb1 +/- propranolol eeeee1 , whose serotonergic actions include antagonism and partial agonism at  bbbbb2 5-HT1 eeeee2  receptors, also increased serotonin and decreased firing (n=4)
CPR:6	 bbbbb1 Methiothepin eeeee1  (intravenous, 1 mg/kg), whose serotonergic actions include  bbbbb2 5-HT1 eeeee2  and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)
CPR:6	 bbbbb1 Methiothepin eeeee1  (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and  bbbbb2 5-HT2 eeeee2  antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)
CPR:6	Iontophoresis of  bbbbb1 +/- propranolol eeeee1 , whose serotonergic actions include antagonism and partial agonism at  bbbbb2 5-HT1 eeeee2  receptors, also increased serotonin and decreased firing (n=4)
CPR:10	Treatment with  bbbbb1 geldanamycin eeeee1 , however, does not affect the activation of  bbbbb2 lysophosphatide acyltransferase eeeee2 , which is a plasma membrane enzyme coupled to the T-cell receptor after T-cell stimulation
CPR:4	In this study, we demonstrate that  bbbbb1 geldanamycin eeeee1  treatment blocks  bbbbb2 interleukin (IL)-2 eeeee2  secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes
CPR:4	In this study, we demonstrate that  bbbbb1 geldanamycin eeeee1  treatment blocks interleukin (IL)-2 secretion,  bbbbb2 IL-2 receptor eeeee2  expression, and proliferation of stimulated T-lymphocytes
CPR:4	Moreover,  bbbbb1 geldanamycin eeeee1  decreases the amount and phosphorylation of  bbbbb2 Lck eeeee2  and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase
CPR:4	Moreover,  bbbbb1 geldanamycin eeeee1  decreases the amount and phosphorylation of Lck and  bbbbb2 Raf-1 eeeee2  kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase
CPR:4	Moreover,  bbbbb1 geldanamycin eeeee1  decreases the amount and phosphorylation of Lck and Raf-1  bbbbb2 kinases eeeee2  and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase
CPR:4	Through demonstrating the selective inhibition of  bbbbb1 kinase eeeee1 -related T-lymphocyte responses by  bbbbb2 geldanamycin eeeee2 , our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.
CPR:4	Improper function of these proteins can be induced by selective disruption of their complexes with  bbbbb1 Hsp90 eeeee1  using the  bbbbb2 benzoquinonoid ansamycin eeeee2  geldanamycin
CPR:4	Improper function of these proteins can be induced by selective disruption of their complexes with  bbbbb1 Hsp90 eeeee1  using the benzoquinonoid ansamycin  bbbbb2 geldanamycin eeeee2 
CPR:4	Moreover,  bbbbb1 geldanamycin eeeee1  decreases the amount and phosphorylation of  bbbbb2 Lck eeeee2  and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase
CPR:4	Moreover,  bbbbb1 geldanamycin eeeee1  decreases the amount and phosphorylation of Lck and  bbbbb2 Raf-1 eeeee2  kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase
CPR:4	Moreover,  bbbbb1 geldanamycin eeeee1  decreases the amount and phosphorylation of Lck and Raf-1  bbbbb2 kinases eeeee2  and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase
CPR:4	Moreover,  bbbbb1 geldanamycin eeeee1  decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the  bbbbb2 extracellular signal regulated kinase (ERK)-2 eeeee2  kinase
CPR:4	Moreover,  bbbbb1 geldanamycin eeeee1  decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2  bbbbb2 kinase eeeee2 
CPR:4	 bbbbb1 Geldanamycin eeeee1  also disrupts the  bbbbb2 T-cell receptor eeeee2 -mediated activation of nuclear factor of activated T-cells (NF-AT)
CPR:4	 bbbbb1 Geldanamycin eeeee1  also disrupts the T-cell receptor-mediated activation of  bbbbb2 nuclear factor of activated T-cells eeeee2  (NF-AT)
CPR:4	 bbbbb1 Geldanamycin eeeee1  also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells ( bbbbb2 NF-AT eeeee2 )
CPR:4	The  bbbbb1 Hsp90 eeeee1 -specific inhibitor  bbbbb2 geldanamycin eeeee2  selectively disrupts kinase-mediated signaling events of T-lymphocyte activation
CPR:4	The Hsp90-specific inhibitor  bbbbb1 geldanamycin eeeee1  selectively disrupts  bbbbb2 kinase eeeee2 -mediated signaling events of T-lymphocyte activation
CPR:2	Purification of gamma-butyrobetaine hydroxylase from rat liver.  bbbbb1 gamma-Butyrobetaine hydroxylase eeeee1  catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on  bbbbb2 Fe2+ eeeee2 , alpha-ketoglutarate, ascorbate and oxygen
CPR:2	Purification of gamma-butyrobetaine hydroxylase from rat liver.  bbbbb1 gamma-Butyrobetaine hydroxylase eeeee1  catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+,  bbbbb2 alpha-ketoglutarate eeeee2 , ascorbate and oxygen
CPR:2	Purification of gamma-butyrobetaine hydroxylase from rat liver.  bbbbb1 gamma-Butyrobetaine hydroxylase eeeee1  catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate,  bbbbb2 ascorbate eeeee2  and oxygen
CPR:2	Purification of gamma-butyrobetaine hydroxylase from rat liver.  bbbbb1 gamma-Butyrobetaine hydroxylase eeeee1  catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and  bbbbb2 oxygen eeeee2 
CPR:9	Purification of gamma-butyrobetaine hydroxylase from rat liver.  bbbbb1 gamma-Butyrobetaine hydroxylase eeeee1  catalyse the last step in  bbbbb2 carnitine eeeee2  biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CPR:9	Purification of gamma-butyrobetaine hydroxylase from rat liver.  bbbbb1 gamma-Butyrobetaine hydroxylase eeeee1  catalyse the last step in carnitine biosynthesis, the formation of  bbbbb2 L-carnitine eeeee2  from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CPR:9	Purification of gamma-butyrobetaine hydroxylase from rat liver.  bbbbb1 gamma-Butyrobetaine hydroxylase eeeee1  catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from  bbbbb2 gamma-butyrobetaine eeeee2 , a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CPR:10	 bbbbb1 Salicylates eeeee1  do not promote dissociation of (125)I- bbbbb2 ET-1 eeeee2  ETB receptor complexes
CPR:10	 bbbbb1 Salicylates eeeee1  do not promote dissociation of (125)I-ET-1  bbbbb2 ETB receptor eeeee2  complexes
CPR:2	 bbbbb1 Salicylic acid eeeee1  promotes dissociation of (125)I- bbbbb2 ET-1 eeeee2  ETA receptor complexes both in the absence and the presence of unlabeled ET-1
CPR:2	 bbbbb1 Salicylic acid eeeee1  promotes dissociation of (125)I-ET-1  bbbbb2 ETA receptor eeeee2  complexes both in the absence and the presence of unlabeled ET-1
CPR:2	Salicylic acid promotes dissociation of  bbbbb1 (125)I eeeee1 - bbbbb2 ET-1 eeeee2  ETA receptor complexes both in the absence and the presence of unlabeled ET-1
CPR:2	Salicylic acid promotes dissociation of  bbbbb1 (125)I eeeee1 -ET-1  bbbbb2 ETA receptor eeeee2  complexes both in the absence and the presence of unlabeled ET-1
CPR:2	It has no influence on the rate of association of  bbbbb1 (125)I eeeee1 - bbbbb2 ET-1 eeeee2  to ETA receptors
CPR:2	It has no influence on the rate of association of  bbbbb1 (125)I eeeee1 -ET-1 to  bbbbb2 ETA receptors eeeee2 
CPR:2	Salicylates do not promote dissociation of  bbbbb1 (125)I eeeee1 - bbbbb2 ET-1 eeeee2  ETB receptor complexes
CPR:2	Salicylates do not promote dissociation of  bbbbb1 (125)I eeeee1 -ET-1  bbbbb2 ETB receptor eeeee2  complexes
CPR:2	 bbbbb1 Salicylates eeeee1  inhibit (125)I- bbbbb2 ET-1 eeeee2  binding to recombinant rat ETA receptors
CPR:2	 bbbbb1 Salicylates eeeee1  inhibit (125)I-ET-1 binding to recombinant  bbbbb2 rat ETA receptors eeeee2 
CPR:2	Salicylates inhibit  bbbbb1 (125)I eeeee1 - bbbbb2 ET-1 eeeee2  binding to recombinant rat ETA receptors
CPR:2	This study shows that  bbbbb1 aspirin eeeee1  and sodium salicylate, its major blood metabolite, reverse contractile actions of  bbbbb2 endothelin-1 eeeee2  (ET-1) in isolated rat aorta and human mammary arteries
CPR:2	This study shows that  bbbbb1 aspirin eeeee1  and sodium salicylate, its major blood metabolite, reverse contractile actions of endothelin-1 ( bbbbb2 ET-1 eeeee2 ) in isolated rat aorta and human mammary arteries
CPR:2	This study shows that aspirin and  bbbbb1 sodium salicylate eeeee1 , its major blood metabolite, reverse contractile actions of  bbbbb2 endothelin-1 eeeee2  (ET-1) in isolated rat aorta and human mammary arteries
CPR:2	This study shows that aspirin and  bbbbb1 sodium salicylate eeeee1 , its major blood metabolite, reverse contractile actions of endothelin-1 ( bbbbb2 ET-1 eeeee2 ) in isolated rat aorta and human mammary arteries
CPR:2	 bbbbb1 Salicylic acid eeeee1  promotes dissociation of (125)I-ET-1 ETA receptor complexes both in the absence and the presence of unlabeled  bbbbb2 ET-1 eeeee2 
CPR:2	Salicylic acid promotes dissociation of  bbbbb1 (125)I eeeee1 -ET-1 ETA receptor complexes both in the absence and the presence of unlabeled  bbbbb2 ET-1 eeeee2 
CPR:2	The results also suggest that: 1) irreversible ET-1 binding probably limits actions of receptor antagonists in vivo, and 2) an association of  bbbbb1 salicylates eeeee1  and ETA receptor antagonists should be used to evaluate the physiopathological role of  bbbbb2 ET-1 eeeee2  and may be of therapeutic interest in the treatment of ischemic heart disease.
CPR:4	Inhibition of the actions of  bbbbb1 ET-1 eeeee1  by  bbbbb2 salicylates eeeee2  is apparently competitive
CPR:7	 bbbbb1 Aspirin eeeee1  and sodium salicylate inhibit endothelin  bbbbb2 ETA receptors eeeee2  by an allosteric type of mechanism
CPR:7	Aspirin and  bbbbb1 sodium salicylate eeeee1  inhibit endothelin  bbbbb2 ETA receptors eeeee2  by an allosteric type of mechanism
CPR:7	It is concluded that  bbbbb1 salicylates eeeee1  are allosteric inhibitors of  bbbbb2 ETA receptors eeeee2 
CPR:2	The cytosolic fractions from liver and colon tissues of NQO1-/- mice showed similar amounts of DNA cross-linking upon exposure to  bbbbb1 MMC eeeee1 , as observed in  bbbbb2 NQO1 eeeee2 +/+ mice
CPR:4	Among the various enzymes,  bbbbb1 dicoumarol eeeee1  inhibitable cytosolic  bbbbb2 NAD(P)H:quinone oxidoreductase1 eeeee2  (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity
CPR:4	Among the various enzymes,  bbbbb1 dicoumarol eeeee1  inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 ( bbbbb2 NQO1 eeeee2 ) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity
CPR:4	This activity, like  bbbbb1 NQO1 eeeee1 , was inhibited by  bbbbb2 dicoumarol eeeee2  and immunologically related to NQO1.
CPR:9	Among the various enzymes, dicoumarol inhibitable cytosolic  bbbbb1 NAD(P)H:quinone oxidoreductase1 eeeee1  (NQO1) was shown to catalyse bioreductive activation of  bbbbb2 MMC eeeee2  leading to cross-linking of the DNA and cytotoxicity
CPR:9	Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 ( bbbbb1 NQO1 eeeee1 ) was shown to catalyse bioreductive activation of  bbbbb2 MMC eeeee2  leading to cross-linking of the DNA and cytotoxicity
CPR:9	However, the role of  bbbbb1 NQO1 eeeee1  in metabolic activation of  bbbbb2 MMC eeeee2  has been disputed
CPR:9	In this report, we present cellular and animal models to demonstrate that  bbbbb1 NQO1 eeeee1  may play only a minor role in metabolic activation of  bbbbb2 MMC eeeee2 
CPR:9	A unique cytosolic activity related but distinct from  bbbbb1 NQO1 eeeee1  catalyses metabolic activation of  bbbbb2 mitomycin C eeeee2 
CPR:2	In this study, we investigated the effect of  bbbbb1 troglitazone eeeee1 , a ligand of the  bbbbb2 nuclear receptor eeeee2  peroxisome proliferator activated receptor-gamma, on PAI-1 expression and secretion in human adipocytes
CPR:2	In this study, we investigated the effect of  bbbbb1 troglitazone eeeee1 , a ligand of the nuclear receptor  bbbbb2 peroxisome proliferator activated receptor-gamma eeeee2 , on PAI-1 expression and secretion in human adipocytes
CPR:4	In cultures from severely obese subjects,  bbbbb1 troglitazone eeeee1  induced a decrease of  bbbbb2 PAI-1 eeeee2  antigen secretion from newly differentiated omental adipocytes by 49 +/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +/- 7% (p < 0.05)
CPR:4	Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to  bbbbb1 troglitazone eeeee1  induced a similar reduction of  bbbbb2 PAI-1 eeeee2  concentration in the culture medium (by 35 +/- 11%, p < 0.05, and 33 +/- 8%, p < 0.05 compared with control, respectively)
CPR:4	CONCLUSION/INTERPRETATION: This study provides evidence that  bbbbb1 troglitazone eeeee1  reduces  bbbbb2 PAI-1 eeeee2  production in human adipocytes, probably at the transcriptional level
CPR:4	RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml  bbbbb1 troglitazone eeeee1  for 72 h caused a reduction of both  bbbbb2 PAI-1 eeeee2  secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05)
CPR:4	RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml  bbbbb1 troglitazone eeeee1  for 72 h caused a reduction of both PAI-1 secretion (by 29 +/- 5%; p < 0.01) and  bbbbb2 PAI-1 eeeee2  mRNA expression (by 26 +/- 3%; p < 0.05)
CPR:4	 bbbbb1 Troglitazone eeeee1  reduces  bbbbb2 plasminogen activator inhibitor-1 eeeee2  expression and secretion in cultured human adipocytes
CPR:6	In these tissues,  bbbbb1 JTH-601 eeeee1 , prazosin (a non-selective  bbbbb2 alpha(1)-adrenoceptor eeeee2  antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner
CPR:6	In these tissues, JTH-601,  bbbbb1 prazosin eeeee1  (a non-selective  bbbbb2 alpha(1)-adrenoceptor eeeee2  antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner
CPR:6	In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and  bbbbb1 tamsulosin eeeee1  (an  bbbbb2 alpha(1A)-adrenoceptor eeeee2  antagonist) competitively antagonized contraction in a concentration-dependent manner
CPR:6	We examined the effect of JTH-601 (3- inverted question mark bbbbb1 N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom eeeee1  ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new  bbbbb2 alpha(1L)-adrenoceptor eeeee2  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs
CPR:6	We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom  bbbbb1 ethyl eeeee1  inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new  bbbbb2 alpha(1L)-adrenoceptor eeeee2  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs
CPR:6	 bbbbb1 JTH-601 eeeee1  is expected to be an effective  bbbbb2 alpha(1)-adrenoceptor eeeee2  antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.
CPR:6	We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark- bbbbb1 4-methoxy-2,5,6-trimethylphenol hemifumarate eeeee1 ), a new  bbbbb2 alpha(1L)-adrenoceptor eeeee2  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs
CPR:6	We examined the effect of  bbbbb1 JTH-601 eeeee1  (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new  bbbbb2 alpha(1L)-adrenoceptor eeeee2  antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs
CPR:9	These data directly demonstrate that  bbbbb1 NKCC1 eeeee1  is the major  bbbbb2 Cl(-) eeeee2  uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.
CPR:9	The salivary fluid secretory mechanism is thought to require  bbbbb1 Na(+)/K(+)/2Cl(-) cotransporter eeeee1 -mediated  bbbbb2 Cl(-) eeeee2  uptake
CPR:2	UNLABELLED: Apparent  bbbbb1 muscarinic acetylcholine (mAch) receptor eeeee1  occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate ( bbbbb2 3H-NMPB eeeee2 ) and 3H-quinuclidinyl benzilate (3H-QNB)
CPR:2	UNLABELLED: Apparent  bbbbb1 muscarinic acetylcholine (mAch) receptor eeeee1  occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and  bbbbb2 3H-quinuclidinyl benzilate eeeee2  (3H-QNB)
CPR:2	UNLABELLED: Apparent  bbbbb1 muscarinic acetylcholine (mAch) receptor eeeee1  occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate ( bbbbb2 3H-QNB eeeee2 )
CPR:2	Both radioligands labeled  bbbbb1 mAch receptors eeeee1  in these brain regions, and the relative regional distributions of the specific binding of  bbbbb2 3H-NMPB eeeee2  in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB
CPR:2	Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of  bbbbb1 3H-NMPB eeeee1  in vivo paralleled the distribution of  bbbbb2 mAch receptors eeeee2 . 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB
CPR:2	A similar discrepancy in sensitivity to competitors between  bbbbb1 3H-NMPB eeeee1  and 3H-QNB was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the  bbbbb2 mAch receptor eeeee2  could not account for the observed differences in sensitivity to competition
CPR:2	A similar discrepancy in sensitivity to competitors between 3H-NMPB and  bbbbb1 3H-QNB eeeee1  was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the  bbbbb2 mAch receptor eeeee2  could not account for the observed differences in sensitivity to competition
CPR:2	A similar discrepancy in sensitivity to competitors between 3H-NMPB and 3H-QNB was also observed when  bbbbb1 biperiden eeeee1  was used as a competitor, indicating that binding to different subtypes of the  bbbbb2 mAch receptor eeeee2  could not account for the observed differences in sensitivity to competition
CPR:2	This finding, together with the more favorable accumulation of 3H-NMPB in cerebral cortex, hippocampus, and striatum, leads us to conclude that  bbbbb1 3H-NMPB eeeee1 , or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of  bbbbb2 mAch receptor eeeee2  occupancy by cholinergic drugs in the brain
CPR:2	UNLABELLED: Apparent  bbbbb1 muscarinic acetylcholine (mAch) receptor eeeee1  occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands:  bbbbb2 3H-N-methyl piperidyl benzilate eeeee2  (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CPR:6	UNLABELLED: Apparent  bbbbb1 muscarinic acetylcholine (mAch) receptor eeeee1  occupancy in mouse cerebral cortex, hippocampus, and striatum by  bbbbb2 scopolamine eeeee2 , an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CPR:6	UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and  bbbbb1 biperiden eeeee1 , a relatively selective  bbbbb2 M1 eeeee2  antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CPR:10	However, in virgin mice,  bbbbb1 bezafibrate eeeee1  and WY-14,643 do not significantly affect  bbbbb2 UCP-3 eeeee2  mRNA expression, whereas troglitazone is at least as effective as it is in lactating dams
CPR:10	However, in virgin mice, bezafibrate and  bbbbb1 WY-14,643 eeeee1  do not significantly affect  bbbbb2 UCP-3 eeeee2  mRNA expression, whereas troglitazone is at least as effective as it is in lactating dams
CPR:2	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.  bbbbb1 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid eeeee1  (WY-14,643), a specific ligand of the  bbbbb2 PPAR-alpha eeeee2  subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CPR:2	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ( bbbbb1 WY-14,643 eeeee1 ), a specific ligand of the  bbbbb2 PPAR-alpha eeeee2  subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CPR:2	Changes in  bbbbb1 UCP-3 eeeee1  mRNA occur in parallel with modifications in the levels of free  bbbbb2 fatty acids eeeee2 , which are reduced in lactation and are upregulated due to weaning or fasting
CPR:2	Conversely, when mice are fed a high-fat diet after parturition, the downregulation of  bbbbb1 UCP-3 eeeee1  mRNA and UCP-3 protein levels due to lactation is partially reversed, as is the reduction in serum free  bbbbb2 fatty acid eeeee2  levels
CPR:2	Conversely, when mice are fed a high-fat diet after parturition, the downregulation of UCP-3 mRNA and  bbbbb1 UCP-3 eeeee1  protein levels due to lactation is partially reversed, as is the reduction in serum free  bbbbb2 fatty acid eeeee2  levels
CPR:2	However, in virgin mice, bezafibrate and WY-14,643 do not significantly affect  bbbbb1 UCP-3 eeeee1  mRNA expression, whereas  bbbbb2 troglitazone eeeee2  is at least as effective as it is in lactating dams
CPR:2	It is proposed that the  bbbbb1 UCP-3 eeeee1  gene is regulated in skeletal muscle during lactation in response to changes in circulating free  bbbbb2 fatty acids eeeee2  by mechanisms involving activation of PPARs
CPR:2	The impaired expression of the  bbbbb1 UCP-3 eeeee1  gene is consistent with the involvement of UCP-3 gene regulation in the reduction of the use of  bbbbb2 fatty acids eeeee2  as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.
CPR:2	The impaired expression of the UCP-3 gene is consistent with the involvement of  bbbbb1 UCP-3 eeeee1  gene regulation in the reduction of the use of  bbbbb2 fatty acids eeeee2  as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.
CPR:3	Treatment of lactating mice with a single injection of  bbbbb1 bezafibrate eeeee1 , an activator of the  bbbbb2 peroxisome proliferator-activated receptor eeeee2  (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CPR:3	Treatment of lactating mice with a single injection of  bbbbb1 bezafibrate eeeee1 , an activator of the peroxisome proliferator-activated receptor ( bbbbb2 PPAR eeeee2 ), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CPR:3	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas  bbbbb1 troglitazone eeeee1 , a specific activator of  bbbbb2 PPAR-gamma eeeee2 , also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CPR:3	It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free  bbbbb1 fatty acids eeeee1  by mechanisms involving activation of  bbbbb2 PPARs eeeee2 
CPR:3	Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and  bbbbb1 troglitazone eeeee1  reverse lactation-induced downregulation of the  bbbbb2 uncoupling protein-3 eeeee2  gene
CPR:3	Treatment of lactating mice with a single injection of  bbbbb1 bezafibrate eeeee1 , an activator of the peroxisome proliferator-activated receptor (PPAR), raises  bbbbb2 UCP-3 eeeee2  mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CPR:3	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.  bbbbb1 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid eeeee1  (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in  bbbbb2 UCP-3 eeeee2  mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CPR:3	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ( bbbbb1 WY-14,643 eeeee1 ), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in  bbbbb2 UCP-3 eeeee2  mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CPR:3	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas  bbbbb1 troglitazone eeeee1 , a specific activator of PPAR-gamma, also significantly increases  bbbbb2 UCP-3 eeeee2  mRNA abundance in skeletal muscle of lactating mice
CPR:3	 bbbbb1 Retigabine eeeee1 , a novel anti-convulsant, enhances activation of KCNQ2/Q3  bbbbb2 potassium channels eeeee2 
CPR:2	This was the first study to investigate platelet  bbbbb1 [3H]paroxetine eeeee1  binding in alcohol-dependent and age-matched control subjects in relation to the  bbbbb2 5-HTTLPR eeeee2  genotype
CPR:2	These results do not support previous results of altered  bbbbb1 [3H]paroxetine eeeee1  binding sites in alcohol-dependent subjects or  bbbbb2 5-HTTLPR eeeee2  S-allele carriers
CPR:2	Blood samples were taken from both alcohol-dependent and control subjects to determine  bbbbb1 5-HTTLPR eeeee1  genotypes using PCR of lymphocyte DNA, and to perform platelet  bbbbb2 [3H]paroxetine eeeee2  binding (binding capacity: B(max); and dissociation constant: K(D))
CPR:2	 bbbbb1 Serotonin transporter eeeee1  gene regulatory region polymorphism (5-HTTLPR),  bbbbb2 [3H]paroxetine eeeee2  binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity
CPR:2	Serotonin transporter gene regulatory region polymorphism ( bbbbb1 5-HTTLPR eeeee1 ),  bbbbb2 [3H]paroxetine eeeee2  binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity
CPR:2	By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of  bbbbb1 arachidonic acid eeeee1  and nonsteroidal anti-inflammatory drugs induces conformational changes in the  bbbbb2 human prostaglandin endoperoxide H(2) synthase enzyme eeeee2  (PGHS-2)
CPR:2	By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of  bbbbb1 arachidonic acid eeeee1  and nonsteroidal anti-inflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H(2) synthase enzyme ( bbbbb2 PGHS-2 eeeee2 )
CPR:2	Proteolysis protection assays had previously provided circumstantial evidence that binding of heme and non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs alters the conformation of  bbbbb2 PGHS eeeee2 , but the present experiments are the first to directly measure such changes
CPR:2	The finding that  bbbbb1 arachidonate eeeee1  can also induce a conformational change in  bbbbb2 PGHS-2 eeeee2  was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the cyclooxygenase catalytic mechanism.
CPR:2	The finding that  bbbbb1 arachidonate eeeee1  can also induce a conformational change in PGHS-2 was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the  bbbbb2 cyclooxygenase eeeee2  catalytic mechanism.
CPR:2	Line shape broadening resulting from spin-spin coupling of  bbbbb1 nitroxide eeeee1  pairs introduced into the membrane-binding helices of  bbbbb2 PGHS-2 eeeee2  was used to calculate the inter-helical distances and changes in these distances that occur in response to binding various ligands
CPR:2	However, inter-helical distances calculated and determined by EPR for  bbbbb1 PGHS-2 eeeee1  complexed with  bbbbb2 arachidonic acid eeeee2 , flurbiprofen, and SC-58125 were in close agreement with those obtained from the cognate crystal structures
CPR:2	However, inter-helical distances calculated and determined by EPR for  bbbbb1 PGHS-2 eeeee1  complexed with arachidonic acid,  bbbbb2 flurbiprofen eeeee2 , and SC-58125 were in close agreement with those obtained from the cognate crystal structures
CPR:2	However, inter-helical distances calculated and determined by EPR for  bbbbb1 PGHS-2 eeeee1  complexed with arachidonic acid, flurbiprofen, and  bbbbb2 SC-58125 eeeee2  were in close agreement with those obtained from the cognate crystal structures
CPR:2	 bbbbb1 Arachidonic acid eeeee1  and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 ( bbbbb2 cyclooxygenase-2 eeeee2 )
CPR:2	 bbbbb1 Arachidonic acid eeeee1  and nonsteroidal anti-inflammatory drugs induce conformational changes in the  bbbbb2 human prostaglandin endoperoxide H2 synthase-2 eeeee2  (cyclooxygenase-2)
CPR:10	Activation of extracellular signal-related kinase (ERK) 1 and 2,  bbbbb1 c-Jun-N-terminal kinase (JNK) 1 eeeee1 , and p38 was unaffected by  bbbbb2 sulfasalazine eeeee2 
CPR:10	Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun-N-terminal kinase (JNK) 1, and  bbbbb1 p38 eeeee1  was unaffected by  bbbbb2 sulfasalazine eeeee2 
CPR:2	Various drugs used in the treatment of IBD, such as glucocorticoids,  bbbbb1 5-aminosalicylic acid eeeee1 , and sulfasalazine, interfere with  bbbbb2 NF-kappaB eeeee2 /Rel signaling
CPR:2	Various drugs used in the treatment of IBD, such as glucocorticoids,  bbbbb1 5-aminosalicylic acid eeeee1 , and sulfasalazine, interfere with NF-kappaB/ bbbbb2 Rel eeeee2  signaling
CPR:2	Various drugs used in the treatment of IBD, such as glucocorticoids, 5-aminosalicylic acid, and  bbbbb1 sulfasalazine eeeee1 , interfere with  bbbbb2 NF-kappaB eeeee2 /Rel signaling
CPR:2	Various drugs used in the treatment of IBD, such as glucocorticoids, 5-aminosalicylic acid, and  bbbbb1 sulfasalazine eeeee1 , interfere with NF-kappaB/ bbbbb2 Rel eeeee2  signaling
CPR:3	RESULTS:  bbbbb1 NF-kappaB eeeee1 /Rel activity induced by tumor necrosis factor alpha,  bbbbb2 12-O-tetradecanoylphorbol-13-acetate eeeee2 , or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine
CPR:3	RESULTS: NF-kappaB/ bbbbb1 Rel eeeee1  activity induced by tumor necrosis factor alpha,  bbbbb2 12-O-tetradecanoylphorbol-13-acetate eeeee2 , or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine
CPR:4	The suppression of  bbbbb1 NF-kappaB eeeee1  activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of  bbbbb2 sulfasalazine eeeee2 .
CPR:4	The suppression of NF-kappaB activation by inhibition of the  bbbbb1 IKKs eeeee1  contributes to the well-known anti-inflammatory and immunosuppressive effects of  bbbbb2 sulfasalazine eeeee2 .
CPR:4	The aim of this study was to define the molecular mechanism by which  bbbbb1 sulfasalazine eeeee1  inhibits  bbbbb2 NF-kappaB eeeee2  activation
CPR:4	RESULTS:  bbbbb1 NF-kappaB eeeee1 /Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by  bbbbb2 sulfasalazine eeeee2 
CPR:4	RESULTS: NF-kappaB/ bbbbb1 Rel eeeee1  activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by  bbbbb2 sulfasalazine eeeee2 
CPR:4	RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of  bbbbb1 NF-kappaB-inducing kinase eeeee1 , IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by  bbbbb2 sulfasalazine eeeee2 
CPR:4	RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase,  bbbbb1 IKK-alpha eeeee1 , IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by  bbbbb2 sulfasalazine eeeee2 
CPR:4	RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha,  bbbbb1 IKK-beta eeeee1 , or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by  bbbbb2 sulfasalazine eeeee2 
CPR:4	RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active  bbbbb1 IKK-alpha eeeee1  and IKK-beta mutants was inhibited dose dependently by  bbbbb2 sulfasalazine eeeee2 
CPR:4	RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and  bbbbb1 IKK-beta eeeee1  mutants was inhibited dose dependently by  bbbbb2 sulfasalazine eeeee2 
CPR:4	 bbbbb1 Sulfasalazine eeeee1  inhibited  bbbbb2 tumor necrosis factor alpha eeeee2 -induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro
CPR:4	 bbbbb1 Sulfasalazine eeeee1  inhibited tumor necrosis factor alpha-induced activation of endogenous  bbbbb2 IKK eeeee2  in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro
CPR:4	 bbbbb1 Sulfasalazine eeeee1  inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified  bbbbb2 IKK-alpha eeeee2  and IKK-beta in vitro
CPR:4	 bbbbb1 Sulfasalazine eeeee1  inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and  bbbbb2 IKK-beta eeeee2  in vitro
CPR:4	Suppression of  bbbbb1 NF-kappaB eeeee1  activity by  bbbbb2 sulfasalazine eeeee2  is mediated by direct inhibition of IkappaB kinases alpha and beta
CPR:4	The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of  bbbbb1 IKKs eeeee1  and can be antagonized by excess  bbbbb2 adenosine triphosphate eeeee2 
CPR:10	Selective COX-2 inhibitors, such as  bbbbb1 meloxicam eeeee1 , celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not  bbbbb2 COX-1 eeeee2 
CPR:10	Selective COX-2 inhibitors, such as meloxicam,  bbbbb1 celecoxib eeeee1  (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not  bbbbb2 COX-1 eeeee2 
CPR:10	Selective COX-2 inhibitors, such as meloxicam, celecoxib ( bbbbb1 SC-58635 eeeee1 ), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not  bbbbb2 COX-1 eeeee2 
CPR:10	Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and  bbbbb1 rofecoxib eeeee1  (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not  bbbbb2 COX-1 eeeee2 
CPR:10	Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib ( bbbbb1 MK-0966 eeeee1 ), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not  bbbbb2 COX-1 eeeee2 
CPR:10	For instance,  bbbbb1 meloxicam eeeee1  inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express COX-2 but has no effect on HCT-116 tumor cells that do not express  bbbbb2 COX-2 eeeee2 
CPR:4	This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of  bbbbb1 Bcl-2 eeeee1 , as has been demonstrated for some nonselective NSAIDs, for instance,  bbbbb2 flurbiprofen eeeee2 
CPR:4	In contrast, aspirin-like nonselective NSAIDs such as sulindac and  bbbbb1 indomethacin eeeee1  inhibit not only the enzymatic action of the highly inducible, proinflammatory  bbbbb2 COX-2 eeeee2  but the constitutively expressed, cytoprotective COX-1 as well
CPR:4	In contrast, aspirin-like nonselective NSAIDs such as sulindac and  bbbbb1 indomethacin eeeee1  inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective  bbbbb2 COX-1 eeeee2  as well
CPR:4	Selective COX-2 inhibitors, such as  bbbbb1 meloxicam eeeee1 , celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  bbbbb2 COX-2 eeeee2  but not COX-1
CPR:4	Selective  bbbbb1 COX-2 eeeee1  inhibitors, such as  bbbbb2 meloxicam eeeee2 , celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1
CPR:4	Selective COX-2 inhibitors, such as meloxicam,  bbbbb1 celecoxib eeeee1  (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  bbbbb2 COX-2 eeeee2  but not COX-1
CPR:4	Selective  bbbbb1 COX-2 eeeee1  inhibitors, such as meloxicam,  bbbbb2 celecoxib eeeee2  (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1
CPR:4	Selective COX-2 inhibitors, such as meloxicam, celecoxib ( bbbbb1 SC-58635 eeeee1 ), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  bbbbb2 COX-2 eeeee2  but not COX-1
CPR:4	Selective  bbbbb1 COX-2 eeeee1  inhibitors, such as meloxicam, celecoxib ( bbbbb2 SC-58635 eeeee2 ), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1
CPR:4	Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and  bbbbb1 rofecoxib eeeee1  (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit  bbbbb2 COX-2 eeeee2  but not COX-1
CPR:4	Selective  bbbbb1 COX-2 eeeee1  inhibitors, such as meloxicam, celecoxib (SC-58635), and  bbbbb2 rofecoxib eeeee2  (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1
CPR:4	Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib ( bbbbb1 MK-0966 eeeee1 ), are NSAIDs that have been modified chemically to preferentially inhibit  bbbbb2 COX-2 eeeee2  but not COX-1
CPR:4	Selective  bbbbb1 COX-2 eeeee1  inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib ( bbbbb2 MK-0966 eeeee2 ), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1
CPR:4	For instance,  bbbbb1 meloxicam eeeee1  inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express  bbbbb2 COX-2 eeeee2  but has no effect on HCT-116 tumor cells that do not express COX-2
CPR:4	In contrast,  bbbbb1 aspirin eeeee1 -like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory  bbbbb2 COX-2 eeeee2  but the constitutively expressed, cytoprotective COX-1 as well
CPR:4	In contrast,  bbbbb1 aspirin eeeee1 -like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective  bbbbb2 COX-1 eeeee2  as well
CPR:4	In contrast, aspirin-like nonselective NSAIDs such as  bbbbb1 sulindac eeeee1  and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory  bbbbb2 COX-2 eeeee2  but the constitutively expressed, cytoprotective COX-1 as well
CPR:4	In contrast, aspirin-like nonselective NSAIDs such as  bbbbb1 sulindac eeeee1  and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective  bbbbb2 COX-1 eeeee2  as well
CPR:9	 bbbbb1 COX-2 eeeee1  produces  bbbbb2 prostaglandins eeeee2  that inhibit apoptosis and stimulate angiogenesis and invasiveness
CPR:2	For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma),  bbbbb1 AAAD eeeee1  activity was correlated with the potency of  bbbbb2 carbidopa eeeee2 -induced cytotoxicity
CPR:4	To assess the feasibility of targeting these high AAAD levels for chemotherapy,  bbbbb1 AAAD eeeee1  inhibitors  bbbbb2 carbidopa eeeee2  (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CPR:4	To assess the feasibility of targeting these high AAAD levels for chemotherapy,  bbbbb1 AAAD eeeee1  inhibitors carbidopa ( bbbbb2 alpha-methyl-dopahydrazine eeeee2 ), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CPR:4	To assess the feasibility of targeting these high AAAD levels for chemotherapy,  bbbbb1 AAAD eeeee1  inhibitors carbidopa (alpha-methyl-dopahydrazine),  bbbbb2 alpha-monofluoromethyldopa eeeee2  (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CPR:4	To assess the feasibility of targeting these high AAAD levels for chemotherapy,  bbbbb1 AAAD eeeee1  inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa ( bbbbb2 MFMD eeeee2 ), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CPR:4	To assess the feasibility of targeting these high AAAD levels for chemotherapy,  bbbbb1 AAAD eeeee1  inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and  bbbbb2 3-hydroxybenzylhydrazine eeeee2  (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CPR:4	To assess the feasibility of targeting these high AAAD levels for chemotherapy,  bbbbb1 AAAD eeeee1  inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine ( bbbbb2 NSD-1015 eeeee2 ) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CPR:2	In a search for less flexible analogues of caproctamine (1), a diamine  bbbbb1 diamide eeeee1  endowed with an interesting  bbbbb2 AChE eeeee2  affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system
CPR:2	In a search for less flexible analogues of  bbbbb1 caproctamine eeeee1  (1), a diamine diamide endowed with an interesting  bbbbb2 AChE eeeee2  affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system
CPR:2	In a search for less flexible analogues of caproctamine (1), a  bbbbb1 diamine eeeee1  diamide endowed with an interesting  bbbbb2 AChE eeeee2  affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system
CPR:4	 bbbbb1 Hexahydrochromeno[4,3-b]pyrrole eeeee1  derivatives as  bbbbb2 acetylcholinesterase eeeee2  inhibitors
CPR:4	Since this compound retains good  bbbbb1 AChE eeeee1  inhibitory activity and its  bbbbb2 hexahydrochromeno[4,3-b]pyrrole eeeee2  moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE
CPR:4	Since this compound retains good  bbbbb1 AChE eeeee1  inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the  bbbbb2 hexahydropyrrolo[2,3-b]indole of physostigmine eeeee2  (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE
CPR:2	Moreover, it was suggested that promotion of  bbbbb1 CYP11A1 eeeee1  mRNA expression in Th2 cells was partially involved due to an increase in level of  bbbbb2 corticosterone eeeee2  in splenic tissue and the breakdown of Th cell responses locally in the splenic tissue, which then affected the maintenance of Th2 cell functions in the microenvironment of tumor-bearing mice.
CPR:4	When the anti-corticosterone drug  bbbbb1 aminoglutethimide eeeee1  (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and  bbbbb2 CYP11A1 eeeee2  mRNA expression were decreased at 14 days after tumor inoculation
CPR:4	When the anti-corticosterone drug  bbbbb1 aminoglutethimide eeeee1  ( bbbbb2 CYP11A1 eeeee2  inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation
CPR:10	Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive  bbbbb1 NADH-->UQ oxidoreductase eeeee1  activity of complex I, which was insensitive to  bbbbb2 cAMP eeeee2  stimulation
CPR:10	Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive NADH-->UQ oxidoreductase activity of  bbbbb1 complex I eeeee1 , which was insensitive to  bbbbb2 cAMP eeeee2  stimulation
CPR:2	Furthermore, h[ bbbbb1 Gly2 eeeee1 ]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(ADP-ribose) polymerase cleavage in heterologous cells transfected with the  bbbbb2 GLP-2 receptor eeeee2 
CPR:2	We report here that a human degradation-resistant  bbbbb1 GLP-2 eeeee1  analogue, h[ bbbbb2 Gly2 eeeee2 ]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CPR:4	Furthermore, h[ bbbbb1 Gly2 eeeee1 ]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited  bbbbb2 poly(ADP-ribose) polymerase eeeee2  cleavage in heterologous cells transfected with the GLP-2 receptor
CPR:4	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of  bbbbb1 topoisomerase I eeeee1  inhibitor  bbbbb2 irinotecan hydrochloride eeeee2  or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CPR:9	OBJECTIVES: The hypothesis of the present study was that differences among  bbbbb1 dopamine transporter eeeee1  (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as  bbbbb2 DA eeeee2  uptake inhibitors
CPR:9	OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter ( bbbbb1 DAT eeeee1 ) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as  bbbbb2 DA eeeee2  uptake inhibitors
CPR:9	Accordingly, self-administration of a group of local anesthetics that are  bbbbb1 DAT eeeee1  ligands was compared to their effects as  bbbbb2 DA eeeee2  uptake blockers in vitro in brain tissue
CPR:2	In conclusion, OMCD tubules from  bbbbb1 deoxycorticosterone pivalate eeeee1 -treated rats secrete Cl- into the luminal fluid through  bbbbb2 NKCC1 eeeee2 -mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane
CPR:9	Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of  bbbbb1 NKCC1 eeeee1 -mediated  bbbbb2 Cl- eeeee2  transport
CPR:9	Contribution of the  bbbbb1 Na+-K+-2Cl- cotransporter eeeee1  NKCC1 to  bbbbb2 Cl- eeeee2  secretion in rat OMCD
CPR:9	Contribution of the Na+-K+-2Cl- cotransporter  bbbbb1 NKCC1 eeeee1  to  bbbbb2 Cl- eeeee2  secretion in rat OMCD
CPR:9	In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete  bbbbb1 Cl- eeeee1  into the luminal fluid through  bbbbb2 NKCC1 eeeee2 -mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane
CPR:9	In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through  bbbbb1 NKCC1 eeeee1 -mediated  bbbbb2 Cl- eeeee2  uptake across the basolateral membrane in series with Cl- efflux across the apical membrane
CPR:9	In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through  bbbbb1 NKCC1 eeeee1 -mediated Cl- uptake across the basolateral membrane in series with  bbbbb2 Cl- eeeee2  efflux across the apical membrane
CPR:9	The physiological role of  bbbbb1 NKCC1 eeeee1 -mediated  bbbbb2 Cl- eeeee2  uptake remains to be determined
CPR:9	The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through  bbbbb1 Cl- eeeee1  uptake across the basolateral membrane mediated by  bbbbb2 NKCC1 eeeee2  in series with Cl- efflux across the apical membrane
CPR:9	The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by  bbbbb1 NKCC1 eeeee1  in series with  bbbbb2 Cl- eeeee2  efflux across the apical membrane
CPR:1	This mutation is the first described in exon 9 and impairs the last 27  bbbbb1 amino acids eeeee1  of the  bbbbb2 hormone-binding domain eeeee2 
CPR:2	The anti-emetic and pharmacological profile of  bbbbb1 AS-8112 eeeee1  ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent dopamine D2, D3 and  bbbbb2 5-hydroxytryptamine-3 (5-HT3) receptors eeeee2  ligand, was investigated in the present study
CPR:2	The anti-emetic and pharmacological profile of AS-8112 ( bbbbb1 (R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate eeeee1 ), a novel and potent dopamine D2, D3 and  bbbbb2 5-hydroxytryptamine-3 (5-HT3) receptors eeeee2  ligand, was investigated in the present study
CPR:2	 bbbbb1 Domperidone eeeee1  and haloperidol, which have affinity for  bbbbb2 dopamine D3 receptor eeeee2 , also inhibited R(+)-7-OH-DPAT-induced hypothermia
CPR:2	Domperidone and  bbbbb1 haloperidol eeeee1 , which have affinity for  bbbbb2 dopamine D3 receptor eeeee2 , also inhibited R(+)-7-OH-DPAT-induced hypothermia
CPR:2	Domperidone and haloperidol, which have affinity for  bbbbb1 dopamine D3 receptor eeeee1 , also inhibited  bbbbb2 R(+)-7-OH-DPAT eeeee2 -induced hypothermia
CPR:4	In mice,  bbbbb1 AS-8112 eeeee1  (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the  bbbbb2 dopamine D3 receptor eeeee2  agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)
CPR:5	In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of  bbbbb1 2-methyl-5HT eeeee1 , a  bbbbb2 5-HT3 receptor eeeee2  agonist (pA2 value of 7.04)
CPR:5	In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the  bbbbb1 dopamine D3 receptor eeeee1  agonist;  bbbbb2 R(+)-7-OH-DPAT eeeee2  (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)
CPR:5	In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the  bbbbb1 dopamine D3 receptor eeeee1  agonist; R(+)-7-OH-DPAT ( bbbbb2 R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline eeeee2 ) (0.3 mg kg(-1) s.c.)
CPR:6	In guinea-pig isolated colon,  bbbbb1 AS-8112 eeeee1  produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a  bbbbb2 5-HT3 receptor eeeee2  agonist (pA2 value of 7.04)
CPR:6	Other  bbbbb1 5-HT3 receptor eeeee1  antagonists also produced such a shift in the following antagonistic-potency order:  bbbbb2 granisetron eeeee2 > ondansetron=AS-8112>>metoclopramide
CPR:6	Other  bbbbb1 5-HT3 receptor eeeee1  antagonists also produced such a shift in the following antagonistic-potency order: granisetron>  bbbbb2 ondansetron eeeee2 =AS-8112>>metoclopramide
CPR:6	Other  bbbbb1 5-HT3 receptor eeeee1  antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron= bbbbb2 AS-8112 eeeee2 >>metoclopramide
CPR:6	Other  bbbbb1 5-HT3 receptor eeeee1  antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>> bbbbb2 metoclopramide eeeee2 
CPR:6	The broad-spectrum anti-emetic activity of  bbbbb1 AS-8112 eeeee1 , a novel dopamine D2, D3 and  bbbbb2 5-HT3 receptors eeeee2  antagonist
CPR:6	In conclusion,  bbbbb1 AS-8112 eeeee1  is a potent dopamine D2, D3 and  bbbbb2 5-HT3 receptors eeeee2  antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96),  bbbbb1 Arg eeeee1 (125), Arg(165), Lys(169), Lys(236), and Arg(240) ( bbbbb2 chymotrypsin eeeee2  numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96),  bbbbb1 Arg eeeee1 (125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of  bbbbb2 factor Xa eeeee2  that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125),  bbbbb1 Arg eeeee1 (165), Lys(169), Lys(236), and Arg(240) ( bbbbb2 chymotrypsin eeeee2  numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125),  bbbbb1 Arg eeeee1 (165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of  bbbbb2 factor Xa eeeee2  that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165),  bbbbb1 Lys eeeee1 (169), Lys(236), and Arg(240) ( bbbbb2 chymotrypsin eeeee2  numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165),  bbbbb1 Lys eeeee1 (169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of  bbbbb2 factor Xa eeeee2  that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169),  bbbbb1 Lys eeeee1 (236), and Arg(240) ( bbbbb2 chymotrypsin eeeee2  numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169),  bbbbb1 Lys eeeee1 (236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of  bbbbb2 factor Xa eeeee2  that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and  bbbbb1 Arg eeeee1 (240) ( bbbbb2 chymotrypsin eeeee2  numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and  bbbbb1 Arg eeeee1 (240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of  bbbbb2 factor Xa eeeee2  that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues  bbbbb1 Arg eeeee1 (93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) ( bbbbb2 chymotrypsin eeeee2  numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues  bbbbb1 Arg eeeee1 (93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of  bbbbb2 factor Xa eeeee2  that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93),  bbbbb1 Lys eeeee1 (96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) ( bbbbb2 chymotrypsin eeeee2  numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Recent studies have indicated that the basic residues Arg(93),  bbbbb1 Lys eeeee1 (96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of  bbbbb2 factor Xa eeeee2  that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CPR:1	Moreover, certain basic residues of this site, particularly  bbbbb1 Arg eeeee1 (165) and Lys(169), play a key role in factor Va and/or prothrombin recognition by  bbbbb2 factor Xa eeeee2  in the prothrombinase complex
CPR:1	Moreover, certain basic residues of this site, particularly Arg(165) and  bbbbb1 Lys eeeee1 (169), play a key role in factor Va and/or prothrombin recognition by  bbbbb2 factor Xa eeeee2  in the prothrombinase complex
CPR:10	 bbbbb1 Rofecoxib eeeee1  is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the  bbbbb2 COX-1 eeeee2  isoenzyme at doses up to 1000 mg/day
CPR:2	Rofecoxib has greater selectivity for  bbbbb1 COX-2 eeeee1  than  bbbbb2 celecoxib eeeee2 , meloxicam, diclofenac and indomethacin
CPR:2	Rofecoxib has greater selectivity for  bbbbb1 COX-2 eeeee1  than celecoxib,  bbbbb2 meloxicam eeeee2 , diclofenac and indomethacin
CPR:2	Rofecoxib has greater selectivity for  bbbbb1 COX-2 eeeee1  than celecoxib, meloxicam,  bbbbb2 diclofenac eeeee2  and indomethacin
CPR:2	Rofecoxib has greater selectivity for  bbbbb1 COX-2 eeeee1  than celecoxib, meloxicam, diclofenac and  bbbbb2 indomethacin eeeee2 
CPR:4	 bbbbb1 Rofecoxib eeeee1  is a selective  bbbbb2 cyclo-oxygenase (COX)-2 eeeee2  inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day
CPR:4	 bbbbb1 Rofecoxib eeeee1  has greater selectivity for  bbbbb2 COX-2 eeeee2  than celecoxib, meloxicam, diclofenac and indomethacin
CPR:2	Different forms of therapy,  bbbbb1 potassium eeeee1  and magnesium substitution, spironolactone and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized  bbbbb2 IGF-I eeeee2  levels in the three patients with short stature
CPR:2	Different forms of therapy, potassium and  bbbbb1 magnesium eeeee1  substitution, spironolactone and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized  bbbbb2 IGF-I eeeee2  levels in the three patients with short stature
CPR:2	Different forms of therapy, potassium and magnesium substitution,  bbbbb1 spironolactone eeeee1  and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized  bbbbb2 IGF-I eeeee2  levels in the three patients with short stature
CPR:2	Different forms of therapy, potassium and magnesium substitution, spironolactone and  bbbbb1 indomethacin eeeee1  failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized  bbbbb2 IGF-I eeeee2  levels in the three patients with short stature
CPR:2	To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a  bbbbb1 PPAR-gamma eeeee1 -specific ligand,  bbbbb2 rosiglitazone eeeee2 , and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction
CPR:2	 bbbbb1 Fibrates eeeee1  bind to the  bbbbb2 peroxisome proliferator-activated receptor (PPAR)-alpha eeeee2 , and thiazolidinediones are ligands of PPAR-gamma
CPR:2	Fibrates bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and  bbbbb1 thiazolidinediones eeeee1  are ligands of  bbbbb2 PPAR-gamma eeeee2 
CPR:2	To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a  bbbbb1 PPAR-alpha eeeee1 -specific compound,  bbbbb2 fenofibrate eeeee2 , a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction
CPR:3	 bbbbb1 Fenofibrate eeeee1  and GW2331 induced expression of  bbbbb2 acyl-coenzyme A (CoA) oxidase eeeee2  and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CPR:3	 bbbbb1 Fenofibrate eeeee1  and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and  bbbbb2 enoyl-CoA hydratase eeeee2  and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CPR:3	Fenofibrate and  bbbbb1 GW2331 eeeee1  induced expression of  bbbbb2 acyl-coenzyme A (CoA) oxidase eeeee2  and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CPR:3	Fenofibrate and  bbbbb1 GW2331 eeeee1  induced expression of acyl-coenzyme A (CoA) oxidase and  bbbbb2 enoyl-CoA hydratase eeeee2  and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CPR:3	 bbbbb1 Rosiglitazone eeeee1  modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of  bbbbb2 glucose transporter 4 eeeee2  and phosphoenolpyruvate carboxykinase in adipose tissue
CPR:3	 bbbbb1 Rosiglitazone eeeee1  modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and  bbbbb2 phosphoenolpyruvate carboxykinase eeeee2  in adipose tissue
CPR:3	 bbbbb1 Rosiglitazone eeeee1  modestly increased  bbbbb2 apolipoprotein C-III eeeee2  mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue
CPR:4	 bbbbb1 Fenofibrate eeeee1  and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced  bbbbb2 apolipoprotein C-III eeeee2  and phosphoenolpyruvate carboxykinase mRNAs
CPR:4	 bbbbb1 Fenofibrate eeeee1  and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  bbbbb2 phosphoenolpyruvate carboxykinase eeeee2  mRNAs
CPR:4	Fenofibrate and  bbbbb1 GW2331 eeeee1  induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced  bbbbb2 apolipoprotein C-III eeeee2  and phosphoenolpyruvate carboxykinase mRNAs
CPR:4	Fenofibrate and  bbbbb1 GW2331 eeeee1  induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  bbbbb2 phosphoenolpyruvate carboxykinase eeeee2  mRNAs
CPR:1	We have previously isolated from human hemofiltrate an  bbbbb1 N eeeee1 -terminally truncated form of the  bbbbb2 hemofiltrate CC chemokine 1 eeeee2  (HCC-1), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent CCR3
CPR:1	We have previously isolated from human hemofiltrate an  bbbbb1 N eeeee1 -terminally truncated form of the hemofiltrate CC chemokine 1 ( bbbbb2 HCC-1 eeeee2 ), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent CCR3
CPR:2	 bbbbb1 Long-chain alkanols eeeee1  are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (AChR) by binding to one or more specific sites on the  bbbbb2 AChR eeeee2 
CPR:2	 bbbbb1 Cembranoid eeeee1  and long-chain alkanol sites on the  bbbbb2 nicotinic acetylcholine receptor eeeee2  and their allosteric interaction
CPR:2	Cembranoid and  bbbbb1 long-chain alkanol eeeee1  sites on the  bbbbb2 nicotinic acetylcholine receptor eeeee2  and their allosteric interaction
CPR:4	 bbbbb1 Long-chain alkanols eeeee1  are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral  bbbbb2 nicotinic acetylcholine receptor eeeee2  (AChR) by binding to one or more specific sites on the AChR
CPR:4	 bbbbb1 Cembranoids eeeee1  are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal  bbbbb2 AChRs eeeee2 , which have no demonstrable general anesthetic activity in vivo
CPR:2	The  bbbbb1 x(c)- cystine transporter eeeee1  represents a novel target for  bbbbb2 sulfasalazine eeeee2 -like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.
CPR:4	 bbbbb1 Sulfasalazine eeeee1  was fortuitously found to be a novel, potent inhibitor of the  bbbbb2 x(c)- transporter eeeee2 
CPR:4	It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of  bbbbb1 x(c) eeeee1 --mediated cystine uptake, in contrast to its colonic metabolites,  bbbbb2 sulfapyridine eeeee2  and 5-aminosalicylic acid
CPR:4	It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of  bbbbb1 x(c) eeeee1 --mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and  bbbbb2 5-aminosalicylic acid eeeee2 
CPR:4	 bbbbb1 Sulfasalazine eeeee1 , a potent suppressor of lymphoma growth by inhibition of the  bbbbb2 x(c)- cystine transporter eeeee2 : a new action for an old drug
CPR:9	It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of  bbbbb1 x(c) eeeee1 --mediated  bbbbb2 cystine eeeee2  uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid
CPR:9	The  bbbbb1 x(c)- cystine transporter eeeee1  represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular  bbbbb2 cyst(e)ine eeeee2 .
CPR:3	Like conventional ACE inhibitors,  bbbbb1 omapatrilat eeeee1  causes extracellular volume reduction and vasodilatation; moreover, it increases levels of  bbbbb2 atrial and brain natriuretic peptides eeeee2  and bradykinin
CPR:3	Like conventional ACE inhibitors,  bbbbb1 omapatrilat eeeee1  causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and  bbbbb2 bradykinin eeeee2 
CPR:4	Like conventional  bbbbb1 ACE eeeee1  inhibitors,  bbbbb2 omapatrilat eeeee2  causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin
CPR:4	Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with  bbbbb1 omapatrilat eeeee1 , a  bbbbb2 vasopeptidase eeeee2  inhibitor
CPR:4	 bbbbb1 Omapatrilat eeeee1 , the prototypical  bbbbb2 vasopeptidase eeeee2  inhibitor, inhibits not only ACE but also neutral endopeptidase
CPR:4	 bbbbb1 Omapatrilat eeeee1 , the prototypical vasopeptidase inhibitor, inhibits not only  bbbbb2 ACE eeeee2  but also neutral endopeptidase
CPR:4	 bbbbb1 Omapatrilat eeeee1 , the prototypical vasopeptidase inhibitor, inhibits not only ACE but also  bbbbb2 neutral endopeptidase eeeee2 
CPR:9	The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to  bbbbb1 Na+ eeeee1 -H+ exchange ( bbbbb2 NHE1 eeeee2  isoform)
CPR:9	The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+- bbbbb1 H+ eeeee1  exchange ( bbbbb2 NHE1 eeeee2  isoform)
CPR:10	 bbbbb1 Salicylates eeeee1  inhibited ATPase activity stimulated by this specific heptapeptide but did not block ATP binding or induce  bbbbb2 BiP eeeee2  expression
CPR:2	 bbbbb1 Aspirin eeeee1  and salicylate bind to  bbbbb2 immunoglobulin heavy chain binding protein eeeee2  (BiP) and inhibit its ATPase activity in human fibroblasts
CPR:2	Aspirin and  bbbbb1 salicylate eeeee1  bind to  bbbbb2 immunoglobulin heavy chain binding protein eeeee2  (BiP) and inhibit its ATPase activity in human fibroblasts
CPR:2	Salicylates inhibited  bbbbb1 ATPase eeeee1  activity stimulated by this specific heptapeptide but did not block  bbbbb2 ATP eeeee2  binding or induce BiP expression
CPR:2	These results indicate that  bbbbb1 salicylates eeeee1  bind specifically to the polypeptide binding site of  bbbbb2 BiP eeeee2  in human cells that may interfere with folding and transport of proteins important in inflammation.
CPR:2	The Kd values of  bbbbb1 SA eeeee1  binding to crude extract and to recombinant  bbbbb2 BiP eeeee2  were 45.2 and 54.6 microM, respectively
CPR:4	 bbbbb1 Salicylates eeeee1  inhibited  bbbbb2 ATPase eeeee2  activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression
CPR:4	 bbbbb1 Aspirin eeeee1  and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its  bbbbb2 ATPase eeeee2  activity in human fibroblasts
CPR:4	Aspirin and  bbbbb1 salicylate eeeee1  bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its  bbbbb2 ATPase eeeee2  activity in human fibroblasts
CPR:9	The specific activity of only  bbbbb1 ornithine aminotransferase eeeee1  (OAT), the rate-limiting enzyme in the conversion of ornithine to  bbbbb2 proline eeeee2 , increased in 2 weeks of hypertrophy
CPR:9	The specific activity of only ornithine aminotransferase ( bbbbb1 OAT eeeee1 ), the rate-limiting enzyme in the conversion of ornithine to  bbbbb2 proline eeeee2 , increased in 2 weeks of hypertrophy
CPR:9	The specific activity of only  bbbbb1 ornithine aminotransferase eeeee1  (OAT), the rate-limiting enzyme in the conversion of  bbbbb2 ornithine eeeee2  to proline, increased in 2 weeks of hypertrophy
CPR:9	The specific activity of only ornithine aminotransferase ( bbbbb1 OAT eeeee1 ), the rate-limiting enzyme in the conversion of  bbbbb2 ornithine eeeee2  to proline, increased in 2 weeks of hypertrophy
CPR:2	Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2) and  bbbbb1 thromboxane B2 eeeee1  (as a biomarker for  bbbbb2 COX-1 eeeee2  activity) with parallel assessments of pain
CPR:2	Celecoxib selectively suppressed PGE2 but not  bbbbb1 TxB2 eeeee1  at time points consistent with  bbbbb2 COX-2 eeeee2  activity, while producing analgesia
CPR:4	A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective  bbbbb1 cyclooxygenase (COX)-2 eeeee1  inhibitor ( bbbbb2 celecoxib eeeee2 ) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac)
CPR:4	A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual  bbbbb1 COX-1 eeeee1 /COX-2 inhibitor ( bbbbb2 ketorolac eeeee2 )
CPR:4	A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/ bbbbb1 COX-2 eeeee1  inhibitor ( bbbbb2 ketorolac eeeee2 )
CPR:4	 bbbbb1 Celecoxib eeeee1  selectively suppressed PGE2 but not TxB2 at time points consistent with  bbbbb2 COX-2 eeeee2  activity, while producing analgesia
CPR:9	Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of  bbbbb1 prostaglandin E2 eeeee1  (PGE2; a product of both  bbbbb2 COX-1 eeeee2  and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain
CPR:9	Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of  bbbbb1 prostaglandin E2 eeeee1  (PGE2; a product of both COX-1 and  bbbbb2 COX-2 eeeee2 ) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain
CPR:9	Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ; a product of both  bbbbb2 COX-1 eeeee2  and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain
CPR:9	Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ; a product of both COX-1 and  bbbbb2 COX-2 eeeee2 ) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain
CPR:9	The time course of  bbbbb1 PGE2 eeeee1  production was consistent with early release due to  bbbbb2 COX-1 eeeee2  activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression
CPR:9	The time course of  bbbbb1 PGE2 eeeee1  production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with  bbbbb2 COX-2 eeeee2  expression
CPR:9	Celecoxib selectively suppressed  bbbbb1 PGE2 eeeee1  but not TxB2 at time points consistent with  bbbbb2 COX-2 eeeee2  activity, while producing analgesia
CPR:9	These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of  bbbbb1 COX-2 eeeee1  mediated  bbbbb2 PGE2 eeeee2  is temporally related to NSAID analgesia.
CPR:2	These data indicate that a  bbbbb1 [3H]dofetilide eeeee1  binding assay using  bbbbb2 HERG eeeee2  membranes may help identify compounds that prolong the QT interval.
CPR:2	 bbbbb1 [3H]dofetilide eeeee1  binding to  bbbbb2 HERG eeeee2  transfected membranes: a potential high throughput preclinical screen
CPR:4	Acute and chronic  bbbbb1 PLZ eeeee1  administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme,  bbbbb2 GABA transaminase eeeee2  (GABA-T). 2
CPR:4	Acute and chronic  bbbbb1 PLZ eeeee1  administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase ( bbbbb2 GABA-T eeeee2 ). 2
CPR:4	The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of  bbbbb1 PLZ eeeee1  on  bbbbb2 alanine transaminase eeeee2  (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CPR:4	The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of  bbbbb1 PLZ eeeee1  on alanine transaminase ( bbbbb2 ALA-T eeeee2 ), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CPR:4	In addition, we also showed that the elevation in alanine levels and the inhibition of  bbbbb1 alanine transaminase eeeee1  in the brain are retained after 14 days of  bbbbb2 PLZ eeeee2  treatment, and that PLZ produces a marked increase in extracellular levels of alanine. 5
CPR:9	As with GABA, the metabolism of  bbbbb1 alanine eeeee1  involves a  bbbbb2 pyridoxal phosphate-dependent transaminase eeeee2 . 3
CPR:9	In the study reported here, the effects of acute PLZ treatment on the levels of various  bbbbb1 amino acids eeeee1 , some of which are also metabolized by  bbbbb2 pyridoxal phosphate-dependent transaminases eeeee2  were compared in rat whole brain
CPR:9	In addition, we also showed that the elevation in  bbbbb1 alanine eeeee1  levels and the inhibition of  bbbbb2 alanine transaminase eeeee2  in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine. 5
CPR:9	The elevation in brain  bbbbb1 alanine eeeee1  levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on  bbbbb2 alanine transaminase eeeee2  (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CPR:9	The elevation in brain  bbbbb1 alanine eeeee1  levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase ( bbbbb2 ALA-T eeeee2 ), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CPR:9	Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the  bbbbb1 GABA eeeee1  metabolizing enzyme,  bbbbb2 GABA transaminase eeeee2  (GABA-T). 2
CPR:9	Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the  bbbbb1 GABA eeeee1  metabolizing enzyme, GABA transaminase ( bbbbb2 GABA-T eeeee2 ). 2
CPR:4	 bbbbb1 Cyclooxygenase-1 eeeee1  (COX-1) inhibitors ( bbbbb2 flurbiprofen eeeee2 , ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction
CPR:4	Cyclooxygenase-1 ( bbbbb1 COX-1 eeeee1 ) inhibitors ( bbbbb2 flurbiprofen eeeee2 , ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction
CPR:4	 bbbbb1 Cyclooxygenase-1 eeeee1  (COX-1) inhibitors (flurbiprofen,  bbbbb2 ketoprofen eeeee2  and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction
CPR:4	Cyclooxygenase-1 ( bbbbb1 COX-1 eeeee1 ) inhibitors (flurbiprofen,  bbbbb2 ketoprofen eeeee2  and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction
CPR:4	 bbbbb1 Cyclooxygenase-1 eeeee1  (COX-1) inhibitors (flurbiprofen, ketoprofen and  bbbbb2 ketrolack eeeee2 ) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction
CPR:4	Cyclooxygenase-1 ( bbbbb1 COX-1 eeeee1 ) inhibitors (flurbiprofen, ketoprofen and  bbbbb2 ketrolack eeeee2 ) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction
CPR:4	Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and  bbbbb1 cyclooxygenase-2 eeeee1  (COX-2) inhibitors at high concentrations ( bbbbb2 nimesulide eeeee2  and NS-389) slightly attenuated the contraction
CPR:4	Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 ( bbbbb1 COX-2 eeeee1 ) inhibitors at high concentrations ( bbbbb2 nimesulide eeeee2  and NS-389) slightly attenuated the contraction
CPR:4	Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and  bbbbb1 cyclooxygenase-2 eeeee1  (COX-2) inhibitors at high concentrations (nimesulide and  bbbbb2 NS-389 eeeee2 ) slightly attenuated the contraction
CPR:4	Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 ( bbbbb1 COX-2 eeeee1 ) inhibitors at high concentrations (nimesulide and  bbbbb2 NS-389 eeeee2 ) slightly attenuated the contraction
CPR:4	A  bbbbb1 TXA2 synthetase eeeee1  inhibitor ( bbbbb2 OKY-046 eeeee2 ) attenuated the contraction to a small extent only at high concentrations
CPR:6	A  bbbbb1 TXA2 receptor eeeee1  antagonist ( bbbbb2 S-1452 eeeee2 ) attenuated the contraction in a concentration-dependent manner
CPR:6	A  bbbbb1 nicotinic receptor eeeee1  antagonist ( bbbbb2 hexamethonium eeeee2 ) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction
CPR:6	A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an  bbbbb1 alpha-adrenoceptor eeeee1  antagonist ( bbbbb2 prazosin eeeee2 ) nearly abolished the contraction
CPR:2	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen,  bbbbb2 zomepirac eeeee2 , indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:2	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac,  bbbbb2 indomethacin eeeee2 , diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:2	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin,  bbbbb2 diclofenac eeeee2  and meclofenamic acid were undertaken using the AMBER program
CPR:2	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and  bbbbb2 meclofenamic acid eeeee2  were undertaken using the AMBER program
CPR:2	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands:  bbbbb2 rofecoxib eeeee2 , ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:2	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib,  bbbbb2 ketoprofen eeeee2 , suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:2	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen,  bbbbb2 suprofen eeeee2 , carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:2	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen,  bbbbb2 carprofen eeeee2 , zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:4	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen,  bbbbb2 zomepirac eeeee2 , indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:4	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac,  bbbbb2 indomethacin eeeee2 , diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:4	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin,  bbbbb2 diclofenac eeeee2  and meclofenamic acid were undertaken using the AMBER program
CPR:4	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and  bbbbb2 meclofenamic acid eeeee2  were undertaken using the AMBER program
CPR:4	Non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs (NSAIDs) are competitive inhibitors of  bbbbb2 cyclooxygenase eeeee2  (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid
CPR:4	Non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ( bbbbb2 COX eeeee2 ), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid
CPR:4	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands:  bbbbb2 rofecoxib eeeee2 , ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:4	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib,  bbbbb2 ketoprofen eeeee2 , suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:4	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen,  bbbbb2 suprofen eeeee2 , carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:4	Accordingly, docking of different  bbbbb1 COX eeeee1  inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen,  bbbbb2 carprofen eeeee2 , zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program
CPR:9	Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of  bbbbb1 cyclooxygenase eeeee1  (COX), the enzyme that mediates biosynthesis of  bbbbb2 prostaglandins eeeee2  and thromboxanes from arachidonic acid
CPR:9	Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ( bbbbb1 COX eeeee1 ), the enzyme that mediates biosynthesis of  bbbbb2 prostaglandins eeeee2  and thromboxanes from arachidonic acid
CPR:9	Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of  bbbbb1 cyclooxygenase eeeee1  (COX), the enzyme that mediates biosynthesis of prostaglandins and  bbbbb2 thromboxanes eeeee2  from arachidonic acid
CPR:9	Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ( bbbbb1 COX eeeee1 ), the enzyme that mediates biosynthesis of prostaglandins and  bbbbb2 thromboxanes eeeee2  from arachidonic acid
CPR:9	Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of  bbbbb1 cyclooxygenase eeeee1  (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from  bbbbb2 arachidonic acid eeeee2 
CPR:9	Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ( bbbbb1 COX eeeee1 ), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from  bbbbb2 arachidonic acid eeeee2 
CPR:2	ICI 182,780 (fulvestrant) (Faslodex) and  bbbbb1 ICI 164,384 eeeee1  are competitive inhibitors of estrogen by binding to the  bbbbb2 estrogen receptor eeeee2  (ER)
CPR:2	ICI 182,780 (fulvestrant) (Faslodex) and  bbbbb1 ICI 164,384 eeeee1  are competitive inhibitors of estrogen by binding to the estrogen receptor ( bbbbb2 ER eeeee2 )
CPR:2	ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of  bbbbb1 estrogen eeeee1  by binding to the  bbbbb2 estrogen receptor eeeee2  (ER)
CPR:2	ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of  bbbbb1 estrogen eeeee1  by binding to the estrogen receptor ( bbbbb2 ER eeeee2 )
CPR:2	 bbbbb1 EM-800 eeeee1  and EM-652 are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to  bbbbb2 ER eeeee2 
CPR:2	EM-800 and  bbbbb1 EM-652 eeeee1  are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to  bbbbb2 ER eeeee2 
CPR:2	EM-800 and EM-652 are the most potent pure antiestrogens and  bbbbb1 EM-652 eeeee1  has the highest affinity of all antiestrogens to  bbbbb2 ER eeeee2 
CPR:2	 bbbbb1 ICI 182,780 eeeee1  (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the  bbbbb2 estrogen receptor eeeee2  (ER)
CPR:2	 bbbbb1 ICI 182,780 eeeee1  (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor ( bbbbb2 ER eeeee2 )
CPR:2	ICI 182,780 ( bbbbb1 fulvestrant eeeee1 ) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the  bbbbb2 estrogen receptor eeeee2  (ER)
CPR:2	ICI 182,780 ( bbbbb1 fulvestrant eeeee1 ) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor ( bbbbb2 ER eeeee2 )
CPR:2	ICI 182,780 (fulvestrant) ( bbbbb1 Faslodex eeeee1 ) and ICI 164,384 are competitive inhibitors of estrogen by binding to the  bbbbb2 estrogen receptor eeeee2  (ER)
CPR:2	ICI 182,780 (fulvestrant) ( bbbbb1 Faslodex eeeee1 ) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor ( bbbbb2 ER eeeee2 )
CPR:10	 bbbbb1 Olopatadine eeeee1  exerted no significant effects on action potential duration in isolated guinea pig ventricular myocytes, myocardium and  bbbbb2 human ether-a-go-go-related gene channel eeeee2 
CPR:6	Olopatadine hydrochloride ( bbbbb1 olopatadine eeeee1 , 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/ bbbbb2 histamine H1-receptor eeeee2  antagonistic drug that was synthesized and evaluated in our laboratories
CPR:6	Olopatadine hydrochloride (olopatadine,  bbbbb1 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride eeeee1 ) is a novel antiallergic/ bbbbb2 histamine H1-receptor eeeee2  antagonistic drug that was synthesized and evaluated in our laboratories
CPR:6	 bbbbb1 Olopatadine eeeee1  is a selective  bbbbb2 histamine H1-receptor eeeee2  antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils
CPR:6	 bbbbb1 Olopatadine hydrochloride eeeee1  (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/ bbbbb2 histamine H1-receptor eeeee2  antagonistic drug that was synthesized and evaluated in our laboratories
CPR:2	Considerable evidence indicates that serotonergic mechanisms, particularly the serotonin transporter ( bbbbb1 5HTT eeeee1 ), may mediate central effects of  bbbbb2 cocaine eeeee2  and may also be involved in impulsive and aggressive behavior
CPR:2	Considerable evidence indicates that serotonergic mechanisms, particularly the  bbbbb1 serotonin transporter eeeee1  (5HTT), may mediate central effects of  bbbbb2 cocaine eeeee2  and may also be involved in impulsive and aggressive behavior
CPR:2	Thus we have shown that low-dose theophylline exerts an anti-asthma effect through increasing activation of  bbbbb1 HDAC eeeee1  which is subsequently recruited by  bbbbb2 corticosteroids eeeee2  to suppress inflammatory genes.
CPR:2	 bbbbb1 Corticosteroids eeeee1  act, at least in part, by recruitment of  bbbbb2 histone deacetylases eeeee2  (HDACs) to the site of active inflammatory gene transcription
CPR:2	 bbbbb1 Corticosteroids eeeee1  act, at least in part, by recruitment of histone deacetylases ( bbbbb2 HDACs eeeee2 ) to the site of active inflammatory gene transcription
CPR:2	This increased  bbbbb1 HDAC eeeee1  activity is then available for  bbbbb2 corticosteroid eeeee2  recruitment and predicts a cooperative interaction between corticosteroids and theophylline
CPR:3	A molecular mechanism of action of  bbbbb1 theophylline eeeee1 : Induction of  bbbbb2 histone deacetylase eeeee2  activity to decrease inflammatory gene expression
CPR:3	Thus we have shown that low-dose  bbbbb1 theophylline eeeee1  exerts an anti-asthma effect through increasing activation of  bbbbb2 HDAC eeeee2  which is subsequently recruited by corticosteroids to suppress inflammatory genes.
CPR:3	We show both in vitro and in vivo that low-dose  bbbbb1 theophylline eeeee1  enhances  bbbbb2 HDAC eeeee2  activity in epithelial cells and macrophages
CPR:2	In conclusion, these results show that  bbbbb1 rifamycin SV eeeee1  and rifampicin interact with  bbbbb2 OATP eeeee2 -mediated substrate transport to different extents
CPR:2	In conclusion, these results show that rifamycin SV and  bbbbb1 rifampicin eeeee1  interact with  bbbbb2 OATP eeeee2 -mediated substrate transport to different extents
CPR:4	Inhibition of  bbbbb1 human liver OATPs eeeee1  can explain the previously observed effects of  bbbbb2 rifamycin SV eeeee2  and rifampicin on hepatic organic anion elimination.
CPR:4	Inhibition of  bbbbb1 human liver OATPs eeeee1  can explain the previously observed effects of rifamycin SV and  bbbbb2 rifampicin eeeee2  on hepatic organic anion elimination.
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited  bbbbb2 human organic anion transporting polypeptide C eeeee2  (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C ( bbbbb2 SLC21A6 eeeee2 ) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) ( bbbbb2 OATP-C eeeee2 ), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C),  bbbbb2 human organic anion transporting polypeptide 8 eeeee2  (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 ( bbbbb2 SLC21A8 eeeee2 ) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) ( bbbbb2 OATP8 eeeee2 ), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8),  bbbbb2 human organic anion transporting polypeptide B eeeee2  (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B ( bbbbb2 SLC21A9 eeeee2 ) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) ( bbbbb2 OATP-B eeeee2 ), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and  bbbbb2 human organic anion transporting polypeptide A eeeee2  (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A ( bbbbb2 SLC21A3 eeeee2 ) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	In complementary RNA (cRNA)-injected Xenopus laevis oocytes,  bbbbb1 rifamycin SV eeeee1  (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) ( bbbbb2 OATP-A eeeee2 ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes
CPR:4	 bbbbb1 Rifampicin eeeee1  (10 micromol/L) inhibited  bbbbb2 OATP8 eeeee2 -mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:4	 bbbbb1 Rifampicin eeeee1  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of  bbbbb2 OATP-C eeeee2 -, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:4	 bbbbb1 Rifampicin eeeee1  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-,  bbbbb2 OATP-B eeeee2 -, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:4	 bbbbb1 Rifampicin eeeee1  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and  bbbbb2 OATP-A eeeee2 -mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:4	In rats,  bbbbb1 rifamycin SV eeeee1  and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the  bbbbb2 organic anion transporting polypeptides eeeee2  Oatp1 and Oatp2
CPR:4	In rats,  bbbbb1 rifamycin SV eeeee1  and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides  bbbbb2 Oatp1 eeeee2  and Oatp2
CPR:4	In rats,  bbbbb1 rifamycin SV eeeee1  and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and  bbbbb2 Oatp2 eeeee2 
CPR:4	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L  bbbbb1 rifampicin eeeee1  inhibited  bbbbb2 OATP-C eeeee2 - and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:4	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L  bbbbb1 rifampicin eeeee1  inhibited OATP-C- and  bbbbb2 OATP8 eeeee2 -, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:4	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L  bbbbb1 rifampicin eeeee1  inhibited OATP-C- and OATP8-,  bbbbb2 OATP-B eeeee2 - and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:4	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L  bbbbb1 rifampicin eeeee1  inhibited OATP-C- and OATP8-, OATP-B- and  bbbbb2 OATP-A eeeee2 -mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:4	In rats, rifamycin SV and  bbbbb1 rifampicin eeeee1  were shown to interfere with hepatic organic anion uptake by inhibition of the  bbbbb2 organic anion transporting polypeptides eeeee2  Oatp1 and Oatp2
CPR:4	In rats, rifamycin SV and  bbbbb1 rifampicin eeeee1  were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides  bbbbb2 Oatp1 eeeee2  and Oatp2
CPR:4	In rats, rifamycin SV and  bbbbb1 rifampicin eeeee1  were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and  bbbbb2 Oatp2 eeeee2 
CPR:9	Rifampicin (10 micromol/L) inhibited  bbbbb1 OATP8 eeeee1 -mediated  bbbbb2 BSP eeeee2  uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:9	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of  bbbbb1 OATP-C eeeee1 -, OATP-B-, and OATP-A-mediated  bbbbb2 BSP eeeee2  transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:9	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-,  bbbbb1 OATP-B eeeee1 -, and OATP-A-mediated  bbbbb2 BSP eeeee2  transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:9	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and  bbbbb1 OATP-A eeeee1 -mediated  bbbbb2 BSP eeeee2  transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CPR:9	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited  bbbbb1 OATP-C eeeee1 - and OATP8-, OATP-B- and OATP-A-mediated  bbbbb2 BSP eeeee2  uptake by 66%, 96%, 25%, and 49%, respectively
CPR:9	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and  bbbbb1 OATP8 eeeee1 -, OATP-B- and OATP-A-mediated  bbbbb2 BSP eeeee2  uptake by 66%, 96%, 25%, and 49%, respectively
CPR:9	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-,  bbbbb1 OATP-B eeeee1 - and OATP-A-mediated  bbbbb2 BSP eeeee2  uptake by 66%, 96%, 25%, and 49%, respectively
CPR:9	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and  bbbbb1 OATP-A eeeee1 -mediated  bbbbb2 BSP eeeee2  uptake by 66%, 96%, 25%, and 49%, respectively
CPR:9	Direct transport of  bbbbb1 rifampicin eeeee1  could be shown for  bbbbb2 OATP-C eeeee2  (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L)
CPR:9	Direct transport of  bbbbb1 rifampicin eeeee1  could be shown for OATP-C (apparent K(m) value 13 micromol/L) and  bbbbb2 OATP8 eeeee2  (2.3 micromol/L)
CPR:2	The increase in  bbbbb1 AMPK alpha2 eeeee1  activity was likely due to a change in muscle energy status because  bbbbb2 ATP eeeee2  and phosphocreatine concentrations were lower after metformin treatment
CPR:2	The increase in  bbbbb1 AMPK alpha2 eeeee1  activity was likely due to a change in muscle energy status because ATP and  bbbbb2 phosphocreatine eeeee2  concentrations were lower after metformin treatment
CPR:3	We recently reported that  bbbbb1 AMPK eeeee1  is activated by  bbbbb2 metformin eeeee2  in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production
CPR:3	In the present study, we evaluated whether therapeutic doses of  bbbbb1 metformin eeeee1  increase  bbbbb2 AMPK eeeee2  activity in vivo in subjects with type 2 diabetes
CPR:3	 bbbbb1 Metformin eeeee1  treatment for 10 weeks significantly increased  bbbbb2 AMPK alpha2 eeeee2  activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity
CPR:3	 bbbbb1 Metformin eeeee1  treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of  bbbbb2 AMPK eeeee2  on Thr172 and decreased acetyl-CoA carboxylase-2 activity
CPR:3	 bbbbb1 Metformin eeeee1  increases  bbbbb2 AMP-activated protein kinase eeeee2  activity in skeletal muscle of subjects with type 2 diabetes
CPR:3	The increase in  bbbbb1 AMPK alpha2 eeeee1  activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after  bbbbb2 metformin eeeee2  treatment
CPR:3	 bbbbb1 Metformin eeeee1 -induced increases in  bbbbb2 AMPK eeeee2  activity were associated with higher rates of glucose disposal and muscle glycogen concentrations
CPR:4	 bbbbb1 Metformin eeeee1  treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased  bbbbb2 acetyl-CoA carboxylase-2 eeeee2  activity
CPR:9	 bbbbb1 AMP-activated protein kinase eeeee1  (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of  bbbbb2 glucose eeeee2  uptake into skeletal muscle and the inhibition of liver gluconeogenesis
CPR:9	AMP-activated protein kinase ( bbbbb1 AMPK eeeee1 ) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of  bbbbb2 glucose eeeee2  uptake into skeletal muscle and the inhibition of liver gluconeogenesis
CPR:2	BACKGROUND & AIMS: Sensitization of Kupffer cells (KCs) to lipopolysaccharide (LPS) and overproduction of  bbbbb1 tumor necrosis factor (TNF) alpha eeeee1  are critical for progression of  bbbbb2 alcoholic eeeee2  liver injury
CPR:4	CONCLUSIONS: These results collectively indicate that  bbbbb1 thalidomide eeeee1  prevents alcoholic liver injury through suppression of  bbbbb2 TNF-alpha eeeee2  production and abolishment of KC sensitization.
CPR:4	 bbbbb1 Thalidomide eeeee1  has been shown to suppress  bbbbb2 TNF-alpha eeeee2  production from macrophages
CPR:4	 bbbbb1 Thalidomide eeeee1  prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and  bbbbb2 TNF-alpha eeeee2  production
CPR:4	Furthermore,  bbbbb1 thalidomide eeeee1  abolished the LPS-induced increase in  bbbbb2 CD14 eeeee2  expression and [Ca2+]i elevation in KCs
CPR:4	Moreover,  bbbbb1 thalidomide eeeee1  reduced the LPS-induced  bbbbb2 TNF-alpha eeeee2  production by KCs by decreasing TNF-alpha messenger RNA
CPR:4	Moreover,  bbbbb1 thalidomide eeeee1  reduced the LPS-induced TNF-alpha production by KCs by decreasing  bbbbb2 TNF-alpha eeeee2  messenger RNA
CPR:10	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified  bbbbb1 oxidase eeeee1  strongly favoured spermine over N (1)-acetylspermine and that it failed to act on  bbbbb2 N (1)-acetylspermidine eeeee2 , spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CPR:10	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified  bbbbb1 oxidase eeeee1  strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine,  bbbbb2 spermidine eeeee2  or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CPR:1	A BLAST search using  bbbbb1 maize PAO eeeee1  sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20  bbbbb2 amino acids eeeee2 
CPR:1	Identification and characterization of a novel  bbbbb1 flavin eeeee1 -containing  bbbbb2 spermine oxidase eeeee2  of mammalian cell origin
CPR:4	The  bbbbb1 PAO eeeee1  inhibitor,  bbbbb2 MDL-72,527 eeeee2 , only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction
CPR:9	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb1 polyamine oxidase eeeee1  (PAO) to produce  bbbbb2 spermidine eeeee2  and putrescine, respectively
CPR:9	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( bbbbb1 PAO eeeee1 ) to produce  bbbbb2 spermidine eeeee2  and putrescine, respectively
CPR:9	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb1 polyamine oxidase eeeee1  (PAO) to produce spermidine and  bbbbb2 putrescine eeeee2 , respectively
CPR:9	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( bbbbb1 PAO eeeee1 ) to produce spermidine and  bbbbb2 putrescine eeeee2 , respectively
CPR:9	During polyamine catabolism,  bbbbb1 spermine eeeee1  and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase ( bbbbb2 SSAT eeeee2 ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CPR:9	During polyamine catabolism,  bbbbb1 spermine eeeee1  and spermidine are first acetylated by  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CPR:9	In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves  bbbbb1 spermine eeeee1  in the absence of prior acetylation by  bbbbb2 SSAT eeeee2 
CPR:9	During polyamine catabolism, spermine and  bbbbb1 spermidine eeeee1  are first acetylated by spermidine/spermine N(1)-acetyltransferase ( bbbbb2 SSAT eeeee2 ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CPR:9	During polyamine catabolism, spermine and  bbbbb1 spermidine eeeee1  are first acetylated by  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CPR:9	During  bbbbb1 polyamine eeeee1  catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase ( bbbbb2 SSAT eeeee2 ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CPR:9	During  bbbbb1 polyamine eeeee1  catabolism, spermine and spermidine are first acetylated by  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CPR:9	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified  bbbbb1 oxidase eeeee1  strongly favoured  bbbbb2 spermine eeeee2  over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CPR:9	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified  bbbbb1 oxidase eeeee1  strongly favoured spermine over  bbbbb2 N (1)-acetylspermine eeeee2  and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CPR:9	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred  bbbbb1 PAO eeeee1  substrate,  bbbbb2 N (1), N (12)-diacetylspermine eeeee2 
CPR:9	The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported  bbbbb1 PAO eeeee1  substrate,  bbbbb2 N (1)-( n -octanesulphonyl)spermine eeeee2 , potently inhibited the reaction
CPR:10	A moderate (twofold) stimulation of  bbbbb1 CD62P eeeee1  expression by abciximab but not by  bbbbb2 tirofiban eeeee2  or eptifibatide was observed in one patient
CPR:10	A moderate (twofold) stimulation of  bbbbb1 CD62P eeeee1  expression by abciximab but not by tirofiban or  bbbbb2 eptifibatide eeeee2  was observed in one patient
CPR:3	In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or  bbbbb1 ADP eeeee1 -stimulated  bbbbb2 CD62P eeeee2  expression
CPR:3	Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or  bbbbb1 ADP eeeee1 -induced  bbbbb2 CD62P eeeee2  expression
CPR:1	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  bbbbb1 beta-lyases eeeee1  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with  bbbbb2 epsilon-amino eeeee2  groups of lysine residues in proteins
CPR:1	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  bbbbb1 beta-lyases eeeee1  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of  bbbbb2 lysine eeeee2  residues in proteins
CPR:9	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  bbbbb1 beta-lyases eeeee1  to  bbbbb2 pyruvate eeeee2 , ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CPR:9	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  bbbbb1 beta-lyases eeeee1  to pyruvate,  bbbbb2 ammonia eeeee2 , and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CPR:9	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  bbbbb1 beta-lyases eeeee1  to pyruvate, ammonia, and an  bbbbb2 alpha-chloroenethiolate eeeee2  (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CPR:9	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  bbbbb1 beta-lyases eeeee1  to pyruvate, ammonia, and an alpha-chloroenethiolate (with  bbbbb2 DCVC eeeee2 ) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CPR:9	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  bbbbb1 beta-lyases eeeee1  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an  bbbbb2 alpha-difluoroalkylthiolate eeeee2  (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CPR:9	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate  bbbbb1 beta-lyases eeeee1  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with  bbbbb2 TFEC eeeee2 ) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CPR:9	Most halogenated  bbbbb1 cysteine S-conjugates eeeee1  are metabolized by cysteine S-conjugate  bbbbb2 beta-lyases eeeee2  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CPR:9	The juvenile visceral steatosis (jvs) mouse, having a mutation in the  bbbbb1 carnitine eeeee1  transporter gene  bbbbb2 Octn2 eeeee2 , is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140)
CPR:10	However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of  bbbbb1 MPP+ eeeee1 , indicating the NAT and not an  bbbbb2 OCT eeeee2  as their primary site of action
CPR:10	No trans-stimulation of  bbbbb1 [3H]-MPP+ eeeee1  outflow was observed by the  bbbbb2 OCTN1 eeeee2  and OCTN2 substrate carnitine at 100 microM
CPR:10	No trans-stimulation of  bbbbb1 [3H]-MPP+ eeeee1  outflow was observed by the OCTN1 and  bbbbb2 OCTN2 eeeee2  substrate carnitine at 100 microM
CPR:4	The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the  bbbbb1 OCT3 eeeee1  inhibitors cyanine 863,  bbbbb2 oestradiol eeeee2  and corticosterone
CPR:4	The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the  bbbbb1 OCT3 eeeee1  inhibitors cyanine 863, oestradiol and  bbbbb2 corticosterone eeeee2 
CPR:9	However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of  bbbbb1 MPP+ eeeee1 , indicating the  bbbbb2 NAT eeeee2  and not an OCT as their primary site of action
CPR:9	Our observations indicate an  bbbbb1 OCT eeeee1 -mediated transmembrane transport of  bbbbb2 [3H]-MPP+ eeeee2 
CPR:9	Amongst the three  bbbbb1 OCTs eeeee1  expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of  bbbbb2 [3H]-MPP+ eeeee2  release.
CPR:9	Amongst the three OCTs expressed in the SCG,  bbbbb1 OCT3 eeeee1  best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of  bbbbb2 [3H]-MPP+ eeeee2  release.
CPR:9	Reuptake of extracellular  bbbbb1 noradrenaline eeeee1  (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the  bbbbb2 noradrenaline transporter eeeee2  (NAT, uptake 1)
CPR:9	Reuptake of extracellular  bbbbb1 noradrenaline eeeee1  (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter ( bbbbb2 NAT eeeee2 , uptake 1)
CPR:9	Reuptake of extracellular noradrenaline ( bbbbb1 NA eeeee1 ) into superior cervical ganglion (SCG) neurones is mediated by means of the  bbbbb2 noradrenaline transporter eeeee2  (NAT, uptake 1)
CPR:9	Reuptake of extracellular noradrenaline ( bbbbb1 NA eeeee1 ) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter ( bbbbb2 NAT eeeee2 , uptake 1)
CPR:9	The outflow of  bbbbb1 [3H]-MPP+ eeeee1  was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for  bbbbb2 OCT eeeee2 -related transmembrane transporters
CPR:9	The outflow of  bbbbb1 [3H]-MPP+ eeeee1  was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related  bbbbb2 transmembrane transporters eeeee2 
CPR:9	The outflow of [3H]-MPP+ was significantly enhanced by  bbbbb1 MPP+ eeeee1 , guanidine, choline and amantadine as potential substrates for  bbbbb2 OCT eeeee2 -related transmembrane transporters
CPR:9	The outflow of [3H]-MPP+ was significantly enhanced by  bbbbb1 MPP+ eeeee1 , guanidine, choline and amantadine as potential substrates for OCT-related  bbbbb2 transmembrane transporters eeeee2 
CPR:9	The outflow of [3H]-MPP+ was significantly enhanced by MPP+,  bbbbb1 guanidine eeeee1 , choline and amantadine as potential substrates for  bbbbb2 OCT eeeee2 -related transmembrane transporters
CPR:9	The outflow of [3H]-MPP+ was significantly enhanced by MPP+,  bbbbb1 guanidine eeeee1 , choline and amantadine as potential substrates for OCT-related  bbbbb2 transmembrane transporters eeeee2 
CPR:9	The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine,  bbbbb1 choline eeeee1  and amantadine as potential substrates for  bbbbb2 OCT eeeee2 -related transmembrane transporters
CPR:9	The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine,  bbbbb1 choline eeeee1  and amantadine as potential substrates for OCT-related  bbbbb2 transmembrane transporters eeeee2 
CPR:9	The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and  bbbbb1 amantadine eeeee1  as potential substrates for  bbbbb2 OCT eeeee2 -related transmembrane transporters
CPR:9	The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and  bbbbb1 amantadine eeeee1  as potential substrates for OCT-related  bbbbb2 transmembrane transporters eeeee2 
CPR:3	Long-term administration of  bbbbb1 propargylamines eeeee1  to rats increased the activities of antioxidative enzymes  bbbbb2 superoxide dismutase eeeee2  (SOD) and catalase in the brain regions containing dopamine neurons
CPR:3	Long-term administration of  bbbbb1 propargylamines eeeee1  to rats increased the activities of antioxidative enzymes superoxide dismutase ( bbbbb2 SOD eeeee2 ) and catalase in the brain regions containing dopamine neurons
CPR:3	Long-term administration of  bbbbb1 propargylamines eeeee1  to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and  bbbbb2 catalase eeeee2  in the brain regions containing dopamine neurons
CPR:3	 bbbbb1 Rasagiline eeeee1  prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic  bbbbb2 Bcl-2 eeeee2  and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF)
CPR:3	 bbbbb1 Rasagiline eeeee1  prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a  bbbbb2 neurotrophic factor eeeee2 , glial cell line-derived neurotrophic factor (GDNF)
CPR:3	 bbbbb1 Rasagiline eeeee1  prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor,  bbbbb2 glial cell line-derived neurotrophic factor eeeee2  (GDNF)
CPR:3	 bbbbb1 Rasagiline eeeee1  prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor ( bbbbb2 GDNF eeeee2 )
CPR:4	An inhibitor of  bbbbb1 type B monoamine oxidase eeeee1  (MAO-B),  bbbbb2 (-)deprenyl eeeee2  (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it
CPR:4	An inhibitor of type B monoamine oxidase ( bbbbb1 MAO-B eeeee1 ),  bbbbb2 (-)deprenyl eeeee2  (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it
CPR:4	An inhibitor of  bbbbb1 type B monoamine oxidase eeeee1  (MAO-B), (-)deprenyl ( bbbbb2 selegiline eeeee2 ), was reported to have neuroprotective activity, but clinical trials failed to confirm it
CPR:4	An inhibitor of type B monoamine oxidase ( bbbbb1 MAO-B eeeee1 ), (-)deprenyl ( bbbbb2 selegiline eeeee2 ), was reported to have neuroprotective activity, but clinical trials failed to confirm it
CPR:2	These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to  bbbbb1 PBZ eeeee1  of the  bbbbb2 cyclo-oxygenase eeeee2  (COX) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors
CPR:2	These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to  bbbbb1 PBZ eeeee1  of the cyclo-oxygenase ( bbbbb2 COX eeeee2 ) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors
CPR:2	These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to  bbbbb1 PBZ eeeee1  of the cyclo-oxygenase (COX) isoenzymes,  bbbbb2 COX-1 eeeee2  and COX-2 or; (d) a combination of these factors
CPR:2	These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to  bbbbb1 PBZ eeeee1  of the cyclo-oxygenase (COX) isoenzymes, COX-1 and  bbbbb2 COX-2 eeeee2  or; (d) a combination of these factors
CPR:6	A streamlined and high-yielding synthesis of  bbbbb1 aprepitant eeeee1  (1), a potent  bbbbb2 substance P (SP) receptor eeeee2  antagonist, is described
CPR:6	Practical asymmetric synthesis of  bbbbb1 aprepitant eeeee1 , a potent human  bbbbb2 NK-1 receptor eeeee2  antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction
CPR:2	Pentosan polysulfate  bbbbb1 sodium eeeee1  (PPS) has been shown to exert antitumor activity by antagonizing the binding of  bbbbb2 bFGF eeeee2  to cell surface receptors
CPR:6	Pentosan polysulfate  bbbbb1 sodium eeeee1  (PPS) has been shown to exert antitumor activity by antagonizing the binding of  bbbbb2 bFGF eeeee2  to cell surface receptors
CPR:2	Colocalization of  bbbbb1 RhBG eeeee1  with carbonic anhydrase II, the  bbbbb2 thiazide eeeee2 -sensitive transporter, and the anion exchangers AE1 and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells
CPR:9	These findings suggest that  bbbbb1 RhBG eeeee1  and RhCG may play important and cell-specific roles in  bbbbb2 ammonium eeeee2  transport and signaling in these regions of the kidney.
CPR:9	These findings suggest that RhBG and  bbbbb1 RhCG eeeee1  may play important and cell-specific roles in  bbbbb2 ammonium eeeee2  transport and signaling in these regions of the kidney.
CPR:4	This approach is validated by the clinical efficacy and safety of  bbbbb1 sildenafil eeeee1 , the pioneering drug for selective  bbbbb2 PDE5 eeeee2  inhibitor therapy for ED
CPR:4	 bbbbb1 Sildenafil eeeee1  exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant  bbbbb2 PDE eeeee2  in the phototransduction cascade in rods
CPR:4	 bbbbb1 Sildenafil eeeee1  exhibits inhibitory potency against  bbbbb2 PDE5 eeeee2  and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods
CPR:4	 bbbbb1 Sildenafil eeeee1  exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment  bbbbb2 PDE6 eeeee2 , the predominant PDE in the phototransduction cascade in rods
CPR:4	As free  bbbbb1 sildenafil eeeee1  plasma concentrations approach concentrations sufficient to inhibit retinal  bbbbb2 PDE6 eeeee2 , usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently
CPR:4	Selective inhibition of  bbbbb1 PDE5 eeeee1  is a rational therapeutic approach in ED, as proved by the clinical success of  bbbbb2 sildenafil eeeee2 .
CPR:4	Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of  bbbbb1 cGMP eeeee1 -specific  bbbbb2 PDE5 eeeee2  is a means of improving erectile function at minimal risk of adverse events
CPR:9	 bbbbb1 PDE5 eeeee1  is the predominant PDE in the corpus cavernosum, and  bbbbb2 cGMP eeeee2  is its primary substrate
CPR:9	PDE5 is the predominant  bbbbb1 PDE eeeee1  in the corpus cavernosum, and  bbbbb2 cGMP eeeee2  is its primary substrate
CPR:10	These two alleles were shown previously to be associated with  bbbbb1 ivermectin eeeee1  susceptibility (HG1A) and resistance ( bbbbb2 HG1E eeeee2 ), respectively
CPR:2	These two alleles were shown previously to be associated with  bbbbb1 ivermectin eeeee1  susceptibility ( bbbbb2 HG1A eeeee2 ) and resistance (HG1E), respectively
CPR:2	Study of the nematode putative  bbbbb1 GABA type-A receptor eeeee1  subunits: evidence for modulation by  bbbbb2 ivermectin eeeee2 
CPR:2	However, when coapplied with 10 micro m GABA, ivermectin potentiated the  bbbbb1 GABA eeeee1 -evoked current of the  bbbbb2 GAB-1 eeeee2 /HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor
CPR:2	However, when coapplied with 10 micro m GABA, ivermectin potentiated the  bbbbb1 GABA eeeee1 -evoked current of the GAB-1/ bbbbb2 HG1A eeeee2  receptor, but attenuated the GABA response of the GAB-1/HG1E receptor
CPR:2	However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the  bbbbb1 GABA eeeee1  response of the  bbbbb2 GAB-1 eeeee2 /HG1E receptor
CPR:2	However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the  bbbbb1 GABA eeeee1  response of the GAB-1/ bbbbb2 HG1E eeeee2  receptor
CPR:2	We demonstrated that the coexpressed  bbbbb1 HG1 eeeee1  and GAB-1 receptors are  bbbbb2 GABA eeeee2 -responsive, and provide evidence for the possible involvement of GABA receptors in the mechanism of ivermectin resistance.
CPR:2	We demonstrated that the coexpressed HG1 and  bbbbb1 GAB-1 eeeee1  receptors are  bbbbb2 GABA eeeee2 -responsive, and provide evidence for the possible involvement of GABA receptors in the mechanism of ivermectin resistance.
CPR:2	We demonstrated that the coexpressed HG1 and GAB-1 receptors are GABA-responsive, and provide evidence for the possible involvement of  bbbbb1 GABA receptors eeeee1  in the mechanism of  bbbbb2 ivermectin eeeee2  resistance.
CPR:3	However, when coapplied with 10 micro m GABA,  bbbbb1 ivermectin eeeee1  potentiated the GABA-evoked current of the  bbbbb2 GAB-1 eeeee2 /HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor
CPR:3	However, when coapplied with 10 micro m GABA,  bbbbb1 ivermectin eeeee1  potentiated the GABA-evoked current of the GAB-1/ bbbbb2 HG1A eeeee2  receptor, but attenuated the GABA response of the GAB-1/HG1E receptor
CPR:4	However, when coapplied with 10 micro m GABA,  bbbbb1 ivermectin eeeee1  potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the  bbbbb2 GAB-1 eeeee2 /HG1E receptor
CPR:4	However, when coapplied with 10 micro m GABA,  bbbbb1 ivermectin eeeee1  potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/ bbbbb2 HG1E eeeee2  receptor
CPR:2	Each dimeric analog showed higher affinities for alpha2A- and alpha2C-adrenoceptor versus the alpha2B-adrenoceptor; and  bbbbb1 yohimbine eeeee1  dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the  bbbbb2 alpha2C-adrenoceptor eeeee2 
CPR:2	The  bbbbb1 yohimbine eeeee1  dimers n = 3 and n = 24 showed the highest potency and selectivity (32- and 82-fold. respectively) for the  bbbbb2 alpha2C-adrenoceptor eeeee2  in receptor binding and in functional studies (42- and 29-fold, respectively) measuring cAMP changes using a cell-based luciferase reporter gene assay
CPR:2	These findings demonstrate that the addition of spacer linkages to bivalent  bbbbb1 yohimbine eeeee1  molecules provides a successful approach to the development of ligands that are potent and highly selective for the  bbbbb2 alpha2C-adrenoceptor eeeee2 .
CPR:2	Initial studies showed that  bbbbb1 yohimbine eeeee1  was about 4- and 15-fold more selective for the  bbbbb2 human alpha2C-adrenoceptor eeeee2  in comparison with the alpha2A- and alpha2B-adrenoceptors, respectively
CPR:2	 bbbbb1 Yohimbine eeeee1  dimers exhibiting selectivity for the  bbbbb2 human alpha 2C-adrenoceptor eeeee2  subtype
CPR:6	 bbbbb1 Yohimbine eeeee1  is a potent and selective  bbbbb2 alpha2- versus alpha1-adrenoceptor eeeee2  antagonist
CPR:2	These results demonstrate that  bbbbb1 imidazoquinoline eeeee1  molecules directly induce pDC maturation as determined by cytokine induction,  bbbbb2 CCR7 eeeee2  and co-stimulatory marker expression and prolonging viability.
CPR:2	Plasmacytoid dendritic cells produce  bbbbb1 cytokines eeeee1  and mature in response to the TLR7 agonists, imiquimod and  bbbbb2 resiquimod eeeee2 
CPR:2	Plasmacytoid dendritic cells produce  bbbbb1 cytokines eeeee1  and mature in response to the TLR7 agonists,  bbbbb2 imiquimod eeeee2  and resiquimod
CPR:2	Results indicate that  bbbbb1 imiquimod eeeee1  and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle  bbbbb2 IFN eeeee2 -producing cells in the blood
CPR:2	Results indicate that imiquimod and  bbbbb1 resiquimod eeeee1  induce  bbbbb2 IFN-alpha eeeee2  and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood
CPR:2	Results indicate that imiquimod and  bbbbb1 resiquimod eeeee1  induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle  bbbbb2 IFN eeeee2 -producing cells in the blood
CPR:3	These results demonstrate that  bbbbb1 imidazoquinoline eeeee1  molecules directly induce pDC maturation as determined by  bbbbb2 cytokine eeeee2  induction, CCR7 and co-stimulatory marker expression and prolonging viability.
CPR:3	The immune response modifiers,  bbbbb1 imiquimod eeeee1  and resiquimod, are TLR7 agonists that induce  bbbbb2 type I interferon eeeee2  in numerous species, including humans
CPR:3	Results indicate that  bbbbb1 imiquimod eeeee1  and resiquimod induce  bbbbb2 IFN-alpha eeeee2  and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood
CPR:3	Results indicate that  bbbbb1 imiquimod eeeee1  and resiquimod induce IFN-alpha and  bbbbb2 IFN-omega eeeee2  from purified pDC, and pDC are the principle IFN-producing cells in the blood
CPR:3	The immune response modifiers, imiquimod and  bbbbb1 resiquimod eeeee1 , are TLR7 agonists that induce  bbbbb2 type I interferon eeeee2  in numerous species, including humans
CPR:3	 bbbbb1 Resiquimod eeeee1 -stimulated pDC also produce a number of other  bbbbb2 cytokines eeeee2  including TNF-alpha and IP-10
CPR:3	 bbbbb1 Resiquimod eeeee1 -stimulated pDC also produce a number of other cytokines including  bbbbb2 TNF-alpha eeeee2  and IP-10
CPR:3	 bbbbb1 Resiquimod eeeee1 -stimulated pDC also produce a number of other cytokines including TNF-alpha and  bbbbb2 IP-10 eeeee2 
CPR:3	 bbbbb1 Resiquimod eeeee1  enhances co-stimulatory marker expression,  bbbbb2 CCR7 eeeee2  expression, and pDC viability
CPR:5	Plasmacytoid dendritic cells produce cytokines and mature in response to the  bbbbb1 TLR7 eeeee1  agonists, imiquimod and  bbbbb2 resiquimod eeeee2 
CPR:5	Plasmacytoid dendritic cells produce cytokines and mature in response to the  bbbbb1 TLR7 eeeee1  agonists,  bbbbb2 imiquimod eeeee2  and resiquimod
CPR:5	The immune response modifiers,  bbbbb1 imiquimod eeeee1  and resiquimod, are  bbbbb2 TLR7 eeeee2  agonists that induce type I interferon in numerous species, including humans
CPR:5	Here, we characterize the activation of human pDC with the  bbbbb1 TLR7 eeeee1  agonists  bbbbb2 imiquimod eeeee2  and resiquimod
CPR:5	Here, we characterize the activation of human pDC with the  bbbbb1 TLR7 eeeee1  agonists imiquimod and  bbbbb2 resiquimod eeeee2 
CPR:5	The immune response modifiers, imiquimod and  bbbbb1 resiquimod eeeee1 , are  bbbbb2 TLR7 eeeee2  agonists that induce type I interferon in numerous species, including humans
CPR:2	It is suggested that HSP expression at the time of  bbbbb1 H2O2 eeeee1  exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro-survival  bbbbb2 Akt eeeee2 .
CPR:3	 bbbbb1 H2O2 eeeee1  caused cell loss and increased cell death with features of apoptosis, i.e. TdT-mediated dUTP nick-end labelling (TUNEL) reaction and  bbbbb2 caspase-3 eeeee2  activation
CPR:3	Pre-treatment with arsenite increased  bbbbb1 protein kinase B eeeee1  (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after  bbbbb2 H2O2 eeeee2 
CPR:3	Pre-treatment with arsenite increased protein kinase B ( bbbbb1 Akt eeeee1 ) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after  bbbbb2 H2O2 eeeee2 
CPR:3	The results show that transient  bbbbb1 arsenite eeeee1  pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of  bbbbb2 Akt eeeee2  following H2O2
CPR:3	The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of  bbbbb1 Akt eeeee1  following  bbbbb2 H2O2 eeeee2 
CPR:3	Induction of  bbbbb1 heat shock proteins eeeee1  (HSPs) by  bbbbb2 sodium arsenite eeeee2  in cultured astrocytes and reduction of hydrogen peroxide-induced cell death
CPR:3	Induction of heat shock proteins ( bbbbb1 HSPs eeeee1 ) by  bbbbb2 sodium arsenite eeeee2  in cultured astrocytes and reduction of hydrogen peroxide-induced cell death
CPR:3	The results show that transient  bbbbb1 arsenite eeeee1  pre-treatment induces  bbbbb2 Hsp72 eeeee2 , HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2
CPR:3	The results show that transient  bbbbb1 arsenite eeeee1  pre-treatment induces Hsp72,  bbbbb2 HO-1 eeeee2  and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2
CPR:3	The results show that transient  bbbbb1 arsenite eeeee1  pre-treatment induces Hsp72, HO-1 and, to a lesser extent,  bbbbb2 Hsp27 eeeee2 ; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2
CPR:3	 bbbbb1 Arsenite eeeee1  triggered strong induction of  bbbbb2 HSPs eeeee2 , which was prevented by 1 micro g/mL cycloheximide (CXH)
CPR:4	Arsenite triggered strong induction of  bbbbb1 HSPs eeeee1 , which was prevented by 1 micro g/mL  bbbbb2 cycloheximide eeeee2  (CXH)
CPR:4	Arsenite triggered strong induction of  bbbbb1 HSPs eeeee1 , which was prevented by 1 micro g/mL cycloheximide ( bbbbb2 CXH eeeee2 )
CPR:4	However, while  bbbbb1 Akt eeeee1  phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by  bbbbb2 CHX eeeee2 
CPR:10	 bbbbb1 GW660511X eeeee1  and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8
CPR:10	 bbbbb1 GW660511X eeeee1  and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2 
CPR:10	GW660511X and  bbbbb1 omapatrilat eeeee1  increased the production of both BrBK1-8 and Br-Phe5 but not that of  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8
CPR:10	GW660511X and  bbbbb1 omapatrilat eeeee1  increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2 
CPR:10	Unlike  bbbbb1 GW660511X eeeee1 , omapatrilat abolished the production of  bbbbb2 BrBK1-5 eeeee2  and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CPR:10	Unlike  bbbbb1 GW660511X eeeee1 , omapatrilat abolished the production of BrBK1-5 and  bbbbb2 BrBK1-7 eeeee2 , suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CPR:10	Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over  bbbbb1 GW660511X eeeee1  as no  bbbbb2 NEP eeeee2  activity was found
CPR:10	The production of  bbbbb1 Br-Phe5 eeeee1  was reduced with GW660511X while no significant change was observed with  bbbbb2 omapatrilat eeeee2  after 4 h of incubation
CPR:2	In human plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of  bbbbb2 GW660511X eeeee2  (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CPR:2	In human plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (3.8 microM) or  bbbbb2 omapatrilat eeeee2  (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CPR:2	Investigation of  bbbbb1 bradykinin eeeee1  metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors  bbbbb2 GW660511X eeeee2  and omapatrilat
CPR:2	Investigation of  bbbbb1 bradykinin eeeee1  metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and  bbbbb2 omapatrilat eeeee2 
CPR:2	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of  bbbbb2 GW660511X eeeee2  (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CPR:2	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (530 nM) or  bbbbb2 omapatrilat eeeee2  (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CPR:3	 bbbbb1 GW660511X eeeee1  and omapatrilat increased the production of both  bbbbb2 BrBK1-8 eeeee2  and Br-Phe5 but not that of BrBK4-8 and BrBK2-8
CPR:3	 bbbbb1 GW660511X eeeee1  and omapatrilat increased the production of both BrBK1-8 and  bbbbb2 Br-Phe5 eeeee2  but not that of BrBK4-8 and BrBK2-8
CPR:3	GW660511X and  bbbbb1 omapatrilat eeeee1  increased the production of both  bbbbb2 BrBK1-8 eeeee2  and Br-Phe5 but not that of BrBK4-8 and BrBK2-8
CPR:3	GW660511X and  bbbbb1 omapatrilat eeeee1  increased the production of both BrBK1-8 and  bbbbb2 Br-Phe5 eeeee2  but not that of BrBK4-8 and BrBK2-8
CPR:3	In addition the production of  bbbbb1 BrBK1-8 eeeee1  was enhanced in the presence of these inhibitors with a greater accumulation being observed with  bbbbb2 omapatrilat eeeee2 
CPR:4	 bbbbb1 GW660511X eeeee1  and omapatrilat reduced the production of  bbbbb2 BrBK1-5 eeeee2  and BrBK1-7 with more effect being observed with omapatrilat
CPR:4	 bbbbb1 GW660511X eeeee1  and omapatrilat reduced the production of BrBK1-5 and  bbbbb2 BrBK1-7 eeeee2  with more effect being observed with omapatrilat
CPR:4	GW660511X and  bbbbb1 omapatrilat eeeee1  reduced the production of  bbbbb2 BrBK1-5 eeeee2  and BrBK1-7 with more effect being observed with omapatrilat
CPR:4	GW660511X and  bbbbb1 omapatrilat eeeee1  reduced the production of BrBK1-5 and  bbbbb2 BrBK1-7 eeeee2  with more effect being observed with omapatrilat
CPR:4	GW660511X and omapatrilat reduced the production of  bbbbb1 BrBK1-5 eeeee1  and BrBK1-7 with more effect being observed with  bbbbb2 omapatrilat eeeee2 
CPR:4	GW660511X and omapatrilat reduced the production of BrBK1-5 and  bbbbb1 BrBK1-7 eeeee1  with more effect being observed with  bbbbb2 omapatrilat eeeee2 
CPR:4	Unlike GW660511X,  bbbbb1 omapatrilat eeeee1  abolished the production of  bbbbb2 BrBK1-5 eeeee2  and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CPR:4	Unlike GW660511X,  bbbbb1 omapatrilat eeeee1  abolished the production of BrBK1-5 and  bbbbb2 BrBK1-7 eeeee2 , suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CPR:4	The production of  bbbbb1 Br-Phe5 eeeee1  was reduced with  bbbbb2 GW660511X eeeee2  while no significant change was observed with omapatrilat after 4 h of incubation
CPR:4	This study shows that the potency of  bbbbb1 GW660511X eeeee1  in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of  bbbbb2 ACE eeeee2 /NEP inhibition in relation to effects in humans.
CPR:4	This study shows that the potency of  bbbbb1 GW660511X eeeee1  in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/ bbbbb2 NEP eeeee2  inhibition in relation to effects in humans.
CPR:4	This study shows that the potency of GW660511X in comparison with  bbbbb1 omapatrilat eeeee1  is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/ bbbbb2 NEP eeeee2  inhibition in relation to effects in humans.
CPR:4	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual  bbbbb1 ACE eeeee1 /NEP inhibitors ( bbbbb2 GW660511X eeeee2  and omapatrilat) currently under clinical trial
CPR:4	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/ bbbbb1 NEP eeeee1  inhibitors ( bbbbb2 GW660511X eeeee2  and omapatrilat) currently under clinical trial
CPR:4	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual  bbbbb1 ACE eeeee1 /NEP inhibitors (GW660511X and  bbbbb2 omapatrilat eeeee2 ) currently under clinical trial
CPR:4	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/ bbbbb1 NEP eeeee1  inhibitors (GW660511X and  bbbbb2 omapatrilat eeeee2 ) currently under clinical trial
CPR:4	Unlike GW660511X,  bbbbb1 omapatrilat eeeee1  abolished the production of BrBK1-5 and BrBK1-7, suggesting a better  bbbbb2 ACE eeeee2  inhibition effect over GW660511X as no NEP activity was found
CPR:4	Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better  bbbbb1 ACE eeeee1  inhibition effect over  bbbbb2 GW660511X eeeee2  as no NEP activity was found
CPR:4	Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual  bbbbb1 ACE eeeee1 /NEP inhibitors  bbbbb2 GW660511X eeeee2  and omapatrilat
CPR:4	Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/ bbbbb1 NEP eeeee1  inhibitors  bbbbb2 GW660511X eeeee2  and omapatrilat
CPR:4	Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual  bbbbb1 ACE eeeee1 /NEP inhibitors GW660511X and  bbbbb2 omapatrilat eeeee2 
CPR:4	Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/ bbbbb1 NEP eeeee1  inhibitors GW660511X and  bbbbb2 omapatrilat eeeee2 
CPR:2	Experimental evidence from the use of agents with enhanced selectivity for  bbbbb1 BuChE eeeee1  ( bbbbb2 cymserine eeeee2  analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias
CPR:2	Experimental evidence from the use of agents with enhanced selectivity for  bbbbb1 BuChE eeeee1  (cymserine analogues,  bbbbb2 MF-8622 eeeee2 ) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias
CPR:4	The development of specific  bbbbb1 BuChE eeeee1  inhibitors and further experience with the dual enzyme inhibitor  bbbbb2 rivastigmine eeeee2  will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.
CPR:4	Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both  bbbbb1 AChE eeeee1  and BuChE,  bbbbb2 rivastigmine eeeee2 , indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias
CPR:4	Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and  bbbbb1 BuChE eeeee1 ,  bbbbb2 rivastigmine eeeee2 , indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias
CPR:4	Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE,  bbbbb1 rivastigmine eeeee1 , indicates potential therapeutic benefits of inhibiting both  bbbbb2 AChE eeeee2  and BuChE in AD and related dementias
CPR:4	Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE,  bbbbb1 rivastigmine eeeee1 , indicates potential therapeutic benefits of inhibiting both AChE and  bbbbb2 BuChE eeeee2  in AD and related dementias
CPR:9	Acetylcholinesterase ( bbbbb1 AChE eeeee1 ) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain  bbbbb2 acetylcholine eeeee2  (ACh) levels
CPR:9	Acetylcholinesterase (AChE) predominates in the healthy brain, with  bbbbb1 butyrylcholinesterase eeeee1  (BuChE) considered to play a minor role in regulating brain  bbbbb2 acetylcholine eeeee2  (ACh) levels
CPR:9	Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase ( bbbbb1 BuChE eeeee1 ) considered to play a minor role in regulating brain  bbbbb2 acetylcholine eeeee2  (ACh) levels
CPR:9	 bbbbb1 Acetylcholinesterase eeeee1  (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain  bbbbb2 acetylcholine eeeee2  (ACh) levels
CPR:9	Acetylcholinesterase ( bbbbb1 AChE eeeee1 ) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine ( bbbbb2 ACh eeeee2 ) levels
CPR:9	Acetylcholinesterase (AChE) predominates in the healthy brain, with  bbbbb1 butyrylcholinesterase eeeee1  (BuChE) considered to play a minor role in regulating brain acetylcholine ( bbbbb2 ACh eeeee2 ) levels
CPR:9	Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase ( bbbbb1 BuChE eeeee1 ) considered to play a minor role in regulating brain acetylcholine ( bbbbb2 ACh eeeee2 ) levels
CPR:9	 bbbbb1 Acetylcholinesterase eeeee1  (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine ( bbbbb2 ACh eeeee2 ) levels
CPR:2	A low toxicity maintenance regime, using  bbbbb1 eicosapentaenoic acid eeeee1  and readily available drugs, for mantle cell lymphoma and other malignancies with excess  bbbbb2 cyclin D1 eeeee2  levels
CPR:4	Agents which have recently been shown to block  bbbbb1 cyclin D1 eeeee1  translation by regulating calcium levels are the  bbbbb2 unsaturated essential fatty acid eeeee2 , eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole
CPR:4	Agents which have recently been shown to block  bbbbb1 cyclin D1 eeeee1  translation by regulating calcium levels are the unsaturated essential fatty acid,  bbbbb2 eicosapentaenoic acid eeeee2  (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole
CPR:4	Agents which have recently been shown to block  bbbbb1 cyclin D1 eeeee1  translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid ( bbbbb2 EPA eeeee2 ), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole
CPR:4	Agents which have recently been shown to block  bbbbb1 cyclin D1 eeeee1  translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic  bbbbb2 thiazolidinediones eeeee2 , and the antifungal agent, clotrimazole
CPR:4	Agents which have recently been shown to block  bbbbb1 cyclin D1 eeeee1  translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent,  bbbbb2 clotrimazole eeeee2 
CPR:2	 bbbbb1 Angiotensin II eeeee1  acting on  bbbbb2 angiotensin AT1 receptors eeeee2  at the central nervous system appears to have an important role in these modulatory processes
CPR:4	We investigated the effect of  bbbbb1 AT1 receptor eeeee1  blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent  bbbbb2 pancuronium bromide eeeee2 
CPR:6	 bbbbb1 Angiotensin AT1 receptor eeeee1  antagonist  bbbbb2 losartan eeeee2  and the defence reaction in the anaesthetised rat
CPR:2	Defective processing of the  bbbbb1 transforming growth factor-beta1 eeeee1  in  bbbbb2 azoxymethane eeeee2 -induced mouse colon tumors
CPR:10	Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2)  bbbbb1 OFQ II(1-28) eeeee1  does not bind or stimulate  bbbbb2 [35S]-GTPgammaS eeeee2  binding in cells expressing the mu opioid receptor.
CPR:10	Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate  bbbbb1 [35S]-GTPgammaS eeeee1  binding in cells expressing the  bbbbb2 mu opioid receptor eeeee2 .
CPR:1	Unlike OFQ II(1-17), high concentrations of its  bbbbb1 C eeeee1 -terminal extension,  bbbbb2 OFQ II(1-28) eeeee2 , stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone
CPR:2	Taken together, these findings support the view that (1)  bbbbb1 OFQ eeeee1  is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate  bbbbb2 [35S]-GTPgammaS eeeee2  binding in cells expressing the mu opioid receptor.
CPR:2	Taken together, these findings support the view that (1) OFQ is the only  bbbbb1 ppOFQ eeeee1  peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate  bbbbb2 [35S]-GTPgammaS eeeee2  binding in cells expressing the mu opioid receptor.
CPR:2	Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the  bbbbb1 ORL1 eeeee1  receptor and (2) OFQ II(1-28) does not bind or stimulate  bbbbb2 [35S]-GTPgammaS eeeee2  binding in cells expressing the mu opioid receptor.
CPR:2	 bbbbb1 Orphanin FQ eeeee1  (OFQ) stimulated  bbbbb2 [35S]-GTPgammaS eeeee2  binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor
CPR:2	Orphanin FQ ( bbbbb1 OFQ eeeee1 ) stimulated  bbbbb2 [35S]-GTPgammaS eeeee2  binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor
CPR:2	Orphanin FQ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [ bbbbb1 125I eeeee1 ]- bbbbb2 OFQ eeeee2  at the endogenous opioid receptor-like (ORL1) receptor
CPR:2	Unlike  bbbbb1 OFQ II(1-17) eeeee1 , high concentrations of its C-terminal extension, OFQ II(1-28), stimulated  bbbbb2 [35S]-GTPgammaS eeeee2  binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone
CPR:2	Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated  bbbbb1 [35S]-GTPgammaS eeeee1  binding in a  bbbbb2 mu (mu) opioid receptor eeeee2 -like distribution and the effect was blocked by naloxone
CPR:2	Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a  bbbbb1 mu (mu) opioid receptor eeeee1 -like distribution and the effect was blocked by  bbbbb2 naloxone eeeee2 
CPR:2	Binding and  bbbbb1 GTPgammaS eeeee1  autoradiographic analysis of preproorphanin precursor peptide products at the  bbbbb2 ORL1 eeeee2  and opioid receptors
CPR:2	Binding and  bbbbb1 GTPgammaS eeeee1  autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and  bbbbb2 opioid receptors eeeee2 
CPR:2	Binding and  bbbbb1 GTPgammaS eeeee1  autoradiographic analysis of  bbbbb2 preproorphanin precursor peptide eeeee2  products at the ORL1 and opioid receptors
CPR:2	Unlike OFQ II(1-17), high concentrations of its C-terminal extension,  bbbbb1 OFQ II(1-28) eeeee1 , stimulated  bbbbb2 [35S]-GTPgammaS eeeee2  binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone
CPR:2	RESULTS:  bbbbb1 Rolipram eeeee1  unmasked the inhibitory effect of  bbbbb2 beta(2)-adrenoceptor eeeee2  stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4)
CPR:2	CONCLUSIONS: Inhibition of PDE4 by  bbbbb1 rolipram eeeee1  unmasks  bbbbb2 beta(2)-adrenergic eeeee2  blockade of LTC(4) synthesis caused by FMLP/B.
CPR:3	RESULTS: Rolipram unmasked the inhibitory effect of  bbbbb1 beta(2)-adrenoceptor eeeee1  stimulation with  bbbbb2 salmeterol eeeee2  and significantly attenuated the stimulated release of AA and subsequent LTC(4)
CPR:4	Inhibition corresponded to increased cAMP production caused by rolipram alone or  bbbbb1 rolipram eeeee1  plus salmeterol and blocked proportionately the phosphorylation and activation of  bbbbb2 gIV-PLA(2) eeeee2  in FMLP/B-activated eosinophils
CPR:4	Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus  bbbbb1 salmeterol eeeee1  and blocked proportionately the phosphorylation and activation of  bbbbb2 gIV-PLA(2) eeeee2  in FMLP/B-activated eosinophils
CPR:4	CONCLUSIONS: Inhibition of  bbbbb1 PDE4 eeeee1  by  bbbbb2 rolipram eeeee2  unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.
CPR:4	OBJECTIVE: To determine (a) whether  bbbbb1 PDE4 eeeee1  inhibition alone with  bbbbb2 rolipram eeeee2  blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP
CPR:9	Blockade of  bbbbb1 LTC4 eeeee1  synthesis caused by additive inhibition of  bbbbb2 gIV-PLA2 eeeee2  phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils
CPR:2	Tazarotene is an acetylenic retinoid which is metabolised to  bbbbb1 tazarotenic acid eeeee1  and which binds selectively to the  bbbbb2 retinoid receptors eeeee2  RARbeta and RARgamma
CPR:2	Tazarotene is an acetylenic retinoid which is metabolised to  bbbbb1 tazarotenic acid eeeee1  and which binds selectively to the retinoid receptors  bbbbb2 RARbeta eeeee2  and RARgamma
CPR:2	Tazarotene is an acetylenic retinoid which is metabolised to  bbbbb1 tazarotenic acid eeeee1  and which binds selectively to the retinoid receptors RARbeta and  bbbbb2 RARgamma eeeee2 
CPR:2	 bbbbb1 Tazarotene eeeee1  is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the  bbbbb2 retinoid receptors eeeee2  RARbeta and RARgamma
CPR:2	 bbbbb1 Tazarotene eeeee1  is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors  bbbbb2 RARbeta eeeee2  and RARgamma
CPR:2	 bbbbb1 Tazarotene eeeee1  is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and  bbbbb2 RARgamma eeeee2 
CPR:2	Tazarotene is an  bbbbb1 acetylenic retinoid eeeee1  which is metabolised to tazarotenic acid and which binds selectively to the  bbbbb2 retinoid receptors eeeee2  RARbeta and RARgamma
CPR:2	Tazarotene is an  bbbbb1 acetylenic retinoid eeeee1  which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors  bbbbb2 RARbeta eeeee2  and RARgamma
CPR:2	Tazarotene is an  bbbbb1 acetylenic retinoid eeeee1  which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and  bbbbb2 RARgamma eeeee2 
CPR:10	These effects were not mimicked by oral administration of the  bbbbb1 beta 2-adrenoceptor eeeee1  agonist salbutamol even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of  bbbbb2 DL-propranolol eeeee2  (200 mg/kg diet)
CPR:10	The potent anabolic effects of the beta 2-adrenoceptor agonist  bbbbb1 clenbuterol eeeee1  on skeletal muscle have been reported to be independent of actions on  bbbbb2 beta-adrenoceptors eeeee2 
CPR:2	These results indicate that the anabolic effects of  bbbbb1 clenbuterol eeeee1  are dependent on interaction with the  bbbbb2 beta 2-adrenoceptor eeeee2 
CPR:3	Anabolic effects of  bbbbb1 clenbuterol eeeee1  on skeletal muscle are mediated by  bbbbb2 beta 2-adrenoceptor eeeee2  activation
CPR:5	These effects were not mimicked by oral administration of the  bbbbb1 beta 2-adrenoceptor eeeee1  agonist  bbbbb2 salbutamol eeeee2  even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet)
CPR:5	These effects were not mimicked by oral administration of the  bbbbb1 beta 2-adrenoceptor eeeee1  agonist salbutamol even at high dose (52 mg/kg diet), and the effects of  bbbbb2 clenbuterol eeeee2  were not inhibited by addition of DL-propranolol (200 mg/kg diet)
CPR:5	The potent anabolic effects of the  bbbbb1 beta 2-adrenoceptor eeeee1  agonist  bbbbb2 clenbuterol eeeee2  on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors
CPR:5	In the hot-plate test in mice, the antinociceptive action of the  bbbbb1 alpha 2-adrenoceptor eeeee1  agonist,  bbbbb2 UK 14,304 eeeee2 , was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CPR:5	The preferential  bbbbb1 alpha 2A-adrenoceptor eeeee1  partial agonist,  bbbbb2 guanfacine eeeee2 , partially inhibited UK 14,304-induced antinociception
CPR:5	The preferential  bbbbb1 alpha 2A-adrenoceptor eeeee1  partial agonist, guanfacine, partially inhibited  bbbbb2 UK 14,304 eeeee2 -induced antinociception
CPR:6	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the  bbbbb1 alpha 2-adrenoceptor eeeee1  antagonist,  bbbbb2 idazoxan eeeee2 , the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CPR:6	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent  bbbbb1 alpha 2A-adrenoceptor eeeee1  antagonist,  bbbbb2 RX 821002 eeeee2  and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CPR:6	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential  bbbbb1 alpha 2A-adrenoceptor eeeee1  antagonist,  bbbbb2 BRL 44408 eeeee2 
CPR:10	These characteristics of the bound PLP suggest that  bbbbb1 SDH eeeee1  catalysis is not facilitated by forming the resonance-stabilized structure of the  bbbbb2 PLP-Ser aldimine eeeee2  as seen in aminotransferases
CPR:1	Formation of pyruvate by  bbbbb1 SDH eeeee1  is a two-step reaction in which the  bbbbb2 hydroxyl eeeee2  group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate
CPR:1	Formation of pyruvate by  bbbbb1 SDH eeeee1  is a two-step reaction in which the hydroxyl group of  bbbbb2 serine eeeee2  is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate
CPR:1	The phosphate group of  bbbbb1 PLP eeeee1  is surrounded by a characteristic  bbbbb2 G-rich sequence eeeee2  ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CPR:1	The phosphate group of PLP is surrounded by a characteristic  bbbbb1 G-rich sequence eeeee1  ((168) bbbbb2 GGGGL eeeee2 (172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CPR:2	These characteristics of the bound  bbbbb1 PLP eeeee1  suggest that  bbbbb2 SDH eeeee2  catalysis is not facilitated by forming the resonance-stabilized structure of the PLP-Ser aldimine as seen in aminotransferases
CPR:2	The  bbbbb1 holo-SDH eeeee1  crystallized with  bbbbb2 O-methylserine eeeee2  (OMS) was also determined at 2.6 A resolution by molecular replacement
CPR:2	The  bbbbb1 holo-SDH eeeee1  crystallized with O-methylserine ( bbbbb2 OMS eeeee2 ) was also determined at 2.6 A resolution by molecular replacement
CPR:2	The  bbbbb1 holo-SDH eeeee1  contained PLP-OMS  bbbbb2 aldimine eeeee2  in the active site, indicating that OMS can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur
CPR:2	The  bbbbb1 holo-SDH eeeee1  contained PLP-OMS aldimine in the active site, indicating that  bbbbb2 OMS eeeee2  can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur
CPR:2	These characteristics of the bound PLP suggest that SDH catalysis is not facilitated by forming the resonance-stabilized structure of the  bbbbb1 PLP-Ser aldimine eeeee1  as seen in  bbbbb2 aminotransferases eeeee2 
CPR:8	 bbbbb1 SDH eeeee1  (L-serine dehydratase, EC 4.3.1.17) catalyzes the  bbbbb2 pyridoxal 5'-phosphate eeeee2  (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia
CPR:8	SDH (L-serine dehydratase,  bbbbb1 EC 4.3.1.17 eeeee1 ) catalyzes the  bbbbb2 pyridoxal 5'-phosphate eeeee2  (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia
CPR:8	SDH  bbbbb1 (L-serine dehydratase eeeee1 , EC 4.3.1.17) catalyzes the  bbbbb2 pyridoxal 5'-phosphate eeeee2  (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia
CPR:8	 bbbbb1 SDH eeeee1  (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate ( bbbbb2 PLP eeeee2 )-dependent dehydration of L-serine to yield pyruvate and ammonia
CPR:8	SDH (L-serine dehydratase,  bbbbb1 EC 4.3.1.17 eeeee1 ) catalyzes the pyridoxal 5'-phosphate ( bbbbb2 PLP eeeee2 )-dependent dehydration of L-serine to yield pyruvate and ammonia
CPR:8	SDH  bbbbb1 (L-serine dehydratase eeeee1 , EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate ( bbbbb2 PLP eeeee2 )-dependent dehydration of L-serine to yield pyruvate and ammonia
CPR:8	The  bbbbb1 holo-SDH eeeee1  contained PLP-OMS aldimine in the active site, indicating that OMS can form the Schiff base linkage with  bbbbb2 PLP eeeee2 , but the subsequent dehydration did not occur
CPR:9	Formation of  bbbbb1 pyruvate eeeee1  by  bbbbb2 SDH eeeee2  is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate
CPR:9	Formation of pyruvate by  bbbbb1 SDH eeeee1  is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce  bbbbb2 pyruvate eeeee2 
CPR:9	 bbbbb1 SDH eeeee1  (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield  bbbbb2 pyruvate eeeee2  and ammonia
CPR:9	SDH (L-serine dehydratase,  bbbbb1 EC 4.3.1.17 eeeee1 ) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield  bbbbb2 pyruvate eeeee2  and ammonia
CPR:9	SDH  bbbbb1 (L-serine dehydratase eeeee1 , EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield  bbbbb2 pyruvate eeeee2  and ammonia
CPR:9	 bbbbb1 SDH eeeee1  (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and  bbbbb2 ammonia eeeee2 
CPR:9	SDH (L-serine dehydratase,  bbbbb1 EC 4.3.1.17 eeeee1 ) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and  bbbbb2 ammonia eeeee2 
CPR:9	SDH  bbbbb1 (L-serine dehydratase eeeee1 , EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and  bbbbb2 ammonia eeeee2 
CPR:9	 bbbbb1 SDH eeeee1  (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of  bbbbb2 L-serine eeeee2  to yield pyruvate and ammonia
CPR:9	SDH (L-serine dehydratase,  bbbbb1 EC 4.3.1.17 eeeee1 ) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of  bbbbb2 L-serine eeeee2  to yield pyruvate and ammonia
CPR:9	SDH  bbbbb1 (L-serine dehydratase eeeee1 , EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of  bbbbb2 L-serine eeeee2  to yield pyruvate and ammonia
CPR:9	Formation of pyruvate by  bbbbb1 SDH eeeee1  is a two-step reaction in which the hydroxyl group of serine is cleaved to produce  bbbbb2 aminoacrylate eeeee2 , and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate
CPR:4	Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI)  bbbbb1 GW572016 eeeee1  decreased the postradiation survival of irradiated  bbbbb2 Ras eeeee2 -transformed cells and normal cells but had no effect on the survival of unirradiated cells
CPR:4	Blocking  bbbbb1 EGFR eeeee1  signaling with the EGFR/HER-2 kinase inhibitor (KI)  bbbbb2 GW572016 eeeee2  decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells
CPR:4	Thus,  bbbbb1 Ras eeeee1  utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI  bbbbb2 GW572016 eeeee2  acts as a radiosensitizer
CPR:4	The observation that  bbbbb1 Ras eeeee1 -transformed cells can be sensitized to killing by ionizing radiation with  bbbbb2 GW572016 eeeee2  demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.
CPR:4	Blocking EGFR signaling with the  bbbbb1 EGFR eeeee1 /HER-2 kinase inhibitor (KI)  bbbbb2 GW572016 eeeee2  decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells
CPR:4	Blocking EGFR signaling with the EGFR/ bbbbb1 HER-2 eeeee1  kinase inhibitor (KI)  bbbbb2 GW572016 eeeee2  decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells
CPR:4	Ras-CM and TGF-alpha also increase  bbbbb1 PI3-K eeeee1  activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by  bbbbb2 GW572016 eeeee2 
CPR:4	Ras-CM and TGF-alpha also increase PI3-K activity downstream of the  bbbbb1 EGFR eeeee1  and increase postradiation survival, both of which are abrogated by  bbbbb2 GW572016 eeeee2 
CPR:4	Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the  bbbbb1 EGFR eeeee1  KI  bbbbb2 GW572016 eeeee2  acts as a radiosensitizer
CPR:4	The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with  bbbbb1 GW572016 eeeee1  demonstrates that  bbbbb2 EGFR eeeee2  KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.
CPR:5	The present study was carried out to characterize beta-adrenoceptor subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional  bbbbb1 beta(3)-adrenoceptor eeeee1  agonist,  bbbbb2 (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride eeeee2  ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations
CPR:5	The present study was carried out to characterize beta-adrenoceptor subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional  bbbbb1 beta(3)-adrenoceptor eeeee1  agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ( bbbbb2 (+/-)-CGP12177A eeeee2 ), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations
CPR:6	Pretreatment with a combination of  bbbbb1 (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate eeeee1  (CGP20712A, a selective  bbbbb2 beta(1)-adrenoceptor eeeee2  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CPR:6	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate ( bbbbb1 CGP20712A eeeee1 , a selective  bbbbb2 beta(1)-adrenoceptor eeeee2  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CPR:6	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and  bbbbb1 (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride eeeee1  (ICI-118,5511, a selective  bbbbb2 beta(2)-adrenoceptor eeeee2  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CPR:6	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride ( bbbbb1 ICI-118,5511 eeeee1 , a selective  bbbbb2 beta(2)-adrenoceptor eeeee2  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CPR:2	BACKGROUND: The  bbbbb1 norepinephrine transporter eeeee1  (NET) is a high-affinity transporter for  bbbbb2 catecholamines eeeee2 
CPR:2	BACKGROUND: The norepinephrine transporter ( bbbbb1 NET eeeee1 ) is a high-affinity transporter for  bbbbb2 catecholamines eeeee2 
CPR:4	The specificity of tracer uptake was determined by adding the  bbbbb1 NET eeeee1  inhibitor  bbbbb2 imipramine eeeee2 
CPR:9	More than 70% of the initial radioactivity was retained in all transduced cell lines after 2 h incubation with tracer-free medium.  bbbbb1 [(131)I]MIBG eeeee1  uptake in PC12 cells, which express the  bbbbb2 NET eeeee2  endogenously, was 20- to 28-fold lower than in transduced cells
CPR:9	In vivo, A431 bbbbb1 NET eeeee1  tumors demonstrated a 33-fold higher  bbbbb2 [(123)I]MIBG eeeee2  uptake than parental tumors
CPR:5	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin,  bbbbb1 formoterol eeeee1 , broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:5	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol,  bbbbb1 broxaterol eeeee1 ) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:5	The aim of this study was, therefore, to provide comparative binding characteristics of agonists ( bbbbb1 epinephrine eeeee1 , norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:5	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine,  bbbbb1 norepinephrine eeeee1 , isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:5	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine,  bbbbb1 isoproterenol eeeee1 , fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:5	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol,  bbbbb1 fenoterol eeeee1 , salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:5	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol,  bbbbb1 salbutamol eeeee1 , salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:5	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol,  bbbbb1 salmeterol eeeee1 , terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:5	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol,  bbbbb1 terbutalin eeeee1 , formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists ( bbbbb1 propranolol eeeee1 , alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol,  bbbbb1 alprenolol eeeee1 , atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol,  bbbbb1 atenolol eeeee1 , metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol,  bbbbb1 metoprolol eeeee1 , bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol,  bbbbb1 bisoprolol eeeee1 , carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol,  bbbbb1 carvedilol eeeee1 , pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol,  bbbbb1 pindolol eeeee1 , BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol,  bbbbb1 BRL 37344 eeeee1 , CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344,  bbbbb1 CGP 20712 eeeee1 , SR 59230A, CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712,  bbbbb1 SR 59230A eeeee1 , CGP 12177, ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A,  bbbbb1 CGP 12177 eeeee1 , ICI 118551) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:6	The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177,  bbbbb1 ICI 118551 eeeee1 ) at all three subtypes of  bbbbb2 human beta-adrenergic receptors eeeee2  in an identical cellular background
CPR:2	Responses to  bbbbb1 isoproterenol eeeee1  could be restored to normal by beta2AR blockade, suggesting a beta2AR-mediated inhibition of  bbbbb2 beta1AR eeeee2  signalling
CPR:2	Responses to  bbbbb1 isoproterenol eeeee1  were largely mediated through the  bbbbb2 beta1AR eeeee2  in control myocytes
CPR:2	Adenovirally-mediated overexpression of  bbbbb1 NCX eeeee1 , at levels, which did not alter basal contraction of myocytes, markedly depressed the  bbbbb2 isoproterenol eeeee2  concentration-response curve
CPR:2	Responses to  bbbbb1 isoproterenol eeeee1  could be restored to normal by  bbbbb2 beta2AR eeeee2  blockade, suggesting a beta2AR-mediated inhibition of beta1AR signalling
CPR:2	Responses to  bbbbb1 isoproterenol eeeee1  could be restored to normal by beta2AR blockade, suggesting a  bbbbb2 beta2AR eeeee2 -mediated inhibition of beta1AR signalling
CPR:2	Pertussis toxin normalised  bbbbb1 isoproterenol eeeee1  responses in NCX cells, indicating that  bbbbb2 beta2AR eeeee2  effects were mediated by Gi
CPR:2	The nonsteroidal anti-inflammatory drugs  bbbbb1 flurbiprofen eeeee1  and ibuprofen were modified in an attempt to alter the kinetics of inhibitor binding by  bbbbb2 COX-1 eeeee2 
CPR:2	The nonsteroidal anti-inflammatory drugs flurbiprofen and  bbbbb1 ibuprofen eeeee1  were modified in an attempt to alter the kinetics of inhibitor binding by  bbbbb2 COX-1 eeeee2 
CPR:4	Manipulation of kinetic profiles in  bbbbb1 2-aryl propionic acid eeeee1   bbbbb2 cyclooxygenase eeeee2  inhibitors
CPR:10	Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of  bbbbb1 GW572016 eeeee1  to inhibit downstream  bbbbb2 ERK eeeee2  and Akt activation, despite inhibition of HER2 phosphorylation
CPR:10	Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of  bbbbb1 GW572016 eeeee1  to inhibit downstream ERK and  bbbbb2 Akt eeeee2  activation, despite inhibition of HER2 phosphorylation
CPR:10	Resistance to  bbbbb1 GW572016 eeeee1  was not due to a lack of receptor inhibition, but rather with a lack of inhibition of  bbbbb2 ERK eeeee2  and Akt, suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation
CPR:10	Resistance to  bbbbb1 GW572016 eeeee1  was not due to a lack of receptor inhibition, but rather with a lack of inhibition of ERK and  bbbbb2 Akt eeeee2 , suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation
CPR:1	RESULTS: GW572016 inhibited constitutive and/or ligand-induced  bbbbb1 EGFR eeeee1  or HER2  bbbbb2 tyrosine eeeee2  phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line
CPR:1	RESULTS: GW572016 inhibited constitutive and/or ligand-induced EGFR or  bbbbb1 HER2 eeeee1   bbbbb2 tyrosine eeeee2  phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line
CPR:2	 bbbbb1 GW572016 eeeee1  radiosensitized  bbbbb2 EGFR eeeee2 -overexpressing cell lines, but HER2-overexpressing cells were unable to form colonies after brief exposure to GW572016 even in the absence of radiation, and thus could not be evaluated for radiosensitization
CPR:2	GW572016 radiosensitized EGFR-overexpressing cell lines, but  bbbbb1 HER2 eeeee1 -overexpressing cells were unable to form colonies after brief exposure to  bbbbb2 GW572016 eeeee2  even in the absence of radiation, and thus could not be evaluated for radiosensitization
CPR:4	Effects of the  bbbbb1 EGFR eeeee1 /HER2 kinase inhibitor  bbbbb2 GW572016 eeeee2  on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance
CPR:4	Effects of the EGFR/ bbbbb1 HER2 eeeee1  kinase inhibitor  bbbbb2 GW572016 eeeee2  on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance
CPR:4	Effects of the EGFR/HER2  bbbbb1 kinase eeeee1  inhibitor  bbbbb2 GW572016 eeeee2  on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance
CPR:4	Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of  bbbbb1 GW572016 eeeee1  to inhibit downstream ERK and Akt activation, despite inhibition of  bbbbb2 HER2 eeeee2  phosphorylation
CPR:4	CONCLUSION:  bbbbb1 GW572016 eeeee1  potently inhibits receptor phosphorylation in either  bbbbb2 EGFR eeeee2 - or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects
CPR:4	CONCLUSION:  bbbbb1 GW572016 eeeee1  potently inhibits receptor phosphorylation in either EGFR- or  bbbbb2 HER2 eeeee2 -overexpressing cell lines and has both antiproliferative and radiosensitizing effects
CPR:4	To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual  bbbbb1 EGFR eeeee1 /HER2 inhibitor,  bbbbb2 GW572016 eeeee2 , on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines
CPR:4	To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/ bbbbb1 HER2 eeeee1  inhibitor,  bbbbb2 GW572016 eeeee2 , on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines
CPR:4	RESULTS:  bbbbb1 GW572016 eeeee1  inhibited constitutive and/or ligand-induced  bbbbb2 EGFR eeeee2  or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line
CPR:4	RESULTS:  bbbbb1 GW572016 eeeee1  inhibited constitutive and/or ligand-induced EGFR or  bbbbb2 HER2 eeeee2  tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line
CPR:2	 bbbbb1 Metformin eeeee1 , but not leptin, regulates  bbbbb2 AMP-activated protein kinase eeeee2  in pancreatic islets: impact on glucose-stimulated insulin secretion
CPR:2	These studies demonstrate that  bbbbb1 AMPK eeeee1  activity is subject to regulation by both  bbbbb2 glucose eeeee2  and metformin in pancreatic islets and clonal beta-cells
CPR:2	These studies demonstrate that  bbbbb1 AMPK eeeee1  activity is subject to regulation by both glucose and  bbbbb2 metformin eeeee2  in pancreatic islets and clonal beta-cells
CPR:3	Incubation with  bbbbb1 metformin eeeee1  (0.2-1 mM) activated  bbbbb2 AMPK eeeee2  in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells
CPR:3	 bbbbb1 Metformin eeeee1 , a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK)
CPR:3	 bbbbb1 Metformin eeeee1 , a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase ( bbbbb2 AMPK eeeee2 )
CPR:3	Whether  bbbbb1 metformin eeeee1  or the satiety factor leptin, which also stimulates  bbbbb2 AMPK eeeee2  in muscle, regulates this enzyme in pancreatic islets is unknown
CPR:3	Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on  bbbbb1 glucose eeeee1 -stimulated  bbbbb2 insulin eeeee2  secretion
CPR:4	Incubation with  bbbbb1 metformin eeeee1  (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of  bbbbb2 insulin eeeee2  secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells
CPR:4	The inhibitory effects of  bbbbb1 metformin eeeee1  on  bbbbb2 insulin eeeee2  secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.
CPR:4	Increases in  bbbbb1 glucose eeeee1  concentration from 0 to 3 and from 3 to 17 mM inhibited  bbbbb2 AMPK eeeee2  activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells
CPR:2	The ability of this cis-acting  bbbbb1 RAR-RXR binding element eeeee1  to activate transcription in response to  bbbbb2 RA eeeee2  also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CPR:2	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to  bbbbb1 RA eeeee1  also depended on downstream sequences where an  bbbbb2 octamer transcription factor 1 eeeee2  (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CPR:2	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to  bbbbb1 RA eeeee1  also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a  bbbbb2 nuclear factor of activated T cells eeeee2  (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CPR:2	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to  bbbbb1 RA eeeee1  also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells ( bbbbb2 NFATc eeeee2 ) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CPR:2	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to  bbbbb1 RA eeeee1  also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a  bbbbb2 cyclic AMP response element binding factor eeeee2  (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CPR:2	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to  bbbbb1 RA eeeee1  also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor ( bbbbb2 CREB eeeee2 ) site between the transcriptional start and first exon of the blr1 gene, were necessary
CPR:2	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to  bbbbb1 RA eeeee1  also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the  bbbbb2 blr1 eeeee2  gene, were necessary
CPR:2	A transcription factor-transcription factor binding array analysis of nuclear lysate from  bbbbb1 RA eeeee1 -treated cells indicated several prominent RARalpha binding partners; among these,  bbbbb2 Oct1 eeeee2 , NFATc3, and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex
CPR:2	A transcription factor-transcription factor binding array analysis of nuclear lysate from  bbbbb1 RA eeeee1 -treated cells indicated several prominent RARalpha binding partners; among these, Oct1,  bbbbb2 NFATc3 eeeee2 , and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex
CPR:2	A transcription factor-transcription factor binding array analysis of nuclear lysate from  bbbbb1 RA eeeee1 -treated cells indicated several prominent RARalpha binding partners; among these, Oct1, NFATc3, and  bbbbb2 CREB2 eeeee2  were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex
CPR:2	In sum the results of the present study indicate that  bbbbb1 RA eeeee1 -induced expression of blr1 expression depends on a novel  bbbbb2 RA response element eeeee2 
CPR:2	Within this sequence DNase I footprinting revealed that  bbbbb1 RA eeeee1  induced binding of a nuclear protein complex to an element containing two  bbbbb2 GT boxes eeeee2 
CPR:2	Within this sequence DNase I footprinting revealed that  bbbbb1 RA eeeee1  induced binding of a  bbbbb2 nuclear protein complex eeeee2  to an element containing two GT boxes
CPR:2	Both  bbbbb1 GT boxes eeeee1  were needed for binding the complex, and mutation of either GT box caused the loss of transcriptional activation by  bbbbb2 RA eeeee2 
CPR:2	A transcription factor-transcription factor binding array analysis of nuclear lysate from  bbbbb1 RA eeeee1 -treated cells indicated several prominent  bbbbb2 RARalpha eeeee2  binding partners; among these, Oct1, NFATc3, and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex
CPR:3	A 5'-flanking region capable of supporting  bbbbb1 RA eeeee1 -induced  bbbbb2 blr1 eeeee2  activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA
CPR:3	RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of  bbbbb1 blr1 eeeee1  expression by  bbbbb2 RA eeeee2 
CPR:3	A novel retinoic acid-responsive element regulates  bbbbb1 retinoic acid eeeee1 -induced  bbbbb2 BLR1 eeeee2  expression
CPR:3	 bbbbb1 RA eeeee1  is known to induce expression of the  bbbbb2 Burkitt's lymphoma receptor 1 eeeee2  (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA
CPR:3	 bbbbb1 RA eeeee1  is known to induce expression of the Burkitt's lymphoma receptor 1 ( bbbbb2 BLR1 eeeee2 ) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA
CPR:3	In sum the results of the present study indicate that  bbbbb1 RA eeeee1 -induced expression of  bbbbb2 blr1 eeeee2  expression depends on a novel RA response element
CPR:4	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to  bbbbb1 RA eeeee1  also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a  bbbbb2 nuclear factor of activated T cells eeeee2  (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CPR:2	Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI. [3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained  bbbbb1 [3H]DMI eeeee1  with the  bbbbb2 NET eeeee2 
CPR:2	The results demonstrate that  bbbbb1 DMI eeeee1  and nisoxetine are persistently retained in cell membranes, at least partly in association with the  bbbbb2 NET eeeee2 
CPR:2	The results demonstrate that DMI and  bbbbb1 nisoxetine eeeee1  are persistently retained in cell membranes, at least partly in association with the  bbbbb2 NET eeeee2 
CPR:2	The retention and slow diffusion of  bbbbb1 DMI eeeee1  and nisoxetine from membranes may contribute to their pharmacological and modulatory action on  bbbbb2 NET eeeee2 .
CPR:2	The retention and slow diffusion of DMI and  bbbbb1 nisoxetine eeeee1  from membranes may contribute to their pharmacological and modulatory action on  bbbbb2 NET eeeee2 .
CPR:2	Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI.  bbbbb1 [3H]DMI eeeee1  trapped in membranes was displaceable by the structurally unrelated  bbbbb2 NET eeeee2  inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET
CPR:4	The persistent membrane retention of  bbbbb1 desipramine eeeee1  causes lasting inhibition of  bbbbb2 norepinephrine transporter eeeee2  function
CPR:4	Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI. [3H]DMI trapped in membranes was displaceable by the structurally unrelated  bbbbb1 NET eeeee1  inhibitor,  bbbbb2 nisoxetine eeeee2 , in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET
CPR:2	AT1-receptor antagonism in hypertension: what has been learned with irbesartan?  bbbbb1 Irbesartan eeeee1  is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype ( bbbbb2 AT1 eeeee2 -receptor)
CPR:4	 bbbbb1 Irbesartan eeeee1  may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of  bbbbb2 angiotensin II eeeee2 
CPR:4	 bbbbb1 Irbesartan eeeee1  may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this  bbbbb2 AT1 eeeee2 -blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II
CPR:6	AT1-receptor antagonism in hypertension: what has been learned with irbesartan?  bbbbb1 Irbesartan eeeee1  is a long-acting  bbbbb2 angiotensin II eeeee2  antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)
CPR:10	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of (-)-isoprenaline and (-)-CGP12177.(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM).  bbbbb1 (-)-[(3)H]-CGP12177 eeeee1  dissociated from the  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CPR:2	We conclude that  bbbbb1 (-)-[(3)H]-CGP12177 eeeee1  binds at two sites in the recombinant  bbbbb2 beta(1)-adrenoceptor eeeee2 . (-)-CGP12177 is an antagonist of catecholamine effects through the H-site and a non-conventional partial agonist through the L-site. beta-blockers are more potent antagonists through the H-site than the L-site
CPR:2	To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites,  bbbbb1 human beta(1)-adrenoceptors eeeee1 , expressed in CHO cells, were labelled with  bbbbb2 (-)-[(3)H]-CGP12177 eeeee2 
CPR:2	To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two  bbbbb1 beta(1)-adrenoceptor eeeee1  sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with  bbbbb2 (-)-[(3)H]-CGP12177 eeeee2 
CPR:2	To verify the hypothesis that the non-conventional partial agonist  bbbbb1 (-)-CGP12177 eeeee1  binds at two beta(1)-adrenoceptor sites,  bbbbb2 human beta(1)-adrenoceptors eeeee2 , expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177
CPR:2	To verify the hypothesis that the non-conventional partial agonist  bbbbb1 (-)-CGP12177 eeeee1  binds at two  bbbbb2 beta(1)-adrenoceptor eeeee2  sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177
CPR:2	Binding of  bbbbb1 (-)-[3H]-CGP12177 eeeee1  at two sites in recombinant  bbbbb2 human beta 1-adrenoceptors eeeee2  and interaction with beta-blockers
CPR:5	To verify the hypothesis that the non-conventional partial agonist  bbbbb1 (-)-CGP12177 eeeee1  binds at two beta(1)-adrenoceptor sites,  bbbbb2 human beta(1)-adrenoceptors eeeee2 , expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177
CPR:5	To verify the hypothesis that the non-conventional partial agonist  bbbbb1 (-)-CGP12177 eeeee1  binds at two  bbbbb2 beta(1)-adrenoceptor eeeee2  sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177
CPR:10	 bbbbb1 Perforin eeeee1  release from peripheral blood CTLs after PMA/ionomycin-stimulation was not influenced significantly by  bbbbb2 IMQ eeeee2 
CPR:3	 bbbbb1 Imiquimod eeeee1  (IMQ), an activator of  bbbbb2 Toll-like receptor-7 eeeee2  (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo
CPR:3	 bbbbb1 Imiquimod eeeee1  (IMQ), an activator of Toll-like receptor-7 ( bbbbb2 TLR-7 eeeee2 ), induces by several routes a profound anti-viral and anti-tumor effect in vivo
CPR:3	Imiquimod ( bbbbb1 IMQ eeeee1 ), an activator of  bbbbb2 Toll-like receptor-7 eeeee2  (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo
CPR:3	Imiquimod ( bbbbb1 IMQ eeeee1 ), an activator of Toll-like receptor-7 ( bbbbb2 TLR-7 eeeee2 ), induces by several routes a profound anti-viral and anti-tumor effect in vivo
CPR:3	Thus, the biological activity of  bbbbb1 IMQ eeeee1  appears to exceed its previously known functions, inasmuch as it boosts up significantly the  bbbbb2 perforin eeeee2 -granule system.
CPR:3	In peripheral lymphocytes of healthy and diseased subjects,  bbbbb1 IMQ eeeee1  induced a significant increase of  bbbbb2 perforin eeeee2 (+) CTLs within 12h in all experiments performed
CPR:3	This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of  bbbbb1 perforin eeeee1 (+) CTLs were induced by 2.5 microg/ml [corrected]  bbbbb2 IMQ eeeee2 
CPR:3	 bbbbb1 Imiquimod eeeee1 , a Toll-like receptor-7 agonist, induces  bbbbb2 perforin eeeee2  in cytotoxic T lymphocytes in vitro
CPR:5	 bbbbb1 Imiquimod eeeee1 , a  bbbbb2 Toll-like receptor-7 eeeee2  agonist, induces perforin in cytotoxic T lymphocytes in vitro
CPR:3	 bbbbb1 Ang II eeeee1  level in plasma and mesenteric arteries in imidapril group was significantly lower than that in  bbbbb2 irbesartan eeeee2  group (P<0.05)
CPR:3	The  bbbbb1 c-Jun eeeee1  absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY,  bbbbb2 imidapril eeeee2 , and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)
CPR:3	The c-Jun absorbed light value/ bbbbb1 GAPDH eeeee1  absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY,  bbbbb2 imidapril eeeee2 , and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)
CPR:3	The  bbbbb1 c-Jun eeeee1  absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and  bbbbb2 irbesartan eeeee2  groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)
CPR:3	The c-Jun absorbed light value/ bbbbb1 GAPDH eeeee1  absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and  bbbbb2 irbesartan eeeee2  groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)
CPR:3	 bbbbb1 Ang II eeeee1  level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in  bbbbb2 irbesartan eeeee2  group and lower in imidapril group
CPR:3	The ratio of  bbbbb1 TGF-beta1 eeeee1  absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group,  bbbbb2 imidapril eeeee2  group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01)
CPR:3	The ratio of TGF-beta1 absorbed light value to  bbbbb1 GAPDH eeeee1  absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group,  bbbbb2 imidapril eeeee2  group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01)
CPR:3	The ratio of  bbbbb1 TGF-beta1 eeeee1  absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and  bbbbb2 irbesartan eeeee2  group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01)
CPR:3	The ratio of TGF-beta1 absorbed light value to  bbbbb1 GAPDH eeeee1  absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and  bbbbb2 irbesartan eeeee2  group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01)
CPR:4	 bbbbb1 Ang II eeeee1  level in plasma and mesenteric arteries in  bbbbb2 imidapril eeeee2  group was significantly lower than that in irbesartan group (P<0.05)
CPR:4	CONCLUSION:  bbbbb1 Imidapril eeeee1  and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of  bbbbb2 TGF-beta1 eeeee2 , c-Jun in SHR
CPR:4	CONCLUSION:  bbbbb1 Imidapril eeeee1  and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1,  bbbbb2 c-Jun eeeee2  in SHR
CPR:4	CONCLUSION: Imidapril and  bbbbb1 irbesartan eeeee1  can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of  bbbbb2 TGF-beta1 eeeee2 , c-Jun in SHR
CPR:4	CONCLUSION: Imidapril and  bbbbb1 irbesartan eeeee1  can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1,  bbbbb2 c-Jun eeeee2  in SHR
CPR:4	 bbbbb1 Ang II eeeee1  level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in  bbbbb2 imidapril eeeee2  group
CPR:2	Plasma from  bbbbb1 duloxetine eeeee1 -treated subjects (ex vivo effect) dose-dependently decreased radioligand binding to  bbbbb2 human NET eeeee2  (maximum inhibition was 60%) (P=0.02)
CPR:6	BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized  bbbbb1 NET eeeee1  by a range of doses of  bbbbb2 duloxetine eeeee2  [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process
CPR:6	BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized  bbbbb1 NET eeeee1  by a range of doses of duloxetine [ bbbbb2 (+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine eeeee2 ], which blocks the NE reuptake process
CPR:9	BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized  bbbbb1 NET eeeee1  by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the  bbbbb2 NE eeeee2  reuptake process
CPR:4	 bbbbb1 Auranofin eeeee1 , an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and  bbbbb2 glutathione peroxidase eeeee2 
CPR:4	 bbbbb1 Auranofin eeeee1 , an antirheumatic gold compound, is an inhibitor of  bbbbb2 selenocysteine enzymes eeeee2 , such as thioredoxin reductase and glutathione peroxidase
CPR:4	 bbbbb1 Auranofin eeeee1 , an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as  bbbbb2 thioredoxin reductase eeeee2  and glutathione peroxidase
CPR:4	There was significantly less  bbbbb1 thioredoxin reductase eeeee1  activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of  bbbbb2 auranofin eeeee2  used was able to selectively inhibit one of these enzyme systems
CPR:2	Even though its inability to shift between the trivalent and a divalent oxidation state precludes that  bbbbb1 gallium eeeee1  behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with  bbbbb2 transferrin eeeee2  and transferrin receptor-mediated endocytosis
CPR:2	Even though its inability to shift between the trivalent and a divalent oxidation state precludes that  bbbbb1 gallium eeeee1  behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and  bbbbb2 transferrin receptor eeeee2 -mediated endocytosis
CPR:2	Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an  bbbbb1 iron eeeee1  analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with  bbbbb2 transferrin eeeee2  and transferrin receptor-mediated endocytosis
CPR:2	Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an  bbbbb1 iron eeeee1  analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and  bbbbb2 transferrin receptor eeeee2 -mediated endocytosis
CPR:2	Apart from the consequences of iron deprivation,  bbbbb1 gallium eeeee1  exerts cytotoxic effects by direct interaction with the iron-dependent enzyme  bbbbb2 ribonucleotide reductase eeeee2 , resulting in reduced dNTP pools and inhibition of DNA synthesis
CPR:2	Apart from the consequences of iron deprivation, gallium exerts cytotoxic effects by direct interaction with the  bbbbb1 iron eeeee1 -dependent enzyme  bbbbb2 ribonucleotide reductase eeeee2 , resulting in reduced dNTP pools and inhibition of DNA synthesis
CPR:2	Both the abundance of  bbbbb1 transferrin receptors eeeee1  and upregulation of ribonucleotide reductase render tumors susceptible to  bbbbb2 gallium eeeee2 -induced cytotoxicity
CPR:2	Both the abundance of transferrin receptors and upregulation of  bbbbb1 ribonucleotide reductase eeeee1  render tumors susceptible to  bbbbb2 gallium eeeee2 -induced cytotoxicity
CPR:4	Furthermore,  bbbbb1 gallium eeeee1  also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on  bbbbb2 vacuolar-type H(+)-ATPases eeeee2 
CPR:4	However, some experimental findings raise the question whether these effects resulting from the  bbbbb1 iron eeeee1 -mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting  bbbbb2 tubulin eeeee2  polymerization
CPR:4	However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of  bbbbb1 gallium eeeee1  are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting  bbbbb2 tubulin eeeee2  polymerization
CPR:2	Here, we show that the  bbbbb1 synaptic vesicle protein SV2A eeeee1  is the brain binding site of  bbbbb2 levetiracetam eeeee2  (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy
CPR:2	Here, we show that the  bbbbb1 synaptic vesicle protein SV2A eeeee1  is the brain binding site of levetiracetam ( bbbbb2 LEV eeeee2 ), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy
CPR:2	The  bbbbb1 synaptic vesicle protein SV2A eeeee1  is the binding site for the antiepileptic drug  bbbbb2 levetiracetam eeeee2 
CPR:2	These experimental results suggest that  bbbbb1 SV2A eeeee1  is the binding site of  bbbbb2 LEV eeeee2  in the brain and that LEV acts by modulating the function of SV2A, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs
CPR:2	These experimental results suggest that SV2A is the binding site of LEV in the brain and that  bbbbb1 LEV eeeee1  acts by modulating the function of  bbbbb2 SV2A eeeee2 , supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs
CPR:2	Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative, indicating that  bbbbb1 SV2A eeeee1  is necessary for  bbbbb2 LEV eeeee2  binding
CPR:2	 bbbbb1 LEV eeeee1  and related compounds bind to  bbbbb2 SV2A eeeee2  expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding
CPR:2	LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that  bbbbb1 SV2A eeeee1  is sufficient for  bbbbb2 LEV eeeee2  binding
CPR:2	Furthermore, there is a high degree of correlation between binding affinities of a series of  bbbbb1 LEV eeeee1  derivatives to  bbbbb2 SV2A eeeee2  in fibroblasts and to the LEV-binding site in brain
CPR:2	Their affinity for  bbbbb1 GABA eeeee1  was moderate (EC50 = 30 microM), and the Hill coefficient was 1.3, corresponding to two  bbbbb2 GABA binding sites eeeee2 
CPR:2	 bbbbb1 GABA eeeee1 -evoked currents were completely and reversibly blocked by the competitive  bbbbb2 GABAA receptor eeeee2  antagonist bicuculline (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors
CPR:2	Furthermore,  bbbbb1 GABA receptors eeeee1  of horizontal cells were modulated by extracellular application of  bbbbb2 diazepam eeeee2 , zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors
CPR:2	Furthermore,  bbbbb1 GABA receptors eeeee1  of horizontal cells were modulated by extracellular application of diazepam,  bbbbb2 zolpidem eeeee2 , methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors
CPR:2	Furthermore,  bbbbb1 GABA receptors eeeee1  of horizontal cells were modulated by extracellular application of diazepam, zolpidem,  bbbbb2 methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate eeeee2 , pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors
CPR:2	Furthermore,  bbbbb1 GABA receptors eeeee1  of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate,  bbbbb2 pentobarbital eeeee2 , and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors
CPR:2	Furthermore,  bbbbb1 GABA receptors eeeee1  of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and  bbbbb2 alphaxalone eeeee2 , thus showing typical pharmacological properties of CNS GABAA receptors
CPR:6	GABA-evoked currents were completely and reversibly blocked by the competitive  bbbbb1 GABAA receptor eeeee1  antagonist  bbbbb2 bicuculline eeeee2  (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors
CPR:2	Cerebral  bbbbb1 histamine H1 receptor eeeee1  (H(1)R) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and  bbbbb2 [(11)C]-doxepin eeeee2 
CPR:2	Cerebral histamine H1 receptor ( bbbbb1 H(1)R eeeee1 ) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and  bbbbb2 [(11)C]-doxepin eeeee2 
CPR:2	Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain  bbbbb1 histamine H1-receptor eeeee1  occupancy using  bbbbb2 11C-doxepin eeeee2  positron emission tomography
CPR:2	This study compared the sedative profiles of the second-generation  bbbbb1 antihistamines eeeee1 , fexofenadine and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of  bbbbb2 histamine H1-receptor eeeee2  occupancy (H1RO) in the brain
CPR:2	This study compared the sedative profiles of the second-generation antihistamines,  bbbbb1 fexofenadine eeeee1  and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of  bbbbb2 histamine H1-receptor eeeee2  occupancy (H1RO) in the brain
CPR:2	This study compared the sedative profiles of the second-generation antihistamines, fexofenadine and  bbbbb1 cetirizine eeeee1 , using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of  bbbbb2 histamine H1-receptor eeeee2  occupancy (H1RO) in the brain
CPR:2	Central effects of  bbbbb1 fexofenadine eeeee1  and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain  bbbbb2 histamine H1-receptor eeeee2  occupancy using 11C-doxepin positron emission tomography
CPR:2	Central effects of fexofenadine and  bbbbb1 cetirizine eeeee1 : measurement of psychomotor performance, subjective sleepiness, and brain  bbbbb2 histamine H1-receptor eeeee2  occupancy using 11C-doxepin positron emission tomography
CPR:6	 bbbbb1 Histamine H1-receptor eeeee1  (H1R) antagonists, or  bbbbb2 antihistamines eeeee2 , often induce sedative side effects when used for the treatment of allergic disorders
CPR:6	Histamine H1-receptor ( bbbbb1 H1R eeeee1 ) antagonists, or  bbbbb2 antihistamines eeeee2 , often induce sedative side effects when used for the treatment of allergic disorders
CPR:6	A novel membrane sensor for  bbbbb1 histamine H1-receptor eeeee1  antagonist " bbbbb2 fexofenadine eeeee2 "
CPR:2	 bbbbb1 Thymidylate synthase eeeee1  (TS) continues to be a critical target for  bbbbb2 5-fluorouracil eeeee2  (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	Thymidylate synthase ( bbbbb1 TS eeeee1 ) continues to be a critical target for  bbbbb2 5-fluorouracil eeeee2  (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	 bbbbb1 Thymidylate synthase eeeee1  (TS) continues to be a critical target for 5-fluorouracil ( bbbbb2 5-FU eeeee2 ) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	Thymidylate synthase ( bbbbb1 TS eeeee1 ) continues to be a critical target for 5-fluorouracil ( bbbbb2 5-FU eeeee2 ) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	 bbbbb1 Thymidylate synthase eeeee1  (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs,  bbbbb2 UFT eeeee2 /LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	Thymidylate synthase ( bbbbb1 TS eeeee1 ) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs,  bbbbb2 UFT eeeee2 /LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	 bbbbb1 Thymidylate synthase eeeee1  (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/ bbbbb2 LV eeeee2  (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	Thymidylate synthase ( bbbbb1 TS eeeee1 ) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/ bbbbb2 LV eeeee2  (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	 bbbbb1 Thymidylate synthase eeeee1  (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV ( bbbbb2 Orzel eeeee2 ), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	Thymidylate synthase ( bbbbb1 TS eeeee1 ) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV ( bbbbb2 Orzel eeeee2 ), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	 bbbbb1 Thymidylate synthase eeeee1  (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel),  bbbbb2 capecitabine eeeee2  (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	Thymidylate synthase ( bbbbb1 TS eeeee1 ) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel),  bbbbb2 capecitabine eeeee2  (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	 bbbbb1 Thymidylate synthase eeeee1  (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine ( bbbbb2 Xeloda eeeee2 ), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	Thymidylate synthase ( bbbbb1 TS eeeee1 ) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine ( bbbbb2 Xeloda eeeee2 ), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	 bbbbb1 Thymidylate synthase eeeee1  (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and  bbbbb2 S-1 eeeee2 , primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:2	Thymidylate synthase ( bbbbb1 TS eeeee1 ) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and  bbbbb2 S-1 eeeee2 , primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CPR:4	While fluoropyrimidine antimetabolites have other sites of action, antifolates  bbbbb1 ZD1694 eeeee1  (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent  bbbbb2 TS eeeee2  inhibitors
CPR:4	While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 ( bbbbb1 raltitrexed eeeee1 , Tomudex) and AG337 (Thymitag) are more specific and potent  bbbbb2 TS eeeee2  inhibitors
CPR:4	While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed,  bbbbb1 Tomudex eeeee1 ) and AG337 (Thymitag) are more specific and potent  bbbbb2 TS eeeee2  inhibitors
CPR:4	While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and  bbbbb1 AG337 eeeee1  (Thymitag) are more specific and potent  bbbbb2 TS eeeee2  inhibitors
CPR:4	While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 ( bbbbb1 Thymitag eeeee1 ) are more specific and potent  bbbbb2 TS eeeee2  inhibitors
CPR:9	 bbbbb1 Thymidylate synthase eeeee1  (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of  bbbbb2 2-deoxythymidine-5-monophosphate eeeee2 , a precursor for DNA synthesis
CPR:9	Thymidylate synthase ( bbbbb1 TS eeeee1 ) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of  bbbbb2 2-deoxythymidine-5-monophosphate eeeee2 , a precursor for DNA synthesis
CPR:9	The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that  bbbbb1 thymidine phosphorylase eeeee1 , the activating enzyme for  bbbbb2 5-FU eeeee2 , is expressed at a higher level in tumor tissue compared with normal tissue counterparts
CPR:4	 bbbbb1 Orlistat eeeee1  is an inhibitor of  bbbbb2 pancreatic lipase eeeee2  which is able to block the absorption of 30% of ingested fat
CPR:2	 bbbbb1 Bosentan eeeee1  also decreased viability as measured by the  bbbbb2 LDH eeeee2 , MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay
CPR:4	 bbbbb1 Troglitazone eeeee1 , bosentan and glibenclamide inhibit the  bbbbb2 bile salt export pump eeeee2  (Bsep) which transports taurocholate into bile
CPR:4	 bbbbb1 Troglitazone eeeee1 , bosentan and glibenclamide inhibit the bile salt export pump ( bbbbb2 Bsep eeeee2 ) which transports taurocholate into bile
CPR:4	Troglitazone,  bbbbb1 bosentan eeeee1  and glibenclamide inhibit the  bbbbb2 bile salt export pump eeeee2  (Bsep) which transports taurocholate into bile
CPR:4	Troglitazone,  bbbbb1 bosentan eeeee1  and glibenclamide inhibit the bile salt export pump ( bbbbb2 Bsep eeeee2 ) which transports taurocholate into bile
CPR:4	Troglitazone, bosentan and  bbbbb1 glibenclamide eeeee1  inhibit the  bbbbb2 bile salt export pump eeeee2  (Bsep) which transports taurocholate into bile
CPR:4	Troglitazone, bosentan and  bbbbb1 glibenclamide eeeee1  inhibit the bile salt export pump ( bbbbb2 Bsep eeeee2 ) which transports taurocholate into bile
CPR:9	Troglitazone, bosentan and glibenclamide inhibit the  bbbbb1 bile salt export pump eeeee1  (Bsep) which transports  bbbbb2 taurocholate eeeee2  into bile
CPR:9	Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump ( bbbbb1 Bsep eeeee1 ) which transports  bbbbb2 taurocholate eeeee2  into bile
CPR:2	Unique binding interactions of  bbbbb1 valdecoxib eeeee1  with  bbbbb2 COX-2 eeeee2  translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib)
CPR:2	The overall saturation binding affinity for  bbbbb1 COX-2 eeeee1  of  bbbbb2 valdecoxib eeeee2  is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min)
CPR:2	The overall saturation binding affinity for  bbbbb1 COX-2 eeeee1  of valdecoxib is 2.6 nM (compared with 1.6 nM for  bbbbb2 celecoxib eeeee2 , 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min)
CPR:2	The overall saturation binding affinity for  bbbbb1 COX-2 eeeee1  of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for  bbbbb2 rofecoxib eeeee2 , and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min)
CPR:2	The overall saturation binding affinity for  bbbbb1 COX-2 eeeee1  of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for  bbbbb2 etoricoxib eeeee2 ), with a slow off-rate (t(1/2) approximately 98 min)
CPR:2	Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of  bbbbb1 COX-2 eeeee1  (110,000 M/s compared with 7000 M/s for  bbbbb2 rofecoxib eeeee2  and 80 M/s for etoricoxib)
CPR:2	 bbbbb1 Valdecoxib eeeee1 : assessment of  bbbbb2 cyclooxygenase-2 eeeee2  potency and selectivity
CPR:2	Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of  bbbbb1 COX-2 eeeee1  (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for  bbbbb2 etoricoxib eeeee2 )
CPR:2	Collectively, these data provide a mechanistic basis for the potency and in vitro selectivity of  bbbbb1 valdecoxib eeeee1  for  bbbbb2 COX-2 eeeee2 
CPR:4	Unique binding interactions of  bbbbb1 valdecoxib eeeee1  with COX-2 translate into a fast rate of inactivation of  bbbbb2 COX-2 eeeee2  (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib)
CPR:4	We report here the pharmacological properties of a third selective  bbbbb1 COX-2 eeeee1  inhibitor,  bbbbb2 valdecoxib eeeee2 , which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied
CPR:4	We report here the pharmacological properties of a third selective COX-2 inhibitor,  bbbbb1 valdecoxib eeeee1 , which is the most potent and in vitro selective of the marketed  bbbbb2 COX-2 eeeee2  inhibitors that we have studied
CPR:4	 bbbbb1 Valdecoxib eeeee1  potently inhibits recombinant  bbbbb2 COX-2 eeeee2 , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib
CPR:4	Valdecoxib potently inhibits recombinant  bbbbb1 COX-2 eeeee1 , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for  bbbbb2 celecoxib eeeee2 , 0.5 microM for rofecoxib, and 5 microM for etoricoxib
CPR:4	Valdecoxib potently inhibits recombinant  bbbbb1 COX-2 eeeee1 , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for  bbbbb2 rofecoxib eeeee2 , and 5 microM for etoricoxib
CPR:4	Valdecoxib potently inhibits recombinant  bbbbb1 COX-2 eeeee1 , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for  bbbbb2 etoricoxib eeeee2 
CPR:4	 bbbbb1 Valdecoxib eeeee1  inhibits  bbbbb2 COX-1 eeeee2  in a competitive fashion only at very high concentrations (IC(50) = 150 microM)
CPR:4	 bbbbb1 Valdecoxib eeeee1  showed similar activity in the  bbbbb2 human whole-blood COX eeeee2  assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)
CPR:4	 bbbbb1 Valdecoxib eeeee1  showed similar activity in the human whole-blood COX assay ( bbbbb2 COX-2 eeeee2  IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)
CPR:4	 bbbbb1 Valdecoxib eeeee1  showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM;  bbbbb2 COX-1 eeeee2  IC(50) = 21.9 microM)
CPR:9	The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing  bbbbb1 prostaglandin eeeee1  formation from  bbbbb2 COX-1 eeeee2 
CPR:3	An angiotensin II AT1 receptor antagonist,  bbbbb1 telmisartan eeeee1  augments glucose uptake and  bbbbb2 GLUT4 eeeee2  protein expression in 3T3-L1 adipocytes
CPR:3	Treatment of both differentiating adipocytes and fully differentiated adipocytes with  bbbbb1 telmisartan eeeee1  caused a dose-dependent increase in mRNA levels for  bbbbb2 PPARgamma eeeee2  target genes such as aP2 and adiponectin
CPR:3	Treatment of both differentiating adipocytes and fully differentiated adipocytes with  bbbbb1 telmisartan eeeee1  caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as  bbbbb2 aP2 eeeee2  and adiponectin
CPR:3	Treatment of both differentiating adipocytes and fully differentiated adipocytes with  bbbbb1 telmisartan eeeee1  caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and  bbbbb2 adiponectin eeeee2 
CPR:3	By contrast,  bbbbb1 telmisartan eeeee1  attenuated  bbbbb2 11beta-hydroxysteroid dehydrogenase type 1 eeeee2  mRNA level in differentiated adipocytes
CPR:3	Of note, we demonstrated for the first time that  bbbbb1 telmisartan eeeee1  augmented  bbbbb2 GLUT4 eeeee2  protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.
CPR:6	An  bbbbb1 angiotensin II AT1 receptor eeeee1  antagonist,  bbbbb2 telmisartan eeeee2  augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes
CPR:9	An angiotensin II AT1 receptor antagonist, telmisartan augments  bbbbb1 glucose eeeee1  uptake and  bbbbb2 GLUT4 eeeee2  protein expression in 3T3-L1 adipocytes
CPR:9	Of note, we demonstrated for the first time that telmisartan augmented  bbbbb1 GLUT4 eeeee1  protein expression and  bbbbb2 2-deoxy glucose eeeee2  uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.
CPR:1	We found a strong interaction of baseline FEV(1) with the  bbbbb1 Arg16Glycine eeeee1  ( bbbbb2 Gly eeeee2 ) polymorphism in predicting bronchodilator response
CPR:2	Genetic variants at the  bbbbb1 beta(2)-adrenergic receptor eeeee1  (beta(2)AR) may modify asthma severity and  bbbbb2 albuterol eeeee2  responsiveness
CPR:2	Genetic variants at the beta(2)-adrenergic receptor ( bbbbb1 beta(2)AR eeeee1 ) may modify asthma severity and  bbbbb2 albuterol eeeee2  responsiveness
CPR:2	We tested the association of  bbbbb1 beta(2)AR eeeee1  genotypes with asthma severity and bronchodilator response to  bbbbb2 albuterol eeeee2  in Puerto Ricans and Mexicans with asthma
CPR:4	Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme  bbbbb1 tyrosinase eeeee1 , as compared to the standard tyrosinase inhibitors  bbbbb2 kojic acid eeeee2  (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.
CPR:4	Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme  bbbbb1 tyrosinase eeeee1 , as compared to the standard tyrosinase inhibitors kojic acid (IC50=16.67 microM) and  bbbbb2 L-mimosine eeeee2  (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.
CPR:10	 bbbbb1 Antag I eeeee1  and Antag II did not alter  bbbbb2 oxytocin receptor eeeee2  number or binding affinity significantly at each time point studied compared with controls
CPR:10	Antag I and  bbbbb1 Antag II eeeee1  did not alter  bbbbb2 oxytocin receptor eeeee2  number or binding affinity significantly at each time point studied compared with controls
CPR:2	In Experiment 2,  bbbbb1 TT-235 eeeee1  induced a significant decrease (p<0.05) in  bbbbb2 oxytocin receptor eeeee2  number and binding affinity at both 0.5 and 4 hours compared with controls
CPR:2	In conclusion,  bbbbb1 TT-235 eeeee1  may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and  bbbbb2 oxytocin eeeee2  binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.
CPR:4	In Experiment 2,  bbbbb1 TT-235 eeeee1  induced a significant decrease (p<0.05) in  bbbbb2 oxytocin receptor eeeee2  number and binding affinity at both 0.5 and 4 hours compared with controls
CPR:4	In conclusion,  bbbbb1 TT-235 eeeee1  may inhibit the uterine response to oxytocin by decreasing  bbbbb2 oxytocin receptor eeeee2  numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.
CPR:4	In conclusion,  bbbbb1 TT-235 eeeee1  may inhibit the uterine response to  bbbbb2 oxytocin eeeee2  by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.
CPR:4	The purpose of the present study was to confirm the duration of  bbbbb1 TT-235 eeeee1  to block  bbbbb2 oxytocin eeeee2 -induced uterine contractions in estrous rats
CPR:4	Oxytocin antagonist (OTA),  bbbbb1 TT-235 eeeee1 , was developed by our group and shown to inhibit either spontaneous or  bbbbb2 oxytocin eeeee2 -induced uterine contractions in primates
CPR:4	In Experiment 1,  bbbbb1 Antag I eeeee1 , Antag II and TT-235 inhibited the integrated uterine response to  bbbbb2 oxytocin eeeee2  at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)
CPR:4	In Experiment 1, Antag I,  bbbbb1 Antag II eeeee1  and TT-235 inhibited the integrated uterine response to  bbbbb2 oxytocin eeeee2  at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)
CPR:4	In Experiment 1, Antag I, Antag II and  bbbbb1 TT-235 eeeee1  inhibited the integrated uterine response to  bbbbb2 oxytocin eeeee2  at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)
CPR:6	In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged  bbbbb1 oxytocin eeeee1  antagonist activity of  bbbbb2 TT-235 eeeee2 .
CPR:6	 bbbbb1 Oxytocin eeeee1  antagonist (OTA),  bbbbb2 TT-235 eeeee2 , was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates
CPR:10	In cellular assays,  bbbbb1 lumiracoxib eeeee1  had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of  bbbbb2 COX-1 eeeee2  at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1). 3
CPR:4	This manuscript presents the preclinical profile of  bbbbb1 lumiracoxib eeeee1 , a novel  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2) selective inhibitor. 2
CPR:4	This manuscript presents the preclinical profile of  bbbbb1 lumiracoxib eeeee1 , a novel cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ) selective inhibitor. 2
CPR:4	Ex vivo,  bbbbb1 lumiracoxib eeeee1  inhibited  bbbbb2 COX-1 eeeee2 -derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CPR:4	reclinical pharmacology of  bbbbb1 lumiracoxib eeeee1 : a novel selective inhibitor of  bbbbb2 cyclooxygenase-2 eeeee2 . 1
CPR:4	However, consistent with its low  bbbbb1 COX-1 eeeee1  inhibitory activity,  bbbbb2 lumiracoxib eeeee2  at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05). 7
CPR:4	 bbbbb1 Lumiracoxib eeeee1  inhibited purified  bbbbb2 COX-1 eeeee2  and COX-2 with K(i) values of 3 and 0.06 microM, respectively
CPR:4	 bbbbb1 Lumiracoxib eeeee1  inhibited purified COX-1 and  bbbbb2 COX-2 eeeee2  with K(i) values of 3 and 0.06 microM, respectively
CPR:4	However, consistent with its low  bbbbb1 COX-1 eeeee1  inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than  bbbbb2 diclofenac eeeee2  (P<0.05). 7
CPR:4	 bbbbb1 Lumiracoxib eeeee1  is a highly selective  bbbbb2 COX-2 eeeee2  inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.
CPR:4	Lumiracoxib is a highly selective  bbbbb1 COX-2 eeeee1  inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with  bbbbb2 diclofenac eeeee2 , the reference NSAID, but with much improved gastrointestinal safety.
CPR:4	In cellular assays,  bbbbb1 lumiracoxib eeeee1  had an IC(50) of 0.14 microM in  bbbbb2 COX-2 eeeee2 -expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1). 3
CPR:4	In a human whole blood assay, IC(50) values for  bbbbb1 lumiracoxib eeeee1  were 0.13 microM for  bbbbb2 COX-2 eeeee2  and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515). 4
CPR:4	In a human whole blood assay, IC(50) values for  bbbbb1 lumiracoxib eeeee1  were 0.13 microM for COX-2 and 67 microM for  bbbbb2 COX-1 eeeee2  (COX-1/COX-2 selectivity ratio 515). 4
CPR:4	In a human whole blood assay, IC(50) values for  bbbbb1 lumiracoxib eeeee1  were 0.13 microM for COX-2 and 67 microM for COX-1 ( bbbbb2 COX-1 eeeee2 /COX-2 selectivity ratio 515). 4
CPR:4	In a human whole blood assay, IC(50) values for  bbbbb1 lumiracoxib eeeee1  were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/ bbbbb2 COX-2 eeeee2  selectivity ratio 515). 4
CPR:9	Ex vivo, lumiracoxib inhibited  bbbbb1 COX-1 eeeee1 -derived  bbbbb2 thromboxane B(2) eeeee2  (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CPR:9	Ex vivo, lumiracoxib inhibited  bbbbb1 COX-1 eeeee1 -derived thromboxane B(2) ( bbbbb2 TxB(2) eeeee2 ) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CPR:9	Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas  bbbbb1 COX-2 eeeee1 -derived production of  bbbbb2 prostaglandin E(2) eeeee2  (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CPR:9	Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas  bbbbb1 COX-2 eeeee1 -derived production of prostaglandin E(2) ( bbbbb2 PGE(2) eeeee2 ) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CPR:9	As  bbbbb1 thiamine eeeee1  metabolism deficiencies have been seen in placental infarcts previously, these indicate that  bbbbb2 PP20 eeeee2 /hTPK may have a role in placental diseases
CPR:9	As  bbbbb1 thiamine eeeee1  metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20/ bbbbb2 hTPK eeeee2  may have a role in placental diseases
CPR:5	 bbbbb1 Denufosol eeeee1  is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated  bbbbb2 P2Y(2) eeeee2  agonists
CPR:5	Safety and tolerability of  bbbbb1 denufosol tetrasodium eeeee1  inhalation solution, a novel  bbbbb2 P2Y2 receptor eeeee2  agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis
CPR:5	 bbbbb1 Denufosol tetrasodium eeeee1  (INS37217) is a selective  bbbbb2 P2Y(2) eeeee2  agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF
CPR:5	Denufosol tetrasodium ( bbbbb1 INS37217 eeeee1 ) is a selective  bbbbb2 P2Y(2) eeeee2  agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF
CPR:9	The  bbbbb1 Cl(-) eeeee1  secretory response is mediated via a non- bbbbb2 CFTR eeeee2  pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport
CPR:2	 bbbbb1 Dextromethorphan eeeee1  and dimemorfan are high-affinity ligands at  bbbbb2 sigma1 receptors eeeee2 
CPR:2	Dextromethorphan and  bbbbb1 dimemorfan eeeee1  are high-affinity ligands at  bbbbb2 sigma1 receptors eeeee2 
CPR:2	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of  bbbbb1 dextromethorphan eeeee1  or dimemorfan is, at least in part, related to  bbbbb2 sigma1 receptor eeeee2 -activated modulation of AP-1 transcription factors
CPR:2	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of  bbbbb1 dextromethorphan eeeee1  or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of  bbbbb2 AP-1 eeeee2  transcription factors
CPR:2	The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via  bbbbb1 sigma1 receptor eeeee1  activation: comparison with the effects of  bbbbb2 dextromethorphan eeeee2 
CPR:2	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or  bbbbb1 dimemorfan eeeee1  is, at least in part, related to  bbbbb2 sigma1 receptor eeeee2 -activated modulation of AP-1 transcription factors
CPR:2	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or  bbbbb1 dimemorfan eeeee1  is, at least in part, related to sigma1 receptor-activated modulation of  bbbbb2 AP-1 eeeee2  transcription factors
CPR:3	Dimemorfan pre-treatment also attenuated the  bbbbb1 KA eeeee1 -induced increases in c-fos/c-jun expression,  bbbbb2 activator protein (AP)-1 eeeee2  DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus
CPR:3	The dextromethorphan analog  bbbbb1 dimemorfan eeeee1  attenuates kainate-induced seizures via  bbbbb2 sigma1 receptor eeeee2  activation: comparison with the effects of dextromethorphan
CPR:3	The  bbbbb1 dextromethorphan eeeee1  analog dimemorfan attenuates kainate-induced seizures via  bbbbb2 sigma1 receptor eeeee2  activation: comparison with the effects of dextromethorphan
CPR:3	Dimemorfan pre-treatment also attenuated the  bbbbb1 KA eeeee1 -induced increases in  bbbbb2 c-fos eeeee2 /c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus
CPR:3	Dimemorfan pre-treatment also attenuated the  bbbbb1 KA eeeee1 -induced increases in c-fos/ bbbbb2 c-jun eeeee2  expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus
CPR:4	 bbbbb1 Dimemorfan eeeee1  pre-treatment also attenuated the KA-induced increases in  bbbbb2 c-fos eeeee2 /c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus
CPR:4	 bbbbb1 Dimemorfan eeeee1  pre-treatment also attenuated the KA-induced increases in c-fos/ bbbbb2 c-jun eeeee2  expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus
CPR:4	 bbbbb1 Dimemorfan eeeee1  pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression,  bbbbb2 activator protein (AP)-1 eeeee2  DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus
CPR:6	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective  bbbbb1 sigma1 receptor eeeee1  antagonist  bbbbb2 BD 1047 eeeee2 , suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors
CPR:1	For both agonists, important binding domains were the extracellular  bbbbb1 N eeeee1 -terminus (=E1) and the extracellular loops E2 and E3 from the  bbbbb2 oxytocin receptor eeeee2 
CPR:2	In contrast, the binding of  bbbbb1 barusiban eeeee1  was significantly improved when the transmembrane domains 1 and 2 were transferred from the oxytocin receptor to the  bbbbb2 vasopressin V2 receptor eeeee2 
CPR:2	The binding domain of  bbbbb1 barusiban eeeee1  differs from the binding domain of the agonists and the nonselective  bbbbb2 oxytocin receptor eeeee2  antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies
CPR:2	We have analyzed binding domains of the  bbbbb1 oxytocin receptor eeeee1  for  bbbbb2 barusiban eeeee2 , a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CPR:2	Binding domains of the  bbbbb1 oxytocin receptor eeeee1  for the selective oxytocin receptor antagonist  bbbbb2 barusiban eeeee2  in comparison to the agonists oxytocin and carbetocin
CPR:2	For the vasopressin V1A/oxytocin receptor antagonist  bbbbb1 atosiban eeeee1 , none of the receptor constructs were able to provide a binding with higher affinity than the starting  bbbbb2 vasopressin V2 receptor eeeee2 
CPR:5	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  bbbbb1 vasopressin V1A/oxytocin receptor eeeee1  antagonist atosiban and the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CPR:5	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  bbbbb1 vasopressin V1A/oxytocin receptor eeeee1  antagonist atosiban and the agonists oxytocin and  bbbbb2 carbetocin eeeee2 
CPR:5	Binding domains of the oxytocin receptor for the selective  bbbbb1 oxytocin receptor eeeee1  antagonist barusiban in comparison to the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CPR:5	Binding domains of the oxytocin receptor for the selective  bbbbb1 oxytocin receptor eeeee1  antagonist barusiban in comparison to the agonists oxytocin and  bbbbb2 carbetocin eeeee2 
CPR:6	The binding domain of barusiban differs from the binding domain of the agonists and the nonselective  bbbbb1 oxytocin receptor eeeee1  antagonist  bbbbb2 d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin eeeee2  that has been used in previous studies
CPR:6	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  bbbbb1 vasopressin V1A/oxytocin receptor eeeee1  antagonist  bbbbb2 atosiban eeeee2  and the agonists oxytocin and carbetocin
CPR:6	We have analyzed binding domains of the oxytocin receptor for  bbbbb1 barusiban eeeee1 , a highly selective  bbbbb2 oxytocin receptor eeeee2  antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CPR:6	Binding domains of the oxytocin receptor for the selective  bbbbb1 oxytocin receptor eeeee1  antagonist  bbbbb2 barusiban eeeee2  in comparison to the agonists oxytocin and carbetocin
CPR:6	For the  bbbbb1 vasopressin V1A/oxytocin receptor eeeee1  antagonist  bbbbb2 atosiban eeeee2 , none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor
CPR:10	Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that  bbbbb1 AZC eeeee1  and PCA did not profoundly affect on  bbbbb2 CD3-zeta chain eeeee2  transcription in Jurkat T leukemia cells clone E6-1
CPR:10	Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that AZC and  bbbbb1 PCA eeeee1  did not profoundly affect on  bbbbb2 CD3-zeta chain eeeee2  transcription in Jurkat T leukemia cells clone E6-1
CPR:4	However, the flowcytometric analysis revealed that  bbbbb1 AZC eeeee1  and PCA decreased intracellular contents of  bbbbb2 CD3-zeta chain eeeee2  in these cells in dose dependent manner
CPR:4	However, the flowcytometric analysis revealed that AZC and  bbbbb1 PCA eeeee1  decreased intracellular contents of  bbbbb2 CD3-zeta chain eeeee2  in these cells in dose dependent manner
CPR:4	The compounds  bbbbb1 5'-azacytidine eeeee1  (AZC) and procainamide (PCA) belong to inhibitors of  bbbbb2 DNMT1 eeeee2 , whose low activity correlates with increase in transcription of various genes
CPR:4	The compounds 5'-azacytidine ( bbbbb1 AZC eeeee1 ) and procainamide (PCA) belong to inhibitors of  bbbbb2 DNMT1 eeeee2 , whose low activity correlates with increase in transcription of various genes
CPR:4	The compounds 5'-azacytidine (AZC) and  bbbbb1 procainamide eeeee1  (PCA) belong to inhibitors of  bbbbb2 DNMT1 eeeee2 , whose low activity correlates with increase in transcription of various genes
CPR:4	The compounds 5'-azacytidine (AZC) and procainamide ( bbbbb1 PCA eeeee1 ) belong to inhibitors of  bbbbb2 DNMT1 eeeee2 , whose low activity correlates with increase in transcription of various genes
CPR:4	These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to  bbbbb1 TS eeeee1  inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate ( bbbbb2 FdUMP eeeee2 )
CPR:4	Clinical studies in cancer patients treated with the new  bbbbb1 fluoropyrimidine eeeee1  analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of  bbbbb2 thymidylate synthase eeeee2  (TS)
CPR:4	Clinical studies in cancer patients treated with the new  bbbbb1 fluoropyrimidine eeeee1  analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ( bbbbb2 TS eeeee2 )
CPR:4	Clinical studies in cancer patients treated with the new fluoropyrimidine analogue  bbbbb1 capecitabine eeeee1  (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of  bbbbb2 thymidylate synthase eeeee2  (TS)
CPR:4	Clinical studies in cancer patients treated with the new fluoropyrimidine analogue  bbbbb1 capecitabine eeeee1  (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ( bbbbb2 TS eeeee2 )
CPR:4	Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine ( bbbbb1 N4-pentoxycarbonyl-5'-5-fluorocytidine eeeee1 ) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of  bbbbb2 thymidylate synthase eeeee2  (TS)
CPR:4	Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine ( bbbbb1 N4-pentoxycarbonyl-5'-5-fluorocytidine eeeee1 ) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ( bbbbb2 TS eeeee2 )
CPR:4	Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma  bbbbb1 2'-deoxyuridine eeeee1  was significantly elevated after 1 week of treatment, consistent with inhibition of  bbbbb2 thymidylate synthase eeeee2  (TS)
CPR:4	Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma  bbbbb1 2'-deoxyuridine eeeee1  was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ( bbbbb2 TS eeeee2 )
CPR:4	These findings suggest that the mechanism of antiproliferative toxicity of  bbbbb1 capecitabine eeeee1  is at least partly due to  bbbbb2 TS eeeee2  inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP)
CPR:4	These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to  bbbbb1 TS eeeee1  inhibitory activity of its active metabolite  bbbbb2 5-fluoro-2'-deoxyuridine monophosphate eeeee2  (FdUMP)
CPR:2	An in vitro kinase assay showed that  bbbbb1 imatinib eeeee1  did not directly affect EGFR  bbbbb2 kinase eeeee2  activity, suggesting involvement of EGFR-activating molecules
CPR:2	An in vitro kinase assay showed that  bbbbb1 imatinib eeeee1  did not directly affect EGFR kinase activity, suggesting involvement of  bbbbb2 EGFR eeeee2 -activating molecules
CPR:2	An in vitro kinase assay showed that  bbbbb1 imatinib eeeee1  did not directly affect  bbbbb2 EGFR eeeee2  kinase activity, suggesting involvement of EGFR-activating molecules
CPR:2	Together, these results suggested that  bbbbb1 imatinib eeeee1  affects  bbbbb2 EGFR eeeee2  activation and signaling pathways through rapid release and increased expression of endogenous EGFR-activating ligands
CPR:2	Induction of  bbbbb1 heparin-binding EGF-like growth factor eeeee1  and activation of EGF receptor in  bbbbb2 imatinib mesylate eeeee2 -treated squamous carcinoma cells
CPR:2	Together, these results suggested that  bbbbb1 imatinib eeeee1  affects  bbbbb2 EGFR eeeee2  activation and signaling pathways through rapid release and increased expression of endogenous EGFR-activating ligands
CPR:3	 bbbbb1 Imatinib eeeee1 -induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of  bbbbb2 EGFR eeeee2  in this process
CPR:3	Western blot analysis of cells incubated with  bbbbb1 imatinib eeeee1  demonstrated activation of  bbbbb2 EGFR eeeee2  and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2
CPR:3	Induction of heparin-binding EGF-like growth factor and activation of  bbbbb1 EGF receptor eeeee1  in  bbbbb2 imatinib mesylate eeeee2 -treated squamous carcinoma cells
CPR:3	Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced  bbbbb1 imatinib eeeee1 -mediated  bbbbb2 mitogen activated protein kinase eeeee2  (MAPK) activation
CPR:3	Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced  bbbbb1 imatinib eeeee1 -mediated mitogen activated protein kinase ( bbbbb2 MAPK eeeee2 ) activation
CPR:3	 bbbbb1 Imatinib eeeee1  stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic  bbbbb2 MAPK eeeee2  activation
CPR:3	Although,  bbbbb1 imatinib eeeee1  primarily inhibits tyrosine kinases, it also stimulates the activity of  bbbbb2 EGFR eeeee2  tyrosine kinase in head and neck squamous tumors
CPR:3	Although,  bbbbb1 imatinib eeeee1  primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR  bbbbb2 tyrosine kinase eeeee2  in head and neck squamous tumors
CPR:3	Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of  bbbbb1 imatinib eeeee1 -induced changes in cell morphology and growth similar to changes associated with  bbbbb2 epidermal growth factor receptor eeeee2  (EGFR) activation
CPR:3	Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of  bbbbb1 imatinib eeeee1 -induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor ( bbbbb2 EGFR eeeee2 ) activation
CPR:3	Western blot analysis of cells incubated with  bbbbb1 imatinib eeeee1  demonstrated activation of  bbbbb2 EGFR eeeee2  and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2
CPR:3	 bbbbb1 Imatinib eeeee1  stimulated the rapid release of soluble  bbbbb2 HB-EGF eeeee2  and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation
CPR:3	 bbbbb1 Imatinib eeeee1  stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound  bbbbb2 HB-EGF eeeee2 , which correlated with biphasic MAPK activation
CPR:3	Together, these results suggested that  bbbbb1 imatinib eeeee1  affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous  bbbbb2 EGFR eeeee2 -activating ligands
CPR:4	 bbbbb1 Imatinib mesylate eeeee1  is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor ( bbbbb2 PDGFR eeeee2 ), and c-kit kinases
CPR:4	 bbbbb1 Imatinib mesylate eeeee1  is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and  bbbbb2 c-kit eeeee2  kinases
CPR:4	 bbbbb1 Imatinib mesylate eeeee1  is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit  bbbbb2 kinases eeeee2 
CPR:4	 bbbbb1 Imatinib mesylate eeeee1  is a  bbbbb2 tyrosine kinase eeeee2  inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases
CPR:4	 bbbbb1 Imatinib mesylate eeeee1  is a tyrosine kinase inhibitor of the  bbbbb2 ABL eeeee2 , platelet-derived growth factor receptor (PDGFR), and c-kit kinases
CPR:4	 bbbbb1 Imatinib mesylate eeeee1  is a tyrosine kinase inhibitor of the ABL,  bbbbb2 platelet-derived growth factor receptor eeeee2  (PDGFR), and c-kit kinases
CPR:4	Although,  bbbbb1 imatinib eeeee1  primarily inhibits  bbbbb2 tyrosine kinases eeeee2 , it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors
CPR:2	 bbbbb1 STI 571 eeeee1  (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since Gleevec targets both  bbbbb2 PDGFRA eeeee2  and c-kit oncoproteins.
CPR:2	 bbbbb1 STI 571 eeeee1  (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and  bbbbb2 c-kit eeeee2  oncoproteins.
CPR:2	STI 571 ( bbbbb1 imatinib mesylate eeeee1  [Gleevec]) might be an effective therapy in this case, since Gleevec targets both  bbbbb2 PDGFRA eeeee2  and c-kit oncoproteins.
CPR:2	STI 571 ( bbbbb1 imatinib mesylate eeeee1  [Gleevec]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and  bbbbb2 c-kit eeeee2  oncoproteins.
CPR:2	STI 571 (imatinib mesylate [ bbbbb1 Gleevec eeeee1 ]) might be an effective therapy in this case, since Gleevec targets both  bbbbb2 PDGFRA eeeee2  and c-kit oncoproteins.
CPR:2	STI 571 (imatinib mesylate [ bbbbb1 Gleevec eeeee1 ]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and  bbbbb2 c-kit eeeee2  oncoproteins.
CPR:2	STI 571 (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since  bbbbb1 Gleevec eeeee1  targets both  bbbbb2 PDGFRA eeeee2  and c-kit oncoproteins.
CPR:2	STI 571 (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since  bbbbb1 Gleevec eeeee1  targets both PDGFRA and  bbbbb2 c-kit eeeee2  oncoproteins.
CPR:4	The identity of the lung  bbbbb1 beta-ADHs eeeee1  was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by  bbbbb2 4-methylpyrazole eeeee2  or 1,10-phenanthroline
CPR:4	The identity of the lung  bbbbb1 beta-ADHs eeeee1  was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or  bbbbb2 1,10-phenanthroline eeeee2 
CPR:9	The results suggest that individuals with high Vmax  bbbbb1 beta 2-ADH eeeee1  and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with  bbbbb2 acetaldehyde eeeee2  accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.
CPR:9	The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial  bbbbb1 ALDH2 eeeee1 , accounting for approximately 45% of the Chinese population, may end up with  bbbbb2 acetaldehyde eeeee2  accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.
CPR:9	These findings indicate that human pulmonary  bbbbb1 ethanol eeeee1 -metabolizing activities differ significantly with respect to genetic polymorphism at both the  bbbbb2 ADH2 eeeee2  and the ALDH2 loci
CPR:9	These findings indicate that human pulmonary  bbbbb1 ethanol eeeee1 -metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the  bbbbb2 ALDH2 eeeee2  loci
CPR:9	The results suggest that individuals with high Vmax  bbbbb1 beta 2-ADH eeeee1  and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during  bbbbb2 alcohol eeeee2  consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.
CPR:9	The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial  bbbbb1 ALDH2 eeeee1 , accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during  bbbbb2 alcohol eeeee2  consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.
CPR:9	The identity of the lung  bbbbb1 beta-ADHs eeeee1  was further demonstrated by their characteristic pH-activity profiles for  bbbbb2 ethanol eeeee2  oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline
CPR:9	The identity of the lung  bbbbb1 beta-ADHs eeeee1  was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and  bbbbb2 ethanol eeeee2 , and inhibition by 4-methylpyrazole or 1,10-phenanthroline
CPR:2	In the presence of  bbbbb1 IL-18 eeeee1 ,  bbbbb2 simvastatin eeeee2  suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin
CPR:2	The effects of simvastatin were abolished by the addition of the product of the HMG-CoA reductase, mevalonate, indicating the involvement of  bbbbb1 HMG-CoA reductase eeeee1  in the action of  bbbbb2 simvastatin eeeee2 .
CPR:3	The IL-18 production is located upstream of the  bbbbb1 cytokine eeeee1  cascade activated by  bbbbb2 simvastatin eeeee2 
CPR:3	In the presence of IL-18,  bbbbb1 simvastatin eeeee1  suppressed the expression of ICAM-1 and CD40 as well as the production of  bbbbb2 IL-12 eeeee2 , TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin
CPR:3	In the presence of IL-18,  bbbbb1 simvastatin eeeee1  suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12,  bbbbb2 TNF-alpha eeeee2  and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin
CPR:3	In the presence of IL-18,  bbbbb1 simvastatin eeeee1  suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and  bbbbb2 IFN-gamma eeeee2  in PBMC, contributing to the anti-inflammatory effect of simvastatin
CPR:3	 bbbbb1 Simvastatin eeeee1  induces  bbbbb2 interleukin-18 eeeee2  production in human peripheral blood mononuclear cells
CPR:3	 bbbbb1 Simvastatin eeeee1 , an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of  bbbbb2 interleukin (IL)-18 eeeee2 , tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)
CPR:3	 bbbbb1 Simvastatin eeeee1 , an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18,  bbbbb2 tumor necrosis factor (TNF)-alpha eeeee2  and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)
CPR:3	 bbbbb1 Simvastatin eeeee1 , an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and  bbbbb2 interferon (IFN)-gamma eeeee2  in human peripheral blood mononuclear cells (PBMC)
CPR:3	The  bbbbb1 IL-18 eeeee1  production is located upstream of the cytokine cascade activated by  bbbbb2 simvastatin eeeee2 
CPR:3	Moreover,  bbbbb1 simvastatin eeeee1  concentration-dependently inhibited the expression of ICAM-1 and induced the expression of  bbbbb2 CD40 eeeee2  on monocytes
CPR:4	In the presence of IL-18,  bbbbb1 simvastatin eeeee1  suppressed the expression of  bbbbb2 ICAM-1 eeeee2  and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin
CPR:4	In the presence of IL-18,  bbbbb1 simvastatin eeeee1  suppressed the expression of ICAM-1 and  bbbbb2 CD40 eeeee2  as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin
CPR:4	Moreover,  bbbbb1 simvastatin eeeee1  concentration-dependently inhibited the expression of  bbbbb2 ICAM-1 eeeee2  and induced the expression of CD40 on monocytes
CPR:4	 bbbbb1 Simvastatin eeeee1 , an  bbbbb2 HMG-CoA reductase eeeee2  inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)
CPR:4	 bbbbb1 Simvastatin eeeee1 , an HMG-CoA reductase inhibitor with mild inhibition of  bbbbb2 LFA-1 eeeee2 , induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)
CPR:9	The effects of simvastatin were abolished by the addition of the product of the  bbbbb1 HMG-CoA reductase eeeee1 ,  bbbbb2 mevalonate eeeee2 , indicating the involvement of HMG-CoA reductase in the action of simvastatin.
CPR:4	However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and  bbbbb1 carprofen eeeee1  (-12.9%) had lower  bbbbb2 COX-2 eeeee2  selectivity than at IC50
CPR:4	We report on the inhibitory activity of the NSAIDs meloxicam,  bbbbb1 carprofen eeeee1 , phenylbutazone and flunixin, on blood  bbbbb2 cyclooxygenases eeeee2  in the horse using in vitro enzyme-linked assays
CPR:4	We report on the inhibitory activity of the NSAIDs meloxicam, carprofen,  bbbbb1 phenylbutazone eeeee1  and flunixin, on blood  bbbbb2 cyclooxygenases eeeee2  in the horse using in vitro enzyme-linked assays
CPR:4	We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and  bbbbb1 flunixin eeeee1 , on blood  bbbbb2 cyclooxygenases eeeee2  in the horse using in vitro enzyme-linked assays
CPR:4	 bbbbb1 COX-1 eeeee1  and COX-2 inhibition in horse blood by  bbbbb2 phenylbutazone eeeee2 , flunixin, carprofen and meloxicam: an in vitro analysis
CPR:4	COX-1 and  bbbbb1 COX-2 eeeee1  inhibition in horse blood by  bbbbb2 phenylbutazone eeeee2 , flunixin, carprofen and meloxicam: an in vitro analysis
CPR:4	 bbbbb1 COX-1 eeeee1  and COX-2 inhibition in horse blood by phenylbutazone,  bbbbb2 flunixin eeeee2 , carprofen and meloxicam: an in vitro analysis
CPR:4	COX-1 and  bbbbb1 COX-2 eeeee1  inhibition in horse blood by phenylbutazone,  bbbbb2 flunixin eeeee2 , carprofen and meloxicam: an in vitro analysis
CPR:4	 bbbbb1 COX-1 eeeee1  and COX-2 inhibition in horse blood by phenylbutazone, flunixin,  bbbbb2 carprofen eeeee2  and meloxicam: an in vitro analysis
CPR:4	COX-1 and  bbbbb1 COX-2 eeeee1  inhibition in horse blood by phenylbutazone, flunixin,  bbbbb2 carprofen eeeee2  and meloxicam: an in vitro analysis
CPR:4	 bbbbb1 COX-1 eeeee1  and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and  bbbbb2 meloxicam eeeee2 : an in vitro analysis
CPR:4	COX-1 and  bbbbb1 COX-2 eeeee1  inhibition in horse blood by phenylbutazone, flunixin, carprofen and  bbbbb2 meloxicam eeeee2 : an in vitro analysis
CPR:4	As expected, comparison of IC50 indicated that  bbbbb1 meloxicam eeeee1  and carprofen are more selective inhibitors of  bbbbb2 COX-2 eeeee2  than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined
CPR:4	As expected, comparison of IC50 indicated that meloxicam and  bbbbb1 carprofen eeeee1  are more selective inhibitors of  bbbbb2 COX-2 eeeee2  than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined
CPR:4	As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of  bbbbb1 COX-2 eeeee1  than  bbbbb2 phenylbutazone eeeee2  and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined
CPR:4	As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of  bbbbb1 COX-2 eeeee1  than phenylbutazone and  bbbbb2 flunixin eeeee2 ; meloxicam was the most advantageous for horses of four NSAIDs examined
CPR:4	However at IC80,  bbbbb1 phenylbutazone eeeee1  (+134.4%) and flunixin (+29.7%) had greater  bbbbb2 COX-2 eeeee2  selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50
CPR:4	However at IC80, phenylbutazone (+134.4%) and  bbbbb1 flunixin eeeee1  (+29.7%) had greater  bbbbb2 COX-2 eeeee2  selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50
CPR:4	However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and  bbbbb1 meloxicam eeeee1  (-41.2%) and carprofen (-12.9%) had lower  bbbbb2 COX-2 eeeee2  selectivity than at IC50
CPR:4	We report on the inhibitory activity of the NSAIDs  bbbbb1 meloxicam eeeee1 , carprofen, phenylbutazone and flunixin, on blood  bbbbb2 cyclooxygenases eeeee2  in the horse using in vitro enzyme-linked assays
CPR:10	Treatment with  bbbbb1 valsartan eeeee1 , doxazosin, or N-acetylcysteine did not significantly affect  bbbbb2 HIF-1alpha eeeee2  and VEGF proteins expression in the banding groups
CPR:10	Treatment with  bbbbb1 valsartan eeeee1 , doxazosin, or N-acetylcysteine did not significantly affect HIF-1alpha and  bbbbb2 VEGF eeeee2  proteins expression in the banding groups
CPR:10	Treatment with valsartan,  bbbbb1 doxazosin eeeee1 , or N-acetylcysteine did not significantly affect  bbbbb2 HIF-1alpha eeeee2  and VEGF proteins expression in the banding groups
CPR:10	Treatment with valsartan,  bbbbb1 doxazosin eeeee1 , or N-acetylcysteine did not significantly affect HIF-1alpha and  bbbbb2 VEGF eeeee2  proteins expression in the banding groups
CPR:10	Treatment with valsartan, doxazosin, or  bbbbb1 N-acetylcysteine eeeee1  did not significantly affect  bbbbb2 HIF-1alpha eeeee2  and VEGF proteins expression in the banding groups
CPR:10	Treatment with valsartan, doxazosin, or  bbbbb1 N-acetylcysteine eeeee1  did not significantly affect HIF-1alpha and  bbbbb2 VEGF eeeee2  proteins expression in the banding groups
CPR:2	Treatment with  bbbbb1 carvedilol eeeee1  is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, BNP, and  bbbbb2 NGF-beta eeeee2  in the hypertrophic myocardium.
CPR:3	Treatment with  bbbbb1 carvedilol eeeee1  reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and  bbbbb2 NGF-beta eeeee2  to the baseline values
CPR:4	 bbbbb1 Carvedilol eeeee1  prevents cardiac hypertrophy and overexpression of  bbbbb2 hypoxia-inducible factor-1alpha eeeee2  and vascular endothelial growth factor in pressure-overloaded rat heart
CPR:4	 bbbbb1 Carvedilol eeeee1  prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and  bbbbb2 vascular endothelial growth factor eeeee2  in pressure-overloaded rat heart
CPR:4	Treatment with  bbbbb1 carvedilol eeeee1  reversed both protein and mRNA of  bbbbb2 HIF-1alpha eeeee2 , VEGF, BNP, and NGF-beta to the baseline values
CPR:4	Treatment with  bbbbb1 carvedilol eeeee1  reversed both protein and mRNA of HIF-1alpha,  bbbbb2 VEGF eeeee2 , BNP, and NGF-beta to the baseline values
CPR:4	Treatment with  bbbbb1 carvedilol eeeee1  reversed both protein and mRNA of HIF-1alpha, VEGF,  bbbbb2 BNP eeeee2 , and NGF-beta to the baseline values
CPR:4	Increased immunohistochemical labeling of  bbbbb1 HIF-1alpha eeeee1 , VEGF, and BNP in the ventricular myocardium was observed in the banding group and  bbbbb2 carvedilol eeeee2  again normalized the labeling
CPR:4	Increased immunohistochemical labeling of HIF-1alpha,  bbbbb1 VEGF eeeee1 , and BNP in the ventricular myocardium was observed in the banding group and  bbbbb2 carvedilol eeeee2  again normalized the labeling
CPR:4	Increased immunohistochemical labeling of HIF-1alpha, VEGF, and  bbbbb1 BNP eeeee1  in the ventricular myocardium was observed in the banding group and  bbbbb2 carvedilol eeeee2  again normalized the labeling
CPR:4	Treatment with  bbbbb1 carvedilol eeeee1  is associated with a reversal of abnormal regulation of  bbbbb2 HIF-1alpha eeeee2 , VEGF, BNP, and NGF-beta in the hypertrophic myocardium.
CPR:4	Treatment with  bbbbb1 carvedilol eeeee1  is associated with a reversal of abnormal regulation of HIF-1alpha,  bbbbb2 VEGF eeeee2 , BNP, and NGF-beta in the hypertrophic myocardium.
CPR:4	Treatment with  bbbbb1 carvedilol eeeee1  is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF,  bbbbb2 BNP eeeee2 , and NGF-beta in the hypertrophic myocardium.
CPR:10	The reported mechanism of  bbbbb1 imatinib eeeee1  resistance in GISTs involves missense mutation in the  bbbbb2 kinase domain eeeee2  of KIT, including Thr670Ile, Tyr823Asp, and Val654Ala
CPR:10	The reported mechanism of  bbbbb1 imatinib eeeee1  resistance in GISTs involves missense mutation in the kinase domain of  bbbbb2 KIT, eeeee2  including Thr670Ile, Tyr823Asp, and Val654Ala
CPR:10	The reported mechanism of  bbbbb1 imatinib eeeee1  resistance in GISTs involves missense mutation in the kinase domain of KIT, including  bbbbb2 Thr670Ile eeeee2 , Tyr823Asp, and Val654Ala
CPR:10	The reported mechanism of  bbbbb1 imatinib eeeee1  resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile,  bbbbb2 Tyr823Asp eeeee2 , and Val654Ala
CPR:10	The reported mechanism of  bbbbb1 imatinib eeeee1  resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile, Tyr823Asp, and  bbbbb2 Val654Ala eeeee2 
CPR:4	 bbbbb1 Imatinib eeeee1  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of  bbbbb2 KIT eeeee2 , ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	 bbbbb1 Imatinib eeeee1  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  bbbbb2 ABL eeeee2 , BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	 bbbbb1 Imatinib eeeee1  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL,  bbbbb2 BCR eeeee2 -ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	 bbbbb1 Imatinib eeeee1  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR- bbbbb2 ABL eeeee2 , PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	 bbbbb1 Imatinib eeeee1  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL,  bbbbb2 PDGFRA eeeee2 , and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	 bbbbb1 Imatinib eeeee1  (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and  bbbbb2 PDGFRB, eeeee2  represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib ( bbbbb1 STI571 eeeee1 , Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of  bbbbb2 KIT eeeee2 , ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib ( bbbbb1 STI571 eeeee1 , Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  bbbbb2 ABL eeeee2 , BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib ( bbbbb1 STI571 eeeee1 , Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL,  bbbbb2 BCR eeeee2 -ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib ( bbbbb1 STI571 eeeee1 , Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR- bbbbb2 ABL eeeee2 , PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib ( bbbbb1 STI571 eeeee1 , Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL,  bbbbb2 PDGFRA eeeee2 , and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib ( bbbbb1 STI571 eeeee1 , Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and  bbbbb2 PDGFRB, eeeee2  represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571,  bbbbb1 Gleevec eeeee1 , Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of  bbbbb2 KIT eeeee2 , ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571,  bbbbb1 Gleevec eeeee1 , Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  bbbbb2 ABL eeeee2 , BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571,  bbbbb1 Gleevec eeeee1 , Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL,  bbbbb2 BCR eeeee2 -ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571,  bbbbb1 Gleevec eeeee1 , Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR- bbbbb2 ABL eeeee2 , PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571,  bbbbb1 Gleevec eeeee1 , Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL,  bbbbb2 PDGFRA eeeee2 , and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571,  bbbbb1 Gleevec eeeee1 , Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and  bbbbb2 PDGFRB, eeeee2  represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571, Gleevec,  bbbbb1 Glivec eeeee1 ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of  bbbbb2 KIT eeeee2 , ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571, Gleevec,  bbbbb1 Glivec eeeee1 ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT,  bbbbb2 ABL eeeee2 , BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571, Gleevec,  bbbbb1 Glivec eeeee1 ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL,  bbbbb2 BCR eeeee2 -ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571, Gleevec,  bbbbb1 Glivec eeeee1 ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR- bbbbb2 ABL eeeee2 , PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571, Gleevec,  bbbbb1 Glivec eeeee1 ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL,  bbbbb2 PDGFRA eeeee2 , and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:4	Imatinib (STI571, Gleevec,  bbbbb1 Glivec eeeee1 ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and  bbbbb2 PDGFRB, eeeee2  represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs
CPR:2	Almost all of the tested H(1)R and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific  bbbbb1 [(3)H]histamine eeeee1  binding to the  bbbbb2 hH(4)R eeeee2  at concentrations up to 10 microM
CPR:2	Most of the tested H(2)R agonists and  bbbbb1 imidazole eeeee1 -based  bbbbb2 H(3)R eeeee2  ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists
CPR:2	Most of the tested H(2)R agonists and  bbbbb1 imidazole eeeee1 -based H(3)R ligands show micromolar-to-nanomolar range  bbbbb2 hH(4)R eeeee2  affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists
CPR:2	Interestingly, we identified  bbbbb1 4-methylhistamine eeeee1  as a high-affinity  bbbbb2 H(4)R eeeee2  ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other histamine receptor subtypes
CPR:2	Interestingly, we identified  bbbbb1 4-methylhistamine eeeee1  as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the  bbbbb2 hH(4)R eeeee2  over the other histamine receptor subtypes
CPR:2	Interestingly, we identified  bbbbb1 4-methylhistamine eeeee1  as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other  bbbbb2 histamine receptor eeeee2  subtypes
CPR:2	The identification of  bbbbb1 4-methylhistamine eeeee1  as a potent H(4)R agonist is of major importance for future studies to unravel the physiological roles of the  bbbbb2 H(4)R eeeee2 .
CPR:3	Moreover,  bbbbb1 4-methylhistamine eeeee1  potently activated the  bbbbb2 hH(4)R eeeee2  (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)
CPR:5	Most of the tested H(2)R agonists and  bbbbb1 imidazole eeeee1 -based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic  bbbbb2 hH(4)R eeeee2  activities, ranging from full agonists to inverse agonists
CPR:5	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of  bbbbb1 4-methylhistamine eeeee1  as the first potent and selective  bbbbb2 H4 receptor eeeee2  agonist
CPR:5	The identification of  bbbbb1 4-methylhistamine eeeee1  as a potent  bbbbb2 H(4)R eeeee2  agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.
CPR:5	Most of the tested H(2)R agonists and  bbbbb1 imidazole eeeee1 -based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic  bbbbb2 hH(4)R eeeee2  activities, ranging from full agonists to inverse agonists
CPR:6	Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective  bbbbb1 H(4)R eeeee1  antagonist  bbbbb2 JNJ 7777120 eeeee2  [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)
CPR:6	Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective  bbbbb1 H(4)R eeeee1  antagonist JNJ 7777120 [ bbbbb2 1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine eeeee2 ] (pA(2) = 7.8)
CPR:2	Late-onset diarrhea appears to be associated with intestinal exposure to  bbbbb1 SN-38 eeeee1  (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to  bbbbb2 Topo I eeeee2  and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa
CPR:2	Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 ( bbbbb1 7-ethyl-10-hydroxycamptothecin eeeee1 ), the major active metabolite of CPT-11, which may bind to  bbbbb2 Topo I eeeee2  and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa
CPR:2	Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (7-ethyl-10-hydroxycamptothecin), the major active metabolite of  bbbbb1 CPT-11 eeeee1 , which may bind to  bbbbb2 Topo I eeeee2  and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa
CPR:3	Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of  bbbbb1 acetylcholinesterase eeeee1  activity, which can be eliminated by administration of  bbbbb2 atropine eeeee2 
CPR:3	 bbbbb1 CPT-11 eeeee1  and SN-38 may also stimulate the production of pro-inflammatory  bbbbb2 cytokines eeeee2  and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)
CPR:3	CPT-11 and  bbbbb1 SN-38 eeeee1  may also stimulate the production of pro-inflammatory  bbbbb2 cytokines eeeee2  and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)
CPR:4	Irinotecan (CPT-11,  bbbbb1 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin eeeee1 ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting  bbbbb2 DNA topoisomerase I eeeee2  (Topo I)
CPR:4	Irinotecan (CPT-11,  bbbbb1 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin eeeee1 ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I ( bbbbb2 Topo I eeeee2 )
CPR:4	Early-onset diarrhea is observed immediately after  bbbbb1 CPT-11 eeeee1  infusion and probably due to the inhibition of  bbbbb2 acetylcholinesterase eeeee2  activity, which can be eliminated by administration of atropine
CPR:4	 bbbbb1 Irinotecan eeeee1  (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting  bbbbb2 DNA topoisomerase I eeeee2  (Topo I)
CPR:4	 bbbbb1 Irinotecan eeeee1  (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I ( bbbbb2 Topo I eeeee2 )
CPR:4	Irinotecan ( bbbbb1 CPT-11 eeeee1 , 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting  bbbbb2 DNA topoisomerase I eeeee2  (Topo I)
CPR:4	Irinotecan ( bbbbb1 CPT-11 eeeee1 , 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I ( bbbbb2 Topo I eeeee2 )
CPR:10	To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine,  bbbbb1 N6-methyl-(R)-roscovitine eeeee1 , and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to  bbbbb2 CDKs eeeee2 
CPR:10	To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and  bbbbb1 O6-(R)-roscovitine eeeee1 , the two latter derivatives being designed to bind to PDXK but not to  bbbbb2 CDKs eeeee2 
CPR:2	Affinity chromatography investigations have shown that  bbbbb1 (R)-roscovitine eeeee1  also interacts with  bbbbb2 PDXK eeeee2 
CPR:2	To understand this interaction, we determined the crystal structure of  bbbbb1 PDXK eeeee1  in complex with  bbbbb2 (R)-roscovitine eeeee2 , N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs
CPR:2	To understand this interaction, we determined the crystal structure of  bbbbb1 PDXK eeeee1  in complex with (R)-roscovitine,  bbbbb2 N6-methyl-(R)-roscovitine eeeee2 , and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs
CPR:2	To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine,  bbbbb1 N6-methyl-(R)-roscovitine eeeee1 , and O6-(R)-roscovitine, the two latter derivatives being designed to bind to  bbbbb2 PDXK eeeee2  but not to CDKs
CPR:2	To understand this interaction, we determined the crystal structure of  bbbbb1 PDXK eeeee1  in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and  bbbbb2 O6-(R)-roscovitine eeeee2 , the two latter derivatives being designed to bind to PDXK but not to CDKs
CPR:2	To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and  bbbbb1 O6-(R)-roscovitine eeeee1 , the two latter derivatives being designed to bind to  bbbbb2 PDXK eeeee2  but not to CDKs
CPR:2	Structural analysis revealed that these three  bbbbb1 roscovitines eeeee1  bind similarly in the pyridoxal-binding site of  bbbbb2 PDXK eeeee2  rather than in the anticipated ATP-binding site
CPR:2	Structural analysis revealed that these three roscovitines bind similarly in the  bbbbb1 pyridoxal eeeee1 -binding site of  bbbbb2 PDXK eeeee2  rather than in the anticipated ATP-binding site
CPR:2	Structural analysis revealed that these three roscovitines bind similarly in the pyridoxal-binding site of  bbbbb1 PDXK eeeee1  rather than in the anticipated  bbbbb2 ATP eeeee2 -binding site
CPR:2	Crystal structure of  bbbbb1 pyridoxal kinase eeeee1  in complex with  bbbbb2 roscovitine eeeee2  and derivatives
CPR:2	This work provides detailed structural information on the interactions between  bbbbb1 PDXK eeeee1  and  bbbbb2 roscovitine eeeee2  and analogs
CPR:2	 bbbbb1 Pyridoxal kinase eeeee1  (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of  bbbbb2 ATP eeeee2  and Zn2+
CPR:2	Pyridoxal kinase ( bbbbb1 PDXK eeeee1 ) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of  bbbbb2 ATP eeeee2  and Zn2+
CPR:2	 bbbbb1 Pyridoxal kinase eeeee1  (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and  bbbbb2 Zn2+ eeeee2 
CPR:2	Pyridoxal kinase ( bbbbb1 PDXK eeeee1 ) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and  bbbbb2 Zn2+ eeeee2 
CPR:2	It could also aid in the design of  bbbbb1 roscovitine eeeee1  derivatives displaying strict selectivity for either  bbbbb2 PDXK eeeee2  or CDKs.
CPR:2	It could also aid in the design of  bbbbb1 roscovitine eeeee1  derivatives displaying strict selectivity for either PDXK or  bbbbb2 CDKs eeeee2 .
CPR:4	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes.  bbbbb1 (R)-Roscovitine eeeee1  (CYC202, Seliciclib) is a relatively selective inhibitor of  bbbbb2 cyclin-dependent kinases eeeee2  (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CPR:4	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes.  bbbbb1 (R)-Roscovitine eeeee1  (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases ( bbbbb2 CDKs eeeee2 ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CPR:4	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine ( bbbbb1 CYC202 eeeee1 , Seliciclib) is a relatively selective inhibitor of  bbbbb2 cyclin-dependent kinases eeeee2  (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CPR:4	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine ( bbbbb1 CYC202 eeeee1 , Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases ( bbbbb2 CDKs eeeee2 ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CPR:4	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202,  bbbbb1 Seliciclib eeeee1 ) is a relatively selective inhibitor of  bbbbb2 cyclin-dependent kinases eeeee2  (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CPR:4	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202,  bbbbb1 Seliciclib eeeee1 ) is a relatively selective inhibitor of cyclin-dependent kinases ( bbbbb2 CDKs eeeee2 ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CPR:9	 bbbbb1 Pyridoxal kinase eeeee1  (PDXK) catalyzes the phosphorylation of  bbbbb2 pyridoxal eeeee2 , pyridoxamine, and pyridoxine in the presence of ATP and Zn2+
CPR:9	Pyridoxal kinase ( bbbbb1 PDXK eeeee1 ) catalyzes the phosphorylation of  bbbbb2 pyridoxal eeeee2 , pyridoxamine, and pyridoxine in the presence of ATP and Zn2+
CPR:9	 bbbbb1 Pyridoxal kinase eeeee1  (PDXK) catalyzes the phosphorylation of pyridoxal,  bbbbb2 pyridoxamine eeeee2 , and pyridoxine in the presence of ATP and Zn2+
CPR:9	Pyridoxal kinase ( bbbbb1 PDXK eeeee1 ) catalyzes the phosphorylation of pyridoxal,  bbbbb2 pyridoxamine eeeee2 , and pyridoxine in the presence of ATP and Zn2+
CPR:9	 bbbbb1 Pyridoxal kinase eeeee1  (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and  bbbbb2 pyridoxine eeeee2  in the presence of ATP and Zn2+
CPR:9	Pyridoxal kinase ( bbbbb1 PDXK eeeee1 ) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and  bbbbb2 pyridoxine eeeee2  in the presence of ATP and Zn2+
CPR:10	The  bbbbb1 gastric mucin eeeee1  secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor,  bbbbb2 PD98059 eeeee2 
CPR:10	The inhibition of ERK, moreover, did not cause attenuation in  bbbbb1 mucin eeeee1  secretion in response to  bbbbb2 cAMP eeeee2  and forskolin
CPR:10	The inhibition of ERK, moreover, did not cause attenuation in  bbbbb1 mucin eeeee1  secretion in response to cAMP and  bbbbb2 forskolin eeeee2 
CPR:2	The  bbbbb1 gastric mucin eeeee1  secretory responses to  bbbbb2 isoproterenol eeeee2 , furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CPR:3	Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as  bbbbb1 adenylate cyclase eeeee1  activator,  bbbbb2 forskolin eeeee2 
CPR:3	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by  bbbbb1 PP2 eeeee1 , a selective inhibitor of tyrosine kinase Src responsible for ligand-independent  bbbbb2 EGFR eeeee2  autophosphorylation, but not by ERK inhibitor, PD98059
CPR:4	Both inhibitors, moreover, blunted the  bbbbb1 mucin eeeee1  secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator,  bbbbb2 forskolin eeeee2 
CPR:4	The  bbbbb1 gastric mucin eeeee1  secretory responses to isoproterenol, furthermore, were inhibited by  bbbbb2 PP2 eeeee2 , a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CPR:4	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on  bbbbb1 mucin eeeee1  secretion was inhibited by EGFR kinase inhibitor,  bbbbb2 PD153035 eeeee2 , as well as wortmannin, a specific inhibitor of PI3K
CPR:4	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on  bbbbb1 mucin eeeee1  secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as  bbbbb2 wortmannin eeeee2 , a specific inhibitor of PI3K
CPR:4	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by  bbbbb1 PP2 eeeee1 , a selective inhibitor of  bbbbb2 tyrosine kinase eeeee2  Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CPR:4	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by  bbbbb1 PP2 eeeee1 , a selective inhibitor of tyrosine kinase  bbbbb2 Src eeeee2  responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CPR:4	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by  bbbbb1 ERK eeeee1  inhibitor,  bbbbb2 PD98059 eeeee2 
CPR:4	The inhibition of  bbbbb1 ERK eeeee1 , moreover, did not cause attenuation in mucin secretion in response to  bbbbb2 cAMP eeeee2  and forskolin
CPR:4	The inhibition of  bbbbb1 ERK eeeee1 , moreover, did not cause attenuation in mucin secretion in response to cAMP and  bbbbb2 forskolin eeeee2 
CPR:4	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by  bbbbb1 EGFR eeeee1  kinase inhibitor,  bbbbb2 PD153035 eeeee2 , as well as wortmannin, a specific inhibitor of PI3K
CPR:4	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR  bbbbb1 kinase eeeee1  inhibitor,  bbbbb2 PD153035 eeeee2 , as well as wortmannin, a specific inhibitor of PI3K
CPR:4	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as  bbbbb1 wortmannin eeeee1 , a specific inhibitor of  bbbbb2 PI3K eeeee2 
CPR:9	Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger,  bbbbb1 cAMP eeeee1  as well as  bbbbb2 adenylate cyclase eeeee2  activator, forskolin
CPR:2	 bbbbb1 Losartan eeeee1  (parent compound), has moderate affinity for the  bbbbb2 AT(1) receptor eeeee2  (competitive inhibition)
CPR:2	 bbbbb1 Losartan eeeee1  is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the  bbbbb2 AT(1) receptor eeeee2  (non-competitive inhibition)
CPR:4	 bbbbb1 Losartan eeeee1  is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the  bbbbb2 AT(1) receptor eeeee2  (non-competitive inhibition)
CPR:4	Clinical experience in heart failure is growing, and recent data suggest an improved survival with  bbbbb1 losartan eeeee1  versus captopril, a drug from the  bbbbb2 angiotensin-converting-enzyme eeeee2  inhibitor class with proven benefit in this population
CPR:4	Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus  bbbbb1 captopril eeeee1 , a drug from the  bbbbb2 angiotensin-converting-enzyme eeeee2  inhibitor class with proven benefit in this population
CPR:4	The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the  bbbbb1 AT(1) receptor eeeee1  with  bbbbb2 losartan eeeee2  compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.
CPR:6	 bbbbb1 Losartan eeeee1 : a selective  bbbbb2 angiotensin II type 1 (AT1) receptor eeeee2  antagonist for the treatment of heart failure
CPR:6	 bbbbb1 Losartan eeeee1  (COZAAR) is the prototype of a new class of potent and selective  bbbbb2 angiotensin II (AII) type 1 (AT(1)) receptor eeeee2  antagonists with the largest published preclinical and clinical data base
CPR:6	Losartan ( bbbbb1 COZAAR eeeee1 ) is the prototype of a new class of potent and selective  bbbbb2 angiotensin II (AII) type 1 (AT(1)) receptor eeeee2  antagonists with the largest published preclinical and clinical data base
CPR:3	Abrupt removal of  bbbbb1 amrinone eeeee1  or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented  bbbbb2 TNF eeeee2  production
CPR:3	Abrupt removal of amrinone or  bbbbb1 pentoxifylline eeeee1  from the culture medium prior to LPS stimulation, however, caused significantly augmented  bbbbb2 TNF eeeee2  production
CPR:4	We now demonstrate that  bbbbb1 amrinone eeeee1 , a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced  bbbbb2 TNF eeeee2  production at concentrations readily achieved in vivo
CPR:4	Combined application of  bbbbb1 dexamethasone eeeee1  and amrinone caused additive inhibition of  bbbbb2 TNF eeeee2  biosynthesis in vitro
CPR:4	Combined application of dexamethasone and  bbbbb1 amrinone eeeee1  caused additive inhibition of  bbbbb2 TNF eeeee2  biosynthesis in vitro
CPR:4	Therefore, decreases of  bbbbb1 PLK eeeee1  and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with  bbbbb2 gamma-aminobutyric acid eeeee2  (GABA) function.
CPR:4	Therefore, decreases of PLK and  bbbbb1 PNPO eeeee1  in the hippocampal CA1 region of aged brains may be involved in aging processes related with  bbbbb2 gamma-aminobutyric acid eeeee2  (GABA) function.
CPR:4	Therefore, decreases of  bbbbb1 PLK eeeee1  and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid ( bbbbb2 GABA eeeee2 ) function.
CPR:4	Therefore, decreases of PLK and  bbbbb1 PNPO eeeee1  in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid ( bbbbb2 GABA eeeee2 ) function.
CPR:9	In the present study, age-related changes of  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP) synthesizing enzymes, pyridoxal kinase ( bbbbb2 PLK eeeee2 ) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CPR:9	In the present study, age-related changes of  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and  bbbbb2 pyridoxine 5'-phosphate oxidase eeeee2  (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CPR:9	In the present study, age-related changes of  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase ( bbbbb2 PNPO eeeee2 ), their protein contents and activities were examined in the gerbil hippocampus proper
CPR:9	In the present study, age-related changes of  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP) synthesizing enzymes,  bbbbb2 pyridoxal kinase eeeee2  (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CPR:9	In the present study, age-related changes of pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 ) synthesizing enzymes, pyridoxal kinase ( bbbbb2 PLK eeeee2 ) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CPR:9	In the present study, age-related changes of pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 ) synthesizing enzymes, pyridoxal kinase (PLK) and  bbbbb2 pyridoxine 5'-phosphate oxidase eeeee2  (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CPR:9	In the present study, age-related changes of pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 ) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase ( bbbbb2 PNPO eeeee2 ), their protein contents and activities were examined in the gerbil hippocampus proper
CPR:9	In the present study, age-related changes of pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 ) synthesizing enzymes,  bbbbb2 pyridoxal kinase eeeee2  (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CPR:2	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by  bbbbb1 H(+) eeeee1 -coupled  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CPR:2	These results provide biochemical evidence of a  bbbbb1 H(+) eeeee1 -coupled and saturable transport system, presumed to be a  bbbbb2 low-affinity monocarboxylate transporter eeeee2  MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.
CPR:2	These results provide biochemical evidence of a  bbbbb1 H(+) eeeee1 -coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter  bbbbb2 MCT4 eeeee2  or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.
CPR:4	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical  bbbbb1 monocarboxylate transporter eeeee1  (MCT) inhibitor,  bbbbb2 alpha-cyano-4-hydroxycinnamic acid eeeee2 , suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CPR:4	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter ( bbbbb1 MCT eeeee1 ) inhibitor,  bbbbb2 alpha-cyano-4-hydroxycinnamic acid eeeee2 , suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CPR:9	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that  bbbbb1 nicotinate eeeee1  uptake by rat astrocytes is mediated by H(+)-coupled  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CPR:9	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that  bbbbb1 nicotinate eeeee1  uptake in rat astrocytes is mediated by  bbbbb2 MCT1 eeeee2  and/or MCT2
CPR:9	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that  bbbbb1 nicotinate eeeee1  uptake in rat astrocytes is mediated by MCT1 and/or  bbbbb2 MCT2 eeeee2 
CPR:9	These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a  bbbbb1 low-affinity monocarboxylate transporter eeeee1  MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for  bbbbb2 nicotinate eeeee2  in rat cerebrocortical astrocytes.
CPR:9	These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter  bbbbb1 MCT4 eeeee1  or other unknown H(+)-coupled monocarboxylate transport system, for  bbbbb2 nicotinate eeeee2  in rat cerebrocortical astrocytes.
CPR:9	These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown  bbbbb1 H(+)-coupled monocarboxylate transport system eeeee1 , for  bbbbb2 nicotinate eeeee2  in rat cerebrocortical astrocytes.
CPR:2	The marked antihypertensive efficacy of  bbbbb1 olmesartan medoxomil eeeee1  may result from a unique pharmacological interaction of the drug with the  bbbbb2 AT1 eeeee2  receptor, resulting in a potent, long-lasting, dose-dependent blockade of A-II
CPR:2	The  bbbbb1 angiotensin II (A-II) type 1 (AT1) receptor eeeee1 -mediated effects of  bbbbb2 A-II eeeee2  play a key role in the pathophysiology of hypertension
CPR:4	A review of the structural and functional features of  bbbbb1 olmesartan medoxomil eeeee1 , an  bbbbb2 angiotensin receptor eeeee2  blocker
CPR:4	The marked antihypertensive efficacy of  bbbbb1 olmesartan medoxomil eeeee1  may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of  bbbbb2 A-II eeeee2 
CPR:4	We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific  bbbbb1 neutrophil elastase eeeee1  inhibitor ( bbbbb2 ONO-5046 eeeee2 ) on acid lung injury in rats
CPR:4	Effects of  bbbbb1 granulocyte colony-stimulating factor eeeee1  (G-CSF) and neutrophil elastase inhibitor ( bbbbb2 ONO-5046 eeeee2 ) on acid-induced lung injury in rats
CPR:4	Effects of granulocyte colony-stimulating factor ( bbbbb1 G-CSF eeeee1 ) and neutrophil elastase inhibitor ( bbbbb2 ONO-5046 eeeee2 ) on acid-induced lung injury in rats
CPR:4	Effects of granulocyte colony-stimulating factor (G-CSF) and  bbbbb1 neutrophil elastase eeeee1  inhibitor ( bbbbb2 ONO-5046 eeeee2 ) on acid-induced lung injury in rats
CPR:4	 bbbbb1 Miglustat eeeee1 , an imino sugar that reversibly inhibits  bbbbb2 glucosylceramide synthase eeeee2  and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option
CPR:4	Miglustat, an  bbbbb1 imino sugar eeeee1  that reversibly inhibits  bbbbb2 glucosylceramide synthase eeeee2  and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option
CPR:10	Nicotinic-receptor potentiator drugs, huprine X and  bbbbb1 galantamine eeeee1 , increase ACh release by blocking AChE activity but not acting on  bbbbb2 nicotinic receptors eeeee2 
CPR:2	 bbbbb1 Nicotinic-receptor eeeee1  potentiator drugs, huprine X and  bbbbb2 galantamine eeeee2 , increase ACh release by blocking AChE activity but not acting on nicotinic receptors
CPR:4	This effect was reverted in the presence of  bbbbb1 atropine eeeee1  (ATR; 0.1 microM), which blocks the pre-synaptic  bbbbb2 muscarinic M2 receptor eeeee2 
CPR:4	This effect was reverted in the presence of atropine ( bbbbb1 ATR eeeee1 ; 0.1 microM), which blocks the pre-synaptic  bbbbb2 muscarinic M2 receptor eeeee2 
CPR:4	Nicotinic-receptor potentiator drugs, huprine X and  bbbbb1 galantamine eeeee1 , increase ACh release by blocking  bbbbb2 AChE eeeee2  activity but not acting on nicotinic receptors
CPR:4	To test the role of  bbbbb1 nicotinic receptors eeeee1  in the drugs' effects on [3H]-ACh release,  bbbbb2 mecamylamine eeeee2  (MEC) 100 microM was used to block such receptors
CPR:4	To test the role of  bbbbb1 nicotinic receptors eeeee1  in the drugs' effects on [3H]-ACh release, mecamylamine ( bbbbb2 MEC eeeee2 ) 100 microM was used to block such receptors
CPR:6	After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of  bbbbb1 haloperidol eeeee1  (HAL; 0.01 microM), a  bbbbb2 dopamine D2 eeeee2  antagonist
CPR:6	After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol ( bbbbb1 HAL eeeee1 ; 0.01 microM), a  bbbbb2 dopamine D2 eeeee2  antagonist
CPR:2	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for  bbbbb1 RAR-alpha eeeee1 , RAR-beta and RAR-gamma, the nuclear receptors for  bbbbb2 retinoic acid eeeee2 , decreased during activation of freshly isolated HSC even with retinoid supplementation
CPR:2	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha,  bbbbb1 RAR-beta eeeee1  and RAR-gamma, the nuclear receptors for  bbbbb2 retinoic acid eeeee2 , decreased during activation of freshly isolated HSC even with retinoid supplementation
CPR:2	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and  bbbbb1 RAR-gamma eeeee1 , the nuclear receptors for  bbbbb2 retinoic acid eeeee2 , decreased during activation of freshly isolated HSC even with retinoid supplementation
CPR:2	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the  bbbbb1 nuclear receptors eeeee1  for  bbbbb2 retinoic acid eeeee2 , decreased during activation of freshly isolated HSC even with retinoid supplementation
CPR:4	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for  bbbbb1 RAR-alpha eeeee1 , RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with  bbbbb2 retinoid eeeee2  supplementation
CPR:4	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha,  bbbbb1 RAR-beta eeeee1  and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with  bbbbb2 retinoid eeeee2  supplementation
CPR:4	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and  bbbbb1 RAR-gamma eeeee1 , the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with  bbbbb2 retinoid eeeee2  supplementation
CPR:4	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the  bbbbb1 nuclear receptors eeeee1  for retinoic acid, decreased during activation of freshly isolated HSC even with  bbbbb2 retinoid eeeee2  supplementation
CPR:2	Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of  bbbbb1 methacholine eeeee1 -contracted preparations in a concentration dependent fashion, indicating desensitization of the  bbbbb2 beta(2)-adrenoceptor eeeee2 
CPR:3	Preincubation with 1 microM of the  bbbbb1 protein kinase C eeeee1  (PKC) activator phorbol 12-myristate 13-acetate ( bbbbb2 PMA eeeee2 ) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization
CPR:3	Preincubation with 1 microM of the protein kinase C ( bbbbb1 PKC eeeee1 ) activator phorbol 12-myristate 13-acetate ( bbbbb2 PMA eeeee2 ) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization
CPR:3	Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate ( bbbbb1 PMA eeeee1 ) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated  bbbbb2 PKC eeeee2 -mediated heterologous beta(2)-adrenoceptor desensitization
CPR:3	Preincubation with 1 microM of the  bbbbb1 protein kinase C eeeee1  (PKC) activator  bbbbb2 phorbol 12-myristate 13-acetate eeeee2  (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization
CPR:3	Preincubation with 1 microM of the protein kinase C ( bbbbb1 PKC eeeee1 ) activator  bbbbb2 phorbol 12-myristate 13-acetate eeeee2  (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization
CPR:3	Preincubation with 1 microM of the protein kinase C (PKC) activator  bbbbb1 phorbol 12-myristate 13-acetate eeeee1  (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated  bbbbb2 PKC eeeee2 -mediated heterologous beta(2)-adrenoceptor desensitization
CPR:4	Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate ( bbbbb1 PMA eeeee1 ) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous  bbbbb2 beta(2)-adrenoceptor eeeee2  desensitization
CPR:4	Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of  bbbbb1 fenoterol eeeee1  decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the  bbbbb2 beta(2)-adrenoceptor eeeee2 
CPR:4	Preincubation with 1 microM of the protein kinase C (PKC) activator  bbbbb1 phorbol 12-myristate 13-acetate eeeee1  (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous  bbbbb2 beta(2)-adrenoceptor eeeee2  desensitization
CPR:4	Moreover, the specific  bbbbb1 PKC eeeee1 -inhibitor  bbbbb2 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide eeeee2  (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented
CPR:4	Moreover, the specific  bbbbb1 PKC eeeee1 -inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide ( bbbbb2 GF 109203X eeeee2 ) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented
CPR:5	Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in  bbbbb1 isoprenaline eeeee1 -induced E(max), indicating activated PKC-mediated heterologous  bbbbb2 beta(2)-adrenoceptor eeeee2  desensitization
CPR:5	Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased  bbbbb1 isoprenaline eeeee1 -induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the  bbbbb2 beta(2)-adrenoceptor eeeee2 
CPR:4	Tyrosine kinase inhibitors are  bbbbb1 quinazoline eeeee1 -derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of  bbbbb2 EGFR eeeee2  signaling
CPR:4	 bbbbb1 Tyrosine kinase eeeee1  inhibitors are  bbbbb2 quinazoline eeeee2 -derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling
CPR:4	Tyrosine kinase inhibitors are  bbbbb1 quinazoline eeeee1 -derived, low molecular weight synthetic molecules that can block the intracellular  bbbbb2 tyrosine kinase domain eeeee2  of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling
CPR:4	Tyrosine kinase inhibitors are  bbbbb1 quinazoline eeeee1 -derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including  bbbbb2 EGFR eeeee2 , Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling
CPR:4	Tyrosine kinase inhibitors are  bbbbb1 quinazoline eeeee1 -derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR,  bbbbb2 Erb2 eeeee2 , and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling
CPR:4	Tyrosine kinase inhibitors are  bbbbb1 quinazoline eeeee1 -derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and  bbbbb2 vascular endothelial growth factor receptor eeeee2 , and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling
CPR:10	When expressed heterologously in a mammalian cell line,  bbbbb1 rabbit PAT1 eeeee1  mediates pH-dependent,  bbbbb2 Na(+) eeeee2 -independent uptake of proline, glycine, l-alanine and alpha-(methylamino)isobutyric acid
CPR:1	The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475  bbbbb1 amino acids eeeee1  (92% identity to  bbbbb2 human PAT1 eeeee2 )
CPR:9	When expressed heterologously in a mammalian cell line,  bbbbb1 rabbit PAT1 eeeee1  mediates pH-dependent, Na(+)-independent uptake of  bbbbb2 proline eeeee2 , glycine, l-alanine and alpha-(methylamino)isobutyric acid
CPR:9	When expressed heterologously in a mammalian cell line,  bbbbb1 rabbit PAT1 eeeee1  mediates pH-dependent, Na(+)-independent uptake of proline,  bbbbb2 glycine eeeee2 , l-alanine and alpha-(methylamino)isobutyric acid
CPR:9	When expressed heterologously in a mammalian cell line,  bbbbb1 rabbit PAT1 eeeee1  mediates pH-dependent, Na(+)-independent uptake of proline, glycine,  bbbbb2 l-alanine eeeee2  and alpha-(methylamino)isobutyric acid
CPR:9	When expressed heterologously in a mammalian cell line,  bbbbb1 rabbit PAT1 eeeee1  mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and  bbbbb2 alpha-(methylamino)isobutyric acid eeeee2 
CPR:9	In the presence of Na+ and under conditions in which  bbbbb1 PAT1 eeeee1  transport function was suppressed, a second  bbbbb2 proline eeeee2  uptake system was detected that exhibited functional characteristics similar to those of the IMINO system
CPR:9	The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that  bbbbb1 PAT1 eeeee1  is the low-affinity transporter of  bbbbb2 proline eeeee2 , glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.
CPR:9	The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that  bbbbb1 PAT1 eeeee1  is the low-affinity transporter of proline,  bbbbb2 glycine eeeee2  and hydroxyproline believed to be defective in patients with iminoglycinuria.
CPR:9	The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that  bbbbb1 PAT1 eeeee1  is the low-affinity transporter of proline, glycine and  bbbbb2 hydroxyproline eeeee2  believed to be defective in patients with iminoglycinuria.
CPR:2	Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived  bbbbb1 IL-10 eeeee1  production, with significant effects elicited by the noradrenaline reuptake inhibitors  bbbbb2 reboxetine eeeee2  and desipramine
CPR:2	Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived  bbbbb1 IL-10 eeeee1  production, with significant effects elicited by the noradrenaline reuptake inhibitors reboxetine and  bbbbb2 desipramine eeeee2 
CPR:2	In this study, antidepressants with selectivity for the  bbbbb1 noradrenaline transporter eeeee1  ( bbbbb2 reboxetine eeeee2  and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CPR:2	In this study, antidepressants with selectivity for the  bbbbb1 noradrenaline transporter eeeee1  (reboxetine and  bbbbb2 desipramine eeeee2 ), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CPR:2	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the  bbbbb1 serotonin transporter eeeee1  ( bbbbb2 fluoxetine eeeee2  and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CPR:2	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the  bbbbb1 serotonin transporter eeeee1  (fluoxetine and  bbbbb2 clomipramine eeeee2 ) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CPR:4	The fact that  bbbbb1 trimipramine eeeee1  also suppressed  bbbbb2 IFN-gamma eeeee2  production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake
CPR:1	 bbbbb1 Leptin eeeee1  is a 167  bbbbb2 amino acid eeeee2  protein encoded by the obesity gene that is synthesized in adipose tissue and interacts with receptors in the hypothalamus linked to the regulation of appetite and metabolism
CPR:2	This increase may suggest that both  bbbbb1 leptin eeeee1  and  bbbbb2 cyproheptadine eeeee2  may affect appetite via similar receptors and that cyproheptadine does not impair leptin activity through these receptors
CPR:2	 bbbbb1 Cyproheptadine eeeee1  is a piperidine antihistamine that increases appetite through its antiserotonergic effect on  bbbbb2 5-HT2 eeeee2  receptors in the brain
CPR:2	Cyproheptadine is a  bbbbb1 piperidine eeeee1  antihistamine that increases appetite through its antiserotonergic effect on  bbbbb2 5-HT2 eeeee2  receptors in the brain
CPR:2	Cyproheptadine is a piperidine  bbbbb1 antihistamine eeeee1  that increases appetite through its antiserotonergic effect on  bbbbb2 5-HT2 eeeee2  receptors in the brain
CPR:3	The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean  bbbbb1 leptin eeeee1  level after 1 week of treatment with  bbbbb2 cyproheptadine eeeee2  (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05)
CPR:10	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group),  bbbbb1 N-acetylcysteine eeeee1  (only -SH group not  bbbbb2 ACE eeeee2  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CPR:10	It was found that a single intragastric gavage by  bbbbb1 L-methionine eeeee1  resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and  bbbbb2 angiotensin-converting enzyme eeeee2  activity compared with the control group
CPR:2	However, there were some significant differences among  bbbbb1 Captopril eeeee1  (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and N-acetylcysteine particular in the activity of  bbbbb2 PON1 eeeee2  and ACE
CPR:2	However, there were some significant differences among  bbbbb1 Captopril eeeee1  (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and N-acetylcysteine particular in the activity of PON1 and  bbbbb2 ACE eeeee2 
CPR:2	However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg),  bbbbb1 enalapril eeeee1  (20 mg/kg), and N-acetylcysteine particular in the activity of  bbbbb2 PON1 eeeee2  and ACE
CPR:2	However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg),  bbbbb1 enalapril eeeee1  (20 mg/kg), and N-acetylcysteine particular in the activity of PON1 and  bbbbb2 ACE eeeee2 
CPR:2	However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and  bbbbb1 N-acetylcysteine eeeee1  particular in the activity of  bbbbb2 PON1 eeeee2  and ACE
CPR:2	However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and  bbbbb1 N-acetylcysteine eeeee1  particular in the activity of PON1 and  bbbbb2 ACE eeeee2 
CPR:3	Given the treatment with three doses of  bbbbb1 Captopril eeeee1  (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of  bbbbb2 PON1 eeeee2  and SOD in serum by single intragastric gavaged L-methionine
CPR:3	Given the treatment with three doses of  bbbbb1 Captopril eeeee1  (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and  bbbbb2 SOD eeeee2  in serum by single intragastric gavaged L-methionine
CPR:3	These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of  bbbbb1 Captopril eeeee1  may be related to attenuating the decrease in  bbbbb2 PON1 eeeee2  activity and NO levels
CPR:4	These results suggested that Captopril can protect the vascular endothelium against the damages induced by  bbbbb1 L-methionine eeeee1  in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in  bbbbb2 PON1 eeeee2  activity and NO levels
CPR:4	We compared the effects of  bbbbb1 Captopril eeeee1  (an  bbbbb2 ACE eeeee2  inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CPR:4	We compared the effects of Captopril (an  bbbbb1 ACE eeeee1  inhibitor with - bbbbb2 SH eeeee2  group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CPR:4	We compared the effects of Captopril (an ACE inhibitor with -SH group),  bbbbb1 enalapril eeeee1  (an  bbbbb2 ACE eeeee2 -inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CPR:4	Comparison of  bbbbb1 captopril eeeee1  and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with  bbbbb2 ACE eeeee2  inhibitors in high dieted methionine mice
CPR:4	Comparison of captopril and  bbbbb1 enalapril eeeee1  to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with  bbbbb2 ACE eeeee2  inhibitors in high dieted methionine mice
CPR:4	Comparison of captopril and enalapril to study the role of the  bbbbb1 sulfhydryl eeeee1 -group in improvement of endothelial dysfunction with  bbbbb2 ACE eeeee2  inhibitors in high dieted methionine mice
CPR:4	It was found that a single intragastric gavage by  bbbbb1 L-methionine eeeee1  resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of  bbbbb2 PON1 eeeee2  and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group
CPR:4	It was found that a single intragastric gavage by  bbbbb1 L-methionine eeeee1  resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and  bbbbb2 SOD eeeee2 , similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group
CPR:3	In addition,  bbbbb1 sorafenib eeeee1  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2,  bbbbb2 VEGFR-3 eeeee2 , platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT
CPR:3	In addition,  bbbbb1 sorafenib eeeee1  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3,  bbbbb2 platelet-derived growth factor (PDGFR)-beta eeeee2  Flt-3, and c-KIT
CPR:3	In addition,  bbbbb1 sorafenib eeeee1  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta  bbbbb2 Flt-3 eeeee2 , and c-KIT
CPR:3	In addition,  bbbbb1 sorafenib eeeee1  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and  bbbbb2 c-KIT eeeee2 
CPR:3	In addition,  bbbbb1 sorafenib eeeee1  demonstrated significant activity against several  bbbbb2 receptor tyrosine kinases eeeee2  involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT
CPR:3	In addition,  bbbbb1 sorafenib eeeee1  demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including  bbbbb2 vascular-endothelial growth factor (VEGFR)-2 eeeee2 , VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT
CPR:4	Further characterization showed that  bbbbb1 sorafenib eeeee1  suppresses both wild-type and  bbbbb2 V599E eeeee2  mutant B-Raf activity in vitro
CPR:4	Further characterization showed that  bbbbb1 sorafenib eeeee1  suppresses both wild-type and V599E mutant  bbbbb2 B-Raf eeeee2  activity in vitro
CPR:4	 bbbbb1 Sorafenib eeeee1 , which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of  bbbbb2 Raf-1 eeeee2  and its favorable kinase selectivity profile
CPR:4	 bbbbb1 Sorafenib eeeee1 , which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable  bbbbb2 kinase eeeee2  selectivity profile
CPR:4	Sorafenib, which belongs chemically to a class that can be described as  bbbbb1 bis-aryl ureas eeeee1 , was selected for further pharmacologic characterization based on potent inhibition of  bbbbb2 Raf-1 eeeee2  and its favorable kinase selectivity profile
CPR:4	Sorafenib, which belongs chemically to a class that can be described as  bbbbb1 bis-aryl ureas eeeee1 , was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable  bbbbb2 kinase eeeee2  selectivity profile
CPR:2	In vivo angiogenesis assay utilising gelfoam sponges,  bbbbb1 bexarotene eeeee1  reduced angiogenesis in sponges containing  bbbbb2 vascular endothelial growth factor eeeee2 , epidermal growth factor and basic fibroblast growth factor to various extent
CPR:2	In vivo angiogenesis assay utilising gelfoam sponges,  bbbbb1 bexarotene eeeee1  reduced angiogenesis in sponges containing vascular endothelial growth factor,  bbbbb2 epidermal growth factor eeeee2  and basic fibroblast growth factor to various extent
CPR:2	In vivo angiogenesis assay utilising gelfoam sponges,  bbbbb1 bexarotene eeeee1  reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic  bbbbb2 fibroblast growth factor eeeee2  to various extent
CPR:3	The ability of  bbbbb1 bexarotene eeeee1  to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner  bbbbb2 peroxisome proliferator-activated receptor gamma eeeee2 
CPR:3	Analysis of tumour-conditioned medium indicated that  bbbbb1 bexarotene eeeee1  decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of  bbbbb2 matrix metalloproteinases eeeee2 
CPR:4	Analysis of tumour-conditioned medium indicated that  bbbbb1 bexarotene eeeee1  decreased the secretion of angiogenic factors and  bbbbb2 matrix metalloproteinases eeeee2  and increased the tissue inhibitor of matrix metalloproteinases
CPR:5	A selective  bbbbb1 retinoid X receptor eeeee1  agonist  bbbbb2 bexarotene eeeee2  (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
CPR:5	A selective  bbbbb1 retinoid X receptor eeeee1  agonist bexarotene ( bbbbb2 LGD1069 eeeee2 , targretin) inhibits angiogenesis and metastasis in solid tumours
CPR:5	A selective  bbbbb1 retinoid X receptor eeeee1  agonist bexarotene (LGD1069,  bbbbb2 targretin eeeee2 ) inhibits angiogenesis and metastasis in solid tumours
CPR:5	The present study determined the influence of a  bbbbb1 retinoid X receptor eeeee1  agonist  bbbbb2 bexarotene eeeee2  on angiogenesis and metastasis in solid tumours
CPR:2	The dysmenorrhea pain evoked by  bbbbb1 vasopressin eeeee1  correlated poorly with area under the curve, which may suggest that the effect is mediated by more than one  bbbbb2 V1a-like receptor eeeee2 
CPR:4	In subjects with dysmenorrhea the increase in pain following the administration of  bbbbb1 vasopressin eeeee1  was significantly lower during  bbbbb2 atosiban eeeee2  than during placebo infusion
CPR:4	CONCLUSIONS:  bbbbb1 Atosiban eeeee1  reduces  bbbbb2 vasopressin eeeee2 -induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea
CPR:2	Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS:  bbbbb1 Thymidylate synthase eeeee1  (TS) is an important enzyme for DNA synthesis and the target for  bbbbb2 5-fluorouracil eeeee2  (5-FU)
CPR:2	Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS: Thymidylate synthase ( bbbbb1 TS eeeee1 ) is an important enzyme for DNA synthesis and the target for  bbbbb2 5-fluorouracil eeeee2  (5-FU)
CPR:2	Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS:  bbbbb1 Thymidylate synthase eeeee1  (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil ( bbbbb2 5-FU eeeee2 )
CPR:2	Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS: Thymidylate synthase ( bbbbb1 TS eeeee1 ) is an important enzyme for DNA synthesis and the target for 5-fluorouracil ( bbbbb2 5-FU eeeee2 )
CPR:1	Removal of Pro128 from the hepatic  bbbbb1 SDH eeeee1  consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for pyridoxal 5'-phosphate, whereas addition of a  bbbbb2 proline eeeee2  residue to the isoform was without effect
CPR:8	Removal of Pro128 from the hepatic  bbbbb1 SDH eeeee1  consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for  bbbbb2 pyridoxal 5'-phosphate eeeee2 , whereas addition of a proline residue to the isoform was without effect
CPR:4	Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the  bbbbb1 acetylcholinesterase eeeee1  inhibitor  bbbbb2 tacrine eeeee2 
CPR:9	Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of  bbbbb1 acetylcholinesterase eeeee1  and of butyrylcholinesterase which is another catalytic enzyme hydrolysing  bbbbb2 acetylcholine eeeee2 
CPR:9	Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of  bbbbb1 butyrylcholinesterase eeeee1  which is another catalytic enzyme hydrolysing  bbbbb2 acetylcholine eeeee2 
CPR:9	Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main  bbbbb1 histamine eeeee1  metabolizing enzyme in the brain,  bbbbb2 N-methyltransferase eeeee2 , chemically show structural elements of the acetylcholinesterase inhibitor tacrine
CPR:4	For some, pharmacologic inhibitors are available, including  bbbbb1 sorafenib eeeee1  for  bbbbb2 BRAF eeeee2 , farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CPR:4	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS,  bbbbb1 PD-0325901 eeeee1  for  bbbbb2 mitogen-activated protein kinase eeeee2 /extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CPR:4	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS,  bbbbb1 PD-0325901 eeeee1  for mitogen-activated protein kinase/ bbbbb2 extracellular signal-regulated kinase kinase eeeee2 , rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CPR:4	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase,  bbbbb1 rapamycin eeeee1  analogues for  bbbbb2 mammalian target of rapamycin eeeee2 , and agents that inhibit either vascular endothelial growth factor or its receptors
CPR:10	Similar to the  bbbbb1 plasma membrane PS transporter eeeee1 , Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the  bbbbb2 sn-2,3-glycerol eeeee2  stereoisomer
CPR:10	Similar to the plasma membrane PS transporter,  bbbbb1 Atp8a1 eeeee1  is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the  bbbbb2 sn-2,3-glycerol eeeee2  stereoisomer
CPR:10	Activation of Atp8a1 is also reduced by these modifications;  bbbbb1 phosphatidylserine-O-methyl ester eeeee1 , lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate  bbbbb2 Atp8a1 eeeee2 
CPR:10	Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester,  bbbbb1 lysophosphatidylserine eeeee1 , glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate  bbbbb2 Atp8a1 eeeee2 
CPR:10	Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine,  bbbbb1 glycerophosphoserine eeeee1 , and phosphoserine, which are not transported by the plasma membrane flippase, do not activate  bbbbb2 Atp8a1 eeeee2 
CPR:10	Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and  bbbbb1 phosphoserine eeeee1 , which are not transported by the plasma membrane flippase, do not activate  bbbbb2 Atp8a1 eeeee2 
CPR:10	The purified  bbbbb1 Atp8a1 eeeee1  is inactive in detergent micelles or in micelles containing  bbbbb2 phosphatidylcholine eeeee2 , phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS
CPR:10	However,  bbbbb1 N-methyl-phosphatidylserine eeeee1 , which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating  bbbbb2 Atp8a1 eeeee2  activity
CPR:10	The purified  bbbbb1 Atp8a1 eeeee1  is inactive in detergent micelles or in micelles containing phosphatidylcholine,  bbbbb2 phosphatidic acid eeeee2 , or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS
CPR:10	The purified  bbbbb1 Atp8a1 eeeee1  is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or  bbbbb2 phosphatidylinositol eeeee2 , is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS
CPR:2	This aminophospholipid " bbbbb1 flippase eeeee1 " selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to  bbbbb2 vanadate eeeee2 , Ca(2+), and modification by sulfhydryl reagents
CPR:2	This aminophospholipid " bbbbb1 flippase eeeee1 " selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate,  bbbbb2 Ca(2+) eeeee2 , and modification by sulfhydryl reagents
CPR:2	This aminophospholipid " bbbbb1 flippase eeeee1 " selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by  bbbbb2 sulfhydryl eeeee2  reagents
CPR:3	Similar to the  bbbbb1 plasma membrane PS transporter eeeee1 , Atp8a1 is activated only by the naturally occurring  bbbbb2 sn-1,2-glycerol eeeee2  isomer of PS and not the sn-2,3-glycerol stereoisomer
CPR:3	Similar to the plasma membrane PS transporter,  bbbbb1 Atp8a1 eeeee1  is activated only by the naturally occurring  bbbbb2 sn-1,2-glycerol eeeee2  isomer of PS and not the sn-2,3-glycerol stereoisomer
CPR:3	Weakly translocated lipids ( bbbbb1 PE eeeee1 , phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak  bbbbb2 Atp8a1 eeeee2  activators
CPR:3	Weakly translocated lipids (PE,  bbbbb1 phosphatidylhydroxypropionate eeeee1 , and phosphatidylhomoserine) are also weak  bbbbb2 Atp8a1 eeeee2  activators
CPR:3	Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and  bbbbb1 phosphatidylhomoserine eeeee1 ) are also weak  bbbbb2 Atp8a1 eeeee2  activators
CPR:3	These results indicate that the  bbbbb1 ATPase eeeee1  activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties ( bbbbb2 PS eeeee2  selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.
CPR:3	These results indicate that the ATPase activity of the secretory granule  bbbbb1 Atp8a1 eeeee1  is activated by phospholipids binding to a specific site whose properties ( bbbbb2 PS eeeee2  selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.
CPR:3	The purified  bbbbb1 Atp8a1 eeeee1  is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by  bbbbb2 phosphatidylglycerol eeeee2  or phosphatidylethanolamine (PE), and is maximally activated by PS
CPR:3	The purified  bbbbb1 Atp8a1 eeeee1  is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or  bbbbb2 phosphatidylethanolamine eeeee2  (PE), and is maximally activated by PS
CPR:3	The purified  bbbbb1 Atp8a1 eeeee1  is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine ( bbbbb2 PE eeeee2 ), and is maximally activated by PS
CPR:3	The purified  bbbbb1 Atp8a1 eeeee1  is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by  bbbbb2 PS eeeee2 
CPR:4	Activation of  bbbbb1 Atp8a1 eeeee1  is also reduced by these modifications;  bbbbb2 phosphatidylserine-O-methyl ester eeeee2 , lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1
CPR:4	Activation of  bbbbb1 Atp8a1 eeeee1  is also reduced by these modifications; phosphatidylserine-O-methyl ester,  bbbbb2 lysophosphatidylserine eeeee2 , glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1
CPR:4	Activation of  bbbbb1 Atp8a1 eeeee1  is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine,  bbbbb2 glycerophosphoserine eeeee2 , and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1
CPR:4	Activation of  bbbbb1 Atp8a1 eeeee1  is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and  bbbbb2 phosphoserine eeeee2 , which are not transported by the plasma membrane flippase, do not activate Atp8a1
CPR:9	However,  bbbbb1 N-methyl-phosphatidylserine eeeee1 , which is transported by the plasma membrane  bbbbb2 flippase eeeee2  at a rate equivalent to PS, is incapable of activating Atp8a1 activity
CPR:9	This aminophospholipid " bbbbb1 flippase eeeee1 " selectively transports  bbbbb2 PS eeeee2  to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents
CPR:2	This fundamental significance of  bbbbb1 NMDA receptor eeeee1 -related excitotoxicity is discussed in the context of the developing clinical success of  bbbbb2 Memantine eeeee2 , but moreover set into relation to various proteomic and genetic markers of said diseases
CPR:4	 bbbbb1 Sorafenib eeeee1  (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of  bbbbb2 tyrosine kinases eeeee2  that are known to be involved in tumor cell proliferation and tumor angiogenesis
CPR:4	Sorafenib ( bbbbb1 BAY 43-9006 eeeee1 ) is a small-molecule inhibitor that has been shown to target members of multiple classes of  bbbbb2 tyrosine kinases eeeee2  that are known to be involved in tumor cell proliferation and tumor angiogenesis
CPR:2	Here, we show that at noncytotoxic concentrations,  bbbbb1 H(2)S eeeee1  was able to inhibit NO production and inducible NO synthase (iNOS) expression via  bbbbb2 heme oxygenase eeeee2  (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CPR:2	Here, we show that at noncytotoxic concentrations,  bbbbb1 H(2)S eeeee1  was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase ( bbbbb2 HO-1 eeeee2 ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CPR:2	 bbbbb1 Hydrogen sulfide eeeee1  inhibits nitric oxide production and nuclear factor-kappaB via  bbbbb2 heme oxygenase-1 eeeee2  expression in RAW264.7 macrophages stimulated with lipopolysaccharide
CPR:2	Interestingly, the inhibitory effect of  bbbbb1 H(2)S eeeee1  on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either  bbbbb2 HO-1 eeeee2  gene transfection or treatment with carbon monoxide (CO), an end product of HO-1
CPR:2	Collectively, our results suggest that  bbbbb1 H(2)S eeeee1  can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of  bbbbb2 HO-1 eeeee2 /CO.
CPR:3	Both  bbbbb1 H(2)S eeeee1  solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the  bbbbb2 extracellular signal-regulated kinase eeeee2  (ERK)
CPR:3	Both  bbbbb1 H(2)S eeeee1  solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase ( bbbbb2 ERK eeeee2 )
CPR:3	Both  bbbbb1 H(2)S eeeee1  solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced  bbbbb2 HO-1 eeeee2  expression through the activation of the extracellular signal-regulated kinase (ERK)
CPR:4	 bbbbb1 CO eeeee1  treatment also inhibited LPS-induced NO production and  bbbbb2 iNOS eeeee2  expression via its inactivation of NF-kappaB
CPR:4	Here, we show that at noncytotoxic concentrations,  bbbbb1 H(2)S eeeee1  was able to inhibit NO production and  bbbbb2 inducible NO synthase eeeee2  (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CPR:4	Here, we show that at noncytotoxic concentrations,  bbbbb1 H(2)S eeeee1  was able to inhibit NO production and inducible NO synthase ( bbbbb2 iNOS eeeee2 ) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CPR:4	Pretreatment with  bbbbb1 H(2)S eeeee1  or NaHS significantly inhibited LPS-induced  bbbbb2 iNOS eeeee2  expression and NO production
CPR:4	Pretreatment with H(2)S or  bbbbb1 NaHS eeeee1  significantly inhibited LPS-induced  bbbbb2 iNOS eeeee2  expression and NO production
CPR:4	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of  bbbbb1 H(2)S eeeee1  on  bbbbb2 iNOS eeeee2  expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CPR:4	 bbbbb1 CO eeeee1  treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of  bbbbb2 NF-kappaB eeeee2 
CPR:4	Collectively, our results suggest that  bbbbb1 H(2)S eeeee1  can inhibit NO production and  bbbbb2 NF-kappaB eeeee2  activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.
CPR:4	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective  bbbbb1 CSE eeeee1  inhibitor  bbbbb2 beta-cyano-L-alanine eeeee2  but not by the CBS inhibitor aminooxyacetic acid
CPR:4	 bbbbb1 Hydrogen sulfide eeeee1  inhibits nitric oxide production and  bbbbb2 nuclear factor-kappaB eeeee2  via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide
CPR:4	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the  bbbbb1 CBS eeeee1  inhibitor  bbbbb2 aminooxyacetic acid eeeee2 
CPR:4	In addition, LPS-induced nuclear factor  bbbbb1 (NF)-kappaB eeeee1  activation was diminished in RAW264.7 macrophages preincubated with  bbbbb2 H(2)S eeeee2 
CPR:4	Interestingly, the inhibitory effect of  bbbbb1 H(2)S eeeee1  on  bbbbb2 NF-kappaB eeeee2  activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1
CPR:9	Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with  bbbbb1 carbon monoxide eeeee1  (CO), an end product of  bbbbb2 HO-1 eeeee2 
CPR:9	Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide ( bbbbb1 CO eeeee1 ), an end product of  bbbbb2 HO-1 eeeee2 
CPR:9	CO treatment also inhibited LPS-induced  bbbbb1 NO eeeee1  production and  bbbbb2 iNOS eeeee2  expression via its inactivation of NF-kappaB
CPR:9	Hydrogen sulfide ( bbbbb1 H(2)S eeeee1 ), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( bbbbb2 CSE eeeee2 ) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide ( bbbbb1 H(2)S eeeee1 ), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  bbbbb2 cystathionine beta-synthase eeeee2  (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide ( bbbbb1 H(2)S eeeee1 ), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( bbbbb2 CBS eeeee2 ) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide ( bbbbb1 H(2)S eeeee1 ), a regulatory gaseous molecule that is endogenously synthesized by  bbbbb2 cystathionine gamma-lyase eeeee2  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of  bbbbb1 HO-1 eeeee1 / bbbbb2 CO eeeee2 .
CPR:9	 bbbbb1 Hydrogen sulfide eeeee1  (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( bbbbb2 CSE eeeee2 ) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	 bbbbb1 Hydrogen sulfide eeeee1  (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  bbbbb2 cystathionine beta-synthase eeeee2  (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	 bbbbb1 Hydrogen sulfide eeeee1  (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( bbbbb2 CBS eeeee2 ) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	 bbbbb1 Hydrogen sulfide eeeee1  (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  bbbbb2 cystathionine gamma-lyase eeeee2  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit  bbbbb1 NO eeeee1  production and  bbbbb2 inducible NO synthase eeeee2  (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CPR:9	Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit  bbbbb1 NO eeeee1  production and inducible NO synthase ( bbbbb2 iNOS eeeee2 ) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CPR:9	Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced  bbbbb1 iNOS eeeee1  expression and  bbbbb2 NO eeeee2  production
CPR:9	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on  bbbbb1 iNOS eeeee1  expression and  bbbbb2 NO eeeee2  production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CPR:9	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( bbbbb1 CSE eeeee1 ) and/or cystathionine beta-synthase (CBS) from  bbbbb2 L-cysteine eeeee2  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  bbbbb1 cystathionine beta-synthase eeeee1  (CBS) from  bbbbb2 L-cysteine eeeee2  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( bbbbb1 CBS eeeee1 ) from  bbbbb2 L-cysteine eeeee2  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  bbbbb1 cystathionine gamma-lyase eeeee1  (CSE) and/or cystathionine beta-synthase (CBS) from  bbbbb2 L-cysteine eeeee2  (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ( bbbbb1 CSE eeeee1 ) and/or cystathionine beta-synthase (CBS) from L-cysteine ( bbbbb2 L-Cys eeeee2 ) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  bbbbb1 cystathionine beta-synthase eeeee1  (CBS) from L-cysteine ( bbbbb2 L-Cys eeeee2 ) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase ( bbbbb1 CBS eeeee1 ) from L-cysteine ( bbbbb2 L-Cys eeeee2 ) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  bbbbb1 cystathionine gamma-lyase eeeee1  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine ( bbbbb2 L-Cys eeeee2 ) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CPR:9	Moreover, NO production in LPS-stimulated macrophages that are expressing  bbbbb1 CSE eeeee1  mRNA was significantly reduced by the addition of  bbbbb2 L-Cys eeeee2 , a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid
CPR:4	However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of  bbbbb1 arginase eeeee1  activity by  bbbbb2 urea eeeee2  in the tissue lysates
CPR:4	CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of  bbbbb1 arginase eeeee1 , the inherent rise in  bbbbb2 urea eeeee2  concentration inhibits its enzymatic activity
CPR:9	L-arg is converted to  bbbbb1 urea eeeee1  by  bbbbb2 arginase I eeeee2  in the liver and arginase II in the kidney
CPR:9	L-arg is converted to  bbbbb1 urea eeeee1  by arginase I in the liver and  bbbbb2 arginase II eeeee2  in the kidney
CPR:9	Sources of  bbbbb1 L-arg eeeee1  include dietary proteins and endogenous synthesis by  bbbbb2 argininosuccinate synthetase eeeee2  and argininosuccinate lyase
CPR:9	Sources of  bbbbb1 L-arg eeeee1  include dietary proteins and endogenous synthesis by argininosuccinate synthetase and  bbbbb2 argininosuccinate lyase eeeee2 
CPR:9	 bbbbb1 L-arg eeeee1  is converted to urea by  bbbbb2 arginase I eeeee2  in the liver and arginase II in the kidney
CPR:9	 bbbbb1 L-arg eeeee1  is converted to urea by arginase I in the liver and  bbbbb2 arginase II eeeee2  in the kidney
CPR:9	We hypothesized that preservation of plasma  bbbbb1 L-arg eeeee1  in CRF may be, partly, due to downregulation/inhibition of  bbbbb2 arginase eeeee2 
CPR:6	However, several promising nonpeptide,  bbbbb1 vasopressin receptor eeeee1  antagonists have been described; these agents are  bbbbb2 VPA-985 eeeee2  (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463
CPR:6	However, several promising nonpeptide,  bbbbb1 vasopressin receptor eeeee1  antagonists have been described; these agents are VPA-985 ( bbbbb2 lixivaptan eeeee2 ), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463
CPR:6	However, several promising nonpeptide,  bbbbb1 vasopressin receptor eeeee1  antagonists have been described; these agents are VPA-985 (lixivaptan),  bbbbb2 YM-087 eeeee2  (conivaptan), OPC-41061 (tolvaptan), and SR-121463
CPR:6	However, several promising nonpeptide,  bbbbb1 vasopressin receptor eeeee1  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 ( bbbbb2 conivaptan eeeee2 ), OPC-41061 (tolvaptan), and SR-121463
CPR:6	However, several promising nonpeptide,  bbbbb1 vasopressin receptor eeeee1  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan),  bbbbb2 OPC-41061 eeeee2  (tolvaptan), and SR-121463
CPR:6	However, several promising nonpeptide,  bbbbb1 vasopressin receptor eeeee1  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 ( bbbbb2 tolvaptan eeeee2 ), and SR-121463
CPR:6	However, several promising nonpeptide,  bbbbb1 vasopressin receptor eeeee1  antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and  bbbbb2 SR-121463 eeeee2 
CPR:6	edation and  bbbbb1 histamine H1-receptor eeeee1  antagonism: studies in man with the enantiomers of chlorpheniramine and  bbbbb2 dimethindene eeeee2 . 1
CPR:6	edation and  bbbbb1 histamine H1-receptor eeeee1  antagonism: studies in man with the enantiomers of  bbbbb2 chlorpheniramine eeeee2  and dimethindene. 1
CPR:4	BG also showed a protective effect in the presence of a  bbbbb1 DNA polymerase beta eeeee1  inhibitor ( bbbbb2 cytosine arabinoside-3-phosphate eeeee2 , Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.
CPR:4	BG also showed a protective effect in the presence of a  bbbbb1 DNA polymerase beta eeeee1  inhibitor (cytosine arabinoside-3-phosphate,  bbbbb2 Ara-C eeeee2 ), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.
CPR:1	METHODS: We identified seven SNP(single  bbbbb1 nucleotide eeeee1  polymorphism) (-141Cins>del, TaqIB, TaqID,  bbbbb2 Ser311Cys eeeee2 , rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks
CPR:1	METHODS: We identified seven SNP(single  bbbbb1 nucleotide eeeee1  polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the  bbbbb2 DRD2 eeeee2  gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks
CPR:2	CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the  bbbbb1 DRD2 eeeee1  gene plays a major role in the individually variable adverse effect induced by  bbbbb2 chlorpromazine eeeee2 , at least in Chinese patients with schizophrenia
CPR:10	Calcium-chelating reagents such as  bbbbb1 EDTA eeeee1  and 1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester prevented the cleavage of  bbbbb2 GAD65 eeeee2 
CPR:10	Calcium-chelating reagents such as EDTA and  bbbbb1 1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester eeeee1  prevented the cleavage of  bbbbb2 GAD65 eeeee2 
CPR:1	Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the  bbbbb1 N eeeee1 -terminus,  bbbbb2 GAD65(Delta1-69) eeeee2 
CPR:2	Agents that specifically target  bbbbb1 BRAF eeeee1 , such as  bbbbb2 sorafenib eeeee2 , as well as new molecules that function both upstream and downstream of BRAF, are being actively investigated.
CPR:4	Our purpose was to test the impact of single and/or combined treatment with the  bbbbb1 AT(1) eeeee1 -receptor blocker  bbbbb2 candesartan eeeee2  and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats
CPR:4	Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the  bbbbb1 HMG-CoA reductase eeeee1  inhibitor  bbbbb2 rosuvastatin eeeee2  and their combination
CPR:4	Reduction of cerebral infarct size by the  bbbbb1 AT1 eeeee1 -receptor blocker  bbbbb2 candesartan eeeee2 , the HMG-CoA reductase inhibitor rosuvastatin and their combination
CPR:4	Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker candesartan and the  bbbbb1 HMG-CoA reductase eeeee1  inhibitor  bbbbb2 rosuvastatin eeeee2  on infarct size and neuroscore in transient cerebral ischemia in rats
CPR:1	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a  bbbbb1 DGKgamma eeeee1  mutant in which Ser-776 and Ser-779 were substituted with  bbbbb2 glutamic acid eeeee2  to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant
CPR:1	Mass spectrometric analysis and mutation studies revealed that  bbbbb1 gammaPKC eeeee1   bbbbb2 phosphorylated Ser eeeee2 -776 and Ser-779 in the AD of DGKgamma
CPR:1	Mass spectrometric analysis and mutation studies revealed that gammaPKC phosphorylated Ser-776 and  bbbbb1 Ser eeeee1 -779 in the AD of  bbbbb2 DGKgamma eeeee2 
CPR:1	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a  bbbbb1 DGKgamma eeeee1  mutant in which  bbbbb2 Ser eeeee2 -776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant
CPR:1	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a  bbbbb1 DGKgamma eeeee1  mutant in which Ser-776 and  bbbbb2 Ser eeeee2 -779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant
CPR:2	Here we show molecular mechanisms of functional coupling of the two kinases.  bbbbb1 gammaPKC eeeee1  directly associated with DGKgamma through its accessory domain (AD), depending on  bbbbb2 Ca2+ eeeee2  as well as phosphatidylserine/diolein in vitro
CPR:2	Here we show molecular mechanisms of functional coupling of the two kinases. gammaPKC directly associated with  bbbbb1 DGKgamma eeeee1  through its accessory domain (AD), depending on  bbbbb2 Ca2+ eeeee2  as well as phosphatidylserine/diolein in vitro
CPR:2	Here we show molecular mechanisms of functional coupling of the two kinases.  bbbbb1 gammaPKC eeeee1  directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as  bbbbb2 phosphatidylserine eeeee2 /diolein in vitro
CPR:2	Here we show molecular mechanisms of functional coupling of the two kinases. gammaPKC directly associated with  bbbbb1 DGKgamma eeeee1  through its accessory domain (AD), depending on Ca2+ as well as  bbbbb2 phosphatidylserine eeeee2 /diolein in vitro
CPR:2	Here we show molecular mechanisms of functional coupling of the two kinases.  bbbbb1 gammaPKC eeeee1  directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/ bbbbb2 diolein eeeee2  in vitro
CPR:2	Here we show molecular mechanisms of functional coupling of the two kinases. gammaPKC directly associated with  bbbbb1 DGKgamma eeeee1  through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/ bbbbb2 diolein eeeee2  in vitro
CPR:7	 bbbbb1 Diacylglycerol eeeee1  (DAG) acts as an allosteric activator of  bbbbb2 protein kinase C eeeee2  (PKC) and is converted to phosphatidic acid by DAG kinase (DGK)
CPR:7	 bbbbb1 Diacylglycerol eeeee1  (DAG) acts as an allosteric activator of protein kinase C ( bbbbb2 PKC eeeee2 ) and is converted to phosphatidic acid by DAG kinase (DGK)
CPR:7	Diacylglycerol ( bbbbb1 DAG eeeee1 ) acts as an allosteric activator of  bbbbb2 protein kinase C eeeee2  (PKC) and is converted to phosphatidic acid by DAG kinase (DGK)
CPR:7	Diacylglycerol ( bbbbb1 DAG eeeee1 ) acts as an allosteric activator of protein kinase C ( bbbbb2 PKC eeeee2 ) and is converted to phosphatidic acid by DAG kinase (DGK)
CPR:9	Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to  bbbbb1 phosphatidic acid eeeee1  by  bbbbb2 DAG kinase eeeee2  (DGK)
CPR:9	Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to  bbbbb1 phosphatidic acid eeeee1  by DAG kinase ( bbbbb2 DGK eeeee2 )
CPR:9	 bbbbb1 Diacylglycerol eeeee1  (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by  bbbbb2 DAG kinase eeeee2  (DGK)
CPR:9	 bbbbb1 Diacylglycerol eeeee1  (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase ( bbbbb2 DGK eeeee2 )
CPR:9	Diacylglycerol ( bbbbb1 DAG eeeee1 ) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by  bbbbb2 DAG kinase eeeee2  (DGK)
CPR:9	Diacylglycerol ( bbbbb1 DAG eeeee1 ) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase ( bbbbb2 DGK eeeee2 )
CPR:2	Among all the organophosphates tested, the combination of a methyl group and a negatively charged  bbbbb1 oxygen eeeee1  attached to the P atom, CH3P(O)(O-)- bbbbb2 AChE eeeee2 , conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.
CPR:2	Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the  bbbbb1 P eeeee1  atom, CH3P(O)(O-)- bbbbb2 AChE eeeee2 , conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.
CPR:2	Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom,  bbbbb1 CH3P(O)(O-) eeeee1 - bbbbb2 AChE eeeee2 , conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.
CPR:2	Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)-AChE, conferred the greatest protection to the active site of aged or nonaged  bbbbb1 organophosphoryl eeeee1  conjugates of  bbbbb2 acetylcholinesterase eeeee2 .
CPR:2	Among all the  bbbbb1 organophosphates eeeee1  tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)- bbbbb2 AChE eeeee2 , conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.
CPR:4	Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of  bbbbb1 acetylcholinesterase eeeee1  against denaturation by heat or  bbbbb2 guanidine eeeee2  following phosphorylation by organophosphorus anticholinesterase compounds
CPR:4	Monoclonal antibody 25B1 generated against  bbbbb1 diisopropyl phosphorofluoridate eeeee1  inhibited fetal  bbbbb2 bovine serum acetylcholinesterase eeeee2  has been extensively characterized with respect to its anticholinesterase properties
CPR:2	The effect of  bbbbb1 folic acid eeeee1  level on this end-point was modulated by the  bbbbb2 MTHFR eeeee2  genotype (P for interaction = 0.02), with TT cells grown at low folic acid concentration apparently resistant to the induction of radiation-induced bridges
CPR:2	The  bbbbb1 C677T eeeee1  polymorphism of the methylene-tetrahydrofolate reductase (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on  bbbbb2 folate eeeee2  status
CPR:2	The C677T polymorphism of the  bbbbb1 methylene-tetrahydrofolate reductase eeeee1  (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on  bbbbb2 folate eeeee2  status
CPR:2	The C677T polymorphism of the methylene-tetrahydrofolate reductase ( bbbbb1 MTHFR eeeee1 ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on  bbbbb2 folate eeeee2  status
CPR:2	The main molecular target of  bbbbb1 azole eeeee1  antifungals is the  bbbbb2 cytochrome P-450 eeeee2  protein Erg11p/Cyp51p
CPR:2	The main molecular target of  bbbbb1 azole eeeee1  antifungals is the cytochrome P-450 protein  bbbbb2 Erg11p eeeee2 /Cyp51p
CPR:2	The main molecular target of  bbbbb1 azole eeeee1  antifungals is the cytochrome P-450 protein Erg11p/ bbbbb2 Cyp51p eeeee2 
CPR:2	The  bbbbb1 phenylmorpholines eeeee1 , of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway:  bbbbb2 Erg24p eeeee2  (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase)
CPR:2	The  bbbbb1 phenylmorpholines eeeee1 , of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p ( bbbbb2 delta 14 reductase eeeee2 ) and Erg2p (delta 8-delta 7 isomerase)
CPR:2	The  bbbbb1 phenylmorpholines eeeee1 , of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and  bbbbb2 Erg2p eeeee2  (delta 8-delta 7 isomerase)
CPR:2	The  bbbbb1 phenylmorpholines eeeee1 , of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p ( bbbbb2 delta 8-delta 7 isomerase eeeee2 )
CPR:2	The phenylmorpholines, of which  bbbbb1 amorolfine eeeee1  is the sole representative in human therapy, affect two targets in the ergosterol pathway:  bbbbb2 Erg24p eeeee2  (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase)
CPR:2	The phenylmorpholines, of which  bbbbb1 amorolfine eeeee1  is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p ( bbbbb2 delta 14 reductase eeeee2 ) and Erg2p (delta 8-delta 7 isomerase)
CPR:2	The phenylmorpholines, of which  bbbbb1 amorolfine eeeee1  is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and  bbbbb2 Erg2p eeeee2  (delta 8-delta 7 isomerase)
CPR:2	The phenylmorpholines, of which  bbbbb1 amorolfine eeeee1  is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p ( bbbbb2 delta 8-delta 7 isomerase eeeee2 )
CPR:4	The  bbbbb1 sordarins eeeee1  group are protein synthesis inhibitors that work by blocking the function of  bbbbb2 fungal translation elongation factor 2 eeeee2 
CPR:2	The short lifetime of  bbbbb1 IP3 eeeee1  makes this detection very challenging in measuring  bbbbb2 GPCR eeeee2  responses
CPR:2	We show here that  bbbbb1 IP1 eeeee1  can be used as a surrogate of IP3 to monitor  bbbbb2 GPCR eeeee2  activation
CPR:2	We show here that IP1 can be used as a surrogate of  bbbbb1 IP3 eeeee1  to monitor  bbbbb2 GPCR eeeee2  activation
CPR:2	 bbbbb1 D-myo-inositol 1-phosphate eeeee1  as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor  bbbbb2 G protein-coupled receptor eeeee2  activation
CPR:2	D-myo-inositol 1-phosphate as a surrogate of  bbbbb1 D-myo-inositol 1,4,5-tris phosphate eeeee1  to monitor  bbbbb2 G protein-coupled receptor eeeee2  activation
CPR:2	 bbbbb1 Phospholipase C beta eeeee1  (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by  bbbbb2 D-myo-inositol 1,4,5-trisphosphate eeeee2  (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CPR:2	Phospholipase C beta ( bbbbb1 PLC-beta eeeee1 )-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by  bbbbb2 D-myo-inositol 1,4,5-trisphosphate eeeee2  (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CPR:2	Phospholipase C beta (PLC-beta)-coupled  bbbbb1 G protein-coupled receptor eeeee1  (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by  bbbbb2 D-myo-inositol 1,4,5-trisphosphate eeeee2  (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CPR:2	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor ( bbbbb1 GPCR eeeee1 ) activities traditionally are assessed by measuring Ca2+ triggered by  bbbbb2 D-myo-inositol 1,4,5-trisphosphate eeeee2  (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CPR:3	It has been known for decades that  bbbbb1 lithium chloride eeeee1  (LiCl) leads to D-myo-inositol 1-phosphate accumulation on  bbbbb2 GPCR eeeee2  activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade
CPR:3	It has been known for decades that lithium chloride ( bbbbb1 LiCl eeeee1 ) leads to D-myo-inositol 1-phosphate accumulation on  bbbbb2 GPCR eeeee2  activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade
CPR:4	It has been known for decades that  bbbbb1 lithium chloride eeeee1  (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting  bbbbb2 inositol monophosphatase eeeee2 , the final enzyme of the IP3 metabolic cascade
CPR:4	It has been known for decades that lithium chloride ( bbbbb1 LiCl eeeee1 ) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting  bbbbb2 inositol monophosphatase eeeee2 , the final enzyme of the IP3 metabolic cascade
CPR:8	It has the advantage over the traditional  bbbbb1 Ca2+ eeeee1  assay of allowing the measurement of inverse agonist activity as well as the analysis of  bbbbb2 PLC-beta eeeee2  activity in any nontransfected primary cultures
CPR:8	 bbbbb1 Phospholipase C beta eeeee1  (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring  bbbbb2 Ca2+ eeeee2  triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CPR:8	Phospholipase C beta ( bbbbb1 PLC-beta eeeee1 )-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring  bbbbb2 Ca2+ eeeee2  triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CPR:9	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by  bbbbb1 D-myo-inositol 1,4,5-trisphosphate eeeee1  (IP3), a  bbbbb2 PLC-beta eeeee2  hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CPR:9	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate ( bbbbb1 IP3 eeeee1 ), a  bbbbb2 PLC-beta eeeee2  hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CPR:9	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a  bbbbb1 PLC-beta eeeee1  hydrolysis product, or by measuring the production of  bbbbb2 inositol phosphate eeeee2  using cumbersome radioactive assays
CPR:9	It has been known for decades that lithium chloride (LiCl) leads to  bbbbb1 D-myo-inositol 1-phosphate eeeee1  accumulation on GPCR activation by inhibiting  bbbbb2 inositol monophosphatase eeeee2 , the final enzyme of the IP3 metabolic cascade
CPR:9	It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting  bbbbb1 inositol monophosphatase eeeee1 , the final enzyme of the  bbbbb2 IP3 eeeee2  metabolic cascade
CPR:9	Once formed, the molecule can be converted to  bbbbb1 glycine eeeee1  by  bbbbb2 alanine-glyoxylate aminotransferase eeeee2  (AGAT)
CPR:9	Once formed, the molecule can be converted to  bbbbb1 glycine eeeee1  by alanine-glyoxylate aminotransferase ( bbbbb2 AGAT eeeee2 )
CPR:2	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates  bbbbb1 cortisone eeeee1  to cortisol to facilitate  bbbbb2 glucocorticoid receptor eeeee2  (GR)-mediated action
CPR:2	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates  bbbbb1 cortisone eeeee1  to cortisol to facilitate glucocorticoid receptor ( bbbbb2 GR eeeee2 )-mediated action
CPR:2	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates cortisone to  bbbbb1 cortisol eeeee1  to facilitate  bbbbb2 glucocorticoid receptor eeeee2  (GR)-mediated action
CPR:2	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates cortisone to  bbbbb1 cortisol eeeee1  to facilitate glucocorticoid receptor ( bbbbb2 GR eeeee2 )-mediated action
CPR:2	By contrast,  bbbbb1 11beta-HSD2 eeeee1  plays a pivotal role in  bbbbb2 aldosterone eeeee2  target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol
CPR:3	By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the  bbbbb1 mineralocorticoid receptor eeeee1  (MR) by  bbbbb2 cortisol eeeee2 
CPR:3	By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor ( bbbbb1 MR eeeee1 ) by  bbbbb2 cortisol eeeee2 
CPR:3	Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which  bbbbb1 cortisol eeeee1  activates the  bbbbb2 MR eeeee2  resulting in severe hypertension and hypokalemia
CPR:4	Ingestion of competitive inhibitors of  bbbbb1 11beta-HSD2 eeeee1  such as liquorice and  bbbbb2 carbenoxolone eeeee2  result in a similar but milder clinical phenotype
CPR:9	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs).  bbbbb1 11Beta-HSD1 eeeee1  activates cortisone to  bbbbb2 cortisol eeeee2  to facilitate glucocorticoid receptor (GR)-mediated action
CPR:9	By contrast,  bbbbb1 11beta-HSD2 eeeee1  plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to  bbbbb2 cortisone eeeee2 ) to prevent activation of the mineralocorticoid receptor (MR) by cortisol
CPR:9	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs).  bbbbb1 11Beta-HSD1 eeeee1  activates  bbbbb2 cortisone eeeee2  to cortisol to facilitate glucocorticoid receptor (GR)-mediated action
CPR:9	By contrast,  bbbbb1 11beta-HSD2 eeeee1  plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of  bbbbb2 cortisol eeeee2  to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol
CPR:3	 bbbbb1 ATRA eeeee1  regulates gene expression via the activation of the  bbbbb2 retinoic acid receptor (RAR)alpha eeeee2  in human DCs, and RARalpha acutely regulates CD1d expression
CPR:3	 bbbbb1 ATRA eeeee1  regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and  bbbbb2 RARalpha eeeee2  acutely regulates CD1d expression
CPR:3	 bbbbb1 ATRA eeeee1  regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates  bbbbb2 CD1d eeeee2  expression
CPR:3	The  bbbbb1 retinoic acid eeeee1 -induced elevated expression of  bbbbb2 CD1d eeeee2  is coupled to enhanced iNKT cell activation
CPR:3	Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit  bbbbb1 retinoid eeeee1  signaling leading to  bbbbb2 CD1d eeeee2  up-regulation
CPR:9	Here we demonstrate that PPARgamma, turns on  bbbbb1 retinoic acid eeeee1  synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as  bbbbb2 retinol dehydrogenase 10 eeeee2  and retinaldehyde dehydrogenase type 2 (RALDH2)
CPR:9	Here we demonstrate that PPARgamma, turns on  bbbbb1 retinoic acid eeeee1  synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and  bbbbb2 retinaldehyde dehydrogenase type 2 eeeee2  (RALDH2)
CPR:9	Here we demonstrate that PPARgamma, turns on  bbbbb1 retinoic acid eeeee1  synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ( bbbbb2 RALDH2 eeeee2 )
CPR:9	Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of  bbbbb1 retinol eeeee1  and retinal metabolizing enzymes such as  bbbbb2 retinol dehydrogenase 10 eeeee2  and retinaldehyde dehydrogenase type 2 (RALDH2)
CPR:9	Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of  bbbbb1 retinol eeeee1  and retinal metabolizing enzymes such as retinol dehydrogenase 10 and  bbbbb2 retinaldehyde dehydrogenase type 2 eeeee2  (RALDH2)
CPR:9	Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of  bbbbb1 retinol eeeee1  and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ( bbbbb2 RALDH2 eeeee2 )
CPR:9	Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and  bbbbb1 retinal eeeee1  metabolizing enzymes such as  bbbbb2 retinol dehydrogenase 10 eeeee2  and retinaldehyde dehydrogenase type 2 (RALDH2)
CPR:9	Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and  bbbbb1 retinal eeeee1  metabolizing enzymes such as retinol dehydrogenase 10 and  bbbbb2 retinaldehyde dehydrogenase type 2 eeeee2  (RALDH2)
CPR:9	Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and  bbbbb1 retinal eeeee1  metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 ( bbbbb2 RALDH2 eeeee2 )
CPR:5	CONTEXT:  bbbbb1 Ramelteon eeeee1  is a novel  bbbbb2 MT1 eeeee2  and MT2 melatonin receptor selective agonist recently approved for insomnia treatment
CPR:5	CONTEXT:  bbbbb1 Ramelteon eeeee1  is a novel MT1 and  bbbbb2 MT2 melatonin receptor eeeee2  selective agonist recently approved for insomnia treatment
CPR:4	Late INa induced by the  bbbbb1 VGSC eeeee1  long QT mutant R1623Q was reduced by  bbbbb2 resveratrol eeeee2  and quercetin
CPR:4	Late INa induced by the VGSC long QT mutant  bbbbb1 R1623Q eeeee1  was reduced by  bbbbb2 resveratrol eeeee2  and quercetin
CPR:4	Late INa induced by the  bbbbb1 VGSC eeeee1  long QT mutant R1623Q was reduced by resveratrol and  bbbbb2 quercetin eeeee2 
CPR:4	Late INa induced by the VGSC long QT mutant  bbbbb1 R1623Q eeeee1  was reduced by resveratrol and  bbbbb2 quercetin eeeee2 
CPR:4	Enhancement of radiosensitivity by  bbbbb1 topoisomerase II eeeee1  inhibitor,  bbbbb2 amrubicin eeeee2  and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction
CPR:4	Enhancement of radiosensitivity by  bbbbb1 topoisomerase II eeeee1  inhibitor, amrubicin and  bbbbb2 amrubicinol eeeee2 , in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction
CPR:4	Similar to  bbbbb1 AMR eeeee1  and AMROH, adriamycin and etoposide (VP-16) are  bbbbb2 DNA topoisomerase II eeeee2  inhibitors
CPR:4	Similar to AMR and  bbbbb1 AMROH eeeee1 , adriamycin and etoposide (VP-16) are  bbbbb2 DNA topoisomerase II eeeee2  inhibitors
CPR:4	Similar to AMR and AMROH,  bbbbb1 adriamycin eeeee1  and etoposide (VP-16) are  bbbbb2 DNA topoisomerase II eeeee2  inhibitors
CPR:4	Similar to AMR and AMROH, adriamycin and  bbbbb1 etoposide eeeee1  (VP-16) are  bbbbb2 DNA topoisomerase II eeeee2  inhibitors
CPR:4	Similar to AMR and AMROH, adriamycin and etoposide ( bbbbb1 VP-16 eeeee1 ) are  bbbbb2 DNA topoisomerase II eeeee2  inhibitors
CPR:10	Accumulated evidence in humans and animals shows that both  bbbbb1 aspirin eeeee1  and H. pylori upregulate the expression of cyclooxygenase (COX)-2 both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of  bbbbb2 COX-1 eeeee2 
CPR:3	It was, therefore, proposed that H. pylori may in fact, antagonize,  bbbbb1 aspirin eeeee1 -induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from  bbbbb2 COX-2 eeeee2  expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF
CPR:3	Accumulated evidence in humans and animals shows that both  bbbbb1 aspirin eeeee1  and H. pylori upregulate the expression of  bbbbb2 cyclooxygenase (COX)-2 eeeee2  both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1
CPR:3	It was, therefore, proposed that H. pylori may in fact, antagonize,  bbbbb1 aspirin eeeee1 -induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as  bbbbb2 TGF alpha eeeee2  and VEGF
CPR:3	It was, therefore, proposed that H. pylori may in fact, antagonize,  bbbbb1 aspirin eeeee1 -induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and  bbbbb2 VEGF eeeee2 
CPR:3	It was, therefore, proposed that H. pylori may in fact, antagonize,  bbbbb1 aspirin eeeee1 -induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from  bbbbb2 COX-2 eeeee2  expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF
CPR:9	It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in  bbbbb1 PGE(2) eeeee1  possibly derived from  bbbbb2 COX-2 eeeee2  expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF
CPR:2	Based on selective nucleoside protection,  bbbbb1 TS eeeee1  was found to be the primary  bbbbb2 pemetrexed eeeee2  target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations
CPR:2	These data indicate that suppression of constitutive MTAP has no effect on  bbbbb1 pemetrexed eeeee1  activity when the primary target is  bbbbb2 TS eeeee2 
CPR:2	There is a modest salutary effect when the  bbbbb1 pemetrexed eeeee1  target is  bbbbb2 GARFT eeeee2  alone.
CPR:4	Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with  bbbbb1 GARFT eeeee1  inhibition requiring 20- to 30-fold higher  bbbbb2 pemetrexed eeeee2  concentrations
CPR:9	 bbbbb1 Methylthioadenosine phosphorylase eeeee1  (MTAP) salvages purines by releasing  bbbbb2 adenine eeeee2  from methylthioadenosine and is often deleted in mesothelioma
CPR:9	Methylthioadenosine phosphorylase ( bbbbb1 MTAP eeeee1 ) salvages purines by releasing  bbbbb2 adenine eeeee2  from methylthioadenosine and is often deleted in mesothelioma
CPR:9	 bbbbb1 Methylthioadenosine phosphorylase eeeee1  (MTAP) salvages purines by releasing adenine from  bbbbb2 methylthioadenosine eeeee2  and is often deleted in mesothelioma
CPR:9	Methylthioadenosine phosphorylase ( bbbbb1 MTAP eeeee1 ) salvages purines by releasing adenine from  bbbbb2 methylthioadenosine eeeee2  and is often deleted in mesothelioma
CPR:2	Our work shows that  bbbbb1 sulfonylureas eeeee1  and glinides additionally bind to  bbbbb2 PPARgamma eeeee2  and exhibit PPARgamma agonistic activity
CPR:2	Our work shows that sulfonylureas and  bbbbb1 glinides eeeee1  additionally bind to  bbbbb2 PPARgamma eeeee2  and exhibit PPARgamma agonistic activity
CPR:2	This dual mode of action of  bbbbb1 sulfonylureas eeeee1  and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the  bbbbb2 sulfonylurea receptor eeeee2  and PPARgamma
CPR:2	This dual mode of action of  bbbbb1 sulfonylureas eeeee1  and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the sulfonylurea receptor and  bbbbb2 PPARgamma eeeee2 
CPR:2	This dual mode of action of sulfonylureas and  bbbbb1 glinides eeeee1  may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the  bbbbb2 sulfonylurea receptor eeeee2  and PPARgamma
CPR:2	This dual mode of action of sulfonylureas and  bbbbb1 glinides eeeee1  may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the sulfonylurea receptor and  bbbbb2 PPARgamma eeeee2 
CPR:2	 bbbbb1 Sulfonylureas eeeee1  and glinides exhibit  bbbbb2 peroxisome proliferator-activated receptor gamma eeeee2  activity: a combined virtual screening and biological assay approach
CPR:2	Sulfonylureas and  bbbbb1 glinides eeeee1  exhibit  bbbbb2 peroxisome proliferator-activated receptor gamma eeeee2  activity: a combined virtual screening and biological assay approach
CPR:2	Most drugs currently employed in the treatment of type 2 diabetes either target the  bbbbb1 sulfonylurea receptor eeeee1  stimulating insulin release ( bbbbb2 sulfonylureas eeeee2 , glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)
CPR:2	Most drugs currently employed in the treatment of type 2 diabetes either target the  bbbbb1 sulfonylurea receptor eeeee1  stimulating insulin release (sulfonylureas,  bbbbb2 glinides eeeee2 ), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)
CPR:2	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the  bbbbb1 peroxisome proliferator-activated receptor eeeee1  (PPARgamma) improving insulin resistance ( bbbbb2 thiazolidinediones eeeee2 )
CPR:2	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor ( bbbbb1 PPARgamma eeeee1 ) improving insulin resistance ( bbbbb2 thiazolidinediones eeeee2 )
CPR:3	The most active of these compounds,  bbbbb1 gliquidone eeeee1 , is shown to be as potent as pioglitazone at inducing  bbbbb2 PPARgamma eeeee2  target gene expression
CPR:3	The most active of these compounds, gliquidone, is shown to be as potent as  bbbbb1 pioglitazone eeeee1  at inducing  bbbbb2 PPARgamma eeeee2  target gene expression
CPR:3	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating  bbbbb1 insulin eeeee1  release ( bbbbb2 sulfonylureas eeeee2 , glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)
CPR:3	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating  bbbbb1 insulin eeeee1  release (sulfonylureas,  bbbbb2 glinides eeeee2 ), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)
CPR:5	Among the measured compounds,  bbbbb1 gliquidone eeeee1  and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit  bbbbb2 PPARgamma eeeee2  agonistic activity at concentrations comparable with those reached under pharmacological treatment
CPR:5	Among the measured compounds, gliquidone and  bbbbb1 glipizide eeeee1  (two sulfonylureas), as well as nateglinide (a glinide), exhibit  bbbbb2 PPARgamma eeeee2  agonistic activity at concentrations comparable with those reached under pharmacological treatment
CPR:5	Among the measured compounds, gliquidone and glipizide (two  bbbbb1 sulfonylureas eeeee1 ), as well as nateglinide (a glinide), exhibit  bbbbb2 PPARgamma eeeee2  agonistic activity at concentrations comparable with those reached under pharmacological treatment
CPR:5	Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as  bbbbb1 nateglinide eeeee1  (a glinide), exhibit  bbbbb2 PPARgamma eeeee2  agonistic activity at concentrations comparable with those reached under pharmacological treatment
CPR:5	Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a  bbbbb1 glinide eeeee1 ), exhibit  bbbbb2 PPARgamma eeeee2  agonistic activity at concentrations comparable with those reached under pharmacological treatment
CPR:5	 bbbbb1 Glinides eeeee1 , sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new  bbbbb2 PPARgamma eeeee2  agonists
CPR:5	Glinides,  bbbbb1 sulfonylureas eeeee1 , and other acidified sulfonamides may be promising leads in the development of new  bbbbb2 PPARgamma eeeee2  agonists
CPR:5	Glinides, sulfonylureas, and other  bbbbb1 acidified sulfonamides eeeee1  may be promising leads in the development of new  bbbbb2 PPARgamma eeeee2  agonists
CPR:5	Our work shows that  bbbbb1 sulfonylureas eeeee1  and glinides additionally bind to PPARgamma and exhibit  bbbbb2 PPARgamma eeeee2  agonistic activity
CPR:5	Our work shows that sulfonylureas and  bbbbb1 glinides eeeee1  additionally bind to PPARgamma and exhibit  bbbbb2 PPARgamma eeeee2  agonistic activity
CPR:2	There is a growing appreciation that the  bbbbb1 cyclic adenosine monophosphate eeeee1  (cAMP)- bbbbb2 protein kinase A eeeee2  (PKA) signaling pathway is organized to form transduction units that function to deliver specific messages
CPR:2	There is a growing appreciation that the  bbbbb1 cyclic adenosine monophosphate eeeee1  (cAMP)-protein kinase A ( bbbbb2 PKA eeeee2 ) signaling pathway is organized to form transduction units that function to deliver specific messages
CPR:2	There is a growing appreciation that the cyclic adenosine monophosphate ( bbbbb1 cAMP eeeee1 )- bbbbb2 protein kinase A eeeee2  (PKA) signaling pathway is organized to form transduction units that function to deliver specific messages
CPR:2	There is a growing appreciation that the cyclic adenosine monophosphate ( bbbbb1 cAMP eeeee1 )-protein kinase A ( bbbbb2 PKA eeeee2 ) signaling pathway is organized to form transduction units that function to deliver specific messages
CPR:3	Such organization results in the local activation of  bbbbb1 PKA eeeee1  subsets through the generation of confined intracellular gradients of  bbbbb2 cAMP eeeee2 , but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified
CPR:9	By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized  bbbbb1 PDE4B eeeee1  and PDE4D are responsible for selectively modulating the concentration of  bbbbb2 cAMP eeeee2  in individual subcellular compartments
CPR:9	By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and  bbbbb1 PDE4D eeeee1  are responsible for selectively modulating the concentration of  bbbbb2 cAMP eeeee2  in individual subcellular compartments
CPR:9	We propose a model whereby compartmentalized  bbbbb1 PDEs eeeee1 , rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different  bbbbb2 cAMP eeeee2  concentrations irrespective of their distance from the site of cAMP synthesis.
CPR:9	We propose a model whereby compartmentalized  bbbbb1 PDEs eeeee1 , rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of  bbbbb2 cAMP eeeee2  synthesis.
CPR:10	We failed to observe any significant activation of  bbbbb1 FAS promoter eeeee1  following exposure to the anti-metabolite  bbbbb2 5-fluorouracil eeeee2 , the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and vincristine
CPR:10	We failed to observe any significant activation of  bbbbb1 FAS promoter eeeee1  following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug  bbbbb2 cisplatin eeeee2 , or the microtubule interfering-agents paclitaxel and vincristine
CPR:10	We failed to observe any significant activation of  bbbbb1 FAS promoter eeeee1  following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents  bbbbb2 paclitaxel eeeee2  and vincristine
CPR:10	We failed to observe any significant activation of  bbbbb1 FAS promoter eeeee1  following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and  bbbbb2 vincristine eeeee2 
CPR:3	SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors  bbbbb1 doxorubicin eeeee1  and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in  bbbbb2 FAS promoter eeeee2  activity when compared with control cells growing in drug-free culture conditions
CPR:3	SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and  bbbbb1 etopoxide eeeee1  (VP-16) demonstrated a 2- to 3-fold increase in  bbbbb2 FAS promoter eeeee2  activity when compared with control cells growing in drug-free culture conditions
CPR:3	SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide ( bbbbb1 VP-16 eeeee1 ) demonstrated a 2- to 3-fold increase in  bbbbb2 FAS promoter eeeee2  activity when compared with control cells growing in drug-free culture conditions
CPR:4	SK-Br3 cells cultured in the presence of  bbbbb1 topoisomerase IIalpha eeeee1  (TOP2A) inhibitors  bbbbb2 doxorubicin eeeee2  and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions
CPR:4	SK-Br3 cells cultured in the presence of topoisomerase IIalpha ( bbbbb1 TOP2A eeeee1 ) inhibitors  bbbbb2 doxorubicin eeeee2  and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions
CPR:4	SK-Br3 cells cultured in the presence of  bbbbb1 topoisomerase IIalpha eeeee1  (TOP2A) inhibitors doxorubicin and  bbbbb2 etopoxide eeeee2  (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions
CPR:4	SK-Br3 cells cultured in the presence of topoisomerase IIalpha ( bbbbb1 TOP2A eeeee1 ) inhibitors doxorubicin and  bbbbb2 etopoxide eeeee2  (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions
CPR:4	SK-Br3 cells cultured in the presence of  bbbbb1 topoisomerase IIalpha eeeee1  (TOP2A) inhibitors doxorubicin and etopoxide ( bbbbb2 VP-16 eeeee2 ) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions
CPR:4	SK-Br3 cells cultured in the presence of topoisomerase IIalpha ( bbbbb1 TOP2A eeeee1 ) inhibitors doxorubicin and etopoxide ( bbbbb2 VP-16 eeeee2 ) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions
CPR:2	 bbbbb1 Mifepristone eeeee1  alters expression of endometrial  bbbbb2 steroid receptors eeeee2  and their cofactors in new users of medroxyprogesterone acetate
CPR:3	RESULT(S): The expression of endometrial  bbbbb1 ERalpha eeeee1 , PRAB, PRB, and SRC-1 was increased significantly after 1 week of  bbbbb2 mifepristone eeeee2 , but the increase was no longer seen after 10 weeks
CPR:3	RESULT(S): The expression of endometrial ERalpha,  bbbbb1 PRAB eeeee1 , PRB, and SRC-1 was increased significantly after 1 week of  bbbbb2 mifepristone eeeee2 , but the increase was no longer seen after 10 weeks
CPR:3	RESULT(S): The expression of endometrial ERalpha, PRAB,  bbbbb1 PRB eeeee1 , and SRC-1 was increased significantly after 1 week of  bbbbb2 mifepristone eeeee2 , but the increase was no longer seen after 10 weeks
CPR:3	RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and  bbbbb1 SRC-1 eeeee1  was increased significantly after 1 week of  bbbbb2 mifepristone eeeee2 , but the increase was no longer seen after 10 weeks
CPR:3	CONCLUSION(S): Short-term exposure of  bbbbb1 mifepristone eeeee1  in new starters of DMPA increases the expression of endometrial  bbbbb2 ERalpha eeeee2 , PRAB, PRB, and SRC-1 and promotes cell proliferation
CPR:3	CONCLUSION(S): Short-term exposure of  bbbbb1 mifepristone eeeee1  in new starters of DMPA increases the expression of endometrial ERalpha,  bbbbb2 PRAB eeeee2 , PRB, and SRC-1 and promotes cell proliferation
CPR:3	CONCLUSION(S): Short-term exposure of  bbbbb1 mifepristone eeeee1  in new starters of DMPA increases the expression of endometrial ERalpha, PRAB,  bbbbb2 PRB eeeee2 , and SRC-1 and promotes cell proliferation
CPR:3	CONCLUSION(S): Short-term exposure of  bbbbb1 mifepristone eeeee1  in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and  bbbbb2 SRC-1 eeeee2  and promotes cell proliferation
CPR:3	The cytosolic fraction obtained from pancreatic islets obtained from  bbbbb1 GalN eeeee1 -treated rats had an increased  bbbbb2 PTB eeeee2  level compared to the levels obtained from the pancreatic islets of control rats
CPR:3	In the present study,  bbbbb1 glucose eeeee1 -stimulated  bbbbb2 insulin eeeee2  secretion was significantly increased in GalN-treated rats compared to controls
CPR:3	In the present study, glucose-stimulated  bbbbb1 insulin eeeee1  secretion was significantly increased in  bbbbb2 GalN eeeee2 -treated rats compared to controls
CPR:3	Levels of mRNA encoding  bbbbb1 insulin 1 eeeee1 , ICA512, and PC1/3 were increased in the pancreatic islets of  bbbbb2 GalN eeeee2 -treated rats
CPR:3	Levels of mRNA encoding insulin 1,  bbbbb1 ICA512 eeeee1 , and PC1/3 were increased in the pancreatic islets of  bbbbb2 GalN eeeee2 -treated rats
CPR:3	When the  bbbbb1 PTB-binding site eeeee1  in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from  bbbbb2 GalN eeeee2 -treated rats compared to the level in control rats
CPR:3	When the PTB-binding site in  bbbbb1 insulin 1 eeeee1  mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from  bbbbb2 GalN eeeee2 -treated rats compared to the level in control rats
CPR:2	The changes in  bbbbb1 CysLT1 receptor eeeee1  expression 24 h after  bbbbb2 NMDA eeeee2  injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed
CPR:2	 bbbbb1 Cysteinyl leukotriene receptor 1 eeeee1  is involved in  bbbbb2 N-methyl-D-aspartate eeeee2 -mediated neuronal injury in mice
CPR:3	RESULTS: In the  bbbbb1 NMDA eeeee1 -injured brain, the  bbbbb2 CysLT1 receptor eeeee2  mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes
CPR:3	CONCLUSION:  bbbbb1 CysLT1 receptor eeeee1  expression in neurons is upregulated after  bbbbb2 NMDA eeeee2  injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.
CPR:3	CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased  bbbbb1 CysLT1 receptor eeeee1  is involved in  bbbbb2 NMDA eeeee2  excitotoxicity.
CPR:4	Pranlukast, ketamine and edaravone decreased NMDA-induced injury;  bbbbb1 pranlukast eeeee1  (0.1 mg/kg) and ketamine inhibited the upregulated expression of the  bbbbb2 CysLT1 receptor eeeee2 
CPR:4	Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and  bbbbb1 ketamine eeeee1  inhibited the upregulated expression of the  bbbbb2 CysLT1 receptor eeeee2 
CPR:6	The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a  bbbbb1 CysLT1 receptor eeeee1  antagonist,  bbbbb2 pranlukast eeeee2  (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed
CPR:6	The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an  bbbbb1 NMDA receptor eeeee1  antagonist,  bbbbb2 ketamine eeeee2  (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed
CPR:1	We have previously demonstrated that phosphorylation of  bbbbb1 Fas-associated death domain-containing protein eeeee1  (FADD) at 194  bbbbb2 serine eeeee2  through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CPR:1	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein ( bbbbb1 FADD eeeee1 ) at 194  bbbbb2 serine eeeee2  through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CPR:2	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that  bbbbb1 Bcl-2 eeeee1  phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by  bbbbb2 paclitaxel eeeee2 
CPR:3	We have previously demonstrated that phosphorylation of  bbbbb1 Fas-associated death domain-containing protein eeeee1  (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by  bbbbb2 paclitaxel eeeee2 
CPR:3	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein ( bbbbb1 FADD eeeee1 ) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by  bbbbb2 paclitaxel eeeee2 
CPR:3	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through  bbbbb1 c-jun NH2-terminal kinase eeeee1  (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by  bbbbb2 paclitaxel eeeee2 
CPR:3	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase ( bbbbb1 JNK eeeee1 ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by  bbbbb2 paclitaxel eeeee2 
CPR:3	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of  bbbbb1 JNK eeeee1 /FADD plays an important role in cell growth suppression by  bbbbb2 paclitaxel eeeee2 
CPR:3	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/ bbbbb1 FADD eeeee1  plays an important role in cell growth suppression by  bbbbb2 paclitaxel eeeee2 
CPR:10	 bbbbb1 Carvedilol eeeee1  produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the  bbbbb2 alpha 2 adrenoceptor eeeee2  mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses
CPR:10	 bbbbb1 Carvedilol eeeee1  had no effect on the pressor response elicited by  bbbbb2 angiotensin II eeeee2 , indicating a lack of nonspecific vasodilator activity
CPR:2	This same dose of carvedilol also inhibited, but to a lesser degree, the  bbbbb1 beta 2 adrenoceptor eeeee1  mediated vasodepressor response to  bbbbb2 salbutamol eeeee2  in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II
CPR:2	Carvedilol produced significant inhibition of the  bbbbb1 alpha 1 adrenoceptor eeeee1  mediated pressor response to  bbbbb2 cirazoline eeeee2  in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses
CPR:2	Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the  bbbbb1 alpha 2 adrenoceptor eeeee1  mediated pressor response to  bbbbb2 B-HT 933 eeeee2 , suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses
CPR:3	Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the  bbbbb1 beta 1 adrenoceptor eeeee1  mediated positive chronotropic response to  bbbbb2 isoproterenol eeeee2 
CPR:3	The vasopressor response to the  bbbbb1 calcium channel eeeee1  activator,  bbbbb2 BAY-K-8644 eeeee2 , which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CPR:3	The vasopressor response to the calcium channel activator,  bbbbb1 BAY-K-8644 eeeee1 , which is mediated through the opening of  bbbbb2 voltage dependent calcium channels eeeee2  and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CPR:4	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of  bbbbb1 voltage dependent calcium channels eeeee1  and the subsequent translocation of extracellular calcium, was significantly inhibited by  bbbbb2 carvedilol eeeee2  (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CPR:4	Thus,  bbbbb1 carvedilol eeeee1  blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the  bbbbb2 beta 1 adrenoceptor eeeee2  subtype
CPR:4	 bbbbb1 Carvedilol eeeee1  (0.3 mg/kg, iv) produced a significant inhibition of the  bbbbb2 beta 1 adrenoceptor eeeee2  mediated positive chronotropic response to isoproterenol
CPR:4	This same dose of  bbbbb1 carvedilol eeeee1  also inhibited, but to a lesser degree, the  bbbbb2 beta 2 adrenoceptor eeeee2  mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II
CPR:4	 bbbbb1 Carvedilol eeeee1  produced significant inhibition of the  bbbbb2 alpha 1 adrenoceptor eeeee2  mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses
CPR:6	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that  bbbbb1 carvedilol eeeee1  is also a  bbbbb2 calcium channel eeeee2  antagonist, consistent with our previous in vitro studies
CPR:6	In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the  bbbbb1 alpha 1 adrenoceptor eeeee1  antagonist,  bbbbb2 prazosin eeeee2  (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors
CPR:6	In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective  bbbbb1 beta adrenoceptor eeeee1  antagonist,  bbbbb2 propranolol eeeee2  (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors
CPR:6	We therefore conclude that  bbbbb1 carvedilol eeeee1 , at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of  bbbbb2 calcium channels eeeee2  in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)
CPR:6	The mechanism(s) responsible for arterial vasodilation observed following acute administration of  bbbbb1 racemic carvedilol eeeee1 , a novel vasodilator/ bbbbb2 beta adrenoceptor eeeee2  antagonist, has been investigated in rats
CPR:6	Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that  bbbbb1 carvedilol eeeee1  is also an  bbbbb2 alpha 1 adrenoceptor eeeee2  antagonist at antihypertensive doses
CPR:9	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of  bbbbb1 voltage dependent calcium channels eeeee1  and the subsequent translocation of extracellular  bbbbb2 calcium eeeee2 , was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CPR:2	Responsiveness to mechanical stimulation was unaffected.  bbbbb1 5-HT3 receptor eeeee1  antagonism with alosetron reduced responses to  bbbbb2 5-HT eeeee2  in controls but not during inflammation
CPR:6	Responsiveness to mechanical stimulation was unaffected.  bbbbb1 5-HT3 receptor eeeee1  antagonism with  bbbbb2 alosetron eeeee2  reduced responses to 5-HT in controls but not during inflammation
CPR:10	Progestin induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of  bbbbb1 progestin eeeee1  on  bbbbb2 cyclin D1 eeeee2  expression and cell cycle was observed in the presence of PR-A
CPR:10	 bbbbb1 Progestin eeeee1  activation of Src/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with  bbbbb2 PR-A eeeee2  that was predominantly nuclear
CPR:2	 bbbbb1 Progestin eeeee1  induction of the  bbbbb2 cyclin D1 eeeee2  gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CPR:2	 bbbbb1 Progestin eeeee1  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the  bbbbb2 Sgk eeeee2  (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CPR:2	 bbbbb1 Progestin eeeee1  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk ( bbbbb2 serum and glucocorticoid regulated kinase eeeee2 ) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CPR:2	The role of extranuclear signaling actions of  bbbbb1 progesterone receptor eeeee1  in mediating  bbbbb2 progesterone eeeee2  regulation of gene expression and the cell cycle
CPR:2	Progestin induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of  bbbbb1 progestin eeeee1  on cyclin D1 expression and cell cycle was observed in the presence of  bbbbb2 PR-A eeeee2 
CPR:2	 bbbbb1 Progestin eeeee1  activation of Src/MAPK occurred outside the nucleus with the  bbbbb2 B isoform of PR eeeee2  that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear
CPR:3	These results highlight the importance of  bbbbb1 PR eeeee1  activation of the Src/MAPK signaling pathway for  bbbbb2 progesterone eeeee2 -induced transcription of select target genes and cell cycle progression.
CPR:3	These results highlight the importance of PR activation of the  bbbbb1 Src eeeee1 /MAPK signaling pathway for  bbbbb2 progesterone eeeee2 -induced transcription of select target genes and cell cycle progression.
CPR:3	These results highlight the importance of PR activation of the Src/ bbbbb1 MAPK eeeee1  signaling pathway for  bbbbb2 progesterone eeeee2 -induced transcription of select target genes and cell cycle progression.
CPR:3	 bbbbb1 Progestin eeeee1  activation of  bbbbb2 Src eeeee2 /MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear
CPR:3	 bbbbb1 Progestin eeeee1  activation of Src/ bbbbb2 MAPK eeeee2  occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear
CPR:3	 bbbbb1 Progestin eeeee1  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on  bbbbb2 PR eeeee2  activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CPR:3	 bbbbb1 Progestin eeeee1  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the  bbbbb2 Src eeeee2 /MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CPR:3	 bbbbb1 Progestin eeeee1  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/ bbbbb2 MAPK eeeee2  pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CPR:6	Relative to WT, electrophysiological recordings from ADNFLE mouse layer II/III cortical pyramidal cells reveal a >20-fold increase in nicotine-evoked inhibitory postsynaptic currents with no effect on excitatory postsynaptic currents. i.p. injection of a subthreshold dose of  bbbbb1 picrotoxin eeeee1 , a use-dependent  bbbbb2 gamma-aminobutyric acid receptor eeeee2  antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane eeeee1  (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ( bbbbb2 SERT eeeee2 , DAT, and NET, respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane eeeee1  (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT,  bbbbb2 DAT eeeee2 , and NET, respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane eeeee1  (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and  bbbbb2 NET eeeee2 , respectively) using transfected cells
CPR:2	Chase studies with  bbbbb1 citalopram eeeee1  and methylphenidate demonstrated that this uptake is the result of preferential binding to the  bbbbb2 SERT eeeee2 .
CPR:2	Chase studies with citalopram and  bbbbb1 methylphenidate eeeee1  demonstrated that this uptake is the result of preferential binding to the  bbbbb2 SERT eeeee2 .
CPR:2	ynthesis, radiosynthesis, and biological evaluation of  bbbbb1 carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes eeeee1 : candidate radioligands for in vivo imaging of the  bbbbb2 serotonin transporter eeeee2  with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane eeeee1  (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ( bbbbb2 SERT eeeee2 , DAT, and NET, respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane eeeee1  (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT,  bbbbb2 DAT eeeee2 , and NET, respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane eeeee1  (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and  bbbbb2 NET eeeee2 , respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane ( bbbbb1 mZBrENT eeeee1 , 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ( bbbbb2 SERT eeeee2 , DAT, and NET, respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane ( bbbbb1 mZBrENT eeeee1 , 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT,  bbbbb2 DAT eeeee2 , and NET, respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane ( bbbbb1 mZBrENT eeeee1 , 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and  bbbbb2 NET eeeee2 , respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane ( bbbbb1 mZIENT eeeee1 , 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ( bbbbb2 SERT eeeee2 , DAT, and NET, respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane ( bbbbb1 mZIENT eeeee1 , 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT,  bbbbb2 DAT eeeee2 , and NET, respectively) using transfected cells
CPR:2	ynthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane ( bbbbb1 mZIENT eeeee1 , 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and  bbbbb2 NET eeeee2 , respectively) using transfected cells
CPR:9	MicroPET imaging in nonhuman primates with [ bbbbb1 11C eeeee1 ]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the  bbbbb2 SERT eeeee2 -rich brain regions and peak uptake being achieved in about 55 min postinjection
CPR:9	MicroPET imaging in nonhuman primates with [11C]1 and [ bbbbb1 11C eeeee1 ]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the  bbbbb2 SERT eeeee2 -rich brain regions and peak uptake being achieved in about 55 min postinjection
CPR:6	This trial investigated the possibility of pharmacokinetic interactions between the  bbbbb1 AT1 receptor eeeee1  antagonist  bbbbb2 olmesartan medoxomil eeeee2  and the thiazide diuretic hydrochlorothiazide in healthy subjects
CPR:2	In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous  bbbbb1 S100P eeeee1  (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of  bbbbb2 gemcitabine eeeee2  (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001)
CPR:2	In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous  bbbbb1 S100P eeeee1  (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of gemcitabine (BxPC-3:  bbbbb2 gemcitabine eeeee2 , mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001)
CPR:2	CONCLUSION: Cromolyn binds  bbbbb1 S100P eeeee1 , prevents activation of RAGE, inhibits tumor growth, and increases the effectiveness of  bbbbb2 gemcitabine eeeee2  in experimental models.
CPR:10	In addition, we found that selenophosphate synthetase 2 could synthesize  bbbbb1 monoselenophosphate eeeee1  in vitro but  bbbbb2 selenophosphate synthetase 1 eeeee2  could not
CPR:8	Herein, comparative genomics and experimental analyses revealed that the  bbbbb1 mammalian Sec synthase eeeee1  (SecS) is the previously identified  bbbbb2 pyridoxal phosphate eeeee2 -containing protein known as the soluble liver antigen
CPR:8	Herein, comparative genomics and experimental analyses revealed that the mammalian Sec synthase ( bbbbb1 SecS eeeee1 ) is the previously identified  bbbbb2 pyridoxal phosphate eeeee2 -containing protein known as the soluble liver antigen
CPR:8	Herein, comparative genomics and experimental analyses revealed that the mammalian Sec synthase (SecS) is the previously identified  bbbbb1 pyridoxal phosphate eeeee1 -containing protein known as the  bbbbb2 soluble liver antigen eeeee2 
CPR:9	 bbbbb1 SecS eeeee1  required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate  bbbbb2 selenocysteyl eeeee2 -tRNA([Ser]Sec)
CPR:9	In addition, we found that  bbbbb1 selenophosphate synthetase 2 eeeee1  could synthesize  bbbbb2 monoselenophosphate eeeee2  in vitro but selenophosphate synthetase 1 could not
CPR:9	 bbbbb1 SecS eeeee1  required selenophosphate and  bbbbb2 O-phosphoseryl eeeee2 -tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)
CPR:9	 bbbbb1 SecS eeeee1  required  bbbbb2 selenophosphate eeeee2  and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)
CPR:10	 bbbbb1 Triflusal eeeee1  (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of  bbbbb2 GFAP eeeee2  or Hsp27 immunostaining
CPR:10	 bbbbb1 Triflusal eeeee1  (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of GFAP or  bbbbb2 Hsp27 eeeee2  immunostaining
CPR:10	Triflusal (30 mg/kg) or  bbbbb1 aspirin eeeee1  treatment (30 mg/kg) did not reduce the levels of  bbbbb2 GFAP eeeee2  or Hsp27 immunostaining
CPR:10	Triflusal (30 mg/kg) or  bbbbb1 aspirin eeeee1  treatment (30 mg/kg) did not reduce the levels of GFAP or  bbbbb2 Hsp27 eeeee2  immunostaining
CPR:10	 bbbbb1 Triflusal eeeee1  (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not  bbbbb2 nuclear factor kappa B eeeee2  or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion
CPR:10	 bbbbb1 Triflusal eeeee1  (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not nuclear factor kappa B or  bbbbb2 tumor necrosis factor-alpha eeeee2  in the cortex ipsilateral to the middle cerebral artery occlusion
CPR:2	 bbbbb1 Triflusal eeeee1 , a selective  bbbbb2 cyclooxygenase-2 eeeee2 , and its active metabolite 3-hydroxy-4-trifluoromethylbenzoic acid may inhibit apoptosis and inflammation after cerebral ischemia
CPR:2	Triflusal, a selective  bbbbb1 cyclooxygenase-2 eeeee1 , and its active metabolite  bbbbb2 3-hydroxy-4-trifluoromethylbenzoic acid eeeee2  may inhibit apoptosis and inflammation after cerebral ischemia
CPR:4	 bbbbb1 Triflusal eeeee1  (30 mg/kg) also significantly decreased the protein levels of  bbbbb2 IL-Ibeta eeeee2  but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion
CPR:10	The  bbbbb1 GRIP1 eeeee1  reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by  bbbbb2 6-cyano-7-nitroquinoxaline-2,3-dione eeeee2  (CNQX), an AMPA receptor antagonist
CPR:10	The  bbbbb1 GRIP1 eeeee1  reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione ( bbbbb2 CNQX eeeee2 ), an AMPA receptor antagonist
CPR:10	EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not  bbbbb1 nifedipine eeeee1 , an L-type Ca2+ channel blocker, prevented  bbbbb2 GRIP1 eeeee2  degradation
CPR:10	Here we report that  bbbbb1 glutamate eeeee1  stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor  bbbbb2 (GluR) 1 eeeee2 , GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures
CPR:10	Here we report that  bbbbb1 glutamate eeeee1  stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1,  bbbbb2 GluR2 eeeee2  and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures
CPR:10	Here we report that  bbbbb1 glutamate eeeee1  stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and  bbbbb2 protein interacting with C kinase 1 eeeee2  (PICK1) in rat primary cortical neuron cultures
CPR:10	Here we report that  bbbbb1 glutamate eeeee1  stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 ( bbbbb2 PICK1 eeeee2 ) in rat primary cortical neuron cultures
CPR:2	Our results suggest that  bbbbb1 glutamate eeeee1  induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating  bbbbb2 GluR2 eeeee2  surface expression.
CPR:2	Furthermore,  bbbbb1 MG132 eeeee1  prevented glutamate-stimulated reduction in surface amount of  bbbbb2 GluR2 eeeee2 , and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons
CPR:2	 bbbbb1 Glutamate eeeee1  stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of  bbbbb2 GluR2 eeeee2 
CPR:2	Down-regulation of  bbbbb1 GRIP1 eeeee1  by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal ( bbbbb2 MG132 eeeee2 ), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin
CPR:2	Our results suggest that  bbbbb1 glutamate eeeee1  induces GRIP1 degradation by  bbbbb2 proteasome eeeee2  through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.
CPR:2	Our results suggest that  bbbbb1 glutamate eeeee1  induces GRIP1 degradation by proteasome through an  bbbbb2 NMDA receptor eeeee2 -Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.
CPR:2	 bbbbb1 Glutamate eeeee1  stimulates glutamate receptor interacting protein 1 degradation by  bbbbb2 ubiquitin eeeee2 -proteasome system to regulate surface expression of GluR2
CPR:2	 bbbbb1 Glutamate eeeee1  stimulates glutamate receptor interacting protein 1 degradation by ubiquitin- bbbbb2 proteasome eeeee2  system to regulate surface expression of GluR2
CPR:2	Down-regulation of  bbbbb1 GRIP1 eeeee1  by glutamate was blocked by  bbbbb2 carbobenzoxyl-leucinyl-leucinyl-leucinal eeeee2  (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin
CPR:3	The  bbbbb1 GRIP1 eeeee1  reduction was inhibited by  bbbbb2 MK-801 eeeee2 , an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist
CPR:3	 bbbbb1 EGTA eeeee1  and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  bbbbb2 GRIP1 eeeee2  degradation
CPR:3	EGTA and  bbbbb1 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis eeeee1  (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  bbbbb2 GRIP1 eeeee2  degradation
CPR:3	EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis ( bbbbb1 BAPTA eeeee1 ), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  bbbbb2 GRIP1 eeeee2  degradation
CPR:4	Our results suggest that  bbbbb1 glutamate eeeee1  induces  bbbbb2 GRIP1 eeeee2  degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.
CPR:4	Our results suggest that  bbbbb1 glutamate eeeee1  induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that  bbbbb2 GRIP1 eeeee2  degradation may play an important role in regulating GluR2 surface expression.
CPR:4	 bbbbb1 Glutamate eeeee1  stimulates  bbbbb2 glutamate receptor interacting protein 1 eeeee2  degradation by ubiquitin-proteasome system to regulate surface expression of GluR2
CPR:4	Down-regulation of  bbbbb1 GRIP1 eeeee1  by  bbbbb2 glutamate eeeee2  was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin
CPR:4	Furthermore, MG132 prevented  bbbbb1 glutamate eeeee1 -stimulated reduction in surface amount of  bbbbb2 GluR2 eeeee2 , and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons
CPR:4	Here we report that  bbbbb1 glutamate eeeee1  stimulation caused a rapid reduction in protein levels of  bbbbb2 GRIP1 eeeee2 , but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures
CPR:4	Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal ( bbbbb1 MG132 eeeee1 ), a  bbbbb2 proteasome eeeee2  inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin
CPR:4	EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not  bbbbb1 nifedipine eeeee1 , an  bbbbb2 L-type Ca2+ channel eeeee2  blocker, prevented GRIP1 degradation
CPR:4	Down-regulation of GRIP1 by glutamate was blocked by  bbbbb1 carbobenzoxyl-leucinyl-leucinyl-leucinal eeeee1  (MG132), a  bbbbb2 proteasome eeeee2  inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin
CPR:6	The GRIP1 reduction was inhibited by  bbbbb1 MK-801 eeeee1 , an  bbbbb2 N-methyl-d-aspartate (NMDA) receptor eeeee2  antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist
CPR:6	The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by  bbbbb1 6-cyano-7-nitroquinoxaline-2,3-dione eeeee1  (CNQX), an  bbbbb2 AMPA receptor eeeee2  antagonist
CPR:6	The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione ( bbbbb1 CNQX eeeee1 ), an  bbbbb2 AMPA receptor eeeee2  antagonist
CPR:2	Cytokines, lipopolysaccharides and other inflammatory mediators such as  bbbbb1 prostaglandin eeeee1  and leukotriene are related to the secretion and production of  bbbbb2 mucin eeeee2 
CPR:2	Cytokines, lipopolysaccharides and other inflammatory mediators such as prostaglandin and  bbbbb1 leukotriene eeeee1  are related to the secretion and production of  bbbbb2 mucin eeeee2 
CPR:2	However, the relationship of  bbbbb1 leukotrienes eeeee1  with  bbbbb2 mucin eeeee2  genes expression is not clear
CPR:3	RESULTS:  bbbbb1 Leukotriene D(4) eeeee1  upregulated  bbbbb2 MUC2/5AC eeeee2  gene expression and mucin secretion in a dose dependent pattern
CPR:3	RESULTS:  bbbbb1 Leukotriene D(4) eeeee1  upregulated MUC2/5AC gene expression and  bbbbb2 mucin eeeee2  secretion in a dose dependent pattern
CPR:3	The inhibitory effect of the leukotriene receptor antagonist on  bbbbb1 leukotriene D4 eeeee1 -induced MUC2/5AC gene expression and  bbbbb2 mucin eeeee2  secretion in human airway epithelial cells
CPR:3	The inhibitory effect of the leukotriene receptor antagonist on  bbbbb1 leukotriene D4 eeeee1 -induced  bbbbb2 MUC2/5AC eeeee2  gene expression and mucin secretion in human airway epithelial cells
CPR:3	Pranlukast hydrate (ONO-1078, 100 microM) downregulated the  bbbbb1 leukotriene D(4) eeeee1 -induced  bbbbb2 MUC2/5AC eeeee2  gene expression and mucin secretion
CPR:3	Pranlukast hydrate (ONO-1078, 100 microM) downregulated the  bbbbb1 leukotriene D(4) eeeee1 -induced MUC2/5AC gene expression and  bbbbb2 mucin eeeee2  secretion
CPR:4	 bbbbb1 Pranlukast hydrate eeeee1  (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced  bbbbb2 MUC2/5AC eeeee2  gene expression and mucin secretion
CPR:4	 bbbbb1 Pranlukast hydrate eeeee1  (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and  bbbbb2 mucin eeeee2  secretion
CPR:4	Pranlukast hydrate ( bbbbb1 ONO-1078 eeeee1 , 100 microM) downregulated the leukotriene D(4)-induced  bbbbb2 MUC2/5AC eeeee2  gene expression and mucin secretion
CPR:4	Pranlukast hydrate ( bbbbb1 ONO-1078 eeeee1 , 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and  bbbbb2 mucin eeeee2  secretion
CPR:6	METHODS: The effect of leukotriene D(4) and the  bbbbb1 leukotriene receptor eeeee1  antagonist,  bbbbb2 pranlukast hydrate eeeee2  (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells
CPR:6	METHODS: The effect of leukotriene D(4) and the  bbbbb1 leukotriene receptor eeeee1  antagonist, pranlukast hydrate ( bbbbb2 ONO-1078 eeeee2 ) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells
CPR:10	CONCLUSION: In postmenopausal women, isolated  bbbbb1 isoflavone eeeee1  treatment does not affect  bbbbb2 ABCA1 eeeee2 -dependent cholesterol efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.
CPR:10	Thus,  bbbbb1 isoflavone eeeee1  supplementation did not affect  bbbbb2 ABCA1 eeeee2 -dependent cholesterol efflux to serum
CPR:2	We studied in a clinical trial whether isolated  bbbbb1 isoflavone eeeee1  treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by  bbbbb2 adenosine triphosphate-binding cassette A1 eeeee2 - (ABCA1), dependent cholesterol efflux from macrophages
CPR:2	We studied in a clinical trial whether isolated  bbbbb1 isoflavone eeeee1  treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- ( bbbbb2 ABCA1 eeeee2 ), dependent cholesterol efflux from macrophages
CPR:3	CONCLUSION: In postmenopausal women, isolated  bbbbb1 isoflavone eeeee1  treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating  bbbbb2 pre-beta high-density lipoprotein eeeee2  level, which could provide beneficial vascular effects.
CPR:3	However, as a novel finding,  bbbbb1 isoflavone eeeee1  treatment increased a subclass of  bbbbb2 high-density lipoprotein eeeee2 , the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations
CPR:3	However, as a novel finding,  bbbbb1 isoflavone eeeee1  treatment increased a subclass of high-density lipoprotein, the  bbbbb2 pre-beta high-density lipoprotein eeeee2  levels by 18% without affecting any other serum lipid concentrations
CPR:9	CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect  bbbbb1 ABCA1 eeeee1 -dependent  bbbbb2 cholesterol eeeee2  efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.
CPR:9	We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by  bbbbb1 adenosine triphosphate-binding cassette A1 eeeee1 - (ABCA1), dependent  bbbbb2 cholesterol eeeee2  efflux from macrophages
CPR:9	We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- ( bbbbb1 ABCA1 eeeee1 ), dependent  bbbbb2 cholesterol eeeee2  efflux from macrophages
CPR:9	Serum samples were collected before and after each treatment period. [H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and  bbbbb1 ABCA1 eeeee1 -dependent  bbbbb2 cholesterol eeeee2  efflux and serum lipid and lipoprotein levels were assessed
CPR:9	Thus, isoflavone supplementation did not affect  bbbbb1 ABCA1 eeeee1 -dependent  bbbbb2 cholesterol eeeee2  efflux to serum
CPR:9	 bbbbb1 ABCA1 eeeee1 -facilitated  bbbbb2 cholesterol eeeee2  efflux and lipid parameters did not differ between equol-producing and non-equol-producing women
CPR:10	The  bbbbb1 imatinib eeeee1 -resistant  bbbbb2 KIT eeeee2 (D816V) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib
CPR:10	The  bbbbb1 imatinib eeeee1 -resistant KIT( bbbbb2 D816V eeeee2 ) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib
CPR:10	The imatinib-resistant  bbbbb1 KIT eeeee1 (D816V) mutant, associated with systemic mastocytosis, was found to be resistant to  bbbbb2 sorafenib eeeee2 
CPR:10	The imatinib-resistant KIT( bbbbb1 D816V eeeee1 ) mutant, associated with systemic mastocytosis, was found to be resistant to  bbbbb2 sorafenib eeeee2 
CPR:2	The direct effect of  bbbbb1 sorafenib eeeee1  on the activity of these  bbbbb2 kinases eeeee2  and their downstream signaling was tested using phospho-specific antibodies
CPR:2	 bbbbb1 Sorafenib eeeee1  (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against  bbbbb2 receptor tyrosine kinases eeeee2  from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	 bbbbb1 Sorafenib eeeee1  (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the  bbbbb2 platelet-derived growth factor receptor eeeee2  (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	 bbbbb1 Sorafenib eeeee1  (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor ( bbbbb2 PDGFR eeeee2 ) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	 bbbbb1 Sorafenib eeeee1  (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and  bbbbb2 vascular endothelial growth factor receptor eeeee2  (VEGFR) families
CPR:2	 bbbbb1 Sorafenib eeeee1  (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor ( bbbbb2 VEGFR eeeee2 ) families
CPR:2	Sorafenib ( bbbbb1 BAY43-9006 eeeee1 , Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against  bbbbb2 receptor tyrosine kinases eeeee2  from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	Sorafenib ( bbbbb1 BAY43-9006 eeeee1 , Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the  bbbbb2 platelet-derived growth factor receptor eeeee2  (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	Sorafenib ( bbbbb1 BAY43-9006 eeeee1 , Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor ( bbbbb2 PDGFR eeeee2 ) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	Sorafenib ( bbbbb1 BAY43-9006 eeeee1 , Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and  bbbbb2 vascular endothelial growth factor receptor eeeee2  (VEGFR) families
CPR:2	Sorafenib ( bbbbb1 BAY43-9006 eeeee1 , Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor ( bbbbb2 VEGFR eeeee2 ) families
CPR:2	Sorafenib (BAY43-9006,  bbbbb1 Nexavar eeeee1 ) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against  bbbbb2 receptor tyrosine kinases eeeee2  from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	Sorafenib (BAY43-9006,  bbbbb1 Nexavar eeeee1 ) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the  bbbbb2 platelet-derived growth factor receptor eeeee2  (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	Sorafenib (BAY43-9006,  bbbbb1 Nexavar eeeee1 ) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor ( bbbbb2 PDGFR eeeee2 ) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	Sorafenib (BAY43-9006,  bbbbb1 Nexavar eeeee1 ) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and  bbbbb2 vascular endothelial growth factor receptor eeeee2  (VEGFR) families
CPR:2	Sorafenib (BAY43-9006,  bbbbb1 Nexavar eeeee1 ) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor ( bbbbb2 VEGFR eeeee2 ) families
CPR:4	We investigated the efficacy of  bbbbb1 sorafenib eeeee1  at inhibiting mutants of the  bbbbb2 receptor tyrosine kinases eeeee2  PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies
CPR:4	We investigated the efficacy of  bbbbb1 sorafenib eeeee1  at inhibiting mutants of the receptor tyrosine kinases  bbbbb2 PDGFRbeta eeeee2 , KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies
CPR:4	We investigated the efficacy of  bbbbb1 sorafenib eeeee1  at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta,  bbbbb2 KIT eeeee2 , and FLT3, which are implicated in the pathogenesis of myeloid malignancies
CPR:4	We investigated the efficacy of  bbbbb1 sorafenib eeeee1  at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and  bbbbb2 FLT3 eeeee2 , which are implicated in the pathogenesis of myeloid malignancies
CPR:4	The ability of  bbbbb1 sorafenib eeeee1  to inhibit oncogenic  bbbbb2 PDGFRbeta eeeee2  and FLT3 mutants and overcome resistance to other small molecule inhibitors
CPR:4	The ability of  bbbbb1 sorafenib eeeee1  to inhibit oncogenic PDGFRbeta and  bbbbb2 FLT3 eeeee2  mutants and overcome resistance to other small molecule inhibitors
CPR:4	RESULTS: We show that  bbbbb1 sorafenib eeeee1  is a potent inhibitor of  bbbbb2 ETV6 eeeee2 -PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors
CPR:4	RESULTS: We show that  bbbbb1 sorafenib eeeee1  is a potent inhibitor of ETV6- bbbbb2 PDGFRbeta eeeee2  and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors
CPR:4	RESULTS: We show that  bbbbb1 sorafenib eeeee1  is a potent inhibitor of ETV6-PDGFRbeta and  bbbbb2 FLT3 eeeee2  mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors
CPR:4	RESULTS: We show that  bbbbb1 sorafenib eeeee1  is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other  bbbbb2 FLT3 eeeee2  inhibitors
CPR:4	 bbbbb1 Sorafenib eeeee1  induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing  bbbbb2 FLT3 eeeee2  with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines
CPR:4	 bbbbb1 Sorafenib eeeee1  (BAY43-9006, Nexavar) is a small molecule  bbbbb2 B-RAF eeeee2  inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CPR:4	INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of  bbbbb1 sorafenib eeeee1  for the treatment of myeloid malignancies expressing activated forms of  bbbbb2 PDGFRbeta eeeee2  and FLT3.
CPR:4	INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of  bbbbb1 sorafenib eeeee1  for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and  bbbbb2 FLT3 eeeee2 .
CPR:4	Sorafenib ( bbbbb1 BAY43-9006 eeeee1 , Nexavar) is a small molecule  bbbbb2 B-RAF eeeee2  inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CPR:4	Sorafenib (BAY43-9006,  bbbbb1 Nexavar eeeee1 ) is a small molecule  bbbbb2 B-RAF eeeee2  inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CPR:2	 bbbbb1 ENaC eeeee1  expression and activity could account for the low  bbbbb2 Na(+) eeeee2  concentration that is typical of milk.
CPR:2	We conclude that  bbbbb1 Na(+) eeeee1  movement across mammary epithelia is modulated by corticosteroids via a  bbbbb2 glucocorticoid receptor eeeee2 -mediated mechanism that regulates the expression of the beta- and gamma-subunits of ENaC
CPR:2	 bbbbb1 ENaC eeeee1  expression and activity could account for the low  bbbbb2 Na(+) eeeee2  concentration that is typical of milk.
CPR:6	Exposure to  bbbbb1 mifepristone eeeee1  (a  bbbbb2 glucocorticoid receptor eeeee2  antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA
CPR:6	Exposure to mifepristone (a glucocorticoid receptor antagonist), but not  bbbbb1 spironolactone eeeee1  (a  bbbbb2 mineralocorticoid receptor eeeee2  antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA
CPR:4	All three  bbbbb1 salicylates eeeee1  inhibited the diabetes-induced translocation of  bbbbb2 p50 eeeee2  (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections
CPR:4	All three  bbbbb1 salicylates eeeee1  inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of  bbbbb2 p50 eeeee2  and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections
CPR:4	All three  bbbbb1 salicylates eeeee1  inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and  bbbbb2 p65 eeeee2  into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections
CPR:4	Oral  bbbbb1 aspirin eeeee1  (as a representative of the salicylate family) inhibited diabetes-induced increase in  bbbbb2 NF-kappaB eeeee2  DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina
CPR:4	Oral aspirin (as a representative of the  bbbbb1 salicylate eeeee1  family) inhibited diabetes-induced increase in  bbbbb2 NF-kappaB eeeee2  DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina
CPR:4	All three  bbbbb1 salicylates eeeee1  inhibited the diabetes-induced translocation of p50 (a subunit of  bbbbb2 NF-kappaB eeeee2 ) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections
CPR:4	 bbbbb1 Sulfasalazine eeeee1  (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by  bbbbb2 NF-kappaB eeeee2 , including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate
CPR:4	 bbbbb1 Sulfasalazine eeeee1  (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule,  bbbbb2 intracellular adhesion molecule-1 eeeee2 , inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate
CPR:4	 bbbbb1 Sulfasalazine eeeee1  (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1,  bbbbb2 inducible nitric oxide synthase eeeee2 , and cyclooxygenase-2 in whole-retinal lysate
CPR:4	 bbbbb1 Sulfasalazine eeeee1  (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and  bbbbb2 cyclooxygenase-2 eeeee2  in whole-retinal lysate
CPR:4	Sulfasalazine (also as a representative of the  bbbbb1 salicylates eeeee1 ) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by  bbbbb2 NF-kappaB eeeee2 , including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate
CPR:4	 bbbbb1 Salicylates eeeee1 , in doses administrated in our experiments, inhibited  bbbbb2 NF-kappa eeeee2 B and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.
CPR:2	We have named this activity 11 beta HSD2 to distinguish it from the  bbbbb1 NADP eeeee1 -dependent  bbbbb2 11 beta HSD eeeee2 
CPR:2	These results demonstrate the presence of a dehydrogenase activity separate from the  bbbbb1 nicotinamide-adenine dinucleotide phosphate eeeee1  (NADP)-dependent  bbbbb2 11 beta hydroxysteroid dehydrogenase eeeee2  recently purified and cloned from rat liver
CPR:2	These results demonstrate the presence of a dehydrogenase activity separate from the nicotinamide-adenine dinucleotide phosphate ( bbbbb1 NADP eeeee1 )-dependent  bbbbb2 11 beta hydroxysteroid dehydrogenase eeeee2  recently purified and cloned from rat liver
CPR:10	 bbbbb1 Fluoxetine eeeee1  affected mainly the hSERT transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total  bbbbb2 hSERT eeeee2  protein content or the hSERT mRNA level
CPR:10	 bbbbb1 Fluoxetine eeeee1  affected mainly the hSERT transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the  bbbbb2 hSERT eeeee2  mRNA level
CPR:10	These results suggest that the effect of  bbbbb1 fluoxetine eeeee1  on the expression of hSERT is post-translational and has shown itself to be independent of  bbbbb2 PKC eeeee2  and PKA activity
CPR:10	These results suggest that the effect of  bbbbb1 fluoxetine eeeee1  on the expression of hSERT is post-translational and has shown itself to be independent of PKC and  bbbbb2 PKA eeeee2  activity
CPR:2	These results suggest that the effect of  bbbbb1 fluoxetine eeeee1  on the expression of  bbbbb2 hSERT eeeee2  is post-translational and has shown itself to be independent of PKC and PKA activity
CPR:2	 bbbbb1 Fluoxetine eeeee1  affected mainly the  bbbbb2 hSERT eeeee2  transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the hSERT mRNA level
CPR:2	Collectively then, these results indicate that  bbbbb1 LFA-1 eeeee1  contributes to the regulation of lymphocytic cholinergic activity via CD11a-mediated pathways and suggest that  bbbbb2 simvastatin eeeee2  exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.
CPR:2	Collectively then, these results indicate that LFA-1 contributes to the regulation of lymphocytic cholinergic activity via  bbbbb1 CD11a eeeee1 -mediated pathways and suggest that  bbbbb2 simvastatin eeeee2  exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.
CPR:3	In addition, activation of protein kinase C and increases in intracellular  bbbbb1 cAMP eeeee1  also enhance cholinergic activity in T cells, and  bbbbb2 lymphocyte function associated antigen-1 eeeee2  (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation
CPR:3	In addition, activation of protein kinase C and increases in intracellular  bbbbb1 cAMP eeeee1  also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 ( bbbbb2 LFA-1 eeeee2 ; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation
CPR:3	In addition, activation of protein kinase C and increases in intracellular  bbbbb1 cAMP eeeee1  also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1;  bbbbb2 CD11a eeeee2 /CD18) is an important mediator of leukocyte migration and T cell activation
CPR:3	In addition, activation of protein kinase C and increases in intracellular  bbbbb1 cAMP eeeee1  also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/ bbbbb2 CD18 eeeee2 ) is an important mediator of leukocyte migration and T cell activation
CPR:4	We found that  bbbbb1 simvastatin eeeee1  abolishes anti- bbbbb2 CD11a eeeee2  mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity
CPR:9	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ( bbbbb1 ACh eeeee1 );  bbbbb2 choline acetyltransferase eeeee2  (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)
CPR:9	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ( bbbbb1 ACh eeeee1 ); choline acetyltransferase ( bbbbb2 ChAT eeeee2 ), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)
CPR:9	Lymphocytes possess the essential components of a cholinergic system, including  bbbbb1 acetylcholine eeeee1  (ACh);  bbbbb2 choline acetyltransferase eeeee2  (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)
CPR:9	Lymphocytes possess the essential components of a cholinergic system, including  bbbbb1 acetylcholine eeeee1  (ACh); choline acetyltransferase ( bbbbb2 ChAT eeeee2 ), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)
CPR:2	In addition, BALB/c and C57BL/6 females were treated with  bbbbb1 progesterone eeeee1  or MPA for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of  bbbbb2 ER eeeee2  and PR
CPR:2	In addition, BALB/c and C57BL/6 females were treated with  bbbbb1 progesterone eeeee1  or MPA for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of ER and  bbbbb2 PR eeeee2 
CPR:2	In addition, BALB/c and C57BL/6 females were treated with progesterone or  bbbbb1 MPA eeeee1  for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of  bbbbb2 ER eeeee2  and PR
CPR:2	In addition, BALB/c and C57BL/6 females were treated with progesterone or  bbbbb1 MPA eeeee1  for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of ER and  bbbbb2 PR eeeee2 
CPR:2	INTRODUCTION: Medroxyprogesterone acetate ( bbbbb1 MPA eeeee1 ) induces estrogen receptor (ER)-positive and  bbbbb2 progesterone receptor eeeee2  (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CPR:3	 bbbbb1 PR isoform B eeeee1  levels were low in virgin control mice and increased after  bbbbb2 progestin eeeee2  treatment in both strains
CPR:3	INTRODUCTION: Medroxyprogesterone acetate ( bbbbb1 MPA eeeee1 ) induces estrogen receptor (ER)-positive and progesterone receptor ( bbbbb2 PR eeeee2 )-positive ductal invasive mammary carcinomas in BALB/c mice
CPR:3	INTRODUCTION: Medroxyprogesterone acetate ( bbbbb1 MPA eeeee1 ) induces  bbbbb2 estrogen receptor eeeee2  (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CPR:3	INTRODUCTION: Medroxyprogesterone acetate ( bbbbb1 MPA eeeee1 ) induces estrogen receptor ( bbbbb2 ER eeeee2 )-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CPR:3	INTRODUCTION:  bbbbb1 Medroxyprogesterone acetate eeeee1  (MPA) induces estrogen receptor (ER)-positive and progesterone receptor ( bbbbb2 PR eeeee2 )-positive ductal invasive mammary carcinomas in BALB/c mice
CPR:3	INTRODUCTION:  bbbbb1 Medroxyprogesterone acetate eeeee1  (MPA) induces  bbbbb2 estrogen receptor eeeee2  (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CPR:3	INTRODUCTION:  bbbbb1 Medroxyprogesterone acetate eeeee1  (MPA) induces estrogen receptor ( bbbbb2 ER eeeee2 )-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CPR:3	INTRODUCTION:  bbbbb1 Medroxyprogesterone acetate eeeee1  (MPA) induces estrogen receptor (ER)-positive and  bbbbb2 progesterone receptor eeeee2  (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CPR:4	The expression of  bbbbb1 ER-alpha eeeee1  and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in  bbbbb2 progestin eeeee2 -treated BALB/c mice (P < 0.05)
CPR:4	The expression of ER-alpha and  bbbbb1 PR isoform A eeeee1  in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in  bbbbb2 progestin eeeee2 -treated BALB/c mice (P < 0.05)
CPR:2	Several genes involved with  bbbbb1 steroid eeeee1  metabolism also showed remarkable expression changes, including increased expression of  bbbbb2 17beta-hydroxysteroid dehydrogenase-7 eeeee2  (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)
CPR:2	Several genes involved with  bbbbb1 steroid eeeee1  metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of  bbbbb2 HSD17beta5 eeeee2  (involved in testosterone production)
CPR:3	Various genes controlled by  bbbbb1 estrogen eeeee1 , including  bbbbb2 X-inactive-specific transcript eeeee2 , anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed
CPR:3	Various genes controlled by  bbbbb1 estrogen eeeee1 , including X-inactive-specific transcript,  bbbbb2 anterior gradient-2 eeeee2 , trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed
CPR:3	Various genes controlled by  bbbbb1 estrogen eeeee1 , including X-inactive-specific transcript, anterior gradient-2,  bbbbb2 trefoil factor-1 eeeee2 , CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed
CPR:3	Various genes controlled by  bbbbb1 estrogen eeeee1 , including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1,  bbbbb2 CRP-ductin eeeee2 , ghrelin, and small proline-rich protein-2A, were dramatically over-expressed
CPR:3	Various genes controlled by  bbbbb1 estrogen eeeee1 , including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin,  bbbbb2 ghrelin eeeee2 , and small proline-rich protein-2A, were dramatically over-expressed
CPR:3	Various genes controlled by  bbbbb1 estrogen eeeee1 , including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and  bbbbb2 small proline-rich protein-2A eeeee2 , were dramatically over-expressed
CPR:3	 bbbbb1 Estrogen eeeee1 -regulated genes including cytokeratin 1-19 and  bbbbb2 Cyp2a4 eeeee2  were over-expressed, although Cyp3a25 was suppressed
CPR:3	 bbbbb1 Estrogen eeeee1 -regulated genes including  bbbbb2 cytokeratin 1-19 eeeee2  and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed
CPR:4	 bbbbb1 Estrogen eeeee1 -regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although  bbbbb2 Cyp3a25 eeeee2  was suppressed
CPR:9	Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of  bbbbb1 17beta-hydroxysteroid dehydrogenase-7 eeeee1  (HSD17beta7; involved in  bbbbb2 estradiol eeeee2  production) and decreased expression of HSD17beta5 (involved in testosterone production)
CPR:9	Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 ( bbbbb1 HSD17beta7 eeeee1 ; involved in  bbbbb2 estradiol eeeee2  production) and decreased expression of HSD17beta5 (involved in testosterone production)
CPR:9	Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of  bbbbb1 HSD17beta5 eeeee1  (involved in  bbbbb2 testosterone eeeee2  production)
CPR:9	The expression of key genes important in  bbbbb1 methionine eeeee1  metabolism, such as  bbbbb2 methionine adenosyltransferase-1a eeeee2 , betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed
CPR:9	The expression of key genes important in  bbbbb1 methionine eeeee1  metabolism, such as methionine adenosyltransferase-1a,  bbbbb2 betaine-homocysteine methyltransferase eeeee2  and thioether S-methyltransferase, were suppressed
CPR:9	The expression of key genes important in  bbbbb1 methionine eeeee1  metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and  bbbbb2 thioether S-methyltransferase eeeee2 , were suppressed
CPR:2	 bbbbb1 Monosodium urate eeeee1  crystals stimulate monocytes and macrophages to release IL-1beta through the  bbbbb2 NALP3 eeeee2  component of the inflammasome
CPR:3	 bbbbb1 Monosodium urate eeeee1  crystals stimulate monocytes and macrophages to release  bbbbb2 IL-1beta eeeee2  through the NALP3 component of the inflammasome
CPR:1	Our structural studies provide a view of a synthetic inhibitory compound in a  bbbbb1 sirtuin eeeee1  active site revealing that suramin binds into the  bbbbb2 NAD(+) eeeee2 , the product, and the substrate-binding site
CPR:2	We identified  bbbbb1 suramin eeeee1  as a compound that binds to  bbbbb2 human SIRT5 eeeee2  and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM
CPR:2	To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of  bbbbb1 SIRT5 eeeee1 , one in complex with  bbbbb2 ADP eeeee2 -ribose, the other bound to suramin
CPR:2	To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of  bbbbb1 SIRT5 eeeee1 , one in complex with ADP-ribose, the other bound to  bbbbb2 suramin eeeee2 
CPR:2	Our structural studies provide a view of a synthetic inhibitory compound in a  bbbbb1 sirtuin eeeee1  active site revealing that  bbbbb2 suramin eeeee2  binds into the NAD(+), the product, and the substrate-binding site
CPR:4	We identified  bbbbb1 suramin eeeee1  as a compound that binds to human SIRT5 and showed that it inhibits  bbbbb2 SIRT5 NAD(+)-dependent deacetylase eeeee2  activity with an IC(50) value of 22 microM
CPR:4	Structural basis of inhibition of the  bbbbb1 human NAD+-dependent deacetylase SIRT5 eeeee1  by  bbbbb2 suramin eeeee2 
CPR:9	In humans,  bbbbb1 methionine synthase eeeee1  deficiency results in the accumulation of  bbbbb2 methyltetrahydrofolate eeeee2  at the expense of folate derivatives required for purine and thymidylate biosynthesis
CPR:3	In summary,  bbbbb1 phenformin eeeee1  and metformin increase  bbbbb2 AMPK eeeee2  activity and phosphorylation in the isolated heart
CPR:3	In summary, phenformin and  bbbbb1 metformin eeeee1  increase  bbbbb2 AMPK eeeee2  activity and phosphorylation in the isolated heart
CPR:3	Cytosolic [AMP] reported metabolically active  bbbbb1 AMP eeeee1 , which triggered increased  bbbbb2 AMPK eeeee2  activity, but measures of total AMP did not.
CPR:3	 bbbbb1 Metformin eeeee1  and phenformin, which are biguanides, have been reported to increase  bbbbb2 AMPK eeeee2  activity without increasing AMP/ATP
CPR:3	Metformin and  bbbbb1 phenformin eeeee1 , which are biguanides, have been reported to increase  bbbbb2 AMPK eeeee2  activity without increasing AMP/ATP
CPR:3	Metformin and phenformin, which are  bbbbb1 biguanides eeeee1 , have been reported to increase  bbbbb2 AMPK eeeee2  activity without increasing AMP/ATP
CPR:3	In hearts treated with  bbbbb1 phenformin eeeee1  for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and  bbbbb2 AMPK eeeee2  activity was elevated at 36 min
CPR:3	In hearts treated with  bbbbb1 metformin eeeee1 , [AMP] was increased at 50 min and  bbbbb2 AMPK eeeee2  activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min
CPR:3	In hearts treated with  bbbbb1 metformin eeeee1 , [AMP] was increased at 50 min and AMPK activity, phosphorylated  bbbbb2 AMPK eeeee2 , and phosphorylated acetyl-CoA carboxylase were elevated at 61 min
CPR:3	In hearts treated with  bbbbb1 metformin eeeee1 , [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and  bbbbb2 phosphorylated acetyl-CoA carboxylase eeeee2  were elevated at 61 min
CPR:3	 bbbbb1 Metformin eeeee1  and phenformin activate  bbbbb2 AMP-activated protein kinase eeeee2  in the heart by increasing cytosolic AMP concentration
CPR:3	Metformin and  bbbbb1 phenformin eeeee1  activate  bbbbb2 AMP-activated protein kinase eeeee2  in the heart by increasing cytosolic AMP concentration
CPR:2	Characterization of  bbbbb1 5-hydroxytryptamine1B eeeee1  receptors in rat spinal cord via  bbbbb2 [125I]iodocyanopindolol eeeee2  binding and inhibition of [3H]-5-hydroxytryptamine release
CPR:2	It is currently not known how much this  bbbbb1 H(1) eeeee1  antagonism of clozapine contributes to the therapeutic or adverse side effects of  bbbbb2 clozapine eeeee2 
CPR:2	 bbbbb1 Histamine H1 receptor eeeee1  involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of  bbbbb2 clozapine eeeee2 
CPR:3	In the current project, we found that the selective  bbbbb1 H(1) eeeee1  antagonist pyrilamine also reversed the  bbbbb2 dizocilpine eeeee2 -induced impairment in PPI of tactile startle with an auditory prepulse
CPR:4	In summary, the therapeutic effect of  bbbbb1 clozapine eeeee1  in reversing PPI impairment was mimicked by the  bbbbb2 H(1) eeeee2  antagonist pyrilamine, while pyrilamine had a mixed effect on cognition
CPR:4	 bbbbb1 Histamine H(1) eeeee1  blockade is one of the more prominent actions of the multi-receptor acting antipsychotic  bbbbb2 clozapine eeeee2 
CPR:6	Thus,  bbbbb1 H(1) eeeee1  antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as  bbbbb2 clozapine eeeee2 .
CPR:6	It is currently not known how much this  bbbbb1 H(1) eeeee1  antagonism of  bbbbb2 clozapine eeeee2  contributes to the therapeutic or adverse side effects of clozapine
CPR:6	In the current project, we found that the selective  bbbbb1 H(1) eeeee1  antagonist  bbbbb2 pyrilamine eeeee2  also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse
CPR:6	In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the  bbbbb1 H(1) eeeee1  antagonist  bbbbb2 pyrilamine eeeee2 , while pyrilamine had a mixed effect on cognition
CPR:6	In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the  bbbbb1 H(1) eeeee1  antagonist pyrilamine, while  bbbbb2 pyrilamine eeeee2  had a mixed effect on cognition
CPR:10	The mRNA expression of  bbbbb1 PtdSer synthase 1 eeeee1  (PSS1) and PtdSer synthase 2 (PSS2) was not reduced by  bbbbb2 ethanol eeeee2 
CPR:10	The mRNA expression of PtdSer synthase 1 ( bbbbb1 PSS1 eeeee1 ) and PtdSer synthase 2 (PSS2) was not reduced by  bbbbb2 ethanol eeeee2 
CPR:10	The mRNA expression of PtdSer synthase 1 (PSS1) and  bbbbb1 PtdSer synthase 2 eeeee1  (PSS2) was not reduced by  bbbbb2 ethanol eeeee2 
CPR:10	The mRNA expression of PtdSer synthase 1 (PSS1) and PtdSer synthase 2 ( bbbbb1 PSS2 eeeee1 ) was not reduced by  bbbbb2 ethanol eeeee2 
CPR:10	Similarly, the  bbbbb1 PSS1 eeeee1  enzyme level did not change after  bbbbb2 ethanol eeeee2  exposure but PSS2 could not be probed with the antibody available currently
CPR:9	Furthermore, the enzymatic activity of  bbbbb1 alanine aminotransferase eeeee1  (ALT), which converts the critical gluconeogenic amino acid alanine into  bbbbb2 pyruvate eeeee2 , is decreased (approximately 50%) in KLF15-/- hepatocytes
CPR:9	Furthermore, the enzymatic activity of alanine aminotransferase ( bbbbb1 ALT eeeee1 ), which converts the critical gluconeogenic amino acid alanine into  bbbbb2 pyruvate eeeee2 , is decreased (approximately 50%) in KLF15-/- hepatocytes
CPR:9	Furthermore, the enzymatic activity of  bbbbb1 alanine aminotransferase eeeee1  (ALT), which converts the critical gluconeogenic  bbbbb2 amino acid eeeee2  alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes
CPR:9	Furthermore, the enzymatic activity of alanine aminotransferase ( bbbbb1 ALT eeeee1 ), which converts the critical gluconeogenic  bbbbb2 amino acid eeeee2  alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes
CPR:9	Furthermore, the enzymatic activity of  bbbbb1 alanine aminotransferase eeeee1  (ALT), which converts the critical gluconeogenic amino acid  bbbbb2 alanine eeeee2  into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes
CPR:9	Furthermore, the enzymatic activity of alanine aminotransferase ( bbbbb1 ALT eeeee1 ), which converts the critical gluconeogenic amino acid  bbbbb2 alanine eeeee2  into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes
CPR:10	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)),  bbbbb1 L-[(3)H]citrulline eeeee1  formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter  bbbbb2 eNOS eeeee2  phosphorylation
CPR:10	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from  bbbbb1 L-[(3)H]arginine eeeee1  (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter  bbbbb2 eNOS eeeee2  phosphorylation
CPR:2	 bbbbb1 D-glucose eeeee1  stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional  bbbbb2 type II TGF-beta receptors eeeee2  in human umbilical vein endothelium
CPR:2	High  bbbbb1 D-glucose eeeee1  increases L-arginine transport and eNOS expression following TbetaRII activation by  bbbbb2 TGF-beta1 eeeee2  involving p42/44(mapk) and Smad2 in HUVEC
CPR:2	We studied whether  bbbbb1 D-glucose eeeee1 -stimulation of L-arginine transport and nitric oxide synthesis involves  bbbbb2 TGF-beta1 eeeee2  in primary cultures of HUVEC
CPR:3	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  increased p42/44(mapk) and  bbbbb2 Smad2 eeeee2  phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)
CPR:3	 bbbbb1 D-glucose eeeee1  stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and  bbbbb2 Smad2 eeeee2  requiring functional type II TGF-beta receptors in human umbilical vein endothelium
CPR:3	High  bbbbb1 D-glucose eeeee1  increases L-arginine transport and eNOS expression following  bbbbb2 TbetaRII eeeee2  activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC
CPR:3	High  bbbbb1 D-glucose eeeee1  increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and  bbbbb2 Smad2 eeeee2  in HUVEC
CPR:3	 bbbbb1 TGF-beta1 eeeee1  release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal)  bbbbb2 D-glucose eeeee2 
CPR:3	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  increased  bbbbb2 hCAT-1 eeeee2  mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CPR:3	High  bbbbb1 D-glucose eeeee1  increases L-arginine transport and  bbbbb2 eNOS eeeee2  expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC
CPR:3	Elevated extracellular  bbbbb1 D-glucose eeeee1  increases  bbbbb2 transforming growth factor beta1 eeeee2  (TGF-beta1) release from human umbilical vein endothelium (HUVEC)
CPR:3	Elevated extracellular  bbbbb1 D-glucose eeeee1  increases transforming growth factor beta1 ( bbbbb2 TGF-beta1 eeeee2 ) release from human umbilical vein endothelium (HUVEC)
CPR:4	TGF-beta1 and high D-glucose increased p42/44(mapk) and  bbbbb1 Smad2 eeeee1  phosphorylation, an effect blocked by  bbbbb2 PD-98059 eeeee2  (MEK1/2 inhibitor)
CPR:9	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of  bbbbb1 NO eeeee1  synthesis) and  bbbbb2 endothelial NO synthase eeeee2  (eNOS) protein abundance, but did not alter eNOS phosphorylation
CPR:9	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of  bbbbb1 NO eeeee1  synthesis) and endothelial NO synthase ( bbbbb2 eNOS eeeee2 ) protein abundance, but did not alter eNOS phosphorylation
CPR:2	We demonstrate that only treatment of HaCaT with GLA and EPA or a  bbbbb1 PPARgamma eeeee1  ligand ( bbbbb2 roziglitazone eeeee2 ), induced COX-2 expression (protein and mRNA)
CPR:2	The inhibitory effects of  bbbbb1 GW9662 eeeee1  and T0070907 (PPARgamma antagonists), on  bbbbb2 COX-2 eeeee2  expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CPR:2	The inhibitory effects of  bbbbb1 GW9662 eeeee1  and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of  bbbbb2 COX-2 promoter eeeee2  activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CPR:2	The inhibitory effects of GW9662 and  bbbbb1 T0070907 eeeee1  (PPARgamma antagonists), on  bbbbb2 COX-2 eeeee2  expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CPR:2	The inhibitory effects of GW9662 and  bbbbb1 T0070907 eeeee1  (PPARgamma antagonists), on COX-2 expression and on stimulation of  bbbbb2 COX-2 promoter eeeee2  activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CPR:2	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of  bbbbb1 COX-2 promoter eeeee1  activity by  bbbbb2 EPA eeeee2  and GLA suggest that PPARgamma is implicated in COX-2 induction
CPR:2	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of  bbbbb1 COX-2 promoter eeeee1  activity by EPA and  bbbbb2 GLA eeeee2  suggest that PPARgamma is implicated in COX-2 induction
CPR:2	Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the  bbbbb1 PUFA eeeee1  effects on  bbbbb2 COX-2 eeeee2  induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation
CPR:3	Moreover stimulation of  bbbbb1 COX-2 promoter eeeee1  activity was increased by those  bbbbb2 PUFAs eeeee2  or rosiglitazone
CPR:3	Moreover stimulation of  bbbbb1 COX-2 promoter eeeee1  activity was increased by those PUFAs or  bbbbb2 rosiglitazone eeeee2 
CPR:3	 bbbbb1 n-3 and n-6 polyunsaturated fatty acids eeeee1  induce the expression of COX-2 via  bbbbb2 PPARgamma eeeee2  activation in human keratinocyte HaCaT cells
CPR:3	Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of  bbbbb1 AA eeeee1  metabolites in  bbbbb2 PPAR eeeee2  activation
CPR:3	These findings demonstrate that  bbbbb1 n-3 and n-6 PUFA eeeee1  increased  bbbbb2 PPARgamma eeeee2  activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells
CPR:3	These findings demonstrate that  bbbbb1 n-3 and n-6 PUFA eeeee1  increased PPARgamma activity is necessary for the  bbbbb2 COX-2 eeeee2  induction in HaCaT human keratinocyte cells
CPR:3	Given the anti-inflammatory properties of EPA, we suggest that induction of  bbbbb1 COX-2 eeeee1  in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of  bbbbb2 PUFAs n-3 eeeee2  or n-6.
CPR:3	We demonstrate that only treatment of HaCaT with  bbbbb1 GLA eeeee1  and EPA or a PPARgamma ligand (roziglitazone), induced  bbbbb2 COX-2 eeeee2  expression (protein and mRNA)
CPR:3	We demonstrate that only treatment of HaCaT with GLA and  bbbbb1 EPA eeeee1  or a PPARgamma ligand (roziglitazone), induced  bbbbb2 COX-2 eeeee2  expression (protein and mRNA)
CPR:3	We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand ( bbbbb1 roziglitazone eeeee1 ), induced  bbbbb2 COX-2 eeeee2  expression (protein and mRNA)
CPR:3	 bbbbb1 n-3 and n-6 polyunsaturated fatty acids eeeee1  induce the expression of  bbbbb2 COX-2 eeeee2  via PPARgamma activation in human keratinocyte HaCaT cells
CPR:4	Finally,  bbbbb1 PLA2 eeeee1  inhibitor methyl  bbbbb2 arachidonyl fluorophosphonate eeeee2  blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation
CPR:4	Finally, PLA2 inhibitor methyl  bbbbb1 arachidonyl fluorophosphonate eeeee1  blocked the PUFA effects on  bbbbb2 COX-2 eeeee2  induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation
CPR:6	The inhibitory effects of  bbbbb1 GW9662 eeeee1  and T0070907 ( bbbbb2 PPARgamma eeeee2  antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CPR:6	The inhibitory effects of GW9662 and  bbbbb1 T0070907 eeeee1  ( bbbbb2 PPARgamma eeeee2  antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CPR:2	OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting  bbbbb1 beta(2)-adrenergic eeeee1  agonist that is the [R,R] isomer of formoterol) and  bbbbb2 salmeterol xinafoate eeeee2  versus placebo in patients with chronic obstructive pulmonary disease (COPD)
CPR:5	OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting  bbbbb1 beta(2)-adrenergic eeeee1  agonist that is the  bbbbb2 [R,R] isomer of formoterol eeeee2 ) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)
CPR:5	OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized  bbbbb1 arformoterol tartrate eeeee1  (a selective, long-acting  bbbbb2 beta(2)-adrenergic eeeee2  agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)
CPR:2	The cytosolic  bbbbb1 ACC1 eeeee1  is expressed primarily in liver and adipose tissue, and uses  bbbbb2 malonyl-coenzyme A eeeee2  as a key building block in fatty acid biosynthesis
CPR:9	The cytosolic  bbbbb1 ACC1 eeeee1  is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in  bbbbb2 fatty acid eeeee2  biosynthesis
CPR:9	The mitochondrial  bbbbb1 ACC2 eeeee1  is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of  bbbbb2 fatty acid eeeee2  oxidation
CPR:9	 bbbbb1 Acetyl-coenzyme A carboxylase eeeee1  (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in  bbbbb2 fatty acid eeeee2  biosynthesis and oxidation
CPR:9	Acetyl-coenzyme A carboxylase ( bbbbb1 ACC eeeee1 ) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in  bbbbb2 fatty acid eeeee2  biosynthesis and oxidation
CPR:9	Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms,  bbbbb1 ACC1 eeeee1  and ACC2, which play critical roles in  bbbbb2 fatty acid eeeee2  biosynthesis and oxidation
CPR:9	Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and  bbbbb1 ACC2 eeeee1 , which play critical roles in  bbbbb2 fatty acid eeeee2  biosynthesis and oxidation
CPR:9	In contrast, the  bbbbb1 RA eeeee1  catabolising enzymes  bbbbb2 Cyp26A1 eeeee2  and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye
CPR:9	In contrast, the  bbbbb1 RA eeeee1  catabolising enzymes Cyp26A1 and  bbbbb2 Cyp26B1 eeeee2  which are known to be RA-responsive were not expressed at all in the developing eye
CPR:2	In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and  bbbbb1 glucose eeeee1 -dependent inhibition of  bbbbb2 glucagon eeeee2  secretion
CPR:2	In contrast,  bbbbb1 GLP-1 eeeee1  exerts glucoregulatory actions via slowing of gastric emptying and  bbbbb2 glucose eeeee2 -dependent inhibition of glucagon secretion
CPR:3	Incretin-receptor activation leads to  bbbbb1 glucose eeeee1 -dependent  bbbbb2 insulin eeeee2  secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis
CPR:10	This report reviews published and unpublished data that suggest that  bbbbb1 aripiprazole eeeee1  acts as a selective partial agonist at the dopamine D(2) receptor and does not affect  bbbbb2 5-HT receptors eeeee2  at therapeutic doses.
CPR:2	It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the  bbbbb1 5-HT(2) eeeee1  receptor contribute to the clinical profile of  bbbbb2 aripiprazole eeeee2 , a so-called dopamine- and 5-HT stabiliser
CPR:5	This report reviews published and unpublished data that suggest that  bbbbb1 aripiprazole eeeee1  acts as a selective partial agonist at the  bbbbb2 dopamine D(2) receptor eeeee2  and does not affect 5-HT receptors at therapeutic doses.
CPR:4	 bbbbb1 Mifepriston'e eeeee1  blocks  bbbbb2 glucocorticoid receptor eeeee2  activation without modifying cortisol synthesis
CPR:2	Autoradiography studies with  bbbbb1 [(3)H](-)-CP 55,940 eeeee1  show that chronic treatment with SR 141716A for 15 days twice daily (1 mg/kg i.p.) significantly increases the density of  bbbbb2 CB1 receptors eeeee2  in the PVN
CPR:2	Autoradiography studies with [(3)H](-)-CP 55,940 show that chronic treatment with  bbbbb1 SR 141716A eeeee1  for 15 days twice daily (1 mg/kg i.p.) significantly increases the density of  bbbbb2 CB1 receptors eeeee2  in the PVN
CPR:4	The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of  bbbbb1 CB1 receptors eeeee1  by  bbbbb2 SR 141716A eeeee2  increases the density of these receptors in the PVN
CPR:6	annabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] ( bbbbb1 SR 141716A eeeee1 ), a selective  bbbbb2 cannabinoid CB1 receptor eeeee2  antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection
CPR:6	annabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [ bbbbb1 N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide eeeee1 ] (SR 141716A), a selective  bbbbb2 cannabinoid CB1 receptor eeeee2  antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection
CPR:2	 bbbbb1 Amyloid eeeee1  activates platelets through 2 pathways: one is through CD36, p38(MAPK),  bbbbb2 thromboxane A2 eeeee2 -mediated induction of aggregation; the other is through glycoprotein Ib alpha-mediated aggregation and agglutination
CPR:4	Modulation of the function of CD36 (CD36-/- mice),  bbbbb1 p38 eeeee1 (MAPK) ( bbbbb2 SB203580 eeeee2 ), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CPR:4	Modulation of the function of CD36 (CD36-/- mice), p38( bbbbb1 MAPK eeeee1 ) ( bbbbb2 SB203580 eeeee2 ), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CPR:4	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580),  bbbbb1 COX-1 eeeee1  ( bbbbb2 indomethacin eeeee2 ), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CPR:9	We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that  bbbbb1 human type 12 RDH eeeee1  reduces dihydrotestosterone to  bbbbb2 androstanediol eeeee2 , and is thus also involved in steroid metabolism
CPR:2	The LS/SS genotype of the promoter for  bbbbb1 SLC6A4 eeeee1  was associated with enhanced weight loss with  bbbbb2 sibutramine eeeee2 
CPR:2	CONCLUSIONS: Weight reduction with  bbbbb1 sibutramine eeeee1  is associated with altered gastric functions and increased peptide YY and is significantly associated with  bbbbb2 SLC6A4 eeeee2  genotype
CPR:2	The role of genetic variation in  bbbbb1 SLC6A4 eeeee1  on weight loss in response to  bbbbb2 sibutramine eeeee2  deserves further study.
CPR:3	The  bbbbb1 sibutramine eeeee1  group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial  bbbbb2 peptide YY eeeee2  compared with the placebo group
CPR:3	CONCLUSIONS: Weight reduction with  bbbbb1 sibutramine eeeee1  is associated with altered gastric functions and increased  bbbbb2 peptide YY eeeee2  and is significantly associated with SLC6A4 genotype
CPR:1	ultiple  bbbbb1 rat brain calpastatin eeeee1  forms are produced by distinct starting points and alternative splicing of the  bbbbb2 N eeeee2 -terminal exons. 5'-RACE was performed on rat brain calpastatin mRNA and two new translation initiation ATG's were found
CPR:2	 bbbbb1 GT-2331 eeeee1  [(+)-1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of histamine by the  bbbbb2 histamine H3 receptor eeeee2 , and as such, is an important biomarker for pharmaceutical companies conducting research in this field
CPR:6	An investigation of the absolute configuration of the potent  bbbbb1 histamine H3 receptor eeeee1  antagonist  bbbbb2 GT-2331 eeeee2  using vibrational circular dichroism
CPR:2	In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of  bbbbb1 atropine eeeee1  induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  bbbbb2 human muscarinic M2 receptors eeeee2  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01)
CPR:2	In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced  bbbbb1 [(3)H]N-methylscopolamine eeeee1  dissociation from Chinese hamster ovary cells expressing recombinant  bbbbb2 human muscarinic M2 receptors eeeee2  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01)
CPR:4	In this study the neuromuscular blocking drug  bbbbb1 vecuronium eeeee1  and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  bbbbb2 human muscarinic M2 receptors eeeee2  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01)
CPR:4	In this study the neuromuscular blocking drug vecuronium and the controls  bbbbb1 gallamine eeeee1  and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  bbbbb2 human muscarinic M2 receptors eeeee2  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01)
CPR:4	In this study the neuromuscular blocking drug vecuronium and the controls gallamine and  bbbbb1 pancuronium eeeee1  slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant  bbbbb2 human muscarinic M2 receptors eeeee2  K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01)
CPR:7	These data indicate that  bbbbb1 vecuronium eeeee1 , gallamine and pancuronium interact with an allosteric site on the  bbbbb2 muscarinic M2 receptor eeeee2  (located on the heart) and this may explain some of their cardiac side effects.
CPR:7	These data indicate that vecuronium,  bbbbb1 gallamine eeeee1  and pancuronium interact with an allosteric site on the  bbbbb2 muscarinic M2 receptor eeeee2  (located on the heart) and this may explain some of their cardiac side effects.
CPR:7	These data indicate that vecuronium, gallamine and  bbbbb1 pancuronium eeeee1  interact with an allosteric site on the  bbbbb2 muscarinic M2 receptor eeeee2  (located on the heart) and this may explain some of their cardiac side effects.
CPR:7	Allosteric interaction of the neuromuscular blockers  bbbbb1 vecuronium eeeee1  and pancuronium with recombinant  bbbbb2 human muscarinic M2 receptors eeeee2 
CPR:7	Allosteric interaction of the neuromuscular blockers vecuronium and  bbbbb1 pancuronium eeeee1  with recombinant  bbbbb2 human muscarinic M2 receptors eeeee2 
CPR:2	Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined  bbbbb1 calcium eeeee1  binding to  bbbbb2 calmodulin eeeee2  in the presence and absence of H(2)O(2) utilising (45)calcium
CPR:2	The results showed that all four  bbbbb1 calcium eeeee1  atoms exchanged per molecule of  bbbbb2 calmodulin eeeee2 
CPR:2	Hydrogen peroxide-mediated oxidative stress disrupts  bbbbb1 calcium eeeee1  binding on  bbbbb2 calmodulin eeeee2 : more evidence for oxidative stress in vitiligo
CPR:2	Taken together H(2)O(2)-mediated oxidation affects  bbbbb1 calcium eeeee1  binding in  bbbbb2 calmodulin eeeee2  leading to perturbed calcium homeostasis and perturbed l-phenylalanine-uptake in the epidermis of acute vitiligo.
CPR:2	Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined calcium binding to  bbbbb1 calmodulin eeeee1  in the presence and absence of  bbbbb2 H(2)O(2) eeeee2  utilising (45)calcium
CPR:2	 bbbbb1 Hydrogen peroxide eeeee1 -mediated oxidative stress disrupts calcium binding on  bbbbb2 calmodulin eeeee2 : more evidence for oxidative stress in vitiligo
CPR:2	Taken together  bbbbb1 H(2)O(2) eeeee1 -mediated oxidation affects calcium binding in  bbbbb2 calmodulin eeeee2  leading to perturbed calcium homeostasis and perturbed l-phenylalanine-uptake in the epidermis of acute vitiligo.
CPR:9	Patients with acute vitiligo have low epidermal  bbbbb1 catalase eeeee1  expression/activities and accumulate 10(-3) M  bbbbb2 H(2)O(2) eeeee2 
CPR:10	Moreover, the  bbbbb1 CDO eeeee1  active site is essentially unreactive toward  bbbbb2 NO eeeee2  in the absence of substrate, suggesting an obligate ordered binding of l-cysteine prior to NO
CPR:1	The active site coordination of  bbbbb1 CDO eeeee1  comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived  bbbbb2 histidines eeeee2 , thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif
CPR:2	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the  bbbbb1 NO eeeee1 -bound  bbbbb2 CDO eeeee2  active site
CPR:2	The active site coordination of  bbbbb1 CDO eeeee1  comprises a mononuclear  bbbbb2 iron eeeee2  ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif
CPR:2	In these experiments,  bbbbb1 CDO eeeee1  exhibits an ordered binding of  bbbbb2 l-cysteine eeeee2  prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes
CPR:2	In these experiments, CDO exhibits an ordered binding of  bbbbb1 l-cysteine eeeee1  prior to NO (and presumably O2) similar to that observed for the  bbbbb2 2H1C class of non-heme iron enzymes eeeee2 
CPR:2	In these experiments,  bbbbb1 CDO eeeee1  exhibits an ordered binding of l-cysteine prior to  bbbbb2 NO eeeee2  (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes
CPR:2	In these experiments, CDO exhibits an ordered binding of l-cysteine prior to  bbbbb1 NO eeeee1  (and presumably O2) similar to that observed for the  bbbbb2 2H1C class of non-heme iron enzymes eeeee2 
CPR:2	In these experiments,  bbbbb1 CDO eeeee1  exhibits an ordered binding of l-cysteine prior to NO (and presumably  bbbbb2 O2 eeeee2 ) similar to that observed for the 2H1C class of non-heme iron enzymes
CPR:2	In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably  bbbbb1 O2 eeeee1 ) similar to that observed for the  bbbbb2 2H1C class of non-heme iron enzymes eeeee2 
CPR:2	Moreover, the  bbbbb1 CDO eeeee1  active site is essentially unreactive toward NO in the absence of substrate, suggesting an obligate ordered binding of  bbbbb2 l-cysteine eeeee2  prior to NO
CPR:2	Moreover, the  bbbbb1 CDO eeeee1  active site is essentially unreactive toward NO in the absence of substrate, suggesting an obligate ordered binding of l-cysteine prior to  bbbbb2 NO eeeee2 
CPR:2	Characterization of the  bbbbb1 nitrosyl eeeee1  adduct of substrate-bound  bbbbb2 mouse cysteine dioxygenase eeeee2  by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications
CPR:2	However, upon addition of  bbbbb1 NO eeeee1  to  bbbbb2 CDO eeeee2  in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops
CPR:8	 bbbbb1 Mammalian cysteine dioxygenase eeeee1  (CDO) is a non-heme  bbbbb2 iron eeeee2  metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism
CPR:8	Mammalian cysteine dioxygenase ( bbbbb1 CDO eeeee1 ) is a non-heme  bbbbb2 iron eeeee2  metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism
CPR:9	However, upon addition of NO to  bbbbb1 CDO eeeee1  in the presence of substrate  bbbbb2 l-cysteine eeeee2 , a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops
CPR:9	 bbbbb1 Mammalian cysteine dioxygenase eeeee1  (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative  bbbbb2 cysteine eeeee2  catabolism
CPR:9	Mammalian cysteine dioxygenase ( bbbbb1 CDO eeeee1 ) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative  bbbbb2 cysteine eeeee2  catabolism
CPR:2	The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by  bbbbb1 Wy-14643 eeeee1  and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of  bbbbb2 PPARalpha2 eeeee2 , 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively
CPR:2	The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and  bbbbb1 5,8,11,14-eicosatetraynoic acid eeeee1  (ETYA) each at 10 microM, respectively, whereas that of  bbbbb2 PPARalpha2 eeeee2 , 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively
CPR:2	The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid ( bbbbb1 ETYA eeeee1 ) each at 10 microM, respectively, whereas that of  bbbbb2 PPARalpha2 eeeee2 , 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively
CPR:3	The transcriptional activity of torafugu  bbbbb1 PPARalpha1 eeeee1  was enhanced 4.5- and 11.5-fold by  bbbbb2 Wy-14643 eeeee2  and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively
CPR:3	The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by  bbbbb1 Wy-14643 eeeee1  and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of  bbbbb2 PPARalpha2 eeeee2 , 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively
CPR:3	The transcriptional activity of torafugu  bbbbb1 PPARalpha1 eeeee1  was enhanced 4.5- and 11.5-fold by Wy-14643 and  bbbbb2 5,8,11,14-eicosatetraynoic acid eeeee2  (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively
CPR:3	The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and  bbbbb1 5,8,11,14-eicosatetraynoic acid eeeee1  (ETYA) each at 10 microM, respectively, whereas that of  bbbbb2 PPARalpha2 eeeee2 , 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively
CPR:3	The transcriptional activity of torafugu  bbbbb1 PPARalpha1 eeeee1  was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid ( bbbbb2 ETYA eeeee2 ) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively
CPR:3	The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid ( bbbbb1 ETYA eeeee1 ) each at 10 microM, respectively, whereas that of  bbbbb2 PPARalpha2 eeeee2 , 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively
CPR:3	Furthermore, the activities of the two  bbbbb1 torafugu PPARalphas eeeee1  were enhanced 4.3- and 7.6-fold by  bbbbb2 arachidonic acid eeeee2 , 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively
CPR:3	Furthermore, the activities of the two  bbbbb1 torafugu PPARalphas eeeee1  were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by  bbbbb2 docosahexaenoic acid eeeee2 , and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively
CPR:3	Furthermore, the activities of the two  bbbbb1 torafugu PPARalphas eeeee1  were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by  bbbbb2 eicosapentaenoic acid eeeee2  each at 50 microM, respectively
CPR:6	Combination chemotherapy with a  bbbbb1 substance P receptor eeeee1  antagonist ( bbbbb2 aprepitant eeeee2 ) and melarsoprol in a mouse model of human African trypanosomiasis
CPR:6	Combination chemotherapy with a  bbbbb1 substance P receptor eeeee1  antagonist (aprepitant) and  bbbbb2 melarsoprol eeeee2  in a mouse model of human African trypanosomiasis
CPR:6	In this study we investigated the effects of combination chemotherapy with melarsoprol and a  bbbbb1 humanised SP receptor eeeee1  antagonist  bbbbb2 aprepitant eeeee2  (EMEND) in this mouse model
CPR:6	In this study we investigated the effects of combination chemotherapy with melarsoprol and a  bbbbb1 humanised SP receptor eeeee1  antagonist aprepitant ( bbbbb2 EMEND eeeee2 ) in this mouse model
CPR:1	PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a  bbbbb1 36-kDa water-soluble protein eeeee1  with 316  bbbbb2 amino acids eeeee2  found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CPR:9	It is thought to play a critical role in the visual cycle by functioning as an acceptor of  bbbbb1 11-cis-retinol eeeee1  from the  bbbbb2 isomerohydrolase eeeee2  reaction
CPR:10	 bbbbb1 Arginase eeeee1  or nitric oxide synthase isoenzymes were not found to influence  bbbbb2 L-citrulline eeeee2  production
CPR:10	Arginase or  bbbbb1 nitric oxide synthase eeeee1  isoenzymes were not found to influence  bbbbb2 L-citrulline eeeee2  production
CPR:4	Using this assay, we found that both  bbbbb1 superoxide eeeee1  and nitric oxide inhibit renal cortical  bbbbb2 DDAH eeeee2  activity in vitro.
CPR:4	Using this assay, we found that both superoxide and  bbbbb1 nitric oxide eeeee1  inhibit renal cortical  bbbbb2 DDAH eeeee2  activity in vitro.
CPR:9	Our optimized  bbbbb1 L-citrulline eeeee1  production assay to measure  bbbbb2 DDAH eeeee2  activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption
CPR:9	 bbbbb1 Dimethylarginine dimethylaminohydrolase eeeee1  (DDAH) metabolizes asymmetric dimethylarginine to generate  bbbbb2 L-citrulline eeeee2  and is present in large quantities in the kidney
CPR:9	Dimethylarginine dimethylaminohydrolase ( bbbbb1 DDAH eeeee1 ) metabolizes asymmetric dimethylarginine to generate  bbbbb2 L-citrulline eeeee2  and is present in large quantities in the kidney
CPR:9	We present a new study that optimizes the Prescott-Jones colorimetric assay to measure  bbbbb1 DDAH eeeee1 -dependent  bbbbb2 L-citrulline eeeee2  generation in kidney homogenates
CPR:9	Our optimized L-citrulline production assay to measure  bbbbb1 DDAH eeeee1  activity correlated closely with the direct measure of the rate of asymmetric  bbbbb2 dimethylarginine eeeee2  consumption
CPR:9	We found that the removal of  bbbbb1 urea eeeee1  with  bbbbb2 urease eeeee2  is necessary since urea also produces a positive reaction
CPR:9	 bbbbb1 Dimethylarginine dimethylaminohydrolase eeeee1  (DDAH) metabolizes asymmetric  bbbbb2 dimethylarginine eeeee2  to generate L-citrulline and is present in large quantities in the kidney
CPR:9	Dimethylarginine dimethylaminohydrolase ( bbbbb1 DDAH eeeee1 ) metabolizes asymmetric  bbbbb2 dimethylarginine eeeee2  to generate L-citrulline and is present in large quantities in the kidney
CPR:2	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage,  bbbbb1 HER2 eeeee1 /neu overexpressing breast cancer sequenced with chemotherapy including  bbbbb2 doxorubicin eeeee2 , cyclophosphamide, and paclitaxel
CPR:2	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/ bbbbb1 neu eeeee1  overexpressing breast cancer sequenced with chemotherapy including  bbbbb2 doxorubicin eeeee2 , cyclophosphamide, and paclitaxel
CPR:2	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage,  bbbbb1 HER2 eeeee1 /neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin,  bbbbb2 cyclophosphamide eeeee2 , and paclitaxel
CPR:2	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/ bbbbb1 neu eeeee1  overexpressing breast cancer sequenced with chemotherapy including doxorubicin,  bbbbb2 cyclophosphamide eeeee2 , and paclitaxel
CPR:2	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage,  bbbbb1 HER2 eeeee1 /neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and  bbbbb2 paclitaxel eeeee2 
CPR:2	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/ bbbbb1 neu eeeee1  overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and  bbbbb2 paclitaxel eeeee2 
CPR:4	The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting  bbbbb1 HER2 eeeee1 /neu as well as the epidermal growth factor receptor (EGFR),  bbbbb2 lapatinib eeeee2 
CPR:4	The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/ bbbbb1 neu eeeee1  as well as the epidermal growth factor receptor (EGFR),  bbbbb2 lapatinib eeeee2 
CPR:4	The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the  bbbbb1 epidermal growth factor receptor eeeee1  (EGFR),  bbbbb2 lapatinib eeeee2 
CPR:4	The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor ( bbbbb1 EGFR eeeee1 ),  bbbbb2 lapatinib eeeee2 
CPR:2	Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas  bbbbb1 l-glutamate eeeee1  (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to  bbbbb2 fibronectin eeeee2 
CPR:2	Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and  bbbbb1 NMDA eeeee1  (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to  bbbbb2 fibronectin eeeee2 
CPR:6	Exposure of Jurkat cells to either  bbbbb1 (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine eeeee1  [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective  bbbbb2 NMDA receptor eeeee2  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin
CPR:6	Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [ bbbbb1 (+)-MK 801 eeeee1 ] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective  bbbbb2 NMDA receptor eeeee2  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin
CPR:6	Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or  bbbbb1 D-(-)-2-amino-5-phosphonopentanoic acid eeeee1  (D-AP5), two selective  bbbbb2 NMDA receptor eeeee2  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin
CPR:6	Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid ( bbbbb1 D-AP5 eeeee1 ), two selective  bbbbb2 NMDA receptor eeeee2  antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin
CPR:10	In an initial search for molecular features that differentially define antagonist binding determinants, we document that Val148 in  bbbbb1 hNET transmembrane domain 3 eeeee1  selectively disrupts  bbbbb2 NIS eeeee2  binding but not that of DVS.
CPR:2	Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the  bbbbb1 hNET eeeee1  expressed in membranes compared with whole cells when competing for  bbbbb2 [(3)H]nisoxetine eeeee2  (NIS) binding
CPR:2	Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the  bbbbb1 hNET eeeee1  expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine ( bbbbb2 NIS eeeee2 ) binding
CPR:2	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for  bbbbb2 DVS eeeee2  at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:2	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by  bbbbb2 [(3)H]NIS eeeee2  was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:6	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the  bbbbb2 DVS eeeee2  analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:6	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog  bbbbb2 rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol eeeee2  (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:6	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol ( bbbbb2 WY-46824 eeeee2 ), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:6	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824),  bbbbb2 methylphenidate eeeee2 , and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:6	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the  bbbbb2 cocaine eeeee2  analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:6	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog  bbbbb2 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester eeeee2  (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:6	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester ( bbbbb2 RTI-55 eeeee2 ) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:6	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb1 hNET eeeee1  antagonists, such as  bbbbb2 NIS eeeee2 , mazindol, tricyclic antidepressants, and cocaine
CPR:6	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb1 hNET eeeee1  antagonists, such as NIS,  bbbbb2 mazindol eeeee2 , tricyclic antidepressants, and cocaine
CPR:6	 bbbbb1 Desvenlafaxine succinate eeeee1  (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ( bbbbb2 hNET eeeee2  and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CPR:6	 bbbbb1 Desvenlafaxine succinate eeeee1  (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and  bbbbb2 hSERT eeeee2 , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CPR:6	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb1 hNET eeeee1  antagonists, such as NIS, mazindol,  bbbbb2 tricyclic eeeee2  antidepressants, and cocaine
CPR:6	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb1 hNET eeeee1  antagonists, such as NIS, mazindol, tricyclic antidepressants, and  bbbbb2 cocaine eeeee2 
CPR:6	 bbbbb1 Desvenlafaxine succinate eeeee1  identifies novel antagonist binding determinants in the  bbbbb2 human norepinephrine transporter eeeee2 
CPR:6	Desvenlafaxine succinate ( bbbbb1 DVS eeeee1 ) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ( bbbbb2 hNET eeeee2  and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CPR:6	Desvenlafaxine succinate ( bbbbb1 DVS eeeee1 ) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and  bbbbb2 hSERT eeeee2 , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CPR:6	Using  bbbbb1 hNET eeeee1  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish  bbbbb2 DVS eeeee2 , the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CPR:1	The key difference in structure of  bbbbb1 Lp(a) eeeee1  and plasminogen is replacement of  bbbbb2 Arg eeeee2  with Ser at position 560
CPR:1	The key difference in structure of Lp(a) and  bbbbb1 plasminogen eeeee1  is replacement of  bbbbb2 Arg eeeee2  with Ser at position 560
CPR:1	The key difference in structure of  bbbbb1 Lp(a) eeeee1  and plasminogen is replacement of Arg with  bbbbb2 Ser eeeee2  at position 560
CPR:1	The key difference in structure of Lp(a) and  bbbbb1 plasminogen eeeee1  is replacement of Arg with  bbbbb2 Ser eeeee2  at position 560
CPR:4	 bbbbb1 Sorafenib eeeee1  and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ( bbbbb2 VEGFR-2 eeeee2 , VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CPR:4	 bbbbb1 Sorafenib eeeee1  and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2,  bbbbb2 VEGFR-3 eeeee2 ) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CPR:4	 bbbbb1 Sorafenib eeeee1  and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and  bbbbb2 platelet-derived growth factor receptor beta eeeee2  (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CPR:4	 bbbbb1 Sorafenib eeeee1  and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta ( bbbbb2 PDGFR-beta eeeee2 ), while temsirolimus is an mTOR inhibitor
CPR:4	Sorafenib and  bbbbb1 sunitinib eeeee1  are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ( bbbbb2 VEGFR-2 eeeee2 , VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CPR:4	Sorafenib and  bbbbb1 sunitinib eeeee1  are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2,  bbbbb2 VEGFR-3 eeeee2 ) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CPR:4	Sorafenib and  bbbbb1 sunitinib eeeee1  are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and  bbbbb2 platelet-derived growth factor receptor beta eeeee2  (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CPR:4	Sorafenib and  bbbbb1 sunitinib eeeee1  are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta ( bbbbb2 PDGFR-beta eeeee2 ), while temsirolimus is an mTOR inhibitor
CPR:4	Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while  bbbbb1 temsirolimus eeeee1  is an  bbbbb2 mTOR eeeee2  inhibitor
CPR:2	One is that the binding of  bbbbb1 retinoids eeeee1  to nuclear  bbbbb2 retinoic acid receptors eeeee2  (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CPR:2	One is that the binding of  bbbbb1 retinoids eeeee1  to nuclear retinoic acid receptors ( bbbbb2 RARs eeeee2 ) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CPR:2	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas  bbbbb1 tazarotene eeeee1  preferentially binds to and activates RAR-beta and -gamma in preference to  bbbbb2 RAR-alpha eeeee2 
CPR:3	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas  bbbbb1 tazarotene eeeee1  preferentially binds to and activates RAR-beta and -gamma in preference to  bbbbb2 RAR-alpha eeeee2 
CPR:10	In experimental models,  bbbbb1 rasagiline eeeee1  has been found to have neuroprotective properties that may be independent of  bbbbb2 MAO-B eeeee2  inhibition
CPR:4	Rasagiline [ bbbbb1 N-propargyl-l(R)-aminoindan eeeee1 ] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain  bbbbb2 MAO-B eeeee2  and is specifically designed for the treatment of Parkinson's disease (PD)
CPR:4	Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation  bbbbb1 propargylamine eeeee1  pharmacophore that selectively and irreversibly inhibits brain  bbbbb2 MAO-B eeeee2  and is specifically designed for the treatment of Parkinson's disease (PD)
CPR:4	Comprehensive review of  bbbbb1 rasagiline eeeee1 , a second-generation  bbbbb2 monoamine oxidase eeeee2  inhibitor, for the treatment of Parkinson's disease
CPR:4	Based on the results from those studies, we concluded that  bbbbb1 rasagiline eeeee1  PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited  bbbbb2 MAO-B eeeee2 
CPR:4	 bbbbb1 Rasagiline eeeee1  [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain  bbbbb2 MAO-B eeeee2  and is specifically designed for the treatment of Parkinson's disease (PD)
CPR:1	We postulate that this conserved  bbbbb1 Gly eeeee1  residue provides a flexible hinge within the  bbbbb2 Top1p eeeee2  catalytic pocket to facilitate linker dynamics and the structural alterations that accompany drug binding of the covalent enzyme-DNA intermediate.
CPR:1	 bbbbb1 Top1p eeeee1  clamps around duplex DNA, wherein the core and  bbbbb2 C eeeee2 -terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket
CPR:1	Top1p clamps around duplex DNA, wherein the core and  bbbbb1 C eeeee1 -terminal domains are connected by extended  bbbbb2 alpha-helices eeeee2  (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket
CPR:1	Top1p clamps around duplex DNA, wherein the core and  bbbbb1 C eeeee1 -terminal domains are connected by extended alpha-helices ( bbbbb2 linker domain eeeee2 ), which position the active site Tyr of the C-terminal domain within the catalytic pocket
CPR:1	We report that mutation of this conserved  bbbbb1 Gly eeeee1  in  bbbbb2 yeast Top1p eeeee2  alters enzyme sensitivity to CPT
CPR:1	 bbbbb1 Top1p eeeee1  clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site  bbbbb2 Tyr eeeee2  of the C-terminal domain within the catalytic pocket
CPR:1	Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended  bbbbb1 alpha-helices eeeee1  (linker domain), which position the active site  bbbbb2 Tyr eeeee2  of the C-terminal domain within the catalytic pocket
CPR:1	 bbbbb1 Top1p eeeee1  clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the  bbbbb2 C eeeee2 -terminal domain within the catalytic pocket
CPR:1	Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices ( bbbbb1 linker domain eeeee1 ), which position the active site Tyr of the  bbbbb2 C eeeee2 -terminal domain within the catalytic pocket
CPR:1	Crystallographic data reveal that a conserved  bbbbb1 Gly eeeee1  residue (located at the juncture between the linker and C-terminal domains) is at one end of a short  bbbbb2 alpha-helix eeeee2 , which extends to the active site Tyr covalently linked to the DNA
CPR:1	Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and  bbbbb1 C eeeee1 -terminal domains) is at one end of a short  bbbbb2 alpha-helix eeeee2 , which extends to the active site Tyr covalently linked to the DNA
CPR:1	Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and C-terminal domains) is at one end of a short  bbbbb1 alpha-helix eeeee1 , which extends to the active site  bbbbb2 Tyr eeeee2  covalently linked to the DNA
CPR:1	In the presence of drug, the linker is rigid and this  bbbbb1 alpha-helix eeeee1  extends to include  bbbbb2 Gly eeeee2  and the preceding Leu
CPR:1	In the presence of drug, the linker is rigid and this  bbbbb1 alpha-helix eeeee1  extends to include Gly and the preceding  bbbbb2 Leu eeeee2 
CPR:2	 bbbbb1 Top1p eeeee1  is the cellular target of the anti-cancer drug  bbbbb2 camptothecin eeeee2  (CPT), which reversibly stabilizes a covalent enzyme-DNA intermediate
CPR:2	 bbbbb1 Top1p eeeee1  is the cellular target of the anti-cancer drug camptothecin ( bbbbb2 CPT eeeee2 ), which reversibly stabilizes a covalent enzyme-DNA intermediate
CPR:2	The physical connection of the linker with the  bbbbb1 Top1p eeeee1  clamp as well as linker flexibility affect enzyme sensitivity to  bbbbb2 CPT eeeee2 
CPR:2	Mutation of Gly721 alters  bbbbb1 DNA topoisomerase I eeeee1  active site architecture and sensitivity to  bbbbb2 camptothecin eeeee2 
CPR:2	We report that mutation of this conserved Gly in  bbbbb1 yeast Top1p eeeee1  alters enzyme sensitivity to  bbbbb2 CPT eeeee2 
CPR:1	The binding of U46619 to the  bbbbb1 PGIS eeeee1  protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at  bbbbb2 C-11 eeeee2 , H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner
CPR:1	The binding of U46619 to the  bbbbb1 PGIS eeeee1  protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11,  bbbbb2 H2C eeeee2 , and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner
CPR:1	The binding of U46619 to the  bbbbb1 PGIS eeeee1  protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and  bbbbb2 H20 eeeee2  of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner
CPR:1	The binding of U46619 to the  bbbbb1 PGIS eeeee1  protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of  bbbbb2 U46619 eeeee2  were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner
CPR:1	The distances between the protons  bbbbb1 H20 eeeee1  and H2, H18 and H2, and H18 and H4 are shorter following their binding to the  bbbbb2 PGIS eeeee2  in solution-down to within 5 A
CPR:1	The distances between the protons H20 and  bbbbb1 H2 eeeee1 , H18 and H2, and H18 and H4 are shorter following their binding to the  bbbbb2 PGIS eeeee2  in solution-down to within 5 A
CPR:1	The distances between the protons H20 and H2,  bbbbb1 H18 eeeee1  and H2, and H18 and H4 are shorter following their binding to the  bbbbb2 PGIS eeeee2  in solution-down to within 5 A
CPR:1	The distances between the protons H20 and H2, H18 and  bbbbb1 H2 eeeee1 , and H18 and H4 are shorter following their binding to the  bbbbb2 PGIS eeeee2  in solution-down to within 5 A
CPR:1	The distances between the protons H20 and H2, H18 and H2, and  bbbbb1 H18 eeeee1  and H4 are shorter following their binding to the  bbbbb2 PGIS eeeee2  in solution-down to within 5 A
CPR:1	The distances between the protons H20 and H2, H18 and H2, and H18 and  bbbbb1 H4 eeeee1  are shorter following their binding to the  bbbbb2 PGIS eeeee2  in solution-down to within 5 A
CPR:2	The binding of  bbbbb1 U46619 eeeee1  to the  bbbbb2 PGIS eeeee2  protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner
CPR:2	The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon  bbbbb1 U46619 eeeee1  binding to the engineered  bbbbb2 PGIS eeeee2  in a concentration-dependent manner
CPR:2	The detailed conformational change and 3D structure of the  bbbbb1 PGIS eeeee1 -bound  bbbbb2 U46619 eeeee2  were further demonstrated by 2D 1H NMR experiments using the transferred NOE technique
CPR:2	High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic ( bbbbb1 U46619 eeeee1 ) to the engineered  bbbbb2 prostacyclin (PGI2) synthase eeeee2  (PGIS) in solution
CPR:2	High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic ( bbbbb1 U46619 eeeee1 ) to the engineered prostacyclin (PGI2) synthase ( bbbbb2 PGIS eeeee2 ) in solution
CPR:2	High-resolution NMR spectroscopy was used to determine the docking of a substrate ( bbbbb1 prostaglandin H2 eeeee1 ) mimic (U46619) to the engineered  bbbbb2 prostacyclin (PGI2) synthase eeeee2  (PGIS) in solution
CPR:2	High-resolution NMR spectroscopy was used to determine the docking of a substrate ( bbbbb1 prostaglandin H2 eeeee1 ) mimic (U46619) to the engineered prostacyclin (PGI2) synthase ( bbbbb2 PGIS eeeee2 ) in solution
CPR:2	The bound conformation of  bbbbb1 U46619 eeeee1  fits the crystal structure of the  bbbbb2 PGIS eeeee2  substrate binding pocket considerably better than that of the unbound U46619
CPR:2	For example, Trp282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the  bbbbb1 PGIS eeeee1 -bound form of  bbbbb2 U46619 eeeee2  and the PGIS crystal structure
CPR:2	For example, Trp282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the PGIS-bound form of  bbbbb1 U46619 eeeee1  and the  bbbbb2 PGIS eeeee2  crystal structure
CPR:2	The noted conformational changes where the C-6 position is closer to the C-9 position of  bbbbb1 U46619 eeeee1  provided the first experimental data for understanding the molecular mechanism of the catalytic function of  bbbbb2 PGIS eeeee2  in the isomerization of PGH2 to prostacyclin.
CPR:4	This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to  bbbbb1 factor Xa eeeee1  ( bbbbb2 rivaroxaban eeeee2  and apixaban) and IIa (dabigatran)
CPR:4	This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to  bbbbb1 factor Xa eeeee1  (rivaroxaban and  bbbbb2 apixaban eeeee2 ) and IIa (dabigatran)
CPR:4	INTERVENTIONS: In the 8-week run-in period, all participants received the  bbbbb1 ACE eeeee1  inhibitor  bbbbb2 cilazapril eeeee2  (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg
CPR:10	Two  bbbbb1 imidazoquinoline eeeee1  molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not  bbbbb2 TLR8 eeeee2 , was activated by the ligands
CPR:10	Two imidazoquinoline molecules,  bbbbb1 imiquimod eeeee1  and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not  bbbbb2 TLR8 eeeee2 , was activated by the ligands
CPR:10	Two imidazoquinoline molecules, imiquimod and  bbbbb1 gardiquimod eeeee1 , markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not  bbbbb2 TLR8 eeeee2 , was activated by the ligands
CPR:1	Both  bbbbb1 porcine TLR7 eeeee1  and TLR8 proteins were expressed in cell lines and were  bbbbb2 N eeeee2 -glycosylated
CPR:1	Both porcine TLR7 and  bbbbb1 TLR8 eeeee1  proteins were expressed in cell lines and were  bbbbb2 N eeeee2 -glycosylated
CPR:2	Two  bbbbb1 imidazoquinoline eeeee1  molecules, imiquimod and gardiquimod, markedly activated both  bbbbb2 porcine TLR7 eeeee2  and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:2	Two  bbbbb1 imidazoquinoline eeeee1  molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and  bbbbb2 TLR8 eeeee2  whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:2	Two  bbbbb1 imidazoquinoline eeeee1  molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only  bbbbb2 human TLR7 eeeee2 , but not TLR8, was activated by the ligands
CPR:2	Two  bbbbb1 imidazoquinoline eeeee1  molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not  bbbbb2 TLR8 eeeee2 , was activated by the ligands
CPR:2	Two imidazoquinoline molecules,  bbbbb1 imiquimod eeeee1  and gardiquimod, markedly activated both  bbbbb2 porcine TLR7 eeeee2  and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:2	Two imidazoquinoline molecules,  bbbbb1 imiquimod eeeee1  and gardiquimod, markedly activated both porcine TLR7 and  bbbbb2 TLR8 eeeee2  whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:2	Two imidazoquinoline molecules,  bbbbb1 imiquimod eeeee1  and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only  bbbbb2 human TLR7 eeeee2 , but not TLR8, was activated by the ligands
CPR:2	Two imidazoquinoline molecules,  bbbbb1 imiquimod eeeee1  and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not  bbbbb2 TLR8 eeeee2 , was activated by the ligands
CPR:2	Two imidazoquinoline molecules, imiquimod and  bbbbb1 gardiquimod eeeee1 , markedly activated both  bbbbb2 porcine TLR7 eeeee2  and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:2	Two imidazoquinoline molecules, imiquimod and  bbbbb1 gardiquimod eeeee1 , markedly activated both porcine TLR7 and  bbbbb2 TLR8 eeeee2  whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:2	Two imidazoquinoline molecules, imiquimod and  bbbbb1 gardiquimod eeeee1 , markedly activated both porcine TLR7 and TLR8 whereas only  bbbbb2 human TLR7 eeeee2 , but not TLR8, was activated by the ligands
CPR:2	Two imidazoquinoline molecules, imiquimod and  bbbbb1 gardiquimod eeeee1 , markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not  bbbbb2 TLR8 eeeee2 , was activated by the ligands
CPR:2	Porcine TLR8 and TLR7 are both activated by a selective  bbbbb1 TLR7 eeeee1  ligand,  bbbbb2 imiquimod eeeee2 
CPR:3	Two  bbbbb1 imidazoquinoline eeeee1  molecules, imiquimod and gardiquimod, markedly activated both  bbbbb2 porcine TLR7 eeeee2  and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:3	Two  bbbbb1 imidazoquinoline eeeee1  molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and  bbbbb2 TLR8 eeeee2  whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:3	Two  bbbbb1 imidazoquinoline eeeee1  molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only  bbbbb2 human TLR7 eeeee2 , but not TLR8, was activated by the ligands
CPR:3	Two imidazoquinoline molecules,  bbbbb1 imiquimod eeeee1  and gardiquimod, markedly activated both  bbbbb2 porcine TLR7 eeeee2  and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:3	Two imidazoquinoline molecules,  bbbbb1 imiquimod eeeee1  and gardiquimod, markedly activated both porcine TLR7 and  bbbbb2 TLR8 eeeee2  whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:3	Two imidazoquinoline molecules,  bbbbb1 imiquimod eeeee1  and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only  bbbbb2 human TLR7 eeeee2 , but not TLR8, was activated by the ligands
CPR:3	Two imidazoquinoline molecules, imiquimod and  bbbbb1 gardiquimod eeeee1 , markedly activated both  bbbbb2 porcine TLR7 eeeee2  and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:3	Two imidazoquinoline molecules, imiquimod and  bbbbb1 gardiquimod eeeee1 , markedly activated both porcine TLR7 and  bbbbb2 TLR8 eeeee2  whereas only human TLR7, but not TLR8, was activated by the ligands
CPR:3	Two imidazoquinoline molecules, imiquimod and  bbbbb1 gardiquimod eeeee1 , markedly activated both porcine TLR7 and TLR8 whereas only  bbbbb2 human TLR7 eeeee2 , but not TLR8, was activated by the ligands
CPR:3	Porcine TLR8 and  bbbbb1 TLR7 eeeee1  are both activated by a selective TLR7 ligand,  bbbbb2 imiquimod eeeee2 
CPR:3	Porcine  bbbbb1 TLR8 eeeee1  and TLR7 are both activated by a selective TLR7 ligand,  bbbbb2 imiquimod eeeee2 
CPR:4	Moreover, activation of transfected cells and porcine PBMC by  bbbbb1 TLR7 eeeee1  ligands was inhibited by  bbbbb2 bafilomycin A(1) eeeee2  indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.
CPR:2	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for  bbbbb1 4-iodopropofol eeeee1 , 4-bromopropofol and 4-chloropropofol in  bbbbb2 Na(V)1.4 eeeee2 , and 450 nM for 4-chloropropofol in Na(V)1.2
CPR:2	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol,  bbbbb1 4-bromopropofol eeeee1  and 4-chloropropofol in  bbbbb2 Na(V)1.4 eeeee2 , and 450 nM for 4-chloropropofol in Na(V)1.2
CPR:2	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and  bbbbb1 4-chloropropofol eeeee1  in  bbbbb2 Na(V)1.4 eeeee2 , and 450 nM for 4-chloropropofol in Na(V)1.2
CPR:2	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for  bbbbb1 4-chloropropofol eeeee1  in  bbbbb2 Na(V)1.2 eeeee2 
CPR:2	CONCLUSIONS AND IMPLICATIONS: Halogenated propofol analogues constitute a novel class of  bbbbb1 sodium channel eeeee1 -blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug  bbbbb2 lidocaine eeeee2 
CPR:4	The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for  bbbbb1 4-chloropropofol eeeee1  in  bbbbb2 Na(V)1.2 eeeee2 
CPR:4	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for  bbbbb1 4-iodopropofol eeeee1 , 4-bromopropofol and 4-chloropropofol in  bbbbb2 Na(V)1.4 eeeee2 , and 450 nM for 4-chloropropofol in Na(V)1.2
CPR:4	High-affinity blockade of  bbbbb1 voltage-operated skeletal muscle and neuronal sodium channels eeeee1  by  bbbbb2 halogenated propofol eeeee2  analogues
CPR:4	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol,  bbbbb1 4-bromopropofol eeeee1  and 4-chloropropofol in  bbbbb2 Na(V)1.4 eeeee2 , and 450 nM for 4-chloropropofol in Na(V)1.2
CPR:4	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and  bbbbb1 4-chloropropofol eeeee1  in  bbbbb2 Na(V)1.4 eeeee2 , and 450 nM for 4-chloropropofol in Na(V)1.2
CPR:4	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for  bbbbb1 4-chloropropofol eeeee1  in  bbbbb2 Na(V)1.2 eeeee2 
CPR:4	CONCLUSIONS AND IMPLICATIONS:  bbbbb1 Halogenated propofol eeeee1  analogues constitute a novel class of  bbbbb2 sodium channel eeeee2 -blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine
CPR:6	 bbbbb1 Irbesartan eeeee1  (Aprovel, Avapro, Irbetan, Karvea), an  bbbbb2 angiotensin II receptor type 1 eeeee2  antagonist, is approved in many countries worldwide for the treatment of hypertension
CPR:6	Irbesartan ( bbbbb1 Aprovel eeeee1 , Avapro, Irbetan, Karvea), an  bbbbb2 angiotensin II receptor type 1 eeeee2  antagonist, is approved in many countries worldwide for the treatment of hypertension
CPR:6	Irbesartan (Aprovel,  bbbbb1 Avapro eeeee1 , Irbetan, Karvea), an  bbbbb2 angiotensin II receptor type 1 eeeee2  antagonist, is approved in many countries worldwide for the treatment of hypertension
CPR:6	Irbesartan (Aprovel, Avapro,  bbbbb1 Irbetan eeeee1 , Karvea), an  bbbbb2 angiotensin II receptor type 1 eeeee2  antagonist, is approved in many countries worldwide for the treatment of hypertension
CPR:6	Irbesartan (Aprovel, Avapro, Irbetan,  bbbbb1 Karvea eeeee1 ), an  bbbbb2 angiotensin II receptor type 1 eeeee2  antagonist, is approved in many countries worldwide for the treatment of hypertension
CPR:2	When  bbbbb1 RAD51 eeeee1 , which is a central component of HR, was depleted by siRNA cells were sensitized to  bbbbb2 raltitrexed eeeee2  (RTX), which specifically inhibits TS
CPR:2	When  bbbbb1 RAD51 eeeee1 , which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed ( bbbbb2 RTX eeeee2 ), which specifically inhibits TS
CPR:2	 bbbbb1 RTX eeeee1  treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with  bbbbb2 RPA2 eeeee2  foci varied
CPR:2	Phosphorylation of  bbbbb1 replication protein A eeeee1  (RPA2 subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of  bbbbb2 RTX eeeee2 
CPR:2	Phosphorylation of replication protein A ( bbbbb1 RPA2 eeeee1  subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of  bbbbb2 RTX eeeee2 
CPR:3	 bbbbb1 RTX eeeee1  treatment also induced foci of  bbbbb2 RAD51 eeeee2 , gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied
CPR:3	 bbbbb1 RTX eeeee1  treatment also induced foci of RAD51,  bbbbb2 gamma-H2AX eeeee2 , phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied
CPR:3	 bbbbb1 RTX eeeee1  treatment also induced foci of RAD51, gamma-H2AX,  bbbbb2 phospho-Chk1 eeeee2 , and phospho-NBS1, although the extent of co-localization with RPA2 foci varied
CPR:3	 bbbbb1 RTX eeeee1  treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and  bbbbb2 phospho-NBS1 eeeee2 , although the extent of co-localization with RPA2 foci varied
CPR:4	When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed ( bbbbb1 RTX eeeee1 ), which specifically inhibits  bbbbb2 TS eeeee2 
CPR:9	DNA damage is accepted as a consequence of  bbbbb1 thymidylate eeeee1  deprivation induced by chemotherapeutic inhibitors of  bbbbb2 thymidylate synthase eeeee2  (TS), but the types of damage and signaling responses remain incompletely understood
CPR:9	DNA damage is accepted as a consequence of  bbbbb1 thymidylate eeeee1  deprivation induced by chemotherapeutic inhibitors of thymidylate synthase ( bbbbb2 TS eeeee2 ), but the types of damage and signaling responses remain incompletely understood
CPR:2	These data support the concept that adipose tissue  bbbbb1 NNMT eeeee1  contributes to the increased plasma homocysteine levels in patients treated with  bbbbb2 NA eeeee2 .
CPR:3	Nicotinic acid ( bbbbb1 NA eeeee1 ), a widely used drug to lower elevated plasma lipid levels, induced  bbbbb2 NNMT eeeee2  enzyme activity in white adipose tissue of mice
CPR:3	 bbbbb1 Nicotinic acid eeeee1  (NA), a widely used drug to lower elevated plasma lipid levels, induced  bbbbb2 NNMT eeeee2  enzyme activity in white adipose tissue of mice
CPR:4	Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the  bbbbb1 NNMT eeeee1  inhibitor  bbbbb2 1-methylnicotinamide eeeee2 
CPR:9	 bbbbb1 Nicotinamide N-methyltransferase eeeee1  (NNMT) catalyses the conversion of nicotinamide to  bbbbb2 1-methylnicotinamide eeeee2  and plays an important role in hepatic detoxification reactions
CPR:9	Nicotinamide N-methyltransferase ( bbbbb1 NNMT eeeee1 ) catalyses the conversion of nicotinamide to  bbbbb2 1-methylnicotinamide eeeee2  and plays an important role in hepatic detoxification reactions
CPR:9	These data support the concept that adipose tissue  bbbbb1 NNMT eeeee1  contributes to the increased plasma  bbbbb2 homocysteine eeeee2  levels in patients treated with NA.
CPR:9	 bbbbb1 Homocysteine eeeee1 , the atherogenic product of the  bbbbb2 NNMT eeeee2 -catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures
CPR:9	 bbbbb1 Nicotinamide N-methyltransferase eeeee1  (NNMT) catalyses the conversion of  bbbbb2 nicotinamide eeeee2  to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions
CPR:9	Nicotinamide N-methyltransferase ( bbbbb1 NNMT eeeee1 ) catalyses the conversion of  bbbbb2 nicotinamide eeeee2  to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions
CPR:2	The L-type calcium channel ( bbbbb1 LTCC eeeee1 ) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine ( bbbbb2 DHP eeeee2 ) binding properties and are both expressed in mammalian brain
CPR:2	The  bbbbb1 L-type calcium channel eeeee1  (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine ( bbbbb2 DHP eeeee2 ) binding properties and are both expressed in mammalian brain
CPR:2	The L-type calcium channel (LTCC) isoforms  bbbbb1 Ca(v)1.2 eeeee1  and Ca(v)1.3 display similar 1,4-dihydropyridine ( bbbbb2 DHP eeeee2 ) binding properties and are both expressed in mammalian brain
CPR:2	The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and  bbbbb1 Ca(v)1.3 eeeee1  display similar 1,4-dihydropyridine ( bbbbb2 DHP eeeee2 ) binding properties and are both expressed in mammalian brain
CPR:2	Inhibition of  bbbbb1 (+)-[(3)H]isradipine eeeee1  binding to Ca(v)1.2DHP(-/-) (predominantly  bbbbb2 Ca(v)1.3 eeeee2 ) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels
CPR:2	Inhibition of  bbbbb1 (+)-[(3)H]isradipine eeeee1  binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly  bbbbb2 Ca(v)1.2 eeeee2 ) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels
CPR:2	Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of  bbbbb1 nitrendipine eeeee1  and nifedipine for the  bbbbb2 Ca(v)1.2 eeeee2  binding pocket, a finding further confirmed with heterologously expressed channels
CPR:2	Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and  bbbbb1 nifedipine eeeee1  for the  bbbbb2 Ca(v)1.2 eeeee2  binding pocket, a finding further confirmed with heterologously expressed channels
CPR:2	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  binding to Ca(v)1.2DHP(-/-) and  bbbbb2 Ca(v) eeeee2 -DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CPR:2	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that  bbbbb2 Ca(v)1.3 eeeee2  accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CPR:2	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain  bbbbb2 LTCCs eeeee2 . qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CPR:2	The L-type calcium channel ( bbbbb1 LTCC eeeee1 ) isoforms Ca(v)1.2 and Ca(v)1.3 display similar  bbbbb2 1,4-dihydropyridine eeeee2  (DHP) binding properties and are both expressed in mammalian brain
CPR:2	The  bbbbb1 L-type calcium channel eeeee1  (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar  bbbbb2 1,4-dihydropyridine eeeee2  (DHP) binding properties and are both expressed in mammalian brain
CPR:2	The L-type calcium channel (LTCC) isoforms  bbbbb1 Ca(v)1.2 eeeee1  and Ca(v)1.3 display similar  bbbbb2 1,4-dihydropyridine eeeee2  (DHP) binding properties and are both expressed in mammalian brain
CPR:2	The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and  bbbbb1 Ca(v)1.3 eeeee1  display similar  bbbbb2 1,4-dihydropyridine eeeee2  (DHP) binding properties and are both expressed in mammalian brain
CPR:2	Expression and  bbbbb1 1,4-dihydropyridine eeeee1 -binding properties of brain  bbbbb2 L-type calcium channel eeeee2  isoforms
CPR:10	 bbbbb1 Bosutinib eeeee1  did not inhibit  bbbbb2 KIT eeeee2  or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases
CPR:10	 bbbbb1 Bosutinib eeeee1  did not inhibit KIT or  bbbbb2 platelet-derived growth factor receptor eeeee2 , but prominently targeted the apoptosis-linked STE20 kinases
CPR:10	Although in vivo  bbbbb1 bosutinib eeeee1  is inactive against  bbbbb2 ABL eeeee2  T315I, we found this clinically important mutant to be enzymatically inhibited in the mid-nanomolar range
CPR:10	Although in vivo  bbbbb1 bosutinib eeeee1  is inactive against ABL  bbbbb2 T315I eeeee2 , we found this clinically important mutant to be enzymatically inhibited in the mid-nanomolar range
CPR:2	 bbbbb1 Bosutinib eeeee1  did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked  bbbbb2 STE20 kinases eeeee2 
CPR:4	A comparison of bosutinib with  bbbbb1 dasatinib eeeee1  across the whole  bbbbb2 kinase eeeee2  panel revealed overlapping, but distinct, inhibition profiles
CPR:4	Global target profile of the  bbbbb1 kinase eeeee1  inhibitor  bbbbb2 bosutinib eeeee2  in primary chronic myeloid leukemia cells
CPR:4	Finally,  bbbbb1 bosutinib eeeee1  is the first  bbbbb2 kinase eeeee2  inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.
CPR:4	Finally,  bbbbb1 bosutinib eeeee1  is the first kinase inhibitor shown to target  bbbbb2 CAMK2G eeeee2 , recently implicated in myeloid leukemia cell proliferation.
CPR:4	Here, we characterized the target profile of the dual  bbbbb1 SRC eeeee1 /ABL inhibitor  bbbbb2 bosutinib eeeee2  employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel
CPR:4	Here, we characterized the target profile of the dual SRC/ bbbbb1 ABL eeeee1  inhibitor  bbbbb2 bosutinib eeeee2  employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel
CPR:4	A comparison of  bbbbb1 bosutinib eeeee1  with dasatinib across the whole  bbbbb2 kinase eeeee2  panel revealed overlapping, but distinct, inhibition profiles
CPR:10	A positively charged derivative,  bbbbb1 estramustine sarcosinate eeeee1 , did not inhibit microtubule assembly or alter the composition of the coassembled  bbbbb2 MAPs eeeee2 
CPR:10	The uncharged  bbbbb1 estramustine eeeee1  bound to both tubulin and MAPs, but no effects were seen on microtubule assembly, the composition of coassembled  bbbbb2 MAPs eeeee2  or the microtubule morphology
CPR:1	Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic  bbbbb1 amino acid eeeee1  repeats of these  bbbbb2 MAPs eeeee2 , considered to be the ultimate tubulin binding domains
CPR:1	Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic  bbbbb1 amino acid eeeee1  repeats of these MAPs, considered to be the ultimate  bbbbb2 tubulin eeeee2  binding domains
CPR:2	Both these  bbbbb1 MAPs eeeee1  were found to have two to three binding sites for  bbbbb2 estramustine phosphate eeeee2  which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains
CPR:2	The Kd for the binding of  bbbbb1 estramustine phosphate eeeee1  to  bbbbb2 MAP2 eeeee2  was estimated to be 20 microM at 4 degrees, and for the binding of tau, 200 microM
CPR:2	The uncharged  bbbbb1 estramustine eeeee1  bound to both  bbbbb2 tubulin eeeee2  and MAPs, but no effects were seen on microtubule assembly, the composition of coassembled MAPs or the microtubule morphology
CPR:2	The uncharged  bbbbb1 estramustine eeeee1  bound to both tubulin and  bbbbb2 MAPs eeeee2 , but no effects were seen on microtubule assembly, the composition of coassembled MAPs or the microtubule morphology
CPR:2	Our results suggest that only negatively charged  bbbbb1 estramustine eeeee1  derivatives have a  bbbbb2 MAP eeeee2 -dependent microtubule inhibitory effect
CPR:2	The negatively charged  bbbbb1 estramustine phosphate eeeee1  has been found previously to be a  bbbbb2 microtubule-associated protein eeeee2  (MAP)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985]
CPR:2	The negatively charged  bbbbb1 estramustine phosphate eeeee1  has been found previously to be a microtubule-associated protein ( bbbbb2 MAP eeeee2 )-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985]
CPR:2	Two new negatively charged  bbbbb1 estramustine eeeee1  derivatives, estramustine sulphate and estramustine glucuronide, were found to be similar  bbbbb2 MAP eeeee2 -dependent microtubule inhibitors
CPR:2	Two new negatively charged estramustine derivatives,  bbbbb1 estramustine sulphate eeeee1  and estramustine glucuronide, were found to be similar  bbbbb2 MAP eeeee2 -dependent microtubule inhibitors
CPR:2	Two new negatively charged estramustine derivatives, estramustine sulphate and  bbbbb1 estramustine glucuronide eeeee1 , were found to be similar  bbbbb2 MAP eeeee2 -dependent microtubule inhibitors
CPR:10	Unlike bacterial  bbbbb1 3-keto-5-ene-steroid isomerase eeeee1 , the human isomerase reaction is stimulated by  bbbbb2 diphosphopyridine nucleotides eeeee2  (NADH, NAD+)
CPR:10	Unlike bacterial  bbbbb1 3-keto-5-ene-steroid isomerase eeeee1 , the human isomerase reaction is stimulated by diphosphopyridine nucleotides ( bbbbb2 NADH eeeee2 , NAD+)
CPR:10	Unlike bacterial  bbbbb1 3-keto-5-ene-steroid isomerase eeeee1 , the human isomerase reaction is stimulated by diphosphopyridine nucleotides (NADH,  bbbbb2 NAD+ eeeee2 )
CPR:10	The  bbbbb1 3 beta-hydroxysteroid eeeee1  substrate, pregnenolone, protects isomerase as well as  bbbbb2 dehydrogenase eeeee2  from inactivation by FSA
CPR:10	The 3 beta-hydroxysteroid substrate,  bbbbb1 pregnenolone eeeee1 , protects isomerase as well as  bbbbb2 dehydrogenase eeeee2  from inactivation by FSA
CPR:2	nalysis of coenzyme binding by  bbbbb1 human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase eeeee1  and steroid 5----4-ene-isomerase using  bbbbb2 5'-[p-(fluorosulfonyl)benzoyl]adenosine eeeee2 , an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CPR:2	nalysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and  bbbbb1 steroid 5----4-ene-isomerase eeeee1  using  bbbbb2 5'-[p-(fluorosulfonyl)benzoyl]adenosine eeeee2 , an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CPR:4	The affinity labeling  bbbbb1 nucleotide eeeee1  analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the  bbbbb2 dehydrogenase eeeee2  and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)
CPR:4	The affinity labeling nucleotide analog,  bbbbb1 5'-[p-(fluorosulfonyl)benzoyl]adenosine eeeee1  (FSA), inactivates the  bbbbb2 dehydrogenase eeeee2  and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)
CPR:4	The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine ( bbbbb1 FSA eeeee1 ), inactivates the  bbbbb2 dehydrogenase eeeee2  and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)
CPR:4	The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as  bbbbb1 dehydrogenase eeeee1  from inactivation by  bbbbb2 FSA eeeee2 
CPR:8	nalysis of coenzyme binding by  bbbbb1 human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase eeeee1  and steroid 5----4-ene-isomerase using  bbbbb2 5'-[p-(fluorosulfonyl)benzoyl]adenosine eeeee2 , an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CPR:8	nalysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and  bbbbb1 steroid 5----4-ene-isomerase eeeee1  using  bbbbb2 5'-[p-(fluorosulfonyl)benzoyl]adenosine eeeee2 , an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CPR:8	FSA is a cofactor site-directed reagent that binds with similar affinity as a competitive inhibitor of  bbbbb1 NAD+ eeeee1  reduction by  bbbbb2 dehydrogenase eeeee2  (Ki = 162 microM) or as a stimulator of isomerase (Km = 153 microM)
CPR:9	Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the  bbbbb1 dehydrogenase eeeee1  and isomerase substrate  bbbbb2 steroids eeeee2  bind at different sites on the same protein
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ( bbbbb1 SU 11248 eeeee1 , Sutent) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ( bbbbb1 SU 11248 eeeee1 , Sutent) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248,  bbbbb1 Sutent eeeee1 ) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248,  bbbbb1 Sutent eeeee1 ) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase,  bbbbb1 AMN107 eeeee1  (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 ( bbbbb1 Nilotinib eeeee1 ) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and  bbbbb1 INNO-406 eeeee1  (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 ( bbbbb1 NS-187 eeeee1 ) specific for  bbbbb2 c-KIT eeeee2  kinase
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development:  bbbbb2 Lapatinib eeeee2  (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib ( bbbbb2 Lapatinib ditosylate eeeee2 , Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate,  bbbbb2 Tykerb eeeee2 , GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb,  bbbbb2 GW-572016 eeeee2 ), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016),  bbbbb2 Canertinib eeeee2  (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib ( bbbbb2 CI-1033 eeeee2 ), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033),  bbbbb2 Zactima eeeee2  (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima ( bbbbb2 ZD6474 eeeee2 ), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474),  bbbbb2 Vatalanib eeeee2  (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib ( bbbbb2 PTK787 eeeee2 /ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ bbbbb2 ZK 222584 eeeee2 ), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584),  bbbbb2 Sorafenib eeeee2  (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib ( bbbbb2 Bay 43-9006 eeeee2 , Nexavar), and Leflunomide (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006,  bbbbb2 Nexavar eeeee2 ), and Leflunomide (SU101, Arava)
CPR:4	Others kinase inhibitors used recently in cancer therapy include  bbbbb1 Dasatinib eeeee1  (BMS-354825) specific for  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include  bbbbb1 Dasatinib eeeee1  (BMS-354825) specific for ABL  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and  bbbbb2 Leflunomide eeeee2  (SU101, Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide ( bbbbb2 SU101 eeeee2 , Arava)
CPR:4	The following  bbbbb1 TK eeeee1  blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101,  bbbbb2 Arava eeeee2 )
CPR:4	The most successful example of  bbbbb1 kinase eeeee1  blockers is  bbbbb2 Imatinib eeeee2  (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of kinase blockers is  bbbbb1 Imatinib eeeee1  (Imatinib mesylate, Gleevec, STI571), the inhibitor of  bbbbb2 Bcr eeeee2 /Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of kinase blockers is  bbbbb1 Imatinib eeeee1  (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/ bbbbb2 Abl eeeee2  oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of  bbbbb1 kinase eeeee1  blockers is Imatinib ( bbbbb2 Imatinib mesylate eeeee2 , Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of kinase blockers is Imatinib ( bbbbb1 Imatinib mesylate eeeee1 , Gleevec, STI571), the inhibitor of  bbbbb2 Bcr eeeee2 /Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of kinase blockers is Imatinib ( bbbbb1 Imatinib mesylate eeeee1 , Gleevec, STI571), the inhibitor of Bcr/ bbbbb2 Abl eeeee2  oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of  bbbbb1 kinase eeeee1  blockers is Imatinib (Imatinib mesylate,  bbbbb2 Gleevec eeeee2 , STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of kinase blockers is Imatinib (Imatinib mesylate,  bbbbb1 Gleevec eeeee1 , STI571), the inhibitor of  bbbbb2 Bcr eeeee2 /Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of kinase blockers is Imatinib (Imatinib mesylate,  bbbbb1 Gleevec eeeee1 , STI571), the inhibitor of Bcr/ bbbbb2 Abl eeeee2  oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of  bbbbb1 kinase eeeee1  blockers is Imatinib (Imatinib mesylate, Gleevec,  bbbbb2 STI571 eeeee2 ), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec,  bbbbb1 STI571 eeeee1 ), the inhibitor of  bbbbb2 Bcr eeeee2 /Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec,  bbbbb1 STI571 eeeee1 ), the inhibitor of Bcr/ bbbbb2 Abl eeeee2  oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib ( bbbbb1 BMS-354825 eeeee1 ) specific for  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase,  bbbbb1 Gefitinib eeeee1  (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase,  bbbbb1 Gefitinib eeeee1  (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib ( bbbbb1 Iressa eeeee1 ), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib ( bbbbb1 Iressa eeeee1 ), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa),  bbbbb1 Erlotinib eeeee1  (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa),  bbbbb1 Erlotinib eeeee1  (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib ( bbbbb1 OSI-774 eeeee1 , Tarceva) and Sunitinib (SU 11248, Sutent) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib ( bbbbb1 OSI-774 eeeee1 , Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774,  bbbbb1 Tarceva eeeee1 ) and Sunitinib (SU 11248, Sutent) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774,  bbbbb1 Tarceva eeeee1 ) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and  bbbbb1 Sunitinib eeeee1  (SU 11248, Sutent) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:4	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and  bbbbb1 Sunitinib eeeee1  (SU 11248, Sutent) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CPR:2	Currently, the use of orally administered  bbbbb1 MAO eeeee1  inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of  bbbbb2 tyramine eeeee2 -provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary tyramine
CPR:4	Currently, the use of orally administered  bbbbb1 MAO eeeee1  inhibitor antidepressants (eg,  bbbbb2 phenelzine eeeee2 , tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary tyramine
CPR:4	Currently, the use of orally administered  bbbbb1 MAO eeeee1  inhibitor antidepressants (eg, phenelzine,  bbbbb2 tranylcypromine eeeee2 ) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary tyramine
CPR:10	 bbbbb1 Atomoxetine eeeee1  has a high affinity and selectivity for norepinephrine transporters, but little or no affinity for various  bbbbb2 neurotransmitter receptors eeeee2 
CPR:2	 bbbbb1 Atomoxetine eeeee1  has a high affinity and selectivity for  bbbbb2 norepinephrine transporters eeeee2 , but little or no affinity for various neurotransmitter receptors
CPR:4	 bbbbb1 CYP2D6 eeeee1  inhibitors, such as  bbbbb2 paroxetine eeeee2 , are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers
CPR:9	It undergoes extensive biotransformation, which is affected by poor metabolism by  bbbbb1 cytochrome P450 (CYP) 2D6 eeeee1  in a small percentage of the population; these patients have greater exposure to and slower elimination of  bbbbb2 atomoxetine eeeee2  than extensive metabolizers
CPR:9	CYP2D6 inhibitors, such as paroxetine, are associated with changes in  bbbbb1 atomoxetine eeeee1  pharmacokinetics similar to those observed among poor  bbbbb2 CYP2D6 eeeee2  metabolizers
CPR:9	 bbbbb1 Atomoxetine eeeee1  appeared better tolerated among extensive  bbbbb2 CYP2D6 eeeee2  metabolizers than among poor metabolizers
CPR:2	 bbbbb1 Hexachlorophene eeeee1  forms a ring around the internal cavity in  bbbbb2 GDH eeeee2  through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves
CPR:2	 bbbbb1 Hexachlorophene eeeee1  forms a ring around the internal cavity in GDH through aromatic stacking interactions between the drug and  bbbbb2 GDH eeeee2  as well as between the drug molecules themselves
CPR:2	 bbbbb1 Mammalian glutamate dehydrogenase eeeee1  (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using  bbbbb2 NAD(P)(+) eeeee2  as coenzyme
CPR:2	Mammalian glutamate dehydrogenase ( bbbbb1 GDH eeeee1 ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using  bbbbb2 NAD(P)(+) eeeee2  as coenzyme
CPR:3	The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by  bbbbb1 GTP eeeee1  causes excessive secretion of  bbbbb2 insulin eeeee2 
CPR:4	Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of  bbbbb1 GDH eeeee1  are inhibited by the green tea polyphenols,  bbbbb2 epigallocatechin gallate eeeee2  and epicatechin gallate
CPR:4	Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of  bbbbb1 GDH eeeee1  are inhibited by the green tea polyphenols, epigallocatechin gallate and  bbbbb2 epicatechin gallate eeeee2 
CPR:7	The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of  bbbbb1 GDH eeeee1  by  bbbbb2 GTP eeeee2  causes excessive secretion of insulin
CPR:9	 bbbbb1 Mammalian glutamate dehydrogenase eeeee1  (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to  bbbbb2 2-oxoglutarate eeeee2  using NAD(P)(+) as coenzyme
CPR:9	Mammalian glutamate dehydrogenase ( bbbbb1 GDH eeeee1 ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to  bbbbb2 2-oxoglutarate eeeee2  using NAD(P)(+) as coenzyme
CPR:9	 bbbbb1 Mammalian glutamate dehydrogenase eeeee1  (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of  bbbbb2 l-glutamate eeeee2  to 2-oxoglutarate using NAD(P)(+) as coenzyme
CPR:9	Mammalian glutamate dehydrogenase ( bbbbb1 GDH eeeee1 ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of  bbbbb2 l-glutamate eeeee2  to 2-oxoglutarate using NAD(P)(+) as coenzyme
CPR:10	Systemic  bbbbb1 bupivacaine eeeee1  did not modify either the hyperalgesia and local inflammation or  bbbbb2 COX eeeee2  expression
CPR:9	BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord  bbbbb1 COX-2 eeeee1  (cyclooxygenase-2), with a subsequent increase in central  bbbbb2 prostaglandin E2 eeeee2  (PGE2) levels associated with the development of hyperalgesia
CPR:9	BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 ( bbbbb1 cyclooxygenase-2 eeeee1 ), with a subsequent increase in central  bbbbb2 prostaglandin E2 eeeee2  (PGE2) levels associated with the development of hyperalgesia
CPR:9	BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord  bbbbb1 COX-2 eeeee1  (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 ( bbbbb2 PGE2 eeeee2 ) levels associated with the development of hyperalgesia
CPR:9	BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 ( bbbbb1 cyclooxygenase-2 eeeee1 ), with a subsequent increase in central prostaglandin E2 ( bbbbb2 PGE2 eeeee2 ) levels associated with the development of hyperalgesia
CPR:2	Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that  bbbbb1 alpha 1-adrenoceptor eeeee1  populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both  bbbbb2 WB4101 eeeee2  and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)
CPR:2	Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that  bbbbb1 alpha 1-adrenoceptor eeeee1  populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and  bbbbb2 5-methyl-urapidil eeeee2 ), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)
CPR:2	Radioligand binding studies with the nonselective  bbbbb1 alpha 1-adrenoceptor eeeee1  antagonist radioligand  bbbbb2 125I-BE2254 eeeee2  showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1)
CPR:2	Radioligand binding studies with the nonselective  bbbbb1 alpha 1-adrenoceptor eeeee1  antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are  bbbbb2 CEC eeeee2  sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1)
CPR:2	Radioligand binding studies with the nonselective  bbbbb1 alpha 1-adrenoceptor eeeee1  antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for  bbbbb2 WB4101 eeeee2  (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1)
CPR:2	Radioligand binding studies with the nonselective  bbbbb1 alpha 1-adrenoceptor eeeee1  antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for  bbbbb2 5-methylurapidil eeeee2  (pKd = 7.1)
CPR:5	The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against  bbbbb1 alpha 1a-adrenoceptor eeeee1 -selective agonist  bbbbb2 methoxamine eeeee2 -induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil
CPR:6	The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against  bbbbb1 alpha 1a-adrenoceptor eeeee1 -selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for  bbbbb2 WB4101 eeeee2  and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil
CPR:6	The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against  bbbbb1 alpha 1a-adrenoceptor eeeee1 -selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for  bbbbb2 5-methyl-urapidil eeeee2 
CPR:6	Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that  bbbbb1 alpha 1-adrenoceptor eeeee1  populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for  bbbbb2 WB4101 eeeee2  and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)
CPR:6	Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that  bbbbb1 alpha 1-adrenoceptor eeeee1  populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for  bbbbb2 5-methyl-urapidil eeeee2 ) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)
CPR:6	Using the  bbbbb1 alpha 1-adrenoceptor eeeee1  subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and  bbbbb2 5-methyl-urapidil eeeee2 , we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta
CPR:6	Using the  bbbbb1 alpha 1-adrenoceptor eeeee1  subtype-selective antagonists  bbbbb2 chlorethylclonidine eeeee2  (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta
CPR:6	Radioligand binding studies with the nonselective  bbbbb1 alpha 1-adrenoceptor eeeee1  antagonist radioligand  bbbbb2 125I-BE2254 eeeee2  showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1)
CPR:6	Using the  bbbbb1 alpha 1-adrenoceptor eeeee1  subtype-selective antagonists chlorethylclonidine ( bbbbb2 CEC eeeee2 ), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta
CPR:6	Using the  bbbbb1 alpha 1-adrenoceptor eeeee1  subtype-selective antagonists chlorethylclonidine (CEC),  bbbbb2 WB4101 eeeee2 , and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta
CPR:6	The Schild plots for the competitive antagonists  bbbbb1 WB4101 eeeee1  and 5-methyl-urapidil against  bbbbb2 alpha 1a-adrenoceptor eeeee2 -selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil
CPR:6	The Schild plots for the competitive antagonists WB4101 and  bbbbb1 5-methyl-urapidil eeeee1  against  bbbbb2 alpha 1a-adrenoceptor eeeee2 -selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil
CPR:6	 bbbbb1 Ambrisentan eeeee1  is an  bbbbb2 endothelin receptor eeeee2  antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH)
CPR:6	 bbbbb1 Ambrisentan eeeee1  is the first  bbbbb2 ET(A) eeeee2  selective ERA approved for use in the US
CPR:2	A series of 4,5-diaryloxazole analogs were designed and the interaction between  bbbbb1 oxaprozin eeeee1  and  bbbbb2 cyclooxygenase-2 eeeee2  studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of oxaprozin
CPR:4	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone,  bbbbb1 promegestone eeeee1 , nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  bbbbb2 sulfatase eeeee2  and 17beta-hydroxysteroid-dehydrogenase type 1 activities
CPR:4	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone,  bbbbb1 promegestone eeeee1 , nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  bbbbb2 17beta-hydroxysteroid-dehydrogenase type 1 eeeee2  activities
CPR:4	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone,  bbbbb1 nomegestrol acetate eeeee1  and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  bbbbb2 sulfatase eeeee2  and 17beta-hydroxysteroid-dehydrogenase type 1 activities
CPR:4	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone,  bbbbb1 nomegestrol acetate eeeee1  and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  bbbbb2 17beta-hydroxysteroid-dehydrogenase type 1 eeeee2  activities
CPR:4	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and  bbbbb1 norelgestromin eeeee1  can reduce intratissular levels of estradiol in breast cancer by blocking  bbbbb2 sulfatase eeeee2  and 17beta-hydroxysteroid-dehydrogenase type 1 activities
CPR:4	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and  bbbbb1 norelgestromin eeeee1  can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  bbbbb2 17beta-hydroxysteroid-dehydrogenase type 1 eeeee2  activities
CPR:4	As discussed in this review, various  bbbbb1 progestogens eeeee1  including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  bbbbb2 sulfatase eeeee2  and 17beta-hydroxysteroid-dehydrogenase type 1 activities
CPR:4	As discussed in this review, various  bbbbb1 progestogens eeeee1  including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  bbbbb2 17beta-hydroxysteroid-dehydrogenase type 1 eeeee2  activities
CPR:4	As discussed in this review, various progestogens including  bbbbb1 dydrogesterone eeeee1  and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  bbbbb2 sulfatase eeeee2  and 17beta-hydroxysteroid-dehydrogenase type 1 activities
CPR:4	As discussed in this review, various progestogens including  bbbbb1 dydrogesterone eeeee1  and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  bbbbb2 17beta-hydroxysteroid-dehydrogenase type 1 eeeee2  activities
CPR:4	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative,  bbbbb1 medrogestone eeeee1 , promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking  bbbbb2 sulfatase eeeee2  and 17beta-hydroxysteroid-dehydrogenase type 1 activities
CPR:4	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative,  bbbbb1 medrogestone eeeee1 , promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  bbbbb2 17beta-hydroxysteroid-dehydrogenase type 1 eeeee2  activities
CPR:9	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of  bbbbb1 estradiol eeeee1  in breast cancer by blocking  bbbbb2 sulfatase eeeee2  and 17beta-hydroxysteroid-dehydrogenase type 1 activities
CPR:9	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of  bbbbb1 estradiol eeeee1  in breast cancer by blocking sulfatase and  bbbbb2 17beta-hydroxysteroid-dehydrogenase type 1 eeeee2  activities
CPR:2	OBJECTIVE:  bbbbb1 Mitiglinide eeeee1 , a rapid- and short-acting insulinotropic  bbbbb2 sulfonylurea receptor eeeee2  ligand, exhibits hypoglycemic action unlike other sulfonylureas
CPR:2	OBJECTIVE: Mitiglinide, a rapid- and short-acting insulinotropic  bbbbb1 sulfonylurea receptor eeeee1  ligand, exhibits hypoglycemic action unlike other  bbbbb2 sulfonylureas eeeee2 
CPR:4	 bbbbb1 Mitiglinide eeeee1  reduced fasting plasma glucose and  bbbbb2 GA eeeee2  levels after 4 weeks and Hb(A1c) levels after 8 weeks
CPR:4	 bbbbb1 Mitiglinide eeeee1  reduced fasting plasma glucose and GA levels after 4 weeks and  bbbbb2 Hb(A1c) eeeee2  levels after 8 weeks
CPR:1	Cyan fluorescent protein was fused to the  bbbbb1 C eeeee1  terminus of the  bbbbb2 M(2) muscarinic receptor eeeee2 , and a specific binding sequence for the small fluorescent compound fluorescein arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH
CPR:2	Cyan fluorescent protein was fused to the C terminus of the  bbbbb1 M(2) muscarinic receptor eeeee1 , and a specific binding sequence for the small fluorescent compound  bbbbb2 fluorescein eeeee2  arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH
CPR:7	Because these speeds are significantly faster than the responses to antagonists, these data indicate that  bbbbb1 gallamine eeeee1  and dimethyl-W84 are allosteric ligands and actively induce a conformation of the  bbbbb2 M(2) receptor eeeee2  with a reduced affinity for its agonists.
CPR:7	Because these speeds are significantly faster than the responses to antagonists, these data indicate that gallamine and  bbbbb1 dimethyl-W84 eeeee1  are allosteric ligands and actively induce a conformation of the  bbbbb2 M(2) receptor eeeee2  with a reduced affinity for its agonists.
CPR:2	Here, we report that the transcription factor  bbbbb1 peroxisome proliferator-activated receptor gamma eeeee1  (PPARgamma) is essential for coupling  bbbbb2 ibuprofen eeeee2  to RhoA inhibition and subsequent neurite growth promotion in neurons
CPR:2	Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma ( bbbbb1 PPARgamma eeeee1 ) is essential for coupling  bbbbb2 ibuprofen eeeee2  to RhoA inhibition and subsequent neurite growth promotion in neurons
CPR:2	Moreover, the effect of  bbbbb1 ibuprofen eeeee1  on  bbbbb2 RhoA eeeee2  activity and neurite growth in neuronal cultures is prevented by selective PPARgamma inhibition
CPR:2	Moreover, the effect of  bbbbb1 ibuprofen eeeee1  on RhoA activity and neurite growth in neuronal cultures is prevented by selective  bbbbb2 PPARgamma eeeee2  inhibition
CPR:2	These findings support that  bbbbb1 PPARgamma eeeee1  plays an essential role in mediating the RhoA-inhibiting effect of  bbbbb2 ibuprofen eeeee2 
CPR:3	 bbbbb1 Ibuprofen eeeee1  activates  bbbbb2 PPARgamma eeeee2  in neuron-like PC12 and B104 cells
CPR:3	In addition, another study suggests that  bbbbb1 ibuprofen eeeee1  reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate  bbbbb2 amyloid-beta42 eeeee2  formation by direct inhibition of the gamma-secretase complex
CPR:4	Recently, we have demonstrated that  bbbbb1 ibuprofen eeeee1  inhibits intracellular signaling of  bbbbb2 RhoA eeeee2  and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents
CPR:4	In addition, another study suggests that  bbbbb1 ibuprofen eeeee1  reduces generation of  bbbbb2 amyloid-beta42 eeeee2  peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex
CPR:4	In addition, another study suggests that  bbbbb1 ibuprofen eeeee1  reduces generation of amyloid-beta42 peptide via inactivation of  bbbbb2 RhoA eeeee2  signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex
CPR:4	The molecular mechanisms by which  bbbbb1 ibuprofen eeeee1  inhibits the  bbbbb2 RhoA eeeee2  signal in neurons, however, remain unclear
CPR:4	Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling  bbbbb1 ibuprofen eeeee1  to  bbbbb2 RhoA eeeee2  inhibition and subsequent neurite growth promotion in neurons
CPR:4	A molecular mechanism for  bbbbb1 ibuprofen eeeee1 -mediated  bbbbb2 RhoA eeeee2  inhibition in neurons
CPR:4	 bbbbb1 Ibuprofen eeeee1  is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of  bbbbb2 cyclooxygenases eeeee2 
CPR:4	Activation of PPARgamma with traditional agonists mimics the  bbbbb1 RhoA eeeee1 -inhibiting properties of  bbbbb2 ibuprofen eeeee2  in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors
CPR:4	These findings support that PPARgamma plays an essential role in mediating the  bbbbb1 RhoA eeeee1 -inhibiting effect of  bbbbb2 ibuprofen eeeee2 
CPR:4	Elucidation of the novel molecular mechanisms linking  bbbbb1 ibuprofen eeeee1  to  bbbbb2 RhoA eeeee2  inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.
CPR:4	In addition, another study suggests that  bbbbb1 ibuprofen eeeee1  reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the  bbbbb2 gamma-secretase complex eeeee2 
CPR:4	Of these, the  bbbbb1 thrombin eeeee1  inhibitor  bbbbb2 dabigatran eeeee2  and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe
CPR:4	Of these, the thrombin inhibitor dabigatran and  bbbbb1 factor Xa eeeee1  inhibitor  bbbbb2 rivaroxaban eeeee2  have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe
CPR:4	In addition, the  bbbbb1 factor Xa eeeee1  inhibitor  bbbbb2 apixaban eeeee2  is in late-stage clinical development
CPR:2	We determined whether an angiotensin-converting enzyme (ACE) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the  bbbbb1 MMP-2 eeeee1 - bbbbb2 captopril eeeee2  complex
CPR:2	Molecular models of the  bbbbb1 MMP-2 eeeee1 - bbbbb2 captopril eeeee2  complex were simulated by 1000 iterations of random docking and energy minimization
CPR:2	RESULTS: Captopril directly inhibited MMP-2 activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that  bbbbb1 captopril eeeee1  binding to the  bbbbb2 MMP-2 eeeee2  active site could be formed in each complex model without molecular distortion
CPR:4	We determined whether an  bbbbb1 angiotensin-converting enzyme eeeee1  (ACE) inhibitor,  bbbbb2 captopril eeeee2 , inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex
CPR:4	We determined whether an angiotensin-converting enzyme ( bbbbb1 ACE eeeee1 ) inhibitor,  bbbbb2 captopril eeeee2 , inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex
CPR:4	METHODS: The inhibitory effect of  bbbbb1 captopril eeeee1  on  bbbbb2 MMP-2 eeeee2  activity was measured in peritoneal effluents from 17 patients on CAPD
CPR:4	RESULTS:  bbbbb1 Captopril eeeee1  directly inhibited  bbbbb2 MMP-2 eeeee2  activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion
CPR:4	CONCLUSION: ACE inhibitors, such as  bbbbb1 captopril eeeee1 , may be applied as important compounds for  bbbbb2 MMP-2 eeeee2  inhibition in inflammation caused by CAPD.
CPR:4	CONCLUSION:  bbbbb1 ACE eeeee1  inhibitors, such as  bbbbb2 captopril eeeee2 , may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD.
CPR:4	 bbbbb1 Captopril eeeee1  directly inhibits  bbbbb2 matrix metalloproteinase-2 eeeee2  activity in continuous ambulatory peritoneal dialysis therapy
CPR:10	Phenformin but not  bbbbb1 metformin eeeee1  inhibits a number of variants of  bbbbb2 K(ATP) eeeee2  including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:10	Phenformin but not  bbbbb1 metformin eeeee1  inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle ( bbbbb2 Kir6.1 eeeee2 /SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:10	Phenformin but not  bbbbb1 metformin eeeee1  inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/ bbbbb2 SUR2B eeeee2  and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:10	Phenformin but not  bbbbb1 metformin eeeee1  inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and  bbbbb2 Kir6.2 eeeee2 /SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:10	Phenformin but not  bbbbb1 metformin eeeee1  inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/ bbbbb2 SUR2B eeeee2 ) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:10	Phenformin but not  bbbbb1 metformin eeeee1  inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells ( bbbbb2 Kir6.2 eeeee2 /SUR1)
CPR:10	Phenformin but not  bbbbb1 metformin eeeee1  inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/ bbbbb2 SUR1 eeeee2 )
CPR:2	These findings suggest that  bbbbb1 phenformin eeeee1  interacts directly with the pore-forming  bbbbb2 Kir6.0 eeeee2  subunit however the sulphonylurea receptor is able to significantly modulate the affinity
CPR:2	Additionally,  bbbbb1 phenformin eeeee1  inhibited the current elicited through the Kir6.2DeltaC26 (functional without  bbbbb2 SUR eeeee2 ) channel with an IC50 of 1.78 mM
CPR:2	These findings suggest that  bbbbb1 phenformin eeeee1  interacts directly with the pore-forming Kir6.0 subunit however the  bbbbb2 sulphonylurea receptor eeeee2  is able to significantly modulate the affinity
CPR:4	 bbbbb1 Phenformin eeeee1  reduced the open probability of  bbbbb2 Kir6.1 eeeee2 /SUR2B channels by approximately 90% in inside-out patches
CPR:4	 bbbbb1 Phenformin eeeee1  reduced the open probability of Kir6.1/ bbbbb2 SUR2B eeeee2  channels by approximately 90% in inside-out patches
CPR:4	 bbbbb1 Phenformin eeeee1  but not metformin inhibits a number of variants of  bbbbb2 K(ATP) eeeee2  including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:4	 bbbbb1 Phenformin eeeee1  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle ( bbbbb2 Kir6.1 eeeee2 /SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:4	 bbbbb1 Phenformin eeeee1  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/ bbbbb2 SUR2B eeeee2  and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:4	 bbbbb1 Phenformin eeeee1  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and  bbbbb2 Kir6.2 eeeee2 /SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:4	 bbbbb1 Phenformin eeeee1  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/ bbbbb2 SUR2B eeeee2 ) and pancreatic beta-cells (Kir6.2/SUR1)
CPR:4	 bbbbb1 Phenformin eeeee1  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells ( bbbbb2 Kir6.2 eeeee2 /SUR1)
CPR:4	 bbbbb1 Phenformin eeeee1  but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/ bbbbb2 SUR1 eeeee2 )
CPR:4	 bbbbb1 Phenformin eeeee1  has a direct inhibitory effect on the  bbbbb2 ATP-sensitive potassium channel eeeee2 
CPR:4	The extent and rate of inhibition are similar to that seen with the known  bbbbb1 K(ATP) eeeee1  blocker  bbbbb2 PNU 37883A eeeee2 
CPR:4	Additionally,  bbbbb1 phenformin eeeee1  inhibited the current elicited through the  bbbbb2 Kir6.2DeltaC26 eeeee2  (functional without SUR) channel with an IC50 of 1.78 mM
CPR:2	In pig parathyroid cells,  bbbbb1 paricalcitol eeeee1  and the active form of doxercalciferol induced  bbbbb2 VDR eeeee2  translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively
CPR:2	In pig parathyroid cells, paricalcitol and the active form of  bbbbb1 doxercalciferol eeeee1  induced  bbbbb2 VDR eeeee2  translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively
CPR:2	Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum  bbbbb1 Ca eeeee1  regulates PTH secretion mediated by the  bbbbb2 Ca-sensing receptor eeeee2  (CaSR)
CPR:2	Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum  bbbbb1 Ca eeeee1  regulates PTH secretion mediated by the Ca-sensing receptor ( bbbbb2 CaSR eeeee2 )
CPR:3	In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although  bbbbb1 paricalcitol eeeee1  induced the expression of  bbbbb2 CaSR eeeee2  mRNA more effectively
CPR:3	Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum  bbbbb1 Ca eeeee1  regulates  bbbbb2 PTH eeeee2  secretion mediated by the Ca-sensing receptor (CaSR)
CPR:4	Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum  bbbbb1 PTH eeeee1  effectively in the 5/6 NX rats, but  bbbbb2 paricalcitol eeeee2  was less potent in raising serum Ca than doxercalciferol
CPR:4	Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum  bbbbb1 PTH eeeee1  effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than  bbbbb2 doxercalciferol eeeee2 
CPR:4	Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed  bbbbb1 PTH eeeee1  mRNA expression and serum PTH effectively in the 5/6 NX rats, but  bbbbb2 paricalcitol eeeee2  was less potent in raising serum Ca than doxercalciferol
CPR:4	Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed  bbbbb1 PTH eeeee1  mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than  bbbbb2 doxercalciferol eeeee2 
CPR:4	In pig parathyroid cells,  bbbbb1 paricalcitol eeeee1  and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed  bbbbb2 PTH eeeee2  mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively
CPR:4	In pig parathyroid cells, paricalcitol and the active form of  bbbbb1 doxercalciferol eeeee1  induced VDR translocation from the cytoplasm into the nucleus, suppressed  bbbbb2 PTH eeeee2  mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively
CPR:2	 bbbbb1 Thalidomide eeeee1  initiates its teratogenic effects by binding to  bbbbb2 CRBN eeeee2  and inhibiting the associated ubiquitin ligase activity
CPR:4	 bbbbb1 Thalidomide eeeee1  initiates its teratogenic effects by binding to CRBN and inhibiting the associated  bbbbb2 ubiquitin ligase eeeee2  activity
CPR:4	 bbbbb1 Telmisartan eeeee1  is an  bbbbb2 angiotensin II receptor eeeee2  blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure
CPR:2	With the pentapeptide linked through the C7alpha position of  bbbbb1 estradiol eeeee1 , the resulting PROTAC shows the most effective ER degradation and highest affinity for the  bbbbb2 estrogen receptor eeeee2 
CPR:2	The  bbbbb1 ER eeeee1 -targeting PROTACs are composed of an  bbbbb2 estradiol eeeee2  on one end and a hypoxia-inducing factor 1alpha (HIF-1alpha)-derived synthetic pentapeptide on the other
CPR:4	With the pentapeptide linked through the C7alpha position of  bbbbb1 estradiol eeeee1 , the resulting PROTAC shows the most effective  bbbbb2 ER eeeee2  degradation and highest affinity for the estrogen receptor
CPR:5	Recent studies indicate that  bbbbb1 tamoxifen eeeee1  initially acts as an antagonist, but later functions as an  bbbbb2 ER eeeee2  agonist, promoting tumor growth
CPR:6	Recent studies indicate that  bbbbb1 tamoxifen eeeee1  initially acts as an antagonist, but later functions as an  bbbbb2 ER eeeee2  agonist, promoting tumor growth
CPR:2	Other ligands (e.g. denopamine for beta(1); clenbuterol, AZ 40140d,  bbbbb1 salbutamol eeeee1  for  bbbbb2 beta(2) eeeee2 ) were found to have subtype-selective intrinsic efficacy
CPR:2	Other ligands (e.g.  bbbbb1 denopamine eeeee1  for  bbbbb2 beta(1) eeeee2 ; clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy
CPR:2	Other ligands (e.g. denopamine for beta(1);  bbbbb1 clenbuterol eeeee1 , AZ 40140d, salbutamol for  bbbbb2 beta(2) eeeee2 ) were found to have subtype-selective intrinsic efficacy
CPR:2	Other ligands (e.g. denopamine for beta(1); clenbuterol,  bbbbb1 AZ 40140d eeeee1 , salbutamol for  bbbbb2 beta(2) eeeee2 ) were found to have subtype-selective intrinsic efficacy
CPR:5	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g.  bbbbb1 salmeterol eeeee1  and formoterol, for the  bbbbb2 beta(2)-adrenoceptor eeeee2  over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity
CPR:5	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g.  bbbbb1 salmeterol eeeee1  and formoterol, for the beta(2)-adrenoceptor over the  bbbbb2 beta(1) eeeee2  or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity
CPR:5	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and  bbbbb1 formoterol eeeee1 , for the  bbbbb2 beta(2)-adrenoceptor eeeee2  over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity
CPR:5	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and  bbbbb1 formoterol eeeee1 , for the beta(2)-adrenoceptor over the beta(1) or  bbbbb2 beta(3) eeeee2 ), while others (e.g. isoprenaline) had little affinity-selectivity
CPR:5	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the  bbbbb1 beta(2)-adrenoceptor eeeee1  over the beta(1) or beta(3)), while others (e.g.  bbbbb2 isoprenaline eeeee2 ) had little affinity-selectivity
CPR:5	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the  bbbbb1 beta(1) eeeee1  or beta(3)), while others (e.g.  bbbbb2 isoprenaline eeeee2 ) had little affinity-selectivity
CPR:5	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or  bbbbb1 beta(3) eeeee1 ), while others (e.g.  bbbbb2 isoprenaline eeeee2 ) had little affinity-selectivity
CPR:3	However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the  bbbbb1 N-propargyl eeeee1  moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating  bbbbb2 Bcl-2 eeeee2  family proteins
CPR:4	 bbbbb1 Rasagiline eeeee1 : a novel anti-Parkinsonian  bbbbb2 monoamine oxidase-B eeeee2  inhibitor with neuroprotective activity
CPR:4	 bbbbb1 Rasagiline eeeee1  (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible  bbbbb2 monoamine oxidase (MAO)-B eeeee2  inhibitor, anti-Parkinsonian drug
CPR:4	Rasagiline ( bbbbb1 N-propargyl-1-(R)-aminoindan eeeee1 ) is a novel, highly potent irreversible  bbbbb2 monoamine oxidase (MAO)-B eeeee2  inhibitor, anti-Parkinsonian drug
CPR:4	Its S-isomer,  bbbbb1 TVP1022 eeeee1  is thousand times less potent as an  bbbbb2 MAO-B eeeee2  inhibitor
CPR:4	However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of  bbbbb1 rasagiline eeeee1  does not depend on inhibition of  bbbbb2 MAO-B eeeee2 , but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins
CPR:10	Supplementation with  bbbbb1 levothyroxine eeeee1  at a dose of >350 microg/day did not normalize the serum  bbbbb2 TSH eeeee2  level; however, the patient showed normal growth and intelligence at 14 years of age
CPR:2	Consistent with the results of a computer analysis, the binding of  bbbbb1 R316C eeeee1  to triiodothyronine ( bbbbb2 T3 eeeee2 ) was significantly decreased to 38% that of the wild type
CPR:2	Consistent with the results of a computer analysis, the binding of  bbbbb1 R316C eeeee1  to  bbbbb2 triiodothyronine eeeee2  (T3) was significantly decreased to 38% that of the wild type
CPR:2	However, a glutathione-S-transferase pull-down assay showed reduced binding of  bbbbb1 R316C eeeee1  with NCoR in the absence of T3 and impaired release in the presence of  bbbbb2 T3 eeeee2 
CPR:2	However, a glutathione-S-transferase pull-down assay showed reduced binding of R316C with  bbbbb1 NCoR eeeee1  in the absence of T3 and impaired release in the presence of  bbbbb2 T3 eeeee2 
CPR:3	Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum  bbbbb1 TSH eeeee1  level with high dose of  bbbbb2 levothyroxine eeeee2  might be optimum for normal growth.
CPR:4	With exposure to  bbbbb1 rofecoxib eeeee1 , a selective  bbbbb2 COX-2 eeeee2  inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.
CPR:4	With exposure to  bbbbb1 rofecoxib eeeee1 , a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective  bbbbb2 COX-2 eeeee2  inhibitors in breast cancer prophylaxis.
CPR:4	METHODS: We conducted a case-control study to measure the association between selective  bbbbb1 cox-2 eeeee1  inhibitors, particularly  bbbbb2 celecoxib eeeee2 , rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk
CPR:4	METHODS: We conducted a case-control study to measure the association between selective  bbbbb1 cox-2 eeeee1  inhibitors, particularly celecoxib,  bbbbb2 rofecoxib eeeee2 , valdecoxib and non-specific NSAID subgroups, and breast cancer risk
CPR:4	METHODS: We conducted a case-control study to measure the association between selective  bbbbb1 cox-2 eeeee1  inhibitors, particularly celecoxib, rofecoxib,  bbbbb2 valdecoxib eeeee2  and non-specific NSAID subgroups, and breast cancer risk
CPR:4	BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2)
CPR:4	BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non- bbbbb1 steroidal eeeee1  anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 )
CPR:10	Pretreatment with  bbbbb1 ceruletide eeeee1  (40 micrograms/100 g b. wt., IP) 3 days or 7 days prior to the injection of SMS 201-995 significantly inhibited the response rate of barrel rotation induced by SMS 201-995, but not that induced by  bbbbb2 arginine-vasopressin eeeee2  (1 microgram/rat, ICV)
CPR:2	These findings suggest that ceruletide specifically suppresses the barrel rotation evoked by  bbbbb1 SMS 201-995 eeeee1  in a long-lasting manner possibly acting through  bbbbb2 CCK-A receptor eeeee2 .
CPR:2	Intracerebroventricular administration of  bbbbb1 SMS 201-995 eeeee1  (5 micrograms/rat), a  bbbbb2 somatostatin eeeee2  analogue, induced barrel rotation in rats
CPR:4	The suppressive effect of  bbbbb1 ceruletide eeeee1  on barrel rotation could be partially countered by MK-329, a selective peripheral  bbbbb2 CCK eeeee2  (CCK-A) receptor antagonist
CPR:4	The suppressive effect of  bbbbb1 ceruletide eeeee1  on barrel rotation could be partially countered by MK-329, a selective peripheral CCK  bbbbb2 (CCK-A) receptor eeeee2  antagonist
CPR:4	These findings suggest that  bbbbb1 ceruletide eeeee1  specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through  bbbbb2 CCK-A receptor eeeee2 .
CPR:6	The suppressive effect of ceruletide on barrel rotation could be partially countered by  bbbbb1 MK-329 eeeee1 , a selective peripheral  bbbbb2 CCK eeeee2  (CCK-A) receptor antagonist
CPR:6	The suppressive effect of ceruletide on barrel rotation could be partially countered by  bbbbb1 MK-329 eeeee1 , a selective peripheral CCK  bbbbb2 (CCK-A) receptor eeeee2  antagonist
CPR:2	The altered genes associated with  bbbbb1 chlorcyclizine eeeee1 -induced cleft palate included Wnt5a,  bbbbb2 Bmp2 eeeee2 , Bmp4, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold)
CPR:2	The altered genes associated with  bbbbb1 chlorcyclizine eeeee1 -induced cleft palate included Wnt5a, Bmp2,  bbbbb2 Bmp4 eeeee2 , Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold)
CPR:2	The altered genes associated with  bbbbb1 chlorcyclizine eeeee1 -induced cleft palate included Wnt5a, Bmp2, Bmp4,  bbbbb2 Fgf10 eeeee2 , Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold)
CPR:2	The altered genes associated with  bbbbb1 chlorcyclizine eeeee1 -induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10,  bbbbb2 Fgfr2 eeeee2 , Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold)
CPR:2	The altered genes associated with  bbbbb1 chlorcyclizine eeeee1 -induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, Fgfr2,  bbbbb2 Msx1 eeeee2 , and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold)
CPR:2	The altered genes associated with  bbbbb1 chlorcyclizine eeeee1 -induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, Fgfr2, Msx1, and  bbbbb2 Insig1 eeeee2  but the magnitude of the change was relatively small (1.5- to 2-fold)
CPR:2	The altered genes associated with  bbbbb1 chlorcyclizine eeeee1 -induced cleft palate included  bbbbb2 Wnt5a eeeee2 , Bmp2, Bmp4, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold)
CPR:6	BACKGROUND: The effects of  bbbbb1 histamine H1 eeeee1  antagonist  bbbbb2 chlorcyclizine eeeee2  on rat palate development were characterized following in utero exposure
CPR:6	Effects of the  bbbbb1 histamine H1 eeeee1  antagonist  bbbbb2 chlorcyclizine eeeee2  on rat fetal palate development
CPR:1	Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane  bbbbb1 amino acids eeeee1  that were affinity labelled in purified  bbbbb2 bovine brain GABA(A)-R eeeee2 
CPR:1	PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate  bbbbb1 GABA(A)-R eeeee1 -mediated inhibitory transmission, site-directed mutagenesis comparing sequences of GABA(A)-R subunits of varying sensitivity led to identification of  bbbbb2 amino acid eeeee2  residues in the transmembrane domain that are critical for the drug actions in vitro
CPR:1	PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate GABA(A)-R-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of  bbbbb1 GABA(A)-R eeeee1  subunits of varying sensitivity led to identification of  bbbbb2 amino acid eeeee2  residues in the transmembrane domain that are critical for the drug actions in vitro
CPR:2	Using a photo incorporable analogue of the general anesthetic,  bbbbb1 R(+)etomidate eeeee1 , we identified two transmembrane amino acids that were affinity labelled in purified  bbbbb2 bovine brain GABA(A)-R eeeee2 
CPR:2	The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the  bbbbb1 Ca2(+) eeeee1 - bbbbb2 calmodulin eeeee2  interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01)
CPR:2	The smooth muscle relaxant,  bbbbb1 W-7 eeeee1 , which is believed relatively specific in inhibiting the Ca2(+)- bbbbb2 calmodulin eeeee2  interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01)
CPR:2	Role of extracellular  bbbbb1 calcium eeeee1  and calmodulin in  bbbbb2 prolactin eeeee2  secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells
CPR:4	The smooth muscle relaxant,  bbbbb1 W-7 eeeee1 , which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced  bbbbb2 PRL eeeee2  secretion in a dose-dependent manner (r = -0.991, p less than 0.01)
CPR:4	Removing medium Ca2+, blocking  bbbbb1 Ca2+ channels eeeee1  with 50 mumol/l  bbbbb2 verapamil eeeee2 , or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CPR:4	Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting  bbbbb1 calmodulin eeeee1  activation with 20 mumol/l  bbbbb2 trifluoperazine eeeee2 , 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CPR:4	Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting  bbbbb1 calmodulin eeeee1  activation with 20 mumol/l trifluoperazine, 10 mumol/l  bbbbb2 chlorpromazine eeeee2  or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CPR:4	Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting  bbbbb1 calmodulin eeeee1  activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l  bbbbb2 pimozide eeeee2  almost completely blocked hyposmolarity-induced secretion
CPR:9	An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement  bbbbb1 spermine eeeee1  and this can be accomplished by breeding with CAG- bbbbb2 SMS eeeee2  mice that express SpmS from a ubiquitous promoter
CPR:9	An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement  bbbbb1 spermine eeeee1  and this can be accomplished by breeding with CAG-SMS mice that express  bbbbb2 SpmS eeeee2  from a ubiquitous promoter
CPR:10	Importantly, treatment with  bbbbb1 cabozantinib eeeee1  did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of VEGF signaling that do not target  bbbbb2 MET eeeee2 
CPR:4	Importantly, treatment with  bbbbb1 cabozantinib eeeee1  did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of  bbbbb2 VEGF eeeee2  signaling that do not target MET
CPR:4	Collectively, these data suggest that  bbbbb1 cabozantinib eeeee1  is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated  bbbbb2 MET eeeee2  and VEGFR signaling.
CPR:4	Collectively, these data suggest that  bbbbb1 cabozantinib eeeee1  is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and  bbbbb2 VEGFR eeeee2  signaling.
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184) is a small-molecule  bbbbb2 kinase eeeee2  inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184) is a small-molecule kinase inhibitor with potent activity toward  bbbbb2 MET eeeee2  and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and  bbbbb2 VEGF receptor 2 eeeee2  (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 ( bbbbb2 VEGFR2 eeeee2 ), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other  bbbbb2 receptor tyrosine kinases eeeee2  that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including  bbbbb2 RET eeeee2 , KIT, AXL, and FLT3
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET,  bbbbb2 KIT eeeee2 , AXL, and FLT3
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT,  bbbbb2 AXL eeeee2 , and FLT3
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and  bbbbb2 FLT3 eeeee2 
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ) is a small-molecule  bbbbb2 kinase eeeee2  inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ) is a small-molecule kinase inhibitor with potent activity toward  bbbbb2 MET eeeee2  and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ) is a small-molecule kinase inhibitor with potent activity toward MET and  bbbbb2 VEGF receptor 2 eeeee2  (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 ( bbbbb2 VEGFR2 eeeee2 ), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other  bbbbb2 receptor tyrosine kinases eeeee2  that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including  bbbbb2 RET eeeee2 , KIT, AXL, and FLT3
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET,  bbbbb2 KIT eeeee2 , AXL, and FLT3
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT,  bbbbb2 AXL eeeee2 , and FLT3
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and  bbbbb2 FLT3 eeeee2 
CPR:4	Treatment with  bbbbb1 cabozantinib eeeee1  inhibited  bbbbb2 MET eeeee2  and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro
CPR:4	Treatment with  bbbbb1 cabozantinib eeeee1  inhibited MET and  bbbbb2 VEGFR2 eeeee2  phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184), a novel  bbbbb2 MET eeeee2  and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
CPR:4	 bbbbb1 Cabozantinib eeeee1  (XL184), a novel MET and  bbbbb2 VEGFR2 eeeee2  inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ), a novel  bbbbb2 MET eeeee2  and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
CPR:4	Cabozantinib ( bbbbb1 XL184 eeeee1 ), a novel MET and  bbbbb2 VEGFR2 eeeee2  inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
CPR:2	KEY RESULTS:  bbbbb1 Thiocolchicoside eeeee1  suppressed osteoclastogenesis induced by  bbbbb2 RANKL eeeee2 , and by breast cancer and multiple myeloma cells
CPR:2	 bbbbb1 Thiocolchicoside eeeee1  suppresses osteoclastogenesis induced by  bbbbb2 RANKL eeeee2  and cancer cells through inhibition of inflammatory pathways: a new use for an old drug
CPR:4	Inhibition of the NF-kappaB pathway was responsible for this effect since the  bbbbb1 colchicoside eeeee1  inhibited RANKL-induced  bbbbb2 NF-kappaB eeeee2  activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB
CPR:4	Inhibition of the NF-kappaB pathway was responsible for this effect since the  bbbbb1 colchicoside eeeee1  inhibited RANKL-induced NF-kappaB activation, activation of  bbbbb2 IkappaB kinase eeeee2  (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB
CPR:4	Inhibition of the NF-kappaB pathway was responsible for this effect since the  bbbbb1 colchicoside eeeee1  inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase ( bbbbb2 IKK eeeee2 ) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB
CPR:4	Inhibition of the NF-kappaB pathway was responsible for this effect since the  bbbbb1 colchicoside eeeee1  inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of  bbbbb2 NF-kappaBalpha eeeee2  (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB
CPR:4	Inhibition of the NF-kappaB pathway was responsible for this effect since the  bbbbb1 colchicoside eeeee1  inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha ( bbbbb2 IkappaBalpha eeeee2 ) phosphorylation and degradation, an inhibitor of NF-kappaB
CPR:4	Inhibition of the NF-kappaB pathway was responsible for this effect since the  bbbbb1 colchicoside eeeee1  inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of  bbbbb2 NF-kappaB eeeee2 
CPR:4	Inhibition of the NF-kappaB pathway was responsible for this effect since the  bbbbb1 colchicoside eeeee1  inhibited  bbbbb2 RANKL eeeee2 -induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB
CPR:4	CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that  bbbbb1 thiocolchicoside eeeee1  significantly suppressed osteoclastogenesis induced by  bbbbb2 RANKL eeeee2  and tumour cells via the NF-kappaB signalling pathway
CPR:4	CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that  bbbbb1 thiocolchicoside eeeee1  significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the  bbbbb2 NF-kappaB eeeee2  signalling pathway
CPR:2	Our findings show evidence that  bbbbb1 eNOS eeeee1  polymorphisms affect the responses of PED and clinical ED patients to  bbbbb2 sildenafil eeeee2 .
CPR:2	Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how  bbbbb1 eNOS eeeee1  polymorphisms and haplotypes affect the responses to  bbbbb2 sildenafil eeeee2 
CPR:2	 bbbbb1 Endothelial nitric oxide synthase eeeee1  genotypes and haplotypes modify the responses to  bbbbb2 sildenafil eeeee2  in patients with erectile dysfunction
CPR:9	Although genetic polymorphisms in the endothelial nitric oxide synthase ( bbbbb1 eNOS eeeee1 ) gene may impair endogenous  bbbbb2 NO eeeee2  formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil
CPR:9	Although genetic polymorphisms in the  bbbbb1 endothelial nitric oxide synthase eeeee1  (eNOS) gene may impair endogenous  bbbbb2 NO eeeee2  formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil
CPR:3	Here, we report biochemical evidence that  bbbbb1 mercury eeeee1  alone induces  bbbbb2 NF-κB eeeee2  activation, resulting in the induced expression of COX-2 and iNOS
CPR:3	Here, we report biochemical evidence that  bbbbb1 mercury eeeee1  alone induces NF-κB activation, resulting in the induced expression of  bbbbb2 COX-2 eeeee2  and iNOS
CPR:3	Here, we report biochemical evidence that  bbbbb1 mercury eeeee1  alone induces NF-κB activation, resulting in the induced expression of COX-2 and  bbbbb2 iNOS eeeee2 
CPR:3	 bbbbb1 Mercury eeeee1  induces the expression of  bbbbb2 cyclooxygenase-2 eeeee2  and inducible nitric oxide synthase
CPR:3	 bbbbb1 Mercury eeeee1  induces the expression of cyclooxygenase-2 and  bbbbb2 inducible nitric oxide synthase eeeee2 
CPR:5	Unexpectedly, both the  bbbbb1 mGluR(5) eeeee1 specific agonist,  bbbbb2 CHPG eeeee2 , and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization
CPR:5	Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the  bbbbb1 group II mGluR eeeee1  (mGlu(2/3)) agonist,  bbbbb2 LY379268 eeeee2  (LY), induced a TTX-insensitive outward current/hyperpolarization
CPR:6	Both outward currents were significantly reduced by the  bbbbb1 mGluR eeeee1  antagonist  bbbbb2 MCPG eeeee2  and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP
CPR:6	Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific  bbbbb1 mGluR(5) eeeee1  antagonist  bbbbb2 MTEP eeeee2 
CPR:4	We have examined the effectiveness of two novel  bbbbb1 Chk1 eeeee1  selective inhibitors,  bbbbb2 AR323 eeeee2  and AR678, in a panel of melanoma cell lines and normal cell types
CPR:4	We have examined the effectiveness of two novel  bbbbb1 Chk1 eeeee1  selective inhibitors, AR323 and  bbbbb2 AR678 eeeee2 , in a panel of melanoma cell lines and normal cell types
CPR:10	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and  bbbbb1 AMPK eeeee1 -independent mechanisms of  bbbbb2 aspirin eeeee2 -induced inhibition of mTOR
CPR:2	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating  bbbbb1 AMPK eeeee1 -dependent and AMPK-independent mechanisms of  bbbbb2 aspirin eeeee2 -induced inhibition of mTOR
CPR:3	Aspirin and  bbbbb1 metformin eeeee1  (an activator of  bbbbb2 AMPK eeeee2 ) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells
CPR:3	CONCLUSIONS:  bbbbb1 Aspirin eeeee1  is an inhibitor of mTOR and an activator of  bbbbb2 AMPK eeeee2 , targeting regulators of intracellular energy homeostasis and metabolism
CPR:3	 bbbbb1 Aspirin eeeee1  inhibits mTOR signaling, activates  bbbbb2 AMP-activated protein kinase eeeee2 , and induces autophagy in colorectal cancer cells
CPR:3	 bbbbb1 Aspirin eeeee1  changed nucleotide ratios and activated  bbbbb2 AMPK eeeee2  in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CPR:3	 bbbbb1 Aspirin eeeee1  and metformin (an activator of  bbbbb2 AMPK eeeee2 ) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells
CPR:4	RESULTS:  bbbbb1 Aspirin eeeee1  reduced  bbbbb2 mTOR eeeee2  signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1
CPR:4	 bbbbb1 Aspirin eeeee1  inhibits  bbbbb2 mTOR eeeee2  signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells
CPR:4	Aspirin and  bbbbb1 metformin eeeee1  (an activator of AMPK) increased inhibition of  bbbbb2 mTOR eeeee2  and Akt, as well as autophagy in CRC cells
CPR:4	Aspirin and  bbbbb1 metformin eeeee1  (an activator of AMPK) increased inhibition of mTOR and  bbbbb2 Akt eeeee2 , as well as autophagy in CRC cells
CPR:4	Rectal mucosal samples from patients given  bbbbb1 aspirin eeeee1  had reduced phosphorylation of  bbbbb2 S6K1 eeeee2  and S6
CPR:4	Rectal mucosal samples from patients given  bbbbb1 aspirin eeeee1  had reduced phosphorylation of S6K1 and  bbbbb2 S6 eeeee2 
CPR:4	CONCLUSIONS:  bbbbb1 Aspirin eeeee1  is an inhibitor of  bbbbb2 mTOR eeeee2  and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism
CPR:4	RESULTS:  bbbbb1 Aspirin eeeee1  reduced mTOR signaling in CRC cells by inhibiting the  bbbbb2 mTOR eeeee2  effectors S6K1 and 4E-BP1
CPR:4	RESULTS:  bbbbb1 Aspirin eeeee1  reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors  bbbbb2 S6K1 eeeee2  and 4E-BP1
CPR:4	RESULTS:  bbbbb1 Aspirin eeeee1  reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and  bbbbb2 4E-BP1 eeeee2 
CPR:4	Aspirin changed nucleotide ratios and activated AMPK in CRC cells.  bbbbb1 mTOR eeeee1  was still inhibited by  bbbbb2 aspirin eeeee2  in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CPR:4	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of  bbbbb1 aspirin eeeee1 -induced inhibition of  bbbbb2 mTOR eeeee2 
CPR:4	 bbbbb1 Aspirin eeeee1  induced autophagy, a feature of  bbbbb2 mTOR eeeee2  inhibition
CPR:4	 bbbbb1 Aspirin eeeee1  and metformin (an activator of AMPK) increased inhibition of  bbbbb2 mTOR eeeee2  and Akt, as well as autophagy in CRC cells
CPR:4	 bbbbb1 Aspirin eeeee1  and metformin (an activator of AMPK) increased inhibition of mTOR and  bbbbb2 Akt eeeee2 , as well as autophagy in CRC cells
CPR:2	Oncogenic  bbbbb1 K-ras eeeee1  expression is associated with derangement of the cAMP/PKA pathway and  bbbbb2 forskolin eeeee2 -reversible alterations of mitochondrial dynamics and respiration
CPR:2	These findings support the notion that  bbbbb1 glucose eeeee1  shortage-induced apoptosis, specific of  bbbbb2 K-ras eeeee2 -transformed cells, is associated to a derangement of PKA signaling that leads to mitochondrial complex I decrease, reduction of ATP formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.
CPR:2	Exogenous stimulation of PKA activity, achieved by  bbbbb1 forskolin eeeee1  treatment, protected  bbbbb2 K-ras eeeee2 -transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CPR:2	Oncogenic K-ras expression is associated with derangement of the cAMP/ bbbbb1 PKA eeeee1  pathway and  bbbbb2 forskolin eeeee2 -reversible alterations of mitochondrial dynamics and respiration
CPR:3	Exogenous stimulation of  bbbbb1 PKA eeeee1  activity, achieved by  bbbbb2 forskolin eeeee2  treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CPR:3	Exogenous stimulation of PKA activity, achieved by  bbbbb1 forskolin eeeee1  treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced  bbbbb2 complex I eeeee2  activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CPR:4	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected  bbbbb1 K-ras eeeee1 -transformed cells from apoptosis induced by  bbbbb2 glucose eeeee2  deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CPR:2	 bbbbb1 Berberine eeeee1  exerts suppressive effects on phenotype changes and ECM production in NPDFs via  bbbbb2 p38 eeeee2  signaling pathway interference
CPR:2	 bbbbb1 Berberine eeeee1  inhibits myofibroblast differentiation in nasal polyp-derived fibroblasts via the  bbbbb2 p38 eeeee2  pathway
CPR:4	 bbbbb1 SB203580 eeeee1  (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of  bbbbb2 collagen type I eeeee2  and α-SMA in TGF-β1-induced NPDFs
CPR:4	 bbbbb1 SB203580 eeeee1  (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and  bbbbb2 α-SMA eeeee2  in TGF-β1-induced NPDFs
CPR:4	 bbbbb1 SB203580 eeeee1  (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and α-SMA in  bbbbb2 TGF-β1 eeeee2 -induced NPDFs
CPR:4	In  bbbbb1 TGF-β1 eeeee1 -induced NPDFs,  bbbbb2 berberine eeeee2  significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced α-SMA and collagen protein levels
CPR:4	In TGF-β1-induced NPDFs,  bbbbb1 berberine eeeee1  significantly inhibited the expression of  bbbbb2 α-SMA eeeee2  and collagen type I mRNA and reduced α-SMA and collagen protein levels
CPR:4	In TGF-β1-induced NPDFs,  bbbbb1 berberine eeeee1  significantly inhibited the expression of α-SMA and  bbbbb2 collagen type I eeeee2  mRNA and reduced α-SMA and collagen protein levels
CPR:4	In TGF-β1-induced NPDFs,  bbbbb1 berberine eeeee1  significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced  bbbbb2 α-SMA eeeee2  and collagen protein levels
CPR:4	In TGF-β1-induced NPDFs,  bbbbb1 berberine eeeee1  significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced α-SMA and  bbbbb2 collagen eeeee2  protein levels
CPR:4	 bbbbb1 Berberine eeeee1  only suppressed the expression of  bbbbb2 pp38 eeeee2  among the evaluated signaling molecules
CPR:4	 bbbbb1 SB203580 eeeee1  (a specific inhibitor of  bbbbb2 p38 eeeee2  kinase) markedly suppressed the increased expression of collagen type I and α-SMA in TGF-β1-induced NPDFs
CPR:4	 bbbbb1 SB203580 eeeee1  (a specific inhibitor of p38  bbbbb2 kinase eeeee2 ) markedly suppressed the increased expression of collagen type I and α-SMA in TGF-β1-induced NPDFs
CPR:10	 bbbbb1 Lenalidomide eeeee1  and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective  bbbbb2 CRBN eeeee2 (YW/AA)
CPR:10	Lenalidomide and  bbbbb1 pomalidomide eeeee1  inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective  bbbbb2 CRBN eeeee2 (YW/AA)
CPR:2	Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug,  bbbbb1 pomalidomide eeeee1 , bound endogenous  bbbbb2 CRBN eeeee2  and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes
CPR:2	Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug,  bbbbb1 pomalidomide eeeee1 , bound endogenous CRBN and recombinant  bbbbb2 CRBN eeeee2 -DNA damage binding protein-1 (DDB1) complexes
CPR:2	Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug,  bbbbb1 pomalidomide eeeee1 , bound endogenous CRBN and recombinant CRBN- bbbbb2 DNA damage binding protein-1 eeeee2  (DDB1) complexes
CPR:2	Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug,  bbbbb1 pomalidomide eeeee1 , bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 ( bbbbb2 DDB1 eeeee2 ) complexes
CPR:2	Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing  bbbbb1 thalidomide eeeee1 -binding competent wild-type  bbbbb2 CRBN eeeee2 , but not thalidomide-binding defective CRBN(YW/AA)
CPR:2	Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not  bbbbb1 thalidomide eeeee1 -binding defective  bbbbb2 CRBN eeeee2 (YW/AA)
CPR:2	Our studies demonstrate that  bbbbb1 thalidomide eeeee1 , lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous  bbbbb2 CRBN eeeee2  and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes
CPR:2	Our studies demonstrate that  bbbbb1 thalidomide eeeee1 , lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant  bbbbb2 CRBN eeeee2 -DNA damage binding protein-1 (DDB1) complexes
CPR:2	Our studies demonstrate that  bbbbb1 thalidomide eeeee1 , lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN- bbbbb2 DNA damage binding protein-1 eeeee2  (DDB1) complexes
CPR:2	Our studies demonstrate that  bbbbb1 thalidomide eeeee1 , lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 ( bbbbb2 DDB1 eeeee2 ) complexes
CPR:2	Our studies demonstrate that thalidomide,  bbbbb1 lenalidomide eeeee1  and another immunomodulatory drug, pomalidomide, bound endogenous  bbbbb2 CRBN eeeee2  and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes
CPR:2	Our studies demonstrate that thalidomide,  bbbbb1 lenalidomide eeeee1  and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant  bbbbb2 CRBN eeeee2 -DNA damage binding protein-1 (DDB1) complexes
CPR:2	Our studies demonstrate that thalidomide,  bbbbb1 lenalidomide eeeee1  and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN- bbbbb2 DNA damage binding protein-1 eeeee2  (DDB1) complexes
CPR:2	Our studies demonstrate that thalidomide,  bbbbb1 lenalidomide eeeee1  and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 ( bbbbb2 DDB1 eeeee2 ) complexes
CPR:2	 bbbbb1 CRBN eeeee1  mediated antiproliferative activities of  bbbbb2 lenalidomide eeeee2  and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells
CPR:2	 bbbbb1 CRBN eeeee1  mediated antiproliferative activities of lenalidomide and  bbbbb2 pomalidomide eeeee2  in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells
CPR:2	 bbbbb1 Cereblon eeeee1  is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and  bbbbb2 pomalidomide eeeee2 
CPR:2	 bbbbb1 Cereblon eeeee1  is a direct protein target for immunomodulatory and antiproliferative activities of  bbbbb2 lenalidomide eeeee2  and pomalidomide
CPR:2	Our biophysical, biochemical and gene silencing studies show that  bbbbb1 CRBN eeeee1  is a proximate, therapeutically important molecular target of  bbbbb2 lenalidomide eeeee2  and pomalidomide.
CPR:2	Our biophysical, biochemical and gene silencing studies show that  bbbbb1 CRBN eeeee1  is a proximate, therapeutically important molecular target of lenalidomide and  bbbbb2 pomalidomide eeeee2 .
CPR:2	The ubiquitously expressed E3 ligase protein  bbbbb1 cereblon eeeee1  (CRBN) has been identified as the primary teratogenic target of  bbbbb2 thalidomide eeeee2 
CPR:2	The ubiquitously expressed E3 ligase protein cereblon ( bbbbb1 CRBN eeeee1 ) has been identified as the primary teratogenic target of  bbbbb2 thalidomide eeeee2 
CPR:3	CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as  bbbbb1 lenalidomide eeeee1 - and pomalidomide-induced  bbbbb2 cytokine eeeee2  production in T cells
CPR:3	CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and  bbbbb1 pomalidomide eeeee1 -induced  bbbbb2 cytokine eeeee2  production in T cells
CPR:3	Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  bbbbb1 pomalidomide eeeee1 -mediated reductions in c-myc and IRF4 expression and increases in p21( bbbbb2 WAF-1 eeeee2 ) expression
CPR:3	Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  bbbbb1 pomalidomide eeeee1 -mediated reductions in c-myc and IRF4 expression and increases in  bbbbb2 p21 eeeee2 (WAF-1) expression
CPR:4	Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  bbbbb1 pomalidomide eeeee1 -mediated reductions in  bbbbb2 c-myc eeeee2  and IRF4 expression and increases in p21(WAF-1) expression
CPR:4	Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  bbbbb1 pomalidomide eeeee1 -mediated reductions in c-myc and  bbbbb2 IRF4 eeeee2  expression and increases in p21(WAF-1) expression
CPR:4	Long-term selection for  bbbbb1 lenalidomide eeeee1  resistance in H929 myeloma cell lines was accompanied by a reduction in  bbbbb2 CRBN eeeee2 , while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable
CPR:4	 bbbbb1 Lenalidomide eeeee1  and pomalidomide inhibited autoubiquitination of  bbbbb2 CRBN eeeee2  in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA)
CPR:4	 bbbbb1 Lenalidomide eeeee1  and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type  bbbbb2 CRBN eeeee2 , but not thalidomide-binding defective CRBN(YW/AA)
CPR:4	Lenalidomide and  bbbbb1 pomalidomide eeeee1  inhibited autoubiquitination of  bbbbb2 CRBN eeeee2  in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA)
CPR:4	Lenalidomide and  bbbbb1 pomalidomide eeeee1  inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type  bbbbb2 CRBN eeeee2 , but not thalidomide-binding defective CRBN(YW/AA)
CPR:4	These  bbbbb1 polyphenols eeeee1 , but not GvEx, showed a certain level of inhibition of human-cDNA-expressed  bbbbb2 CYPs eeeee2 
CPR:2	Emerging data suggest that  bbbbb1 crizotinib eeeee1  may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the  bbbbb2 MET eeeee2  oncogene, or translocation of the ROS1 oncogene
CPR:2	Emerging data suggest that  bbbbb1 crizotinib eeeee1  may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the MET oncogene, or translocation of the  bbbbb2 ROS1 eeeee2  oncogene
CPR:2	 bbbbb1 Crizotinib eeeee1  has demonstrated efficacy against  bbbbb2 ALK eeeee2 -rearranged NSCLC, and has potential for broader application in select subsets of lung cancer.
CPR:2	 bbbbb1 Crizotinib eeeee1  is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing  bbbbb2 ALK eeeee2 
CPR:4	 bbbbb1 Crizotinib eeeee1  is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the  bbbbb2 ALK eeeee2  fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK
CPR:4	 bbbbb1 Crizotinib eeeee1  is an oral  bbbbb2 tyrosine kinase eeeee2  inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK
CPR:2	There was no escape of i.c.v.-administered [3H]R-PIA from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of  bbbbb1 ethanol eeeee1 - bbbbb2 adenosine eeeee2  interaction.(ABSTRACT TRUNCATED AT 250 WORDS)
CPR:2	To clarify if the behavioral interaction between  bbbbb1 ethanol eeeee1  and  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CPR:2	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of  bbbbb1 adenosine eeeee1  modulation of this effect of  bbbbb2 ethanol eeeee2  and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CPR:2	Results from R-PIA and  bbbbb1 N6-(S-phenylisopropyl)adenosine eeeee1  experiments showed nearly a 40-fold greater potency of R-vs. S-diastereoisomer, suggesting predominance of  bbbbb2 adenosine A1 eeeee2  subtype
CPR:2	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in  bbbbb1 ethanol eeeee1 - bbbbb2 adenosine eeeee2  interactions
CPR:2	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  bbbbb1 adenosine receptor eeeee1  mechanism(s) in  bbbbb2 ethanol eeeee2 -adenosine interactions
CPR:2	However,  bbbbb1 5'-(N-cyclopropyl)-carboxamidoadenosine eeeee1  data indicate complexity of the mechanism(s) and point toward an additional involvement of a yet unknown subtype of  bbbbb2 adenosine A2 eeeee2 
CPR:2	No effect of ethanol on blood or brain levels of [3H]R-PIA was noted and sufficient amount of the latter entered the brain to suggest  bbbbb1 adenosine receptor eeeee1  activation adequate to produce behavioral interaction with  bbbbb2 ethanol eeeee2 
CPR:4	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.  bbbbb1 Enprofylline eeeee1 , a weak adenosine antagonist but potent inhibitor of  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CPR:5	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb1 adenosine eeeee1  agonists,  bbbbb2 N6-(R-phenylisopropyl)adenosine eeeee2  (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CPR:5	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb1 adenosine eeeee1  agonists, N6-(R-phenylisopropyl)adenosine ( bbbbb2 R-PIA eeeee2 ), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CPR:5	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb1 adenosine eeeee1  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA),  bbbbb2 N6-(S-phenylisopropyl)adenosine eeeee2 , 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CPR:5	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb1 adenosine eeeee1  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine,  bbbbb2 5'-(N-cyclopropyl)-carboxamidoadenosine eeeee2 , antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CPR:6	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb1 adenosine eeeee1  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists,  bbbbb2 theophylline eeeee2  and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CPR:6	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb1 adenosine eeeee1  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and  bbbbb2 8-p-(sulfophenyl)theophylline eeeee2  as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CPR:6	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb1 adenosine eeeee1  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as  bbbbb2 enprofylline eeeee2  on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CPR:6	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.  bbbbb1 Enprofylline eeeee1 , a weak  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CPR:2	 bbbbb1 Celastrol eeeee1  highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic  bbbbb2 TGF-β eeeee2 -NF-κB signal pathway.
CPR:2	 bbbbb1 Celastrol eeeee1  highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-β- bbbbb2 NF-κB eeeee2  signal pathway.
CPR:3	 bbbbb1 Celastrol eeeee1  also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and  bbbbb2 Annexin V eeeee2  markers of apoptosis
CPR:4	 bbbbb1 Celastrol eeeee1 , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased  bbbbb2 TGF-β1 eeeee2 -induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity
CPR:4	 bbbbb1 Celastrol eeeee1 , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal,  bbbbb2 TGF-β1 eeeee2 - and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity
CPR:4	 bbbbb1 Celastrol eeeee1 , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and  bbbbb2 tumor necrosis factor-alpha eeeee2  (TNF-α)-induced NF-κB reporter gene activity
CPR:4	 bbbbb1 Celastrol eeeee1 , a  bbbbb2 TAK1 eeeee2  inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity
CPR:4	 bbbbb1 Celastrol eeeee1 , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of  bbbbb2 TAK1 eeeee2  and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity
CPR:4	 bbbbb1 Celastrol eeeee1 , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and  bbbbb2 RELA eeeee2 , and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity
CPR:4	 bbbbb1 Celastrol eeeee1 , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced  bbbbb2 NF-κB eeeee2  reporter gene activity
CPR:4	 bbbbb1 Celastrol eeeee1  highlights the therapeutic potential of agents targeting  bbbbb2 TAK1 eeeee2  as a key node in this pro-oncogenic TGF-β-NF-κB signal pathway.
CPR:2	When combined, mianserin antagonized the effects of the full  bbbbb1 kappa-opioid receptor eeeee1  agonists in  bbbbb2 [(35)S]GTPgammaS eeeee2  assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A
CPR:2	In  bbbbb1 [(35)S]GTPgammaS eeeee1  assays, mianserin selectively activated  bbbbb2 kappa-opioid receptors eeeee2 
CPR:2	In rat striatum and nucleus accumbens, mianserin stimulated  bbbbb1 [35S]GTPgammaS eeeee1  binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full  bbbbb2 kappa-opioid eeeee2  agonists (-)-U50,488 and dynorphin A
CPR:2	 bbbbb1 Mianserin eeeee1  and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing  bbbbb2 kappa-opioid receptors eeeee2  and C6 cells, and these effects were antagonized by nor-BNI
CPR:2	Mianserin and  bbbbb1 mirtazapine eeeee1  increased ERK1/2 phosphorylation in CHO cells expressing  bbbbb2 kappa-opioid receptors eeeee2  and C6 cells, and these effects were antagonized by nor-BNI
CPR:2	Mianserin and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing  bbbbb1 kappa-opioid receptors eeeee1  and C6 cells, and these effects were antagonized by  bbbbb2 nor-BNI eeeee2 
CPR:2	In rat striatum and nucleus accumbens,  bbbbb1 mianserin eeeee1  stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full  bbbbb2 kappa-opioid eeeee2  agonists (-)-U50,488 and dynorphin A
CPR:2	In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a  bbbbb1 nor-BNI eeeee1 -sensitive manner with maximal effects lower than those of the full  bbbbb2 kappa-opioid eeeee2  agonists (-)-U50,488 and dynorphin A
CPR:3	When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of  bbbbb1 p38 eeeee1  MAPK and ERK1/2 phosphorylation by  bbbbb2 dynorphin A eeeee2 
CPR:3	When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38  bbbbb1 MAPK eeeee1  and ERK1/2 phosphorylation by  bbbbb2 dynorphin A eeeee2 
CPR:3	CONCLUSIONS AND IMPLICATIONS: In different cell systems,  bbbbb1 mianserin eeeee1  directly activates  bbbbb2 kappa-opioid receptors eeeee2 , displaying partial agonist activity at brain receptors
CPR:3	In [(35)S]GTPgammaS assays,  bbbbb1 mianserin eeeee1  selectively activated  bbbbb2 kappa-opioid receptors eeeee2 
CPR:4	The agonist activity was antagonized by the selective  bbbbb1 kappa-opioid eeeee1  blocker  bbbbb2 nor-binaltorphimine eeeee2  (nor-BNI)
CPR:4	The agonist activity was antagonized by the selective  bbbbb1 kappa-opioid eeeee1  blocker nor-binaltorphimine ( bbbbb2 nor-BNI eeeee2 )
CPR:4	When combined,  bbbbb1 mianserin eeeee1  antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of  bbbbb2 p38 eeeee2  MAPK and ERK1/2 phosphorylation by dynorphin A
CPR:4	When combined,  bbbbb1 mianserin eeeee1  antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38  bbbbb2 MAPK eeeee2  and ERK1/2 phosphorylation by dynorphin A
CPR:5	We previously reported that  bbbbb1 tricyclic eeeee1  antidepressants act as agonists at distinct  bbbbb2 opioid receptors eeeee2 
CPR:5	CONCLUSIONS AND IMPLICATIONS: In different cell systems,  bbbbb1 mianserin eeeee1  directly activates  bbbbb2 kappa-opioid receptors eeeee2 , displaying partial agonist activity at brain receptors
CPR:5	The  bbbbb1 mianserin eeeee1  analogue mirtazapine also displayed  bbbbb2 kappa-opioid eeeee2  agonist activity
CPR:5	The mianserin analogue  bbbbb1 mirtazapine eeeee1  also displayed  bbbbb2 kappa-opioid eeeee2  agonist activity
CPR:5	The atypical antidepressant  bbbbb1 mianserin eeeee1  exhibits agonist activity at  bbbbb2 kappa-opioid receptors eeeee2 
CPR:5	In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full  bbbbb1 kappa-opioid eeeee1  agonists  bbbbb2 (-)-U50,488 eeeee2  and dynorphin A
CPR:5	In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full  bbbbb1 kappa-opioid eeeee1  agonists (-)-U50,488 and  bbbbb2 dynorphin A eeeee2 
CPR:6	The agonist activity was antagonized by the selective  bbbbb1 kappa-opioid eeeee1  blocker  bbbbb2 nor-binaltorphimine eeeee2  (nor-BNI)
CPR:6	The agonist activity was antagonized by the selective  bbbbb1 kappa-opioid eeeee1  blocker nor-binaltorphimine ( bbbbb2 nor-BNI eeeee2 )
CPR:6	When combined,  bbbbb1 mianserin eeeee1  antagonized the effects of the full  bbbbb2 kappa-opioid receptor eeeee2  agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A
CPR:6	In the present study we tested whether  bbbbb1 propranolol eeeee1 , a  bbbbb2 β-receptor eeeee2  antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8)
CPR:2	Effect of  bbbbb1 chalcones eeeee1  on lipid peroxidation,  bbbbb2 heme oxygenase 1 eeeee2 (HO-1), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.
CPR:2	Effect of  bbbbb1 chalcones eeeee1  on lipid peroxidation, heme oxygenase 1( bbbbb2 HO-1 eeeee2 ), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.
CPR:2	Effect of  bbbbb1 chalcones eeeee1  on lipid peroxidation, heme oxygenase 1(HO-1),  bbbbb2 cyclooxygenase eeeee2  (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.
CPR:2	Effect of  bbbbb1 chalcones eeeee1  on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase ( bbbbb2 COX eeeee2 ), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.
CPR:2	Effect of  bbbbb1 chalcones eeeee1  on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX),  bbbbb2 interleukin 5 eeeee2  (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.
CPR:2	Effect of  bbbbb1 chalcones eeeee1  on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), interleukin 5 ( bbbbb2 IL-5 eeeee2 ), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.
CPR:2	The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by LXR of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of  bbbbb1 oxysterol eeeee1  generation for expression of  bbbbb2 LXR eeeee2 -dependent genes.
CPR:3	The purpose of this review is to summarize current knowledge about  bbbbb1 oxysterol eeeee1 -dependent activation by  bbbbb2 LXR eeeee2  of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.
CPR:3	 bbbbb1 LXRs eeeee1  are thought to be activated predominantly by  bbbbb2 oxysterols eeeee2  generated enzymatically from cholesterol in different cell organelles
CPR:9	Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in  bbbbb1 sterol-27-hydroxylase eeeee1  activity lead to specific blocks in  bbbbb2 oxysterol eeeee2  production and impaired LXR-dependent gene activation
CPR:1	Mass spectral analysis of CBDP-inhibited  bbbbb1 BChE eeeee1  digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on  bbbbb2 lysine eeeee2  499, a residue far from the active site, but not on His-438
CPR:1	Mass spectral analysis of CBDP-inhibited  bbbbb1 BChE eeeee1  digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on  bbbbb2 His eeeee2 -438
CPR:1	Cresyl saligenin phosphate makes multiple adducts on free histidine, but does not form an adduct on  bbbbb1 histidine eeeee1  438 of  bbbbb2 human butyrylcholinesterase eeeee2 
CPR:1	CBDP irreversibly inhibits  bbbbb1 butyrylcholinesterase eeeee1  (BChE) in human plasma by forming adducts on the active site  bbbbb2 serine eeeee2  (Ser-198)
CPR:1	CBDP irreversibly inhibits butyrylcholinesterase ( bbbbb1 BChE eeeee1 ) in human plasma by forming adducts on the active site  bbbbb2 serine eeeee2  (Ser-198)
CPR:1	CBDP irreversibly inhibits  bbbbb1 butyrylcholinesterase eeeee1  (BChE) in human plasma by forming adducts on the active site serine ( bbbbb2 Ser eeeee2 -198)
CPR:1	CBDP irreversibly inhibits butyrylcholinesterase ( bbbbb1 BChE eeeee1 ) in human plasma by forming adducts on the active site serine ( bbbbb2 Ser eeeee2 -198)
CPR:2	Mass spectral analysis of CBDP-inhibited  bbbbb1 BChE eeeee1  digested with Glu-C showed an  bbbbb2 o-hydroxybenzyl eeeee2  adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438
CPR:2	Mass spectral analysis of CBDP-inhibited  bbbbb1 BChE eeeee1  digested with  bbbbb2 Glu eeeee2 -C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438
CPR:2	 bbbbb1 Cresyl saligenin phosphate eeeee1  makes multiple adducts on free histidine, but does not form an adduct on histidine 438 of  bbbbb2 human butyrylcholinesterase eeeee2 
CPR:4	Mass spectral analysis of  bbbbb1 CBDP eeeee1 -inhibited  bbbbb2 BChE eeeee2  digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438
CPR:4	 bbbbb1 CBDP eeeee1  irreversibly inhibits  bbbbb2 butyrylcholinesterase eeeee2  (BChE) in human plasma by forming adducts on the active site serine (Ser-198)
CPR:4	 bbbbb1 CBDP eeeee1  irreversibly inhibits butyrylcholinesterase ( bbbbb2 BChE eeeee2 ) in human plasma by forming adducts on the active site serine (Ser-198)
CPR:3	We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by  bbbbb1 α-tocopherol eeeee1  in the rat dentate gyrus, increasing  bbbbb2 cyclic adenosine monophosphate response element binding protein eeeee2  phosphorylation
CPR:10	After  bbbbb1 SU5416 eeeee1  treatment, cell viability,  bbbbb2 PARP-1 eeeee2 , and caspase-3 protein levels were not changed. p53 and p27 protein levels decreased while p21 protein levels increased
CPR:10	After  bbbbb1 SU5416 eeeee1  treatment, cell viability, PARP-1, and  bbbbb2 caspase-3 eeeee2  protein levels were not changed. p53 and p27 protein levels decreased while p21 protein levels increased
CPR:2	 bbbbb1 CCAAT/Enhancer-binding protein-homologous protein eeeee1  sensitizes to  bbbbb2 SU5416 eeeee2  by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells
CPR:2	CCAAT/Enhancer-binding protein-homologous protein sensitizes to  bbbbb1 SU5416 eeeee1  by modulating  bbbbb2 p21 eeeee2  and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells
CPR:2	CCAAT/Enhancer-binding protein-homologous protein sensitizes to  bbbbb1 SU5416 eeeee1  by modulating p21 and  bbbbb2 PI3K eeeee2 /Akt signal pathway in FRO anaplastic thyroid carcinoma cells
CPR:2	CCAAT/Enhancer-binding protein-homologous protein sensitizes to  bbbbb1 SU5416 eeeee1  by modulating p21 and PI3K/ bbbbb2 Akt eeeee2  signal pathway in FRO anaplastic thyroid carcinoma cells
CPR:2	In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to  bbbbb1 SU5416 eeeee1  thereby inhibiting cell survival by modulating  bbbbb2 p21 eeeee2  and PI3K/Akt signal pathway
CPR:2	In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to  bbbbb1 SU5416 eeeee1  thereby inhibiting cell survival by modulating p21 and  bbbbb2 PI3K eeeee2 /Akt signal pathway
CPR:2	In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to  bbbbb1 SU5416 eeeee1  thereby inhibiting cell survival by modulating p21 and PI3K/ bbbbb2 Akt eeeee2  signal pathway
CPR:2	Furthermore, these findings imply that  bbbbb1 CHOP eeeee1  may be a possible candidate as the chemosensitizing factor for induction of cytotoxicity in ATC cells exposed to  bbbbb2 SU5416 eeeee2 .
CPR:2	Moreover, we investigated the roles of  bbbbb1 CHOP eeeee1  in cell survival under condition of  bbbbb2 SU5416 eeeee2  treatment in FRO ATC cells
CPR:2	 bbbbb1 Galantamine eeeee1  is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of  bbbbb2 nicotinic acetylcholine receptors eeeee2  (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CPR:2	 bbbbb1 Galantamine eeeee1  is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors ( bbbbb2 nAChR eeeee2 -APL) that shares many common structural elements with morphinan-based opioids
CPR:2	The structurally diverse opioids  bbbbb1 codeine eeeee1  and eseroline, like galantamine, are also  bbbbb2 nAChR eeeee2 -APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development
CPR:2	The structurally diverse opioids  bbbbb1 codeine eeeee1  and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for  bbbbb2 AChE eeeee2 , representing potential lead compounds for selective nAChR-APL development
CPR:2	The structurally diverse opioids codeine and  bbbbb1 eseroline eeeee1 , like galantamine, are also  bbbbb2 nAChR eeeee2 -APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development
CPR:2	The structurally diverse opioids codeine and  bbbbb1 eseroline eeeee1 , like galantamine, are also nAChR-APL that have greatly diminished affinity for  bbbbb2 AChE eeeee2 , representing potential lead compounds for selective nAChR-APL development
CPR:2	The structurally diverse opioids codeine and eseroline, like  bbbbb1 galantamine eeeee1 , are also  bbbbb2 nAChR eeeee2 -APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development
CPR:2	The structurally diverse opioids codeine and eseroline, like  bbbbb1 galantamine eeeee1 , are also nAChR-APL that have greatly diminished affinity for  bbbbb2 AChE eeeee2 , representing potential lead compounds for selective nAChR-APL development
CPR:4	 bbbbb1 Galantamine eeeee1  is a reversible, competitive  bbbbb2 acetylcholinesterase eeeee2  (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CPR:4	 bbbbb1 Galantamine eeeee1  is a reversible, competitive acetylcholinesterase ( bbbbb2 AChE eeeee2 ) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CPR:7	 bbbbb1 Galantamine eeeee1  is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of  bbbbb2 nicotinic acetylcholine receptors eeeee2  (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CPR:7	 bbbbb1 Galantamine eeeee1  is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors ( bbbbb2 nAChR eeeee2 -APL) that shares many common structural elements with morphinan-based opioids
CPR:7	The structurally diverse opioids  bbbbb1 codeine eeeee1  and eseroline, like galantamine, are also  bbbbb2 nAChR eeeee2 -APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development
CPR:7	The structurally diverse opioids  bbbbb1 codeine eeeee1  and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective  bbbbb2 nAChR eeeee2 -APL development
CPR:7	The structurally diverse opioids codeine and  bbbbb1 eseroline eeeee1 , like galantamine, are also  bbbbb2 nAChR eeeee2 -APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development
CPR:7	The structurally diverse opioids codeine and  bbbbb1 eseroline eeeee1 , like galantamine, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective  bbbbb2 nAChR eeeee2 -APL development
CPR:7	The structurally diverse opioids codeine and eseroline, like  bbbbb1 galantamine eeeee1 , are also  bbbbb2 nAChR eeeee2 -APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development
CPR:7	The structurally diverse opioids codeine and eseroline, like  bbbbb1 galantamine eeeee1 , are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective  bbbbb2 nAChR eeeee2 -APL development
CPR:2	Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic),  bbbbb1 GnRH eeeee1  analogues,  bbbbb2 Danazol eeeee2  and Levonorgestrel releasing intra uterine system (LNG IUS).
CPR:2	Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic),  bbbbb1 GnRH eeeee1  analogues, Danazol and  bbbbb2 Levonorgestrel eeeee2  releasing intra uterine system (LNG IUS).
CPR:2	These results suggest that the regulation of nitrergic system by  bbbbb1 ERs eeeee1  may play a role in the control of  bbbbb2 oestrogen eeeee2 -dependent physiological mechanisms regulated by the SON and the PVN.
CPR:5	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  bbbbb1 ERβ eeeee1  agonist- bbbbb2 DPN eeeee2  [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CPR:5	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  bbbbb1 ERβ eeeee1  agonist-DPN [ bbbbb2 2,3-bis(4-hydroxyphenyl)-propionitrile eeeee2 ], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CPR:5	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective  bbbbb1 ERα eeeee1  agonist- bbbbb2 PPT eeeee2  [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CPR:5	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective  bbbbb1 ERα eeeee1  agonist-PPT [ bbbbb2 4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol eeeee2 ], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CPR:6	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  bbbbb1 ERα eeeee1  antagonist- bbbbb2 MPP eeeee2  [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CPR:6	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  bbbbb1 ERα eeeee1  antagonist-MPP [ bbbbb2 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol eeeee2 ]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CPR:6	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  bbbbb1 ERα eeeee1  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]- bbbbb2 1H-pyrazole dihydrochloride eeeee2 ] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CPR:6	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  bbbbb1 ERβ eeeee1  antagonist- bbbbb2 PHTPP eeeee2  (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CPR:6	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  bbbbb1 ERβ eeeee1  antagonist-PHTPP ( bbbbb2 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol eeeee2 )
CPR:9	Modulation of the  bbbbb1 nitric oxide eeeee1  producing system (demonstrated via the  bbbbb2 NADPH-diaphorase eeeee2  histochemical reaction) by oestradiol has been established in several structures of the rat brain
CPR:2	The residence time of a stoichiometric bioscavenger, human butyrylcholinesterase ( bbbbb1 huBuChE eeeee1 ), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs ( bbbbb2 oxime eeeee2 , anti-muscarinic, anticonvulsant)
CPR:2	The residence time of a stoichiometric bioscavenger,  bbbbb1 human butyrylcholinesterase eeeee1  (huBuChE), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs ( bbbbb2 oxime eeeee2 , anti-muscarinic, anticonvulsant)
CPR:2	A combination of nerve agent therapy drugs ( bbbbb1 oxime eeeee1 , anti-muscarinic, anticonvulsant) with  bbbbb2 huBuChE eeeee2  (i.m.) protected 100% (8/8) of guinea-pigs from a lethal dose of VX (0.74mg/kg) to 48h, even when administered on signs of poisoning
CPR:2	Therefore, we examined whether  bbbbb1 verrucarin A eeeee1  (VA) sensitize  bbbbb2 TRAIL eeeee2 -induced apoptosis in cancer cells by induction of ER stress
CPR:2	 bbbbb1 Verrucarin A eeeee1  sensitizes  bbbbb2 TRAIL eeeee2 -induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner
CPR:3	Furthermore,  bbbbb1 salubrinal eeeee1 , a specific  bbbbb2 eIF2α eeeee2  phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA
CPR:3	Furthermore,  bbbbb1 salubrinal eeeee1 , a specific eIF2α phosphorylation-inducing agent, increased  bbbbb2 CHOP eeeee2  and DR5 expression in the presence of VA
CPR:3	Furthermore,  bbbbb1 salubrinal eeeee1 , a specific eIF2α phosphorylation-inducing agent, increased CHOP and  bbbbb2 DR5 eeeee2  expression in the presence of VA
CPR:3	 bbbbb1 Verrucarin A eeeee1  sensitizes TRAIL-induced apoptosis via the upregulation of  bbbbb2 DR5 eeeee2  in an eIF2α/CHOP-dependent manner
CPR:3	 bbbbb1 Verrucarin A eeeee1  sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an  bbbbb2 eIF2α eeeee2 /CHOP-dependent manner
CPR:3	 bbbbb1 Verrucarin A eeeee1  sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/ bbbbb2 CHOP eeeee2 -dependent manner
CPR:1	Though microtubule mediated actin remodeling through PKCζ, reorganization of microtubule depended on  bbbbb1 tyrosine eeeee1  phosphorylation of  bbbbb2 insulin receptor eeeee2 , the mechanism is different from insulin-induced actin remodeling, which relied on the activity of PI3-kinase and PKCζ
CPR:9	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface  bbbbb1 glucose transporter isoform 4 eeeee1  (GLUT4) and  bbbbb2 glucose eeeee2  uptake
CPR:9	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 ( bbbbb1 GLUT4 eeeee1 ) and  bbbbb2 glucose eeeee2  uptake
CPR:2	Androstanol and  bbbbb1 androstenol eeeee1 , estrone, 17β-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both  bbbbb2 CARs eeeee2 
CPR:2	Androstanol and androstenol,  bbbbb1 estrone eeeee1 , 17β-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both  bbbbb2 CARs eeeee2 
CPR:2	Androstanol and androstenol, estrone,  bbbbb1 17β-estradiol eeeee1 , TCPOBOP, and CITCO showed compound-specific but similar affinities for both  bbbbb2 CARs eeeee2 
CPR:2	Androstanol and androstenol, estrone, 17β-estradiol,  bbbbb1 TCPOBOP eeeee1 , and CITCO showed compound-specific but similar affinities for both  bbbbb2 CARs eeeee2 
CPR:2	Androstanol and androstenol, estrone, 17β-estradiol, TCPOBOP, and  bbbbb1 CITCO eeeee1  showed compound-specific but similar affinities for both  bbbbb2 CARs eeeee2 
CPR:2	 bbbbb1 Androstanol eeeee1  and androstenol, estrone, 17β-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both  bbbbb2 CARs eeeee2 
CPR:2	Other groups received either an infusion of the selective  bbbbb1 NMDA receptor eeeee1  antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to  bbbbb2 PILO eeeee2  preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900)
CPR:2	Our data also indicate that  bbbbb1 NMDA receptor eeeee1  pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by  bbbbb2 PILO eeeee2 
CPR:4	Our data also indicate that  bbbbb1 NMDA receptor eeeee1  pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since  bbbbb2 AP7 eeeee2  microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO
CPR:6	Other groups received either an infusion of the selective  bbbbb1 NMDA receptor eeeee1  antagonist ( bbbbb2 AP7 eeeee2 ; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900)
CPR:9	The acetylation of  bbbbb1 TETA eeeee1  is increased in  bbbbb2 SSAT1 eeeee2 -overexpressing mice compared with wild-type mice
CPR:9	However, SSAT1-deficient mice metabolize  bbbbb1 TETA eeeee1  at the same rate as the wild-type mice, indicating the existence of another  bbbbb2 N-acetylase eeeee2  respons 2ible for its metabolism in mice
CPR:9	Here, we show that siRNA-mediated knockdown of  bbbbb1 SSAT2 eeeee1  in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of  bbbbb2 TETA eeeee2  to MAT
CPR:9	By contrast,  bbbbb1 1,12-diamino-3,6,9-triazadodecane eeeee1 (SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by  bbbbb2 SSAT1 eeeee2  in HEPG2 cells and in wild-type primary hepatocytes
CPR:9	By contrast,  bbbbb1 1,12-diamino-3,6,9-triazadodecane eeeee1 (SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of  bbbbb2 human recombinant SSAT2 eeeee2  and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes
CPR:9	By contrast, 1,12-diamino-3,6,9-triazadodecane( bbbbb1 SpmTrien eeeee1 ), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by  bbbbb2 SSAT1 eeeee2  in HEPG2 cells and in wild-type primary hepatocytes
CPR:9	By contrast, 1,12-diamino-3,6,9-triazadodecane( bbbbb1 SpmTrien eeeee1 ), a charge-deficient spermine analog, was an extremely poor substrate of  bbbbb2 human recombinant SSAT2 eeeee2  and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes
CPR:9	By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient  bbbbb1 spermine eeeee1  analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by  bbbbb2 SSAT1 eeeee2  in HEPG2 cells and in wild-type primary hepatocytes
CPR:9	By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient  bbbbb1 spermine eeeee1  analog, was an extremely poor substrate of  bbbbb2 human recombinant SSAT2 eeeee2  and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes
CPR:9	Metabolism of  bbbbb1 triethylenetetramine eeeee1  and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and  bbbbb2 thialysine acetyltransferase eeeee2 
CPR:9	Metabolism of  bbbbb1 triethylenetetramine eeeee1  and 1,12-diamino-3,6,9-triazadodecane by the  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  and thialysine acetyltransferase
CPR:9	Metabolism of triethylenetetramine and  bbbbb1 1,12-diamino-3,6,9-triazadodecane eeeee1  by the spermidine/spermine-N(1)-acetyltransferase and  bbbbb2 thialysine acetyltransferase eeeee2 
CPR:9	Metabolism of triethylenetetramine and  bbbbb1 1,12-diamino-3,6,9-triazadodecane eeeee1  by the  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  and thialysine acetyltransferase
CPR:9	Thus, despite the similar structures of TETA and SpmTrien,  bbbbb1 SSAT2 eeeee1  is the main acetylator of  bbbbb2 TETA eeeee2 , whereas SpmTrien is primarily acetylated by SSAT1.
CPR:9	Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas  bbbbb1 SpmTrien eeeee1  is primarily acetylated by  bbbbb2 SSAT1 eeeee2 .
CPR:9	We recently showed that  bbbbb1 TETA eeeee1  is metabolized in vitro by polyamine catabolic enzyme  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CPR:9	We recently showed that  bbbbb1 TETA eeeee1  is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ( bbbbb2 SSAT1 eeeee2 ) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CPR:9	We recently showed that  bbbbb1 TETA eeeee1  is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by  bbbbb2 thialysine acetyltransferase eeeee2  (SSAT2) to its monoacetylated derivative (MAT)
CPR:9	We recently showed that  bbbbb1 TETA eeeee1  is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase ( bbbbb2 SSAT2 eeeee2 ) to its monoacetylated derivative (MAT)
CPR:9	We recently showed that TETA is metabolized in vitro by  bbbbb1 polyamine eeeee1  catabolic enzyme  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CPR:9	We recently showed that TETA is metabolized in vitro by  bbbbb1 polyamine eeeee1  catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ( bbbbb2 SSAT1 eeeee2 ) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CPR:2	 bbbbb1 Cytochrome b5 eeeee1  has shown to be an essential component in P450 3A4 catalyzed  bbbbb2 5-hydroxyelzasonan eeeee2  formation and provides insights on the disconnect between human liver microsomes data and that of rCYP
CPR:6	In vitro metabolism of the  bbbbb1 5-hydroxytryptamine1B eeeee1  receptor antagonist  bbbbb2 elzasonan eeeee2 
CPR:9	Cytochrome b5 has shown to be an essential component in  bbbbb1 P450 3A4 eeeee1  catalyzed  bbbbb2 5-hydroxyelzasonan eeeee2  formation and provides insights on the disconnect between human liver microsomes data and that of rCYP
CPR:9	The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each  bbbbb1 rCYP eeeee1  in the metabolism of  bbbbb2 elzasonan eeeee2 
CPR:1	The mutant Fc domain ( bbbbb1 AglycoT-Fc1004 eeeee1 ) contained a total of 5  bbbbb2 amino acid eeeee2  substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:FcγRIIb)
CPR:1	The mutant Fc domain (AglycoT-Fc1004) contained a total of 5  bbbbb1 amino acid eeeee1  substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio;  bbbbb2 FcyRIIa eeeee2 -R131:FcγRIIb)
CPR:1	The mutant Fc domain (AglycoT-Fc1004) contained a total of 5  bbbbb1 amino acid eeeee1  substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131: bbbbb2 FcγRIIb eeeee2 )
CPR:1	The mutant  bbbbb1 Fc domain eeeee1  (AglycoT-Fc1004) contained a total of 5  bbbbb2 amino acid eeeee2  substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:FcγRIIb)
CPR:10	In contrast,  bbbbb1 VPD eeeee1  had little effect on limb morphology and no significant effect on  bbbbb2 HDAC eeeee2  activity or the expression of marker genes
CPR:10	Disturbances in these signaling pathways are likely to be a consequence of  bbbbb1 HDAC eeeee1  inhibition because  bbbbb2 VPD eeeee2  did not affect their expressions.
CPR:10	 bbbbb1 Valpromide eeeee1  (VPD), the amide derivative of VPA, does not inhibit  bbbbb2 HDAC eeeee2  activity and is a weak teratogen in vivo
CPR:10	Valpromide ( bbbbb1 VPD eeeee1 ), the amide derivative of VPA, does not inhibit  bbbbb2 HDAC eeeee2  activity and is a weak teratogen in vivo
CPR:10	Valpromide (VPD), the  bbbbb1 amide eeeee1  derivative of VPA, does not inhibit  bbbbb2 HDAC eeeee2  activity and is a weak teratogen in vivo
CPR:10	Valpromide (VPD), the amide derivative of  bbbbb1 VPA eeeee1 , does not inhibit  bbbbb2 HDAC eeeee2  activity and is a weak teratogen in vivo
CPR:4	The signaling of both  bbbbb1 Sox9 eeeee1  and Runx2, key regulators of chondrogenesis, was downregulated by  bbbbb2 VPA eeeee2 
CPR:4	The signaling of both Sox9 and  bbbbb1 Runx2 eeeee1 , key regulators of chondrogenesis, was downregulated by  bbbbb2 VPA eeeee2 
CPR:4	 bbbbb1 VPA eeeee1  caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its  bbbbb2 HDAC eeeee2  inhibitory effect
CPR:4	In utero exposure to  bbbbb1 valproic acid eeeee1  (VPA), a  bbbbb2 histone deacetylase eeeee2  (HDAC) inhibitor, causes neural tube, heart, and limb defects
CPR:4	In utero exposure to  bbbbb1 valproic acid eeeee1  (VPA), a histone deacetylase ( bbbbb2 HDAC eeeee2 ) inhibitor, causes neural tube, heart, and limb defects
CPR:4	In utero exposure to valproic acid ( bbbbb1 VPA eeeee1 ), a  bbbbb2 histone deacetylase eeeee2  (HDAC) inhibitor, causes neural tube, heart, and limb defects
CPR:4	In utero exposure to valproic acid ( bbbbb1 VPA eeeee1 ), a histone deacetylase ( bbbbb2 HDAC eeeee2 ) inhibitor, causes neural tube, heart, and limb defects
CPR:3	In summary, activation of  bbbbb1 caspases eeeee1  and oxidative stress were observed after  bbbbb2 AMD eeeee2 /TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.
CPR:4	On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/TNF cotreatment.  bbbbb1 α-TOCO eeeee1  plus a  bbbbb2 pancaspase eeeee2  inhibitor completely abolished AMD/TNF-induced cytotoxicity
CPR:1	Studies have indicated that the three-dimensional structure and the domains of  bbbbb1 HuBChE eeeee1  ( bbbbb2 acyl eeeee2  pocket, lip of the active center gorge, and the anionic substrate-binding domain) that are critical for the binding of substrate are also essential for the selectivity and binding of inhibitors including OPs
CPR:1	 bbbbb1 Amino acid eeeee1  residues at the N- and C-termini are essential for the folding of active  bbbbb2 human butyrylcholinesterase eeeee2  polypeptide
CPR:9	Human serum butyrylcholinesterase ( bbbbb1 HuBChE eeeee1 ) is currently the most suitable bioscavenger for the prophylaxis of highly toxic  bbbbb2 organophosphate eeeee2  (OP) nerve agents
CPR:9	 bbbbb1 Human serum butyrylcholinesterase eeeee1  (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic  bbbbb2 organophosphate eeeee2  (OP) nerve agents
CPR:2	Claudin-3 and claudin-4 regulate sensitivity to  bbbbb1 cisplatin eeeee1  by controlling expression of the copper and cisplatin influx transporter  bbbbb2 CTR1 eeeee2 
CPR:2	Claudin-3 and claudin-4 regulate sensitivity to  bbbbb1 cisplatin eeeee1  by controlling expression of the  bbbbb2 copper and cisplatin influx transporter eeeee2  CTR1
CPR:2	 bbbbb1 Claudin-3 eeeee1  and claudin-4 regulate sensitivity to  bbbbb2 cisplatin eeeee2  by controlling expression of the copper and cisplatin influx transporter CTR1
CPR:2	Claudin-3 and  bbbbb1 claudin-4 eeeee1  regulate sensitivity to  bbbbb2 cisplatin eeeee2  by controlling expression of the copper and cisplatin influx transporter CTR1
CPR:2	 bbbbb1 Cu eeeee1 -dependent  bbbbb2 tyrosinase eeeee2  activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA
CPR:9	Cu-dependent  bbbbb1 tyrosinase eeeee1  activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate  bbbbb2 l-DOPA eeeee2 
CPR:4	Protein expression of  bbbbb1 Ugt1a6 eeeee1  also decreased and corresponded with reduced in vitro glucuronidation of  bbbbb2 bisphenol A eeeee2  in S9 fractions from livers of pregnant mice
CPR:2	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as  bbbbb1 NQO1 eeeee1 , HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of  bbbbb2 DMF eeeee2  on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CPR:2	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1,  bbbbb1 HO-1 eeeee1  and glutathione S-transferase (GST) did not reverse the inhibitory effect of  bbbbb2 DMF eeeee2  on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CPR:2	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione S-transferase eeeee1  (GST) did not reverse the inhibitory effect of  bbbbb2 DMF eeeee2  on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CPR:2	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase ( bbbbb1 GST eeeee1 ) did not reverse the inhibitory effect of  bbbbb2 DMF eeeee2  on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CPR:2	However, downregulation of the  bbbbb1 antioxidant response element eeeee1  (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of  bbbbb2 DMF eeeee2  on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CPR:2	However, downregulation of the antioxidant response element ( bbbbb1 ARE eeeee1 )-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of  bbbbb2 DMF eeeee2  on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CPR:2	However, downregulation of the antioxidant response element (ARE)-driven  bbbbb1 Nrf2 eeeee1  target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of  bbbbb2 DMF eeeee2  on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CPR:2	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an  bbbbb1 ARE eeeee1 -independent anti-fibrotic activity of  bbbbb2 DMF eeeee2 
CPR:2	In summary,  bbbbb1 DMF eeeee1  attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/Smad3 signaling in an  bbbbb2 ARE eeeee2 -independent manner, suggesting that DMF could be used to treat renal fibrosis.
CPR:2	Results showed that DMF increased nuclear levels of Nrf2, and both  bbbbb1 DMF eeeee1  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in  bbbbb2 TGF-beta eeeee2 -treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CPR:2	 bbbbb1 Dimethylfumarate eeeee1  attenuates renal fibrosis via  bbbbb2 NF-E2-related factor 2 eeeee2 -mediated inhibition of transforming growth factor-beta/Smad signaling
CPR:2	In summary,  bbbbb1 DMF eeeee1  attenuated renal fibrosis via the  bbbbb2 Nrf2 eeeee2 -mediated inhibition of TGF-beta/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.
CPR:3	Results showed that  bbbbb1 DMF eeeee1  increased nuclear levels of  bbbbb2 Nrf2 eeeee2 , and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CPR:3	Results showed that DMF increased nuclear levels of Nrf2, and both  bbbbb1 DMF eeeee1  and adenovirus-mediated overexpression of  bbbbb2 Nrf2 eeeee2  (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CPR:3	Finally,  bbbbb1 DMF eeeee1  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of  bbbbb2 Nrf2 eeeee2  and phospho-Smad3, respectively
CPR:4	Additionally,  bbbbb1 DMF eeeee1  and Ad-Nrf2 repressed  bbbbb2 TGF-beta eeeee2 -stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression
CPR:4	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of  bbbbb1 DMF eeeee1  on  bbbbb2 TGF-beta eeeee2 -induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CPR:4	Results showed that DMF increased nuclear levels of Nrf2, and both  bbbbb1 DMF eeeee1  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased  bbbbb2 PAI-1 eeeee2 , alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CPR:4	Results showed that DMF increased nuclear levels of Nrf2, and both  bbbbb1 DMF eeeee1  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1,  bbbbb2 alpha-smooth muscle actin eeeee2  (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CPR:4	Results showed that DMF increased nuclear levels of Nrf2, and both  bbbbb1 DMF eeeee1  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin ( bbbbb2 alpha-SMA eeeee2 ), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CPR:4	Results showed that DMF increased nuclear levels of Nrf2, and both  bbbbb1 DMF eeeee1  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA),  bbbbb2 fibronectin eeeee2  and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CPR:4	Results showed that DMF increased nuclear levels of Nrf2, and both  bbbbb1 DMF eeeee1  and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and  bbbbb2 type 1 collagen eeeee2  expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CPR:4	 bbbbb1 Dimethylfumarate eeeee1  attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/ bbbbb2 Smad eeeee2  signaling
CPR:4	 bbbbb1 Dimethylfumarate eeeee1  attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of  bbbbb2 transforming growth factor-beta eeeee2 /Smad signaling
CPR:4	Finally,  bbbbb1 DMF eeeee1  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and  bbbbb2 alpha-SMA eeeee2 , fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively
CPR:4	Finally,  bbbbb1 DMF eeeee1  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA,  bbbbb2 fibronectin eeeee2  and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively
CPR:4	Finally,  bbbbb1 DMF eeeee1  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and  bbbbb2 type 1 collagen eeeee2  expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively
CPR:4	Finally,  bbbbb1 DMF eeeee1  suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and  bbbbb2 phospho-Smad3 eeeee2 , respectively
CPR:4	In summary,  bbbbb1 DMF eeeee1  attenuated renal fibrosis via the Nrf2-mediated inhibition of  bbbbb2 TGF-beta eeeee2 /Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.
CPR:4	In summary,  bbbbb1 DMF eeeee1  attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/ bbbbb2 Smad3 eeeee2  signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.
CPR:4	Additionally,  bbbbb1 DMF eeeee1  and Ad-Nrf2 repressed TGF-beta-stimulated  bbbbb2 Smad3 eeeee2  activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression
CPR:4	Additionally,  bbbbb1 DMF eeeee1  and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting  bbbbb2 Smad3 eeeee2  phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression
CPR:3	The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while  bbbbb1 osteocalcin eeeee1  (OCN) was augmented in CCL3(-/-) and  bbbbb2 Met eeeee2 -RANTES-treated mice
CPR:3	The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin ( bbbbb1 OCN eeeee1 ) was augmented in CCL3(-/-) and  bbbbb2 Met eeeee2 -RANTES-treated mice
CPR:4	The expression of the osteoblast markers runt-related transcription factor 2 ( bbbbb1 RUNX2 eeeee1 ) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and  bbbbb2 Met eeeee2 -RANTES-treated mice
CPR:4	The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and  bbbbb1 periostin eeeee1  was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and  bbbbb2 Met eeeee2 -RANTES-treated mice
CPR:4	The expression of the osteoblast markers  bbbbb1 runt-related transcription factor 2 eeeee1  (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and  bbbbb2 Met eeeee2 -RANTES-treated mice
CPR:4	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of  bbbbb1 receptor activator of nuclear factor kappa-B eeeee1  (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb2 Met eeeee2 -RANTES
CPR:4	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B ( bbbbb1 RANK eeeee1 ), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb2 Met eeeee2 -RANTES
CPR:4	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand  bbbbb1 RANKL eeeee1 , tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb2 Met eeeee2 -RANTES
CPR:4	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL,  bbbbb1 tumor necrosis factor alpha eeeee1  (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb2 Met eeeee2 -RANTES
CPR:4	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha ( bbbbb1 TNF-α eeeee1 ) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb2 Met eeeee2 -RANTES
CPR:4	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and  bbbbb1 RANKL eeeee1 /osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb2 Met eeeee2 -RANTES
CPR:4	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/ bbbbb1 osteoprotegerin eeeee1  (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb2 Met eeeee2 -RANTES
CPR:4	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin ( bbbbb1 OPG eeeee1 ) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb2 Met eeeee2 -RANTES
CPR:4	 bbbbb1 Met eeeee1 -RANTES treatment also reduced the levels of  bbbbb2 cathepsin K eeeee2  and metalloproteinase 13 (MMP13)
CPR:4	 bbbbb1 Met eeeee1 -RANTES treatment also reduced the levels of cathepsin K and  bbbbb2 metalloproteinase 13 eeeee2  (MMP13)
CPR:4	 bbbbb1 Met eeeee1 -RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 ( bbbbb2 MMP13 eeeee2 )
CPR:6	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of  bbbbb2 CCR5 eeeee2  and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CPR:6	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and  bbbbb2 CCR1 eeeee2 ). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CPR:4	The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and  bbbbb1 matrine eeeee1  carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  bbbbb2 hERG eeeee2  blocking activity
CPR:4	The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of  bbbbb1 O=C=N-C-C-C-N eeeee1  that possessed positive ionotropic effect and  bbbbb2 hERG eeeee2  blocking activity
CPR:4	The  bbbbb1 quinolizidine alkaloids eeeee1  (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  bbbbb2 hERG eeeee2  blocking activity
CPR:4	The quinolizidine alkaloids (natural products) such as  bbbbb1 oxymatrine eeeee1 , sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  bbbbb2 hERG eeeee2  blocking activity
CPR:4	The quinolizidine alkaloids (natural products) such as oxymatrine,  bbbbb1 sophoridine eeeee1 , sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  bbbbb2 hERG eeeee2  blocking activity
CPR:4	The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine,  bbbbb1 sophocarpine eeeee1  and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and  bbbbb2 hERG eeeee2  blocking activity
CPR:2	Multifunctional targets of dietary  bbbbb1 polyphenols eeeee1  in disease: a case for the  bbbbb2 chemokine eeeee2  network and energy metabolism
CPR:3	Several effects of  bbbbb1 polyphenols eeeee1  are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors,  bbbbb2 AMPK eeeee2  activators, calorie-restriction mimetics or epigenetic regulators
CPR:4	Several effects of  bbbbb1 polyphenols eeeee1  are useful in this scenario, including a reduction in the activities of  bbbbb2 cytokines eeeee2  and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators
CPR:4	Several effects of  bbbbb1 polyphenols eeeee1  are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through  bbbbb2 histone deacetylase eeeee2  inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators
CPR:4	 bbbbb1 NFD eeeee1  suppressed  bbbbb2 EGF eeeee2 -mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity
CPR:4	 bbbbb1 NFD eeeee1  abrogated  bbbbb2 EGF eeeee2 -induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt
CPR:4	Furthermore, the EGFR inhibitor  bbbbb1 AG1478 eeeee1  inhibited EGF-induced  bbbbb2 MMP-9 eeeee2  expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation
CPR:4	These findings suggest that  bbbbb1 NFD eeeee1  inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent  bbbbb2 PI3K eeeee2 /Akt signaling, leading to the down-regulation of MMP-9 expression
CPR:4	These findings suggest that  bbbbb1 NFD eeeee1  inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/ bbbbb2 Akt eeeee2  signaling, leading to the down-regulation of MMP-9 expression
CPR:4	These findings suggest that  bbbbb1 NFD eeeee1  inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/Akt signaling, leading to the down-regulation of  bbbbb2 MMP-9 eeeee2  expression
CPR:4	 bbbbb1 NFD eeeee1  suppressed EGF-mediated protein levels of  bbbbb2 c-Jun eeeee2  and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity
CPR:4	 bbbbb1 NFD eeeee1  suppressed EGF-mediated protein levels of c-Jun and  bbbbb2 c-Fos eeeee2 , and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity
CPR:4	 bbbbb1 NFD eeeee1  suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced  bbbbb2 MMP-9 eeeee2  expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity
CPR:4	Furthermore, the EGFR inhibitor  bbbbb1 AG1478 eeeee1  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that  bbbbb2 PI3K eeeee2 /Akt activation occur downstream of EGFR activation
CPR:4	Furthermore, the EGFR inhibitor  bbbbb1 AG1478 eeeee1  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/ bbbbb2 Akt eeeee2  activation occur downstream of EGFR activation
CPR:4	Furthermore, the EGFR inhibitor  bbbbb1 AG1478 eeeee1  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of  bbbbb2 EGFR eeeee2  activation
CPR:4	Furthermore, the  bbbbb1 EGFR eeeee1  inhibitor  bbbbb2 AG1478 eeeee2  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation
CPR:4	Furthermore, the EGFR inhibitor  bbbbb1 AG1478 eeeee1  inhibited  bbbbb2 EGF eeeee2 -induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation
CPR:4	Furthermore, the EGFR inhibitor  bbbbb1 AG1478 eeeee1  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of  bbbbb2 PI3K eeeee2 /Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation
CPR:4	Furthermore, the EGFR inhibitor  bbbbb1 AG1478 eeeee1  inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/ bbbbb2 Akt eeeee2 , suggesting that PI3K/Akt activation occur downstream of EGFR activation
CPR:4	Inhibition of  bbbbb1 EGF eeeee1 /EGFR activation with  bbbbb2 naphtho[1,2-b]furan-4,5-dione eeeee2  blocks migration and invasion of MDA-MB-231 cells
CPR:4	Inhibition of EGF/ bbbbb1 EGFR eeeee1  activation with  bbbbb2 naphtho[1,2-b]furan-4,5-dione eeeee2  blocks migration and invasion of MDA-MB-231 cells
CPR:4	These findings suggest that  bbbbb1 NFD eeeee1  inhibited the  bbbbb2 EGF eeeee2 -induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression
CPR:4	These findings suggest that  bbbbb1 NFD eeeee1  inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via  bbbbb2 EGFR eeeee2 -dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression
CPR:4	 bbbbb1 NFD eeeee1  suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced  bbbbb2 MMP-9 eeeee2  expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity
CPR:4	 bbbbb1 NFD eeeee1  abrogated EGF-induced phosphorylation of  bbbbb2 EGF receptor eeeee2  (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt
CPR:4	 bbbbb1 NFD eeeee1  abrogated EGF-induced phosphorylation of EGF receptor ( bbbbb2 EGFR eeeee2 ) and phosphatidylinositol 3-kinase (PI3K)/Akt
CPR:4	 bbbbb1 NFD eeeee1  abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and  bbbbb2 phosphatidylinositol 3-kinase eeeee2  (PI3K)/Akt
CPR:4	 bbbbb1 NFD eeeee1  abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase ( bbbbb2 PI3K eeeee2 )/Akt
CPR:4	 bbbbb1 NFD eeeee1  abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/ bbbbb2 Akt eeeee2 
CPR:4	The specific  bbbbb1 PI3K eeeee1  inhibitor,  bbbbb2 wortmannin eeeee2 , blocked significantly EGF-induced cell migration and invasion
CPR:4	The specific PI3K inhibitor,  bbbbb1 wortmannin eeeee1 , blocked significantly  bbbbb2 EGF eeeee2 -induced cell migration and invasion
CPR:4	Herein, we report the identification and characterization of  bbbbb1 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile eeeee1  (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated  bbbbb2 insulin eeeee2  secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( bbbbb1 ESI-09 eeeee1 ), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated  bbbbb2 insulin eeeee2  secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  bbbbb1 nucleotide eeeee1  EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated  bbbbb2 insulin eeeee2  secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of  bbbbb1 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile eeeee1  (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular  bbbbb2 EPAC eeeee2 -mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of  bbbbb1 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile eeeee1  (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated  bbbbb2 Rap1 eeeee2  activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of  bbbbb1 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile eeeee1  (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and  bbbbb2 Akt eeeee2  phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of  bbbbb1 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile eeeee1  (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as  bbbbb2 EPAC eeeee2 -mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( bbbbb1 ESI-09 eeeee1 ), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular  bbbbb2 EPAC eeeee2 -mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( bbbbb1 ESI-09 eeeee1 ), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated  bbbbb2 Rap1 eeeee2  activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( bbbbb1 ESI-09 eeeee1 ), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and  bbbbb2 Akt eeeee2  phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( bbbbb1 ESI-09 eeeee1 ), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as  bbbbb2 EPAC eeeee2 -mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  bbbbb1 nucleotide eeeee1  EPAC antagonist that is capable of specifically blocking intracellular  bbbbb2 EPAC eeeee2 -mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  bbbbb1 nucleotide eeeee1  EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated  bbbbb2 Rap1 eeeee2  activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  bbbbb1 nucleotide eeeee1  EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and  bbbbb2 Akt eeeee2  phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:4	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  bbbbb1 nucleotide eeeee1  EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as  bbbbb2 EPAC eeeee2 -mediated insulin secretion in pancreatic β cells
CPR:6	Herein, we report the identification and characterization of  bbbbb1 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile eeeee1  (ESI-09), a novel noncyclic nucleotide  bbbbb2 EPAC eeeee2  antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:6	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile ( bbbbb1 ESI-09 eeeee1 ), a novel noncyclic nucleotide  bbbbb2 EPAC eeeee2  antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:6	Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic  bbbbb1 nucleotide eeeee1   bbbbb2 EPAC eeeee2  antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells
CPR:2	Our results show that  bbbbb1 Metformin eeeee1  directly inhibits stomach ghrelin production and secretion through  bbbbb2 AMPK eeeee2 
CPR:2	 bbbbb1 Metformin eeeee1  directly inhibits ghrelin secretion through  bbbbb2 AMP-activated protein kinase eeeee2  in rat primary gastric cells
CPR:3	Furthermore, the  bbbbb1 AMPK eeeee1  activator  bbbbb2 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide eeeee2  (AICAR) significantly inhibited ghrelin secretion
CPR:3	Furthermore, the  bbbbb1 AMPK eeeee1  activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide ( bbbbb2 AICAR eeeee2 ) significantly inhibited ghrelin secretion
CPR:3	Finally,  bbbbb1 Metformin eeeee1  treatment caused a significant increase in the level of  bbbbb2 phosphorylated (active) AMPK eeeee2 
CPR:3	Metformin significantly reduced  bbbbb1 ghrelin eeeee1  secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor  bbbbb2 compound C eeeee2 
CPR:3	Metformin significantly reduced ghrelin secretion and  bbbbb1 proghrelin eeeee1  mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor  bbbbb2 compound C eeeee2 
CPR:4	Our results show that  bbbbb1 Metformin eeeee1  directly inhibits stomach  bbbbb2 ghrelin eeeee2  production and secretion through AMPK
CPR:4	 bbbbb1 Metformin eeeee1  treatment is also associated with lower circulating levels of the  bbbbb2 orexigenic hormone eeeee2  ghrelin
CPR:4	 bbbbb1 Metformin eeeee1  treatment is also associated with lower circulating levels of the orexigenic hormone  bbbbb2 ghrelin eeeee2 
CPR:4	 bbbbb1 Metformin eeeee1  directly inhibits  bbbbb2 ghrelin eeeee2  secretion through AMP-activated protein kinase in rat primary gastric cells
CPR:4	 bbbbb1 Metformin eeeee1  significantly reduced  bbbbb2 ghrelin eeeee2  secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C
CPR:4	 bbbbb1 Metformin eeeee1  significantly reduced ghrelin secretion and  bbbbb2 proghrelin eeeee2  mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C
CPR:4	Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide ( bbbbb1 AICAR eeeee1 ) significantly inhibited  bbbbb2 ghrelin eeeee2  secretion
CPR:4	Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the  bbbbb1 AMPK eeeee1  inhibitor  bbbbb2 compound C eeeee2 
CPR:2	Through identification of mammary  bbbbb1 ABCG2 eeeee1  as a novel target gene of pesticide  bbbbb2 prochloraz eeeee2  and dioxin, our results may therefore help to improve the protection of breast-feeding infants and the consumer of dairy products.
CPR:2	Through identification of mammary  bbbbb1 ABCG2 eeeee1  as a novel target gene of pesticide prochloraz and  bbbbb2 dioxin eeeee2 , our results may therefore help to improve the protection of breast-feeding infants and the consumer of dairy products.
CPR:2	 bbbbb1 TCDD eeeee1  or prochloraz doubled  bbbbb2 ABCG2 eeeee2 -mediated Hoechst H33342 secretion
CPR:2	TCDD or  bbbbb1 prochloraz eeeee1  doubled  bbbbb2 ABCG2 eeeee2 -mediated Hoechst H33342 secretion
CPR:2	Fungicide  bbbbb1 prochloraz eeeee1  and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the  bbbbb2 arylhydrocarbon receptor eeeee2  signaling pathway
CPR:2	Fungicide prochloraz and environmental pollutant  bbbbb1 dioxin eeeee1  induce the ABCG2 transporter in bovine mammary epithelial cells by the  bbbbb2 arylhydrocarbon receptor eeeee2  signaling pathway
CPR:3	Induction of AhR by  bbbbb1 TCDD eeeee1  and prochloraz resulted in a time- and dose-dependent increase of  bbbbb2 ABCG2 eeeee2  gene expression and transporter protein levels
CPR:3	Induction of AhR by TCDD and  bbbbb1 prochloraz eeeee1  resulted in a time- and dose-dependent increase of  bbbbb2 ABCG2 eeeee2  gene expression and transporter protein levels
CPR:3	Fungicide  bbbbb1 prochloraz eeeee1  and environmental pollutant dioxin induce the  bbbbb2 ABCG2 eeeee2  transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway
CPR:3	Fungicide prochloraz and environmental pollutant  bbbbb1 dioxin eeeee1  induce the  bbbbb2 ABCG2 eeeee2  transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway
CPR:3	Induction of  bbbbb1 AhR eeeee1  by  bbbbb2 TCDD eeeee2  and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels
CPR:3	Induction of  bbbbb1 AhR eeeee1  by TCDD and  bbbbb2 prochloraz eeeee2  resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels
CPR:4	This effect was almost completely reversed by specific  bbbbb1 ABCG2 eeeee1  inhibitor  bbbbb2 Ko143 eeeee2 
CPR:5	As these regulatory motifs mediate regulation of target genes by  bbbbb1 AhR eeeee1  agonists including  bbbbb2 TCDD eeeee2  and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells
CPR:5	As these regulatory motifs mediate regulation of target genes by  bbbbb1 AhR eeeee1  agonists including TCDD and  bbbbb2 prochloraz eeeee2 , we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells
CPR:6	Receptor binding was significantly reduced by specific  bbbbb1 AhR eeeee1  antagonist  bbbbb2 salicyl amide eeeee2 
CPR:9	TCDD or prochloraz doubled  bbbbb1 ABCG2 eeeee1 -mediated  bbbbb2 Hoechst H33342 eeeee2  secretion
CPR:2	We found that  bbbbb1 Ag eeeee1  NPs were highly cytotoxic to hepatocytes (LC(50)  bbbbb2 lactate dehydrogenase eeeee2 : 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing albumin release
CPR:3	We observed similar effects of  bbbbb1 Ag eeeee1  NPs on inflammatory mediator expression in vitro and in vivo with increase of  bbbbb2 interleukin-8 eeeee2  (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro
CPR:3	We observed similar effects of  bbbbb1 Ag eeeee1  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 ( bbbbb2 IL-8 eeeee2 )/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro
CPR:3	We observed similar effects of  bbbbb1 Ag eeeee1  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/ bbbbb2 macrophage inflammatory protein 2 eeeee2 , IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro
CPR:3	We observed similar effects of  bbbbb1 Ag eeeee1  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2,  bbbbb2 IL-1RI eeeee2 , and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro
CPR:3	We observed similar effects of  bbbbb1 Ag eeeee1  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and  bbbbb2 tumor necrosis factor-α eeeee2  expression in both models and increased IL-8 protein release in vitro
CPR:3	We observed similar effects of  bbbbb1 Ag eeeee1  NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased  bbbbb2 IL-8 eeeee2  protein release in vitro
CPR:4	We found that  bbbbb1 Ag eeeee1  NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing  bbbbb2 albumin eeeee2  release
CPR:10	Moreover, mutation of  bbbbb1 ECII eeeee1  can alter this coupled equilibrium from  bbbbb2 GTP eeeee2 -insensitive agonist binding to more conventional GTP-sensitive binding
CPR:10	Moreover, mutation of  bbbbb1 ECII eeeee1  can alter this coupled equilibrium from GTP-insensitive agonist binding to more conventional  bbbbb2 GTP eeeee2 -sensitive binding
CPR:10	Unlike the majority of G protein-coupled receptors, the  bbbbb1 prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor eeeee1  binds agonist with high affinity that is insensitive to the presence of  bbbbb2 guanosine 5[prime]-O-(3-thio)triphosphate eeeee2  (GTPγS)
CPR:10	Unlike the majority of G protein-coupled receptors, the  bbbbb1 prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor eeeee1  binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate ( bbbbb2 GTPγS eeeee2 )
CPR:2	Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the  bbbbb1 W203A eeeee1  receptor, conditions where high GTP levels are present; however, high affinity binding  bbbbb2 [(3)H]PGE(2) eeeee2  was observed in broken cell preparations washed free of GTP
CPR:2	The  bbbbb1 [(3)H]PGE(2) eeeee1  binding of  bbbbb2 W203A eeeee2  in broken cell membrane fractions was inhibited by addition of GTPγS (IC(50) 21 ± 1.8 nM)
CPR:2	The [(3)H]PGE(2) binding of  bbbbb1 W203A eeeee1  in broken cell membrane fractions was inhibited by addition of  bbbbb2 GTPγS eeeee2  (IC(50) 21 ± 1.8 nM)
CPR:2	This suggests that for the mutant receptors, ECII plays a critical role in linking the agonist bound receptor conformation to the  bbbbb1 G protein eeeee1   bbbbb2 nucleotide eeeee2  bound state.
CPR:2	 bbbbb1 Extracellular loop II eeeee1  modulates  bbbbb2 GTP eeeee2  sensitivity of the prostaglandin EP3 receptor
CPR:2	Extracellular loop II modulates  bbbbb1 GTP eeeee1  sensitivity of the  bbbbb2 prostaglandin EP3 receptor eeeee2 
CPR:2	Seven point mutations were introduced into the conserved motif in the  bbbbb1 second extracellular loop eeeee1  (ECII) of EP3, resulting in acquisition of  bbbbb2 GTP eeeee2 -sensitive agonist binding
CPR:2	Seven point mutations were introduced into the conserved motif in the second extracellular loop ( bbbbb1 ECII eeeee1 ) of EP3, resulting in acquisition of  bbbbb2 GTP eeeee2 -sensitive agonist binding
CPR:2	Seven point mutations were introduced into the conserved motif in the second extracellular loop (ECII) of  bbbbb1 EP3 eeeee1 , resulting in acquisition of  bbbbb2 GTP eeeee2 -sensitive agonist binding
CPR:2	Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the  bbbbb1 W203A eeeee1  receptor, conditions where high  bbbbb2 GTP eeeee2  levels are present; however, high affinity binding [(3)H]PGE(2) was observed in broken cell preparations washed free of GTP
CPR:4	Blood pressure was increased in rats exposed to IH, and treatment with the  bbbbb1 PDK-1 eeeee1  inhibitor  bbbbb2 OSU-03012 eeeee2  [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg/day) lowered blood pressure in IH but not sham group rats
CPR:4	Blood pressure was increased in rats exposed to IH, and treatment with the  bbbbb1 PDK-1 eeeee1  inhibitor OSU-03012 [ bbbbb2 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide eeeee2 ] (33 mg/day) lowered blood pressure in IH but not sham group rats
CPR:2	Interestingly, there was a loss in the binding of  bbbbb1 ICAM2 eeeee1  to actin during  bbbbb2 CdCl₂ eeeee2 -induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring
CPR:3	Following  bbbbb1 CdCl₂ eeeee1  treatment,  bbbbb2 ICAM2 eeeee2  was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h
CPR:4	Interestingly, there was a loss in the binding of ICAM2 to  bbbbb1 actin eeeee1  during  bbbbb2 CdCl₂ eeeee2 -induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring
CPR:4	The reaction was inhibited by the specific  bbbbb1 CYP2D eeeee1  inhibitors  bbbbb2 quinine eeeee2  and fluoxetine
CPR:4	The reaction was inhibited by the specific  bbbbb1 CYP2D eeeee1  inhibitors quinine and  bbbbb2 fluoxetine eeeee2 
CPR:9	Of the rat CYP isoforms studied,  bbbbb1 CYP2D eeeee1  isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to  bbbbb2 serotonin eeeee2 , but they were less effective than the human isoform CYP2D6
CPR:9	Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to  bbbbb1 serotonin eeeee1 , but they were less effective than the  bbbbb2 human isoform CYP2D6 eeeee2 
CPR:9	The catalytic competence of  bbbbb1 cytochrome P450 eeeee1  in the synthesis of  bbbbb2 serotonin eeeee2  from 5-methoxytryptamine in the brain: an in vitro study
CPR:9	Human liver microsomes of the wild-type  bbbbb1 CYP2D6 eeeee1  metabolized 5-methoxytryptamine to  bbbbb2 serotonin eeeee2  more effectively than did the defective CYP2D6*4*4 ones
CPR:9	Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to  bbbbb1 serotonin eeeee1  more effectively than did the defective  bbbbb2 CYP2D6 eeeee2 *4*4 ones
CPR:9	The obtained results indicate that  bbbbb1 rat brain CYP2D eeeee1  isoforms catalyze the formation of  bbbbb2 serotonin eeeee2  from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain
CPR:9	The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of  bbbbb1 CYP2D eeeee1  may affect  bbbbb2 serotonin eeeee2  metabolism in the brain
CPR:9	Of the rat CYP isoforms studied,  bbbbb1 CYP2D eeeee1  isoforms were the most efficient in catalyzing the  bbbbb2 O eeeee2 -demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6
CPR:9	Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the  bbbbb1 O eeeee1 -demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the  bbbbb2 human isoform CYP2D6 eeeee2 
CPR:9	Of the rat CYP isoforms studied,  bbbbb1 CYP2D eeeee1  isoforms were the most efficient in catalyzing the O-demethylation of  bbbbb2 5-methoxytryptamine eeeee2  to serotonin, but they were less effective than the human isoform CYP2D6
CPR:9	Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of  bbbbb1 5-methoxytryptamine eeeee1  to serotonin, but they were less effective than the  bbbbb2 human isoform CYP2D6 eeeee2 
CPR:9	The catalytic competence of  bbbbb1 cytochrome P450 eeeee1  in the synthesis of serotonin from  bbbbb2 5-methoxytryptamine eeeee2  in the brain: an in vitro study
CPR:9	Human liver microsomes of the wild-type  bbbbb1 CYP2D6 eeeee1  metabolized  bbbbb2 5-methoxytryptamine eeeee2  to serotonin more effectively than did the defective CYP2D6*4*4 ones
CPR:9	Human liver microsomes of the wild-type CYP2D6 metabolized  bbbbb1 5-methoxytryptamine eeeee1  to serotonin more effectively than did the defective  bbbbb2 CYP2D6 eeeee2 *4*4 ones
CPR:9	The obtained results indicate that  bbbbb1 rat brain CYP2D eeeee1  isoforms catalyze the formation of serotonin from  bbbbb2 5-methoxytryptamine eeeee2 , and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain
CPR:2	In breast cancer (BC) epithelial cells, the mitogenic action of  bbbbb1 estradiol eeeee1  is transduced through binding to two receptors,  bbbbb2 ERα eeeee2  and ERβ, which act as transcription factors
CPR:2	In breast cancer (BC) epithelial cells, the mitogenic action of  bbbbb1 estradiol eeeee1  is transduced through binding to two receptors, ERα and  bbbbb2 ERβ eeeee2 , which act as transcription factors
CPR:2	 bbbbb1 Estrogen eeeee1  effects are mediated not only through nuclear  bbbbb2 ERs eeeee2  but also through cytoplasmic/membrane ERs and G-protein-coupled ERs
CPR:2	 bbbbb1 Estrogen eeeee1  effects are mediated not only through nuclear ERs but also through cytoplasmic/membrane  bbbbb2 ERs eeeee2  and G-protein-coupled ERs
CPR:2	 bbbbb1 Estrogen eeeee1  effects are mediated not only through nuclear ERs but also through cytoplasmic/membrane ERs and  bbbbb2 G-protein eeeee2 -coupled ERs
CPR:2	 bbbbb1 Estrogen eeeee1  effects are mediated not only through nuclear ERs but also through cytoplasmic/membrane ERs and G-protein-coupled  bbbbb2 ERs eeeee2 
CPR:2	Taken together, our study suggested, for the first time, that the pro-apoptotic effects of  bbbbb1 TSN eeeee1  on HL-60 cells were mediated through  bbbbb2 JNK eeeee2  signaling pathway.
CPR:4	 bbbbb1 Toosendanin eeeee1  induces apoptosis through suppression of  bbbbb2 JNK eeeee2  signaling pathway in HL-60 cells
CPR:4	Western blot analysis indicated that  bbbbb1 TSN eeeee1  inhibits the  bbbbb2 CDC42 eeeee2 /MEKK1/JNK pathway
CPR:4	Western blot analysis indicated that  bbbbb1 TSN eeeee1  inhibits the CDC42/ bbbbb2 MEKK1 eeeee2 /JNK pathway
CPR:4	Western blot analysis indicated that  bbbbb1 TSN eeeee1  inhibits the CDC42/MEKK1/ bbbbb2 JNK eeeee2  pathway
CPR:3	Administration of low, but not high, doses of oral  bbbbb1 nicotine eeeee1  in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of  bbbbb2 tumor necrosis factor-α eeeee2 
CPR:1	Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical  bbbbb1 hydrogen eeeee1  bonds required to stabilise the  bbbbb2 KIR eeeee2 -Keap1 complex
CPR:1	Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical  bbbbb1 hydrogen eeeee1  bonds required to stabilise the KIR- bbbbb2 Keap1 eeeee2  complex
CPR:2	 bbbbb1 Orexin-A eeeee1  (a  bbbbb2 glucose eeeee2 -sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism
CPR:4	The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of  bbbbb1 orexin-A eeeee1  was reversed by the administration of  bbbbb2 SB334867 eeeee2  as well as by hypothalamic BDNF knockdown
CPR:4	The MCAO-induced decrease in  bbbbb1 insulin receptor eeeee1  levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of  bbbbb2 SB334867 eeeee2  as well as by hypothalamic BDNF knockdown
CPR:6	Small interfering RNA directed BDNF, orexin-A, and  bbbbb1 SB334867 eeeee1  [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific  bbbbb2 orexin-1 receptor eeeee2  antagonist] were administered directly into the hypothalamus
CPR:6	Small interfering RNA directed BDNF, orexin-A, and SB334867 [ bbbbb1 N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea eeeee1 ; a specific  bbbbb2 orexin-1 receptor eeeee2  antagonist] were administered directly into the hypothalamus
CPR:2	Filtering and analysis of data identified three oncogenic pathways interfered by  bbbbb1 5-ASA eeeee1 : MAPK/ERK pathway, cell adhesion and  bbbbb2 β-catenin eeeee2 /Wnt signaling
CPR:2	Filtering and analysis of data identified three oncogenic pathways interfered by  bbbbb1 5-ASA eeeee1 : MAPK/ERK pathway, cell adhesion and β-catenin/ bbbbb2 Wnt eeeee2  signaling
CPR:2	Filtering and analysis of data identified three oncogenic pathways interfered by  bbbbb1 5-ASA eeeee1 :  bbbbb2 MAPK eeeee2 /ERK pathway, cell adhesion and β-catenin/Wnt signaling
CPR:2	Filtering and analysis of data identified three oncogenic pathways interfered by  bbbbb1 5-ASA eeeee1 : MAPK/ bbbbb2 ERK eeeee2  pathway, cell adhesion and β-catenin/Wnt signaling
CPR:2	 bbbbb1 PAK1 eeeee1  emerged as a consensus target of  bbbbb2 5-ASA eeeee2 , orchestrating these pathways
CPR:2	Our data demonstrates novel pharmacological mechanism of  bbbbb1 mesalamine eeeee1  in modulation of cell adhesion and role of  bbbbb2 PAK1 eeeee2  in APC(min) polyposis
CPR:3	Moreover,  bbbbb1 5-ASA eeeee1  treatment restored membranous expression of adhesion molecules  bbbbb2 E-cadherin eeeee2  and β-catenin
CPR:3	Moreover,  bbbbb1 5-ASA eeeee1  treatment restored membranous expression of adhesion molecules E-cadherin and  bbbbb2 β-catenin eeeee2 
CPR:4	 bbbbb1 PAK1 eeeee1  expression was elevated in APC(min) polyps and  bbbbb2 5-ASA eeeee2  treatment reduced its expression
CPR:4	We propose that inhibition of  bbbbb1 PAK1 eeeee1  expression by  bbbbb2 5-ASA eeeee2  can impede with neoplastic progression in colorectal carcinogenesis
CPR:4	 bbbbb1 Mesalamine eeeee1  modulates intercellular adhesion through inhibition of  bbbbb2 p-21 activated kinase-1 eeeee2 
CPR:4	The mechanism of  bbbbb1 PAK1 eeeee1  inhibition and induction of membranous translocation of adhesion proteins by  bbbbb2 5-ASA eeeee2  might be independent of its known anti-inflammatory action.
CPR:3	This study shows ability of  bbbbb1 EGCG eeeee1  to raise plasma bile acid concentrations, mainly through  bbbbb2 Cyp7a1 eeeee2  upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow
CPR:4	In contrast,  bbbbb1 EGCG eeeee1  markedly downregulated major  bbbbb2 bile acid transporters eeeee2  (Asbt and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum
CPR:4	In contrast,  bbbbb1 EGCG eeeee1  markedly downregulated major bile acid transporters ( bbbbb2 Asbt eeeee2  and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum
CPR:4	In contrast,  bbbbb1 EGCG eeeee1  markedly downregulated major bile acid transporters (Asbt and  bbbbb2 Ostα eeeee2 ) and regulatory molecules (Shp and Fgf15) in the ileum
CPR:4	In contrast,  bbbbb1 EGCG eeeee1  markedly downregulated major bile acid transporters (Asbt and Ostα) and regulatory molecules ( bbbbb2 Shp eeeee2  and Fgf15) in the ileum
CPR:4	In contrast,  bbbbb1 EGCG eeeee1  markedly downregulated major bile acid transporters (Asbt and Ostα) and regulatory molecules (Shp and  bbbbb2 Fgf15 eeeee2 ) in the ileum
CPR:1	The serotonin (5-HT) receptors of type 6 ( bbbbb1 5-HT6 eeeee1 ) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long  bbbbb2 C eeeee2 -terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CPR:1	The  bbbbb1 serotonin (5-HT) receptors eeeee1  of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long  bbbbb2 C eeeee2 -terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CPR:2	These results reveal, for the first time, the differential distribution of P-CREB in fast- and slow-twitch muscles, which might support the crucial role of  bbbbb1 cAMP eeeee1 -dependent signaling in controlling the synapse-specific expression of  bbbbb2 ColQ-1a eeeee2  in fast-twitch muscles.
CPR:2	 bbbbb1 ColQ-1a eeeee1  is expressed at the neuromuscular junction (NMJ) in fast-twitch muscle, and this expression depends on trophic factors supplied by motor neurons signaling via a  bbbbb2 cAMP eeeee2 -dependent pathway in muscle
CPR:4	Data at transcriptional level also demonstrated that  bbbbb1 catalpol eeeee1  potently attenuated gene expressions involved in inflammation, such as  bbbbb2 iNOS eeeee2 , COX-2 and TLR4
CPR:4	Data at transcriptional level also demonstrated that  bbbbb1 catalpol eeeee1  potently attenuated gene expressions involved in inflammation, such as iNOS,  bbbbb2 COX-2 eeeee2  and TLR4
CPR:4	Data at transcriptional level also demonstrated that  bbbbb1 catalpol eeeee1  potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and  bbbbb2 TLR4 eeeee2 
CPR:4	In addition, our exploration further revealed that the suppressive action of  bbbbb1 catalpol eeeee1  on inflammation was mediated via inhibiting nuclear factor-κB ( bbbbb2 NF-κB eeeee2 ) activation
CPR:4	In addition, our exploration further revealed that the suppressive action of  bbbbb1 catalpol eeeee1  on inflammation was mediated via inhibiting  bbbbb2 nuclear factor-κB eeeee2  (NF-κB) activation
CPR:4	 bbbbb1 Catalpol eeeee1  inhibits LPS plus  bbbbb2 IFN-γ eeeee2 -induced inflammatory response in astrocytes primary cultures
CPR:4	Collectively, these results suggest that  bbbbb1 catalpol eeeee1  can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of  bbbbb2 NF-κB eeeee2  could be the major determinant for its anti-inflammatory mechanism
CPR:4	Biochemical analyses showed that NO and ROS production and  bbbbb1 iNOS eeeee1  activity were significantly reduced by  bbbbb2 catalpol eeeee2 
CPR:4	 bbbbb1 Protein tyrosine phosphatase 1B eeeee1  inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum  bbbbb2 saponins eeeee2 
CPR:4	 bbbbb1 Protein tyrosine phosphatase 1B eeeee1  inhibitory effect by  bbbbb2 dammarane eeeee2 -type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins
CPR:4	 bbbbb1 Protein tyrosine phosphatase 1B eeeee1  inhibitory effect by dammarane-type  bbbbb2 triterpenes eeeee2  from hydrolyzate of total Gynostemma pentaphyllum saponins
CPR:10	Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however  bbbbb1 phospho-GSK-3-β eeeee1  (Ser9) was not altered in  bbbbb2 (PhTe)(2) eeeee2  injected rat
CPR:1	Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however  bbbbb1 phospho-GSK-3-β eeeee1  ( bbbbb2 Ser eeeee2 9) was not altered in (PhTe)(2) injected rat
CPR:3	Therefore, the present results show that the earlier cerebellar responses to  bbbbb1 (PhTe)(2) eeeee1  include disruption of cytoskeletal homeostasis that could be related with  bbbbb2 MAPK eeeee2  and PKA activation and reactive astrogliosis
CPR:3	Therefore, the present results show that the earlier cerebellar responses to  bbbbb1 (PhTe)(2) eeeee1  include disruption of cytoskeletal homeostasis that could be related with MAPK and  bbbbb2 PKA eeeee2  activation and reactive astrogliosis
CPR:3	Also, reactive astrogliosis takes part of the early responses to the insult with  bbbbb1 (PhTe)(2) eeeee1 , evidenced by upregulated  bbbbb2 GFAP eeeee2  in Western blot, PCR and immunofluorescence analysis
CPR:4	Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for  bbbbb1 NeuN eeeee1 , suggesting that the in vivo exposure to  bbbbb2 (PhTe)(2) eeeee2  progressed to neuronal death
CPR:4	Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased  bbbbb1 Akt eeeee1  immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in  bbbbb2 (PhTe)(2) eeeee2  injected rat
CPR:9	Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted  bbbbb1 quinone eeeee1  substrate by the cancer-associated  bbbbb2 human NAD(P)H:quinone oxidoreductase isozyme 1 eeeee2  (hNQO1)
CPR:9	Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted  bbbbb1 quinone eeeee1  substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 ( bbbbb2 hNQO1 eeeee2 )
CPR:4	Synthesis, biological evaluation, and molecular modeling of  bbbbb1 glycyrrhizin eeeee1  derivatives as potent  bbbbb2 high-mobility group box-1 eeeee2  inhibitors with anti-heart-failure activity in vivo
CPR:6	Within the  bbbbb1 TPBP eeeee1  scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan- bbbbb2 mAChR eeeee2  antagonism, which was demonstrated to be mediated via the orthosteric site
CPR:6	Within the TPBP scaffold, either electronic or steric perturbations to the central  bbbbb1 piperidine eeeee1  ring led to a loss of selective M(1) allosteric agonism and afforded pan- bbbbb2 mAChR eeeee2  antagonism, which was demonstrated to be mediated via the orthosteric site
CPR:6	Additional SAR around a related M(1) allosteric agonist family ( bbbbb1 VU0357017 eeeee1 ) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan- bbbbb2 mAChR eeeee2  orthosteric antagonism
CPR:9	ffects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a  bbbbb1 P-gp eeeee1  substrate,  bbbbb2 risperidone eeeee2 , and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CPR:9	ffects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a  bbbbb1 P-gp eeeee1  substrate, risperidone, and its major metabolite,  bbbbb2 9-hydroxyrisperidone eeeee2 , in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CPR:1	In this study, we present the synthesis and pharmacological properties of new analogues of  bbbbb1 arginine vasopressin eeeee1  modified in the  bbbbb2 N eeeee2 -terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid
CPR:6	On the other hand, peptides modified with  bbbbb1 (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid eeeee1 , apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to  bbbbb2 arginine vasopressin eeeee2 
CPR:3	 bbbbb1 Liver X Receptor (LXR) α eeeee1  and LXR β are nuclear receptors activated by  bbbbb2 oxysterols eeeee2 , oxidized derivatives of cholesterol
CPR:3	Liver X Receptor (LXR) α and  bbbbb1 LXR β eeeee1  are nuclear receptors activated by  bbbbb2 oxysterols eeeee2 , oxidized derivatives of cholesterol
CPR:2	For example, involvement of  bbbbb1 β-catenin eeeee1  in LHβ induction by  bbbbb2 GnRH eeeee2  has been discovered
CPR:3	β-catenin regulates  bbbbb1 GnRH eeeee1 -induced  bbbbb2 FSHβ eeeee2  gene expression
CPR:3	Furthermore, knockdown of Brms1L significantly attenuated  bbbbb1 GnRH eeeee1 -induced  bbbbb2 FSHβ eeeee2  expression
CPR:3	Thus, our findings indicate that the expression of Brms1L depends on β-catenin activity and contributes to  bbbbb1 FSHβ eeeee1  induction by  bbbbb2 GnRH eeeee2 .
CPR:3	 bbbbb1 GnRH eeeee1  caused a sustained increase in nuclear  bbbbb2 β-catenin eeeee2  levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition
CPR:3	Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of  bbbbb1 FSHβ eeeee1  mRNA by  bbbbb2 GnRH eeeee2  depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the JNK-c-jun pathway. β-Catenin depletion had no impact on FSHβ mRNA stability
CPR:2	In conclusion, in this cellular model,  bbbbb1 DOX eeeee1  effectively protects against PQ toxicity by inducing P-gp and through the interaction with the  bbbbb2 choline transporter eeeee2 , suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.
CPR:3	In conclusion, in this cellular model,  bbbbb1 DOX eeeee1  effectively protects against PQ toxicity by inducing  bbbbb2 P-gp eeeee2  and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.
CPR:3	The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether  bbbbb1 doxorubicin eeeee1  (DOX), a known  bbbbb2 P-gp eeeee2  inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario
CPR:3	The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin ( bbbbb1 DOX eeeee1 ), a known  bbbbb2 P-gp eeeee2  inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario
CPR:9	The herbicide  bbbbb1 paraquat eeeee1  (PQ) is a  bbbbb2 P-gp eeeee2  substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote
CPR:4	 bbbbb1 P505-15 eeeee1  successfully inhibited SYK-mediated  bbbbb2 B-cell receptor eeeee2  signaling and decreased cell viability in NHL and CLL
CPR:4	The selective  bbbbb1 SYK eeeee1  inhibitor  bbbbb2 P505-15 eeeee2  (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia
CPR:4	The selective  bbbbb1 SYK eeeee1  inhibitor P505-15 ( bbbbb2 PRT062607 eeeee2 ) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia
CPR:4	 bbbbb1 P505-15 eeeee1  (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule  bbbbb2 SYK eeeee2  inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases
CPR:4	 bbbbb1 P505-15 eeeee1  (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor ( bbbbb2 SYK eeeee2  IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases
CPR:4	 bbbbb1 P505-15 eeeee1  (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti- bbbbb2 SYK eeeee2  activity that is at least 80-fold greater than its affinity for other kinases
CPR:4	P505-15 (also known as  bbbbb1 PRT062607 eeeee1 ) is a novel, highly selective, and orally bioavailable small molecule  bbbbb2 SYK eeeee2  inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases
CPR:4	P505-15 (also known as  bbbbb1 PRT062607 eeeee1 ) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor ( bbbbb2 SYK eeeee2  IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases
CPR:4	P505-15 (also known as  bbbbb1 PRT062607 eeeee1 ) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti- bbbbb2 SYK eeeee2  activity that is at least 80-fold greater than its affinity for other kinases
CPR:4	 bbbbb1 P505-15 eeeee1  successfully inhibited  bbbbb2 SYK eeeee2 -mediated B-cell receptor signaling and decreased cell viability in NHL and CLL
CPR:2	Alleles of  bbbbb1 RPB1 eeeee1  (RPO21) with elevated slippage rates were identified among  bbbbb2 6-azauracil eeeee2 -sensitive mutants and were also isolated using a slippage-dependent reporter gene
CPR:2	Alleles of RPB1 ( bbbbb1 RPO21 eeeee1 ) with elevated slippage rates were identified among  bbbbb2 6-azauracil eeeee2 -sensitive mutants and were also isolated using a slippage-dependent reporter gene
CPR:2	We demonstrated that  bbbbb1 AhR eeeee1  protein not only functions as a downstream target of  bbbbb2 17-AAG eeeee2 , but also enhances anticancer activity of 17-AAG in lung AD cells.
CPR:2	 bbbbb1 Aryl hydrocarbon receptor eeeee1  is a target of  bbbbb2 17-Allylamino-17-demethoxygeldanamycin eeeee2  and enhances its anticancer activity in lung adenocarcinoma cells
CPR:4	Although treatment with  bbbbb1 17-AAG eeeee1  reduced  bbbbb2 AhR eeeee2  levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG
CPR:4	Although treatment with  bbbbb1 17-AAG eeeee1  reduced AhR levels and  bbbbb2 AhR eeeee2 -regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG
CPR:4	In addition,  bbbbb1 17-AAG eeeee1  treatment reduced cell viability,  bbbbb2 CDK2 eeeee2 , CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells
CPR:4	In addition,  bbbbb1 17-AAG eeeee1  treatment reduced cell viability, CDK2,  bbbbb2 CDK4 eeeee2 , cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells
CPR:4	In addition,  bbbbb1 17-AAG eeeee1  treatment reduced cell viability, CDK2, CDK4,  bbbbb2 cyclin E eeeee2 , cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells
CPR:4	In addition,  bbbbb1 17-AAG eeeee1  treatment reduced cell viability, CDK2, CDK4, cyclin E,  bbbbb2 cyclin D1 eeeee2 , and phosphorylated Rb levels in AhR-expressing lung AD cells
CPR:4	In addition,  bbbbb1 17-AAG eeeee1  treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and  bbbbb2 phosphorylated Rb eeeee2  levels in AhR-expressing lung AD cells
CPR:4	AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm.  bbbbb1 17-Allylamino-17-demethoxygeldanamycin eeeee1  (17-AAG), an  bbbbb2 Hsp90 eeeee2  inhibitor, is currently under evaluation for its anticancer activity in clinical trials
CPR:4	AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin ( bbbbb1 17-AAG eeeee1 ), an  bbbbb2 Hsp90 eeeee2  inhibitor, is currently under evaluation for its anticancer activity in clinical trials
CPR:10	 bbbbb1 DCK eeeee1  did not significantly contribute to  bbbbb2 dFdU eeeee2  monophosphorylation
CPR:10	In conclusion, the  bbbbb1 Lys27Gln eeeee1  substitution does not significantly modulate CDA activity toward dFdC, and therefore would not contribute to interindividual variability in response to  bbbbb2 gemcitabine eeeee2 
CPR:10	In conclusion, the Lys27Gln substitution does not significantly modulate  bbbbb1 CDA eeeee1  activity toward dFdC, and therefore would not contribute to interindividual variability in response to  bbbbb2 gemcitabine eeeee2 
CPR:9	Wild-type enzymes and variants of  bbbbb1 CDA eeeee1  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( bbbbb2 Ara-C eeeee2 ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA ( bbbbb1 Lys27Gln eeeee1  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( bbbbb2 Ara-C eeeee2 ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and  bbbbb1 Ala70Thr eeeee1 ) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( bbbbb2 Ara-C eeeee2 ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  bbbbb1 DCK eeeee1  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( bbbbb2 Ara-C eeeee2 ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( bbbbb1 Ile24Val eeeee1 , Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( bbbbb2 Ara-C eeeee2 ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  bbbbb1 Ala119Gly eeeee1 , and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( bbbbb2 Ara-C eeeee2 ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  bbbbb1 Pro122Ser eeeee1 ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ( bbbbb2 Ara-C eeeee2 ), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of  bbbbb1 CDA eeeee1  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  bbbbb2 dFdC eeeee2 , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA ( bbbbb1 Lys27Gln eeeee1  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  bbbbb2 dFdC eeeee2 , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and  bbbbb1 Ala70Thr eeeee1 ) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  bbbbb2 dFdC eeeee2 , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  bbbbb1 DCK eeeee1  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  bbbbb2 dFdC eeeee2 , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( bbbbb1 Ile24Val eeeee1 , Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  bbbbb2 dFdC eeeee2 , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  bbbbb1 Ala119Gly eeeee1 , and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  bbbbb2 dFdC eeeee2 , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  bbbbb1 Pro122Ser eeeee1 ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C),  bbbbb2 dFdC eeeee2 , and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of  bbbbb1 CDA eeeee1  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  bbbbb2 2',2'-difluorodeoxyuridine eeeee2  (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA ( bbbbb1 Lys27Gln eeeee1  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  bbbbb2 2',2'-difluorodeoxyuridine eeeee2  (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and  bbbbb1 Ala70Thr eeeee1 ) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  bbbbb2 2',2'-difluorodeoxyuridine eeeee2  (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  bbbbb1 DCK eeeee1  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  bbbbb2 2',2'-difluorodeoxyuridine eeeee2  (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( bbbbb1 Ile24Val eeeee1 , Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  bbbbb2 2',2'-difluorodeoxyuridine eeeee2  (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  bbbbb1 Ala119Gly eeeee1 , and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  bbbbb2 2',2'-difluorodeoxyuridine eeeee2  (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  bbbbb1 Pro122Ser eeeee1 ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite  bbbbb2 2',2'-difluorodeoxyuridine eeeee2  (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of  bbbbb1 CDA eeeee1  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ( bbbbb2 dFdU eeeee2 ) as substrates
CPR:9	All three  bbbbb1 CDA eeeee1  proteins showed similar K(m) and V(max) for  bbbbb2 Ara-C eeeee2  and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination
CPR:9	All three  bbbbb1 CDA eeeee1  proteins showed similar K(m) and V(max) for Ara-C and  bbbbb2 dFdC eeeee2  deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination
CPR:9	All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for  bbbbb1 CDA eeeee1 70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for  bbbbb2 Ara-C eeeee2  deamination
CPR:9	All four  bbbbb1 DCK eeeee1  proteins yielded comparable metabolic activity for  bbbbb2 Ara-C eeeee2  and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)
CPR:9	All four  bbbbb1 DCK eeeee1  proteins yielded comparable metabolic activity for Ara-C and  bbbbb2 dFdC eeeee2  monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)
CPR:9	 bbbbb1 Gemcitabine eeeee1  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ( bbbbb2 DCK eeeee2 ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	 bbbbb1 Gemcitabine eeeee1  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by  bbbbb2 cytidine deaminase eeeee2  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	 bbbbb1 Gemcitabine eeeee1  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase ( bbbbb2 CDA eeeee2 ) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	 bbbbb1 Gemcitabine eeeee1  (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  bbbbb2 deoxycytidine kinase eeeee2  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for  bbbbb1 DCK eeeee1 24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of  bbbbb2 dFdC eeeee2  monophosphorylation due to a 40% decrease in K(m) (P < 0.05)
CPR:9	In conclusion, the  bbbbb1 Lys27Gln eeeee1  substitution does not significantly modulate CDA activity toward  bbbbb2 dFdC eeeee2 , and therefore would not contribute to interindividual variability in response to gemcitabine
CPR:9	In conclusion, the Lys27Gln substitution does not significantly modulate  bbbbb1 CDA eeeee1  activity toward  bbbbb2 dFdC eeeee2 , and therefore would not contribute to interindividual variability in response to gemcitabine
CPR:9	Gemcitabine ( bbbbb1 dFdC eeeee1 , 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ( bbbbb2 DCK eeeee2 ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	Gemcitabine ( bbbbb1 dFdC eeeee1 , 2',2'-difluorodeoxycytidine) is metabolized by  bbbbb2 cytidine deaminase eeeee2  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	Gemcitabine ( bbbbb1 dFdC eeeee1 , 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase ( bbbbb2 CDA eeeee2 ) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	Gemcitabine ( bbbbb1 dFdC eeeee1 , 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  bbbbb2 deoxycytidine kinase eeeee2  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	The higher in vitro catalytic efficiency of  bbbbb1 DCK eeeee1 24Val toward  bbbbb2 dFdC eeeee2  monophosphorylation may be relevant to dFdC clinical response
CPR:9	The higher in vitro catalytic efficiency of  bbbbb1 DCK eeeee1 24Val toward dFdC monophosphorylation may be relevant to  bbbbb2 dFdC eeeee2  clinical response
CPR:9	Gemcitabine (dFdC,  bbbbb1 2',2'-difluorodeoxycytidine eeeee1 ) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ( bbbbb2 DCK eeeee2 ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	Gemcitabine (dFdC,  bbbbb1 2',2'-difluorodeoxycytidine eeeee1 ) is metabolized by  bbbbb2 cytidine deaminase eeeee2  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	Gemcitabine (dFdC,  bbbbb1 2',2'-difluorodeoxycytidine eeeee1 ) is metabolized by cytidine deaminase ( bbbbb2 CDA eeeee2 ) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	Gemcitabine (dFdC,  bbbbb1 2',2'-difluorodeoxycytidine eeeee1 ) is metabolized by cytidine deaminase (CDA) and  bbbbb2 deoxycytidine kinase eeeee2  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CPR:9	Wild-type enzymes and variants of  bbbbb1 CDA eeeee1  (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  bbbbb2 cytarabine eeeee2  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA ( bbbbb1 Lys27Gln eeeee1  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  bbbbb2 cytarabine eeeee2  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and  bbbbb1 Ala70Thr eeeee1 ) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  bbbbb2 cytarabine eeeee2  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and  bbbbb1 DCK eeeee1  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  bbbbb2 cytarabine eeeee2  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK ( bbbbb1 Ile24Val eeeee1 , Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  bbbbb2 cytarabine eeeee2  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val,  bbbbb1 Ala119Gly eeeee1 , and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  bbbbb2 cytarabine eeeee2  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:9	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and  bbbbb1 Pro122Ser eeeee1 ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for  bbbbb2 cytarabine eeeee2  (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CPR:4	A series of compounds based on a  bbbbb1 4-phenyl-2-phenylaminopyridine eeeee1  scaffold that are potent and selective inhibitors of  bbbbb2 Traf2- and Nck-interacting kinase eeeee2  (TNIK) activity are described
CPR:4	A series of compounds based on a  bbbbb1 4-phenyl-2-phenylaminopyridine eeeee1  scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase ( bbbbb2 TNIK eeeee2 ) activity are described
CPR:4	Discovery of  bbbbb1 4-phenyl-2-phenylaminopyridine eeeee1  based  bbbbb2 TNIK eeeee2  inhibitors
CPR:4	Here we present  bbbbb1 boronic eeeee1  and borinic acid derivatives as a new class of potent and nontoxic  bbbbb2 APT eeeee2  inhibitors
CPR:4	Here we present boronic and  bbbbb1 borinic acid eeeee1  derivatives as a new class of potent and nontoxic  bbbbb2 APT eeeee2  inhibitors
CPR:4	 bbbbb1 Boron eeeee1 -based inhibitors of  bbbbb2 acyl protein thioesterases 1 and 2 eeeee2 
CPR:10	 bbbbb1 Genistein eeeee1  had no effect on resting intracellular [Ca(2+)] or  bbbbb2 thrombin eeeee2 -induced increase in Ca(2+) mobilization
CPR:1	Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of  bbbbb1 myosin light chain eeeee1  (MLC) on  bbbbb2 Ser eeeee2 (19)/Thr(18) in endothelial cells (ECs)
CPR:1	Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain ( bbbbb1 MLC eeeee1 ) on  bbbbb2 Ser eeeee2 (19)/Thr(18) in endothelial cells (ECs)
CPR:1	Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of  bbbbb1 myosin light chain eeeee1  (MLC) on Ser(19)/ bbbbb2 Thr eeeee2 (18) in endothelial cells (ECs)
CPR:1	Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain ( bbbbb1 MLC eeeee1 ) on Ser(19)/ bbbbb2 Thr eeeee2 (18) in endothelial cells (ECs)
CPR:2	Phytoestrogen  bbbbb1 genistein eeeee1  protects against endothelial barrier dysfunction in vascular endothelial cells through PKA-mediated suppression of  bbbbb2 RhoA eeeee2  signaling
CPR:2	These findings demonstrated that  bbbbb1 genistein eeeee1  improves thrombin-induced endothelial barrier dysfunction in ECs through PKA-mediated suppression of  bbbbb2 RhoA eeeee2  signaling.
CPR:2	Phytoestrogen  bbbbb1 genistein eeeee1  protects against endothelial barrier dysfunction in vascular endothelial cells through  bbbbb2 PKA eeeee2 -mediated suppression of RhoA signaling
CPR:2	Inhibition of PKA significantly attenuated the effect of  bbbbb1 genistein eeeee1  on  bbbbb2 thrombin eeeee2 -induced EC permeability, MLC phosphorylation, and RhoA membrane translocation in ECs
CPR:2	Inhibition of PKA significantly attenuated the effect of  bbbbb1 genistein eeeee1  on thrombin-induced EC permeability,  bbbbb2 MLC eeeee2  phosphorylation, and RhoA membrane translocation in ECs
CPR:2	Inhibition of PKA significantly attenuated the effect of  bbbbb1 genistein eeeee1  on thrombin-induced EC permeability, MLC phosphorylation, and  bbbbb2 RhoA eeeee2  membrane translocation in ECs
CPR:2	These findings demonstrated that  bbbbb1 genistein eeeee1  improves  bbbbb2 thrombin eeeee2 -induced endothelial barrier dysfunction in ECs through PKA-mediated suppression of RhoA signaling.
CPR:2	These findings demonstrated that  bbbbb1 genistein eeeee1  improves thrombin-induced endothelial barrier dysfunction in ECs through  bbbbb2 PKA eeeee2 -mediated suppression of RhoA signaling.
CPR:4	Furthermore,  bbbbb1 thrombin eeeee1  diminished cAMP production in ECs, which were prevented by treatment with  bbbbb2 genistein eeeee2 
CPR:4	Here, we report that  bbbbb1 genistein eeeee1  at physiologically relevant concentrations (0.1-10 μM) significantly inhibited  bbbbb2 thrombin eeeee2 -induced increase in endothelial monolayer permeability
CPR:4	 bbbbb1 Genistein eeeee1  also reduced the formation of stress fibers by  bbbbb2 thrombin eeeee2  and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)
CPR:4	 bbbbb1 Genistein eeeee1  also reduced the formation of stress fibers by thrombin and suppressed  bbbbb2 thrombin eeeee2 -induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)
CPR:4	 bbbbb1 Genistein eeeee1  also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of  bbbbb2 myosin light chain eeeee2  (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)
CPR:4	 bbbbb1 Genistein eeeee1  also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain ( bbbbb2 MLC eeeee2 ) on Ser(19)/Thr(18) in endothelial cells (ECs)
CPR:10	In contrast,  bbbbb1 GSK1292263 eeeee1  did not inhibit  bbbbb2 OATP1B1 eeeee2  based on the lack of changes in simvastatin acid exposure [mean AUC(0-inf) ratio (90% CI) of 1.05 (0.91, 1.21)]. 5. GSK1292263 has a weak drug interaction with simvastatin and rosuvastain
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  demonstrated little/weak inhibition (IC50 values >30 μM) towards  bbbbb2 CYPs eeeee2  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs ( bbbbb2 CYP1A2 eeeee2 , 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2,  bbbbb2 2C9 eeeee2 , 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9,  bbbbb2 2C19 eeeee2 , 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19,  bbbbb2 2D6 eeeee2 , 3A4), Pgp, OATP1B3, or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  bbbbb2 3A4 eeeee2 ), Pgp, OATP1B3, or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  bbbbb2 Pgp eeeee2 , OATP1B3, or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  bbbbb2 OATP1B3 eeeee2 , or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  bbbbb2 OCT2 eeeee2 
CPR:4	However,  bbbbb1 GSK1292263 eeeee1  inhibited  bbbbb2 BCRP eeeee2  and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4
CPR:4	However,  bbbbb1 GSK1292263 eeeee1  inhibited BCRP and  bbbbb2 OATP1B1 eeeee2 , which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4
CPR:4	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with  bbbbb1 GSK1292263 eeeee1 , which is consistent with an inhibitory effect on intestinal BCRP and  bbbbb2 CYP3A4 eeeee2 
CPR:4	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with  bbbbb1 GSK1292263 eeeee1 , which is consistent with an inhibitory effect on intestinal  bbbbb2 BCRP eeeee2  and CYP3A4
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the  bbbbb1 HMG-coA reductase eeeee1  inhibitors  bbbbb2 simvastatin eeeee2  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:4	This study provides a mechanistic understanding of the in vivo inhibition of  bbbbb1 transporters eeeee1  and enzymes by  bbbbb2 GSK1292263 eeeee2 .
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the  bbbbb1 HMG-coA reductase eeeee1  inhibitors simvastatin and  bbbbb2 rosuvastatin eeeee2 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of  bbbbb1 transporters eeeee1  and CYP enzymes by  bbbbb2 GSK1292263 eeeee2 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:4	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and  bbbbb1 CYP eeeee1  enzymes by  bbbbb2 GSK1292263 eeeee2 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:5	valuation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel  bbbbb2 GPR119 eeeee2  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:5	valuation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a  bbbbb2 GPR119 eeeee2  agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CPR:10	Proteins  bbbbb1 Aus1 eeeee1  and Dan1 were not found to be involved in  bbbbb2 steroid eeeee2  import
CPR:10	Proteins Aus1 and  bbbbb1 Dan1 eeeee1  were not found to be involved in  bbbbb2 steroid eeeee2  import
CPR:4	The presence of  bbbbb1 steroid eeeee1  hormones most probably causes the degradation of the  bbbbb2 Tat2 eeeee2  permease and impairment of tryptophan import.
CPR:2	Promoter replacements conferring constitutive expression of  bbbbb1 MSH2 eeeee1  revealed that the transcriptional induction in response to  bbbbb2 MMS eeeee2  is required to maintain induced levels of Msh2
CPR:2	Promoter replacements conferring constitutive expression of MSH2 revealed that the transcriptional induction in response to  bbbbb1 MMS eeeee1  is required to maintain induced levels of  bbbbb2 Msh2 eeeee2 
CPR:4	Further study showed that  bbbbb1 icariin eeeee1  dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory  bbbbb2 cytokine eeeee2  levels of activated T cells
CPR:4	Inhibition of Th1/Th17 responses via suppression of  bbbbb1 STAT1 eeeee1  and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside  bbbbb2 icariin eeeee2 
CPR:4	Inhibition of Th1/Th17 responses via suppression of STAT1 and  bbbbb1 STAT3 eeeee1  activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside  bbbbb2 icariin eeeee2 
CPR:4	Moreover,  bbbbb1 icariin eeeee1  treatment inhibited the phosphorylations of  bbbbb2 STAT1 eeeee2  and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively
CPR:4	Moreover,  bbbbb1 icariin eeeee1  treatment inhibited the phosphorylations of STAT1 and  bbbbb2 STAT3 eeeee2  in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively
CPR:4	Inhibition of Th1/Th17 responses via suppression of  bbbbb1 STAT1 eeeee1  and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural  bbbbb2 flavonoid eeeee2  glucoside icariin
CPR:4	Inhibition of Th1/Th17 responses via suppression of STAT1 and  bbbbb1 STAT3 eeeee1  activation contributes to the amelioration of murine experimental colitis by a natural  bbbbb2 flavonoid eeeee2  glucoside icariin
CPR:4	Pharmacological inhibition of MTORC1 with  bbbbb1 rapamycin eeeee1  abrogated the  bbbbb2 insulin eeeee2 -induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6
CPR:4	Furthermore,  bbbbb1 insulin eeeee1 -stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by  bbbbb2 rapamycin eeeee2 
CPR:4	Furthermore, insulin-stimulated T-I cell proliferation and the expression of  bbbbb1 cell cycle regulatory proteins eeeee1  CDK4, CCND3 and PCNA were also blocked by  bbbbb2 rapamycin eeeee2 
CPR:4	Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins  bbbbb1 CDK4 eeeee1 , CCND3 and PCNA were also blocked by  bbbbb2 rapamycin eeeee2 
CPR:4	Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4,  bbbbb1 CCND3 eeeee1  and PCNA were also blocked by  bbbbb2 rapamycin eeeee2 
CPR:4	Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and  bbbbb1 PCNA eeeee1  were also blocked by  bbbbb2 rapamycin eeeee2 
CPR:4	Pharmacological inhibition of  bbbbb1 MTORC1 eeeee1  with  bbbbb2 rapamycin eeeee2  abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6
CPR:4	Pharmacological inhibition of MTORC1 with  bbbbb1 rapamycin eeeee1  abrogated the insulin-induced phosphorylation of  bbbbb2 EIF4EBP1 eeeee2 , RPS6KB1 and its downstream effector, RPS6
CPR:4	Pharmacological inhibition of MTORC1 with  bbbbb1 rapamycin eeeee1  abrogated the insulin-induced phosphorylation of EIF4EBP1,  bbbbb2 RPS6KB1 eeeee2  and its downstream effector, RPS6
CPR:4	Pharmacological inhibition of MTORC1 with  bbbbb1 rapamycin eeeee1  abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector,  bbbbb2 RPS6 eeeee2 
CPR:1	AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the  bbbbb1 N eeeee1 -terminal PHD fingers of  bbbbb2 AF10 eeeee2 
CPR:2	We demonstrate that the PHD1-PHD2 region is essential for viability and that the first PHD finger contributes to the preferred binding of  bbbbb1 PHD1-PHD2 eeeee1  to  bbbbb2 lysine eeeee2  4-methylated histone H3 tails
CPR:5	We report the discovery of novel series of highly potent  bbbbb1 TLR7 eeeee1  agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various  bbbbb2 tertiary amines eeeee2  onto the N(9)-position of the adenine moiety
CPR:5	We report the discovery of novel series of highly potent  bbbbb1 TLR7 eeeee1  agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the  bbbbb2 N eeeee2 (9)-position of the adenine moiety
CPR:5	We report the discovery of novel series of highly potent  bbbbb1 TLR7 eeeee1  agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the  bbbbb2 adenine eeeee2  moiety
CPR:5	The introduction of the  bbbbb1 amino eeeee1  group resulted in not only improved water solubility but also enhanced  bbbbb2 TLR7 eeeee2  agonistic activity
CPR:5	We report the discovery of novel series of highly potent  bbbbb1 TLR7 eeeee1  agonists based on  bbbbb2 8-oxoadenines eeeee2 , 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety
CPR:5	Synthesis and evaluation of  bbbbb1 8-oxoadenine eeeee1  derivatives as potent  bbbbb2 Toll-like receptor 7 eeeee2  agonists with high water solubility
CPR:4	Inhibitors based on a  bbbbb1 benzo-fused spirocyclic oxazepine eeeee1  scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 ( bbbbb2 SCD1 eeeee2 ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model
CPR:4	Inhibitors based on a  bbbbb1 benzo-fused spirocyclic oxazepine eeeee1  scaffold were discovered for  bbbbb2 stearoyl-coenzyme A (CoA) desaturase 1 eeeee2  (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model
CPR:4	The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited  bbbbb1 human Hsp60 eeeee1  chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of  bbbbb2 ETB eeeee2  (IC(50): 10.9 ± 0.63 μM).
CPR:2	 bbbbb1 Apocynin eeeee1  and raisanberine alleviate intermittent hypoxia induced abnormal  bbbbb2 StAR eeeee2  and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes
CPR:2	 bbbbb1 Apocynin eeeee1  and raisanberine alleviate intermittent hypoxia induced abnormal StAR and  bbbbb2 3β-HSD eeeee2  and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes
CPR:2	Apocynin and  bbbbb1 raisanberine eeeee1  alleviate intermittent hypoxia induced abnormal  bbbbb2 StAR eeeee2  and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes
CPR:4	 bbbbb1 Apocynin eeeee1  and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated  bbbbb2 p66Shc eeeee2  in rat testes
CPR:4	Apocynin and  bbbbb1 raisanberine eeeee1  alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated  bbbbb2 p66Shc eeeee2  in rat testes
CPR:4	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore,  bbbbb1 APO eeeee1  (apocynin) an inhibitor of  bbbbb2 NOX eeeee2  and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CPR:4	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO ( bbbbb1 apocynin eeeee1 ) an inhibitor of  bbbbb2 NOX eeeee2  and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CPR:4	 bbbbb1 APO eeeee1  and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and  bbbbb2 p66Shc eeeee2  in testes.
CPR:9	Apocynin and  bbbbb1 raisanberine eeeee1  alleviate intermittent hypoxia induced abnormal StAR and  bbbbb2 3β-HSD eeeee2  and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes
CPR:10	Here we found that  bbbbb1 arsenic trioxide eeeee1 , a frontline agent for acute promyelocytic leukemia, inhibits ΔNp63 but not  bbbbb2 TAp63 eeeee2  expression in time- and dose-dependent manners
CPR:2	In addition, we found that  bbbbb1 arsenic trioxide eeeee1  decreases the stability of ΔNp63 protein via a proteasome-dependent pathway but has little effect on the level of  bbbbb2 ΔNp63 eeeee2  transcript
CPR:2	 bbbbb1 Arsenic eeeee1  suppresses cell survival via Pirh2-mediated proteasomal degradation of  bbbbb2 ΔNp63 eeeee2  protein
CPR:2	Together, these data suggest that  bbbbb1 arsenic eeeee1  degrades ΔNp63 protein at least in part via  bbbbb2 Pirh2 eeeee2 -dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to arsenic-induced death.
CPR:2	In addition, we found that  bbbbb1 arsenic trioxide eeeee1  decreases the stability of ΔNp63 protein via a  bbbbb2 proteasome eeeee2 -dependent pathway but has little effect on the level of ΔNp63 transcript
CPR:2	 bbbbb1 Arsenic eeeee1  suppresses cell survival via  bbbbb2 Pirh2 eeeee2 -mediated proteasomal degradation of ΔNp63 protein
CPR:3	Furthermore, we found that  bbbbb1 arsenic trioxide eeeee1  activates the  bbbbb2 Pirh2 promoter eeeee2  and consequently induces Pirh2 expression
CPR:3	Furthermore, we found that  bbbbb1 arsenic trioxide eeeee1  activates the Pirh2 promoter and consequently induces  bbbbb2 Pirh2 eeeee2  expression
CPR:4	Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances,  bbbbb1 arsenic eeeee1 -induced degradation of  bbbbb2 ΔNp63 eeeee2  protein
CPR:4	Together, these data suggest that  bbbbb1 arsenic eeeee1  degrades  bbbbb2 ΔNp63 eeeee2  protein at least in part via Pirh2-dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to arsenic-induced death.
CPR:4	Together, these data suggest that  bbbbb1 arsenic eeeee1  degrades ΔNp63 protein at least in part via Pirh2-dependent proteolysis and that inhibition of  bbbbb2 ΔNp63 eeeee2  expression facilitates tumor cells to arsenic-induced death.
CPR:4	Here we found that  bbbbb1 arsenic trioxide eeeee1 , a frontline agent for acute promyelocytic leukemia, inhibits  bbbbb2 ΔNp63 eeeee2  but not TAp63 expression in time- and dose-dependent manners
CPR:4	In addition, we found that  bbbbb1 arsenic trioxide eeeee1  decreases the stability of  bbbbb2 ΔNp63 eeeee2  protein via a proteasome-dependent pathway but has little effect on the level of ΔNp63 transcript
CPR:2	 bbbbb1 Jaceosidin eeeee1  induced G2/M phase cell cycle arrest and modulated the levels of  bbbbb2 cyclin B eeeee2  and p-Cdc2 in Hec1A cells
CPR:2	 bbbbb1 Jaceosidin eeeee1  induced G2/M phase cell cycle arrest and modulated the levels of cyclin B and  bbbbb2 p-Cdc2 eeeee2  in Hec1A cells
CPR:2	Moreover,  bbbbb1 jaceosidin eeeee1  treatment resulted in phosphorylation of  bbbbb2 ERK eeeee2 , and pretreatment with the ERK inhibitor, PD98059, attenuated cell growth inhibition by jaceosidin
CPR:2	These data suggest that  bbbbb1 jaceosidin eeeee1 , isolated from Japanese mugwort, modulates the  bbbbb2 ERK eeeee2 /ATM/Chk1/2 pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.
CPR:2	These data suggest that  bbbbb1 jaceosidin eeeee1 , isolated from Japanese mugwort, modulates the ERK/ bbbbb2 ATM eeeee2 /Chk1/2 pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.
CPR:3	Additional mechanistic studies revealed that  bbbbb1 jaceosidin eeeee1  treatment resulted in an increase in phosphorylation of  bbbbb2 Cdc25C eeeee2  and ATM-Chk1/2
CPR:3	Additional mechanistic studies revealed that  bbbbb1 jaceosidin eeeee1  treatment resulted in an increase in phosphorylation of Cdc25C and  bbbbb2 ATM eeeee2 -Chk1/2
CPR:3	 bbbbb1 Jaceosidin eeeee1 , isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via  bbbbb2 ATM eeeee2 -Chk1/2 activation
CPR:4	 bbbbb1 Jaceosidin eeeee1 , isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating  bbbbb2 cdc25C eeeee2 -cdc2 via ATM-Chk1/2 activation
CPR:4	 bbbbb1 Jaceosidin eeeee1 , isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C- bbbbb2 cdc2 eeeee2  via ATM-Chk1/2 activation
CPR:4	Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the  bbbbb1 ERK eeeee1  inhibitor,  bbbbb2 PD98059 eeeee2 , attenuated cell growth inhibition by jaceosidin
CPR:4	These data suggest that  bbbbb1 jaceosidin eeeee1 , isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the  bbbbb2 Cdc2 eeeee2 -cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.
CPR:4	These data suggest that  bbbbb1 jaceosidin eeeee1 , isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2- bbbbb2 cyclin B1 eeeee2  complex, followed by G2/M cell cycle arrest in endometrial cancer cells.
CPR:2	Electrical Stimuli Release  bbbbb1 ATP eeeee1  to Increase  bbbbb2 GLUT4 eeeee2  Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells
CPR:2	Electrical Stimuli Release  bbbbb1 ATP eeeee1  to Increase GLUT4 Translocation and Glucose Uptake via  bbbbb2 PI3Kγ eeeee2 -Akt-AS160 in Skeletal Muscle Cells
CPR:2	Electrical Stimuli Release  bbbbb1 ATP eeeee1  to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ- bbbbb2 Akt eeeee2 -AS160 in Skeletal Muscle Cells
CPR:2	Electrical Stimuli Release  bbbbb1 ATP eeeee1  to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt- bbbbb2 AS160 eeeee2  in Skeletal Muscle Cells
CPR:2	 bbbbb1 ATP eeeee1  caused translocation of  bbbbb2 GLUT4 eeeee2 myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or PI3Kγ kinase-dead mutants, and potentiated by myristoylated PI3Kγ
CPR:2	 bbbbb1 ATP eeeee1  is released from skeletal muscle by contractile activity and can autocrinely signal through  bbbbb2 purinergic receptors eeeee2 , and we hypothesized it may influence glucose uptake
CPR:3	Exogenous  bbbbb1 ATP eeeee1  transiently activated  bbbbb2 Akt eeeee2  and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CPR:4	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by  bbbbb1 adenosine-phosphate phosphatase eeeee1  and by purinergic receptor blockade ( bbbbb2 suramin eeeee2 )
CPR:4	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by  bbbbb1 purinergic receptor eeeee1  blockade ( bbbbb2 suramin eeeee2 )
CPR:4	Electrical stimulation transiently elevated extracellular ATP and caused  bbbbb1 Akt eeeee1  phosphorylation that was additive to insulin and inhibited by  bbbbb2 suramin eeeee2 
CPR:4	ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the  bbbbb1 phosphatidylinositol 3-kinase-γ eeeee1  (PI3Kγ) inhibitor  bbbbb2 AS605240 eeeee2 
CPR:4	ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ ( bbbbb1 PI3Kγ eeeee1 ) inhibitor  bbbbb2 AS605240 eeeee2 
CPR:9	Electrical Stimuli Release ATP to Increase  bbbbb1 GLUT4 eeeee1  Translocation and  bbbbb2 Glucose eeeee2  Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells
CPR:1	The CSN/IRF5 interaction occurred on the  bbbbb1 carboxyl eeeee1  and amino termini of  bbbbb2 IRF5 eeeee2 ; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability
CPR:1	The CSN/IRF5 interaction occurred on the carboxyl and  bbbbb1 amino eeeee1  termini of  bbbbb2 IRF5 eeeee2 ; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability
CPR:1	The CSN/IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from  bbbbb1 amino acids eeeee1  455 to 466 (Δ455-466) was found to significantly reduce  bbbbb2 IRF5 eeeee2  protein stability
CPR:2	A series of  bbbbb1 anthra[1,2-d]imidazole-6,11-dione eeeee1  derivatives were synthesized and evaluated for telomerase inhibition,  bbbbb2 hTERT eeeee2  expression and suppression of cancer cell growth in vitro
CPR:4	A series of  bbbbb1 anthra[1,2-d]imidazole-6,11-dione eeeee1  derivatives were synthesized and evaluated for  bbbbb2 telomerase eeeee2  inhibition, hTERT expression and suppression of cancer cell growth in vitro
CPR:4	Structure-based design, synthesis and evaluation of novel  bbbbb1 anthra[1,2-d]imidazole-6,11-dione eeeee1  derivatives as  bbbbb2 telomerase eeeee2  inhibitors and potential for cancer polypharmacology
CPR:2	In addition,  bbbbb1 TSA eeeee1  induced  bbbbb2 Nrf2 eeeee2  nuclear translocation and up-regulated the expression of Nrf2-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation
CPR:2	The present study aimed at investigating the role of reactive oxygen species (ROS) scavenging by  bbbbb1 TSA eeeee1  on  bbbbb2 transforming growth factor-β eeeee2  (TGF-β)-induced myofibroblast differentiation of corneal fibroblasts in vitro
CPR:2	Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the  bbbbb1 TGF-β eeeee1 -induced myofibroblast differentiation as compared with treatment with  bbbbb2 DPI eeeee2  or NAC
CPR:2	Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the  bbbbb1 TGF-β eeeee1 -induced myofibroblast differentiation as compared with treatment with DPI or  bbbbb2 NAC eeeee2 
CPR:3	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the  bbbbb1 NF-E2-related factor 2 eeeee1 -antioxidant response element (Nrf2-ARE) activator  bbbbb2 sulforaphane eeeee2 , or small interfering RNA
CPR:3	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2- bbbbb1 antioxidant response element eeeee1  (Nrf2-ARE) activator  bbbbb2 sulforaphane eeeee2 , or small interfering RNA
CPR:3	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element ( bbbbb1 Nrf2 eeeee1 -ARE) activator  bbbbb2 sulforaphane eeeee2 , or small interfering RNA
CPR:3	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2- bbbbb1 ARE eeeee1 ) activator  bbbbb2 sulforaphane eeeee2 , or small interfering RNA
CPR:3	In conclusion, this study provides the first evidence implicating that  bbbbb1 TSA eeeee1  inhibits TGF-β-induced ROS accumulation and myofibroblast differentiation via enhanced  bbbbb2 Nrf2 eeeee2 -ARE signaling.
CPR:3	In conclusion, this study provides the first evidence implicating that  bbbbb1 TSA eeeee1  inhibits TGF-β-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2- bbbbb2 ARE eeeee2  signaling.
CPR:3	 bbbbb1 Trichostatin A eeeee1  inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced  bbbbb2 NF-E2-related factor 2 eeeee2 -antioxidant response element signaling
CPR:3	 bbbbb1 Trichostatin A eeeee1  inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2- bbbbb2 antioxidant response element eeeee2  signaling
CPR:3	In addition,  bbbbb1 TSA eeeee1  induced Nrf2 nuclear translocation and up-regulated the expression of  bbbbb2 Nrf2 eeeee2 -ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation
CPR:3	In addition,  bbbbb1 TSA eeeee1  induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2- bbbbb2 ARE eeeee2  downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation
CPR:4	In conclusion, this study provides the first evidence implicating that  bbbbb1 TSA eeeee1  inhibits  bbbbb2 TGF-β eeeee2 -induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling.
CPR:4	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the  bbbbb1 NAD(P)H oxidase eeeee1  inhibitor  bbbbb2 diphenyleneiodonium eeeee2  (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CPR:4	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the  bbbbb1 NAD(P)H oxidase eeeee1  inhibitor diphenyleneiodonium ( bbbbb2 DPI eeeee2 ), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CPR:4	Treatment with  bbbbb1 TSA eeeee1  and the Nrf2-ARE activator resulted in increased inhibition of the  bbbbb2 TGF-β eeeee2 -induced myofibroblast differentiation as compared with treatment with DPI or NAC
CPR:4	 bbbbb1 Trichostatin A eeeee1  inhibits  bbbbb2 transforming growth factor-β eeeee2 -induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling
CPR:4	Furthermore,  bbbbb1 TSA eeeee1  also decreased cellular ROS and H(2)O(2) accumulation induced by  bbbbb2 TGF-β eeeee2 , whereas it elevated intracellular GSH level and cellular total antioxidant capacity
CPR:2	In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist  bbbbb1 AM4113 eeeee1  were compared for their ability to modify  bbbbb2 CB(1) receptor eeeee2 -mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CPR:2	In the present studies, the CB(1) inverse agonist  bbbbb1 SR141716A eeeee1  (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify  bbbbb2 CB(1) receptor eeeee2 -mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CPR:2	In the present studies, the CB(1) inverse agonist SR141716A ( bbbbb1 rimonabant eeeee1 ) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify  bbbbb2 CB(1) receptor eeeee2 -mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CPR:3	Results indicate that  bbbbb1 AM4054 eeeee1  serves as an effective  bbbbb2 CB(1) eeeee2  discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CPR:5	In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel  bbbbb1 CB(1) eeeee1  full agonist  bbbbb2 AM4054 eeeee2 
CPR:5	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  bbbbb1 CB(1) eeeee1  agonist  bbbbb2 Δ(9)-tetrahydrocannabinol eeeee2 , and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CPR:5	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  bbbbb1 CB(1) eeeee1  agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the  bbbbb2 AM4054 eeeee2  dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CPR:5	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  bbbbb1 CB(1) eeeee1  agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of  bbbbb2 AM4054 eeeee2 
CPR:5	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  bbbbb1 CB(1) eeeee1  agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist  bbbbb2 rimonabant eeeee2  and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CPR:5	In the present studies, the  bbbbb1 CB(1) eeeee1  inverse agonist  bbbbb2 SR141716A eeeee2  (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CPR:5	In the present studies, the  bbbbb1 CB(1) eeeee1  inverse agonist SR141716A ( bbbbb2 rimonabant eeeee2 ) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CPR:5	 bbbbb1 Cannabinoid receptor 1 eeeee1  (CB(1)) inverse agonists (e.g.,  bbbbb2 rimonabant eeeee2 ) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications
CPR:5	Cannabinoid receptor 1 ( bbbbb1 CB(1) eeeee1 ) inverse agonists (e.g.,  bbbbb2 rimonabant eeeee2 ) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications
CPR:6	In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the  bbbbb1 CB(1) eeeee1  neutral antagonist  bbbbb2 AM4113 eeeee2  were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CPR:6	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  bbbbb1 CB(1) eeeee1  agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist  bbbbb2 AM4113 eeeee2  produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CPR:2	In early pregnancy, there were no significant differences in  bbbbb1 insulin eeeee1  sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the- bbbbb2 glucose eeeee2 -curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups
CPR:4	 bbbbb1 Dabigatran eeeee1  has an advantage over the indirect  bbbbb2 thrombin eeeee2  inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin
CPR:4	 bbbbb1 Dabigatran eeeee1  has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and  bbbbb2 fibrin eeeee2 -bound thrombin
CPR:4	 bbbbb1 Dabigatran eeeee1  has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound  bbbbb2 thrombin eeeee2 
CPR:4	The reversible binding of  bbbbb1 dabigatran eeeee1  may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent  bbbbb2 thrombin eeeee2  inhibitors, e.g. hirudin
CPR:4	 bbbbb1 FXa eeeee1  inhibitors, e.g.  bbbbb2 rivaroxaban eeeee2  and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa
CPR:4	FXa inhibitors, e.g.  bbbbb1 rivaroxaban eeeee1  and apixaban, are potent, oral direct inhibitors of  bbbbb2 prothrombinase eeeee2 -bound, clot-associated or free FXa
CPR:4	FXa inhibitors, e.g.  bbbbb1 rivaroxaban eeeee1  and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free  bbbbb2 FXa eeeee2 
CPR:4	 bbbbb1 FXa eeeee1  inhibitors, e.g. rivaroxaban and  bbbbb2 apixaban eeeee2 , are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa
CPR:4	FXa inhibitors, e.g. rivaroxaban and  bbbbb1 apixaban eeeee1 , are potent, oral direct inhibitors of  bbbbb2 prothrombinase eeeee2 -bound, clot-associated or free FXa
CPR:4	FXa inhibitors, e.g. rivaroxaban and  bbbbb1 apixaban eeeee1 , are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free  bbbbb2 FXa eeeee2 
CPR:4	Although parenteral oral direct  bbbbb1 thrombin eeeee1  inhibitors (DTIs), such as  bbbbb2 argatroban eeeee2  and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists
CPR:6	Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as  bbbbb1 dabigatran eeeee1  are novel synthetic  bbbbb2 thrombin eeeee2  antagonists
CPR:2	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the  bbbbb1 ALDH1 eeeee1 - bbbbb2 NADH eeeee2  complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CPR:2	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the  bbbbb1 ALDH1 eeeee1 - bbbbb2 NADH eeeee2  complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CPR:2	Physiologic levels of Mg(2+) ions decrease  bbbbb1 ALDH1 eeeee1  activity in part by increasing  bbbbb2 NADH eeeee2  binding affinity to the enzyme
CPR:2	This shift in conformational population at higher Mg(2+) ion concentrations and to lower enzyme activity may be due to longer residence time of the  bbbbb1 NADH eeeee1  in the  bbbbb2 ALDH1 eeeee2  pocket
CPR:2	The results from monitoring enzyme catalysis in the absence of magnesium suggests that the  bbbbb1 ALDH1 eeeee1 - bbbbb2 NADH eeeee2  complex with the shorter fluorescence lifetime is the form initially produced, and the complex with the longer fluorescence lifetime is produced through isomerization.
CPR:2	From the resolved free and bound NADH fluorescence signatures, the KD values for both  bbbbb1 NADH eeeee1  conformations in  bbbbb2 ALDH1A1 eeeee2  ranged from about 24 μM to 1 μM for Mg(2+) ion concentrations of 0-6000 μM, respectively
CPR:2	Fluorescence lifetime analysis and effect of magnesium ions on binding of  bbbbb1 NADH eeeee1  to  bbbbb2 human aldehyde dehydrogenase 1 eeeee2 
CPR:2	From the resolved free and bound NADH fluorescence signatures, the KD values for both NADH conformations in  bbbbb1 ALDH1A1 eeeee1  ranged from about 24 μM to 1 μM for  bbbbb2 Mg(2+) eeeee2  ion concentrations of 0-6000 μM, respectively
CPR:4	This shift in conformational population at higher  bbbbb1 Mg(2+) eeeee1  ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the  bbbbb2 ALDH1 eeeee2  pocket
CPR:4	As the  bbbbb1 Mg(2+) eeeee1  ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the  bbbbb2 ALDH1 eeeee2 -NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CPR:4	Physiologic levels of  bbbbb1 Mg(2+) eeeee1  ions decrease  bbbbb2 ALDH1 eeeee2  activity in part by increasing NADH binding affinity to the enzyme
CPR:9	 bbbbb1 Aldehyde dehydrogenase 1 eeeee1  (ALDH1A1) catalyzes the oxidation of toxic aldehydes to  bbbbb2 carboxylic acids eeeee2 
CPR:9	Aldehyde dehydrogenase 1 ( bbbbb1 ALDH1A1 eeeee1 ) catalyzes the oxidation of toxic aldehydes to  bbbbb2 carboxylic acids eeeee2 
CPR:9	 bbbbb1 Aldehyde dehydrogenase 1 eeeee1  (ALDH1A1) catalyzes the oxidation of toxic  bbbbb2 aldehydes eeeee2  to carboxylic acids
CPR:9	Aldehyde dehydrogenase 1 ( bbbbb1 ALDH1A1 eeeee1 ) catalyzes the oxidation of toxic  bbbbb2 aldehydes eeeee2  to carboxylic acids
CPR:2	Interestingly,  bbbbb1 Acrolein eeeee1  increased proteins' levels of amyloid precursor protein ( bbbbb2 APP eeeee2 ), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels
CPR:3	Moreover,  bbbbb1 Acrolein eeeee1  resulted in activation of astrocytes, up-regulation of  bbbbb2 BACE-1 eeeee2  in cortex and down-regulation of ADAM-10 in hippocampus and cortex
CPR:3	Interestingly,  bbbbb1 Acrolein eeeee1  increased proteins' levels of  bbbbb2 amyloid precursor protein eeeee2  (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels
CPR:3	Interestingly,  bbbbb1 Acrolein eeeee1  increased proteins' levels of amyloid precursor protein (APP),  bbbbb2 β-secretase eeeee2  (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels
CPR:3	Interestingly,  bbbbb1 Acrolein eeeee1  increased proteins' levels of amyloid precursor protein (APP), β-secretase ( bbbbb2 BACE-1 eeeee2 ) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels
CPR:3	Interestingly,  bbbbb1 Acrolein eeeee1  increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the  bbbbb2 amyloid β-peptide transporter eeeee2  receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels
CPR:3	Interestingly,  bbbbb1 Acrolein eeeee1  increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter  bbbbb2 receptor for advanced glycation end products eeeee2 , and decreased A-disintegrin and metalloprotease (ADAM) 10 levels
CPR:4	Moreover,  bbbbb1 Acrolein eeeee1  resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of  bbbbb2 ADAM-10 eeeee2  in hippocampus and cortex
CPR:4	Interestingly,  bbbbb1 Acrolein eeeee1  increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased  bbbbb2 A-disintegrin and metalloprotease (ADAM) 10 eeeee2  levels
CPR:3	Regulation of sexual reproduction by  bbbbb1 estradiol eeeee1  involves the activation of  bbbbb2 estrogen receptors eeeee2  (ERs) in the hypothalamus
CPR:3	Regulation of sexual reproduction by  bbbbb1 estradiol eeeee1  involves the activation of estrogen receptors ( bbbbb2 ERs eeeee2 ) in the hypothalamus
CPR:3	Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant  bbbbb1 estradiol eeeee1  elevated plasma membrane  bbbbb2 ERα eeeee2  protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane
CPR:3	These results indicate that membrane  bbbbb1 ERα eeeee1  levels in N-38 neurons are dynamically autoregulated by  bbbbb2 estradiol eeeee2 .
CPR:3	Using surface biotinylation, we observed that treatment of N-38 neurons with  bbbbb1 estradiol eeeee1  or with a membrane impermeant estradiol elevated plasma membrane  bbbbb2 ERα eeeee2  protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane
CPR:4	Insertion of  bbbbb1 ERα eeeee1  was blocked by the ER antagonist  bbbbb2 ICI 182,780 eeeee2  or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)
CPR:4	Insertion of  bbbbb1 ERα eeeee1  was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor  bbbbb2 bisindolylmaleimide eeeee2  (BIS)
CPR:4	Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the  bbbbb1 protein kinase C eeeee1  (PKC) pathway inhibitor  bbbbb2 bisindolylmaleimide eeeee2  (BIS)
CPR:4	Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C ( bbbbb1 PKC eeeee1 ) pathway inhibitor  bbbbb2 bisindolylmaleimide eeeee2  (BIS)
CPR:4	Insertion of  bbbbb1 ERα eeeee1  was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide ( bbbbb2 BIS eeeee2 )
CPR:4	Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the  bbbbb1 protein kinase C eeeee1  (PKC) pathway inhibitor bisindolylmaleimide ( bbbbb2 BIS eeeee2 )
CPR:4	Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C ( bbbbb1 PKC eeeee1 ) pathway inhibitor bisindolylmaleimide ( bbbbb2 BIS eeeee2 )
CPR:6	Insertion of ERα was blocked by the  bbbbb1 ER eeeee1  antagonist  bbbbb2 ICI 182,780 eeeee2  or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)
CPR:2	These findings indicate that the neuroprotective effect of  bbbbb1 EHT eeeee1  against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of  bbbbb2 PP2A eeeee2 
CPR:2	These findings indicate that the neuroprotective effect of EHT against  bbbbb1 MPTP eeeee1  is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of  bbbbb2 PP2A eeeee2 
CPR:2	One of these compounds is  bbbbb1 eicosanoyl-5-hydroxytryptamide eeeee1  (EHT), which ameliorates the phenotype of  bbbbb2 α-synuclein eeeee2  transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation
CPR:2	One of these compounds is eicosanoyl-5-hydroxytryptamide ( bbbbb1 EHT eeeee1 ), which ameliorates the phenotype of  bbbbb2 α-synuclein eeeee2  transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation
CPR:3	Reductions in striatal dopamine and  bbbbb1 tyrosine hydroxylase eeeee1  content were also less pronounced with  bbbbb2 EHT eeeee2  treatment
CPR:3	Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of  bbbbb1 phosphoprotein phosphatase 2A eeeee1  (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by  bbbbb2 EHT eeeee2 
CPR:3	Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A ( bbbbb1 PP2A eeeee1 ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by  bbbbb2 EHT eeeee2 
CPR:4	Additionally, in SH-SY5Y cells,  bbbbb1 MPP(+) eeeee1 -induced demethylation of  bbbbb2 phosphoprotein phosphatase 2A eeeee2  (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT
CPR:4	Additionally, in SH-SY5Y cells,  bbbbb1 MPP(+) eeeee1 -induced demethylation of phosphoprotein phosphatase 2A ( bbbbb2 PP2A eeeee2 ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT
CPR:4	The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and  bbbbb1 JNK eeeee1  activation were significantly prevented with  bbbbb2 EHT eeeee2 
CPR:4	In cultured primary microglia and astrocytes,  bbbbb1 EHT eeeee1  had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced  bbbbb2 NFκB eeeee2  activation, iNOS induction, and nitric oxide production
CPR:4	In cultured primary microglia and astrocytes,  bbbbb1 EHT eeeee1  had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFκB activation,  bbbbb2 iNOS eeeee2  induction, and nitric oxide production
CPR:2	Substantial evidence shows that  bbbbb1 H(2)S eeeee1  is involved in aging by inhibiting free-radical reactions, activating SIRT1, and probably interacting with the age-related gene  bbbbb2 Klotho eeeee2 
CPR:3	Substantial evidence shows that  bbbbb1 H(2)S eeeee1  is involved in aging by inhibiting free-radical reactions, activating  bbbbb2 SIRT1 eeeee2 , and probably interacting with the age-related gene Klotho
CPR:10	The induction of  bbbbb1 HO-1 eeeee1  by EIH was inhibited by SB203580 but not by  bbbbb2 SP600125 eeeee2 , PD98059, nor LY294002
CPR:10	The induction of  bbbbb1 HO-1 eeeee1  by EIH was inhibited by SB203580 but not by SP600125,  bbbbb2 PD98059 eeeee2 , nor LY294002
CPR:10	The induction of  bbbbb1 HO-1 eeeee1  by EIH was inhibited by SB203580 but not by SP600125, PD98059, nor  bbbbb2 LY294002 eeeee2 
CPR:3	nduction of  bbbbb1 HO-1 eeeee1  through p38 MAPK/Nrf2 signaling pathway by  bbbbb2 ethanol eeeee2  extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice
CPR:3	nduction of HO-1 through  bbbbb1 p38 eeeee1  MAPK/Nrf2 signaling pathway by  bbbbb2 ethanol eeeee2  extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice
CPR:3	nduction of HO-1 through p38  bbbbb1 MAPK eeeee1 /Nrf2 signaling pathway by  bbbbb2 ethanol eeeee2  extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice
CPR:4	The induction of  bbbbb1 HO-1 eeeee1  by EIH was inhibited by  bbbbb2 SB203580 eeeee2  but not by SP600125, PD98059, nor LY294002
CPR:2	FMO3 expression is induced by dietary  bbbbb1 bile acids eeeee1  by a mechanism that involves the  bbbbb2 farnesoid X receptor eeeee2  (FXR), a bile acid-activated nuclear receptor
CPR:2	FMO3 expression is induced by dietary  bbbbb1 bile acids eeeee1  by a mechanism that involves the farnesoid X receptor ( bbbbb2 FXR eeeee2 ), a bile acid-activated nuclear receptor
CPR:3	FMO3 expression is induced by dietary bile acids by a mechanism that involves the  bbbbb1 farnesoid X receptor eeeee1  (FXR), a  bbbbb2 bile acid eeeee2 -activated nuclear receptor
CPR:3	FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor ( bbbbb1 FXR eeeee1 ), a  bbbbb2 bile acid eeeee2 -activated nuclear receptor
CPR:3	 bbbbb1 FMO3 eeeee1  expression is induced by dietary  bbbbb2 bile acids eeeee2  by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor
CPR:4	In mice, this reduction in  bbbbb1 FMO3 eeeee1  expression is due primarily to downregulation by  bbbbb2 androgens eeeee2 
CPR:9	Analysis of natural genetic variation among inbred strains of mice indicates that  bbbbb1 FMO3 eeeee1  and  bbbbb2 TMAO eeeee2  are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis.
CPR:9	We demonstrate that two  bbbbb1 flavin mono-oxygenase eeeee1  family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to  bbbbb2 TMAO eeeee2 
CPR:9	We demonstrate that two flavin mono-oxygenase family members,  bbbbb1 FMO1 eeeee1  and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to  bbbbb2 TMAO eeeee2 
CPR:9	We demonstrate that two flavin mono-oxygenase family members, FMO1 and  bbbbb1 FMO3 eeeee1 , oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to  bbbbb2 TMAO eeeee2 
CPR:9	FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing  bbbbb1 FMO3 eeeee1  decreases  bbbbb2 TMAO eeeee2  levels
CPR:9	We demonstrate that two  bbbbb1 flavin mono-oxygenase eeeee1  family members, FMO1 and FMO3, oxidize  bbbbb2 trimethylamine eeeee2  (TMA), derived from gut flora metabolism of choline, to TMAO
CPR:9	We demonstrate that two flavin mono-oxygenase family members,  bbbbb1 FMO1 eeeee1  and FMO3, oxidize  bbbbb2 trimethylamine eeeee2  (TMA), derived from gut flora metabolism of choline, to TMAO
CPR:9	We demonstrate that two flavin mono-oxygenase family members, FMO1 and  bbbbb1 FMO3 eeeee1 , oxidize  bbbbb2 trimethylamine eeeee2  (TMA), derived from gut flora metabolism of choline, to TMAO
CPR:9	We demonstrate that two  bbbbb1 flavin mono-oxygenase eeeee1  family members, FMO1 and FMO3, oxidize trimethylamine ( bbbbb2 TMA eeeee2 ), derived from gut flora metabolism of choline, to TMAO
CPR:9	We demonstrate that two flavin mono-oxygenase family members,  bbbbb1 FMO1 eeeee1  and FMO3, oxidize trimethylamine ( bbbbb2 TMA eeeee2 ), derived from gut flora metabolism of choline, to TMAO
CPR:9	We demonstrate that two flavin mono-oxygenase family members, FMO1 and  bbbbb1 FMO3 eeeee1 , oxidize trimethylamine ( bbbbb2 TMA eeeee2 ), derived from gut flora metabolism of choline, to TMAO
CPR:9	We demonstrate that two  bbbbb1 flavin mono-oxygenase eeeee1  family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of  bbbbb2 choline eeeee2 , to TMAO
CPR:9	We demonstrate that two flavin mono-oxygenase family members,  bbbbb1 FMO1 eeeee1  and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of  bbbbb2 choline eeeee2 , to TMAO
CPR:9	We demonstrate that two flavin mono-oxygenase family members, FMO1 and  bbbbb1 FMO3 eeeee1 , oxidize trimethylamine (TMA), derived from gut flora metabolism of  bbbbb2 choline eeeee2 , to TMAO
CPR:9	 bbbbb1 FMO3 eeeee1  overexpression in mice significantly increases plasma  bbbbb2 TMAO eeeee2  levels while silencing FMO3 decreases TMAO levels
CPR:2	However, other  bbbbb1 steroids eeeee1 , including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to  bbbbb2 estrogen receptor-α eeeee2  (ERα) and ERβ
CPR:2	However, other  bbbbb1 steroids eeeee1 , including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α ( bbbbb2 ERα eeeee2 ) and ERβ
CPR:2	However, other  bbbbb1 steroids eeeee1 , including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and  bbbbb2 ERβ eeeee2 
CPR:2	However, other steroids, including  bbbbb1 Δ(5)-androstenediol eeeee1 , 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to  bbbbb2 estrogen receptor-α eeeee2  (ERα) and ERβ
CPR:2	However, other steroids, including  bbbbb1 Δ(5)-androstenediol eeeee1 , 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α ( bbbbb2 ERα eeeee2 ) and ERβ
CPR:2	However, other steroids, including  bbbbb1 Δ(5)-androstenediol eeeee1 , 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and  bbbbb2 ERβ eeeee2 
CPR:2	However, other steroids, including Δ(5)-androstenediol,  bbbbb1 5α-androstanediol eeeee1  and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to  bbbbb2 estrogen receptor-α eeeee2  (ERα) and ERβ
CPR:2	However, other steroids, including Δ(5)-androstenediol,  bbbbb1 5α-androstanediol eeeee1  and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α ( bbbbb2 ERα eeeee2 ) and ERβ
CPR:2	However, other steroids, including Δ(5)-androstenediol,  bbbbb1 5α-androstanediol eeeee1  and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and  bbbbb2 ERβ eeeee2 
CPR:2	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and  bbbbb1 27-hydroxycholesterol eeeee1 , which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to  bbbbb2 estrogen receptor-α eeeee2  (ERα) and ERβ
CPR:2	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and  bbbbb1 27-hydroxycholesterol eeeee1 , which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α ( bbbbb2 ERα eeeee2 ) and ERβ
CPR:2	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and  bbbbb1 27-hydroxycholesterol eeeee1 , which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and  bbbbb2 ERβ eeeee2 
CPR:2	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a  bbbbb1 3β-hydroxyl eeeee1  and a C19 methyl group, also mediate physiological responses through binding to  bbbbb2 estrogen receptor-α eeeee2  (ERα) and ERβ
CPR:2	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a  bbbbb1 3β-hydroxyl eeeee1  and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α ( bbbbb2 ERα eeeee2 ) and ERβ
CPR:2	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a  bbbbb1 3β-hydroxyl eeeee1  and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and  bbbbb2 ERβ eeeee2 
CPR:2	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19  bbbbb1 methyl eeeee1  group, also mediate physiological responses through binding to  bbbbb2 estrogen receptor-α eeeee2  (ERα) and ERβ
CPR:2	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19  bbbbb1 methyl eeeee1  group, also mediate physiological responses through binding to estrogen receptor-α ( bbbbb2 ERα eeeee2 ) and ERβ
CPR:2	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19  bbbbb1 methyl eeeee1  group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and  bbbbb2 ERβ eeeee2 
CPR:2	Moreover, selective  bbbbb1 estrogen eeeee1  response modulators (SERMs) with diverse structures also regulate transcription of  bbbbb2 ERα eeeee2  and ERβ
CPR:2	Moreover, selective  bbbbb1 estrogen eeeee1  response modulators (SERMs) with diverse structures also regulate transcription of ERα and  bbbbb2 ERβ eeeee2 
CPR:2	Further studies of the role of these  bbbbb1 steroids eeeee1  and SERMs in regulating responses mediated by  bbbbb2 ERα eeeee2  and ERβ a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities.
CPR:2	Further studies of the role of these  bbbbb1 steroids eeeee1  and SERMs in regulating responses mediated by ERα and  bbbbb2 ERβ eeeee2  a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities.
CPR:4	Synthesis of  bbbbb1 quinoline eeeee1  derivatives: discovery of a potent and selective  bbbbb2 phosphodiesterase 5 eeeee2  inhibitor for the treatment of Alzheimer's disease
CPR:9	Phosphodiesterase type 5 ( bbbbb1 PDE5 eeeee1 ) mediates the degradation of  bbbbb2 cGMP eeeee2  in a variety of tissues including brain
CPR:9	 bbbbb1 Phosphodiesterase type 5 eeeee1  (PDE5) mediates the degradation of  bbbbb2 cGMP eeeee2  in a variety of tissues including brain
CPR:2	A novel potent compound,  bbbbb1 N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide eeeee1  (12c), which binds  bbbbb2 Mcl-1 eeeee2  with an IC(50) value of 54 nM was obtained
CPR:4	A novel potent compound,  bbbbb1 N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide eeeee1  (12c), which binds  bbbbb2 Mcl-1 eeeee2  with an IC(50) value of 54 nM was obtained
CPR:4	We have previously reported a nanomolar inhibitor of antiapoptotic  bbbbb1 Mcl-1 eeeee1  protein,  bbbbb2 3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile eeeee2  (S1)
CPR:4	Fragment-based design, synthesis, and biological evaluation of  bbbbb1 N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide eeeee1  derivatives as novel  bbbbb2 Mcl-1 eeeee2  inhibitors
CPR:3	 bbbbb1 Peginesatide eeeee1 , a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the  bbbbb2 erythropoietin receptor eeeee2  dimer that governs erythropoiesis
CPR:3	Peginesatide, a  bbbbb1 polyethylene glycol eeeee1  (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the  bbbbb2 erythropoietin receptor eeeee2  dimer that governs erythropoiesis
CPR:3	Peginesatide, a polyethylene glycol ( bbbbb1 PEG eeeee1 )ylated peptide-based erythropoiesis-stimulating agent, stimulates the  bbbbb2 erythropoietin receptor eeeee2  dimer that governs erythropoiesis
CPR:2	Electron paramagnetic resonance (EPR) studies using  bbbbb1 nucleotide eeeee1  analog spin label probes showed that dephosphorylated myosin heads are highly ordered in the relaxed fibers and have very low  bbbbb2 ATPase eeeee2  activity
CPR:2	Electron paramagnetic resonance (EPR) studies using  bbbbb1 nucleotide eeeee1  analog spin label probes showed that  bbbbb2 dephosphorylated myosin eeeee2  heads are highly ordered in the relaxed fibers and have very low ATPase activity
CPR:2	LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of  bbbbb1 LPA eeeee1  by driving  bbbbb2 MRTF eeeee2 -dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J
CPR:2	There has been much recent interest in lysophosphatidic acid (LPA) signaling through one of its receptors, LPA1, in fibrotic diseases, but the mechanisms by which  bbbbb1 LPA eeeee1 - bbbbb2 LPA1 eeeee2  signaling promotes pathological fibrosis remain to be fully elucidated
CPR:2	There has been much recent interest in  bbbbb1 lysophosphatidic acid eeeee1  (LPA) signaling through one of its receptors,  bbbbb2 LPA1 eeeee2 , in fibrotic diseases, but the mechanisms by which LPA-LPA1 signaling promotes pathological fibrosis remain to be fully elucidated
CPR:3	LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of  bbbbb1 LPA eeeee1  by driving MRTF-dependent  bbbbb2 CTGF eeeee2  expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J
CPR:2	Styrene oxide and  bbbbb1 4-vinylphenol eeeee1  possessed similar affinity for  bbbbb2 CYP2E1 eeeee2 
CPR:2	We hypothesized that  bbbbb1 styrene eeeee1  metabolites have lower affinity than styrene toward  bbbbb2 CYP2E1 eeeee2  and limited ability to induce cooperative effects during metabolism
CPR:2	We hypothesized that styrene metabolites have lower affinity than  bbbbb1 styrene eeeee1  toward  bbbbb2 CYP2E1 eeeee2  and limited ability to induce cooperative effects during metabolism
CPR:2	 bbbbb1 Styrene oxide eeeee1  and 4-vinylphenol possessed similar affinity for  bbbbb2 CYP2E1 eeeee2 
CPR:2	Cooperative effects for  bbbbb1 CYP2E1 eeeee1  differ between  bbbbb2 styrene eeeee2  and its metabolites
CPR:3	 bbbbb1 Bile acids eeeee1  are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor,  bbbbb2 constitutive androstane receptor eeeee2 , and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CPR:3	 bbbbb1 Bile acids eeeee1  are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and  bbbbb2 vitamin D receptor eeeee2 , and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CPR:3	 bbbbb1 Bile acids eeeee1  are signaling molecules that activate  bbbbb2 nuclear receptors eeeee2 , such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CPR:3	 bbbbb1 Bile acids eeeee1  are signaling molecules that activate nuclear receptors, such as  bbbbb2 farnesoid X receptor eeeee2 , pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CPR:3	 bbbbb1 Bile acids eeeee1  are signaling molecules that activate nuclear receptors, such as farnesoid X receptor,  bbbbb2 pregnane X receptor eeeee2 , constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CPR:2	The peptide  bbbbb1 YR-11 eeeee1  (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited  bbbbb2 RANK eeeee2 -RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:2	The peptide  bbbbb1 YR-11 eeeee1  (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK- bbbbb2 RANKL eeeee2  binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:2	The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of  bbbbb1 cysteine eeeee1  with a serine residue in the template sequence, significantly (p<0.05) inhibited  bbbbb2 RANK eeeee2 -RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:2	The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of  bbbbb1 cysteine eeeee1  with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK- bbbbb2 RANKL eeeee2  binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:2	The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a  bbbbb1 serine eeeee1  residue in the template sequence, significantly (p<0.05) inhibited  bbbbb2 RANK eeeee2 -RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:2	The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a  bbbbb1 serine eeeee1  residue in the template sequence, significantly (p<0.05) inhibited RANK- bbbbb2 RANKL eeeee2  binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:4	Results confirmed that  bbbbb1 YR-11 eeeee1  peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of  bbbbb2 NF-κB eeeee2 
CPR:4	The peptide  bbbbb1 YR-11 eeeee1  (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and  bbbbb2 RANKL eeeee2  induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:4	The peptide  bbbbb1 YR-11 eeeee1  (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced  bbbbb2 TRAP eeeee2  activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:4	The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of  bbbbb1 cysteine eeeee1  with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and  bbbbb2 RANKL eeeee2  induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:4	The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of  bbbbb1 cysteine eeeee1  with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced  bbbbb2 TRAP eeeee2  activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:4	The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a  bbbbb1 serine eeeee1  residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and  bbbbb2 RANKL eeeee2  induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:4	The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a  bbbbb1 serine eeeee1  residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced  bbbbb2 TRAP eeeee2  activity and formation of multinucleated osteoclasts without any cytotoxicity
CPR:4	Results confirmed that  bbbbb1 YR-11 eeeee1  peptide inhibited pro-inflammatory  bbbbb2 cytokines eeeee2  in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-κB
CPR:4	Results confirmed that  bbbbb1 YR-11 eeeee1  peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on  bbbbb2 RANKL eeeee2  induced nuclear translocation of NF-κB
CPR:2	RESULTS: In contrast to immune stimulatory sequence ISS 1018, BCG DNA spontaneously formed nanoparticulate structures and induced  bbbbb1 actin eeeee1  polymerization as did synthetic  bbbbb2 silica eeeee2  nanoparticles
CPR:3	The activation of  bbbbb1 Rac1 eeeee1  was induced by  bbbbb2 silica eeeee2  nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation
CPR:2	In this small library of novel bioactive macrocyclic  bbbbb1 lathyrane diterpene eeeee1  derivatives, designed to evaluate structure-activity relationships essential in overcoming multidrug resistance (MDR), some correlations between MDR reversal and molecular weight, accessible solvent areas, and octanol/water partition coefficient were identified that can contribute to the development of new selective  bbbbb2 P-gp eeeee2  reversal agents.
CPR:3	Additionally, these effects of  bbbbb1 ATO eeeee1  on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an  bbbbb2 ATM eeeee2  inhibitor
CPR:3	Osteoblasts survive the  bbbbb1 arsenic trioxide eeeee1  treatment by activation of  bbbbb2 ATM eeeee2 -mediated pathway
CPR:3	Additionally, these effects of  bbbbb1 ATO eeeee1  on γ-H2AX,  bbbbb2 Chk1 eeeee2 , Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor
CPR:3	Additionally, these effects of  bbbbb1 ATO eeeee1  on γ-H2AX, Chk1,  bbbbb2 Chk2 eeeee2 , p53, and p21(waf1/cip1) were reduced by an ATM inhibitor
CPR:3	Additionally, these effects of  bbbbb1 ATO eeeee1  on γ-H2AX, Chk1, Chk2,  bbbbb2 p53 eeeee2 , and p21(waf1/cip1) were reduced by an ATM inhibitor
CPR:3	Additionally, these effects of  bbbbb1 ATO eeeee1  on γ-H2AX, Chk1, Chk2, p53, and  bbbbb2 p21 eeeee2 (waf1/cip1) were reduced by an ATM inhibitor
CPR:3	Additionally, these effects of  bbbbb1 ATO eeeee1  on γ-H2AX, Chk1, Chk2, p53, and p21( bbbbb2 waf1 eeeee2 /cip1) were reduced by an ATM inhibitor
CPR:3	Additionally, these effects of  bbbbb1 ATO eeeee1  on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/ bbbbb2 cip1 eeeee2 ) were reduced by an ATM inhibitor
CPR:3	Additionally, these effects of  bbbbb1 ATO eeeee1  on γ- bbbbb2 H2AX eeeee2 , Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor
CPR:3	Furthermore, a mixture of  bbbbb1 isoflavonoid eeeee1  parent compounds, and a mixture of isoflavonoid metabolites were found to have  bbbbb2 PPARγ eeeee2  activating abilities
CPR:3	Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of  bbbbb1 isoflavonoid eeeee1  metabolites were found to have  bbbbb2 PPARγ eeeee2  activating abilities
CPR:10	Both  bbbbb1 fatty acids eeeee1 , but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker  bbbbb2 CD69 eeeee2  was unaltered on activated T cells
CPR:10	Both fatty acids, but  bbbbb1 DHA eeeee1  to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker  bbbbb2 CD69 eeeee2  was unaltered on activated T cells
CPR:10	Both fatty acids, but DHA to a lesser extent compared with  bbbbb1 EPA eeeee1 , selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker  bbbbb2 CD69 eeeee2  was unaltered on activated T cells
CPR:10	In monocytes, both  bbbbb1 EPA eeeee1  and DHA increased interleukin (IL)-10 without affecting  bbbbb2 tumor necrosis factor (TNF)-α eeeee2  and IL-6
CPR:10	In monocytes, both  bbbbb1 EPA eeeee1  and DHA increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-α and  bbbbb2 IL-6 eeeee2 
CPR:10	In monocytes, both EPA and  bbbbb1 DHA eeeee1  increased interleukin (IL)-10 without affecting  bbbbb2 tumor necrosis factor (TNF)-α eeeee2  and IL-6
CPR:10	In monocytes, both EPA and  bbbbb1 DHA eeeee1  increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-α and  bbbbb2 IL-6 eeeee2 
CPR:2	Both  bbbbb1 fatty acids eeeee1 , but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a  bbbbb2 peroxisome proliferator-activated receptor (PPAR)γ eeeee2 -dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells
CPR:2	Both fatty acids, but  bbbbb1 DHA eeeee1  to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a  bbbbb2 peroxisome proliferator-activated receptor (PPAR)γ eeeee2 -dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells
CPR:2	Both fatty acids, but DHA to a lesser extent compared with  bbbbb1 EPA eeeee1 , selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a  bbbbb2 peroxisome proliferator-activated receptor (PPAR)γ eeeee2 -dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells
CPR:3	In monocytes, both  bbbbb1 EPA eeeee1  and DHA increased  bbbbb2 interleukin (IL)-10 eeeee2  without affecting tumor necrosis factor (TNF)-α and IL-6
CPR:3	In monocytes, both EPA and  bbbbb1 DHA eeeee1  increased  bbbbb2 interleukin (IL)-10 eeeee2  without affecting tumor necrosis factor (TNF)-α and IL-6
CPR:4	Both  bbbbb1 fatty acids eeeee1 , but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of  bbbbb2 cytokine eeeee2 -expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells
CPR:4	Both fatty acids, but  bbbbb1 DHA eeeee1  to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of  bbbbb2 cytokine eeeee2 -expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells
CPR:4	Both fatty acids, but DHA to a lesser extent compared with  bbbbb1 EPA eeeee1 , selectively and dose-dependently reduced the percentage of  bbbbb2 cytokine eeeee2 -expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells
CPR:9	In the in vitro model we observed high permeability of  bbbbb1 imperatorin eeeee1  and isoimperatorin with the  bbbbb2 P-gp eeeee2 -mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82
CPR:9	In the in vitro model we observed high permeability of imperatorin and  bbbbb1 isoimperatorin eeeee1  with the  bbbbb2 P-gp eeeee2 -mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82
CPR:9	In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the  bbbbb1 P-gp eeeee1 -mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of  bbbbb2 cnidilin eeeee2  with 0.82
CPR:2	In agreement with these data, the exogenous treatment of  bbbbb1 SAH eeeee1  or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of  bbbbb2 actin eeeee2  cytoskeleton, and a change of the colocalization pattern between actin and Src
CPR:2	In agreement with these data, the exogenous treatment of  bbbbb1 SAH eeeee1  or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between  bbbbb2 actin eeeee2  and Src
CPR:2	In agreement with these data, the exogenous treatment of  bbbbb1 SAH eeeee1  or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and  bbbbb2 Src eeeee2 
CPR:2	Involvement of  bbbbb1 Src eeeee1  and the actin cytoskeleton in the antitumorigenic action of  bbbbb2 adenosine dialdehyde eeeee2 
CPR:2	Involvement of Src and the  bbbbb1 actin eeeee1  cytoskeleton in the antitumorigenic action of  bbbbb2 adenosine dialdehyde eeeee2 
CPR:2	Taken together, these results suggest that  bbbbb1 SAH eeeee1 /SAHH-mediated transmethylation could be linked to the tumorigenic processes through cross-regulation between the  bbbbb2 actin eeeee2  cytoskeleton and Src kinase activity.
CPR:2	Taken together, these results suggest that  bbbbb1 SAH eeeee1 /SAHH-mediated transmethylation could be linked to the tumorigenic processes through cross-regulation between the actin cytoskeleton and  bbbbb2 Src eeeee2  kinase activity.
CPR:2	Taken together, these results suggest that  bbbbb1 SAH eeeee1 /SAHH-mediated transmethylation could be linked to the tumorigenic processes through cross-regulation between the actin cytoskeleton and Src  bbbbb2 kinase eeeee2  activity.
CPR:4	In agreement with these data, the exogenous treatment of  bbbbb1 SAH eeeee1  or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on  bbbbb2 Src eeeee2 , the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src
CPR:4	Through immunoblotting analysis, it was found that  bbbbb1 AdOx eeeee1  was capable of indirectly diminishing the phosphorylation of oncogenic  bbbbb2 Src eeeee2  and its kinase activity
CPR:4	Interestingly,  bbbbb1 AdOx eeeee1  disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of  bbbbb2 Src eeeee2  and p85/PI3K, which is linked to various tumorigenic responses
CPR:4	Interestingly,  bbbbb1 AdOx eeeee1  disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and  bbbbb2 p85 eeeee2 /PI3K, which is linked to various tumorigenic responses
CPR:4	Interestingly,  bbbbb1 AdOx eeeee1  disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/ bbbbb2 PI3K eeeee2 , which is linked to various tumorigenic responses
CPR:4	Through immunoblotting analysis, it was found that  bbbbb1 AdOx eeeee1  was capable of indirectly diminishing the phosphorylation of oncogenic Src and its  bbbbb2 kinase eeeee2  activity
CPR:4	Interestingly,  bbbbb1 AdOx eeeee1  disrupted  bbbbb2 actin eeeee2  cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/PI3K, which is linked to various tumorigenic responses
CPR:4	In agreement with these data, the exogenous treatment of SAH or inhibition of  bbbbb1 SAHH eeeee1  by specific siRNA or another type of inhibitor,  bbbbb2 3-deazaadenosine eeeee2  (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src
CPR:4	In agreement with these data, the exogenous treatment of SAH or inhibition of  bbbbb1 SAHH eeeee1  by specific siRNA or another type of inhibitor, 3-deazaadenosine ( bbbbb2 DAZA eeeee2 ), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src
CPR:4	Treatment with  bbbbb1 adenosine dialdehyde eeeee1  (AdOx), an inhibitor of transmethylation-suppressive  bbbbb2 adenosylhomocysteine (SAH) hydrolase eeeee2  (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CPR:4	Treatment with  bbbbb1 adenosine dialdehyde eeeee1  (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase ( bbbbb2 SAHH eeeee2 ), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CPR:4	Treatment with adenosine dialdehyde ( bbbbb1 AdOx eeeee1 ), an inhibitor of transmethylation-suppressive  bbbbb2 adenosylhomocysteine (SAH) hydrolase eeeee2  (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CPR:4	Treatment with adenosine dialdehyde ( bbbbb1 AdOx eeeee1 ), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase ( bbbbb2 SAHH eeeee2 ), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CPR:9	Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive  bbbbb1 adenosylhomocysteine (SAH) hydrolase eeeee1  (SAHH), enhanced the level of  bbbbb2 SAH eeeee2  and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CPR:9	Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase ( bbbbb1 SAHH eeeee1 ), enhanced the level of  bbbbb2 SAH eeeee2  and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CPR:4	A series of  bbbbb1 MMP-1 eeeee1  inhibitors have been identified based upon a  bbbbb2 methyl rosmarinate eeeee2  scaffold using structure-based drug design methods
CPR:4	Synthesis of derivatives of  bbbbb1 methyl rosmarinate eeeee1  and their inhibitory activities against matrix metalloproteinase-1 ( bbbbb2 MMP-1 eeeee2 )
CPR:4	Synthesis of derivatives of  bbbbb1 methyl rosmarinate eeeee1  and their inhibitory activities against  bbbbb2 matrix metalloproteinase-1 eeeee2  (MMP-1)
CPR:9	All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as  bbbbb1 cyclooxygenase-2 eeeee1  (COX-2)-derived  bbbbb2 prostaglandin E2 eeeee2  (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line
CPR:9	All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 ( bbbbb1 COX-2 eeeee1 )-derived  bbbbb2 prostaglandin E2 eeeee2  (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line
CPR:9	All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as  bbbbb1 cyclooxygenase-2 eeeee1  (COX-2)-derived prostaglandin E2 ( bbbbb2 PGE2 eeeee2 ) inhibitory activity of murine macrophage RAW 264.7 cell line
CPR:9	All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 ( bbbbb1 COX-2 eeeee1 )-derived prostaglandin E2 ( bbbbb2 PGE2 eeeee2 ) inhibitory activity of murine macrophage RAW 264.7 cell line
CPR:2	It had higher levels of  bbbbb1 oleocanthal eeeee1  (p-HPEA-EDA), a nutraceutical compound exerting actions against  bbbbb2 COX1 eeeee2  and COX2 (cycloxygenases)
CPR:2	It had higher levels of  bbbbb1 oleocanthal eeeee1  (p-HPEA-EDA), a nutraceutical compound exerting actions against COX1 and  bbbbb2 COX2 eeeee2  (cycloxygenases)
CPR:2	It had higher levels of  bbbbb1 oleocanthal eeeee1  (p-HPEA-EDA), a nutraceutical compound exerting actions against COX1 and COX2 ( bbbbb2 cycloxygenases eeeee2 )
CPR:2	It had higher levels of oleocanthal ( bbbbb1 p-HPEA-EDA eeeee1 ), a nutraceutical compound exerting actions against  bbbbb2 COX1 eeeee2  and COX2 (cycloxygenases)
CPR:2	It had higher levels of oleocanthal ( bbbbb1 p-HPEA-EDA eeeee1 ), a nutraceutical compound exerting actions against COX1 and  bbbbb2 COX2 eeeee2  (cycloxygenases)
CPR:2	It had higher levels of oleocanthal ( bbbbb1 p-HPEA-EDA eeeee1 ), a nutraceutical compound exerting actions against COX1 and COX2 ( bbbbb2 cycloxygenases eeeee2 )
CPR:9	Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the  bbbbb1 lipoxygenase eeeee1  (LOX)-pathway (one having as precursors the  bbbbb2 polyunsaturated fatty acids eeeee2  containing a cis-cis-1,4-pentadiene system)
CPR:9	Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase ( bbbbb1 LOX eeeee1 )-pathway (one having as precursors the  bbbbb2 polyunsaturated fatty acids eeeee2  containing a cis-cis-1,4-pentadiene system)
CPR:9	Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the  bbbbb1 lipoxygenase eeeee1  (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a  bbbbb2 cis-cis-1,4-pentadiene eeeee2  system)
CPR:9	Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase ( bbbbb1 LOX eeeee1 )-pathway (one having as precursors the polyunsaturated fatty acids containing a  bbbbb2 cis-cis-1,4-pentadiene eeeee2  system)
CPR:2	The contrasting activity of  bbbbb1 iodido eeeee1  versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance,  bbbbb2 p53 eeeee2  dependence, and apoptosis pathway
CPR:2	The contrasting activity of iodido versus  bbbbb1 chlorido ruthenium eeeee1  and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance,  bbbbb2 p53 eeeee2  dependence, and apoptosis pathway
CPR:2	The contrasting activity of iodido versus chlorido ruthenium and  bbbbb1 osmium arene azo- and imino-pyridine eeeee1  anticancer complexes: control of cell selectivity, cross-resistance,  bbbbb2 p53 eeeee2  dependence, and apoptosis pathway
CPR:2	The  bbbbb1 iodido eeeee1  complexes retain potency in  bbbbb2 p53 eeeee2  mutant colon cells
CPR:4	In general, antiproliferative activity is greatly enhanced by low levels of the  bbbbb1 glutathione synthase eeeee1  inhibitor  bbbbb2 l-buthionine sulfoxime eeeee2 
CPR:9	The recent identification of  bbbbb1 zinc eeeee1  permeability of the lysosomal ion channel  bbbbb2 TRPML1 eeeee2  (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport
CPR:9	The recent identification of  bbbbb1 zinc eeeee1  permeability of the lysosomal ion channel TRPML1 ( bbbbb2 transient receptor potential mucolipin 1 eeeee2 ), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport
CPR:9	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for  bbbbb1 TRPML1 eeeee1  in  bbbbb2 zinc eeeee2  transport
CPR:9	Cellular  bbbbb1 zinc eeeee1  is controlled by  bbbbb2 zinc-chelating proteins eeeee2  and by zinc transporters
CPR:9	Cellular  bbbbb1 zinc eeeee1  is controlled by zinc-chelating proteins and by  bbbbb2 zinc transporters eeeee2 
CPR:9	These results underscore a role for  bbbbb1 TRPML1 eeeee1  in  bbbbb2 zinc eeeee2  metabolism
CPR:9	Furthermore, they suggest that  bbbbb1 TRPML1 eeeee1  works in concert with ZnT4 to regulate  bbbbb2 zinc eeeee2  translocation between the cytoplasm and lysosomes.
CPR:9	Furthermore, they suggest that TRPML1 works in concert with  bbbbb1 ZnT4 eeeee1  to regulate  bbbbb2 zinc eeeee2  translocation between the cytoplasm and lysosomes.
CPR:2	Similarly, intraperitoneal administration of  bbbbb1 α-santalol eeeee1  (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase,  bbbbb2 catalase eeeee2 , free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice
CPR:2	Similarly, intraperitoneal administration of  bbbbb1 α-santalol eeeee1  (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum  bbbbb2 aminotransferases eeeee2 , alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice
CPR:2	Similarly, intraperitoneal administration of  bbbbb1 α-santalol eeeee1  (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases,  bbbbb2 alkaline phosphatase eeeee2 , bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice
CPR:2	Similarly, intraperitoneal administration of  bbbbb1 α-santalol eeeee1  (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin,  bbbbb2 superoxide dismutase eeeee2 , catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice
CPR:10	The increase in SAA expression is specific to ritodrine-induced liver damage, because  bbbbb1 SAA eeeee1  expression was not induced by other hepatotoxic drugs such as  bbbbb2 acetaminophen eeeee2 , valproic acid, or metformin
CPR:10	The increase in SAA expression is specific to ritodrine-induced liver damage, because  bbbbb1 SAA eeeee1  expression was not induced by other hepatotoxic drugs such as acetaminophen,  bbbbb2 valproic acid eeeee2 , or metformin
CPR:10	The increase in SAA expression is specific to ritodrine-induced liver damage, because  bbbbb1 SAA eeeee1  expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or  bbbbb2 metformin eeeee2 
CPR:10	Our in vitro studies showed that  bbbbb1 cyclic adenosine 3',5'-monophosphate eeeee1  (cAMP) accumulation was not a primary cause of the ritodrine-induced  bbbbb2 SAA eeeee2  increase
CPR:10	Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate ( bbbbb1 cAMP eeeee1 ) accumulation was not a primary cause of the ritodrine-induced  bbbbb2 SAA eeeee2  increase
CPR:2	The tocolytic agent  bbbbb1 ritodrine eeeee1  acts on the  bbbbb2 β2-adrenoceptor eeeee2  and is an effective treatment option for preterm labor
CPR:3	Importantly, expression of the acute-phase reactant  bbbbb1 serum amyloid A eeeee1  (SAA) significantly increased after  bbbbb2 ritodrine eeeee2  injection, with values indicating the largest fold-change
CPR:3	Importantly, expression of the acute-phase reactant serum amyloid A ( bbbbb1 SAA eeeee1 ) significantly increased after  bbbbb2 ritodrine eeeee2  injection, with values indicating the largest fold-change
CPR:3	 bbbbb1 Serum amyloid A eeeee1  upsurge precedes standard biomarkers of hepatotoxicity in  bbbbb2 ritodrine eeeee2 -injected mice
CPR:3	The increase in  bbbbb1 SAA eeeee1  expression is specific to  bbbbb2 ritodrine eeeee2 -induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin
CPR:3	Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the  bbbbb1 ritodrine eeeee1 -induced  bbbbb2 SAA eeeee2  increase
CPR:10	Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus  bbbbb1 β-lactamase eeeee1 -producing Gram-negative bacilli that are not inhibited by  bbbbb2 ceftazidime eeeee2  alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates
CPR:2	Although not a β-lactam, the chemical structure of avibactam closely resembles portions of the  bbbbb1 cephem eeeee1  bicyclic ring system, and avibactam has been shown to bond covalently to  bbbbb2 β-lactamases eeeee2 
CPR:2	Although not a β-lactam, the chemical structure of avibactam closely resembles portions of the cephem bicyclic ring system, and  bbbbb1 avibactam eeeee1  has been shown to bond covalently to  bbbbb2 β-lactamases eeeee2 
CPR:2	Potential future roles for  bbbbb1 ceftazidime eeeee1 -avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing  bbbbb2 extended-spectrum ß-lactamase eeeee2  (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases
CPR:2	Potential future roles for  bbbbb1 ceftazidime eeeee1 -avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase ( bbbbb2 ESBL eeeee2 ), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases
CPR:2	Potential future roles for  bbbbb1 ceftazidime eeeee1 -avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL),  bbbbb2 Klebsiella pneumoniae carbapenemases eeeee2  (KPCs) and/or AmpC ß-lactamases
CPR:2	Potential future roles for  bbbbb1 ceftazidime eeeee1 -avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases ( bbbbb2 KPCs eeeee2 ) and/or AmpC ß-lactamases
CPR:2	Potential future roles for  bbbbb1 ceftazidime eeeee1 -avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or  bbbbb2 AmpC ß-lactamases eeeee2 
CPR:2	Potential future roles for ceftazidime- bbbbb1 avibactam eeeee1  include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing  bbbbb2 extended-spectrum ß-lactamase eeeee2  (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases
CPR:2	Potential future roles for ceftazidime- bbbbb1 avibactam eeeee1  include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase ( bbbbb2 ESBL eeeee2 ), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases
CPR:2	Potential future roles for ceftazidime- bbbbb1 avibactam eeeee1  include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL),  bbbbb2 Klebsiella pneumoniae carbapenemases eeeee2  (KPCs) and/or AmpC ß-lactamases
CPR:2	Potential future roles for ceftazidime- bbbbb1 avibactam eeeee1  include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases ( bbbbb2 KPCs eeeee2 ) and/or AmpC ß-lactamases
CPR:2	Potential future roles for ceftazidime- bbbbb1 avibactam eeeee1  include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or  bbbbb2 AmpC ß-lactamases eeeee2 
CPR:4	Pharmacodynamic data suggest that  bbbbb1 ceftazidime eeeee1 -avibactam is rapidly bactericidal versus  bbbbb2 β-lactamase eeeee2 -producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates
CPR:4	Pharmacodynamic data suggest that ceftazidime- bbbbb1 avibactam eeeee1  is rapidly bactericidal versus  bbbbb2 β-lactamase eeeee2 -producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates
CPR:4	Avibactam (formerly  bbbbb1 NXL104 eeeee1 , AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some  bbbbb2 Ambler class D eeeee2  enzymes
CPR:4	Avibactam (formerly  bbbbb1 NXL104 eeeee1 , AVE1330A) is a synthetic non-β-lactam,  bbbbb2 β-lactamase eeeee2  inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes
CPR:4	 bbbbb1 Avibactam eeeee1  (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some  bbbbb2 Ambler class D eeeee2  enzymes
CPR:4	 bbbbb1 Avibactam eeeee1  (formerly NXL104, AVE1330A) is a synthetic non-β-lactam,  bbbbb2 β-lactamase eeeee2  inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes
CPR:4	Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion,  bbbbb1 avibactam eeeee1  serves to broaden the spectrum of ceftazidime versus  bbbbb2 ß-lactamase eeeee2 -producing Gram-negative bacilli
CPR:4	Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of  bbbbb1 ceftazidime eeeee1  versus  bbbbb2 ß-lactamase eeeee2 -producing Gram-negative bacilli
CPR:4	Avibactam (formerly NXL104,  bbbbb1 AVE1330A eeeee1 ) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some  bbbbb2 Ambler class D eeeee2  enzymes
CPR:4	Avibactam (formerly NXL104,  bbbbb1 AVE1330A eeeee1 ) is a synthetic non-β-lactam,  bbbbb2 β-lactamase eeeee2  inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes
CPR:4	The addition of  bbbbb1 avibactam eeeee1  greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of  bbbbb2 β-lactamase eeeee2  enzyme(s)
CPR:4	The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of  bbbbb1 ceftazidime eeeee1  versus most species of Enterobacteriaceae depending on the presence or absence of  bbbbb2 β-lactamase eeeee2  enzyme(s)
CPR:4	 bbbbb1 Ceftazidime eeeee1 -avibactam: a novel cephalosporin/ bbbbb2 β-lactamase eeeee2  inhibitor combination
CPR:4	Ceftazidime- bbbbb1 avibactam eeeee1 : a novel cephalosporin/ bbbbb2 β-lactamase eeeee2  inhibitor combination
CPR:4	Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective  bbbbb1 cyclooxygenase-2 eeeee1  inhibitor,  bbbbb2 celecoxib eeeee2 , improved vascular function, and also attenuated obesity
CPR:4	 bbbbb1 Upamostat eeeee1  (Mesupron®) is a new small molecule  bbbbb2 serine protease eeeee2  inhibitor
CPR:4	Upamostat ( bbbbb1 Mesupron eeeee1 ®) is a new small molecule  bbbbb2 serine protease eeeee2  inhibitor
CPR:1	Moreover, we show that  bbbbb1 USP22 eeeee1  is acetylated on multiple  bbbbb2 lysine eeeee2  residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core SAGA complex
CPR:1	Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single  bbbbb1 lysine eeeee1  (K129) within the  bbbbb2 ZnF-UBP domain eeeee2  is sufficient to alter interaction of the DUBm with the core SAGA complex
CPR:2	Transcripts of GPx4 genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the  bbbbb1 GPx1 eeeee1  genes were more responsive to  bbbbb2 selenium eeeee2  exposure in vitro, especially to the organic form
CPR:2	Interestingly,  bbbbb1 GPx1a eeeee1  was the most sensitive to  bbbbb2 selenium eeeee2  availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells
CPR:2	Our results lead us to conclude that trout  bbbbb1 GPx1 eeeee1  transcripts expression level may represent a sensitive biomarker for  bbbbb2 selenium eeeee2  intake, helping to evaluate if selenium concentration and chemical speciation impact on cell homeostasis.
CPR:2	Characterization of  bbbbb1 cytosolic glutathione peroxidase eeeee1  and phospholipid-hydroperoxide glutathione peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro  bbbbb2 selenium eeeee2  exposure
CPR:2	Characterization of cytosolic glutathione peroxidase and  bbbbb1 phospholipid-hydroperoxide glutathione peroxidase eeeee1  genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro  bbbbb2 selenium eeeee2  exposure
CPR:3	Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas  bbbbb1 GPx1b1 eeeee1  and GPx1b2 were highly induced by exposure to  bbbbb2 selenium eeeee2  levels that had some toxic effects on the cells
CPR:3	Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and  bbbbb1 GPx1b2 eeeee1  were highly induced by exposure to  bbbbb2 selenium eeeee2  levels that had some toxic effects on the cells
CPR:3	These findings are the first to show that long-term exposure to  bbbbb1 Mn eeeee1  during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers,  bbbbb2 p38 eeeee2 (MAPK) phosphorylation and caspase activity in the striatum
CPR:3	These findings are the first to show that long-term exposure to  bbbbb1 Mn eeeee1  during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38( bbbbb2 MAPK eeeee2 ) phosphorylation and caspase activity in the striatum
CPR:3	These findings are the first to show that long-term exposure to  bbbbb1 Mn eeeee1  during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK) phosphorylation and  bbbbb2 caspase eeeee2  activity in the striatum
CPR:3	 bbbbb1 Mn eeeee1  exposure (20 mg/kg) increased  bbbbb2 p38 eeeee2 (MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation
CPR:3	 bbbbb1 Mn eeeee1  exposure (20 mg/kg) increased p38( bbbbb2 MAPK eeeee2 ) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation
CPR:3	 bbbbb1 Mn eeeee1  exposure (20 mg/kg) increased p38(MAPK) and  bbbbb2 Akt eeeee2  phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation
CPR:3	 bbbbb1 Mn eeeee1  (10 and 20 mg/kg) increased  bbbbb2 caspase eeeee2  activity and F(2)-isoprostane production (a biological marker of lipid peroxidation)
CPR:3	Notably, the antioxidant Trolox™ reversed the  bbbbb1 Mn eeeee1  (20 mg/kg)-dependent augmentation in  bbbbb2 p38 eeeee2 (MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production
CPR:3	Notably, the antioxidant Trolox™ reversed the  bbbbb1 Mn eeeee1  (20 mg/kg)-dependent augmentation in p38( bbbbb2 MAPK eeeee2 ) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production
CPR:3	Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the  bbbbb1 Mn eeeee1  (20 mg/kg)-induced  bbbbb2 caspase eeeee2  activity and F(2)-isoprostane production
CPR:4	 bbbbb1 Mn eeeee1  exposure (20 mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased  bbbbb2 DARPP-32 eeeee2 -Thr-34 phosphorylation
CPR:4	Notably, the antioxidant  bbbbb1 Trolox eeeee1 ™ reversed the Mn (20 mg/kg)-dependent augmentation in  bbbbb2 p38 eeeee2 (MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production
CPR:4	Notably, the antioxidant  bbbbb1 Trolox eeeee1 ™ reversed the Mn (20 mg/kg)-dependent augmentation in p38( bbbbb2 MAPK eeeee2 ) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production
CPR:4	Notably, the antioxidant  bbbbb1 Trolox eeeee1 ™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced  bbbbb2 caspase eeeee2  activity and F(2)-isoprostane production
CPR:4	 bbbbb1 Nocapyrone H eeeee1  (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and  bbbbb2 interleukin-1β eeeee2  (IL-1β)
CPR:4	 bbbbb1 Nocapyrone H eeeee1  (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1β ( bbbbb2 IL-1β eeeee2 )
CPR:4	Investigating the enteroenteric recirculation of  bbbbb1 apixaban eeeee1 , a  bbbbb2 factor Xa eeeee2  inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats
CPR:4	The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with  bbbbb1 GF-120918 eeeee1 , a dual  bbbbb2 BCRP eeeee2  and P-gp inhibitor)
CPR:4	The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with  bbbbb1 GF-120918 eeeee1 , a dual BCRP and  bbbbb2 P-gp eeeee2  inhibitor)
CPR:9	 bbbbb1 BCRP eeeee1  appeared to play a more important role for absorption and intestinal and renal elimination of  bbbbb2 apixaban eeeee2  than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species
CPR:9	BCRP appeared to play a more important role for absorption and intestinal and renal elimination of  bbbbb1 apixaban eeeee1  than  bbbbb2 P-gp eeeee2  in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species
CPR:1	The enzyme (TcCA) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform  bbbbb1 hCA II eeeee1 , although it is devoid of the  bbbbb2 His eeeee2 64 proton shuttle
CPR:4	A large number of  bbbbb1 aromatic/heterocyclic sulfonamides eeeee1  and some 5-mercapto-1,3,4-thiadiazoles were investigated as  bbbbb2 TcCA eeeee2  inhibitors
CPR:4	A large number of aromatic/heterocyclic sulfonamides and some  bbbbb1 5-mercapto-1,3,4-thiadiazoles eeeee1  were investigated as  bbbbb2 TcCA eeeee2  inhibitors
CPR:4	Cloning, Characterization, and  bbbbb1 Sulfonamide eeeee1  and Thiol Inhibition Studies of an  bbbbb2 α-Carbonic Anhydrase eeeee2  from Trypanosoma cruzi, the Causative Agent of Chagas Disease
CPR:4	Cloning, Characterization, and Sulfonamide and  bbbbb1 Thiol eeeee1  Inhibition Studies of an  bbbbb2 α-Carbonic Anhydrase eeeee2  from Trypanosoma cruzi, the Causative Agent of Chagas Disease
CPR:9	The enzyme (TcCA) has a very high catalytic activity for the  bbbbb1 CO(2) eeeee1  hydration reaction, being similar kinetically to the human (h) isoform  bbbbb2 hCA II eeeee2 , although it is devoid of the His64 proton shuttle
CPR:9	The enzyme ( bbbbb1 TcCA eeeee1 ) has a very high catalytic activity for the  bbbbb2 CO(2) eeeee2  hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle
CPR:10	However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of  bbbbb1 Insl3 eeeee1 , Hsd17b3 and Hsd11b1 in the  bbbbb2 DEHP eeeee2 -treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells
CPR:10	However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3,  bbbbb1 Hsd17b3 eeeee1  and Hsd11b1 in the  bbbbb2 DEHP eeeee2 -treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells
CPR:10	However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and  bbbbb1 Hsd11b1 eeeee1  in the  bbbbb2 DEHP eeeee2 -treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells
CPR:10	The mRNA level for  bbbbb1 nestin eeeee1  (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the  bbbbb2 DEHP eeeee2  treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes
CPR:10	The mRNA level for nestin ( bbbbb1 Nes eeeee1 , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the  bbbbb2 DEHP eeeee2  treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes
CPR:2	However, there were detectable concentrations of  bbbbb1 Lhcgr eeeee1 , Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the  bbbbb2 DEHP eeeee2 -treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells
CPR:2	However, there were detectable concentrations of Lhcgr,  bbbbb1 Cyp11a1 eeeee1  and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the  bbbbb2 DEHP eeeee2 -treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells
CPR:2	However, there were detectable concentrations of Lhcgr, Cyp11a1 and  bbbbb1 Cyp17a1 eeeee1  mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the  bbbbb2 DEHP eeeee2 -treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells
CPR:3	The mRNA level for  bbbbb1 nestin eeeee1  (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post- bbbbb2 EDS eeeee2 , but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes
CPR:3	The mRNA level for nestin ( bbbbb1 Nes eeeee1 , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post- bbbbb2 EDS eeeee2 , but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes
CPR:2	Expression of pituitary  bbbbb1 FSH eeeee1  and LH, under the control of pulsatile  bbbbb2 GnRH eeeee2 , is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CPR:2	Expression of pituitary FSH and  bbbbb1 LH eeeee1 , under the control of pulsatile  bbbbb2 GnRH eeeee2 , is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CPR:2	We hypothesized that CREB is activated by a distinct signaling pathway in response to pulsatile  bbbbb1 GnRH eeeee1  in a frequency-dependent manner to dictate the  bbbbb2 FSHβ eeeee2  transcriptional response
CPR:2	A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased  bbbbb1 GnRH eeeee1  stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on  bbbbb2 LHβ eeeee2 LUC activity, indicating relative specificity of this pathway
CPR:3	A dominant negative PKA (DNPKA) reduced  bbbbb1 GnRH eeeee1 -stimulated  bbbbb2 pCREB eeeee2  and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CPR:3	A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased  bbbbb1 GnRH eeeee1  stimulation of FSHβ mRNA and  bbbbb2 FSHβ eeeee2 LUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CPR:3	In perifusion studies, FSHβ mRNA levels and  bbbbb1 FSHβ eeeee1 LUC activities were increased by pulsatile  bbbbb2 GnRH eeeee2 , with significantly greater increases at low compared with high pulse frequencies
CPR:3	 bbbbb1 GnRH eeeee1  pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and  bbbbb2 CREB eeeee2 
CPR:3	 bbbbb1 GnRH eeeee1  pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of  bbbbb2 PKA eeeee2  and CREB
CPR:3	Correlating with  bbbbb1 FSHβ eeeee1  activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high  bbbbb2 GnRH eeeee2  pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies
CPR:3	Correlating with FSHβ activation, both  bbbbb1 PKA eeeee1  activity and levels of pCREB were increased to a greater extent by low compared with high  bbbbb2 GnRH eeeee2  pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies
CPR:3	Correlating with FSHβ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high  bbbbb1 GnRH eeeee1  pulse frequencies, and the induction of  bbbbb2 pCREB eeeee2  was also attenuated by overexpression of DNPKA at both low and high pulse frequencies
CPR:3	Taken together, these data indicate that a PKA-mediated signaling pathway mediates  bbbbb1 GnRH eeeee1  activation of  bbbbb2 CREB eeeee2  at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSHβ activation.
CPR:3	Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic  bbbbb1 GnRH eeeee1  signal to result in frequency-dependent  bbbbb2 FSHβ eeeee2  activation.
CPR:3	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb1 GnRH eeeee1  regulates  bbbbb2 CREB eeeee2  activation remain poorly understood
CPR:3	We hypothesized that  bbbbb1 CREB eeeee1  is activated by a distinct signaling pathway in response to pulsatile  bbbbb2 GnRH eeeee2  in a frequency-dependent manner to dictate the FSHβ transcriptional response
CPR:3	 bbbbb1 GnRH eeeee1  stimulation of  bbbbb2 CREB eeeee2  phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89
CPR:3	 bbbbb1 GnRH eeeee1  stimulation of CREB phosphorylation ( bbbbb2 pCREB eeeee2 ) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89
CPR:3	A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased  bbbbb1 GnRH eeeee1  stimulation of  bbbbb2 FSHβ eeeee2  mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CPR:3	In perifusion studies,  bbbbb1 FSHβ eeeee1  mRNA levels and FSHβLUC activities were increased by pulsatile  bbbbb2 GnRH eeeee2 , with significantly greater increases at low compared with high pulse frequencies
CPR:3	 bbbbb1 GnRH eeeee1  pulse frequency-dependent stimulation of  bbbbb2 FSHβ eeeee2  transcription is mediated via activation of PKA and CREB
CPR:3	DNPKA markedly reduced these  bbbbb1 GnRH eeeee1 -stimulated  bbbbb2 FSHβ eeeee2  responses at both low and high pulse frequencies
CPR:3	Correlating with FSHβ activation, both PKA activity and levels of  bbbbb1 pCREB eeeee1  were increased to a greater extent by low compared with high  bbbbb2 GnRH eeeee2  pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies
CPR:4	GnRH stimulation of  bbbbb1 CREB eeeee1  phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor,  bbbbb2 H89 eeeee2 
CPR:4	GnRH stimulation of CREB phosphorylation ( bbbbb1 pCREB eeeee1 ) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor,  bbbbb2 H89 eeeee2 
CPR:4	GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a  bbbbb1 protein kinase A eeeee1  (PKA) inhibitor,  bbbbb2 H89 eeeee2 
CPR:4	GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A ( bbbbb1 PKA eeeee1 ) inhibitor,  bbbbb2 H89 eeeee2 
CPR:2	 bbbbb1 Sophocarpine eeeee1 , an effective compound derived from foxtail-like sophora herb and seed, has been reported that it can alleviate non-alcoholic steatohepatitis (NASH) in rats and affect  bbbbb2 adipocytokine eeeee2  synthesis
CPR:3	We concluded that  bbbbb1 sophocarpine eeeee1  could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of  bbbbb2 AMPK eeeee2 .
CPR:3	 bbbbb1 Sophocarpine eeeee1  alleviates hepatocyte steatosis through activating  bbbbb2 AMPK eeeee2  signaling pathway
CPR:3	Moreover, compared with the model group,  bbbbb1 sophocarpine eeeee1  could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and  bbbbb2 ACC eeeee2  (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression
CPR:3	Moreover, compared with the model group,  bbbbb1 sophocarpine eeeee1  could significantly increase  bbbbb2 P-AMPKα eeeee2  (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression
CPR:3	Moreover, compared with the model group,  bbbbb1 sophocarpine eeeee1  could significantly increase P-AMPKα (>5.82-fold),  bbbbb2 AMPKα eeeee2  (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression
CPR:3	While  bbbbb1 sophocarpine eeeee1  treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of  bbbbb2 adiponectin eeeee2  expression (>1.48-fold)
CPR:4	Moreover, compared with the model group,  bbbbb1 sophocarpine eeeee1  could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce  bbbbb2 P-ACC eeeee2  (<0.30-fold) and HNF-4α (<0.20-fold) protein expression
CPR:4	Moreover, compared with the model group,  bbbbb1 sophocarpine eeeee1  could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and  bbbbb2 HNF-4α eeeee2  (<0.20-fold) protein expression
CPR:4	While  bbbbb1 sophocarpine eeeee1  treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of  bbbbb2 leptin eeeee2  expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold)
CPR:4	The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the  bbbbb1 P-gp eeeee1  inhibitor  bbbbb2 zosuquidar eeeee2 
CPR:4	Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of  bbbbb1 ketoconazole eeeee1  on  bbbbb2 P-gp eeeee2  as the main mechanism for the increased transport of darunavir across the small intestine.
CPR:9	The involvement of  bbbbb1 P-gp eeeee1  in the absorption of  bbbbb2 darunavir eeeee2  was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar
CPR:9	Involvement of  bbbbb1 P450 eeeee1  mediated metabolism in the absorption of  bbbbb2 darunavir eeeee2  could not be demonstrated in this rat model
CPR:9	Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on  bbbbb1 P-gp eeeee1  as the main mechanism for the increased transport of  bbbbb2 darunavir eeeee2  across the small intestine.
CPR:9	To evaluate to what extent the regional differences in expression of  bbbbb1 P-gp eeeee1  and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of  bbbbb2 darunavir eeeee2  across different small intestinal segments (duodenum, proximal jejunum and ileum)
CPR:9	To evaluate to what extent the regional differences in expression of P-gp and  bbbbb1 P450 enzymes eeeee1  affect the absorption of a dual substrate, we investigated the transport of  bbbbb2 darunavir eeeee2  across different small intestinal segments (duodenum, proximal jejunum and ileum)
CPR:4	In another experiment, topical application of CFB, CFE or  bbbbb1 CLS eeeee1  prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of  bbbbb2 COX-2 eeeee2 , iNOS, and TNF-α
CPR:4	In another experiment, topical application of CFB, CFE or  bbbbb1 CLS eeeee1  prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2,  bbbbb2 iNOS eeeee2 , and TNF-α
CPR:4	In another experiment, topical application of CFB, CFE or  bbbbb1 CLS eeeee1  prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and  bbbbb2 TNF-α eeeee2 
CPR:4	In HaCaT cells,  bbbbb1 buthanol eeeee1  and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells,  bbbbb1 buthanol eeeee1  and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells,  bbbbb1 buthanol eeeee1  and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2),  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells,  bbbbb1 buthanol eeeee1  and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ( bbbbb2 iNOS eeeee2 ), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells,  bbbbb1 buthanol eeeee1  and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and  bbbbb2 tumor necrosis factor-α eeeee2  (TNF- α)
CPR:4	In HaCaT cells,  bbbbb1 buthanol eeeee1  and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α ( bbbbb2 TNF- α eeeee2 )
CPR:4	In HaCaT cells, buthanol and  bbbbb1 ethylacetate eeeee1  fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and  bbbbb1 ethylacetate eeeee1  fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and  bbbbb1 ethylacetate eeeee1  fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2),  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and  bbbbb1 ethylacetate eeeee1  fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ( bbbbb2 iNOS eeeee2 ), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and  bbbbb1 ethylacetate eeeee1  fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and  bbbbb2 tumor necrosis factor-α eeeee2  (TNF- α)
CPR:4	In HaCaT cells, buthanol and  bbbbb1 ethylacetate eeeee1  fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α ( bbbbb2 TNF- α eeeee2 )
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80%  bbbbb1 methanol eeeee1  C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80%  bbbbb1 methanol eeeee1  C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80%  bbbbb1 methanol eeeee1  C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2),  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80%  bbbbb1 methanol eeeee1  C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ( bbbbb2 iNOS eeeee2 ), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80%  bbbbb1 methanol eeeee1  C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and  bbbbb2 tumor necrosis factor-α eeeee2  (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80%  bbbbb1 methanol eeeee1  C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α ( bbbbb2 TNF- α eeeee2 )
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound,  bbbbb1 clerosterol eeeee1  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound,  bbbbb1 clerosterol eeeee1  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound,  bbbbb1 clerosterol eeeee1  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2),  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound,  bbbbb1 clerosterol eeeee1  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ( bbbbb2 iNOS eeeee2 ), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound,  bbbbb1 clerosterol eeeee1  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and  bbbbb2 tumor necrosis factor-α eeeee2  (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound,  bbbbb1 clerosterol eeeee1  (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α ( bbbbb2 TNF- α eeeee2 )
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol ( bbbbb1 CLS eeeee1 ) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol ( bbbbb1 CLS eeeee1 ) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol ( bbbbb1 CLS eeeee1 ) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2),  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol ( bbbbb1 CLS eeeee1 ) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ( bbbbb2 iNOS eeeee2 ), and tumor necrosis factor-α (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol ( bbbbb1 CLS eeeee1 ) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and  bbbbb2 tumor necrosis factor-α eeeee2  (TNF- α)
CPR:4	In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol ( bbbbb1 CLS eeeee1 ) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α ( bbbbb2 TNF- α eeeee2 )
CPR:2	Interaction of silymarin  bbbbb1 flavonolignans eeeee1  with  bbbbb2 organic anion-transporting polypeptides eeeee2 
CPR:2	The extent of silymarin-drug interactions depends on  bbbbb1 OATP eeeee1  isoform specificity and concentrations of  bbbbb2 flavonolignans eeeee2  at the site of drug transport
CPR:4	In overexpressing cell lines,  bbbbb1 OATP1B1 eeeee1 - and OATP1B3-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin  bbbbb2 flavonolignans eeeee2  investigated
CPR:4	In overexpressing cell lines, OATP1B1- and  bbbbb1 OATP1B3 eeeee1 -mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin  bbbbb2 flavonolignans eeeee2  investigated
CPR:4	In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17β-glucuronide uptake and  bbbbb1 OATP2B1 eeeee1 -mediated estrone-3-sulfate uptake were inhibited by most of the silymarin  bbbbb2 flavonolignans eeeee2  investigated
CPR:4	 bbbbb1 OATP1B1 eeeee1 -, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively),  bbbbb2 silybin A eeeee2  (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)
CPR:4	OATP1B1-,  bbbbb1 OATP1B3 eeeee1 -, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively),  bbbbb2 silybin A eeeee2  (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)
CPR:4	OATP1B1-, OATP1B3-, and  bbbbb1 OATP2B1 eeeee1 -mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively),  bbbbb2 silybin A eeeee2  (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)
CPR:4	 bbbbb1 OATP1B1 eeeee1 -, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively),  bbbbb2 silybin B eeeee2  (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)
CPR:4	OATP1B1-,  bbbbb1 OATP1B3 eeeee1 -, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively),  bbbbb2 silybin B eeeee2  (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)
CPR:4	OATP1B1-, OATP1B3-, and  bbbbb1 OATP2B1 eeeee1 -mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively),  bbbbb2 silybin B eeeee2  (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)
CPR:4	 bbbbb1 OATP1B1 eeeee1 -, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and  bbbbb2 silychristin eeeee2  (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)
CPR:4	OATP1B1-,  bbbbb1 OATP1B3 eeeee1 -, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and  bbbbb2 silychristin eeeee2  (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)
CPR:4	OATP1B1-, OATP1B3-, and  bbbbb1 OATP2B1 eeeee1 -mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and  bbbbb2 silychristin eeeee2  (IC50 values of 9.0, 36.4, and 3.6 µM, respectively)
CPR:4	Furthermore, silymarin,  bbbbb1 silybin A eeeee1 , and silybin B (100 µM) significantly inhibited  bbbbb2 OATP eeeee2 -mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes
CPR:4	Furthermore, silymarin, silybin A, and  bbbbb1 silybin B eeeee1  (100 µM) significantly inhibited  bbbbb2 OATP eeeee2 -mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes
CPR:9	In overexpressing cell lines,  bbbbb1 OATP1B1 eeeee1 - and OATP1B3-mediated  bbbbb2 estradiol-17β-glucuronide eeeee2  uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated
CPR:9	In overexpressing cell lines, OATP1B1- and  bbbbb1 OATP1B3 eeeee1 -mediated  bbbbb2 estradiol-17β-glucuronide eeeee2  uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated
CPR:9	In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17β-glucuronide uptake and  bbbbb1 OATP2B1 eeeee1 -mediated  bbbbb2 estrone-3-sulfate eeeee2  uptake were inhibited by most of the silymarin flavonolignans investigated
CPR:9	Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited  bbbbb1 OATP eeeee1 -mediated  bbbbb2 estradiol-17β-glucuronide eeeee2  and rosuvastatin uptake into human hepatocytes
CPR:9	Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited  bbbbb1 OATP eeeee1 -mediated estradiol-17β-glucuronide and  bbbbb2 rosuvastatin eeeee2  uptake into human hepatocytes
CPR:2	Selective oxidation of ω-tertiary amine self-assembled thiol monolayers to  bbbbb1 tertiary amine N-oxides eeeee1  is shown to transform the adhesion of model proteins  bbbbb2 lysozyme eeeee2  and fibrinogen upon them
CPR:2	Selective oxidation of ω-tertiary amine self-assembled thiol monolayers to  bbbbb1 tertiary amine N-oxides eeeee1  is shown to transform the adhesion of model proteins lysozyme and  bbbbb2 fibrinogen eeeee2  upon them
CPR:2	Tertiary amine-functionalized sensors adsorbed multilayers of aggregated  bbbbb1 lysozyme eeeee1 , whereas  bbbbb2 tertiary amine N-oxides eeeee2  and triethylene glycol-terminated monolayers are consistent with small protein aggregates
CPR:2	Tertiary amine-functionalized sensors adsorbed multilayers of aggregated  bbbbb1 lysozyme eeeee1 , whereas tertiary amine N-oxides and  bbbbb2 triethylene glycol eeeee2 -terminated monolayers are consistent with small protein aggregates
CPR:2	Selective oxidation of  bbbbb1 ω-tertiary amine eeeee1  self-assembled thiol monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins  bbbbb2 lysozyme eeeee2  and fibrinogen upon them
CPR:2	Selective oxidation of  bbbbb1 ω-tertiary amine eeeee1  self-assembled thiol monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins lysozyme and  bbbbb2 fibrinogen eeeee2  upon them
CPR:2	Selective oxidation of ω-tertiary amine self-assembled  bbbbb1 thiol eeeee1  monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins  bbbbb2 lysozyme eeeee2  and fibrinogen upon them
CPR:2	Selective oxidation of ω-tertiary amine self-assembled  bbbbb1 thiol eeeee1  monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins lysozyme and  bbbbb2 fibrinogen eeeee2  upon them
CPR:2	Oxidation with  bbbbb1 hydrogen peroxide eeeee1  was similarly assessed, and adhesion of  bbbbb2 lysozyme eeeee2  and fibrinogen from phosphate buffered saline was then assayed by QCM and imaged by AFM
CPR:2	Oxidation with  bbbbb1 hydrogen peroxide eeeee1  was similarly assessed, and adhesion of lysozyme and  bbbbb2 fibrinogen eeeee2  from phosphate buffered saline was then assayed by QCM and imaged by AFM
CPR:3	Further investigation demonstrated that 8k reduced  bbbbb1 H2O2 eeeee1 -induced activation of mitochondrial apoptosis by inhibiting the expression of  bbbbb2 Bax eeeee2  and elevating the expression of Bcl-2
CPR:4	Further investigation demonstrated that 8k reduced  bbbbb1 H2O2 eeeee1 -induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of  bbbbb2 Bcl-2 eeeee2 
CPR:2	 bbbbb1 Insulin eeeee1  levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, GLP-1 first and second phases, and  bbbbb2 arginine eeeee2 )
CPR:3	Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  bbbbb1 insulin eeeee1  (achieved by administering insulin plus  bbbbb2 glucose eeeee2 , glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)
CPR:3	Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  bbbbb1 insulin eeeee1  (achieved by administering insulin plus glucose,  bbbbb2 glucose eeeee2  only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)
CPR:3	Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  bbbbb1 insulin eeeee1  (achieved by administering insulin plus glucose, glucose only,  bbbbb2 glucose eeeee2  and GLP-1, and glucose and GLP-1 combined with arginine)
CPR:3	Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  bbbbb1 insulin eeeee1  (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and  bbbbb2 glucose eeeee2  and GLP-1 combined with arginine)
CPR:3	Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of  bbbbb1 insulin eeeee1  (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with  bbbbb2 arginine eeeee2 )
CPR:1	In a mouse tumor model, removal of only the  bbbbb1 C eeeee1 -terminal propeptide from full-length  bbbbb2 VEGF-D eeeee2  was sufficient to enhance angiogenesis and tumor growth
CPR:1	We report for the first time that VEGF-D binds heparin, and that the  bbbbb1 C eeeee1 -terminal propeptide significantly enhances this interaction (removal of this propeptide from full-length  bbbbb2 VEGF-D eeeee2  completely prevents heparin binding)
CPR:1	We also show that removal of either the  bbbbb1 N eeeee1 - or C-terminal propeptide is required for  bbbbb2 VEGF-D eeeee2  to drive formation of VEGFR-2/VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting
CPR:1	We also show that removal of either the N- or  bbbbb1 C eeeee1 -terminal propeptide is required for  bbbbb2 VEGF-D eeeee2  to drive formation of VEGFR-2/VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting
CPR:2	The  bbbbb1 CRF(1) receptor eeeee1  antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with  bbbbb2 paroxetine eeeee2  and D-cycloserine
CPR:2	The  bbbbb1 CRF(1) receptor eeeee1  antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and  bbbbb2 D-cycloserine eeeee2 
CPR:5	Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial  bbbbb1 N-methyl-D-aspartate (NMDA) receptor eeeee1  agonist,  bbbbb2 D-cycloserine eeeee2  (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD
CPR:6	RATIONALE: The selective  bbbbb1 CRF(1) (corticotropin releasing factor type 1) receptor eeeee1  antagonist  bbbbb2 SSR125543 eeeee2  has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure
CPR:6	The  bbbbb1 CRF(1) receptor eeeee1  antagonist  bbbbb2 SSR125543 eeeee2  prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine
CPR:6	CONCLUSIONS: These findings confirm that the  bbbbb1 CRF(1) receptor eeeee1  antagonist  bbbbb2 SSR125543 eeeee2  is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.
CPR:2	 bbbbb1 Aryl sulfonamide eeeee1  antagonists bind to  bbbbb2 CCR4 eeeee2  at an intracellular allosteric site denoted site II
CPR:6	A series of  bbbbb1 indazole arylsulfonamides eeeee1  were synthesized and examined as  bbbbb2 human CCR4 eeeee2  antagonists
CPR:7	Synthesis and structure-activity relationships of  bbbbb1 indazole arylsulfonamides eeeee1  as allosteric CC-chemokine receptor 4 ( bbbbb2 CCR4 eeeee2 ) antagonists
CPR:7	Synthesis and structure-activity relationships of  bbbbb1 indazole arylsulfonamides eeeee1  as allosteric  bbbbb2 CC-chemokine receptor 4 eeeee2  (CCR4) antagonists
CPR:2	Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased  bbbbb1 CB(1) eeeee1  receptor density and function in brain, as assessed in  bbbbb2 [(3)H]SR141716A eeeee2  binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively
CPR:2	Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased  bbbbb1 CB(1) eeeee1  receptor density and function in brain, as assessed in [(3)H]SR141716A binding and  bbbbb2 CP55,940 eeeee2 -stimulated [(35)S]GTPγS binding assays, respectively
CPR:2	Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased  bbbbb1 CB(1) eeeee1  receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [ bbbbb2 (35)S eeeee2 ]GTPγS binding assays, respectively
CPR:2	In contrast, normal  bbbbb1 CB(1) eeeee1  receptor expression and function were maintained following repeated administration of low dose  bbbbb2 JZL184 eeeee2  (≤8 mg/kg)
CPR:2	Repeated Low Dose Administration of the Monoacylglycerol Lipase Inhibitor  bbbbb1 JZL184 eeeee1  Retains  bbbbb2 CB1 eeeee2  Receptor Mediated Antinociceptive and Gastroprotective Effects
CPR:2	In contrast, normal  bbbbb1 CB(1) eeeee1  receptor expression and function were maintained following repeated administration of low dose  bbbbb2 JZL184 eeeee2  (≤8 mg/kg)
CPR:4	Mice given daily injections of high dose  bbbbb1 JZL184 eeeee1  (≥16 mg/kg) for six days displayed decreased  bbbbb2 CB(1) eeeee2  receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively
CPR:4	The monoacylglycerol lipase ( bbbbb1 MAGL eeeee1 ) inhibitor  bbbbb2 JZL184 eeeee2  produces antinociceptive and anti-inflammatory effects
CPR:4	The  bbbbb1 monoacylglycerol lipase eeeee1  (MAGL) inhibitor  bbbbb2 JZL184 eeeee2  produces antinociceptive and anti-inflammatory effects
CPR:4	Repeated Low Dose Administration of the  bbbbb1 Monoacylglycerol Lipase eeeee1  Inhibitor  bbbbb2 JZL184 eeeee2  Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects
CPR:4	 bbbbb1 Bicyclic pyrazinone and pyrimidinone amides eeeee1  were designed and synthesized as potent TF- bbbbb2 FVIIa eeeee2  inhibitors
CPR:4	 bbbbb1 Bicyclic pyrazinone and pyrimidinone amides eeeee1  were designed and synthesized as potent  bbbbb2 TF eeeee2 -FVIIa inhibitors
CPR:4	Design and synthesis of  bbbbb1 bicyclic pyrazinone and pyrimidinone amides eeeee1  as potent  bbbbb2 TF eeeee2 -FVIIa inhibitors
CPR:4	Design and synthesis of  bbbbb1 bicyclic pyrazinone and pyrimidinone amides eeeee1  as potent TF- bbbbb2 FVIIa eeeee2  inhibitors
CPR:1	While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA,  bbbbb1 HIF-1α eeeee1  is degraded under normoxia, which involves its  bbbbb2 proline eeeee2  hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex
CPR:3	The most potent compound 5 ( bbbbb1 HJC0123 eeeee1 ) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved  bbbbb2 caspase-3 eeeee2 , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values
CPR:4	The most potent compound 5 ( bbbbb1 HJC0123 eeeee1 ) has demonstrated to inhibit  bbbbb2 STAT3 promoter eeeee2  activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values
CPR:4	The most potent compound 5 ( bbbbb1 HJC0123 eeeee1 ) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of  bbbbb2 STAT3 eeeee2 , increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values
CPR:4	Fragment-based drug design and identification of  bbbbb1 HJC0123 eeeee1 , a novel orally bioavailable  bbbbb2 STAT3 eeeee2  inhibitor for cancer therapy
CPR:2	To map supercoiling, we used  bbbbb1 biotinylated trimethylpsoralen eeeee1  as a DNA structure probe to show that the human genome is organized into  bbbbb2 supercoiling domains eeeee2 
CPR:4	Therefore, we examined whether the  bbbbb1 PDE5 eeeee1 -I  bbbbb2 vardenafil eeeee2  improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults
CPR:4	The effects of the  bbbbb1 phosphodiesterase type 5 eeeee1  inhibitor  bbbbb2 vardenafil eeeee2  on cognitive performance in healthy adults: a behavioral- electroencephalography study
CPR:10	 bbbbb1 Catalase eeeee1 , glutathione-S-transferase and xanthine oxidase activities were not altered by  bbbbb2 atorvastatin eeeee2  treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CPR:10	Catalase,  bbbbb1 glutathione-S-transferase eeeee1  and xanthine oxidase activities were not altered by  bbbbb2 atorvastatin eeeee2  treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CPR:10	Catalase, glutathione-S-transferase and  bbbbb1 xanthine oxidase eeeee1  activities were not altered by  bbbbb2 atorvastatin eeeee2  treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CPR:3	We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased  bbbbb1 NADPH oxidase eeeee1  activity and immunoreactivity for the protein nitration marker  bbbbb2 3-nitrotyrosine eeeee2  in the cerebral cortex
CPR:9	Statins are inhibitors of the enzyme  bbbbb1 3-hydroxy-3-methylglutaryl coenzyme A reductase eeeee1 , the rate-limiting step in  bbbbb2 cholesterol eeeee2  biosynthesis
CPR:2	Hyperthyroidism-induced oxidative stress, reduction in  bbbbb1 cytochrome c oxidase eeeee1  activity, and myocardial ATP concentration were also significantly checked by  bbbbb2 Bzf eeeee2 
CPR:5	Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8 μg/100 g body weight (BW), i.p.) for 15 days or along with a  bbbbb1 peroxisome proliferator-activated receptor alpha eeeee1  agonist  bbbbb2 bezafibrate eeeee2  (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition
CPR:5	Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8 μg/100 g body weight (BW), i.p.) for 15 days or along with a  bbbbb1 peroxisome proliferator-activated receptor alpha eeeee1  agonist bezafibrate ( bbbbb2 Bzf eeeee2 ; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition
CPR:2	The serum or  bbbbb1 dexamethasone eeeee1 -induced oscillation in the expression of  bbbbb2 DRD3 eeeee2  in cells was abrogated by the downregulation or overexpression of REV-ERBα, suggesting that REV-ERBα functions as a regulator of DRD3 oscillations in the cellular autonomous clock
CPR:2	The serum or  bbbbb1 dexamethasone eeeee1 -induced oscillation in the expression of DRD3 in cells was abrogated by the downregulation or overexpression of  bbbbb2 REV-ERBα eeeee2 , suggesting that REV-ERBα functions as a regulator of DRD3 oscillations in the cellular autonomous clock
CPR:5	Moreover, the effects of the  bbbbb1 DRD3 eeeee1  agonist  bbbbb2 7-hydroxy-N,N-dipropyl-2-aminotetralin eeeee2  (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant
CPR:5	Moreover, the effects of the DRD3 agonist  bbbbb1 7-hydroxy-N,N-dipropyl-2-aminotetralin eeeee1  (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when  bbbbb2 DRD3 eeeee2  proteins were abundant
CPR:5	Moreover, the effects of the  bbbbb1 DRD3 eeeee1  agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin ( bbbbb2 7-OH-DPAT eeeee2 )-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant
CPR:5	Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin ( bbbbb1 7-OH-DPAT eeeee1 )-induced locomotor hypoactivity were significantly increased when  bbbbb2 DRD3 eeeee2  proteins were abundant
CPR:2	Racemic IKM-159 was crystallized with the ligand-binding domain of  bbbbb1 GluA2 eeeee1 , and the structure revealed a complex containing  bbbbb2 (2R)-IKM-159 eeeee2  at the glutamate binding site. (2R)-IKM-159 locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors
CPR:2	 bbbbb1 Racemic IKM-159 eeeee1  was crystallized with the ligand-binding domain of  bbbbb2 GluA2 eeeee2 , and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site. (2R)-IKM-159 locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors
CPR:4	Racemic IKM-159 was crystallized with the ligand-binding domain of GluA2, and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site.  bbbbb1 (2R)-IKM-159 eeeee1  locks the  bbbbb2 GluA2 eeeee2  in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.
CPR:6	Racemic IKM-159 was crystallized with the ligand-binding domain of GluA2, and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site.  bbbbb1 (2R)-IKM-159 eeeee1  locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of  bbbbb2 AMPA receptors eeeee2 .
CPR:6	Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid  bbbbb1 (AMPA) receptor eeeee1  antagonist  bbbbb2 IKM-159 eeeee2 : asymmetric synthesis, neuroactivity, and structural characterization
CPR:6	 bbbbb1 IKM-159 eeeee1  was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as  bbbbb2 AMPA receptor eeeee2 -selective antagonists
CPR:6	IKM-159 was developed and identified as a member of a new class of heterotricyclic  bbbbb1 glutamate eeeee1  analogues that act as  bbbbb2 AMPA receptor eeeee2 -selective antagonists
CPR:2	In addition, benzo[c]phenanthrene,  bbbbb1 fluoranthene eeeee1 , 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene,  bbbbb1 2,3-dihydroxy-2,3-dihydrofluoranthene eeeee1 , pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene,  bbbbb1 pyrene eeeee1 , 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene,  bbbbb1 1-hydroxypyrene eeeee1 , 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene,  bbbbb1 1-nitropyrene eeeee1 , 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene,  bbbbb1 1-acetylpyrene eeeee1 , 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene,  bbbbb1 2-acetylpyrene eeeee1 , 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene,  bbbbb1 2,5,2',5'-tetrachlorobiphenyl eeeee1 , 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl,  bbbbb1 7-hydroxyflavone eeeee1 , chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone,  bbbbb1 chrysin eeeee1 , and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and  bbbbb1 galangin eeeee1  were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:2	In addition,  bbbbb1 benzo[c]phenanthrene eeeee1 , fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with  bbbbb2 P450 2A13 eeeee2 
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene,  bbbbb2 flavanone eeeee2 , chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by  bbbbb2 2'-methoxy-5,7-dihydroxyflavone eeeee2 , 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone,  bbbbb2 2-ethynylnaphthalene eeeee2 , 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene,  bbbbb2 2'-methoxyflavone eeeee2 , 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone,  bbbbb2 2-naphththalene propargyl ether eeeee2 , acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether,  bbbbb2 acenaphthene eeeee2 , acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone,  bbbbb2 chrysin eeeee2 , 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene,  bbbbb2 acenaphthylene eeeee2 , naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene,  bbbbb2 naphthalene eeeee2 , 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene,  bbbbb2 1-acetylpyrene eeeee2 , flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin,  bbbbb2 3-ethynylphenanthrene eeeee2 , flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene,  bbbbb2 flavone eeeee2 , and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:4	Coumarin 7-hydroxylation, catalyzed by  bbbbb1 P450 2A13 eeeee1 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and  bbbbb2 7-hydroxyflavone eeeee2 ; these chemicals induced Type I spectral changes with low Ks values
CPR:9	 bbbbb1 Coumarin eeeee1  7-hydroxylation, catalyzed by  bbbbb2 P450 2A13 eeeee2 , was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values
CPR:5	Full agonists to the  bbbbb1 peroxisome proliferator-activated receptor (PPAR)γ eeeee1 , such as  bbbbb2 Rosiglitazone eeeee2 , have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity
CPR:1	In contrast, the  bbbbb1 EL2 eeeee1  sequence showed well-defined structure only near its  bbbbb2 C eeeee2 -terminal residues
CPR:9	PURPOSE:  bbbbb1 Omeprazole eeeee1  has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with  bbbbb2 cytochrome P450 (CYP) 2C19 eeeee2  genotype groups
CPR:9	The  bbbbb1 (R)-omeprazole eeeee1  hydroxylation index reflects  bbbbb2 CYP2C19 eeeee2  activity in healthy Japanese volunteers
CPR:9	Additionally, there was a significant difference in plasma concentrations of  bbbbb1 (R)-5-hydroxyomeprazole eeeee1  among  bbbbb2 CYP2C19 eeeee2  genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole
CPR:9	Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among  bbbbb1 CYP2C19 eeeee1  genotype groups, whereas no significant differences were observed in that of  bbbbb2 (S)-5-hydroxyomeprazole eeeee2 
CPR:9	CONCLUSION: Our findings demonstrate that  bbbbb1 (R)-omeprazole eeeee1  HI correlated better with  bbbbb2 CYP2C19 eeeee2  genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.
CPR:9	CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with  bbbbb1 CYP2C19 eeeee1  genotype groups than  bbbbb2 racemic-omeprazole eeeee2  HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.
CPR:10	Neither  bbbbb1 oxycodone eeeee1  nor its metabolites activated  bbbbb2 PXR eeeee2 , CAR, or AhR
CPR:10	Neither  bbbbb1 oxycodone eeeee1  nor its metabolites activated PXR,  bbbbb2 CAR eeeee2 , or AhR
CPR:10	Neither  bbbbb1 oxycodone eeeee1  nor its metabolites activated PXR, CAR, or  bbbbb2 AhR eeeee2 
CPR:2	Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that  bbbbb1 oxycodone eeeee1  alters the expression of many transporters and DMEs (without direct activation of  bbbbb2 PXR eeeee2 , CAR, and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.
CPR:2	Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that  bbbbb1 oxycodone eeeee1  alters the expression of many transporters and DMEs (without direct activation of PXR,  bbbbb2 CAR eeeee2 , and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.
CPR:2	Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that  bbbbb1 oxycodone eeeee1  alters the expression of many transporters and DMEs (without direct activation of PXR, CAR, and  bbbbb2 AhR eeeee2 ), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.
CPR:2	Induction of  bbbbb1 xenobiotic receptors eeeee1 , transporters, and drug metabolizing enzymes by  bbbbb2 oxycodone eeeee2 
CPR:3	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite,  bbbbb1 all-trans retinoic acid eeeee1  (atRA), which regulates the expression of a battery of target genes through several families of  bbbbb2 nuclear receptors eeeee2  (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CPR:3	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite,  bbbbb1 all-trans retinoic acid eeeee1  (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors ( bbbbb2 RARs eeeee2 , RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CPR:3	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite,  bbbbb1 all-trans retinoic acid eeeee1  (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs,  bbbbb2 RXRs eeeee2  and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CPR:3	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite,  bbbbb1 all-trans retinoic acid eeeee1  (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ),  bbbbb2 polymorphic retinoic acid (RA) response elements eeeee2  and multiple coregulators
CPR:3	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid ( bbbbb1 atRA eeeee1 ), which regulates the expression of a battery of target genes through several families of  bbbbb2 nuclear receptors eeeee2  (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CPR:3	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid ( bbbbb1 atRA eeeee1 ), which regulates the expression of a battery of target genes through several families of nuclear receptors ( bbbbb2 RARs eeeee2 , RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CPR:3	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid ( bbbbb1 atRA eeeee1 ), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs,  bbbbb2 RXRs eeeee2  and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CPR:3	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid ( bbbbb1 atRA eeeee1 ), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ),  bbbbb2 polymorphic retinoic acid (RA) response elements eeeee2  and multiple coregulators
CPR:3	Interestingly,  bbbbb1 miR-21 eeeee1  expression positively correlated with urine albumin  bbbbb2 creatine eeeee2  ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CPR:4	Interestingly,  bbbbb1 miR-21 eeeee1  expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  bbbbb2 creatine eeeee2  clearance ratio (Ccr) and MMP-9 protein
CPR:1	Thus, the formation of  bbbbb1 disulfide eeeee1  bonds in  bbbbb2 hSULT2A1 eeeee2  is a potentially important reversible mechanism for alterations in the rates of sulfation of both endogenous and xenobiotic substrates.
CPR:1	Modification of the Catalytic Function of  bbbbb1 Human Hydroxysteroid Sulfotransferase hSULT2A1 eeeee1  by Formation of  bbbbb2 Disulfide eeeee2  Bonds
CPR:9	Studies on the kinetics of the  bbbbb1 hSULT2A1 eeeee1 -catalyzed sulfation of  bbbbb2 dehydroepiandrosterone eeeee2  (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme
CPR:9	Studies on the kinetics of the  bbbbb1 hSULT2A1 eeeee1 -catalyzed sulfation of dehydroepiandrosterone ( bbbbb2 DHEA eeeee2 ) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme
CPR:9	The  bbbbb1 human cytosolic sulfotransferase hSULT2A1 eeeee1  catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous  bbbbb2 hydroxysteroids eeeee2  and bile acids
CPR:9	The  bbbbb1 human cytosolic sulfotransferase hSULT2A1 eeeee1  catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and  bbbbb2 bile acids eeeee2 
CPR:2	These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce ER antagonists with  bbbbb1 ER eeeee1  affinity comparable to that of  bbbbb2 ICI-182,780 eeeee2 .
CPR:6	Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in a manner similar to that of  bbbbb1 ICI-182,780 eeeee1 , a pure  bbbbb2 ER eeeee2  antagonist
CPR:6	These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce ER antagonists with  bbbbb1 ER eeeee1  affinity comparable to that of  bbbbb2 ICI-182,780 eeeee2 .
CPR:4	iscovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia.  bbbbb1 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole eeeee1  11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as  bbbbb2 activin receptor-like kinase 5 eeeee2  or ALK5) inhibitor
CPR:4	iscovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia.  bbbbb1 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole eeeee1  11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or  bbbbb2 ALK5 eeeee2 ) inhibitor
CPR:4	iscovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia.  bbbbb1 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole eeeee1  11 (TASP0382088) was synthesized and evaluated as  bbbbb2 transforming growth factor-β (TGF-β) type I receptor eeeee2  (also known as activin receptor-like kinase 5 or ALK5) inhibitor
CPR:4	iscovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 ( bbbbb1 TASP0382088 eeeee1 ) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as  bbbbb2 activin receptor-like kinase 5 eeeee2  or ALK5) inhibitor
CPR:4	iscovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 ( bbbbb1 TASP0382088 eeeee1 ) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or  bbbbb2 ALK5 eeeee2 ) inhibitor
CPR:4	iscovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 ( bbbbb1 TASP0382088 eeeee1 ) was synthesized and evaluated as  bbbbb2 transforming growth factor-β (TGF-β) type I receptor eeeee2  (also known as activin receptor-like kinase 5 or ALK5) inhibitor
CPR:4	iscovery of  bbbbb1 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole eeeee1  (TASP0382088): a potent and selective  bbbbb2 transforming growth factor-β type I receptor eeeee2  inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor
CPR:4	iscovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole ( bbbbb1 TASP0382088 eeeee1 ): a potent and selective  bbbbb2 transforming growth factor-β type I receptor eeeee2  inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor
CPR:10	Here, we provide evidence that p14ARF physically interacts with AR and functions as an  bbbbb1 AR eeeee1  corespressor in both an androgen-dependent and  bbbbb2 androgen eeeee2 -independent manner
CPR:1	Furthermore, we demonstrated that p14ARF binds to both the  bbbbb1 N eeeee1 -terminal domain and the ligand-binding domain of  bbbbb2 AR eeeee2 , and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CPR:1	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the  bbbbb1 N eeeee1  terminus and C terminus of  bbbbb2 AR eeeee2 
CPR:1	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and  bbbbb1 C eeeee1  terminus of  bbbbb2 AR eeeee2 
CPR:2	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the  bbbbb1 androgen eeeee1 -induced interaction between the N terminus and C terminus of  bbbbb2 AR eeeee2 
CPR:2	Here, we provide evidence that p14ARF physically interacts with AR and functions as an  bbbbb1 AR eeeee1  corespressor in both an  bbbbb2 androgen eeeee2 -dependent and androgen-independent manner
CPR:2	This study evaluates the production of inflammatory biomarkers ( bbbbb1 IL-1β eeeee1 , IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by  bbbbb2 7-ketosterols eeeee2  (stigmasterol/cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β,  bbbbb1 IL-8 eeeee1 , IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by  bbbbb2 7-ketosterols eeeee2  (stigmasterol/cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8,  bbbbb1 IL-10 eeeee1 , TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by  bbbbb2 7-ketosterols eeeee2  (stigmasterol/cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10,  bbbbb1 TNFα eeeee1 ) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by  bbbbb2 7-ketosterols eeeee2  (stigmasterol/cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism ( bbbbb1 NPC1L1 eeeee1 , ABCG5/8, HMGCoA, ACAT) produced by  bbbbb2 7-ketosterols eeeee2  (stigmasterol/cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1,  bbbbb1 ABCG5/8 eeeee1 , HMGCoA, ACAT) produced by  bbbbb2 7-ketosterols eeeee2  (stigmasterol/cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1 , ACAT) produced by  bbbbb2 7-ketosterols eeeee2  (stigmasterol/cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA,  bbbbb1 ACAT eeeee1 ) produced by  bbbbb2 7-ketosterols eeeee2  (stigmasterol/cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers ( bbbbb1 IL-1β eeeee1 , IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols ( bbbbb2 stigmasterol eeeee2 /cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β,  bbbbb1 IL-8 eeeee1 , IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols ( bbbbb2 stigmasterol eeeee2 /cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8,  bbbbb1 IL-10 eeeee1 , TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols ( bbbbb2 stigmasterol eeeee2 /cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10,  bbbbb1 TNFα eeeee1 ) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols ( bbbbb2 stigmasterol eeeee2 /cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism ( bbbbb1 NPC1L1 eeeee1 , ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols ( bbbbb2 stigmasterol eeeee2 /cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1,  bbbbb1 ABCG5/8 eeeee1 , HMGCoA, ACAT) produced by 7-ketosterols ( bbbbb2 stigmasterol eeeee2 /cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1 , ACAT) produced by 7-ketosterols ( bbbbb2 stigmasterol eeeee2 /cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA,  bbbbb1 ACAT eeeee1 ) produced by 7-ketosterols ( bbbbb2 stigmasterol eeeee2 /cholesterol) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers ( bbbbb1 IL-1β eeeee1 , IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/ bbbbb2 cholesterol eeeee2 ) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β,  bbbbb1 IL-8 eeeee1 , IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/ bbbbb2 cholesterol eeeee2 ) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8,  bbbbb1 IL-10 eeeee1 , TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/ bbbbb2 cholesterol eeeee2 ) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10,  bbbbb1 TNFα eeeee1 ) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/ bbbbb2 cholesterol eeeee2 ) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism ( bbbbb1 NPC1L1 eeeee1 , ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/ bbbbb2 cholesterol eeeee2 ) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1,  bbbbb1 ABCG5/8 eeeee1 , HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/ bbbbb2 cholesterol eeeee2 ) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1 , ACAT) produced by 7-ketosterols (stigmasterol/ bbbbb2 cholesterol eeeee2 ) in Caco-2 cells
CPR:2	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA,  bbbbb1 ACAT eeeee1 ) produced by 7-ketosterols (stigmasterol/ bbbbb2 cholesterol eeeee2 ) in Caco-2 cells
CPR:2	In non-pre-treated cells, only efflux transporters were down-regulated by  bbbbb1 7-ketosterols eeeee1 , showing a greater influence upon  bbbbb2 ABCG5 eeeee2  expression
CPR:2	Cell-pre-incubation with  bbbbb1 bradykinin eeeee1  induced changes in ABCG expression levels after  bbbbb2 7-ketostigmasterol eeeee2 -incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells
CPR:2	Cell-pre-incubation with bradykinin induced changes in  bbbbb1 ABCG eeeee1  expression levels after  bbbbb2 7-ketostigmasterol eeeee2 -incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells
CPR:2	Relative expression of c bbbbb1 holesterol transport-related proteins eeeee1  and inflammation markers through the induction of  bbbbb2 7-ketosterol eeeee2 -mediated stress in Caco-2 cells
CPR:2	These results suggest that internalization and excretion of 7-ketostigmasterol is probably influenced by [ bbbbb1 Ca eeeee1 ]i, which also could mediate  bbbbb2 HMGCoA eeeee2  activity in POPs metabolism
CPR:3	In non-pre-treated cells,  bbbbb1 HMG-CoA eeeee1  was up-regulated by both  bbbbb2 7-ketosterols eeeee2 
CPR:4	In non-pre-treated cells, only  bbbbb1 efflux transporters eeeee1  were down-regulated by  bbbbb2 7-ketosterols eeeee2 , showing a greater influence upon ABCG5 expression
CPR:4	Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced  bbbbb1 NPC1L1 eeeee1  expression only in  bbbbb2 7-ketocholesterol eeeee2 -incubated cells
CPR:3	In lymphocytes, the NTPDase and  bbbbb1 ADA eeeee1  activities were increased in all groups treated with  bbbbb2 caffeic acid eeeee2  when compared to control (P<0.05)
CPR:3	In lymphocytes, the  bbbbb1 NTPDase eeeee1  and ADA activities were increased in all groups treated with  bbbbb2 caffeic acid eeeee2  when compared to control (P<0.05)
CPR:1	We demonstrate that activation of  bbbbb1 STAT3 eeeee1   bbbbb2 serine eeeee2 -727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation
CPR:1	We demonstrate that activation of  bbbbb1 STAT3 eeeee1  serine-727 and  bbbbb2 tyrosine eeeee2 -705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation
CPR:10	When mice were treated ip with the major neonicotinoid  bbbbb1 imidacloprid eeeee1  (IMI), metabolism by  bbbbb2 CYP eeeee2  oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice
CPR:10	When mice were treated ip with the major neonicotinoid imidacloprid ( bbbbb1 IMI eeeee1 ), metabolism by  bbbbb2 CYP eeeee2  oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice
CPR:4	The procedure was to reduce liver  bbbbb1 AOX eeeee1  activity by providing  bbbbb2 tungsten eeeee2  or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain
CPR:4	The procedure was to reduce liver  bbbbb1 AOX eeeee1  activity by providing tungsten or  bbbbb2 hydralazine eeeee2  in the drinking water or to use the AOX-deficient DBA/2 mouse strain
CPR:4	Liver  bbbbb1 AOX eeeee1  activity was reduced by 45% with  bbbbb2 tungsten eeeee2  and 61% with hydralazine and 81% in AOX-deficient mice relative to controls
CPR:4	Liver  bbbbb1 AOX eeeee1  activity was reduced by 45% with tungsten and 61% with  bbbbb2 hydralazine eeeee2  and 81% in AOX-deficient mice relative to controls
CPR:4	When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the  bbbbb1 AOX eeeee1 -generated nitrosoguanidine metabolite was decreased by 30% with  bbbbb2 tungsten eeeee2  and 56% with hydralazine and 86% in the AOX-deficient mice
CPR:4	When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the  bbbbb1 AOX eeeee1 -generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with  bbbbb2 hydralazine eeeee2  and 86% in the AOX-deficient mice
CPR:9	When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the  bbbbb1 AOX eeeee1 -generated  bbbbb2 nitrosoguanidine eeeee2  metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice
CPR:9	Possible  bbbbb1 AOX eeeee1  involvement in  bbbbb2 IMI eeeee2  metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains
CPR:9	Possible AOX involvement in  bbbbb1 IMI eeeee1  metabolism in insects was evaluated using  bbbbb2 AOX eeeee2 -expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains
CPR:9	This is the first study to establish the in vivo relevance of  bbbbb1 AOX eeeee1  in  bbbbb2 neonicotinoid eeeee2  metabolism in mammals and one of the first for xenobiotics in general.
CPR:9	Currently, the most important insecticides are  bbbbb1 neonicotinoids eeeee1 , which are metabolized in vitro by  bbbbb2 AOX eeeee2  on reduction of the nitroimino group and by CYPs via oxidation reactions
CPR:9	Currently, the most important insecticides are  bbbbb1 neonicotinoids eeeee1 , which are metabolized in vitro by AOX on reduction of the nitroimino group and by  bbbbb2 CYPs eeeee2  via oxidation reactions
CPR:9	Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by  bbbbb1 AOX eeeee1  on reduction of the  bbbbb2 nitroimino eeeee2  group and by CYPs via oxidation reactions
CPR:9	Thus, decreasing liver  bbbbb1 AOX eeeee1  activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of  bbbbb2 IMI eeeee2 -treated mice
CPR:4	Recommended management may include use of  bbbbb1 acetylcholinesterase eeeee1  inhibitors (e.g.  bbbbb2 neostigmine eeeee2 ) and wound care on a case-by-case basis
CPR:4	Of the compounds active in the present assay system, the most potent compound 7,  bbbbb1 platyphyllonol-5-O-β-d-xylopyranoside eeeee1 , significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and  bbbbb2 CCAAT/enhancer binding protein α eeeee2  (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist
CPR:4	Of the compounds active in the present assay system, the most potent compound 7,  bbbbb1 platyphyllonol-5-O-β-d-xylopyranoside eeeee1 , significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α ( bbbbb2 C/EBPα eeeee2 ) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist
CPR:4	Of the compounds active in the present assay system, the most potent compound 7,  bbbbb1 platyphyllonol-5-O-β-d-xylopyranoside eeeee1 , significantly suppressed the induction of  bbbbb2 peroxisome proliferator activated receptor γ eeeee2  (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist
CPR:4	Of the compounds active in the present assay system, the most potent compound 7,  bbbbb1 platyphyllonol-5-O-β-d-xylopyranoside eeeee1 , significantly suppressed the induction of peroxisome proliferator activated receptor γ ( bbbbb2 PPARγ eeeee2  and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist
CPR:5	Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by  bbbbb1 troglitazone eeeee1 , a  bbbbb2 PPARγ eeeee2  agonist
CPR:4	Based on our previously published work on CXCR4 antagonists, we have synthesized a series of  bbbbb1 aryl sulfonamides eeeee1  that inhibit the  bbbbb2 CXCR4 eeeee2 /CXCL12 interaction
CPR:4	Based on our previously published work on CXCR4 antagonists, we have synthesized a series of  bbbbb1 aryl sulfonamides eeeee1  that inhibit the CXCR4/ bbbbb2 CXCL12 eeeee2  interaction
CPR:4	These data demonstrate that  bbbbb1 benzenesulfonamides eeeee1  are a unique class of  bbbbb2 CXCR4 eeeee2  inhibitors with high potency.
CPR:4	 bbbbb1 Benzenesulfonamides eeeee1 : a unique class of  bbbbb2 chemokine receptor type 4 eeeee2  inhibitors
CPR:9	Measurement of Transport Activities of  bbbbb1 3β-Hydroxy-Δ(5)-bile Acids eeeee1  in  bbbbb2 Bile Salt Export Pump eeeee2  and Multidrug Resistance-Associated Proteins Using LC-MS/MS
CPR:9	Measurement of Transport Activities of  bbbbb1 3β-Hydroxy-Δ(5)-bile Acids eeeee1  in Bile Salt Export Pump and  bbbbb2 Multidrug Resistance-Associated Proteins eeeee2  Using LC-MS/MS
CPR:9	The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and  bbbbb1 human bile salt export pump eeeee1 -expressing Sf9 cells for conjugated  bbbbb2 3β-hydroxy-Δ(5)-bile acids eeeee2 
CPR:9	The present study demonstrated that  bbbbb1 human multidrug resistance-associated protein 3 eeeee1  vesicles accepted conjugated  bbbbb2 3β-hydroxy-Δ(5)-bile acids eeeee2  along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.
CPR:9	The present study demonstrated that  bbbbb1 human multidrug resistance-associated protein 3 eeeee1  vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common  bbbbb2 bile acids eeeee2  such as glycocholic acid and taurolithocholic acid 3-sulfate.
CPR:9	The present study demonstrated that  bbbbb1 human multidrug resistance-associated protein 3 eeeee1  vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common bile acids such as  bbbbb2 glycocholic acid eeeee2  and taurolithocholic acid 3-sulfate.
CPR:9	The present study demonstrated that  bbbbb1 human multidrug resistance-associated protein 3 eeeee1  vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common bile acids such as glycocholic acid and  bbbbb2 taurolithocholic acid 3-sulfate eeeee2 .
CPR:1	Here, we report that a specific 29- bbbbb1 amino acid eeeee1  peptide derived from the intracellular domain fragment of  bbbbb2 p75(NTR) eeeee2  interacts with and potentiates binding of NGF to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and Akt signaling
CPR:1	An endogenous intracellular domain fragment of  bbbbb1 p75(NTR) eeeee1  (p75(ICD)) containing these 29  bbbbb2 amino acids eeeee2  is produced by regulated proteolysis of the full-length receptor
CPR:1	An endogenous intracellular domain fragment of p75(NTR) ( bbbbb1 p75(ICD) eeeee1 ) containing these 29  bbbbb2 amino acids eeeee2  is produced by regulated proteolysis of the full-length receptor
CPR:4	A series of substituted  bbbbb1 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines eeeee1  has been synthesised and tested in vitro as potential pro-apoptotic  bbbbb2 Bcl-2 eeeee2 -inhibitory anticancer agents
CPR:4	Active compounds, such as the  bbbbb1 nitrobenzyl eeeee1  analogue 6c, were found to exhibit sub-micromolar IC50 values in  bbbbb2 Bcl-2 eeeee2  expressing human cancer cell lines
CPR:4	Synthesis and evaluation of  bbbbb1 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines eeeee1  as  bbbbb2 Bcl-2 eeeee2  inhibitory anticancer agents
CPR:10	 bbbbb1 Glutathione-S-transferase eeeee1 , a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to  bbbbb2 nicotine eeeee2 
CPR:10	 bbbbb1 Glutathione-S-transferase eeeee1 , a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in  bbbbb2 arsenic eeeee2 -treated animals pre-exposed to nicotine
CPR:3	Upon  bbbbb1 nicotine eeeee1  pre-exposure, brain  bbbbb2 acetylcholinesterase eeeee2  increased, while monoamine oxidase (MAO) decreased
CPR:4	Upon  bbbbb1 nicotine eeeee1  pre-exposure, brain acetylcholinesterase increased, while  bbbbb2 monoamine oxidase eeeee2  (MAO) decreased
CPR:4	Upon  bbbbb1 nicotine eeeee1  pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase ( bbbbb2 MAO eeeee2 ) decreased
CPR:4	The toxic effects of  bbbbb1 MAO eeeee1  significantly attenuated with  bbbbb2 nicotine eeeee2  pre-exposure
CPR:4	 bbbbb1 Glutathione-S-transferase eeeee1 , a phase II enzyme, was inhibited by both  bbbbb2 arsenic eeeee2  and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine
CPR:4	 bbbbb1 Glutathione-S-transferase eeeee1 , a phase II enzyme, was inhibited by both arsenic and  bbbbb2 nicotine eeeee2  but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine
CPR:2	The model accurately predicted  bbbbb1 CYP19A eeeee1  mRNA fold changes for controls and three  bbbbb2 FAD eeeee2  doses (0, 0.5, and 3 µg/l) and plasma E2 dose response from the 4-day study
CPR:4	We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the  bbbbb1 aromatase eeeee1  inhibitor,  bbbbb2 fadrozole eeeee2  (FAD)
CPR:4	We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the  bbbbb1 aromatase eeeee1  inhibitor, fadrozole ( bbbbb2 FAD eeeee2 )
CPR:1	Our results suggest that modification of multiple  bbbbb1 cysteine eeeee1  residues by electrophilic compounds can generate both activation and desensitization of the  bbbbb2 TRPA1 eeeee2  channel.
CPR:1	Electrophilic chemicals activate both insect and vertebrate  bbbbb1 TRPA1 eeeee1  via covalent modification of  bbbbb2 cysteine eeeee2  residues in the amino-terminal region
CPR:1	Electrophilic chemicals activate both insect and vertebrate  bbbbb1 TRPA1 eeeee1  via covalent modification of cysteine residues in the  bbbbb2 amino eeeee2 -terminal region
CPR:1	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or  bbbbb1 TRPA1 eeeee1  with three  bbbbb2 serine eeeee2 -substituted cysteines crucial for electrophile activation (C621S, C641S, C665S)
CPR:1	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three  bbbbb1 serine eeeee1 -substituted cysteines crucial for electrophile activation ( bbbbb2 C621S eeeee2 , C641S, C665S)
CPR:1	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three  bbbbb1 serine eeeee1 -substituted cysteines crucial for electrophile activation (C621S,  bbbbb2 C641S eeeee2 , C665S)
CPR:1	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three  bbbbb1 serine eeeee1 -substituted cysteines crucial for electrophile activation (C621S, C641S,  bbbbb2 C665S eeeee2 )
CPR:1	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or  bbbbb1 TRPA1 eeeee1  with three serine-substituted  bbbbb2 cysteines eeeee2  crucial for electrophile activation (C621S, C641S, C665S)
CPR:1	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted  bbbbb1 cysteines eeeee1  crucial for electrophile activation ( bbbbb2 C621S eeeee2 , C641S, C665S)
CPR:1	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted  bbbbb1 cysteines eeeee1  crucial for electrophile activation (C621S,  bbbbb2 C641S eeeee2 , C665S)
CPR:1	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted  bbbbb1 cysteines eeeee1  crucial for electrophile activation (C621S, C641S,  bbbbb2 C665S eeeee2 )
CPR:1	Benzoquinone Reveals a  bbbbb1 Cysteine eeeee1 -Dependent Desensitization Mechanism of  bbbbb2 TRPA1 eeeee2 
CPR:1	Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist carvacrol, whereas the triple  bbbbb1 cysteine eeeee1  mutant  bbbbb2 TRPA1 eeeee2  retained its full response
CPR:2	 bbbbb1 Benzoquinone eeeee1  Reveals a Cysteine-Dependent Desensitization Mechanism of  bbbbb2 TRPA1 eeeee2 
CPR:2	The current reduction we found at higher  bbbbb1 pBQN eeeee1  concentrations was a cysteine-dependent desensitization of  bbbbb2 TRPA1 eeeee2 , and did not require prior activation
CPR:2	Interestingly, following  bbbbb1 pBQN eeeee1  desensitization, wild-type  bbbbb2 TRPA1 eeeee2  had dramatically reduced response to the nonelectrophile agonist carvacrol, whereas the triple cysteine mutant TRPA1 retained its full response
CPR:3	We found that  bbbbb1 pBQN eeeee1  activates  bbbbb2 TRPA1 eeeee2  starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline
CPR:5	Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist  bbbbb1 carvacrol eeeee1 , whereas the triple cysteine mutant  bbbbb2 TRPA1 eeeee2  retained its full response
CPR:5	Although naturally occurring electrophilic plant compounds, such as mustard oil and  bbbbb1 cinnamaldehyde eeeee1 , are  bbbbb2 TRPA1 eeeee2  agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1
CPR:5	Interestingly, following pBQN desensitization, wild-type  bbbbb1 TRPA1 eeeee1  had dramatically reduced response to the nonelectrophile agonist  bbbbb2 carvacrol eeeee2 , whereas the triple cysteine mutant TRPA1 retained its full response
CPR:4	Synthesis and in-silico studies of some  bbbbb1 diaryltriazole eeeee1  derivatives as potential  bbbbb2 cyclooxygenase eeeee2  inhibitors
CPR:1	We found that, both in a cell-free system and in cells, NO/SNO donors such as S-nitrosocysteine and S-nitrosoglutathione readily induced the  bbbbb1 S eeeee1 -nitrosylation of  bbbbb2 Prx1 eeeee2 , causing structural and functional alterations
CPR:1	In particular, nitrosylation promoted disulfide formation involving the pair of catalytic  bbbbb1 cysteines eeeee1  (Cys-52 and Cys-173) and disrupted the oligomeric structure of  bbbbb2 Prx1 eeeee2 , leading to loss of peroxidase activity
CPR:1	In particular, nitrosylation promoted disulfide formation involving the pair of catalytic  bbbbb1 cysteines eeeee1  (Cys-52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of  bbbbb2 peroxidase eeeee2  activity
CPR:1	In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines ( bbbbb1 Cys eeeee1 -52 and Cys-173) and disrupted the oligomeric structure of  bbbbb2 Prx1 eeeee2 , leading to loss of peroxidase activity
CPR:1	In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines ( bbbbb1 Cys eeeee1 -52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of  bbbbb2 peroxidase eeeee2  activity
CPR:1	In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (Cys-52 and  bbbbb1 Cys eeeee1 -173) and disrupted the oligomeric structure of  bbbbb2 Prx1 eeeee2 , leading to loss of peroxidase activity
CPR:1	In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (Cys-52 and  bbbbb1 Cys eeeee1 -173) and disrupted the oligomeric structure of Prx1, leading to loss of  bbbbb2 peroxidase eeeee2  activity
CPR:2	Our findings that NO/ bbbbb1 SNO eeeee1  target both  bbbbb2 Prx eeeee2  and Trx reductase may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.
CPR:2	Our findings that NO/ bbbbb1 SNO eeeee1  target both Prx and  bbbbb2 Trx reductase eeeee2  may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.
CPR:2	We found that, both in a cell-free system and in cells,  bbbbb1 NO eeeee1 /SNO donors such as S-nitrosocysteine and S-nitrosoglutathione readily induced the S-nitrosylation of  bbbbb2 Prx1 eeeee2 , causing structural and functional alterations
CPR:2	We found that, both in a cell-free system and in cells, NO/ bbbbb1 SNO eeeee1  donors such as S-nitrosocysteine and S-nitrosoglutathione readily induced the S-nitrosylation of  bbbbb2 Prx1 eeeee2 , causing structural and functional alterations
CPR:2	We found that, both in a cell-free system and in cells, NO/SNO donors such as  bbbbb1 S-nitrosocysteine eeeee1  and S-nitrosoglutathione readily induced the S-nitrosylation of  bbbbb2 Prx1 eeeee2 , causing structural and functional alterations
CPR:2	We found that, both in a cell-free system and in cells, NO/SNO donors such as S-nitrosocysteine and  bbbbb1 S-nitrosoglutathione eeeee1  readily induced the S-nitrosylation of  bbbbb2 Prx1 eeeee2 , causing structural and functional alterations
CPR:2	A highly potent inhibition of the peroxidase catalytic reaction by  bbbbb1 NO eeeee1 /SNO was seen in assays employing the coupled  bbbbb2 Prx eeeee2 -Trx system
CPR:2	A highly potent inhibition of the peroxidase catalytic reaction by  bbbbb1 NO eeeee1 /SNO was seen in assays employing the coupled Prx- bbbbb2 Trx eeeee2  system
CPR:2	A highly potent inhibition of the peroxidase catalytic reaction by NO/ bbbbb1 SNO eeeee1  was seen in assays employing the coupled  bbbbb2 Prx eeeee2 -Trx system
CPR:2	A highly potent inhibition of the peroxidase catalytic reaction by NO/ bbbbb1 SNO eeeee1  was seen in assays employing the coupled Prx- bbbbb2 Trx eeeee2  system
CPR:2	This effect appeared to be due to both competition between  bbbbb1 S-nitrosocysteine eeeee1  and Prx1 for the  bbbbb2 Trx eeeee2  system and direct modulation by S-nitrosocysteine of Trx reductase activity
CPR:2	This effect appeared to be due to both competition between S-nitrosocysteine and Prx1 for the Trx system and direct modulation by  bbbbb1 S-nitrosocysteine eeeee1  of  bbbbb2 Trx reductase eeeee2  activity
CPR:2	Our findings that  bbbbb1 NO eeeee1 /SNO target both  bbbbb2 Prx eeeee2  and Trx reductase may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.
CPR:2	Our findings that  bbbbb1 NO eeeee1 /SNO target both Prx and  bbbbb2 Trx reductase eeeee2  may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.
CPR:4	A highly potent inhibition of the  bbbbb1 peroxidase eeeee1  catalytic reaction by  bbbbb2 NO eeeee2 /SNO was seen in assays employing the coupled Prx-Trx system
CPR:4	A highly potent inhibition of the  bbbbb1 peroxidase eeeee1  catalytic reaction by NO/ bbbbb2 SNO eeeee2  was seen in assays employing the coupled Prx-Trx system
CPR:4	In this setting,  bbbbb1 S-nitrosocysteine eeeee1  (10 μm) effectively blocked the  bbbbb2 Trx eeeee2 -mediated regeneration of oxidized Prx1
CPR:4	In this setting,  bbbbb1 S-nitrosocysteine eeeee1  (10 μm) effectively blocked the Trx-mediated regeneration of  bbbbb2 oxidized Prx1 eeeee2 
CPR:2	 bbbbb1 DMN eeeee1  treatment for 4weeks led to marked liver fibrosis as assessed by serum biochemistry, histopathological examination, and hepatic lipid peroxidation and  bbbbb2 collagen eeeee2  content
CPR:3	CK significantly inhibited  bbbbb1 DMN eeeee1 -induced increases in serum  bbbbb2 alanine aminotransferase eeeee2  (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CPR:3	CK significantly inhibited  bbbbb1 DMN eeeee1 -induced increases in serum alanine aminotransferase ( bbbbb2 ALT eeeee2 ) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CPR:3	CK significantly inhibited  bbbbb1 DMN eeeee1 -induced increases in serum alanine aminotransferase (ALT) and  bbbbb2 aspartate aminotransferase eeeee2  (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CPR:3	CK significantly inhibited  bbbbb1 DMN eeeee1 -induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase ( bbbbb2 AST eeeee2 ) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CPR:3	 bbbbb1 DMN eeeee1 -induced cyclooxygenase-2 (COX-2) expression and  bbbbb2 nuclear factor-kappa B eeeee2  (NF-κB) activation was reduced by CK treatment
CPR:3	 bbbbb1 DMN eeeee1 -induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B ( bbbbb2 NF-κB eeeee2 ) activation was reduced by CK treatment
CPR:3	CK significantly inhibited  bbbbb1 DMN eeeee1 -induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and  bbbbb2 collagen eeeee2  content
CPR:3	Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  bbbbb1 DMN eeeee1 -induced increases in  bbbbb2 matrix metalloproteinase-13 eeeee2  (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein
CPR:3	Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  bbbbb1 DMN eeeee1 -induced increases in matrix metalloproteinase-13 ( bbbbb2 MMP-13 eeeee2 ), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein
CPR:3	Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  bbbbb1 DMN eeeee1 -induced increases in matrix metalloproteinase-13 (MMP-13),  bbbbb2 tissue inhibitor of metalloproteinase-1 eeeee2  (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein
CPR:3	Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  bbbbb1 DMN eeeee1 -induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 ( bbbbb2 TIMP-1 eeeee2 ), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein
CPR:3	Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  bbbbb1 DMN eeeee1 -induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and  bbbbb2 tumor necrosis factor-α eeeee2  (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein
CPR:3	Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  bbbbb1 DMN eeeee1 -induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α ( bbbbb2 TNF-α eeeee2 ) mRNA, and collagen type I and α-smooth muscle actin protein
CPR:3	Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  bbbbb1 DMN eeeee1 -induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and  bbbbb2 collagen type I eeeee2  and α-smooth muscle actin protein
CPR:3	Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited  bbbbb1 DMN eeeee1 -induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and  bbbbb2 α-smooth muscle actin eeeee2  protein
CPR:3	 bbbbb1 DMN eeeee1 -induced  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2) expression and nuclear factor-kappa B (NF-κB) activation was reduced by CK treatment
CPR:3	 bbbbb1 DMN eeeee1 -induced cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ) expression and nuclear factor-kappa B (NF-κB) activation was reduced by CK treatment
CPR:2	Further analyses revealed that  bbbbb1 CdTe eeeee1 -QD exposure resulted in apoptosis, indicated by changes in levels of  bbbbb2 caspase-3 eeeee2  activity, poly ADP-ribose polymerase (PARP) cleavage and phosphatidylserine externalization
CPR:2	Further analyses revealed that  bbbbb1 CdTe eeeee1 -QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity,  bbbbb2 poly ADP-ribose polymerase eeeee2  (PARP) cleavage and phosphatidylserine externalization
CPR:2	Further analyses revealed that  bbbbb1 CdTe eeeee1 -QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase ( bbbbb2 PARP eeeee2 ) cleavage and phosphatidylserine externalization
CPR:3	Extrinsic apoptotic pathway markers such as Fas levels and  bbbbb1 caspase-8 eeeee1  activity increased as a result of  bbbbb2 CdTe eeeee2 -QD exposure
CPR:3	Our findings reveal that  bbbbb1 CdTe eeeee1 -QDs cause oxidative stress, interfere with antioxidant defenses and activate protein  bbbbb2 kinases eeeee2 , leading to apoptosis via both extrinsic and intrinsic pathways
CPR:3	Extrinsic apoptotic pathway markers such as  bbbbb1 Fas eeeee1  levels and caspase-8 activity increased as a result of  bbbbb2 CdTe eeeee2 -QD exposure
CPR:2	A low molecular weight  bbbbb1 polyethyleneimine eeeee1  modified with deoxycholic acid (PEI1.8-DA)-based delivery strategy was suggested for the cardiac application of  bbbbb2 SHP-1 eeeee2  siRNA to overcome the poor gene delivery efficiency to myocardium due to the highly charged structures of the compact cardiac muscles
CPR:2	A low molecular weight polyethyleneimine modified with  bbbbb1 deoxycholic acid eeeee1  (PEI1.8-DA)-based delivery strategy was suggested for the cardiac application of  bbbbb2 SHP-1 eeeee2  siRNA to overcome the poor gene delivery efficiency to myocardium due to the highly charged structures of the compact cardiac muscles
CPR:2	Taken together, our data demonstrate that  bbbbb1 puerarin eeeee1  attenuates MPTP-induced dopaminergic neuronal degeneration via modulating  bbbbb2 GDNF eeeee2  expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression
CPR:2	Taken together, our data demonstrate that puerarin attenuates  bbbbb1 MPTP eeeee1 -induced dopaminergic neuronal degeneration via modulating  bbbbb2 GDNF eeeee2  expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression
CPR:2	Taken together, our data demonstrate that  bbbbb1 puerarin eeeee1  attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression,  bbbbb2 PI3K eeeee2 /Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression
CPR:2	Taken together, our data demonstrate that  bbbbb1 puerarin eeeee1  attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/ bbbbb2 Akt eeeee2  pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression
CPR:2	Taken together, our data demonstrate that puerarin attenuates  bbbbb1 MPTP eeeee1 -induced dopaminergic neuronal degeneration via modulating GDNF expression,  bbbbb2 PI3K eeeee2 /Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression
CPR:2	Taken together, our data demonstrate that puerarin attenuates  bbbbb1 MPTP eeeee1 -induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/ bbbbb2 Akt eeeee2  pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression
CPR:3	 bbbbb1 Puerarin eeeee1  administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and  bbbbb2 PI3K eeeee2 /Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CPR:3	 bbbbb1 Puerarin eeeee1  administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/ bbbbb2 Akt eeeee2  pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CPR:3	 bbbbb1 Puerarin eeeee1  administration enhanced glutathione (GSH) activity,  bbbbb2 glial cell line-derived neurotrophic factor eeeee2  (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CPR:3	 bbbbb1 Puerarin eeeee1  administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor ( bbbbb2 GDNF eeeee2 ) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CPR:4	In addition to the effect on ROS,  bbbbb1 puerarin eeeee1  ameliorated MPTP-reduced lysosome-associated membrane protein type 2A ( bbbbb2 Lamp 2A eeeee2 ) expression
CPR:4	In addition to the effect on ROS, puerarin ameliorated  bbbbb1 MPTP eeeee1 -reduced  bbbbb2 lysosome-associated membrane protein type 2A eeeee2  (Lamp 2A) expression
CPR:4	In addition to the effect on ROS, puerarin ameliorated  bbbbb1 MPTP eeeee1 -reduced lysosome-associated membrane protein type 2A ( bbbbb2 Lamp 2A eeeee2 ) expression
CPR:4	Taken together, our data demonstrate that  bbbbb1 puerarin eeeee1  attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of  bbbbb2 Lamp 2A eeeee2  expression
CPR:4	Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate  bbbbb1 MPTP eeeee1 -induced ROS formation and decrease of  bbbbb2 Lamp 2A eeeee2  expression
CPR:2	After 18 h incubation with 0.5 μM  bbbbb1 Py3MeO-TBPo eeeee1  and subsequent red light irradiation (3.6 J/cm(2)), a high number of cells die by apoptosis, as evaluated by morphological alterations, immunofluorescent relocalization of  bbbbb2 Bax eeeee2  from cytosol to mitochondria, and TUNEL assay
CPR:1	The  bbbbb1 gp41 eeeee1  subunit contains several functional domains: the  bbbbb2 N eeeee2 -terminal heptad repeat (NHR) domains fold a triple stranded coiled-coil forming a meta-stable prefusion intermediate
CPR:2	Our results revealed an important role of base excision repair (BER) as the  bbbbb1 ntg1 eeeee1 , ntg2, apn1 and apn2 mutants showed pronounced sensitivity to essential oil and  bbbbb2 nerolidol eeeee2 
CPR:2	Our results revealed an important role of base excision repair (BER) as the ntg1,  bbbbb1 ntg2 eeeee1 , apn1 and apn2 mutants showed pronounced sensitivity to essential oil and  bbbbb2 nerolidol eeeee2 
CPR:2	Our results revealed an important role of base excision repair (BER) as the ntg1, ntg2,  bbbbb1 apn1 eeeee1  and apn2 mutants showed pronounced sensitivity to essential oil and  bbbbb2 nerolidol eeeee2 
CPR:2	Our results revealed an important role of base excision repair (BER) as the ntg1, ntg2, apn1 and  bbbbb1 apn2 eeeee1  mutants showed pronounced sensitivity to essential oil and  bbbbb2 nerolidol eeeee2 
CPR:2	The radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [ bbbbb1 (3)H eeeee1 ]- bbbbb2 MRP4 eeeee2  and [(3)H]-SSB siRNA, respectively)
CPR:9	Instead, radiolabeled  bbbbb1 nucleosides eeeee1  resulting from  bbbbb2 nuclease eeeee2  hydrolysis were observed
CPR:10	We also rescued  bbbbb1 RO3306 eeeee1 -resistant clones using exogenous  bbbbb2 Cdk1 eeeee2  without inhibitory phosphorylation sites, indicating that the mitotic surge of Cdk1 activity is dispensable for cell proliferation
CPR:10	We rescued cells lethally depleted of endogenous Cdk1 with an exogenous  bbbbb1 Cdk1 eeeee1  conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another ( bbbbb2 RO3306 eeeee2 )
CPR:2	We rescued cells lethally depleted of endogenous Cdk1 with an exogenous  bbbbb1 Cdk1 eeeee1  conferring sensitivity to one ATP analogue inhibitor ( bbbbb2 1NMPP1 eeeee2 ) and resistance to another (RO3306)
CPR:2	At no  bbbbb1 1NMPP1 eeeee1  concentration was mitosis in rescued clones prevented without also inducing endoreduplication, suggesting that these two key roles for  bbbbb2 Cdk1 eeeee2  are not simply controlled by different Cdk1 activity thresholds
CPR:2	A series of  bbbbb1 N eeeee1 -substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the  bbbbb2 vesicular monoamine transporter eeeee2  and for their inhibition of vesicular [(3)H]dopamine uptake
CPR:2	A series of N-substituted  bbbbb1 lobelane eeeee1  analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the  bbbbb2 vesicular monoamine transporter eeeee2  and for their inhibition of vesicular [(3)H]dopamine uptake
CPR:2	A series of N-substituted lobelane analogues was synthesized and evaluated for their  bbbbb1 [(3)H]dihydrotetrabenazine eeeee1  binding affinity at the  bbbbb2 vesicular monoamine transporter eeeee2  and for their inhibition of vesicular [(3)H]dopamine uptake
CPR:2	Exploring the effect of N-substitution in  bbbbb1 nor-lobelane eeeee1  on the interaction with  bbbbb2 VMAT2 eeeee2 : discovery of a potential clinical candidate for treatment of methamphetamine abuse
CPR:2	Exploring the effect of  bbbbb1 N eeeee1 -substitution in nor-lobelane on the interaction with  bbbbb2 VMAT2 eeeee2 : discovery of a potential clinical candidate for treatment of methamphetamine abuse
CPR:9	A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the  bbbbb1 vesicular monoamine transporter eeeee1  and for their inhibition of vesicular  bbbbb2 [(3)H]dopamine eeeee2  uptake
CPR:2	 bbbbb1 IPI-926 eeeee1  is highly bound to plasma proteins and has minimal interaction with  bbbbb2 human α-1-acid glycoprotein eeeee2 . 4
CPR:4	 bbbbb1 IPI-926 eeeee1  is both a substrate and inhibitor (IC50 = 1.9 µM) of  bbbbb2 P-glycoprotein eeeee2 . 6
CPR:9	 bbbbb1 IPI-926 eeeee1  is both a substrate and inhibitor (IC50 = 1.9 µM) of  bbbbb2 P-glycoprotein eeeee2 . 6
CPR:5	Oral  bbbbb1 lorcaserin eeeee1  (BELVIQ(®)), a selective serotonin  bbbbb2 5-HT2C eeeee2  receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes)
CPR:5	Oral lorcaserin ( bbbbb1 BELVIQ eeeee1 (®)), a selective serotonin  bbbbb2 5-HT2C eeeee2  receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes)
CPR:4	Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the  bbbbb1 cyclopropyl-substituted phenylalanine eeeee1  derivative 11h displayed the most potent  bbbbb2 DPP-4 eeeee2  inhibitory activity with an IC50 value of 0.247 μM
CPR:4	Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a  bbbbb1 2-Cyanopyrrolidine eeeee1  Moiety as Potent  bbbbb2 Dipeptidyl Peptidase 4 eeeee2  Inhibitors
CPR:4	Design, Synthesis, Biological Evaluation, and Docking Studies of  bbbbb1 (S)-Phenylalanine eeeee1  Derivatives with a 2-Cyanopyrrolidine Moiety as Potent  bbbbb2 Dipeptidyl Peptidase 4 eeeee2  Inhibitors
CPR:2	 bbbbb1 TCPOBOP eeeee1 , a  bbbbb2 CAR eeeee2  ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation
CPR:2	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with  bbbbb1 pregnenolone-16α-carbonitrile eeeee1  (PCN), a strong  bbbbb2 PXR eeeee2  ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CPR:2	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile ( bbbbb1 PCN eeeee1 ), a strong  bbbbb2 PXR eeeee2  ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CPR:2	All three agents induced  bbbbb1 mdr1a eeeee1 .fLUC expression (bioluminescence), but only  bbbbb2 PCN eeeee2  and docetaxel appeared to act primarily via PXR
CPR:2	All three agents induced  bbbbb1 mdr1a eeeee1 .fLUC expression (bioluminescence), but only PCN and  bbbbb2 docetaxel eeeee2  appeared to act primarily via PXR
CPR:2	 bbbbb1 TCPOBOP eeeee1 , a CAR ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in  bbbbb2 mdr1a eeeee2  regulation
CPR:2	All three agents induced mdr1a.fLUC expression (bioluminescence), but only  bbbbb1 PCN eeeee1  and docetaxel appeared to act primarily via  bbbbb2 PXR eeeee2 
CPR:2	All three agents induced mdr1a.fLUC expression (bioluminescence), but only PCN and  bbbbb1 docetaxel eeeee1  appeared to act primarily via  bbbbb2 PXR eeeee2 
CPR:2	 bbbbb1 TCPOBOP eeeee1 , a CAR ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with  bbbbb2 CAR eeeee2 's minor role in mdr1a regulation
CPR:3	 bbbbb1 TCPOBOP eeeee1 , a CAR ligand, modestly induced  bbbbb2 mdr1a eeeee2 .fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation
CPR:2	The inhibitory effect of  bbbbb1 galangin eeeee1  on theses pro-inflammatory cytokines was related with  bbbbb2 c-Jun eeeee2  N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1
CPR:2	The inhibitory effect of  bbbbb1 galangin eeeee1  on theses pro-inflammatory cytokines was related with c-Jun  bbbbb2 N-terminal kinases eeeee2 , and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1
CPR:2	The inhibitory effect of  bbbbb1 galangin eeeee1  on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and  bbbbb2 p38 eeeee2  mitogen-activated protein kinase, nuclear factor-κB, and caspase-1
CPR:2	The inhibitory effect of  bbbbb1 galangin eeeee1  on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38  bbbbb2 mitogen-activated protein kinase eeeee2 , nuclear factor-κB, and caspase-1
CPR:2	The inhibitory effect of  bbbbb1 galangin eeeee1  on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase,  bbbbb2 nuclear factor-κB eeeee2 , and caspase-1
CPR:2	The inhibitory effect of  bbbbb1 galangin eeeee1  on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and  bbbbb2 caspase-1 eeeee2 
CPR:4	Furthermore,  bbbbb1 galangin eeeee1  attenuated  bbbbb2 IgE eeeee2 -mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue
CPR:4	 bbbbb1 Galangin eeeee1  decreased expression of pro-inflammatory  bbbbb2 cytokines eeeee2 , such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and IL-8
CPR:4	 bbbbb1 Galangin eeeee1  decreased expression of pro-inflammatory cytokines, such as  bbbbb2 tumor necrosis factor (TNF)-α eeeee2 , interleukin (IL)-6, IL-1β, and IL-8
CPR:4	 bbbbb1 Galangin eeeee1  decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α,  bbbbb2 interleukin eeeee2  (IL)-6, IL-1β, and IL-8
CPR:4	 bbbbb1 Galangin eeeee1  decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin  bbbbb2 (IL)-6 eeeee2 , IL-1β, and IL-8
CPR:4	 bbbbb1 Galangin eeeee1  decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6,  bbbbb2 IL-1β eeeee2 , and IL-8
CPR:4	 bbbbb1 Galangin eeeee1  decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and  bbbbb2 IL-8 eeeee2 
CPR:4	The inhibitory effect of  bbbbb1 galangin eeeee1  on theses pro-inflammatory  bbbbb2 cytokines eeeee2  was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1
CPR:4	Furthermore,  bbbbb1 galangin eeeee1  attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of  bbbbb2 histamine receptor 1 eeeee2  at the inflamed tissue
CPR:4	Our results showed that  bbbbb1 galangin eeeee1  down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory  bbbbb2 cytokines eeeee2 
CPR:2	 bbbbb1 HP1α eeeee1  responded only to  bbbbb2 BHA eeeee2 
CPR:10	Furthermore,  bbbbb1 nobiletin eeeee1  could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and  bbbbb2 p38 eeeee2 
CPR:4	Next,  bbbbb1 nobiletin eeeee1  significantly decreased the levels of  bbbbb2 phospho-ERK2 eeeee2  and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration
CPR:4	Next,  bbbbb1 nobiletin eeeee1  significantly decreased the levels of phospho-ERK2 and  bbbbb2 phospho-Akt eeeee2  in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration
CPR:4	Next,  bbbbb1 nobiletin eeeee1  significantly decreased the levels of phospho-ERK2 and phospho-Akt in  bbbbb2 ERK2 eeeee2  or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration
CPR:4	Next,  bbbbb1 nobiletin eeeee1  significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or  bbbbb2 Akt eeeee2  siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration
CPR:4	 bbbbb1 Nobiletin eeeee1  attenuates metastasis via both  bbbbb2 ERK eeeee2  and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells
CPR:4	 bbbbb1 Nobiletin eeeee1  attenuates metastasis via both ERK and  bbbbb2 PI3K eeeee2 /Akt pathways in HGF-treated liver cancer HepG2 cells
CPR:4	 bbbbb1 Nobiletin eeeee1  attenuates metastasis via both ERK and PI3K/ bbbbb2 Akt eeeee2  pathways in HGF-treated liver cancer HepG2 cells
CPR:4	In conclusion,  bbbbb1 nobiletin eeeee1  attenuates  bbbbb2 HGF eeeee2 -induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.
CPR:4	In conclusion,  bbbbb1 nobiletin eeeee1  attenuates HGF-induced HepG2 cells metastasis involving both  bbbbb2 ERK eeeee2  and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.
CPR:4	In conclusion,  bbbbb1 nobiletin eeeee1  attenuates HGF-induced HepG2 cells metastasis involving both ERK and  bbbbb2 PI3K eeeee2 /Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.
CPR:4	In conclusion,  bbbbb1 nobiletin eeeee1  attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K/ bbbbb2 Akt eeeee2  pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.
CPR:4	Among them,  bbbbb1 nobiletin eeeee1  markedly inhibited  bbbbb2 HGF eeeee2 -induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations
CPR:4	Data also showed  bbbbb1 nobiletin eeeee1  inhibited  bbbbb2 HGF eeeee2 -induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia
CPR:4	Furthermore,  bbbbb1 nobiletin eeeee1  could inhibit  bbbbb2 HGF eeeee2 -induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38
CPR:4	Furthermore,  bbbbb1 nobiletin eeeee1  could inhibit HGF-induced the membrane localization of phosphorylated  bbbbb2 c-Met eeeee2 , ERK2, and Akt, but not phosphorylated JNK1/2 and p38
CPR:4	Furthermore,  bbbbb1 nobiletin eeeee1  could inhibit HGF-induced the membrane localization of phosphorylated c-Met,  bbbbb2 ERK2 eeeee2 , and Akt, but not phosphorylated JNK1/2 and p38
CPR:4	Furthermore,  bbbbb1 nobiletin eeeee1  could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and  bbbbb2 Akt eeeee2 , but not phosphorylated JNK1/2 and p38
CPR:10	In contrast, the latter pathway likely involves  bbbbb1 MHC eeeee1  binding peptides displayed as a consequence of abacavir exposure, but not  bbbbb2 abacavir eeeee2  itself.
CPR:2	These data suggest that T-cells can be activated by  bbbbb1 abacavir eeeee1  through a direct interaction with surface and intracellular  bbbbb2 major histocompatibility complex eeeee2  (MHC) molecules
CPR:2	These data suggest that T-cells can be activated by  bbbbb1 abacavir eeeee1  through a direct interaction with surface and intracellular major histocompatibility complex ( bbbbb2 MHC eeeee2 ) molecules
CPR:2	With the former,  bbbbb1 abacavir eeeee1  seemingly participates in the  bbbbb2 MHC eeeee2  T-cell receptor binding interaction
CPR:2	With the former,  bbbbb1 abacavir eeeee1  seemingly participates in the MHC  bbbbb2 T-cell receptor eeeee2  binding interaction
CPR:2	In contrast, the latter pathway likely involves  bbbbb1 MHC eeeee1  binding peptides displayed as a consequence of  bbbbb2 abacavir eeeee2  exposure, but not abacavir itself.
CPR:2	Seventy-four CD8+ clones expressing different  bbbbb1 Vβ receptors eeeee1  were shown to proliferate and kill target cells via different mechanisms when exposed to  bbbbb2 abacavir eeeee2 
CPR:2	Excess of  bbbbb1 cholesterol eeeee1  converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for  bbbbb2 Aβ eeeee2  and Tau
CPR:2	Excess of  bbbbb1 cholesterol eeeee1  converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for Aβ and  bbbbb2 Tau eeeee2 
CPR:3	Excess of  bbbbb1 cholesterol eeeee1  converted into 24OHC may up-regulate  bbbbb2 ApoE eeeee2  synthesis which is a scavenger for Aβ and Tau
CPR:3	Excess of cholesterol converted into  bbbbb1 24OHC eeeee1  may up-regulate  bbbbb2 ApoE eeeee2  synthesis which is a scavenger for Aβ and Tau
CPR:4	 bbbbb1 Cholesterol eeeee1  also increases  bbbbb2 Amyloid β eeeee2  (Aβ) deposition and tau pathology
CPR:4	 bbbbb1 Cholesterol eeeee1  also increases Amyloid β ( bbbbb2 Aβ eeeee2 ) deposition and tau pathology
CPR:4	 bbbbb1 Cholesterol eeeee1  also increases Amyloid β (Aβ) deposition and  bbbbb2 tau eeeee2  pathology
CPR:2	While the function of  bbbbb1 N-type calcium channels eeeee1  within astrocytes is controversial, these voltage-gated calcium channels have been linked to  bbbbb2 calcium eeeee2 -dependent vesicular gliotransmitter release
CPR:2	While the function of N-type calcium channels within astrocytes is controversial, these  bbbbb1 voltage-gated calcium channels eeeee1  have been linked to  bbbbb2 calcium eeeee2 -dependent vesicular gliotransmitter release
CPR:9	In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular  bbbbb1 glutamate eeeee1  is reduced when  bbbbb2 CaMKII eeeee2  is inhibited
CPR:10	Remarkably,  bbbbb1 3-HPT eeeee1  gives no inhibition of  bbbbb2 HDAC 1 eeeee2 
CPR:4	We have identified  bbbbb1 3-hydroxypyridin-2-thione eeeee1  (3-HPT) as a novel ZBG that is compatible with  bbbbb2 HDAC eeeee2  inhibition. 3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively
CPR:4	We have identified 3-hydroxypyridin-2-thione ( bbbbb1 3-HPT eeeee1 ) as a novel ZBG that is compatible with  bbbbb2 HDAC eeeee2  inhibition. 3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively
CPR:4	We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition.  bbbbb1 3-HPT eeeee1  inhibits  bbbbb2 HDAC 6 eeeee2  and HDAC 8 with an IC50 of 681 and 3675 nM, respectively
CPR:4	We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition.  bbbbb1 3-HPT eeeee1  inhibits HDAC 6 and  bbbbb2 HDAC 8 eeeee2  with an IC50 of 681 and 3675 nM, respectively
CPR:4	Small molecules bearing hydroxamic acid as the  bbbbb1 zinc eeeee1  binding group (ZBG) have been the most effective  bbbbb2 histone deacetylase eeeee2  inhibitors (HDACi) to date
CPR:4	Small molecules bearing hydroxamic acid as the  bbbbb1 zinc eeeee1  binding group (ZBG) have been the most effective histone deacetylase inhibitors ( bbbbb2 HDAC eeeee2 i) to date
CPR:4	Subsequent optimization led to several novel  bbbbb1 3HPT eeeee1 -based  bbbbb2 HDAC eeeee2 i that are selective for HDAC 6 and HDAC 8
CPR:4	Subsequent optimization led to several novel  bbbbb1 3HPT eeeee1 -based HDACi that are selective for  bbbbb2 HDAC 6 eeeee2  and HDAC 8
CPR:4	Subsequent optimization led to several novel  bbbbb1 3HPT eeeee1 -based HDACi that are selective for HDAC 6 and  bbbbb2 HDAC 8 eeeee2 
CPR:4	 bbbbb1 3-Hydroxypyridin-2-thione eeeee1  as Novel Zinc Binding Group for Selective  bbbbb2 Histone Deacetylase eeeee2  Inhibition
CPR:4	3-Hydroxypyridin-2-thione as Novel  bbbbb1 Zinc eeeee1  Binding Group for Selective  bbbbb2 Histone Deacetylase eeeee2  Inhibition
CPR:2	Native GLP-1 stimulates  bbbbb1 insulin eeeee1  secretion in a  bbbbb2 glucose eeeee2 -dependent manner, as well as suppressing glucagon production and slowing gastric emptying
CPR:3	Maqui berry (Aristotelia chilensis) and the constituent  bbbbb1 delphinidin glycoside eeeee1  inhibit  bbbbb2 photoreceptor eeeee2  cell death induced by visible light
CPR:4	These findings indicate that MBE and its  bbbbb1 anthocyanidins eeeee1  suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of  bbbbb2 phosphorylated-p38 eeeee2  may be involved in the underlying mechanism.
CPR:4	Moreover,  bbbbb1 curcumin eeeee1  could also down-regulate the expression and activity of  bbbbb2 matrix metalloproteinase-9 eeeee2  (MMP-9)
CPR:4	Moreover,  bbbbb1 curcumin eeeee1  could also down-regulate the expression and activity of matrix metalloproteinase-9 ( bbbbb2 MMP-9 eeeee2 )
CPR:4	Moreover,  bbbbb1 curcumin eeeee1  could also down-regulate the expression and activity of  bbbbb2 matrix metalloproteinase-9 eeeee2  (MMP-9)
CPR:4	Moreover,  bbbbb1 curcumin eeeee1  could also down-regulate the expression and activity of matrix metalloproteinase-9 ( bbbbb2 MMP-9 eeeee2 )
CPR:1	Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of  bbbbb1 Histone 3 eeeee1  at  bbbbb2 Ser eeeee2 10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c
CPR:1	Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of  bbbbb1 Cdk1 eeeee1  at  bbbbb2 Tyr eeeee2 15, expression of cyclin B1, and decreased expression of Cdc25c
CPR:3	Treatment with  bbbbb1 EVn-50 eeeee1  or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of  bbbbb2 Histone 3 eeeee2  at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c
CPR:3	Treatment with  bbbbb1 EVn-50 eeeee1  or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of  bbbbb2 Cdk1 eeeee2  at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c
CPR:3	Treatment with EVn-50 or  bbbbb1 VB1 eeeee1  resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of  bbbbb2 Histone 3 eeeee2  at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c
CPR:3	Treatment with EVn-50 or  bbbbb1 VB1 eeeee1  resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of  bbbbb2 Cdk1 eeeee2  at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c
CPR:3	Treatment with  bbbbb1 EVn-50 eeeee1  or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of  bbbbb2 cyclin B1 eeeee2 , and decreased expression of Cdc25c
CPR:3	Treatment with EVn-50 or  bbbbb1 VB1 eeeee1  resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of  bbbbb2 cyclin B1 eeeee2 , and decreased expression of Cdc25c
CPR:4	Treatment with  bbbbb1 EVn-50 eeeee1  or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of  bbbbb2 Cdc25c eeeee2 
CPR:4	Treatment with EVn-50 or  bbbbb1 VB1 eeeee1  resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of  bbbbb2 Cdc25c eeeee2 
CPR:2	Finally, the involvement of  bbbbb1 PKC eeeee1  and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of  bbbbb2 CAT eeeee2 
CPR:2	Finally, the involvement of PKC and  bbbbb1 PKA eeeee1  was also studied, and we showed that both play a role in the antinociceptive mechanism of  bbbbb2 CAT eeeee2 
CPR:2	Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part,  bbbbb1 TRPV1 eeeee1 , TRPM8, ASIC, glutamate receptors, PKC and PKA participate in  bbbbb2 CAT eeeee2 's antinociceptive mechanism.
CPR:2	Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1,  bbbbb1 TRPM8 eeeee1 , ASIC, glutamate receptors, PKC and PKA participate in  bbbbb2 CAT eeeee2 's antinociceptive mechanism.
CPR:2	Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8,  bbbbb1 ASIC eeeee1 , glutamate receptors, PKC and PKA participate in  bbbbb2 CAT eeeee2 's antinociceptive mechanism.
CPR:2	Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC,  bbbbb1 glutamate receptors eeeee1 , PKC and PKA participate in  bbbbb2 CAT eeeee2 's antinociceptive mechanism.
CPR:2	Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, glutamate receptors,  bbbbb1 PKC eeeee1  and PKA participate in  bbbbb2 CAT eeeee2 's antinociceptive mechanism.
CPR:2	Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, glutamate receptors, PKC and  bbbbb1 PKA eeeee1  participate in  bbbbb2 CAT eeeee2 's antinociceptive mechanism.
CPR:2	In an investigation into the participation of  bbbbb1 TRP channels eeeee1  and ASICs in  bbbbb2 CAT eeeee2 's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98)
CPR:2	In an investigation into the participation of TRP channels and  bbbbb1 ASICs eeeee1  in  bbbbb2 CAT eeeee2 's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98)
CPR:2	In an investigation into the participation of  bbbbb1 TRP channels eeeee1  and ASICs in CAT's antinociceptive mechanism, we used  bbbbb2 capsaicin eeeee2  (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98)
CPR:2	In an investigation into the participation of TRP channels and  bbbbb1 ASICs eeeee1  in CAT's antinociceptive mechanism, we used  bbbbb2 capsaicin eeeee2  (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98)
CPR:2	In an investigation into the participation of  bbbbb1 TRP channels eeeee1  and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw),  bbbbb2 cinnamaldehyde eeeee2  (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98)
CPR:2	In an investigation into the participation of TRP channels and  bbbbb1 ASICs eeeee1  in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw),  bbbbb2 cinnamaldehyde eeeee2  (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98)
CPR:2	In an investigation into the participation of  bbbbb1 TRP channels eeeee1  and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw),  bbbbb2 menthol eeeee2  (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98)
CPR:2	In an investigation into the participation of TRP channels and  bbbbb1 ASICs eeeee1  in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw),  bbbbb2 menthol eeeee2  (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98)
CPR:2	In an investigation into the participation of  bbbbb1 TRP channels eeeee1  and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2%  bbbbb2 acetic acid eeeee2 , pH 1.98)
CPR:2	In an investigation into the participation of TRP channels and  bbbbb1 ASICs eeeee1  in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2%  bbbbb2 acetic acid eeeee2 , pH 1.98)
CPR:2	Importantly, 2-hydroxychalcone and xanthohumol exerted more potent inhibitory effects on the proliferation,  bbbbb1 MMP-9 eeeee1  expression and invasive phenotype of MDA-MB-231 than  bbbbb2 chalcone eeeee2 
CPR:4	 bbbbb1 Xanthohumol eeeee1  and 2-hydroxychalcone induced apoptosis by  bbbbb2 Bcl-2 eeeee2  downregulation
CPR:4	Xanthohumol and  bbbbb1 2-hydroxychalcone eeeee1  induced apoptosis by  bbbbb2 Bcl-2 eeeee2  downregulation
CPR:4	Importantly,  bbbbb1 2-hydroxychalcone eeeee1  and xanthohumol exerted more potent inhibitory effects on the proliferation,  bbbbb2 MMP-9 eeeee2  expression and invasive phenotype of MDA-MB-231 than chalcone
CPR:4	Importantly, 2-hydroxychalcone and  bbbbb1 xanthohumol eeeee1  exerted more potent inhibitory effects on the proliferation,  bbbbb2 MMP-9 eeeee2  expression and invasive phenotype of MDA-MB-231 than chalcone
CPR:2	We investigated the ability of the initial fragment hit, 3-hydroxy-pyridine-2(1H)-one, to fill this subpocket with the aid of complex structure information.  bbbbb1 3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one eeeee1  exhibited the predicted binding mode and demonstrated high inhibitory activity for  bbbbb2 human DAAO eeeee2  in enzyme- and cell-based assays
CPR:4	We investigated the ability of the initial fragment hit, 3-hydroxy-pyridine-2(1H)-one, to fill this subpocket with the aid of complex structure information.  bbbbb1 3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one eeeee1  exhibited the predicted binding mode and demonstrated high inhibitory activity for  bbbbb2 human DAAO eeeee2  in enzyme- and cell-based assays
CPR:4	We identified a series of  bbbbb1 4-hydroxypyridazin-3(2H)-one eeeee1  derivatives as novel  bbbbb2 DAAO eeeee2  inhibitors with high potency and substantial cell permeability using fragment-based drug design
CPR:5	-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including  bbbbb1 d-serine eeeee1 , a coagonist of the  bbbbb2 N-methyl-d-aspartate receptor eeeee2 
CPR:9	-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.  bbbbb1 d-Amino acid oxidase eeeee1  (DAAO) catalyzes the oxidation of d-amino acids including  bbbbb2 d-serine eeeee2 , a coagonist of the N-methyl-d-aspartate receptor
CPR:9	-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase ( bbbbb1 DAAO eeeee1 ) catalyzes the oxidation of d-amino acids including  bbbbb2 d-serine eeeee2 , a coagonist of the N-methyl-d-aspartate receptor
CPR:9	-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.  bbbbb1 d-Amino acid oxidase eeeee1  (DAAO) catalyzes the oxidation of  bbbbb2 d-amino acids eeeee2  including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CPR:9	-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase ( bbbbb1 DAAO eeeee1 ) catalyzes the oxidation of  bbbbb2 d-amino acids eeeee2  including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CPR:10	Fourteen of 17 parabens exhibited hERα and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17  bbbbb1 parabens eeeee1  showed  bbbbb2 AR eeeee2  agonistic or antagonistic activity
CPR:2	Comparative study on transcriptional activity of 17  bbbbb1 parabens eeeee1  mediated by estrogen receptor α and β and  bbbbb2 androgen receptor eeeee2 
CPR:5	Among 12 parabens with linear alkyl chains ranging in length from C1 to C12,  bbbbb1 heptylparaben eeeee1  (C7) and pentylparaben (C5) showed the most potent  bbbbb2 ERα eeeee2  and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12
CPR:5	Among 12 parabens with linear alkyl chains ranging in length from C1 to C12,  bbbbb1 heptylparaben eeeee1  (C7) and pentylparaben (C5) showed the most potent ERα and  bbbbb2 ERβ eeeee2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12
CPR:5	Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and  bbbbb1 pentylparaben eeeee1  (C5) showed the most potent  bbbbb2 ERα eeeee2  and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12
CPR:5	Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and  bbbbb1 pentylparaben eeeee1  (C5) showed the most potent ERα and  bbbbb2 ERβ eeeee2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12
CPR:5	Most  bbbbb1 parabens eeeee1  showing estrogenic activity exhibited  bbbbb2 ERβ eeeee2 -agonistic activity at lower concentrations than those inducing ERα-agonistic activity
CPR:5	Most  bbbbb1 parabens eeeee1  showing estrogenic activity exhibited ERβ-agonistic activity at lower concentrations than those inducing  bbbbb2 ERα eeeee2 -agonistic activity
CPR:5	These results indicate that  bbbbb1 parabens eeeee1  are selective agonists for  bbbbb2 ERβ eeeee2  over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.
CPR:5	These results indicate that  bbbbb1 parabens eeeee1  are selective agonists for ERβ over  bbbbb2 ERα eeeee2 ; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.
CPR:5	Fourteen of 17  bbbbb1 parabens eeeee1  exhibited  bbbbb2 hERα eeeee2  and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity
CPR:5	Fourteen of 17  bbbbb1 parabens eeeee1  exhibited hERα and/or  bbbbb2 hERβ eeeee2  agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity
CPR:5	Among 12  bbbbb1 parabens eeeee1  with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent  bbbbb2 ERα eeeee2  and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12
CPR:5	Among 12  bbbbb1 parabens eeeee1  with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ERα and  bbbbb2 ERβ eeeee2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12
CPR:5	Among 12 parabens with linear  bbbbb1 alkyl eeeee1  chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent  bbbbb2 ERα eeeee2  and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12
CPR:5	Among 12 parabens with linear  bbbbb1 alkyl eeeee1  chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ERα and  bbbbb2 ERβ eeeee2  agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12
CPR:9	These results indicate that  bbbbb1 parabens eeeee1  are selective agonists for ERβ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by  bbbbb2 carboxylesterases eeeee2 , leading to attenuation of their estrogenic activity.
CPR:4	Wattakaka volubilis  bbbbb1 steroidal glycoside eeeee1  mixture (WVSM) and PPG (1-50μM) significantly inhibited the  bbbbb2 COX-2 eeeee2  and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells
CPR:4	Wattakaka volubilis  bbbbb1 steroidal glycoside eeeee1  mixture (WVSM) and PPG (1-50μM) significantly inhibited the COX-2 and  bbbbb2 iNOS eeeee2  enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells
CPR:4	Wattakaka volubilis steroidal glycoside mixture (WVSM) and  bbbbb1 PPG eeeee1  (1-50μM) significantly inhibited the  bbbbb2 COX-2 eeeee2  and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells
CPR:4	Wattakaka volubilis steroidal glycoside mixture (WVSM) and  bbbbb1 PPG eeeee1  (1-50μM) significantly inhibited the COX-2 and  bbbbb2 iNOS eeeee2  enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells
CPR:2	 bbbbb1 E-cadherin eeeee1  is a transmembrane glycoprotein that mediates  bbbbb2 calcium eeeee2 -dependent interactions between adjacent epithelial cells
CPR:2	However, the precise mechanism by which quercetin counteracts  bbbbb1 CYP2E1 eeeee1 -mediated  bbbbb2 ethanol eeeee2  hepatotoxicity through HO-1 system is still remained unclear
CPR:2	CO scavenging blocked the suppression of  bbbbb1 quercetin eeeee1  only on  bbbbb2 CYP2E1 eeeee2  activity
CPR:2	Quercetin suppressed  bbbbb1 CYP2E1 eeeee1 -dependent  bbbbb2 ethanol eeeee2  hepatotoxicity via depleting heme pool and releasing CO
CPR:2	Thus,  bbbbb1 CYP2E1 eeeee1 -mediated  bbbbb2 ethanol eeeee2  hepatotoxicity was alleviated by quercetin through HO-1 induction
CPR:2	However, the precise mechanism by which  bbbbb1 quercetin eeeee1  counteracts CYP2E1-mediated ethanol hepatotoxicity through  bbbbb2 HO-1 eeeee2  system is still remained unclear
CPR:3	Our data showed that chronic  bbbbb1 ethanol eeeee1  over-activated  bbbbb2 CYP2E1 eeeee2  but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.)
CPR:3	 bbbbb1 Quercetin eeeee1  (100μM) induced  bbbbb2 HO-1 eeeee2  and depleted heme pool when incubated to human hepatocytes
CPR:3	 bbbbb1 Ethanol eeeee1 -stimulated (100mM)  bbbbb2 CYP2E1 eeeee2  upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation
CPR:3	CO donor dose-dependently inactivated  bbbbb1 CYP2E1 eeeee1  of  bbbbb2 ethanol eeeee2 -incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger
CPR:3	Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by  bbbbb1 quercetin eeeee1  through  bbbbb2 HO-1 eeeee2  induction
CPR:4	Our data showed that chronic  bbbbb1 ethanol eeeee1  over-activated CYP2E1 but suppressed  bbbbb2 HO-1 eeeee2  with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.)
CPR:4	Ethanol-stimulated (100mM)  bbbbb1 CYP2E1 eeeee1  upregulation was suppressed by  bbbbb2 quercetin eeeee2  but further enhanced by HO-1 inhibition with resultant heme accumulation
CPR:4	 bbbbb1 CO eeeee1  scavenging blocked the suppression of quercetin only on  bbbbb2 CYP2E1 eeeee2  activity
CPR:4	 bbbbb1 CO eeeee1  donor dose-dependently inactivated  bbbbb2 CYP2E1 eeeee2  of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger
CPR:4	 bbbbb1 Quercetin eeeee1  suppressed  bbbbb2 CYP2E1 eeeee2 -dependent ethanol hepatotoxicity via depleting heme pool and releasing CO
CPR:4	CO donor dose-dependently inactivated  bbbbb1 CYP2E1 eeeee1  of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by  bbbbb2 CO eeeee2  scavenger
CPR:4	However, the precise mechanism by which  bbbbb1 quercetin eeeee1  counteracts  bbbbb2 CYP2E1 eeeee2 -mediated ethanol hepatotoxicity through HO-1 system is still remained unclear
CPR:4	 bbbbb1 Ethanol eeeee1 -stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by  bbbbb2 HO-1 eeeee2  inhibition with resultant heme accumulation
CPR:4	Depleted heme pool and  bbbbb1 CO eeeee1  releasing limited protein synthesis and inhibited enzymatic activity of  bbbbb2 CYP2E1 eeeee2 , respectively.
CPR:9	Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by  bbbbb1 HO-1 eeeee1  inhibition with resultant  bbbbb2 heme eeeee2  accumulation
CPR:4	Novel racemic  bbbbb1 tetrahydrocurcuminoid dihydropyrimidinone eeeee1  analogues as potent  bbbbb2 acetylcholinesterase eeeee2  inhibitors
CPR:10	Both  bbbbb1 ICI eeeee1  treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine  bbbbb2 progesterone receptor eeeee2  (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CPR:10	Both  bbbbb1 ICI eeeee1  treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor ( bbbbb2 PR eeeee2 ) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CPR:1	We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of  bbbbb1 Akt eeeee1  phosphorylation at  bbbbb2 Ser eeeee2  473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters
CPR:2	Both  bbbbb1 ICI eeeee1  treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of  bbbbb2 cyclin D1 eeeee2 , in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CPR:2	Furthermore, we detected that  bbbbb1 ICI eeeee1  treatment induced glycogen synthase kinase (Gsk3-β) Ser 9 phosphorylation, which correlates with  bbbbb2 cyclin D1 eeeee2  nuclear localization
CPR:3	Furthermore, we detected that  bbbbb1 ICI eeeee1  treatment induced  bbbbb2 glycogen synthase kinase eeeee2  (Gsk3-β) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization
CPR:3	Furthermore, we detected that  bbbbb1 ICI eeeee1  treatment induced glycogen synthase kinase ( bbbbb2 Gsk3-β eeeee2 ) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization
CPR:3	Agonistic activity of  bbbbb1 ICI 182 780 eeeee1  on activation of GSK 3β/ bbbbb2 AKT eeeee2  pathway in the rat uterus during the estrous cycle
CPR:3	The overall results indicate that  bbbbb1 ICI eeeee1  may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the  bbbbb2 Akt eeeee2  pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.
CPR:4	Both  bbbbb1 ICI eeeee1  treatments, induced a significant decrease (p<0.01) in uterine  bbbbb2 estrogen receptor alpha eeeee2  (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CPR:4	Both  bbbbb1 ICI eeeee1  treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha ( bbbbb2 ERα eeeee2 ) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CPR:4	We observed that the administration of  bbbbb1 ICI eeeee1  at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of  bbbbb2 Akt eeeee2  phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters
CPR:5	Agonistic activity of  bbbbb1 ICI 182 780 eeeee1  on activation of  bbbbb2 GSK 3β eeeee2 /AKT pathway in the rat uterus during the estrous cycle
CPR:2	A series of  bbbbb1 aminopropylindenes eeeee1 , designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) ( bbbbb2 OSC eeeee2 )-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone
CPR:2	A series of  bbbbb1 aminopropylindenes eeeee1 , designed as mimics of a cationic high energy intermediate in the  bbbbb2 oxidosqualene cyclase(1) eeeee2  (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone
CPR:4	A  bbbbb1 N,N-dimethylaminopropyl eeeee1  derivative showed promising inhibition of  bbbbb2 Trypanosoma cruzi OSC eeeee2  in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.
CPR:4	 bbbbb1 Aminopropylindenes eeeee1  derived from Grundmann's ketone as a novel chemotype of  bbbbb2 oxidosqualene cyclase eeeee2  inhibitors
CPR:4	Aminopropylindenes derived from  bbbbb1 Grundmann's ketone eeeee1  as a novel chemotype of  bbbbb2 oxidosqualene cyclase eeeee2  inhibitors
CPR:9	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) ( bbbbb1 OSC eeeee1 )-mediated cyclization of 2,3-oxidosqualen to  bbbbb2 lanosterol eeeee2  was prepared from Grundmann's ketone
CPR:9	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the  bbbbb1 oxidosqualene cyclase(1) eeeee1  (OSC)-mediated cyclization of 2,3-oxidosqualen to  bbbbb2 lanosterol eeeee2  was prepared from Grundmann's ketone
CPR:9	A N,N-dimethylaminopropyl derivative showed promising inhibition of  bbbbb1 Trypanosoma cruzi OSC eeeee1  in combination with low cytotoxicity, and showed significant reduction of  bbbbb2 cholesterol eeeee2  biosynthesis in a human cell line.
CPR:9	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) ( bbbbb1 OSC eeeee1 )-mediated cyclization of  bbbbb2 2,3-oxidosqualen eeeee2  to lanosterol was prepared from Grundmann's ketone
CPR:9	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the  bbbbb1 oxidosqualene cyclase(1) eeeee1  (OSC)-mediated cyclization of  bbbbb2 2,3-oxidosqualen eeeee2  to lanosterol was prepared from Grundmann's ketone
CPR:10	MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles  bbbbb1 ATP eeeee1  activates P2Y1 but not  bbbbb2 P2X receptors eeeee2 
CPR:1	Phosphorylation on  bbbbb1 Ser eeeee1  and Thr residues of  bbbbb2 pannexin1 eeeee2  was increased during potentiation, possibly mediating HC opening
CPR:1	Phosphorylation on Ser and  bbbbb1 Thr eeeee1  residues of  bbbbb2 pannexin1 eeeee2  was increased during potentiation, possibly mediating HC opening
CPR:2	Immunocytochemical analyses and function were consistent with  bbbbb1 pannexin1 eeeee1  localization to T-tubules intercalated with  bbbbb2 dihydropyridine eeeee2  and ryanodine receptors in slow (soleus) and fast (extensor digitorum longus, EDL) muscles
CPR:3	During repetitive stimulation of skeletal muscle, extracellular  bbbbb1 ATP eeeee1  levels raise, activating  bbbbb2 purinergic receptors eeeee2 , increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation
CPR:3	MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles  bbbbb1 ATP eeeee1  activates  bbbbb2 P2Y1 eeeee2  but not P2X receptors
CPR:9	Consistent with two  bbbbb1 glucose eeeee1  uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or  bbbbb2 glucose transporter eeeee2  (GLUT4), and blocked by dual blockade
CPR:9	Consistent with two  bbbbb1 glucose eeeee1  uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter ( bbbbb2 GLUT4 eeeee2 ), and blocked by dual blockade
CPR:9	Consistent with two glucose uptake pathways, induced uptake of  bbbbb1 2-NBDG eeeee1 , a fluorescent glucose derivative, was decreased by inhibition of HCs or  bbbbb2 glucose transporter eeeee2  (GLUT4), and blocked by dual blockade
CPR:9	Consistent with two glucose uptake pathways, induced uptake of  bbbbb1 2-NBDG eeeee1 , a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter ( bbbbb2 GLUT4 eeeee2 ), and blocked by dual blockade
CPR:9	The  bbbbb1 ATP eeeee1  required for potentiation of skeletal muscle contraction is released via  bbbbb2 pannexin eeeee2  hemichannels
CPR:9	Opening of  bbbbb1 Panx1 eeeee1  HCs during repetitive activation allows efflux of  bbbbb2 ATP eeeee2 , influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction
CPR:9	Opening of  bbbbb1 Panx1 eeeee1  HCs during repetitive activation allows efflux of ATP, influx of  bbbbb2 glucose eeeee2  and possibly Ca(2+) too, which are required for potentiation of contraction
CPR:9	Opening of  bbbbb1 Panx1 eeeee1  HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly  bbbbb2 Ca(2+) eeeee2  too, which are required for potentiation of contraction
CPR:3	The rate limiting enzyme of beta-oxidation ( bbbbb1 ACOX1 eeeee1 ) was significantly over-expressed in the liver with  bbbbb2 tBHQ eeeee2  treatment
CPR:3	These results indicate that  bbbbb1 tBHQ eeeee1  suppresses body weight gain in mice, possibly at least related to the up-regulation of  bbbbb2 ACOX1 eeeee2  gene expression.
CPR:3	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the  bbbbb1 VEGF eeeee1  release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  bbbbb2 PLGA eeeee2  and more than 45% with HMW core PLGA
CPR:3	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of  bbbbb1 PDGF eeeee1 , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  bbbbb2 PLGA eeeee2  and more than 45% with HMW core PLGA
CPR:3	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the  bbbbb1 VEGF eeeee1  release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core  bbbbb2 PLGA eeeee2 
CPR:3	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of  bbbbb1 PDGF eeeee1 , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core  bbbbb2 PLGA eeeee2 
CPR:4	Potency switch between CHK1 and  bbbbb1 MK2 eeeee1 : Discovery of  bbbbb2 imidazo[1,2-a]pyrazine eeeee2 - and imidazo[1,2-c]pyrimidine-based kinase inhibitors
CPR:4	Potency switch between CHK1 and MK2: Discovery of  bbbbb1 imidazo[1,2-a]pyrazine eeeee1 - and imidazo[1,2-c]pyrimidine-based  bbbbb2 kinase eeeee2  inhibitors
CPR:4	Potency switch between  bbbbb1 CHK1 eeeee1  and MK2: Discovery of  bbbbb2 imidazo[1,2-a]pyrazine eeeee2 - and imidazo[1,2-c]pyrimidine-based kinase inhibitors
CPR:4	Potency switch between CHK1 and  bbbbb1 MK2 eeeee1 : Discovery of imidazo[1,2-a]pyrazine- and  bbbbb2 imidazo[1,2-c]pyrimidine eeeee2 -based kinase inhibitors
CPR:4	Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and  bbbbb1 imidazo[1,2-c]pyrimidine eeeee1 -based  bbbbb2 kinase eeeee2  inhibitors
CPR:4	Potency switch between  bbbbb1 CHK1 eeeee1  and MK2: Discovery of imidazo[1,2-a]pyrazine- and  bbbbb2 imidazo[1,2-c]pyrimidine eeeee2 -based kinase inhibitors
CPR:1	In the present report, we show that Fer associates with the activated  bbbbb1 PDGFbeta receptor eeeee1  (PDGFRbeta) through multiple autophosphorylation sites, i.e.  bbbbb2 Tyr eeeee2 579, Tyr581, Tyr740 and Tyr1021
CPR:1	In the present report, we show that Fer associates with the activated PDGFbeta receptor ( bbbbb1 PDGFRbeta eeeee1 ) through multiple autophosphorylation sites, i.e.  bbbbb2 Tyr eeeee2 579, Tyr581, Tyr740 and Tyr1021
CPR:1	In the present report, we show that Fer associates with the activated  bbbbb1 PDGFbeta receptor eeeee1  (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579,  bbbbb2 Tyr eeeee2 581, Tyr740 and Tyr1021
CPR:1	In the present report, we show that Fer associates with the activated PDGFbeta receptor ( bbbbb1 PDGFRbeta eeeee1 ) through multiple autophosphorylation sites, i.e. Tyr579,  bbbbb2 Tyr eeeee2 581, Tyr740 and Tyr1021
CPR:1	In the present report, we show that Fer associates with the activated  bbbbb1 PDGFbeta receptor eeeee1  (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581,  bbbbb2 Tyr eeeee2 740 and Tyr1021
CPR:1	In the present report, we show that Fer associates with the activated PDGFbeta receptor ( bbbbb1 PDGFRbeta eeeee1 ) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581,  bbbbb2 Tyr eeeee2 740 and Tyr1021
CPR:1	In the present report, we show that Fer associates with the activated  bbbbb1 PDGFbeta receptor eeeee1  (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581, Tyr740 and  bbbbb2 Tyr eeeee2 1021
CPR:1	In the present report, we show that Fer associates with the activated PDGFbeta receptor ( bbbbb1 PDGFRbeta eeeee1 ) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581, Tyr740 and  bbbbb2 Tyr eeeee2 1021
CPR:6	A series of structurally novel  bbbbb1 aryl ureas eeeee1  was derived from optimization of the HTS lead as selective  bbbbb2 histamine H3 receptor eeeee2  (H3R) antagonists
CPR:6	A series of structurally novel  bbbbb1 aryl ureas eeeee1  was derived from optimization of the HTS lead as selective histamine H3 receptor ( bbbbb2 H3R eeeee2 ) antagonists
CPR:6	Discovery of  bbbbb1 aryl ureas eeeee1  and aryl amides as potent and selective  bbbbb2 histamine H3 receptor eeeee2  antagonists for the treatment of obesity (Part I)
CPR:6	Discovery of aryl ureas and  bbbbb1 aryl amides eeeee1  as potent and selective  bbbbb2 histamine H3 receptor eeeee2  antagonists for the treatment of obesity (Part I)
CPR:2	An increase in the energy required to remove the same anion from the  bbbbb1 tridentate receptor eeeee1  when compared to the bidentate and monodentate receptors is explained as being due to the increase in  bbbbb2 halogen eeeee2  bonding interactions
CPR:9	In terms of the mechanisms, we found that fatty acid amide hydrolase ( bbbbb1 FAAH eeeee1 ) which degrades  bbbbb2 anandamide eeeee2 , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences
CPR:9	In terms of the mechanisms, we found that  bbbbb1 fatty acid amide hydrolase eeeee1  (FAAH) which degrades  bbbbb2 anandamide eeeee2 , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences
CPR:9	However, enzymes contributing to oxidative metabolism of  bbbbb1 anandamide eeeee1 , namely  bbbbb2 cyclooxygenase-1 eeeee2  and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide
CPR:9	However, enzymes contributing to oxidative metabolism of  bbbbb1 anandamide eeeee1 , namely cyclooxygenase-1 and  bbbbb2 Cyp2D6 eeeee2 , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide
CPR:9	However, enzymes contributing to oxidative metabolism of anandamide, namely  bbbbb1 cyclooxygenase-1 eeeee1  and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of  bbbbb2 anandamide eeeee2 
CPR:9	However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and  bbbbb1 Cyp2D6 eeeee1 , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of  bbbbb2 anandamide eeeee2 
CPR:10	When the expression of ABCA1 and ABCG1 was induced,  bbbbb1 24-OHC eeeee1  efflux was stimulated in the presence of high density lipoprotein (HDL), whereas  bbbbb2 apolipoprotein A-I eeeee2  was not an efficient acceptor
CPR:2	The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and  bbbbb1 retinoic acid eeeee1 , which are ligands of the  bbbbb2 nuclear receptors eeeee2  LXR/RXR
CPR:2	The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and  bbbbb1 retinoic acid eeeee1 , which are ligands of the nuclear receptors  bbbbb2 LXR eeeee2 /RXR
CPR:2	The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and  bbbbb1 retinoic acid eeeee1 , which are ligands of the nuclear receptors LXR/ bbbbb2 RXR eeeee2 
CPR:2	The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as  bbbbb1 TO901317 eeeee1  and retinoic acid, which are ligands of the  bbbbb2 nuclear receptors eeeee2  LXR/RXR
CPR:2	The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as  bbbbb1 TO901317 eeeee1  and retinoic acid, which are ligands of the nuclear receptors  bbbbb2 LXR eeeee2 /RXR
CPR:2	The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as  bbbbb1 TO901317 eeeee1  and retinoic acid, which are ligands of the nuclear receptors LXR/ bbbbb2 RXR eeeee2 
CPR:2	When the expression of ABCA1 and ABCG1 was induced,  bbbbb1 24-OHC eeeee1  efflux was stimulated in the presence of  bbbbb2 high density lipoprotein eeeee2  (HDL), whereas apolipoprotein A-I was not an efficient acceptor
CPR:2	When the expression of ABCA1 and ABCG1 was induced,  bbbbb1 24-OHC eeeee1  efflux was stimulated in the presence of high density lipoprotein ( bbbbb2 HDL eeeee2 ), whereas apolipoprotein A-I was not an efficient acceptor
CPR:2	To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or ABCG1; we clearly observed  bbbbb1 24-OHC eeeee1  efflux in the presence of  bbbbb2 HDL eeeee2 , whereas efflux in the presence of apolipoprotein A-I was marginal
CPR:2	To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or ABCG1; we clearly observed  bbbbb1 24-OHC eeeee1  efflux in the presence of HDL, whereas efflux in the presence of  bbbbb2 apolipoprotein A-I eeeee2  was marginal
CPR:2	These results suggest that ABCA1 actively eliminates  bbbbb1 24-OHC eeeee1  in the presence of  bbbbb2 HDL eeeee2  as a lipid acceptor and protects neuronal cells
CPR:3	The expression of  bbbbb1 ABCA1 eeeee1  and ABCG1 was induced by 24-OHC, as well as TO901317 and  bbbbb2 retinoic acid eeeee2 , which are ligands of the nuclear receptors LXR/RXR
CPR:3	The expression of ABCA1 and  bbbbb1 ABCG1 eeeee1  was induced by 24-OHC, as well as TO901317 and  bbbbb2 retinoic acid eeeee2 , which are ligands of the nuclear receptors LXR/RXR
CPR:3	The expression of  bbbbb1 ABCA1 eeeee1  and ABCG1 was induced by  bbbbb2 24-OHC eeeee2 , as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR
CPR:3	The expression of ABCA1 and  bbbbb1 ABCG1 eeeee1  was induced by  bbbbb2 24-OHC eeeee2 , as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR
CPR:3	The expression of  bbbbb1 ABCA1 eeeee1  and ABCG1 was induced by 24-OHC, as well as  bbbbb2 TO901317 eeeee2  and retinoic acid, which are ligands of the nuclear receptors LXR/RXR
CPR:3	The expression of ABCA1 and  bbbbb1 ABCG1 eeeee1  was induced by 24-OHC, as well as  bbbbb2 TO901317 eeeee2  and retinoic acid, which are ligands of the nuclear receptors LXR/RXR
CPR:9	Because  bbbbb1 24(S)-hydroxycholesterol eeeee1  (24-OHC), produced by  bbbbb2 24-hydroxylase eeeee2 , induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells
CPR:9	Because 24(S)-hydroxycholesterol ( bbbbb1 24-OHC eeeee1 ), produced by  bbbbb2 24-hydroxylase eeeee2 , induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells
CPR:9	To confirm the role of each transporter, we analyzed HEK293 cells stably expressing  bbbbb1 human ABCA1 eeeee1  or ABCG1; we clearly observed  bbbbb2 24-OHC eeeee2  efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal
CPR:9	To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or  bbbbb1 ABCG1 eeeee1 ; we clearly observed  bbbbb2 24-OHC eeeee2  efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal
CPR:9	 bbbbb1 24(S)-hydroxycholesterol eeeee1  is actively eliminated from neuronal cells by  bbbbb2 ABCA1 eeeee2 
CPR:9	These results suggest that  bbbbb1 ABCA1 eeeee1  actively eliminates  bbbbb2 24-OHC eeeee2  in the presence of HDL as a lipid acceptor and protects neuronal cells
CPR:9	High  bbbbb1 cholesterol eeeee1  turnover catalyzed by  bbbbb2 cholesterol 24-hydroxylase eeeee2  is essential for neural functions, especially learning
CPR:1	Molecular docking studies were performed with  bbbbb1 Human Serum Albumin eeeee1  (HSA: PDB 1E78), showing binding pattern with  bbbbb2 amino acid eeeee2  residues Arg218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target
CPR:1	Molecular docking studies were performed with Human Serum Albumin ( bbbbb1 HSA eeeee1 : PDB 1E78), showing binding pattern with  bbbbb2 amino acid eeeee2  residues Arg218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target
CPR:1	Molecular docking studies were performed with  bbbbb1 Human Serum Albumin eeeee1  (HSA: PDB 1E78), showing binding pattern with amino acid residues  bbbbb2 Arg eeeee2 218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target
CPR:1	Molecular docking studies were performed with Human Serum Albumin ( bbbbb1 HSA eeeee1 : PDB 1E78), showing binding pattern with amino acid residues  bbbbb2 Arg eeeee2 218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target
CPR:1	Molecular docking studies were performed with  bbbbb1 Human Serum Albumin eeeee1  (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218,  bbbbb2 Arg eeeee2 222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target
CPR:1	Molecular docking studies were performed with Human Serum Albumin ( bbbbb1 HSA eeeee1 : PDB 1E78), showing binding pattern with amino acid residues Arg218,  bbbbb2 Arg eeeee2 222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target
CPR:1	Molecular docking studies were performed with  bbbbb1 Human Serum Albumin eeeee1  (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and  bbbbb2 Lys eeeee2 444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target
CPR:1	Molecular docking studies were performed with Human Serum Albumin ( bbbbb1 HSA eeeee1 : PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and  bbbbb2 Lys eeeee2 444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target
CPR:2	These experiments show that in striatonigral projections,  bbbbb1 CaMKIIα eeeee1  inhibits the action of D3 receptors in a  bbbbb2 Ca(2+) eeeee2  dependent manner blocking their modulatory effects on GABA release
CPR:2	These experiments show that in striatonigral projections, CaMKIIα inhibits the action of  bbbbb1 D3 receptors eeeee1  in a  bbbbb2 Ca(2+) eeeee2  dependent manner blocking their modulatory effects on GABA release
CPR:2	Immunoblot studies showed that K(+)-depolarization increased CaMKIIα phosphorylation in a  bbbbb1 KN-62 eeeee1  sensitive manner and promoted  bbbbb2 CaMKIIα eeeee2  binding to D3 receptors
CPR:2	Immunoblot studies showed that K(+)-depolarization increased CaMKIIα phosphorylation in a  bbbbb1 KN-62 eeeee1  sensitive manner and promoted CaMKIIα binding to  bbbbb2 D3 receptors eeeee2 
CPR:2	Immunoblot studies showed that K(+)-depolarization increased  bbbbb1 CaMKIIα eeeee1  phosphorylation in a  bbbbb2 KN-62 eeeee2  sensitive manner and promoted CaMKIIα binding to D3 receptors
CPR:2	Immunoblot studies showed that  bbbbb1 K(+) eeeee1 -depolarization increased  bbbbb2 CaMKIIα eeeee2  phosphorylation in a KN-62 sensitive manner and promoted CaMKIIα binding to D3 receptors
CPR:2	Presynaptic  bbbbb1 CaMKIIα eeeee1  modulates dopamine D3 receptor activation in striatonigral terminals of the rat brain in a  bbbbb2 Ca(2+) eeeee2  dependent manner
CPR:2	Presynaptic CaMKIIα modulates  bbbbb1 dopamine D3 receptor eeeee1  activation in striatonigral terminals of the rat brain in a  bbbbb2 Ca(2+) eeeee2  dependent manner
CPR:4	The selective  bbbbb1 CaMKIIα eeeee1  inhibitor  bbbbb2 KN-62 eeeee2  reversed the blockade produced by ionomycin and K(+)-depolarization
CPR:4	The selective  bbbbb1 CaMKIIα eeeee1  inhibitor KN-62 reversed the blockade produced by  bbbbb2 ionomycin eeeee2  and K(+)-depolarization
CPR:4	In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when  bbbbb1 CaMKIIα eeeee1  was blocked with  bbbbb2 KN-62 eeeee2 
CPR:5	In the presence of this inhibitor, the selective  bbbbb1 D3 eeeee1  agonist  bbbbb2 PD 128,907 eeeee2  reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4 nM
CPR:5	In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the  bbbbb1 D1 eeeee1  agonist  bbbbb2 SKF 38393 eeeee2  from 56 to 4 nM
CPR:3	Additionally, treatment with  bbbbb1 glucose eeeee1 /iron showed a higher  bbbbb2 HO eeeee2  activity
CPR:3	Additionally, treatment with glucose/ bbbbb1 iron eeeee1  showed a higher  bbbbb2 HO eeeee2  activity
CPR:3	The  bbbbb1 Bcl2 eeeee1 /Bax ratio increased and Mfn2 expression decreased in MIN6 cells after  bbbbb2 glucose eeeee2  stimulation
CPR:3	The Bcl2/ bbbbb1 Bax eeeee1  ratio increased and Mfn2 expression decreased in MIN6 cells after  bbbbb2 glucose eeeee2  stimulation
CPR:3	Our study revealed that high  bbbbb1 glucose eeeee1 /Fe concentrations in MIN6 cells induced an increase of the  bbbbb2 Bcl2 eeeee2 /Bax ratio, an indicator of increased cell apoptosis.
CPR:3	Our study revealed that high  bbbbb1 glucose eeeee1 /Fe concentrations in MIN6 cells induced an increase of the Bcl2/ bbbbb2 Bax eeeee2  ratio, an indicator of increased cell apoptosis.
CPR:3	Our study revealed that high glucose/ bbbbb1 Fe eeeee1  concentrations in MIN6 cells induced an increase of the  bbbbb2 Bcl2 eeeee2 /Bax ratio, an indicator of increased cell apoptosis.
CPR:3	Our study revealed that high glucose/ bbbbb1 Fe eeeee1  concentrations in MIN6 cells induced an increase of the Bcl2/ bbbbb2 Bax eeeee2  ratio, an indicator of increased cell apoptosis.
CPR:4	The Bcl2/Bax ratio increased and  bbbbb1 Mfn2 eeeee1  expression decreased in MIN6 cells after  bbbbb2 glucose eeeee2  stimulation
CPR:9	Targeted disruption of the gene encoding the  bbbbb1 N-glycosyltransferase eeeee1 , prlH, abolished  bbbbb2 pyralomicin eeeee2  production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.
CPR:9	Targeted disruption of the gene encoding the N-glycosyltransferase,  bbbbb1 prlH eeeee1 , abolished  bbbbb2 pyralomicin eeeee2  production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.
CPR:9	Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of  bbbbb1 PrlA eeeee1  confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the  bbbbb2 C7 eeeee2 -cyclitol moiety.
CPR:9	Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a  bbbbb1 sugar phosphate cyclase eeeee1  involved in the formation of the  bbbbb2 C7 eeeee2 -cyclitol moiety.
CPR:9	Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of  bbbbb1 PrlA eeeee1  confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7- bbbbb2 cyclitol eeeee2  moiety.
CPR:9	Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a  bbbbb1 sugar phosphate cyclase eeeee1  involved in the formation of the C7- bbbbb2 cyclitol eeeee2  moiety.
CPR:9	This includes  bbbbb1 nonribosomal peptide synthetases eeeee1  (NRPS) and polyketide synthases (PKS) required for the formation of the  bbbbb2 benzopyranopyrrole eeeee2  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CPR:9	This includes nonribosomal peptide synthetases ( bbbbb1 NRPS eeeee1 ) and polyketide synthases (PKS) required for the formation of the  bbbbb2 benzopyranopyrrole eeeee2  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CPR:9	This includes nonribosomal peptide synthetases (NRPS) and  bbbbb1 polyketide synthases eeeee1  (PKS) required for the formation of the  bbbbb2 benzopyranopyrrole eeeee2  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CPR:9	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases ( bbbbb1 PKS eeeee1 ) required for the formation of the  bbbbb2 benzopyranopyrrole eeeee2  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CPR:9	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the  bbbbb1 benzopyranopyrrole eeeee1  core unit, as well as a suite of tailoring enzymes (e.g., four  bbbbb2 halogenases eeeee2 , an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CPR:9	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the  bbbbb1 benzopyranopyrrole eeeee1  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  bbbbb2 O-methyltransferase eeeee2 , and an N-glycosyltransferase) necessary for further modifications of the core structure
CPR:9	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the  bbbbb1 benzopyranopyrrole eeeee1  core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  bbbbb2 N-glycosyltransferase eeeee2 ) necessary for further modifications of the core structure
CPR:2	Here, we report that  bbbbb1 synaptotagmin-1 eeeee1  is necessary for expression of the vesicular  bbbbb2 Ca(2+) eeeee2  /H(+) -antiport
CPR:2	Here, we report that  bbbbb1 synaptotagmin-1 eeeee1  is necessary for expression of the vesicular Ca(2+) / bbbbb2 H(+) eeeee2  -antiport
CPR:2	The results were congruent and highly significant:  bbbbb1 Ca(2+) eeeee1  /H(+) -antiport activity is detectable only in acidic organelles expressing functional  bbbbb2 synaptotagmin-1 eeeee2 
CPR:2	The results were congruent and highly significant: Ca(2+) / bbbbb1 H(+) eeeee1  -antiport activity is detectable only in acidic organelles expressing functional  bbbbb2 synaptotagmin-1 eeeee2 
CPR:2	 bbbbb1 Synaptotagmin 1 eeeee1  is required for vesicular  bbbbb2 Ca(2+) eeeee2  /H(+) -antiport activity
CPR:2	 bbbbb1 Synaptotagmin 1 eeeee1  is required for vesicular Ca(2+) / bbbbb2 H(+) eeeee2  -antiport activity
CPR:2	Therefore, in addition to its previously described functions,  bbbbb1 synaptotagmin-1 eeeee1  is involved in a rapid vesicular  bbbbb2 Ca(2+) eeeee2  sequestration through a Ca(2+) /H(+) antiport
CPR:2	Therefore, in addition to its previously described functions,  bbbbb1 synaptotagmin-1 eeeee1  is involved in a rapid vesicular Ca(2+) sequestration through a  bbbbb2 Ca(2+) eeeee2  /H(+) antiport
CPR:2	Therefore, in addition to its previously described functions,  bbbbb1 synaptotagmin-1 eeeee1  is involved in a rapid vesicular Ca(2+) sequestration through a Ca(2+) / bbbbb2 H(+) eeeee2  antiport
CPR:2	 bbbbb1 Synaptotagmin-1 eeeee1 , a vesicular protein interacting with membranes upon low-affinity  bbbbb2 Ca(2+) eeeee2  -binding, plays a major role in excitation-release coupling, by synchronizing calcium entry with fast neurotransmitter release
CPR:2	 bbbbb1 Synaptotagmin-1 eeeee1 , a vesicular protein interacting with membranes upon low-affinity Ca(2+) -binding, plays a major role in excitation-release coupling, by synchronizing  bbbbb2 calcium eeeee2  entry with fast neurotransmitter release
CPR:2	Estradiol replacement enhances  bbbbb1 cocaine eeeee1 -stimulated locomotion in female C57BL/6 mice through  bbbbb2 estrogen receptor alpha eeeee2 
CPR:2	These results suggest that E2 enhances  bbbbb1 cocaine eeeee1 -stimulated locomotion in mice predominantly through  bbbbb2 ERα eeeee2 .
CPR:5	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the  bbbbb1 ERα eeeee1 -selective agonist  bbbbb2 PPT eeeee2  or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates
CPR:5	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the  bbbbb1 ERβ eeeee1 -selective agonist  bbbbb2 DPN eeeee2  were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates
CPR:9	The  bbbbb1 Intermediate-conductance Calcium-activated Potassium Channel KCa3.1 eeeee1  Regulates Vascular Smooth Muscle Cell Proliferation via Controlling  bbbbb2 Calcium eeeee2 -dependent Signaling
CPR:5	The current study examined the bioactivation potential of  bbbbb1 ghrelin receptor eeeee1  inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and  bbbbb2 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone eeeee2  (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure
CPR:5	The current study examined the bioactivation potential of  bbbbb1 ghrelin receptor eeeee1  inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused  bbbbb2 imidazo[2,1-b]thiazole eeeee2  motif in the core structure
CPR:5	The current study examined the bioactivation potential of  bbbbb1 ghrelin receptor eeeee1  inverse agonists,  bbbbb2 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone eeeee2  (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure
CPR:5	Reactive Metabolite Trapping Studies on  bbbbb1 Imidazo- and 2-Methylimidazo[2,1-b]thiazole eeeee1 -based Inverse Agonists of the  bbbbb2 Ghrelin Receptor eeeee2 
CPR:2	Moreover, the active permethylated  bbbbb1 vancomycin eeeee1  aglycon derivatives examined exhibit  bbbbb2 VanB eeeee2  VRE antimicrobial activity at levels that approach (typically within 2-fold) their activity against sensitive bacteria
CPR:2	 bbbbb1 DEHP eeeee1  exposure significantly decreased the levels of these four FAs only in pregnant  bbbbb2 mPPARα eeeee2  mice
CPR:2	Taken together, the levels of plasma four FAs with shorter carbon chains were higher in pregnant mPPARα mice than in other genotypes, and  bbbbb1 DEHP eeeee1  exposure decreased these specific FA concentrations only in  bbbbb2 mPPARα eeeee2  mice, similarly to triglyceride levels.
CPR:2	Interestingly,  bbbbb1 polySia eeeee1  chains of secreted  bbbbb2 NCAM eeeee2  neutralized the cytotoxic activity of extracellular histones as well as DNA/histone-network-containing "neutrophil extracellular traps", which are formed during invasion of microorganisms
CPR:2	In mature lung tissue of healthy donors,  bbbbb1 polySia eeeee1  was exclusively attached to the transmembrane isoform  bbbbb2 NCAM-140 eeeee2  and located to intracellular compartments of epithelial cells
CPR:2	As shown in a cell culture model,  bbbbb1 polySia eeeee1 - bbbbb2 NCAM-140 eeeee2  was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM
CPR:2	Interestingly,  bbbbb1 polySia eeeee1  chains of secreted NCAM neutralized the cytotoxic activity of extracellular  bbbbb2 histones eeeee2  as well as DNA/histone-network-containing "neutrophil extracellular traps", which are formed during invasion of microorganisms
CPR:2	Interestingly,  bbbbb1 polySia eeeee1  chains of secreted NCAM neutralized the cytotoxic activity of extracellular histones as well as DNA/ bbbbb2 histone eeeee2 -network-containing "neutrophil extracellular traps", which are formed during invasion of microorganisms
CPR:2	Processing of  bbbbb1 polysialylated NCAM eeeee1  was reproduced in a mouse model by  bbbbb2 bleomycin eeeee2  administration leading to an activation of the inflammasome and secretion of interleukin (IL)-1β
CPR:2	Posttranslational modification of the  bbbbb1 neural cell adhesion molecule eeeee1  (NCAM) by polysialic acid ( bbbbb2 polySia eeeee2 ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity
CPR:2	Posttranslational modification of the neural cell adhesion molecule ( bbbbb1 NCAM eeeee1 ) by polysialic acid ( bbbbb2 polySia eeeee2 ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity
CPR:2	Posttranslational modification of the  bbbbb1 neural cell adhesion molecule eeeee1  (NCAM) by  bbbbb2 polysialic acid eeeee2  (polySia) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity
CPR:2	Posttranslational modification of the neural cell adhesion molecule ( bbbbb1 NCAM eeeee1 ) by  bbbbb2 polysialic acid eeeee2  (polySia) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity
CPR:3	Processing of polysialylated NCAM was reproduced in a mouse model by  bbbbb1 bleomycin eeeee1  administration leading to an activation of the inflammasome and secretion of  bbbbb2 interleukin (IL)-1β eeeee2 
CPR:2	 bbbbb1 Vildagliptin eeeee1 +metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR,  bbbbb2 glucagon eeeee2  and insulin resistance measurements
CPR:2	 bbbbb1 Vildagliptin eeeee1 +metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and  bbbbb2 insulin eeeee2  resistance measurements
CPR:2	Vildagliptin+ bbbbb1 metformin eeeee1  were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR,  bbbbb2 glucagon eeeee2  and insulin resistance measurements
CPR:2	Vildagliptin+ bbbbb1 metformin eeeee1  were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and  bbbbb2 insulin eeeee2  resistance measurements
CPR:2	Vildagliptin+metformin were more effective than placebo+ bbbbb1 metformin eeeee1  in reducing body weight and BMI, glycemic control, HOMA-IR,  bbbbb2 glucagon eeeee2  and insulin resistance measurements
CPR:2	Vildagliptin+metformin were more effective than placebo+ bbbbb1 metformin eeeee1  in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and  bbbbb2 insulin eeeee2  resistance measurements
CPR:2	We also recorded a significant correlation between M value increase and the decrease of  bbbbb1 vaspin eeeee1 , visfatin, and omentin-1 obtained with  bbbbb2 vildagliptin eeeee2 +metformin
CPR:2	We also recorded a significant correlation between M value increase and the decrease of vaspin,  bbbbb1 visfatin eeeee1 , and omentin-1 obtained with  bbbbb2 vildagliptin eeeee2 +metformin
CPR:2	We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and  bbbbb1 omentin-1 eeeee1  obtained with  bbbbb2 vildagliptin eeeee2 +metformin
CPR:2	We also recorded a significant correlation between M value increase and the decrease of  bbbbb1 vaspin eeeee1 , visfatin, and omentin-1 obtained with vildagliptin+ bbbbb2 metformin eeeee2 
CPR:2	We also recorded a significant correlation between M value increase and the decrease of vaspin,  bbbbb1 visfatin eeeee1 , and omentin-1 obtained with vildagliptin+ bbbbb2 metformin eeeee2 
CPR:2	We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and  bbbbb1 omentin-1 eeeee1  obtained with vildagliptin+ bbbbb2 metformin eeeee2 
CPR:2	 bbbbb1 Vildagliptin eeeee1 , in addition to metformin, proved to be effective in improving β-cell function and in reducing  bbbbb2 insulin eeeee2  resistance measurements.
CPR:2	Vildagliptin, in addition to  bbbbb1 metformin eeeee1 , proved to be effective in improving β-cell function and in reducing  bbbbb2 insulin eeeee2  resistance measurements.
CPR:10	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα).  bbbbb1 4-Hydroxytamoxifen eeeee1  (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of  bbbbb2 cyclin E eeeee2  and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CPR:10	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen ( bbbbb1 OHT eeeee1 , tamoxifen's active form) failed to prevent E2-induced proteolysis of  bbbbb2 cyclin E eeeee2  and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CPR:10	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT,  bbbbb1 tamoxifen eeeee1 's active form) failed to prevent E2-induced proteolysis of  bbbbb2 cyclin E eeeee2  and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CPR:2	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα).  bbbbb1 4-Hydroxytamoxifen eeeee1  (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered  bbbbb2 cyclin E eeeee2  cleavage coincident with augmented migration
CPR:2	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen ( bbbbb1 OHT eeeee1 , tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered  bbbbb2 cyclin E eeeee2  cleavage coincident with augmented migration
CPR:2	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT,  bbbbb1 tamoxifen eeeee1 's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered  bbbbb2 cyclin E eeeee2  cleavage coincident with augmented migration
CPR:2	 bbbbb1 OHT eeeee1 -induced  bbbbb2 cyclin E eeeee2  truncation also occurred in SK-BR-3 cells that express GPR30 and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor ERα
CPR:2	Furthermore,  bbbbb1 OHT eeeee1 -stimulated cleavage of  bbbbb2 cyclin E eeeee2  and migration were tremendously attenuated by G15, a GPR30 antagonist, or siRNA against GPR30
CPR:2	In addition, inhibitors for EGFR or ERK1/2 remarkably suppressed  bbbbb1 OHT eeeee1 -induced truncation of  bbbbb2 cyclin E eeeee2 , suggesting involvement of EGFR signaling
CPR:2	In addition, inhibitors for EGFR or ERK1/2 remarkably suppressed  bbbbb1 OHT eeeee1 -induced truncation of cyclin E, suggesting involvement of  bbbbb2 EGFR eeeee2  signaling
CPR:2	 bbbbb1 OHT eeeee1 -induced cyclin E truncation also occurred in SK-BR-3 cells that express  bbbbb2 GPR30 eeeee2  and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor ERα
CPR:2	 bbbbb1 4-Hydroxytamoxifen eeeee1 -stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 ( bbbbb2 GPR30) eeeee2  and accompanied by enhanced migration in MCF-7 breast cancer cells
CPR:2	 bbbbb1 4-Hydroxytamoxifen eeeee1 -stimulated processing of cyclin E is mediated via  bbbbb2 G protein-coupled receptor 30 eeeee2  (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells
CPR:2	Collectively, our data indicate that  bbbbb1 OHT eeeee1  contributes to the production of proteolyzed cyclin E via  bbbbb2 GPR30 eeeee2  with augmented migration in MCF-7 cells.
CPR:3	 bbbbb1 4-Hydroxytamoxifen eeeee1 -stimulated processing of  bbbbb2 cyclin E eeeee2  is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells
CPR:3	Over-expression of cleaved cyclin E in breast tumors is closely associated with tumor progression and resistance to antiestrogens.  bbbbb1 17β-Estradiol eeeee1  (E2) has been recently shown to induce  bbbbb2 cyclin E eeeee2  processing in breast cancer cells
CPR:3	Collectively, our data indicate that  bbbbb1 OHT eeeee1  contributes to the production of proteolyzed  bbbbb2 cyclin E eeeee2  via GPR30 with augmented migration in MCF-7 cells.
CPR:1	NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these  bbbbb1 cysteines eeeee1  during  bbbbb2 hSOD1 eeeee2  copper acquisition
CPR:2	We recently showed that the first domain of  bbbbb1 human CCS eeeee1  (hCCSD1) is responsible for  bbbbb2 copper eeeee2  transfer to its protein partner, human SOD1 (hSOD1)
CPR:2	We recently showed that the first domain of human CCS ( bbbbb1 hCCSD1 eeeee1 ) is responsible for  bbbbb2 copper eeeee2  transfer to its protein partner, human SOD1 (hSOD1)
CPR:2	We recently showed that the first domain of human CCS (hCCSD1) is responsible for  bbbbb1 copper eeeee1  transfer to its protein partner,  bbbbb2 human SOD1 eeeee2  (hSOD1)
CPR:2	We recently showed that the first domain of human CCS (hCCSD1) is responsible for  bbbbb1 copper eeeee1  transfer to its protein partner, human SOD1 ( bbbbb2 hSOD1 eeeee2 )
CPR:2	The NMR solution structure of the  bbbbb1 copper(I) eeeee1 -loaded form of  bbbbb2 hCCSD1 eeeee2  reported here contributes further to characterization of the copper-transfer mechanism to hSOD1
CPR:2	Together, the information on both hCCS and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the  bbbbb1 copper eeeee1 -transfer process from  bbbbb2 hCCS eeeee2  to hSOD1.
CPR:2	Together, the information on both hCCS and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the  bbbbb1 copper eeeee1 -transfer process from hCCS to  bbbbb2 hSOD1 eeeee2 .
CPR:2	Mechanistic Aspects of  bbbbb1 hSOD1 eeeee1  Maturation from the Solution Structure of  bbbbb2 Cu(I) eeeee2  -Loaded hCCS Domain 1 and Analysis of Disulfide-Free hSOD1 Mutants
CPR:2	Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of  bbbbb1 Cu(I) eeeee1  -Loaded  bbbbb2 hCCS Domain 1 eeeee2  and Analysis of Disulfide-Free hSOD1 Mutants
CPR:2	Design, Synthesis and Biological Evaluation of  bbbbb1 Aminoalkylindole eeeee1  Derivatives as  bbbbb2 Cannabinoid Receptor eeeee2  Ligands with Potential for Treatment of Alcohol Abuse
CPR:5	In the current study, we show that systematic modification of an  bbbbb1 aminoalkylindole eeeee1  scaffold identifies two new compounds with dual CB1R antagonist/ bbbbb2 CB2R eeeee2  agonist activity
CPR:5	Collectively, these initial findings suggest that design and systematic modification of  bbbbb1 aminoalkylindoles eeeee1  such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/ bbbbb2 CB2R eeeee2  agonist activity with potential for use as treatments of alcohol abuse.
CPR:6	We have recently reported that a mono-hydroxylated metabolite of the synthetic  bbbbb1 aminoalkylindole eeeee1  cannabinoid JHW-073 (3) exhibits neutral antagonist activity at  bbbbb2 CB1Rs eeeee2  and thus may serve as a promising lead for the development of novel alcohol abuse therapies
CPR:6	We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid  bbbbb1 JHW-073 eeeee1  (3) exhibits neutral antagonist activity at  bbbbb2 CB1Rs eeeee2  and thus may serve as a promising lead for the development of novel alcohol abuse therapies
CPR:6	In the current study, we show that systematic modification of an  bbbbb1 aminoalkylindole eeeee1  scaffold identifies two new compounds with dual  bbbbb2 CB1R eeeee2  antagonist/CB2R agonist activity
CPR:6	Collectively, these initial findings suggest that design and systematic modification of  bbbbb1 aminoalkylindoles eeeee1  such as 3 may lead to development of novel cannabinoid ligands with dual  bbbbb2 CB1R eeeee2  antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.
CPR:2	Immunoregulatory effects of  bbbbb1 Glycyrrhizic acid eeeee1  exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in  bbbbb2 ovalbumin eeeee2 -sensitized mice
CPR:2	Immunoregulatory effects of  bbbbb1 Glycyrrhizic acid eeeee1  exerts anti-asthmatic effects via modulation of Th1/Th2  bbbbb2 cytokines eeeee2  and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in ovalbumin-sensitized mice
CPR:4	The improved survival rates for obese mice chronically treated with  bbbbb1 vildagliptin eeeee1  suggest that chronic  bbbbb2 DPP4 eeeee2  inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.
CPR:4	METHODS: After 1 month of HFD alone, the mice were given the  bbbbb1 DPP4 eeeee1  inhibitor  bbbbb2 vildagliptin eeeee2  for a further 11 months
CPR:4	Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the  bbbbb1 dipeptidyl peptidase-4 eeeee1  inhibitor  bbbbb2 vildagliptin eeeee2  in an advanced-aged diet-induced obesity mouse model
CPR:9	Protein levels of the  bbbbb1 glucose transporter eeeee1  (GLUT4) involved in  bbbbb2 glucose eeeee2  transport via these two pathways were also increased
CPR:9	Protein levels of the glucose transporter ( bbbbb1 GLUT4 eeeee1 ) involved in  bbbbb2 glucose eeeee2  transport via these two pathways were also increased
CPR:2	Using small interfering double-stranded RNA technology, we further demonstrate that the effects of  bbbbb1 puerarin eeeee1  on proliferation, differentiation and survival are mediated by both  bbbbb2 ERα eeeee2  and ERβ
CPR:2	Using small interfering double-stranded RNA technology, we further demonstrate that the effects of  bbbbb1 puerarin eeeee1  on proliferation, differentiation and survival are mediated by both ERα and  bbbbb2 ERβ eeeee2 
CPR:2	Here we show that puerarin increases proliferation and differentiation and opposes  bbbbb1 cisplatin eeeee1 -induced apoptosis in human osteoblastic MG-63 cells containing two  bbbbb2 estrogen receptor eeeee2  (ER) isoforms
CPR:2	Here we show that puerarin increases proliferation and differentiation and opposes  bbbbb1 cisplatin eeeee1 -induced apoptosis in human osteoblastic MG-63 cells containing two estrogen receptor ( bbbbb2 ER eeeee2 ) isoforms
CPR:2	Treatment with the  bbbbb1 ER eeeee1  antagonist ICI 182,780 abolishes the above actions of  bbbbb2 puerarin eeeee2  on osteoblast-derived cells
CPR:2	 bbbbb1 Puerarin eeeee1  stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via  bbbbb2 ER eeeee2 -dependent MEK/ERK and PI3K/Akt activation
CPR:2	Here we show that  bbbbb1 puerarin eeeee1  increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two  bbbbb2 estrogen receptor eeeee2  (ER) isoforms
CPR:2	Here we show that  bbbbb1 puerarin eeeee1  increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two estrogen receptor ( bbbbb2 ER eeeee2 ) isoforms
CPR:3	 bbbbb1 Puerarin eeeee1  stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent  bbbbb2 MEK eeeee2 /ERK and PI3K/Akt activation
CPR:3	 bbbbb1 Puerarin eeeee1  stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ bbbbb2 ERK eeeee2  and PI3K/Akt activation
CPR:3	 bbbbb1 Puerarin eeeee1  stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and  bbbbb2 PI3K eeeee2 /Akt activation
CPR:3	 bbbbb1 Puerarin eeeee1  stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/ bbbbb2 Akt eeeee2  activation
CPR:3	Moreover, we also demonstrate that  bbbbb1 puerarin eeeee1  functions at least partially through activation of  bbbbb2 MEK eeeee2 /ERK and PI3K/Akt signaling
CPR:3	Moreover, we also demonstrate that  bbbbb1 puerarin eeeee1  functions at least partially through activation of MEK/ bbbbb2 ERK eeeee2  and PI3K/Akt signaling
CPR:3	Puerarin promotes proliferation by altering cell cycle distribution whereas  bbbbb1 puerarin eeeee1 -mediated survival may be associated with up-regulation of  bbbbb2 Bcl-xL eeeee2  expression
CPR:3	Moreover, we also demonstrate that  bbbbb1 puerarin eeeee1  functions at least partially through activation of MEK/ERK and  bbbbb2 PI3K eeeee2 /Akt signaling
CPR:3	Moreover, we also demonstrate that  bbbbb1 puerarin eeeee1  functions at least partially through activation of MEK/ERK and PI3K/ bbbbb2 Akt eeeee2  signaling
CPR:6	Treatment with the  bbbbb1 ER eeeee1  antagonist  bbbbb2 ICI 182,780 eeeee2  abolishes the above actions of puerarin on osteoblast-derived cells
CPR:2	The preventive effect of uncarboxylated osteocalcin against  bbbbb1 free fatty acid eeeee1 -induced endothelial apoptosis through the activation of  bbbbb2 phosphatidylinositol 3-kinase eeeee2 /Akt signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis
CPR:2	The preventive effect of uncarboxylated osteocalcin against  bbbbb1 free fatty acid eeeee1 -induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/ bbbbb2 Akt eeeee2  signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis
CPR:4	RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the  bbbbb1 phosphatidylinositol 3-kinase eeeee1  (PI3-kinase) inhibitor,  bbbbb2 wortmannin eeeee2 
CPR:4	RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase ( bbbbb1 PI3-kinase eeeee1 ) inhibitor,  bbbbb2 wortmannin eeeee2 
CPR:2	Chronic exposure to  bbbbb1 oxyfluorfen eeeee1  provoked then structural changes but also functional changes in the capacity of biofilm  bbbbb2 CAT eeeee2  activity to respond to a sudden increase in concentration, suggesting a selection of species with higher antioxidant capacity
CPR:3	In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1)  bbbbb1 oxyfluorfen eeeee1  showed a higher  bbbbb2 CAT eeeee2  activity than controls
CPR:6	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using  bbbbb1 D1 eeeee1 /D5 ( bbbbb2 SCH23390 eeeee2 ), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CPR:6	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/ bbbbb1 D5 eeeee1  ( bbbbb2 SCH23390 eeeee2 ), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CPR:6	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390),  bbbbb1 D2 eeeee1 /D3 ( bbbbb2 raclopride eeeee2 , amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CPR:6	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/ bbbbb1 D3 eeeee1  ( bbbbb2 raclopride eeeee2 , amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CPR:6	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390),  bbbbb1 D2 eeeee1 /D3 (raclopride,  bbbbb2 amisulpride eeeee2 ) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CPR:6	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/ bbbbb1 D3 eeeee1  (raclopride,  bbbbb2 amisulpride eeeee2 ) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CPR:6	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and  bbbbb1 D3 eeeee1  ( bbbbb2 S33084 eeeee2 ) receptor antagonists, and by using D2 receptor knockout mice
CPR:1	These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of  bbbbb1 rpS6 eeeee1  at  bbbbb2 Ser eeeee2 240/244, in a subpopulation of striatal MSNs expressing D2Rs
CPR:2	 bbbbb1 Haloperidol eeeee1  promotes  bbbbb2 mTORC1 eeeee2 -dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1
CPR:2	 bbbbb1 Haloperidol eeeee1  promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via  bbbbb2 dopamine- and cAMP-regulated phosphoprotein of 32 kDa eeeee2  and inhibition of protein phosphatase-1
CPR:2	These results show that  bbbbb1 haloperidol eeeee1  promotes  bbbbb2 mTORC1 eeeee2 - and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs
CPR:2	These results show that  bbbbb1 haloperidol eeeee1  promotes mTORC1- and  bbbbb2 S6K1 eeeee2 -dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs
CPR:2	These results show that  bbbbb1 haloperidol eeeee1  promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing  bbbbb2 D2Rs eeeee2 
CPR:2	Administration of  bbbbb1 haloperidol eeeee1  increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express  bbbbb2 dopamine D2 receptors eeeee2  (D2Rs)
CPR:2	Administration of  bbbbb1 haloperidol eeeee1  increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors ( bbbbb2 D2Rs eeeee2 )
CPR:3	 bbbbb1 Haloperidol eeeee1  promotes mTORC1-dependent phosphorylation of  bbbbb2 ribosomal protein S6 eeeee2  via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1
CPR:3	These results show that  bbbbb1 haloperidol eeeee1  promotes mTORC1- and S6K1-dependent phosphorylation of  bbbbb2 rpS6 eeeee2  at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs
CPR:4	This effect was prevented by  bbbbb1 rapamycin eeeee1 , an inhibitor of the  bbbbb2 mammalian target of rapamycin complex 1 eeeee2  (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)
CPR:4	This effect was prevented by  bbbbb1 rapamycin eeeee1 , an inhibitor of the mammalian target of rapamycin complex 1 ( bbbbb2 mTORC1 eeeee2 ), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)
CPR:4	This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by  bbbbb1 PF470867 eeeee1 , a selective inhibitor of the  bbbbb2 p70 ribosomal S6 kinase 1 eeeee2  (S6K1)
CPR:4	This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by  bbbbb1 PF470867 eeeee1 , a selective inhibitor of the p70 ribosomal S6 kinase 1 ( bbbbb2 S6K1 eeeee2 )
CPR:4	In line with this observation, incubation of striatal slices with  bbbbb1 okadaic acid eeeee1  and calyculin A, two inhibitors of  bbbbb2 PP-1 eeeee2 , increased Ser240/244 phosphorylation
CPR:4	 bbbbb1 Haloperidol eeeee1  promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of  bbbbb2 protein phosphatase-1 eeeee2 
CPR:4	In line with this observation, incubation of striatal slices with okadaic acid and  bbbbb1 calyculin A eeeee1 , two inhibitors of  bbbbb2 PP-1 eeeee2 , increased Ser240/244 phosphorylation
CPR:1	These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the  bbbbb1 Arg-Gly-Asp eeeee1  (RGD) sequence of  bbbbb2 fibrinogen eeeee2  to obtain designed multiple ligands with potential antithrombotic activity
CPR:4	These compounds resulted from our efforts to merge the pharmacophores of selective  bbbbb1 factor Xa eeeee1  inhibitor  bbbbb2 rivaroxaban eeeee2  with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity
CPR:4	Resulting from this study, a structurally novel class of submicromolar fibrinogen  bbbbb1 GPIIb/IIIa eeeee1  binding inhibitor bearing  bbbbb2 1,2,4-oxadiazol-5(4H)-one eeeee2  moiety is also described.
CPR:3	The  bbbbb1 caspase-3 eeeee1  immunopositivity was increased in degenerating neurons of the  bbbbb2 Cd eeeee2  group
CPR:4	Rats intoxicated with  bbbbb1 Cd eeeee1  for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants  bbbbb2 superoxide dismutase eeeee2 , glutathione peroxidase and catalase in the frontal cortex tissue
CPR:4	Rats intoxicated with  bbbbb1 Cd eeeee1  for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase,  bbbbb2 glutathione peroxidase eeeee2  and catalase in the frontal cortex tissue
CPR:4	Rats intoxicated with  bbbbb1 Cd eeeee1  for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and  bbbbb2 catalase eeeee2  in the frontal cortex tissue
CPR:4	In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the  bbbbb1 sodium iodide symporter eeeee1 , was significantly inhibited by  bbbbb2 17beta-oestradiol eeeee2 .In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells
CPR:2	The editing of  bbbbb1 ndhD-2 eeeee1  is also completely lost in albino mutants and  bbbbb2 norflurazon eeeee2 -treated seedlings
CPR:2	In addition, the expression of nucleus-encoded  bbbbb1 RNA polymerase eeeee1  dependent transcripts is specifically induced by  bbbbb2 lincomycin eeeee2 , and the splicing of ndhB transcripts is significantly reduced in the albino mutants and inhibitor-treated seedlings
CPR:2	In addition, the expression of nucleus-encoded RNA polymerase dependent transcripts is specifically induced by  bbbbb1 lincomycin eeeee1 , and the splicing of  bbbbb2 ndhB eeeee2  transcripts is significantly reduced in the albino mutants and inhibitor-treated seedlings
CPR:2	By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of  bbbbb1 ndhB-149 eeeee1 , ndhB-1255, and ndhD-2 is completely lost in roots and in  bbbbb2 lincomycin eeeee2 -treated seedlings
CPR:2	By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of ndhB-149,  bbbbb1 ndhB-1255 eeeee1 , and ndhD-2 is completely lost in roots and in  bbbbb2 lincomycin eeeee2 -treated seedlings
CPR:2	By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of ndhB-149, ndhB-1255, and  bbbbb1 ndhD-2 eeeee1  is completely lost in roots and in  bbbbb2 lincomycin eeeee2 -treated seedlings
CPR:4	Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent  bbbbb1 CYP3A eeeee1  inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or  bbbbb2 boceprevir eeeee2 , and therefore their coadministration is contraindicated
CPR:4	All HIV PIs except nelfinavir are coadministered with a low dose of  bbbbb1 ritonavir eeeee1 , a potent  bbbbb2 CYP3A eeeee2  inhibitor to improve their pharmacokinetic properties
CPR:4	The HCV-PIs  bbbbb1 boceprevir eeeee1  and telaprevir are both, to different extents, inhibitors of  bbbbb2 CYP3A eeeee2 
CPR:4	The HCV-PIs boceprevir and  bbbbb1 telaprevir eeeee1  are both, to different extents, inhibitors of  bbbbb2 CYP3A eeeee2 
CPR:4	Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent  bbbbb1 CYP3A eeeee1  inhibitors such as  bbbbb2 ritonavir eeeee2 - or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CPR:4	Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent  bbbbb1 CYP3A eeeee1  inhibitors such as ritonavir- or  bbbbb2 cobicistat eeeee2 -boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CPR:4	Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent  bbbbb1 CYP3A eeeee1  inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI,  bbbbb2 telaprevir eeeee2  or boceprevir, and therefore their coadministration is contraindicated
CPR:9	 bbbbb1 Atorvastatin eeeee1  is also a  bbbbb2 CYP3A eeeee2  substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors
CPR:9	Drug-drug interactions are dependent on statins' pharmacokinetic profile:  bbbbb1 simvastatin eeeee1 , lovastatin and atorvastatin are metabolized through  bbbbb2 cytochrome P450 (CYP) 3A eeeee2 , while the metabolism of the other statins is independent of this CYP
CPR:9	Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin,  bbbbb1 lovastatin eeeee1  and atorvastatin are metabolized through  bbbbb2 cytochrome P450 (CYP) 3A eeeee2 , while the metabolism of the other statins is independent of this CYP
CPR:9	Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and  bbbbb1 atorvastatin eeeee1  are metabolized through  bbbbb2 cytochrome P450 (CYP) 3A eeeee2 , while the metabolism of the other statins is independent of this CYP
CPR:9	 bbbbb1 Simvastatin eeeee1  and lovastatin metabolized through  bbbbb2 CYP3A eeeee2  have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CPR:9	Simvastatin and  bbbbb1 lovastatin eeeee1  metabolized through  bbbbb2 CYP3A eeeee2  have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CPR:4	The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective  bbbbb1 anaplastic lymphoma kinase eeeee1  inhibitor 15b ( bbbbb2 LDK378 eeeee2 ) are described
CPR:4	In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation  bbbbb1 ALK eeeee1  inhibitor 4 ( bbbbb2 TAE684 eeeee2 )
CPR:10	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant  bbbbb1 BDZ eeeee1  which does not bind to high affinity  bbbbb2 BDZ receptors eeeee2  (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CPR:10	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity  bbbbb1 BDZ receptors eeeee1  ( bbbbb2 Ro 5-4864 eeeee2 ) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CPR:10	These findings suggest that limitation of SRF was produced by binding of BDZs, but not  bbbbb1 beta CCs eeeee1 , to  bbbbb2 voltage-dependent sodium channels eeeee2  and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation
CPR:10	These findings suggest that limitation of SRF was produced by binding of BDZs, but not  bbbbb1 beta CCs eeeee1 , to voltage-dependent sodium channels and not to high affinity central  bbbbb2 BDZ receptors eeeee2 , and that BDZs limit SRF by slowing recovery of sodium channels from inactivation
CPR:2	These findings suggest that limitation of SRF was produced by binding of  bbbbb1 BDZs eeeee1 , but not beta CCs, to  bbbbb2 voltage-dependent sodium channels eeeee2  and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation
CPR:2	These findings suggest that limitation of SRF was produced by binding of  bbbbb1 BDZs eeeee1 , but not beta CCs, to voltage-dependent sodium channels and not to high affinity central  bbbbb2 BDZ receptors eeeee2 , and that BDZs limit SRF by slowing recovery of sodium channels from inactivation
CPR:2	The limitation of SRF by  bbbbb1 diazepam eeeee1  was not prevented by inverse or partial agonists at the  bbbbb2 BDZ receptor eeeee2 , including Ro 15-1788 and the beta CCs
CPR:3	These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that  bbbbb1 BDZs eeeee1  limit SRF by slowing recovery of  bbbbb2 sodium channels eeeee2  from inactivation
CPR:5	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb1 BDZ receptor eeeee1  weak partial agonist ( bbbbb2 Ro 15-1788 eeeee2 ) at micromolar concentrations
CPR:5	The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  bbbbb1 BDZ receptor eeeee1 , including  bbbbb2 Ro 15-1788 eeeee2  and the beta CCs
CPR:5	The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  bbbbb1 BDZ receptor eeeee1 , including Ro 15-1788 and the  bbbbb2 beta CCs eeeee2 
CPR:5	The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  bbbbb1 BDZ receptor eeeee1 , including  bbbbb2 Ro 15-1788 eeeee2  and the beta CCs
CPR:5	The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  bbbbb1 BDZ receptor eeeee1 , including Ro 15-1788 and the  bbbbb2 beta CCs eeeee2 
CPR:2	The mitogenic effect of  bbbbb1 DHT eeeee1  on bone cells was inhibited by antiandrogens (hydroxyflutamide and cyproterone acetate) which compete for binding to the  bbbbb2 androgen receptor eeeee2 
CPR:2	The mitogenic effect of DHT on bone cells was inhibited by antiandrogens ( bbbbb1 hydroxyflutamide eeeee1  and cyproterone acetate) which compete for binding to the  bbbbb2 androgen receptor eeeee2 
CPR:2	The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (hydroxyflutamide and  bbbbb1 cyproterone acetate eeeee1 ) which compete for binding to the  bbbbb2 androgen receptor eeeee2 
CPR:2	We conclude that  bbbbb1 androgens eeeee1  can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker ALP, presumably by an  bbbbb2 androgen receptor eeeee2  mediated mechanism.
CPR:3	In addition to effects on cell proliferation,  bbbbb1 DHT eeeee1  increased the percentage of  bbbbb2 alkaline phosphatase eeeee2  (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens
CPR:3	In addition to effects on cell proliferation,  bbbbb1 DHT eeeee1  increased the percentage of alkaline phosphatase ( bbbbb2 ALP eeeee2 ) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens
CPR:3	We conclude that  bbbbb1 androgens eeeee1  can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the  bbbbb2 osteoblast-line differentiation marker eeeee2  ALP, presumably by an androgen receptor mediated mechanism.
CPR:3	We conclude that  bbbbb1 androgens eeeee1  can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker  bbbbb2 ALP eeeee2 , presumably by an androgen receptor mediated mechanism.
CPR:6	The effect of  bbbbb1 histamine-H1 receptor eeeee1  antagonism with  bbbbb2 terfenadine eeeee2  on concentration-related AMP-induced bronchoconstriction in asthma
CPR:2	Given its efficacy and tolerability, once-daily, oral  bbbbb1 ibrutinib eeeee1  is an emerging treatment option for patients with relapsed/refractory MCL or CLL and CLL patients with del 17p or  bbbbb2 TP53 eeeee2  mutation.
CPR:2	Oral  bbbbb1 ibrutinib eeeee1  is indicated for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or  bbbbb2 TP53 eeeee2  mutation
CPR:4	 bbbbb1 Ibrutinib eeeee1  (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits  bbbbb2 B-cell antigen receptor eeeee2  signalling downstream of BTK
CPR:4	Ibrutinib ( bbbbb1 Imbruvica(R) eeeee1 ) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits  bbbbb2 B-cell antigen receptor eeeee2  signalling downstream of BTK
CPR:4	 bbbbb1 Ibrutinib eeeee1  (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase ( bbbbb2 BTK eeeee2 ) that inhibits B-cell antigen receptor signalling downstream of BTK
CPR:4	 bbbbb1 Ibrutinib eeeee1  (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of  bbbbb2 BTK eeeee2 
CPR:4	 bbbbb1 Ibrutinib eeeee1  (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of  bbbbb2 Bruton's tyrosine kinase eeeee2  (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK
CPR:4	Ibrutinib ( bbbbb1 Imbruvica(R) eeeee1 ) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase ( bbbbb2 BTK eeeee2 ) that inhibits B-cell antigen receptor signalling downstream of BTK
CPR:4	Ibrutinib ( bbbbb1 Imbruvica(R) eeeee1 ) is a first-in-class, potent, orally administered, covalent inhibitor of  bbbbb2 Bruton's tyrosine kinase eeeee2  (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK
CPR:10	 bbbbb1 Alprenolol eeeee1  treatment (4 X 100 mg/day) led to a rapid fall in PRA, but did not significantly affect  bbbbb2 beta 2-adrenoceptor eeeee2  density
CPR:2	The affinity of  bbbbb1 ICYP eeeee1  to  bbbbb2 beta 2-adrenoceptors eeeee2  was not changed during or after treatment
CPR:3	 bbbbb1 Propranolol eeeee1  treatment (4 X 40 mg/day) increased the density of  bbbbb2 beta 2-adrenoceptors eeeee2  by 25% after 2 days; concomitantly PRA and heart rate were reduced
CPR:4	 bbbbb1 Mepindolol eeeee1  treatment (2 X 5 mg/day) caused a 30% decrease of  bbbbb2 beta 2-adrenoceptor eeeee2  density and PRA after 2 days; both parameters remained reduced during treatment
CPR:6	To study the mechanism underlying this phenomenon, the effects of the nonselective  bbbbb1 beta-adrenoceptor eeeee1  antagonists  bbbbb2 propranolol eeeee2  [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CPR:6	To study the mechanism underlying this phenomenon, the effects of the nonselective  bbbbb1 beta-adrenoceptor eeeee1  antagonists propranolol [no intrinsic sympathomimetic activity (ISA)],  bbbbb2 alprenolol eeeee2  (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CPR:6	To study the mechanism underlying this phenomenon, the effects of the nonselective  bbbbb1 beta-adrenoceptor eeeee1  antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and  bbbbb2 mepindolol eeeee2  (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CPR:4	Inhibition of  bbbbb1 5-lipoxygenase eeeee1  pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and  bbbbb2 5-aminosalicylic acid eeeee2 
CPR:4	Inhibition of  bbbbb1 5-lipoxygenase eeeee1  pathway of arachidonic acid metabolism in human neutrophils by  bbbbb2 sulfasalazine eeeee2  and 5-aminosalicylic acid
CPR:4	Interference with  bbbbb1 lipoxygenase eeeee1  enzymes, rather than a  bbbbb2 steroid eeeee2 -like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.
CPR:9	Inhibition of  bbbbb1 5-lipoxygenase eeeee1  pathway of  bbbbb2 arachidonic acid eeeee2  metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid
CPR:9	Interference with  bbbbb1 lipoxygenase eeeee1  enzymes, rather than a steroid-like inhibition of  bbbbb2 arachidonic acid eeeee2  release from intracellular phospholipids, seems to be the mode of action.
CPR:2	Evidence has been obtained in man for interaction with  bbbbb1 alpha-adrenoceptors eeeee1  in the brain; and in the peripheral circulation  bbbbb2 bevantolol eeeee2  does not, as do other beta blockers, increase peripheral vascular resistance, but reduces it
CPR:5	It is suggested that all the additional actions of  bbbbb1 bevantolol eeeee1  can be attributed to a partial agonist action on  bbbbb2 alpha-adrenoceptors eeeee2 .
CPR:6	UNLABELLED:  bbbbb1 Bevantolol eeeee1  is a  bbbbb2 beta-1 adrenoceptor eeeee2  antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension
CPR:6	 bbbbb1 Bevantolol eeeee1 : a  bbbbb2 beta-1 adrenoceptor eeeee2  antagonist with unique additional actions
CPR:2	 bbbbb1 Benzodiazepine receptor eeeee1  binding of  bbbbb2 triazolobenzodiazepines eeeee2  in vivo: increased receptor number with low-dose alprazolam
CPR:2	The apparent affinity of  bbbbb1 benzodiazepine receptors eeeee1  for  bbbbb2 clonazepam eeeee2  in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)
CPR:2	 bbbbb1 Benzodiazepine receptor eeeee1  binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose  bbbbb2 alprazolam eeeee2 
CPR:2	The apparent affinity of  bbbbb1 benzodiazepine receptors eeeee1  for clonazepam in mice receiving  bbbbb2 alprazolam eeeee2  (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)
CPR:3	The apparent affinity of  bbbbb1 benzodiazepine receptors eeeee1  for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of  bbbbb2 alprazolam eeeee2  increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)
CPR:2	In vitro binding affinities of chlorpromazine,  bbbbb1 fluphenazine eeeee1 , levomepromazine, perphenazine and some of their metabolites for  bbbbb2 dopamine D2 receptors eeeee2 , alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories
CPR:2	Chlorpromazine,  bbbbb1 levomepromazine eeeee1 , and their metabolites had 5-30 times higher binding affinities for  bbbbb2 muscarinic cholinergic receptors eeeee2  than fluphenazine, perphenazine and their metabolites
CPR:2	Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for  bbbbb1 muscarinic cholinergic receptors eeeee1  than  bbbbb2 fluphenazine eeeee2 , perphenazine and their metabolites
CPR:2	In vitro binding affinities of chlorpromazine, fluphenazine,  bbbbb1 levomepromazine eeeee1 , perphenazine and some of their metabolites for  bbbbb2 dopamine D2 receptors eeeee2 , alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories
CPR:2	Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for  bbbbb1 muscarinic cholinergic receptors eeeee1  than fluphenazine,  bbbbb2 perphenazine eeeee2  and their metabolites
CPR:2	 bbbbb1 Levomepromazine eeeee1  was the most potent and fluphenazine the least potent of the four drugs in  bbbbb2 histamine H1 receptor eeeee2  binding. 7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in histamine H1 receptor binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system
CPR:2	Levomepromazine was the most potent and  bbbbb1 fluphenazine eeeee1  the least potent of the four drugs in  bbbbb2 histamine H1 receptor eeeee2  binding. 7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in histamine H1 receptor binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system
CPR:2	Levomepromazine was the most potent and fluphenazine the least potent of the four drugs in histamine H1 receptor binding.  bbbbb1 7-Hydroxy levomepromazine eeeee1 , 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in  bbbbb2 histamine H1 receptor eeeee2  binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system
CPR:2	In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine,  bbbbb1 perphenazine eeeee1  and some of their metabolites for  bbbbb2 dopamine D2 receptors eeeee2 , alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories
CPR:2	Levomepromazine was the most potent and fluphenazine the least potent of the four drugs in histamine H1 receptor binding. 7-Hydroxy levomepromazine,  bbbbb1 3-hydroxy levomepromazine eeeee1  and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in  bbbbb2 histamine H1 receptor eeeee2  binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system
CPR:2	Levomepromazine was the most potent and fluphenazine the least potent of the four drugs in histamine H1 receptor binding. 7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and  bbbbb1 7-hydroxy fluphenazine eeeee1  had only 10% of the potency of the parent drug in  bbbbb2 histamine H1 receptor eeeee2  binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system
CPR:2	Levomepromazine was the most potent and fluphenazine the least potent of the four drugs in histamine H1 receptor binding. 7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in  bbbbb1 histamine H1 receptor eeeee1  binding, while the  bbbbb2 7-hydroxy eeeee2 -metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system
CPR:2	Levomepromazine was the most potent and fluphenazine the least potent of the four drugs in histamine H1 receptor binding. 7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in  bbbbb1 histamine H1 receptor eeeee1  binding, while the 7-hydroxy-metabolites of  bbbbb2 chlorpromazine eeeee2  and perphenazine had about 75% of the potency of the parent drug in this binding system
CPR:2	Levomepromazine was the most potent and fluphenazine the least potent of the four drugs in histamine H1 receptor binding. 7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in  bbbbb1 histamine H1 receptor eeeee1  binding, while the 7-hydroxy-metabolites of chlorpromazine and  bbbbb2 perphenazine eeeee2  had about 75% of the potency of the parent drug in this binding system
CPR:2	Muscarinic cholinergic and  bbbbb1 histamine H1 receptor eeeee1  binding of  bbbbb2 phenothiazine eeeee2  drug metabolites
CPR:2	Their  bbbbb1 histamine H1 receptor eeeee1  binding affinities indicate that metabolites may contribute to the sedative effects of  bbbbb2 chlorpromazine eeeee2  and levomepromazine.
CPR:2	Their  bbbbb1 histamine H1 receptor eeeee1  binding affinities indicate that metabolites may contribute to the sedative effects of chlorpromazine and  bbbbb2 levomepromazine eeeee2 .
CPR:2	In vitro binding affinities of  bbbbb1 chlorpromazine eeeee1 , fluphenazine, levomepromazine, perphenazine and some of their metabolites for  bbbbb2 dopamine D2 receptors eeeee2 , alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories
CPR:2	The present study reports the in vitro binding affinities of the same compounds for  bbbbb1 muscarinic cholinergic receptors eeeee1  and for histamine H1 receptors in rat brain, using  bbbbb2 3H-quinuclidinyl benzilate eeeee2  and 3H-mepyramine as radioligands
CPR:2	The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for  bbbbb1 histamine H1 receptors eeeee1  in rat brain, using  bbbbb2 3H-quinuclidinyl benzilate eeeee2  and 3H-mepyramine as radioligands
CPR:2	The present study reports the in vitro binding affinities of the same compounds for  bbbbb1 muscarinic cholinergic receptors eeeee1  and for histamine H1 receptors in rat brain, using 3H-quinuclidinyl benzilate and  bbbbb2 3H-mepyramine eeeee2  as radioligands
CPR:2	The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for  bbbbb1 histamine H1 receptors eeeee1  in rat brain, using 3H-quinuclidinyl benzilate and  bbbbb2 3H-mepyramine eeeee2  as radioligands
CPR:2	 bbbbb1 Chlorpromazine eeeee1 , levomepromazine, and their metabolites had 5-30 times higher binding affinities for  bbbbb2 muscarinic cholinergic receptors eeeee2  than fluphenazine, perphenazine and their metabolites
CPR:10	In contrast, serum  bbbbb1 alkaline phosphatase eeeee1  was elevated in animals dosed with 13cisRA or 4HPR but not in those dose with  bbbbb2 ROAc eeeee2 
CPR:10	The  bbbbb1 retinoids eeeee1  had no effect on  bbbbb2 prothrombin eeeee2  times of animals fed the supplemented diet
CPR:10	This effect was observed as early as Day 7 and was accompanied by one confirmed hemorrhagic death.  bbbbb1 13cisRA eeeee1 -dosed animals showed no change in  bbbbb2 prothrombin eeeee2  times
CPR:2	Hence, the degree of retinoid-induced hemorrhage, but not the incidence of bone fractures, was inversely related to vitamin K levels in the diet. 13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma  bbbbb1 osteocalcin eeeee1 , an effect that correlated with  bbbbb2 retinoid eeeee2 -induced bone effects
CPR:2	Hence, plasma  bbbbb1 osteocalcin eeeee1  is a better predictor of  bbbbb2 retinoid eeeee2 -induced bone effects than serum alkaline phosphatase.
CPR:2	Hence, plasma osteocalcin is a better predictor of  bbbbb1 retinoid eeeee1 -induced bone effects than serum  bbbbb2 alkaline phosphatase eeeee2 .
CPR:2	For all  bbbbb1 retinoid eeeee1 -dosed groups maintained on the purified diet, changes in  bbbbb2 prothrombin eeeee2  times occured as early as 1 week
CPR:3	In contrast, serum  bbbbb1 alkaline phosphatase eeeee1  was elevated in animals dosed with  bbbbb2 13cisRA eeeee2  or 4HPR but not in those dose with ROAc
CPR:3	In contrast, serum  bbbbb1 alkaline phosphatase eeeee1  was elevated in animals dosed with 13cisRA or  bbbbb2 4HPR eeeee2  but not in those dose with ROAc
CPR:3	When menadione was omitted from the diet, however,  bbbbb1 4HPR eeeee1 -dosed animals had elevated  bbbbb2 prothrombin eeeee2  times
CPR:3	In the high-dose  bbbbb1 ROAc eeeee1  group, there was a twofold increase in  bbbbb2 prothrombin eeeee2  times but only after prolonged dosing
CPR:3	The order of effect was  bbbbb1 4HPR eeeee1  greater than ROAc greater than 13cisRA, with increases in  bbbbb2 prothrombin eeeee2  times correlating with increases in hemorrhagic deaths
CPR:3	The order of effect was 4HPR greater than  bbbbb1 ROAc eeeee1  greater than 13cisRA, with increases in  bbbbb2 prothrombin eeeee2  times correlating with increases in hemorrhagic deaths
CPR:3	The order of effect was 4HPR greater than ROAc greater than  bbbbb1 13cisRA eeeee1 , with increases in  bbbbb2 prothrombin eeeee2  times correlating with increases in hemorrhagic deaths
CPR:4	Hence, the degree of retinoid-induced hemorrhage, but not the incidence of bone fractures, was inversely related to vitamin K levels in the diet.  bbbbb1 13cisRA eeeee1  and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma  bbbbb2 osteocalcin eeeee2 , an effect that correlated with retinoid-induced bone effects
CPR:4	Hence, the degree of retinoid-induced hemorrhage, but not the incidence of bone fractures, was inversely related to vitamin K levels in the diet. 13cisRA and  bbbbb1 ROAc eeeee1 , but not 4HPR, caused a dose-dependent reduction in plasma  bbbbb2 osteocalcin eeeee2 , an effect that correlated with retinoid-induced bone effects
CPR:4	Hence, the degree of retinoid-induced hemorrhage, but not the incidence of bone fractures, was inversely related to vitamin K levels in the diet. 13cisRA and ROAc, but not  bbbbb1 4HPR eeeee1 , caused a dose-dependent reduction in plasma  bbbbb2 osteocalcin eeeee2 , an effect that correlated with retinoid-induced bone effects
CPR:2	Multiple affinity states of  bbbbb1 opiate receptor eeeee1  can be demonstrated further by Scatchard analysis of saturation binding studies with  bbbbb2 [3H]DADLE eeeee2 
CPR:2	These multiple affinity states of receptor in the hybrid cells are agonist-specific, and the percentage of total  bbbbb1 opiate receptor eeeee1  in high affinity state is relatively constant in various concentrations of  bbbbb2 Na+ eeeee2 
CPR:4	However, in the presence of 100 mM  bbbbb1 Na+ eeeee1 , which is required for opiate inhibition of  bbbbb2 adenylate cyclase eeeee2  activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM
CPR:10	In contrast to diethylcarbamazine,  bbbbb1 piriprost eeeee1  (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the  bbbbb2 leukotriene synthetase eeeee2  of these cells
CPR:10	In contrast to diethylcarbamazine, piriprost ( bbbbb1 U-60,257 eeeee1 ; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the  bbbbb2 leukotriene synthetase eeeee2  of these cells
CPR:10	In contrast to diethylcarbamazine, piriprost (U-60,257;  bbbbb1 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1 eeeee1 ), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the  bbbbb2 leukotriene synthetase eeeee2  of these cells
CPR:2	Kinetic analysis revealed that the inhibition of the  bbbbb1 leukotriene C synthetase eeeee1  reaction by diethylcarbamazine was competitive with respect to  bbbbb2 LTA4 eeeee2 
CPR:4	Kinetic analysis revealed that the inhibition of the  bbbbb1 leukotriene C synthetase eeeee1  reaction by  bbbbb2 diethylcarbamazine eeeee2  was competitive with respect to LTA4
CPR:4	In contrast to  bbbbb1 diethylcarbamazine eeeee1 , piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the  bbbbb2 5-lipoxygenase eeeee2  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells
CPR:4	In contrast to  bbbbb1 diethylcarbamazine eeeee1 , piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the  bbbbb2 leukotriene synthetase eeeee2  of these cells
CPR:4	In contrast to diethylcarbamazine,  bbbbb1 piriprost eeeee1  (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the  bbbbb2 5-lipoxygenase eeeee2  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells
CPR:4	In contrast to diethylcarbamazine, piriprost ( bbbbb1 U-60,257 eeeee1 ; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the  bbbbb2 5-lipoxygenase eeeee2  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells
CPR:4	In contrast to diethylcarbamazine, piriprost (U-60,257;  bbbbb1 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1 eeeee1 ), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the  bbbbb2 5-lipoxygenase eeeee2  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells
CPR:4	Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between  bbbbb1 diethylcarbamazine eeeee1  and piriprost, a  bbbbb2 5-lipoxygenase eeeee2  inhibitor
CPR:4	Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and  bbbbb1 piriprost eeeee1 , a  bbbbb2 5-lipoxygenase eeeee2  inhibitor
CPR:4	Inhibition of the  bbbbb1 leukotriene synthetase eeeee1  of rat basophil leukemia cells by  bbbbb2 diethylcarbamazine eeeee2 , and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor
CPR:9	Similar concentrations also inhibited the formation of  bbbbb1 leukotriene C4 eeeee1  (LTC4) by  bbbbb2 LTC synthetase eeeee2 , a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione
CPR:9	Similar concentrations also inhibited the formation of leukotriene C4 ( bbbbb1 LTC4 eeeee1 ) by  bbbbb2 LTC synthetase eeeee2 , a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione
CPR:9	In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of  bbbbb1 sulfidopeptide leuktrienes eeeee1  in RBL cells at the  bbbbb2 5-lipoxygenase eeeee2  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells
CPR:9	These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of  bbbbb1 LTA4 eeeee1  in the  bbbbb2 leukotriene C synthetase eeeee2  reaction.
CPR:9	Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by  bbbbb1 LTC synthetase eeeee1 , a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling  bbbbb2 LTA4 eeeee2  to glutathione
CPR:9	The EC50 for inhibition of the  bbbbb1 leukotriene C synthetase eeeee1  of RBL cells was directly proportional to the  bbbbb2 LTA4 eeeee2  concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4
CPR:9	The test procedure was verified with respect to intestinal  bbbbb1 lactose eeeee1  hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal  bbbbb2 lactase eeeee2  activity by in vitro assay (R2 = 0.95) in a further group of subjects
CPR:9	The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between  bbbbb1 lactose eeeee1 /lactulose excretion and log jejunal mucosal  bbbbb2 lactase eeeee2  activity by in vitro assay (R2 = 0.95) in a further group of subjects
CPR:9	The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/ bbbbb1 lactulose eeeee1  excretion and log jejunal mucosal  bbbbb2 lactase eeeee2  activity by in vitro assay (R2 = 0.95) in a further group of subjects
CPR:9	Differential  bbbbb1 lactose eeeee1 /lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal  bbbbb2 lactase eeeee2  deficiency.
CPR:9	Differential lactose/ bbbbb1 lactulose eeeee1 /L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal  bbbbb2 lactase eeeee2  deficiency.
CPR:9	Differential lactose/lactulose/ bbbbb1 L-rhamnose eeeee1  absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal  bbbbb2 lactase eeeee2  deficiency.
CPR:10	The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as  bbbbb1 prazosin eeeee1 , yohimbine and clonidine failed to bind to  bbbbb2 calmodulin eeeee2  when examined under the same experimental conditions
CPR:10	The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin,  bbbbb1 yohimbine eeeee1  and clonidine failed to bind to  bbbbb2 calmodulin eeeee2  when examined under the same experimental conditions
CPR:10	The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and  bbbbb1 clonidine eeeee1  failed to bind to  bbbbb2 calmodulin eeeee2  when examined under the same experimental conditions
CPR:10	In addition,  bbbbb1 phenoxybenzamine eeeee1  showed little or no calcium-dependent binding to the  bbbbb2 S-100 protein eeeee2 , bovine serum albumin or cytochrome c
CPR:10	In addition,  bbbbb1 phenoxybenzamine eeeee1  showed little or no calcium-dependent binding to the S-100 protein,  bbbbb2 bovine serum albumin eeeee2  or cytochrome c
CPR:10	In addition,  bbbbb1 phenoxybenzamine eeeee1  showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or  bbbbb2 cytochrome c eeeee2 
CPR:2	The site at which  bbbbb1 phenoxybenzamine eeeee1  bound to  bbbbb2 calmodulin eeeee2  appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin
CPR:2	To determine the factors that influence the interaction between  bbbbb1 phenoxybenzamine eeeee1  and  bbbbb2 calmodulin eeeee2 , the binding of phenoxybenzamine to calmodulin was determined by equilibrium dialysis under a variety of experimental conditions
CPR:2	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including  bbbbb1 penfluridol eeeee1 , pimozide and spiroperidol, prevented the binding of phenoxybenzamine to  bbbbb2 calmodulin eeeee2 
CPR:2	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol,  bbbbb1 pimozide eeeee1  and spiroperidol, prevented the binding of phenoxybenzamine to  bbbbb2 calmodulin eeeee2 
CPR:2	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and  bbbbb1 spiroperidol eeeee1 , prevented the binding of phenoxybenzamine to  bbbbb2 calmodulin eeeee2 
CPR:2	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of  bbbbb1 phenoxybenzamine eeeee1  to  bbbbb2 calmodulin eeeee2 
CPR:2	However, in contrast to the reversible binding of most  bbbbb1 phenothiazines eeeee1  to  bbbbb2 calmodulin eeeee2 , phenoxybenzamine bound to calmodulin irreversibly
CPR:2	However, in contrast to the reversible binding of most phenothiazines to calmodulin,  bbbbb1 phenoxybenzamine eeeee1  bound to  bbbbb2 calmodulin eeeee2  irreversibly
CPR:2	The binding of  bbbbb1 phenoxybenzamine eeeee1  to  bbbbb2 calmodulin eeeee2  was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions
CPR:2	Characteristics of the binding of  bbbbb1 phenoxybenzamine eeeee1  to  bbbbb2 calmodulin eeeee2 
CPR:2	To determine the factors that influence the interaction between phenoxybenzamine and calmodulin, the binding of  bbbbb1 phenoxybenzamine eeeee1  to  bbbbb2 calmodulin eeeee2  was determined by equilibrium dialysis under a variety of experimental conditions
CPR:2	In addition, phenoxybenzamine showed little or no  bbbbb1 calcium eeeee1 -dependent binding to the S-100 protein, bovine serum albumin or  bbbbb2 cytochrome c eeeee2 
CPR:2	The irreversible complex between  bbbbb1 phenoxybenzamine eeeee1  and  bbbbb2 calmodulin eeeee2  may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.
CPR:2	This interaction was found to be similar in some respects to the interaction between  bbbbb1 phenothiazines eeeee1  and  bbbbb2 calmodulin eeeee2 
CPR:2	The binding of phenoxybenzamine to calmodulin was fairly selective in that other  bbbbb1 alpha-adrenergic eeeee1  agents such as  bbbbb2 prazosin eeeee2 , yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions
CPR:2	The binding of phenoxybenzamine to calmodulin was fairly selective in that other  bbbbb1 alpha-adrenergic eeeee1  agents such as prazosin,  bbbbb2 yohimbine eeeee2  and clonidine failed to bind to calmodulin when examined under the same experimental conditions
CPR:2	The binding of phenoxybenzamine to calmodulin was fairly selective in that other  bbbbb1 alpha-adrenergic eeeee1  agents such as prazosin, yohimbine and  bbbbb2 clonidine eeeee2  failed to bind to calmodulin when examined under the same experimental conditions
CPR:2	In addition, phenoxybenzamine showed little or no  bbbbb1 calcium eeeee1 -dependent binding to the  bbbbb2 S-100 protein eeeee2 , bovine serum albumin or cytochrome c
CPR:2	In addition, phenoxybenzamine showed little or no  bbbbb1 calcium eeeee1 -dependent binding to the S-100 protein,  bbbbb2 bovine serum albumin eeeee2  or cytochrome c
CPR:4	The irreversible complex between  bbbbb1 phenoxybenzamine eeeee1  and calmodulin may be useful for inhibiting certain  bbbbb2 calmodulin eeeee2 -dependent reactions and for studying the various biological functions of calmodulin.
CPR:2	The following was demonstrated in the rat and confirmed in man: interaction of  bbbbb1 Anandron eeeee1  with the  bbbbb2 prostatic androgen receptor eeeee2 , antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens
CPR:2	Replacement of the methyl groups of theophylline with  bbbbb1 n-propyl eeeee1  or larger alkyl groups yields xanthines with selectivity for  bbbbb2 A1 receptors eeeee2 , particularly when combined with an 8-phenyl moiety
CPR:2	Replacement of the methyl groups of theophylline with n-propyl or larger  bbbbb1 alkyl eeeee1  groups yields xanthines with selectivity for  bbbbb2 A1 receptors eeeee2 , particularly when combined with an 8-phenyl moiety
CPR:2	Replacement of the methyl groups of theophylline with n-propyl or larger alkyl groups yields  bbbbb1 xanthines eeeee1  with selectivity for  bbbbb2 A1 receptors eeeee2 , particularly when combined with an 8-phenyl moiety
CPR:2	Replacement of the methyl groups of theophylline with n-propyl or larger alkyl groups yields xanthines with selectivity for  bbbbb1 A1 receptors eeeee1 , particularly when combined with an  bbbbb2 8-phenyl eeeee2  moiety
CPR:2	Certain analogs of  bbbbb1 caffeine eeeee1  in which the methyl group at the 1- or 7-position is replaced with a propargyl or propyl group display selectivity for  bbbbb2 A2 receptors eeeee2 
CPR:2	Certain analogs of caffeine in which the  bbbbb1 methyl eeeee1  group at the 1- or 7-position is replaced with a propargyl or propyl group display selectivity for  bbbbb2 A2 receptors eeeee2 
CPR:2	Certain analogs of caffeine in which the methyl group at the 1- or 7-position is replaced with a propargyl or  bbbbb1 propyl eeeee1  group display selectivity for  bbbbb2 A2 receptors eeeee2 
CPR:2	The profile of a series of  bbbbb1 adenosine eeeee1  analogs or of xanthine antagonists can be used to define the nature of  bbbbb2 adenosine receptors eeeee2 .
CPR:2	The profile of a series of adenosine analogs or of  bbbbb1 xanthine eeeee1  antagonists can be used to define the nature of  bbbbb2 adenosine receptors eeeee2 .
CPR:2	 bbbbb1 Adenosine eeeee1  analogs in particular the N6-substituted compounds are more potent at  bbbbb2 A1 receptors eeeee2  than at A2 receptors
CPR:2	 bbbbb1 Adenosine eeeee1  analogs in particular the N6-substituted compounds are more potent at A1 receptors than at  bbbbb2 A2 receptors eeeee2 
CPR:2	Adenosine analogs in particular the  bbbbb1 N6 eeeee1 -substituted compounds are more potent at  bbbbb2 A1 receptors eeeee2  than at A2 receptors
CPR:2	Adenosine analogs in particular the  bbbbb1 N6 eeeee1 -substituted compounds are more potent at A1 receptors than at  bbbbb2 A2 receptors eeeee2 
CPR:2	Certain of the  bbbbb1 adenosine eeeee1  conjugates are highly selective for  bbbbb2 A1 receptors eeeee2 
CPR:2	The subregion of the  bbbbb1 adenosine receptor eeeee1  that interacts with the  bbbbb2 N6 eeeee2 -substituent is different for A1 and A2 receptors, particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity
CPR:2	The subregion of the  bbbbb1 adenosine receptor eeeee1  that interacts with the N6-substituent is different for A1 and A2 receptors, particularly with respect to  bbbbb2 phenyl eeeee2  interactions, bulk tolerance and stereoselectivity
CPR:2	Replacement of the  bbbbb1 methyl eeeee1  groups of theophylline with n-propyl or larger alkyl groups yields xanthines with selectivity for  bbbbb2 A1 receptors eeeee2 , particularly when combined with an 8-phenyl moiety
CPR:2	Replacement of the methyl groups of  bbbbb1 theophylline eeeee1  with n-propyl or larger alkyl groups yields xanthines with selectivity for  bbbbb2 A1 receptors eeeee2 , particularly when combined with an 8-phenyl moiety
CPR:4	 bbbbb1 Xanthines eeeee1  are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of  bbbbb2 adenosine receptors eeeee2 
CPR:6	 bbbbb1 Xanthines eeeee1  are classical antagonists for  bbbbb2 adenosine receptors eeeee2  for many of their pharmacological actions may be due to blockade of adenosine receptors
CPR:10	Co-incubation with human serum albumin or poly-L-lysine but not lysine protected  bbbbb1 human and hamster LDH-X eeeee1  from  bbbbb2 gossypol eeeee2 .
CPR:10	Co-incubation with human serum albumin or poly-L-lysine but not  bbbbb1 lysine eeeee1  protected  bbbbb2 human and hamster LDH-X eeeee2  from gossypol.
CPR:2	Co-incubation with human serum albumin or  bbbbb1 poly-L-lysine eeeee1  but not lysine protected  bbbbb2 human and hamster LDH-X eeeee2  from gossypol.
CPR:4	Inhibition of testicular  bbbbb1 LDH-X eeeee1  from laboratory animals and man by  bbbbb2 gossypol eeeee2  and its isomers
CPR:4	 bbbbb1 Gossypol acetic acid eeeee1  (0-100 mumol/l) inhibited  bbbbb2 LDH-X eeeee2  prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster
CPR:4	The inhibitory effect of  bbbbb1 (+)-, (-)-, (+/-)-gossypol eeeee1  and (+/-)-gossypol acetic acid upon testicular cytosolic  bbbbb2 LDH-X eeeee2  was measured in vitro
CPR:4	 bbbbb1 Gossypol eeeee1  and its isomers were non-competitive inhibitors of  bbbbb2 human and hamster LDH-X eeeee2  with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate
CPR:4	The inhibitory effect of (+)-, (-)-, (+/-)-gossypol and  bbbbb1 (+/-)-gossypol acetic acid eeeee1  upon testicular cytosolic  bbbbb2 LDH-X eeeee2  was measured in vitro
CPR:4	Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme  bbbbb1 NADH eeeee1 , competitive inhibitors of  bbbbb2 human LDH-X eeeee2  and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate
CPR:9	Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of  bbbbb1 hamster LDH-X eeeee1  with respect to the substrate  bbbbb2 alpha-ketobutyrate eeeee2 
CPR:4	Most reducing cofactors for the peroxidase protect  bbbbb1 PHS eeeee1  and prostacyclin synthase from inactivation by  bbbbb2 hydroperoxides eeeee2 
CPR:4	Most reducing cofactors for the peroxidase protect PHS and  bbbbb1 prostacyclin synthase eeeee1  from inactivation by  bbbbb2 hydroperoxides eeeee2 
CPR:4	Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of  bbbbb1 PHS eeeee1  is markedly increased in the presence of 100 microM  bbbbb2 H2O2 eeeee2 
CPR:4	Inactivation of  bbbbb1 prostaglandin H synthase eeeee1  and prostacyclin synthase by  bbbbb2 phenylbutazone eeeee2 
CPR:4	Inactivation of prostaglandin H synthase and  bbbbb1 prostacyclin synthase eeeee1  by  bbbbb2 phenylbutazone eeeee2 
CPR:8	Phenylbutazone ( bbbbb1 PB eeeee1 ), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of  bbbbb2 prostaglandin H synthase eeeee2  (PHS)
CPR:8	Phenylbutazone ( bbbbb1 PB eeeee1 ), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase ( bbbbb2 PHS eeeee2 )
CPR:8	 bbbbb1 Phenylbutazone eeeee1  (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of  bbbbb2 prostaglandin H synthase eeeee2  (PHS)
CPR:8	 bbbbb1 Phenylbutazone eeeee1  (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase ( bbbbb2 PHS eeeee2 )
CPR:8	Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that  bbbbb1 PB eeeee1 -dependent inactivation of  bbbbb2 PHS eeeee2  is markedly increased in the presence of 100 microM H2O2
CPR:9	Chromatographic analysis of the metabolism of  bbbbb1 14C-labeled arachidonic acid eeeee1  in this system revealed that PB-dependent inactivation of  bbbbb2 PHS eeeee2  is markedly increased in the presence of 100 microM H2O2
CPR:2	Isolation and characterization of labeled peptides from  bbbbb1 phenoxybenzamine eeeee1 -modified  bbbbb2 calmodulins eeeee2  indicated that peptides encompassing residues 38-75, 107-126, and 127-148 contained phenoxybenzamine label
CPR:2	Isolation and characterization of labeled peptides from phenoxybenzamine-modified  bbbbb1 calmodulins eeeee1  indicated that peptides encompassing residues 38-75, 107-126, and 127-148 contained  bbbbb2 phenoxybenzamine eeeee2  label
CPR:2	Drug-protein interactions: isolation and characterization of covalent adducts of  bbbbb1 phenoxybenzamine eeeee1  and  bbbbb2 calmodulin eeeee2 
CPR:2	 bbbbb1 Phenoxybenzamine eeeee1 , an alpha-adrenergic antagonist containing a (chloroethyl)amine group, labels  bbbbb2 calmodulin eeeee2  in the presence of calcium
CPR:2	Adducts of  bbbbb1 calmodulin eeeee1  and  bbbbb2 phenoxybenzamine eeeee2  were separated by high-performance liquid chromatography into four major fractions: two containing 0.6 and 1.2 mol of drug per mol of protein and two different fractions each containing 2.0 mol/mol
CPR:2	Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the  bbbbb1 chlorpromazine eeeee1  binding capacities of the phenoxybenzamine- bbbbb2 calmodulin eeeee2  adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CPR:2	Phenoxybenzamine, an alpha-adrenergic antagonist containing a  bbbbb1 (chloroethyl)amine eeeee1  group, labels  bbbbb2 calmodulin eeeee2  in the presence of calcium
CPR:2	Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the  bbbbb1 phenoxybenzamine eeeee1 - bbbbb2 calmodulin eeeee2  adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CPR:2	In plasma membranes prepared from these isolated brown fat cells by  bbbbb1 borate eeeee1  extraction there was a similar enrichment of activity of SSAO and of the plasma membrane marker enzyme,  bbbbb2 phosphodiesterase I eeeee2 
CPR:2	 bbbbb1 Amine oxidase eeeee1  activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive ( bbbbb2 clorgyline eeeee2 -resistant) activity at the fat cell membrane
CPR:2	 bbbbb1 Amine oxidase eeeee1  activities in brown adipose tissue of the rat: identification of  bbbbb2 semicarbazide eeeee2 -sensitive (clorgyline-resistant) activity at the fat cell membrane
CPR:3	In plasma membranes prepared from these isolated brown fat cells by  bbbbb1 borate eeeee1  extraction there was a similar enrichment of activity of  bbbbb2 SSAO eeeee2  and of the plasma membrane marker enzyme, phosphodiesterase I
CPR:4	Staining was largely absent when substrate was omitted or after pretreatment with the irreversible  bbbbb1 SSAO eeeee1  inhibitor,  bbbbb2 hydralazine eeeee2  and the slowly reversible inhibitor, semicarbazide
CPR:4	Staining was largely absent when substrate was omitted or after pretreatment with the irreversible  bbbbb1 SSAO eeeee1  inhibitor, hydralazine and the slowly reversible inhibitor,  bbbbb2 semicarbazide eeeee2 
CPR:9	Positive staining of mitochondria was achieved in the presence of the  bbbbb1 MAO eeeee1  substrate,  bbbbb2 tryptamine eeeee2 
CPR:9	Staining around the edges of the brown fat cells was observed with the  bbbbb1 SSAO eeeee1  substrates,  bbbbb2 tyramine eeeee2  and benzylamine
CPR:9	Staining around the edges of the brown fat cells was observed with the  bbbbb1 SSAO eeeee1  substrates, tyramine and  bbbbb2 benzylamine eeeee2 
CPR:2	Binding of  bbbbb1 penicillins eeeee1  to penicillin-binding protein 1Bs produces lysis, binding to  bbbbb2 penicillin-binding protein 2 eeeee2  produces round cells, and binding to penicillin-binding protein 3 produces long filaments
CPR:2	Binding of  bbbbb1 penicillins eeeee1  to penicillin-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to  bbbbb2 penicillin-binding protein 3 eeeee2  produces long filaments
CPR:2	Binding of  bbbbb1 penicillins eeeee1  to  bbbbb2 penicillin-binding protein 1Bs eeeee2  produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments
CPR:2	 bbbbb1 Amdinocillin eeeee1  is a beta-amidino penicillanic acid derivative that binds specifically to  bbbbb2 penicillin-binding protein 2 eeeee2 
CPR:2	Amdinocillin is a  bbbbb1 beta-amidino penicillanic acid eeeee1  derivative that binds specifically to  bbbbb2 penicillin-binding protein 2 eeeee2 
CPR:2	 bbbbb1 Penicillin-binding proteins eeeee1  and role of  bbbbb2 amdinocillin eeeee2  in causing bacterial cell death
CPR:2	The compound is more  bbbbb1 beta-lactamase eeeee1  stable than  bbbbb2 ampicillin eeeee2  and has no major delay in entry into the periplasmic space as do some penicillins
CPR:3	This agent acts synergistically with many  bbbbb1 penicillins eeeee1 , such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  bbbbb2 peptidoglycan eeeee2  of the bacterial cell wall
CPR:3	This agent acts synergistically with many penicillins, such as  bbbbb1 ampicillin eeeee1 , carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  bbbbb2 peptidoglycan eeeee2  of the bacterial cell wall
CPR:3	This agent acts synergistically with many penicillins, such as ampicillin,  bbbbb1 carbenicillin eeeee1 , and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  bbbbb2 peptidoglycan eeeee2  of the bacterial cell wall
CPR:3	This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with  bbbbb1 cephalosporins eeeee1 , cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  bbbbb2 peptidoglycan eeeee2  of the bacterial cell wall
CPR:3	This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins,  bbbbb1 cefazolin eeeee1 , cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  bbbbb2 peptidoglycan eeeee2  of the bacterial cell wall
CPR:3	This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin,  bbbbb1 cefamandole eeeee1 , or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  bbbbb2 peptidoglycan eeeee2  of the bacterial cell wall
CPR:3	This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or  bbbbb1 cefoxitin eeeee1  to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the  bbbbb2 peptidoglycan eeeee2  of the bacterial cell wall
CPR:10	 bbbbb1 W-7 eeeee1  did not induce a loss of cell surface  bbbbb2 beta 2-microglobulin eeeee2 , a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of W-7 was specific for membrane receptors and not a result of bulk depletion of plasma membrane
CPR:2	We have found that certain  bbbbb1 naphthalenesulfonamides eeeee1  [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for  bbbbb2 alpha 2-macroglobulin eeeee2 , and epidermal growth factor (EGF) in fibroblasts
CPR:2	We have found that certain  bbbbb1 naphthalenesulfonamides eeeee1  [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and  bbbbb2 epidermal growth factor eeeee2  (EGF) in fibroblasts
CPR:2	We have found that certain  bbbbb1 naphthalenesulfonamides eeeee1  [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ( bbbbb2 EGF eeeee2 ) in fibroblasts
CPR:2	The extent of  bbbbb1 EGF receptor eeeee1  loss is less than for alpha 2-macroglobulin, and the EGF receptors do not reappear at the surface when  bbbbb2 W-7 eeeee2  is removed
CPR:2	We have found that certain naphthalenesulfonamides [e.g.,  bbbbb1 N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide eeeee1  (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for  bbbbb2 alpha 2-macroglobulin eeeee2 , and epidermal growth factor (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g.,  bbbbb1 N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide eeeee1  (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and  bbbbb2 epidermal growth factor eeeee2  (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g.,  bbbbb1 N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide eeeee1  (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ( bbbbb2 EGF eeeee2 ) in fibroblasts
CPR:2	Loss of alpha 2-macroglobulin and  bbbbb1 epidermal growth factor eeeee1  surface binding induced by phenothiazines and  bbbbb2 naphthalene sulfonamides eeeee2 
CPR:2	Loss of  bbbbb1 alpha 2-macroglobulin eeeee1  and epidermal growth factor surface binding induced by phenothiazines and  bbbbb2 naphthalene sulfonamides eeeee2 
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide ( bbbbb1 W-7 eeeee1 )] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for  bbbbb2 alpha 2-macroglobulin eeeee2 , and epidermal growth factor (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide ( bbbbb1 W-7 eeeee1 )] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and  bbbbb2 epidermal growth factor eeeee2  (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide ( bbbbb1 W-7 eeeee1 )] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ( bbbbb2 EGF eeeee2 ) in fibroblasts
CPR:2	Loss of alpha 2-macroglobulin and  bbbbb1 epidermal growth factor eeeee1  surface binding induced by  bbbbb2 phenothiazines eeeee2  and naphthalene sulfonamides
CPR:2	Loss of  bbbbb1 alpha 2-macroglobulin eeeee1  and epidermal growth factor surface binding induced by  bbbbb2 phenothiazines eeeee2  and naphthalene sulfonamides
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and  bbbbb1 phenothiazines eeeee1  [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for  bbbbb2 alpha 2-macroglobulin eeeee2 , and epidermal growth factor (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and  bbbbb1 phenothiazines eeeee1  [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and  bbbbb2 epidermal growth factor eeeee2  (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and  bbbbb1 phenothiazines eeeee1  [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ( bbbbb2 EGF eeeee2 ) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g.,  bbbbb1 trifluoperazine eeeee1  (TFP)] induce a loss of cell-surface receptors for  bbbbb2 alpha 2-macroglobulin eeeee2 , and epidermal growth factor (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g.,  bbbbb1 trifluoperazine eeeee1  (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and  bbbbb2 epidermal growth factor eeeee2  (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g.,  bbbbb1 trifluoperazine eeeee1  (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ( bbbbb2 EGF eeeee2 ) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine ( bbbbb1 TFP eeeee1 )] induce a loss of cell-surface receptors for  bbbbb2 alpha 2-macroglobulin eeeee2 , and epidermal growth factor (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine ( bbbbb1 TFP eeeee1 )] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and  bbbbb2 epidermal growth factor eeeee2  (EGF) in fibroblasts
CPR:2	We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine ( bbbbb1 TFP eeeee1 )] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ( bbbbb2 EGF eeeee2 ) in fibroblasts
CPR:2	Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using  bbbbb1 rhodamine eeeee1 -labeled  bbbbb2 alpha 2-macroglobulin eeeee2 , we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin
CPR:2	Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of  bbbbb1 rhodamine eeeee1 -labeled  bbbbb2 alpha 2-macroglobulin eeeee2 
CPR:4	Since both  bbbbb1 TFP eeeee1  and W-7 are potent inhibitors of  bbbbb2 calmodulin eeeee2 , we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors
CPR:4	Since both TFP and  bbbbb1 W-7 eeeee1  are potent inhibitors of  bbbbb2 calmodulin eeeee2 , we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors
CPR:4	Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1)  bbbbb1 Promethazine eeeee1 , a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several  bbbbb2 calmodulin eeeee2  functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin
CPR:4	Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a  bbbbb1 phenothiazine eeeee1  that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several  bbbbb2 calmodulin eeeee2  functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin
CPR:4	Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as  bbbbb1 TFP eeeee1  at inhibiting endocytosis; calmidazolium, a potent inhibitor of several  bbbbb2 calmodulin eeeee2  functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin
CPR:2	From these results, it is proposed that  bbbbb1 tyrosine hydroxylase eeeee1  activity determines  bbbbb2 p-HPAA eeeee2  concentrations by regulating p-tyrosine availability
CPR:9	From these results, it is proposed that  bbbbb1 tyrosine hydroxylase eeeee1  activity determines p-HPAA concentrations by regulating  bbbbb2 p-tyrosine eeeee2  availability
CPR:4	The binding of  bbbbb1 FHA eeeee1 -HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists  bbbbb2 diphenhydramine eeeee2  and clemastine
CPR:4	The binding of  bbbbb1 FHA eeeee1 -HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and  bbbbb2 clemastine eeeee2 
CPR:4	The histamine H2 receptor antagonist  bbbbb1 cimetidine eeeee1  blocked the  bbbbb2 FHA eeeee2 -HIS binding on 14-37% of the platelets
CPR:6	The binding of FHA-HIS was inhibited on 35-79% of the platelets by the  bbbbb1 histamine H1 receptor eeeee1  antagonists  bbbbb2 diphenhydramine eeeee2  and clemastine
CPR:6	The binding of FHA-HIS was inhibited on 35-79% of the platelets by the  bbbbb1 histamine H1 receptor eeeee1  antagonists diphenhydramine and  bbbbb2 clemastine eeeee2 
CPR:6	The  bbbbb1 histamine H2 receptor eeeee1  antagonist  bbbbb2 cimetidine eeeee2  blocked the FHA-HIS binding on 14-37% of the platelets
CPR:9	 bbbbb1 Alanine:glyoxylate aminotransferase eeeee1  (AGT) in the liver catalyzes most of the  bbbbb2 glyoxylate eeeee2  transamination in mammalian tissues (E
CPR:9	Alanine:glyoxylate aminotransferase ( bbbbb1 AGT eeeee1 ) in the liver catalyzes most of the  bbbbb2 glyoxylate eeeee2  transamination in mammalian tissues (E
CPR:9	The holo activity of combined peroxisomal and mitochondrial  bbbbb1 AGT 1 eeeee1  with a low Km for  bbbbb2 L-alanine eeeee2  rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days)
CPR:9	The holo activity of AGT 2 with a high Km for  bbbbb1 L-alanine eeeee1  decreased more slowly than  bbbbb2 AGT 1 eeeee2  (by 33% in 14 days, by 60% in 28 days)
CPR:9	The holo activity of  bbbbb1 AGT 2 eeeee1  with a high Km for  bbbbb2 L-alanine eeeee2  decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days)
CPR:4	 bbbbb1 Triclosan eeeee1  inhibited both  bbbbb2 cyclooxygenase 1 eeeee2  and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively
CPR:4	 bbbbb1 Triclosan eeeee1  inhibited both cyclooxygenase 1 and  bbbbb2 cyclo-oxygenase 2 eeeee2  with IC-50 values of 43 microM and 227 microM, respectively
CPR:4	 bbbbb1 Triclosan eeeee1  also inhibited  bbbbb2 5-lipoxygenase eeeee2  with an IC-50 of 43 microM
CPR:4	The  bbbbb1 15-lipoxygenase eeeee1  was similarly inhibited by  bbbbb2 triclosan eeeee2  with an IC-50 of 61 microM
CPR:4	Hence,  bbbbb1 triclosan eeeee1  has the ability to inhibit both the  bbbbb2 cyclo-oxygenase eeeee2  and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy
CPR:4	Hence,  bbbbb1 triclosan eeeee1  has the ability to inhibit both the cyclo-oxygenase and  bbbbb2 lipoxygenase eeeee2  pathways of arachidonic acid metabolism with similar efficacy
CPR:4	In cell culture experiments, it was found that  bbbbb1 triclosan eeeee1  inhibited  bbbbb2 IL-1 beta eeeee2  induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations
CPR:9	In cell culture experiments, it was found that triclosan inhibited  bbbbb1 IL-1 beta eeeee1  induced  bbbbb2 prostaglandin E2 eeeee2  production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations
CPR:9	Hence, triclosan has the ability to inhibit both the  bbbbb1 cyclo-oxygenase eeeee1  and lipoxygenase pathways of  bbbbb2 arachidonic acid eeeee2  metabolism with similar efficacy
CPR:9	Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and  bbbbb1 lipoxygenase eeeee1  pathways of  bbbbb2 arachidonic acid eeeee2  metabolism with similar efficacy
CPR:2	Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin ( bbbbb1 CN-Cbl eeeee1 ) bound to  bbbbb2 transcobalamin II eeeee2  (transcobalamin, TC)
CPR:2	Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin ( bbbbb1 CN-Cbl eeeee1 ) bound to transcobalamin II ( bbbbb2 transcobalamin eeeee2 , TC)
CPR:2	Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin ( bbbbb1 CN-Cbl eeeee1 ) bound to transcobalamin II (transcobalamin,  bbbbb2 TC eeeee2 )
CPR:2	Intracellular protein-bound  bbbbb1 [57Co]Cbl eeeee1  fractionated with  bbbbb2 methionine synthase eeeee2  (MS) and methylmalonyl-CoA mutase (MU) activity
CPR:2	Intracellular protein-bound  bbbbb1 [57Co]Cbl eeeee1  fractionated with methionine synthase ( bbbbb2 MS eeeee2 ) and methylmalonyl-CoA mutase (MU) activity
CPR:2	Intracellular protein-bound  bbbbb1 [57Co]Cbl eeeee1  fractionated with methionine synthase (MS) and  bbbbb2 methylmalonyl-CoA mutase eeeee2  (MU) activity
CPR:2	Intracellular protein-bound  bbbbb1 [57Co]Cbl eeeee1  fractionated with methionine synthase (MS) and methylmalonyl-CoA mutase ( bbbbb2 MU eeeee2 ) activity
CPR:2	Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of  bbbbb1 [57Co]cyanocobalamin eeeee1  (CN-Cbl) bound to  bbbbb2 transcobalamin II eeeee2  (transcobalamin, TC)
CPR:2	Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of  bbbbb1 [57Co]cyanocobalamin eeeee1  (CN-Cbl) bound to transcobalamin II ( bbbbb2 transcobalamin eeeee2 , TC)
CPR:2	Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of  bbbbb1 [57Co]cyanocobalamin eeeee1  (CN-Cbl) bound to transcobalamin II (transcobalamin,  bbbbb2 TC eeeee2 )
CPR:3	Cells propagated in medium containing  bbbbb1 N5-methyltetrahydrofolate eeeee1  and homocysteine showed a substantial increase in  bbbbb2 MS eeeee2  activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.
CPR:3	Cells propagated in medium containing N5-methyltetrahydrofolate and  bbbbb1 homocysteine eeeee1  showed a substantial increase in  bbbbb2 MS eeeee2  activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.
CPR:2	 bbbbb1 Ergovaline eeeee1  inhibition of radioligand binding to the  bbbbb2 D2 dopamine receptor eeeee2  and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CPR:2	Our results indicate that ergot compounds, especially  bbbbb1 ergovaline eeeee1 , bind to  bbbbb2 D2 dopamine receptors eeeee2  and elicit second messenger responses similar to that of dopamine
CPR:2	Our results indicate that ergot compounds, especially ergovaline, bind to  bbbbb1 D2 dopamine receptors eeeee1  and elicit second messenger responses similar to that of  bbbbb2 dopamine eeeee2 
CPR:2	 bbbbb1 Ergovaline eeeee1  binding and activation of  bbbbb2 D2 dopamine receptors eeeee2  in GH4ZR7 cells
CPR:2	 bbbbb1 Ergovaline eeeee1  inhibition of the binding of the  bbbbb2 D2 eeeee2 -specific radioligand, [3H]YM-09151-2, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas dopamine was much less potent (370 +/- 160 nM)
CPR:2	Ergovaline inhibition of the binding of the  bbbbb1 D2 eeeee1 -specific radioligand,  bbbbb2 [3H]YM-09151-2 eeeee2 , exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas dopamine was much less potent (370 +/- 160 nM)
CPR:2	Ergovaline inhibition of the binding of the  bbbbb1 D2 eeeee1 -specific radioligand, [3H]YM-09151-2, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas  bbbbb2 dopamine eeeee2  was much less potent (370 +/- 160 nM)
CPR:3	 bbbbb1 Ergovaline eeeee1  binding and activation of  bbbbb2 D2 dopamine receptors eeeee2  in GH4ZR7 cells
CPR:3	These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several  bbbbb1 ergot alkaloids eeeee1  including ergovaline, may be due to  bbbbb2 D2 dopamine receptor eeeee2  activation.
CPR:3	These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including  bbbbb1 ergovaline eeeee1 , may be due to  bbbbb2 D2 dopamine receptor eeeee2  activation.
CPR:4	 bbbbb1 Ergot alkaloids eeeee1  were also effective in inhibiting  bbbbb2 VIP eeeee2 -stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively
CPR:4	Ergot alkaloids were also effective in inhibiting  bbbbb1 VIP eeeee1 -stimulated cyclic AMP production, with EC50 values for  bbbbb2 ergovaline eeeee2 , ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively
CPR:4	Ergot alkaloids were also effective in inhibiting  bbbbb1 VIP eeeee1 -stimulated cyclic AMP production, with EC50 values for ergovaline,  bbbbb2 ergonovine eeeee2 , alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively
CPR:4	Ergot alkaloids were also effective in inhibiting  bbbbb1 VIP eeeee1 -stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine,  bbbbb2 alpha-ergocryptine eeeee2 , ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively
CPR:4	Ergot alkaloids were also effective in inhibiting  bbbbb1 VIP eeeee1 -stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine,  bbbbb2 ergotamine eeeee2 , and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively
CPR:4	Ergot alkaloids were also effective in inhibiting  bbbbb1 VIP eeeee1 -stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and  bbbbb2 dopamine eeeee2  of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively
CPR:4	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and  bbbbb1 ergot alkaloid eeeee1  inhibition of  bbbbb2 vasoactive intestinal peptide eeeee2  (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CPR:4	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and  bbbbb1 ergot alkaloid eeeee1  inhibition of vasoactive intestinal peptide ( bbbbb2 VIP eeeee2 )-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CPR:6	Inhibition of cyclic AMP production by ergovaline was blocked by the  bbbbb1 dopamine receptor eeeee1  antagonist,  bbbbb2 (-)-sulpiride eeeee2  (IC50, 300 +/- 150 nM)
CPR:9	Ergot alkaloids were also effective in inhibiting  bbbbb1 VIP eeeee1 -stimulated  bbbbb2 cyclic AMP eeeee2  production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively
CPR:9	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of  bbbbb1 vasoactive intestinal peptide eeeee1  (VIP)-stimulated  bbbbb2 cyclic AMP eeeee2  production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CPR:9	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide ( bbbbb1 VIP eeeee1 )-stimulated  bbbbb2 cyclic AMP eeeee2  production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CPR:2	Saturation experiments showed that  bbbbb1 [3H]prazosin eeeee1  labelled a single population of binding sites in the spleen ( bbbbb2 alpha 1B eeeee2 ) and hippocampus (alpha 1A and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively)
CPR:2	Saturation experiments showed that  bbbbb1 [3H]prazosin eeeee1  labelled a single population of binding sites in the spleen (alpha 1B) and hippocampus ( bbbbb2 alpha 1A eeeee2  and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively)
CPR:2	Saturation experiments showed that  bbbbb1 [3H]prazosin eeeee1  labelled a single population of binding sites in the spleen (alpha 1B) and hippocampus (alpha 1A and  bbbbb2 alpha 1B eeeee2 ) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively)
CPR:2	The binding of the antipsychotic drugs risperidone, (+)-butaclamol,  bbbbb1 clozapine eeeee1 , haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the  bbbbb2 alpha 1-adrenoceptor eeeee2 
CPR:2	The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine,  bbbbb1 haloperidol eeeee1 , spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the  bbbbb2 alpha 1-adrenoceptor eeeee2 
CPR:2	The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol,  bbbbb1 spiperone eeeee1 , thioridazine and YM-09151-2 was studied at the subtypes of the  bbbbb2 alpha 1-adrenoceptor eeeee2 
CPR:2	Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors:  bbbbb1 risperidone eeeee1  is selective for the  bbbbb2 alpha 1B-adrenoceptors eeeee2 
CPR:2	With the exception of  bbbbb1 risperidone eeeee1 , all the antipsychotic drugs tested failed to show selectivity for either of the  bbbbb2 alpha 1-adrenoceptor eeeee2  subtypes
CPR:2	The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, spiperone,  bbbbb1 thioridazine eeeee1  and YM-09151-2 was studied at the subtypes of the  bbbbb2 alpha 1-adrenoceptor eeeee2 
CPR:2	 bbbbb1 Risperidone eeeee1  was 120-fold more selective for the  bbbbb2 alpha 1B-adrenoceptor eeeee2  with respect to the alpha 1A-adrenoceptor (Ki values: 2.3 +/- 1.2 nM and 283.6 +/- 174.1 nM respectively).
CPR:2	 bbbbb1 Risperidone eeeee1  was 120-fold more selective for the alpha 1B-adrenoceptor with respect to the  bbbbb2 alpha 1A-adrenoceptor eeeee2  (Ki values: 2.3 +/- 1.2 nM and 283.6 +/- 174.1 nM respectively).
CPR:2	The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and  bbbbb1 YM-09151-2 eeeee1  was studied at the subtypes of the  bbbbb2 alpha 1-adrenoceptor eeeee2 
CPR:2	The binding of the antipsychotic drugs  bbbbb1 risperidone eeeee1 , (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the  bbbbb2 alpha 1-adrenoceptor eeeee2 
CPR:2	The binding of the antipsychotic drugs risperidone,  bbbbb1 (+)-butaclamol eeeee1 , clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the  bbbbb2 alpha 1-adrenoceptor eeeee2 
CPR:2	Incubation of rat aortic membranes with the irreversible  bbbbb1 alpha 1B-adrenoceptor eeeee1  antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of  bbbbb2 [3H]-prazosin eeeee2  binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax). 3
CPR:2	The subtypes of  bbbbb1 alpha 1-adrenoceptor eeeee1  mediating contractions to exogenous  bbbbb2 noradrenaline eeeee2  (NA) in rat aorta have been examined in both biochemical and functional studies. 2
CPR:2	The subtypes of  bbbbb1 alpha 1-adrenoceptor eeeee1  mediating contractions to exogenous noradrenaline ( bbbbb2 NA eeeee2 ) in rat aorta have been examined in both biochemical and functional studies. 2
CPR:2	ediation of  bbbbb1 noradrenaline eeeee1 -induced contractions of rat aorta by the  bbbbb2 alpha 1B-adrenoceptor eeeee2  subtype. 1
CPR:2	The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively.  bbbbb1 5-Methylurapidil eeeee1  and phentolamine were confirmed as selective for the  bbbbb2 alpha 1A-adrenoceptors eeeee2 , whereas spiperone was alpha 1B-selective. 6
CPR:2	The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and  bbbbb1 phentolamine eeeee1  were confirmed as selective for the  bbbbb2 alpha 1A-adrenoceptors eeeee2 , whereas spiperone was alpha 1B-selective. 6
CPR:6	Incubation of rat aortic membranes with the irreversible  bbbbb1 alpha 1B-adrenoceptor eeeee1  antagonist,  bbbbb2 chloroethylclonidine eeeee2  (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax). 3
CPR:6	Incubation of rat aortic membranes with the irreversible  bbbbb1 alpha 1B-adrenoceptor eeeee1  antagonist, chloroethylclonidine ( bbbbb2 CEC eeeee2 : 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax). 3
CPR:10	Beta 2- but not  bbbbb1 beta 1-adrenoceptors eeeee1  are involved in  bbbbb2 desipramine eeeee2  enhancement of aggressive behavior in long-term isolated mice
CPR:2	Taken together with our previous finding that the  bbbbb1 desipramine eeeee1 -induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also  bbbbb2 beta 2-adrenoceptor eeeee2  stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.
CPR:5	Moreover,  bbbbb1 clenbuterol HCl eeeee1  (0.1-0.5 mg/kg, IP), a lipophilic  bbbbb2 beta 2-adrenoceptor eeeee2  agonist, significantly increased the duration of basal aggressive behavior
CPR:6	Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by  bbbbb1 yohimbine eeeee1 , an  bbbbb2 alpha 2-adrenoceptor eeeee2  antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.
CPR:6	Intraperitoneal administration of  bbbbb1 (+/- )propranolol HCl eeeee1  (2.5-10 mg/kg), a nonselective  bbbbb2 beta-adrenoceptor eeeee2  antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses
CPR:6	 bbbbb1 ICI118,551 HCl eeeee1  (1.25-5 mg/kg, IP), a selective  bbbbb2 beta 2-adrenoceptor eeeee2  antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it
CPR:6	ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas  bbbbb1 metoprolol tartrate eeeee1  (5-20 mg/kg, IP), a selective  bbbbb2 beta 1-adrenoceptor eeeee2  antagonist, did not affect it
CPR:3	Furthermore, the phosphorylation of  bbbbb1 myosin light chain eeeee1  produced by  bbbbb2 norepinephrine eeeee2  was greater than that produced by clonidine
CPR:3	Furthermore, the phosphorylation of  bbbbb1 myosin light chain eeeee1  produced by norepinephrine was greater than that produced by  bbbbb2 clonidine eeeee2 
CPR:6	In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective  bbbbb1 alpha 1A-adrenoceptor eeeee1  antagonist  bbbbb2 WB 4101 eeeee2  (100 nM)
CPR:10	We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by  bbbbb1 STZ eeeee1 , and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not  bbbbb2 GLUT1 eeeee2 .
CPR:9	The drug had a potent cytotoxic effect on RIN cells expressing  bbbbb1 GLUT2 eeeee1 , but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood  bbbbb2 glucose eeeee2  levels of treated animals
CPR:9	Consistent with these data, only  bbbbb1 GLUT2 eeeee1 -expressing RIN or AtT-20ins cells transported  bbbbb2 STZ eeeee2  efficiently
CPR:9	We conclude that expression of  bbbbb1 GLUT2 eeeee1  is required for efficient killing of neuroendocrine cells by  bbbbb2 STZ eeeee2 , and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.
CPR:9	We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by  bbbbb1 STZ eeeee1 , and this effect is related to specific recognition of the drug as a transported substrate by  bbbbb2 GLUT2 eeeee2  but not GLUT1.
CPR:2	The present study utilized blood from normal volunteers and  bbbbb1 125I eeeee1 - bbbbb2 fibrinogen eeeee2  in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA
CPR:4	The data suggest that  bbbbb1 lysine eeeee1  analogues, even at low concentrations, reduce the rate of  bbbbb2 t-PA eeeee2  induced whole blood clot lysis by several mechanisms.
CPR:4	 bbbbb1 AMCA eeeee1  (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous  bbbbb2 t-PA eeeee2  or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue
CPR:4	 bbbbb1 AMCA eeeee1  (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous  bbbbb2 t-PA eeeee2  and a lysine analogue
CPR:4	AMCA (0.06 mM) and  bbbbb1 EACA eeeee1  (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous  bbbbb2 t-PA eeeee2  or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue
CPR:4	AMCA (0.06 mM) and  bbbbb1 EACA eeeee1  (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous  bbbbb2 t-PA eeeee2  and a lysine analogue
CPR:4	Inhibitory effects of  bbbbb1 lysine eeeee1  analogues on  bbbbb2 t-PA eeeee2  induced whole blood clot lysis
CPR:4	However, their inhibitory effect was markedly reduced if clots were formed in the presence of  bbbbb1 t-PA eeeee1  and then exposed to either of the  bbbbb2 lysine eeeee2  analogues
CPR:4	The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of  bbbbb1 lysine eeeee1  analogues required for inhibition of clot lysis induced by exogenous  bbbbb2 t-PA eeeee2 
CPR:3	 bbbbb1 Histamine eeeee1  enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via  bbbbb2 H1-receptor eeeee2  activation
CPR:3	In summary, these results show that the excitatory effect of  bbbbb1 histamine eeeee1  on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the  bbbbb2 H1-receptor eeeee2 -mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.
CPR:5	The enhancement of the depolarizing afterpotential by histamine was mimicked by the  bbbbb1 histamine H1-receptor eeeee1  agonist  bbbbb2 2-thiazolylethylamine eeeee2  and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine
CPR:6	The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the  bbbbb1 H1-receptor eeeee1  antagonist  bbbbb2 promethazine eeeee2 , but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine
CPR:6	The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the  bbbbb1 histamine H2-receptor eeeee1  antagonist,  bbbbb2 cimetidine eeeee2 
CPR:10	Furthermore,  bbbbb1 adapalene eeeee1  does not bind to members of the cellular  bbbbb2 retinoic acid binding protein eeeee2  family
CPR:4	Finally, the three drugs were compared with the  bbbbb1 angiotensin converting enzyme eeeee1  inhibitor  bbbbb2 cilazapril eeeee2 
CPR:4	The goal of the present study was to compare the effects of three potent reference  bbbbb1 renin eeeee1  inhibitors ( bbbbb2 remikiren eeeee2 , CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys
CPR:4	The goal of the present study was to compare the effects of three potent reference  bbbbb1 renin eeeee1  inhibitors (remikiren,  bbbbb2 CGP 38560A eeeee2 , and enalkiren) in sodium-depleted normotensive squirrel monkeys
CPR:4	The goal of the present study was to compare the effects of three potent reference  bbbbb1 renin eeeee1  inhibitors (remikiren, CGP 38560A, and  bbbbb2 enalkiren eeeee2 ) in sodium-depleted normotensive squirrel monkeys
CPR:4	One possible explanation is that, in our model,  bbbbb1 remikiren eeeee1  in contrast to CGP 38560A and enalkiren is able to inhibit  bbbbb2 renin eeeee2  in a functionally important extraplasmatic compartment.
CPR:4	One possible explanation is that, in our model, remikiren in contrast to  bbbbb1 CGP 38560A eeeee1  and enalkiren is able to inhibit  bbbbb2 renin eeeee2  in a functionally important extraplasmatic compartment.
CPR:4	One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and  bbbbb1 enalkiren eeeee1  is able to inhibit  bbbbb2 renin eeeee2  in a functionally important extraplasmatic compartment.
CPR:4	RESULTS:  bbbbb1 Nedocromil sodium eeeee1  inhibited the chemotactic response toward FMLP and NAF/IL-8 of  bbbbb2 GM-CSF eeeee2  primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L)
CPR:4	Inhibition of  bbbbb1 cytokine eeeee1 -primed eosinophil chemotaxis by  bbbbb2 nedocromil sodium eeeee2 
CPR:4	CONCLUSIONS: The chemotactic responses toward  bbbbb1 C5a eeeee1  were inhibited by  bbbbb2 nedocromil sodium eeeee2  at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L)
CPR:4	RESULTS:  bbbbb1 Nedocromil sodium eeeee1  inhibited the chemotactic response toward FMLP and NAF/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of  bbbbb2 IL-3 eeeee2  primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L)
CPR:4	RESULTS:  bbbbb1 Nedocromil sodium eeeee1  inhibited the chemotactic response toward FMLP and  bbbbb2 NAF eeeee2 /IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L)
CPR:4	RESULTS:  bbbbb1 Nedocromil sodium eeeee1  inhibited the chemotactic response toward FMLP and NAF/ bbbbb2 IL-8 eeeee2  of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L)
CPR:10	 bbbbb1 Glutathione eeeee1 -independent prostaglandin D synthase [ bbbbb2 prostaglandin-H2 D-isomerase eeeee2 ; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CPR:10	 bbbbb1 Glutathione eeeee1 -independent prostaglandin D synthase [prostaglandin-H2 D-isomerase;  bbbbb2 (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase eeeee2 , EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CPR:10	 bbbbb1 Glutathione eeeee1 -independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase,  bbbbb2 EC 5.3.99.2 eeeee2 ] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CPR:10	 bbbbb1 Glutathione eeeee1 -independent  bbbbb2 prostaglandin D synthase eeeee2  [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CPR:9	Glutathione-independent prostaglandin D synthase [ bbbbb1 prostaglandin-H2 D-isomerase eeeee1 ; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of  bbbbb2 prostaglandin D2 eeeee2  in the central nervous system
CPR:9	Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase;  bbbbb1 (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase eeeee1 , EC 5.3.99.2] is an enzyme responsible for biosynthesis of  bbbbb2 prostaglandin D2 eeeee2  in the central nervous system
CPR:9	Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase,  bbbbb1 EC 5.3.99.2 eeeee1 ] is an enzyme responsible for biosynthesis of  bbbbb2 prostaglandin D2 eeeee2  in the central nervous system
CPR:9	Glutathione-independent  bbbbb1 prostaglandin D synthase eeeee1  [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of  bbbbb2 prostaglandin D2 eeeee2  in the central nervous system
CPR:1	This cDNA clone, designated  bbbbb1 EAA3a eeeee1 , shares a 90%  bbbbb2 nucleotide eeeee2  identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions
CPR:1	This cDNA clone, designated EAA3a, shares a 90%  bbbbb1 nucleotide eeeee1  identity with the previously reported  bbbbb2 rat GluR5-2b eeeee2  cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions
CPR:1	This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from  bbbbb1 human GluR5-1d eeeee1  in the  bbbbb2 amino eeeee2  and carboxy terminal regions
CPR:1	This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from  bbbbb1 human GluR5-1d eeeee1  in the amino and  bbbbb2 carboxy eeeee2  terminal regions
CPR:2	The relative potency of compounds in displacing [3H]-kainate binding to  bbbbb1 EAA3a eeeee1  receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA >  bbbbb2 dihydrokainate eeeee2  > NMDA.
CPR:2	The relative potency of compounds in displacing [3H]-kainate binding to  bbbbb1 EAA3a eeeee1  receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate >  bbbbb2 NMDA eeeee2 .
CPR:2	Cell lines stably expressing  bbbbb1 EAA3a eeeee1  protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate,  bbbbb2 kainate eeeee2 , L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA)
CPR:2	Cell lines stably expressing  bbbbb1 EAA3a eeeee1  protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate,  bbbbb2 L-glutamate eeeee2  and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA)
CPR:2	Cell lines stably expressing  bbbbb1 EAA3a eeeee1  protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and  bbbbb2 (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate eeeee2  (AMPA)
CPR:2	Cell lines stably expressing  bbbbb1 EAA3a eeeee1  protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate ( bbbbb2 AMPA eeeee2 )
CPR:2	Ligand binding studies with the recombinant  bbbbb1 EAA3a eeeee1  receptor expressed in mammalian cells indicated a high affinity  bbbbb2 kainate eeeee2  binding site (Kd = 120 +/- 15.0 nM)
CPR:2	 bbbbb1 Kainate eeeee1  and AMPA activated the heteromeric channel with significantly higher affinities than observed for  bbbbb2 EAA3a eeeee2  alone
CPR:2	Kainate and  bbbbb1 AMPA eeeee1  activated the heteromeric channel with significantly higher affinities than observed for  bbbbb2 EAA3a eeeee2  alone
CPR:2	The relative potency of compounds in displacing  bbbbb1 [3H]-kainate eeeee1  binding to  bbbbb2 EAA3a eeeee2  receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.
CPR:2	The relative potency of compounds in displacing [3H]-kainate binding to  bbbbb1 EAA3a eeeee1  receptor was: domoate >  bbbbb2 kainate eeeee2  > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.
CPR:2	The relative potency of compounds in displacing [3H]-kainate binding to  bbbbb1 EAA3a eeeee1  receptor was: domoate > kainate >  bbbbb2 L-glutamate eeeee2  = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.
CPR:2	The relative potency of compounds in displacing [3H]-kainate binding to  bbbbb1 EAA3a eeeee1  receptor was: domoate > kainate > L-glutamate =  bbbbb2 quisqualate eeeee2  > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.
CPR:2	The relative potency of compounds in displacing [3H]-kainate binding to  bbbbb1 EAA3a eeeee1  receptor was: domoate > kainate > L-glutamate = quisqualate >  bbbbb2 6,7-dinitroquinoxaline-2,3-dione eeeee2  (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.
CPR:2	The relative potency of compounds in displacing [3H]-kainate binding to  bbbbb1 EAA3a eeeee1  receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione ( bbbbb2 DNQX eeeee2 ) = CNQX > AMPA > dihydrokainate > NMDA.
CPR:2	The relative potency of compounds in displacing [3H]-kainate binding to  bbbbb1 EAA3a eeeee1  receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) =  bbbbb2 CNQX eeeee2  > AMPA > dihydrokainate > NMDA.
CPR:2	The relative potency of compounds in displacing [3H]-kainate binding to  bbbbb1 EAA3a eeeee1  receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX >  bbbbb2 AMPA eeeee2  > dihydrokainate > NMDA.
CPR:6	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non- bbbbb1 N-methyl-D-aspartate (NMDA) receptor eeeee1  antagonist  bbbbb2 CNQX eeeee2  (6-cyano-7-nitro-quinoxalinedione)
CPR:6	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non- bbbbb1 N-methyl-D-aspartate (NMDA) receptor eeeee1  antagonist CNQX ( bbbbb2 6-cyano-7-nitro-quinoxalinedione eeeee2 )
CPR:4	Although  bbbbb1 DEC eeeee1  exerts local antioxidant activity with beneficial effects on lung tissue, this  bbbbb2 5-LO eeeee2  inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.
CPR:4	One group of experimental animals was treated with  bbbbb1 5-lipoxygenase eeeee1  (5-LO) inhibitor,  bbbbb2 diethylcarbamazine eeeee2  (DEC, Sigma, St
CPR:4	One group of experimental animals was treated with 5-lipoxygenase ( bbbbb1 5-LO eeeee1 ) inhibitor,  bbbbb2 diethylcarbamazine eeeee2  (DEC, Sigma, St
CPR:4	One group of experimental animals was treated with  bbbbb1 5-lipoxygenase eeeee1  (5-LO) inhibitor, diethylcarbamazine ( bbbbb2 DEC eeeee2 , Sigma, St
CPR:4	One group of experimental animals was treated with 5-lipoxygenase ( bbbbb1 5-LO eeeee1 ) inhibitor, diethylcarbamazine ( bbbbb2 DEC eeeee2 , Sigma, St
CPR:6	 bbbbb1 Tamsulosin eeeee1 , the first prostate-selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist
CPR:10	Expressions of insulin and PC3, but not  bbbbb1 PC2 eeeee1 , are coordinately regulated by  bbbbb2 glucose eeeee2 , consistent with the important role of PC3 in regulating proinsulin processing
CPR:1	Single-strand conformational analysis and  bbbbb1 nucleotide eeeee1  sequencing of the entire coding region of the  bbbbb2 PC3 eeeee2  gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population
CPR:1	Single-strand conformational analysis and  bbbbb1 nucleotide eeeee1  sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 ( bbbbb2 Arg/Gln53 eeeee2 ) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population
CPR:1	Single-strand conformational analysis and  bbbbb1 nucleotide eeeee1  sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 ( bbbbb2 Gln/Glu638 eeeee2 ), neither of which was associated with NIDDM in this population
CPR:1	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of  bbbbb1 proinsulin eeeee1  to insulin by cleaving the proinsulin molecule on the  bbbbb2 COOH eeeee2 -terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide
CPR:1	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the  bbbbb1 proinsulin eeeee1  molecule on the  bbbbb2 COOH eeeee2 -terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide
CPR:1	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of  bbbbb1 proinsulin eeeee1  to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and  bbbbb2 C eeeee2 -peptide
CPR:1	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the  bbbbb1 proinsulin eeeee1  molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and  bbbbb2 C eeeee2 -peptide
CPR:3	Expressions of  bbbbb1 insulin eeeee1  and PC3, but not PC2, are coordinately regulated by  bbbbb2 glucose eeeee2 , consistent with the important role of PC3 in regulating proinsulin processing
CPR:3	Expressions of insulin and  bbbbb1 PC3 eeeee1 , but not PC2, are coordinately regulated by  bbbbb2 glucose eeeee2 , consistent with the important role of PC3 in regulating proinsulin processing
CPR:10	Administration of  bbbbb1 DMI eeeee1  for 14 or 21 days did not further reduce the number of  bbbbb2 beta-adrenoceptors eeeee2 
CPR:4	The present results suggest that the action of  bbbbb1 DMI eeeee1  in this animal model is unlikely to be directly related to a reduction in  bbbbb2 beta-adrenoceptors eeeee2  but may be related to a reduction in frontal cortical 5-HT2A receptors.
CPR:4	After 7 days of  bbbbb1 DMI eeeee1  administration the number of  bbbbb2 beta-adrenoceptors eeeee2  was lower in frontal and occipital cortex and hippocampus
CPR:4	The  bbbbb1 DMI eeeee1  induced reduction in  bbbbb2 beta-adrenoceptors eeeee2  did not differ in OB and sham-operated control rats. 5
CPR:4	 bbbbb1 DMI eeeee1  administration for up to 21 days produced a progressive reduction in the number of  bbbbb2 5-HT2A eeeee2  receptors in frontal cortex, without significant alterations in occipital cortex. 6
CPR:4	The time course of the reduction in the number of  bbbbb1 5-HT2A eeeee1  receptors was similar to that of the  bbbbb2 DMI eeeee2 -induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different. 7
CPR:4	The time course of the reduction in the number of 5-HT2A receptors was similar to that of the  bbbbb1 DMI eeeee1 -induced behavioural changes whereas that for the reduction in  bbbbb2 beta-adrenoceptors eeeee2  was clearly different. 7
CPR:4	The present results suggest that the action of  bbbbb1 DMI eeeee1  in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical  bbbbb2 5-HT2A eeeee2  receptors.
CPR:2	We show that the binding of  bbbbb1 thalidomide eeeee1  photoaffinity label to authentic  bbbbb2 human AGP eeeee2  is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.
CPR:2	Binding of  bbbbb1 thalidomide eeeee1  to  bbbbb2 alpha1-acid glycoprotein eeeee2  may be involved in its inhibition of tumor necrosis factor alpha production
CPR:2	We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that  bbbbb1 AGP eeeee1  may be involved in the immunomodulatory activity of  bbbbb2 thalidomide eeeee2 .
CPR:4	We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both  bbbbb1 thalidomide eeeee1  and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of  bbbbb2 tumor necrosis factor alpha eeeee2  from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.
CPR:4	Binding of  bbbbb1 thalidomide eeeee1  to alpha1-acid glycoprotein may be involved in its inhibition of  bbbbb2 tumor necrosis factor alpha eeeee2  production
CPR:4	The immunomodulatory activity of  bbbbb1 thalidomide eeeee1  has been ascribed to the selective inhibition of  bbbbb2 tumor necrosis factor alpha eeeee2  from monocytes
CPR:2	Coexpression of the flip and flop splice variants of  bbbbb1 GluR-A eeeee1 , in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to  bbbbb2 cyclothiazide eeeee2 , similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit
CPR:2	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to  bbbbb1 cyclothiazide eeeee1 , similar to responses observed for the combinations  bbbbb2 GluR-AoBi eeeee2  or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit
CPR:2	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to  bbbbb1 cyclothiazide eeeee1 , similar to responses observed for the combinations GluR-AoBi or  bbbbb2 GluR-AiBo eeeee2 , could be generated independently of the presence of the GluR-B subunit
CPR:2	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to  bbbbb1 cyclothiazide eeeee1 , similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the  bbbbb2 GluR-B eeeee2  subunit
CPR:2	However, recovery from modulation by  bbbbb1 cyclothiazide eeeee1  was twofold slower for  bbbbb2 GluR-AiBi eeeee2  than for homomeric GluR-Ai, indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to cyclothiazide. 5
CPR:2	However, recovery from modulation by  bbbbb1 cyclothiazide eeeee1  was twofold slower for GluR-AiBi than for homomeric  bbbbb2 GluR-Ai eeeee2 , indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to cyclothiazide. 5
CPR:2	The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization by glutamate, and the extent of attenuation of  bbbbb1 AMPA receptor eeeee1  desensitization by  bbbbb2 cyclothiazide eeeee2 , showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CPR:2	The complex patterns of sensitivity to  bbbbb1 cyclothiazide eeeee1  seen in hippocampal neurons could be reconstituted by assembly of recombinant  bbbbb2 AMPA receptor eeeee2  subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and GluR-B subunits
CPR:2	The complex patterns of sensitivity to  bbbbb1 cyclothiazide eeeee1  seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the  bbbbb2 GluR-A eeeee2  and GluR-B subunits
CPR:2	The complex patterns of sensitivity to  bbbbb1 cyclothiazide eeeee1  seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and  bbbbb2 GluR-B eeeee2  subunits
CPR:2	Recovery from modulation by  bbbbb1 cyclothiazide eeeee1  was slower for  bbbbb2 GluR-AiBi eeeee2  and GluR-AoBi than for GluR-AiBo and GluR-AoBo. 4
CPR:2	Recovery from modulation by  bbbbb1 cyclothiazide eeeee1  was slower for GluR-AiBi and  bbbbb2 GluR-AoBi eeeee2  than for GluR-AiBo and GluR-AoBo. 4
CPR:2	Recovery from modulation by  bbbbb1 cyclothiazide eeeee1  was slower for GluR-AiBi and GluR-AoBi than for  bbbbb2 GluR-AiBo eeeee2  and GluR-AoBo. 4
CPR:2	Recovery from modulation by  bbbbb1 cyclothiazide eeeee1  was slower for GluR-AiBi and GluR-AoBi than for GluR-AiBo and  bbbbb2 GluR-AoBo eeeee2 . 4
CPR:2	The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid  bbbbb1 (AMPA) receptor eeeee1  desensitization by  bbbbb2 glutamate eeeee2 , and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CPR:2	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric  bbbbb1 AMPA receptors eeeee1  with intermediate sensitivity to  bbbbb2 cyclothiazide eeeee2 , similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit
CPR:2	However, recovery from modulation by cyclothiazide was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the  bbbbb1 GluR-A eeeee1  and GluR-B subunits are not functionally equivalent in controlling sensitivity to  bbbbb2 cyclothiazide eeeee2 . 5
CPR:2	However, recovery from modulation by cyclothiazide was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the GluR-A and  bbbbb1 GluR-B eeeee1  subunits are not functionally equivalent in controlling sensitivity to  bbbbb2 cyclothiazide eeeee2 . 5
CPR:2	Striatal DAT protein (-25 to -46%) and VMAT2 (-17 to -22%) were reduced, whereas  bbbbb1 DAT eeeee1  determined by  bbbbb2 [3H]WIN 35,428 eeeee2  binding was normal
CPR:4	In conclusion, our data suggest that chronic  bbbbb1 cocaine eeeee1  use is associated with modestly reduced levels of striatal DA and the  bbbbb2 DA transporter eeeee2  in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.
CPR:1	The predicted structure of  bbbbb1 PHBP eeeee1  showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its  bbbbb2 N eeeee2 -terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.
CPR:1	The predicted structure of PHBP showed three  bbbbb1 epidermal growth factor (EGF) domains eeeee1 , a kringle domain and a serine protease domain, from its  bbbbb2 N eeeee2 -terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.
CPR:1	The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a  bbbbb1 kringle domain eeeee1  and a serine protease domain, from its  bbbbb2 N eeeee2 -terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.
CPR:1	The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a  bbbbb1 serine protease domain eeeee1 , from its  bbbbb2 N eeeee2 -terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.
CPR:1	The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although  bbbbb1 HGFA eeeee1  has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its  bbbbb2 N eeeee2 -terminus.
CPR:1	The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a  bbbbb1 fibronectin type II domain eeeee1 , an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its  bbbbb2 N eeeee2 -terminus.
CPR:1	The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an  bbbbb1 EGF domain eeeee1 , a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its  bbbbb2 N eeeee2 -terminus.
CPR:1	The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a  bbbbb1 fibronectin type I domain eeeee1 , an EGF domain, a kringle domain, and a serine protease domain, from its  bbbbb2 N eeeee2 -terminus.
CPR:1	The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an  bbbbb1 EGF domain eeeee1 , a kringle domain, and a serine protease domain, from its  bbbbb2 N eeeee2 -terminus.
CPR:1	The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a  bbbbb1 kringle domain eeeee1 , and a serine protease domain, from its  bbbbb2 N eeeee2 -terminus.
CPR:1	The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a  bbbbb1 serine protease domain eeeee1 , from its  bbbbb2 N eeeee2 -terminus.
CPR:1	Thus,  bbbbb1 PHBP eeeee1  was a heterodimer composed of 50-kDa and 17-kDa subunits, bridged by a  bbbbb2 disulfide eeeee2  linkage
CPR:1	The  bbbbb1 amino acid eeeee1  sequence deduced from the nucleotide sequence of the cloned  bbbbb2 PHBP eeeee2  cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA)
CPR:1	The amino acid sequence deduced from the  bbbbb1 nucleotide eeeee1  sequence of the cloned  bbbbb2 PHBP eeeee2  cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA)
CPR:2	It appears likely that the  bbbbb1 histamine H2 receptor eeeee1  blocked by cimetidine obviated the pulmonary vasodilator effect of  bbbbb2 tolazoline eeeee2  therapy.
CPR:4	It appears likely that the  bbbbb1 histamine H2 receptor eeeee1  blocked by  bbbbb2 cimetidine eeeee2  obviated the pulmonary vasodilator effect of tolazoline therapy.
CPR:2	In conclusion,  bbbbb1 cyclothiazide eeeee1  and the 2,3-benzodiazepines seem to bind to different sites on  bbbbb2 AMPA receptors eeeee2  but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site
CPR:2	In conclusion, cyclothiazide and the  bbbbb1 2,3-benzodiazepines eeeee1  seem to bind to different sites on  bbbbb2 AMPA receptors eeeee2  but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site
CPR:2	The interactions of  bbbbb1 GYKI 52466 eeeee1  and cyclothiazide on  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.
CPR:2	The interactions of GYKI 52466 and  bbbbb1 cyclothiazide eeeee1  on  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.
CPR:2	 bbbbb1 Cyclothiazide eeeee1  (330 microM) shifted the concentration-response curve for the effects of GYKI 52466 on  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.c. peak amplitude to the right (GYKI 52466 IC50 26.9 +/- 9.4 microM)
CPR:2	Cyclothiazide (330 microM) shifted the concentration-response curve for the effects of  bbbbb1 GYKI 52466 eeeee1  on  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.c. peak amplitude to the right (GYKI 52466 IC50 26.9 +/- 9.4 microM)
CPR:2	Likewise,  bbbbb1 GYKI 52466 eeeee1  (30-100 microM)) shifted the concentration-response curve for the effects of cyclothiazide on  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.c. decay time constants to the right. 8
CPR:2	Likewise, GYKI 52466 (30-100 microM)) shifted the concentration-response curve for the effects of  bbbbb1 cyclothiazide eeeee1  on  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.c. decay time constants to the right. 8
CPR:2	nteractions of  bbbbb1 2,3-benzodiazepines eeeee1  and cyclothiazide at  bbbbb2 AMPA receptors eeeee2 : patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. 1
CPR:2	nteractions of 2,3-benzodiazepines and  bbbbb1 cyclothiazide eeeee1  at  bbbbb2 AMPA receptors eeeee2 : patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. 1
CPR:4	 bbbbb1 GYKI 52466 eeeee1  decreased the peak amplitude of hippocampal area CA1  bbbbb2 AMPA receptor eeeee2 -mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics
CPR:4	 bbbbb1 Cyclothiazide eeeee1  prolonged the decay time constant of  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude. 7
CPR:2	 bbbbb1 Naphazoline eeeee1  was the most selective compound for the high affinity state of the  bbbbb2 alpha-2A adrenoceptor eeeee2 , displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1-midazoline binding sites, respectively
CPR:2	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for  bbbbb1 [125I]p-iodoclonidine eeeee1  binding have been compared at  bbbbb2 human platelet I1-imidazoline binding sites eeeee2  (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CPR:3	Activation of cytoprotective  bbbbb1 prostaglandin synthase-1 eeeee1  by  bbbbb2 minoxidil eeeee2  as a possible explanation for its hair growth-stimulating effect
CPR:3	We thus speculated that activation of  bbbbb1 PGHS-1 eeeee1  might be a mechanism by which  bbbbb2 minoxidil eeeee2  (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo
CPR:3	We thus speculated that activation of  bbbbb1 PGHS-1 eeeee1  might be a mechanism by which minoxidil ( bbbbb2 2,4-diamino-6-piperidinopyrimidine-3-oxyde eeeee2 ) stimulates hair growth in vivo
CPR:3	We demonstrate here that  bbbbb1 minoxidil eeeee1  is a potent activator of purified  bbbbb2 PGHS-1 eeeee2  (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production
CPR:1	In Drosophila,  bbbbb1 glutamyl-prolyl-tRNA synthetase eeeee1  is a multifunctional synthetase encoded by a unique gene and composed of three domains: the  bbbbb2 amino eeeee2 - and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. 10, 4267-4277]
CPR:1	In Drosophila,  bbbbb1 glutamyl-prolyl-tRNA synthetase eeeee1  is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and  bbbbb2 carboxy eeeee2 -terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. 10, 4267-4277]
CPR:1	In Drosophila,  bbbbb1 glutamyl-prolyl-tRNA synthetase eeeee1  is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of  bbbbb2 glutamic acid eeeee2  and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. 10, 4267-4277]
CPR:1	In Drosophila,  bbbbb1 glutamyl-prolyl-tRNA synthetase eeeee1  is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75  bbbbb2 amino acids eeeee2  repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. 10, 4267-4277]
CPR:2	Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and  bbbbb1 tretinoin eeeee1  for the  bbbbb2 nuclear transcription factors eeeee2 , retinoic acid receptors (RARs)
CPR:2	Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and  bbbbb1 tretinoin eeeee1  for the nuclear transcription factors,  bbbbb2 retinoic acid receptors eeeee2  (RARs)
CPR:2	Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and  bbbbb1 tretinoin eeeee1  for the nuclear transcription factors, retinoic acid receptors ( bbbbb2 RARs eeeee2 )
CPR:2	Binding and transactivation assays were used to compare affinities and transcriptional activities of  bbbbb1 adapalene eeeee1  and tretinoin for the  bbbbb2 nuclear transcription factors eeeee2 , retinoic acid receptors (RARs)
CPR:2	Binding and transactivation assays were used to compare affinities and transcriptional activities of  bbbbb1 adapalene eeeee1  and tretinoin for the nuclear transcription factors,  bbbbb2 retinoic acid receptors eeeee2  (RARs)
CPR:2	Binding and transactivation assays were used to compare affinities and transcriptional activities of  bbbbb1 adapalene eeeee1  and tretinoin for the nuclear transcription factors, retinoic acid receptors ( bbbbb2 RARs eeeee2 )
CPR:2	The  bbbbb1 nuclear gene transcription factors eeeee1  RAR beta and RAR gamma mediate the retinoid activity of  bbbbb2 adapalene eeeee2 .
CPR:2	The nuclear gene transcription factors  bbbbb1 RAR beta eeeee1  and RAR gamma mediate the retinoid activity of  bbbbb2 adapalene eeeee2 .
CPR:2	The nuclear gene transcription factors RAR beta and  bbbbb1 RAR gamma eeeee1  mediate the retinoid activity of  bbbbb2 adapalene eeeee2 .
CPR:10	On the contrary, pretreatment with  bbbbb1 5-HT eeeee1  worsened ethanol-induced erosions, however, did not affect gastric mucus secretion,  bbbbb2 glycoprotein eeeee2  content or PGE2 levels, although the non-protein SH fraction was significantly decreased
CPR:2	On the contrary, pretreatment with 5-HT worsened  bbbbb1 ethanol eeeee1 -induced erosions, however, did not affect gastric mucus secretion,  bbbbb2 glycoprotein eeeee2  content or PGE2 levels, although the non-protein SH fraction was significantly decreased
CPR:2	We suggest that  bbbbb1 5-HT eeeee1  dependent mechanisms through  bbbbb2 5-HT2 eeeee2  receptor blockade and 5-HT1 receptor activation could be also involved.
CPR:2	We suggest that  bbbbb1 5-HT eeeee1  dependent mechanisms through 5-HT2 receptor blockade and  bbbbb2 5-HT1 eeeee2  receptor activation could be also involved.
CPR:5	This study was designed to determine the gastroprotective properties of  bbbbb1 cinitapride eeeee1  (CNT), a novel prokinetic benzamide derivative agonist of  bbbbb2 5-HT4 eeeee2  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol
CPR:5	This study was designed to determine the gastroprotective properties of  bbbbb1 cinitapride eeeee1  (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and  bbbbb2 5-HT1 eeeee2  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol
CPR:5	This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic  bbbbb1 benzamide eeeee1  derivative agonist of  bbbbb2 5-HT4 eeeee2  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol
CPR:5	This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic  bbbbb1 benzamide eeeee1  derivative agonist of 5-HT4 and  bbbbb2 5-HT1 eeeee2  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol
CPR:5	This study was designed to determine the gastroprotective properties of cinitapride ( bbbbb1 CNT eeeee1 ), a novel prokinetic benzamide derivative agonist of  bbbbb2 5-HT4 eeeee2  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol
CPR:5	This study was designed to determine the gastroprotective properties of cinitapride ( bbbbb1 CNT eeeee1 ), a novel prokinetic benzamide derivative agonist of 5-HT4 and  bbbbb2 5-HT1 eeeee2  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol
CPR:6	This study was designed to determine the gastroprotective properties of  bbbbb1 cinitapride eeeee1  (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and  bbbbb2 5-HT2 eeeee2  antagonist, on mucosal injury produced by 50% (v/v) ethanol
CPR:6	This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic  bbbbb1 benzamide eeeee1  derivative agonist of 5-HT4 and 5-HT1 receptors and  bbbbb2 5-HT2 eeeee2  antagonist, on mucosal injury produced by 50% (v/v) ethanol
CPR:6	This study was designed to determine the gastroprotective properties of cinitapride ( bbbbb1 CNT eeeee1 ), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and  bbbbb2 5-HT2 eeeee2  antagonist, on mucosal injury produced by 50% (v/v) ethanol
CPR:9	We have identified  bbbbb1 adenosine deaminase eeeee1 , an enzyme involved in  bbbbb2 purine eeeee2  metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2
CPR:10	 bbbbb1 Alendronate eeeee1  inhibited PTPmeg1 with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit  bbbbb2 PTP epsilon eeeee2  at concentrations up to 1 mM
CPR:1	 bbbbb1 PTP eeeee1  inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a  bbbbb2 cysteine eeeee2  residue are required for full inhibition
CPR:2	These observations show substrate- and enzyme-specific PTP inhibition by alendronate and support the possibility that a certain  bbbbb1 PTP eeeee1 (s) may be the molecular target for  bbbbb2 alendronate eeeee2  action.
CPR:2	The hydrolysis of fluorescein diphosphate by  bbbbb1 PTP epsilon eeeee1  and PTPmeg1 was sensitive to  bbbbb2 alendronate eeeee2 , with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate
CPR:2	The hydrolysis of fluorescein diphosphate by PTP epsilon and  bbbbb1 PTPmeg1 eeeee1  was sensitive to  bbbbb2 alendronate eeeee2 , with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate
CPR:2	Similarly, with the src-pY527 substrate,  bbbbb1 alendronate eeeee1  inhibition was also  bbbbb2 PTP eeeee2  dependent
CPR:2	 bbbbb1 PTP eeeee1  inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent  bbbbb2 EDTA eeeee2 , or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition
CPR:2	 bbbbb1 PTP eeeee1  inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent  bbbbb2 dithiothreitol eeeee2 , suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition
CPR:4	Here we report that  bbbbb1 alendronate eeeee1  is a potent inhibitor of the  bbbbb2 protein-tyrosine-phosphatase-meg1 eeeee2  (PTPmeg1)
CPR:4	Here we report that  bbbbb1 alendronate eeeee1  is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 ( bbbbb2 PTPmeg1 eeeee2 )
CPR:4	With either substrate,  bbbbb1 alendronate eeeee1  was a slow binding inhibitor of  bbbbb2 PTPmeg1 eeeee2 
CPR:4	Among the other  bbbbb1 bisphosphonates eeeee1  studied, alendronate was more potent and selective for  bbbbb2 PTPmeg1 eeeee2 
CPR:4	Among the other bisphosphonates studied,  bbbbb1 alendronate eeeee1  was more potent and selective for  bbbbb2 PTPmeg1 eeeee2 
CPR:4	The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM;  bbbbb1 PTPsigma eeeee1 , however, under the same conditions, was inhibited by only 50% with 141 microM  bbbbb2 alendronate eeeee2 
CPR:4	 bbbbb1 Alendronate eeeee1  inhibited  bbbbb2 PTPmeg1 eeeee2  with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM
CPR:4	 bbbbb1 Alendronate eeeee1  inhibited PTPmeg1 with an IC50 value of 23 microM,  bbbbb2 PTPsigma eeeee2  with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM
CPR:4	 bbbbb1 Alendronate eeeee1  inhibition of  bbbbb2 protein-tyrosine-phosphatase-meg1 eeeee2 
CPR:4	The  bbbbb1 alendronate eeeee1  inhibition of these three  bbbbb2 PTPs eeeee2  and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor
CPR:4	 bbbbb1 PTP eeeee1  inhibition by  bbbbb2 hisphosphonates eeeee2  or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition
CPR:4	 bbbbb1 PTP eeeee1  inhibition by hisphosphonates or  bbbbb2 vanadate eeeee2  was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition
CPR:4	These observations show substrate- and enzyme-specific  bbbbb1 PTP eeeee1  inhibition by  bbbbb2 alendronate eeeee2  and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.
CPR:9	The hydrolysis of fluorescein  bbbbb1 diphosphate eeeee1  by  bbbbb2 PTP epsilon eeeee2  and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate
CPR:9	The hydrolysis of fluorescein  bbbbb1 diphosphate eeeee1  by PTP epsilon and  bbbbb2 PTPmeg1 eeeee2  was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate
CPR:10	The two receptors were discriminated by  bbbbb1 butaprost eeeee1 , AH-13205 and AH-6809 that bound to the EP2 receptor but not to the  bbbbb2 EP4 eeeee2  receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor. 6
CPR:10	The two receptors were discriminated by butaprost,  bbbbb1 AH-13205 eeeee1  and AH-6809 that bound to the EP2 receptor but not to the  bbbbb2 EP4 eeeee2  receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor. 6
CPR:10	The two receptors were discriminated by butaprost, AH-13205 and  bbbbb1 AH-6809 eeeee1  that bound to the EP2 receptor but not to the  bbbbb2 EP4 eeeee2  receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor. 6
CPR:10	The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by  bbbbb1 1-OH-PGE1 eeeee1  that bound to the EP4 but not to the  bbbbb2 EP2 eeeee2  receptor. 6
CPR:10	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM.  bbbbb1 16,16-dimethyl-PGE2 eeeee1  and two putative  bbbbb2 EP1 eeeee2  antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CPR:10	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative  bbbbb1 EP1 eeeee1  antagonists,  bbbbb2 AH6809 eeeee2  and SC-19220, did not show any significant binding to this receptor
CPR:10	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative  bbbbb1 EP1 eeeee1  antagonists, AH6809 and  bbbbb2 SC-19220 eeeee2 , did not show any significant binding to this receptor
CPR:2	The two receptors were discriminated by  bbbbb1 butaprost eeeee1 , AH-13205 and AH-6809 that bound to the  bbbbb2 EP2 eeeee2  receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor. 6
CPR:2	The two receptors were discriminated by butaprost,  bbbbb1 AH-13205 eeeee1  and AH-6809 that bound to the  bbbbb2 EP2 eeeee2  receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor. 6
CPR:2	The two receptors were discriminated by butaprost, AH-13205 and  bbbbb1 AH-6809 eeeee1  that bound to the  bbbbb2 EP2 eeeee2  receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor. 6
CPR:2	The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by  bbbbb1 1-OH-PGE1 eeeee1  that bound to the  bbbbb2 EP4 eeeee2  but not to the EP2 receptor. 6
CPR:2	The  bbbbb1 EP3 eeeee1  receptor showed the broadest binding profile, and bound  bbbbb2 sulprostone eeeee2 , M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM
CPR:2	The  bbbbb1 EP3 eeeee1  receptor showed the broadest binding profile, and bound sulprostone,  bbbbb2 M&B-28767 eeeee2 , GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM
CPR:2	The  bbbbb1 EP3 eeeee1  receptor showed the broadest binding profile, and bound sulprostone, M&B-28767,  bbbbb2 GR63799X eeeee2 , 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM
CPR:2	The  bbbbb1 EP3 eeeee1  receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X,  bbbbb2 11-deoxy-PGE1 eeeee2 , 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM
CPR:2	The  bbbbb1 EP3 eeeee1  receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1,  bbbbb2 16,16-dimethyl-PGE2 eeeee2  and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM
CPR:2	The  bbbbb1 EP3 eeeee1  receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and  bbbbb2 17-phenyl-PGE2 eeeee2 , in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM
CPR:2	The  bbbbb1 EP1 eeeee1  receptor bound  bbbbb2 17-phenyl-PGE2 eeeee2 , sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CPR:2	The  bbbbb1 EP3 eeeee1  receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to  bbbbb2 PGE2 eeeee2  and PGE1, with Ki values of 0.6-3.7 nM
CPR:2	The  bbbbb1 EP3 eeeee1  receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and  bbbbb2 PGE1 eeeee2 , with Ki values of 0.6-3.7 nM
CPR:2	In addition, three  bbbbb1 IP eeeee1  ligands,  bbbbb2 iloprost eeeee2 , carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7. 8-Epi-PGF2 alpha showed only weak binding to the IP, TP, FP, EP2 and EP3 receptor at 10 microM concentration
CPR:2	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost,  bbbbb2 carbacyclin eeeee2  and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7. 8-Epi-PGF2 alpha showed only weak binding to the IP, TP, FP, EP2 and EP3 receptor at 10 microM concentration
CPR:2	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost, carbacyclin and  bbbbb2 isocarbacyclin eeeee2 , and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7. 8-Epi-PGF2 alpha showed only weak binding to the IP, TP, FP, EP2 and EP3 receptor at 10 microM concentration
CPR:2	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  ligand,  bbbbb2 STA2 eeeee2 , bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7. 8-Epi-PGF2 alpha showed only weak binding to the IP, TP, FP, EP2 and EP3 receptor at 10 microM concentration
CPR:2	The  bbbbb1 EP1 eeeee1  receptor bound 17-phenyl-PGE2,  bbbbb2 sulprostone eeeee2  and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CPR:2	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.  bbbbb1 7. 8-Epi-PGF2 eeeee1  alpha showed only weak binding to the IP, TP, FP, EP2 and  bbbbb2 EP3 eeeee2  receptor at 10 microM concentration.
CPR:2	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.  bbbbb1 7. 8-Epi-PGF2 eeeee1  alpha showed only weak binding to the  bbbbb2 IP eeeee2 , TP, FP, EP2 and EP3 receptor at 10 microM concentration.
CPR:2	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.  bbbbb1 7. 8-Epi-PGF2 eeeee1  alpha showed only weak binding to the IP,  bbbbb2 TP eeeee2 , FP, EP2 and EP3 receptor at 10 microM concentration.
CPR:2	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.  bbbbb1 7. 8-Epi-PGF2 eeeee1  alpha showed only weak binding to the IP, TP,  bbbbb2 FP eeeee2 , EP2 and EP3 receptor at 10 microM concentration.
CPR:2	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.  bbbbb1 7. 8-Epi-PGF2 eeeee1  alpha showed only weak binding to the IP, TP, FP,  bbbbb2 EP2 eeeee2  and EP3 receptor at 10 microM concentration.
CPR:2	The  bbbbb1 EP1 eeeee1  receptor bound 17-phenyl-PGE2, sulprostone and  bbbbb2 iloprost eeeee2  in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CPR:2	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as  bbbbb1 PGD2 eeeee1 , BW245C and BW868C for  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CPR:2	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2,  bbbbb1 BW245C eeeee1  and BW868C for  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CPR:2	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and  bbbbb1 BW868C eeeee1  for  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CPR:2	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP,  bbbbb1 cicaprost eeeee1 , iloprost and isocabacyclin for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CPR:2	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost,  bbbbb1 iloprost eeeee1  and isocabacyclin for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CPR:2	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and  bbbbb1 isocabacyclin eeeee1  for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CPR:2	The  bbbbb1 EP1 eeeee1  receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to  bbbbb2 PGE2 eeeee2  and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CPR:2	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and  bbbbb1 S-145 eeeee1 , I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CPR:2	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145,  bbbbb1 I-BOP eeeee1  and GR 32191 for  bbbbb2 TP eeeee2 . 3
CPR:2	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and  bbbbb1 GR 32191 eeeee1  for  bbbbb2 TP eeeee2 . 3
CPR:2	The  bbbbb1 FP receptor eeeee1  bound  bbbbb2 PGF2 eeeee2  alpha and fluprostenol with Ki values of 3-4 nM
CPR:2	The  bbbbb1 FP receptor eeeee1  bound PGF2 alpha and  bbbbb2 fluprostenol eeeee2  with Ki values of 3-4 nM
CPR:2	The  bbbbb1 EP1 eeeee1  receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and  bbbbb2 PGE1 eeeee2 , with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CPR:5	 bbbbb1 M&B-28767 eeeee1 , a putative  bbbbb2 EP3 eeeee2  agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM. 5
CPR:5	M&B-28767, a putative EP3 agonist, and  bbbbb1 misoprostol eeeee1 , a putative  bbbbb2 EP2 eeeee2 /EP3 agonist, also bound to this receptor with Ki values of 120 nM. 5
CPR:5	M&B-28767, a putative EP3 agonist, and  bbbbb1 misoprostol eeeee1 , a putative EP2/ bbbbb2 EP3 eeeee2  agonist, also bound to this receptor with Ki values of 120 nM. 5
CPR:6	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative  bbbbb1 EP1 eeeee1  antagonists,  bbbbb2 AH6809 eeeee2  and SC-19220, did not show any significant binding to this receptor
CPR:6	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative  bbbbb1 EP1 eeeee1  antagonists, AH6809 and  bbbbb2 SC-19220 eeeee2 , did not show any significant binding to this receptor
CPR:1	Thymidine kinase from Herpes simplex virus type 1 ( bbbbb1 TK eeeee1 ) was crystallized in an  bbbbb2 N eeeee2 -terminally truncated but fully active form
CPR:2	The structures of  bbbbb1 TK eeeee1  complexed with  bbbbb2 ADP eeeee2  at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively
CPR:2	 bbbbb1 Thymidine kinase eeeee1  from Herpes simplex virus type 1 (TK) was crystallized in an  bbbbb2 N eeeee2 -terminally truncated but fully active form
CPR:2	The  bbbbb1 human ether-a-go-go-related gene eeeee1  (HERG), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of  bbbbb2 cisapride eeeee2 
CPR:2	The human ether-a-go-go-related gene ( bbbbb1 HERG eeeee1 ), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of  bbbbb2 cisapride eeeee2 
CPR:4	At -20 mV, 10 nM  bbbbb1 cisapride eeeee1  reduced  bbbbb2 HERG eeeee2  tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells)
CPR:4	Block of  bbbbb1 HERG eeeee1  with  bbbbb2 cisapride eeeee2  after channel activation was voltage dependent
CPR:4	Blockage of the  bbbbb1 HERG human cardiac K+ channel eeeee1  by the gastrointestinal prokinetic agent  bbbbb2 cisapride eeeee2 
CPR:4	We conclude that  bbbbb1 cisapride eeeee1  is a potent blocker of  bbbbb2 HERG eeeee2  channels expressed in HEK293 cells
CPR:4	We tested the hypothesis that  bbbbb1 cisapride eeeee1  blocks  bbbbb2 HERG eeeee2 
CPR:4	Under voltage-clamp conditions,  bbbbb1 cisapride eeeee1  block of  bbbbb2 HERG eeeee2  is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells)
CPR:2	 bbbbb1 NMDA receptors eeeee1  in postmortem human spinal cord were analyzed using  bbbbb2 [3H]MK-801 eeeee2  ligand binding and immunoblotting with NMDA receptor subunit-specific antibodies
CPR:2	 bbbbb1 Monoamine transporter eeeee1  and sodium channel mechanisms in the rapid pressor response to  bbbbb2 cocaine eeeee2 
CPR:2	Monoamine transporter and  bbbbb1 sodium channel eeeee1  mechanisms in the rapid pressor response to  bbbbb2 cocaine eeeee2 
CPR:4	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb1 monoamine transporter eeeee1  selectivities ( bbbbb2 BTCP eeeee2 , indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CPR:4	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb1 monoamine transporter eeeee1  selectivities (BTCP,  bbbbb2 indatraline eeeee2 , GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CPR:4	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb1 monoamine transporter eeeee1  selectivities (BTCP, indatraline,  bbbbb2 GBR 12935 eeeee2 , mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CPR:4	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb1 monoamine transporter eeeee1  selectivities (BTCP, indatraline, GBR 12935,  bbbbb2 mazindol eeeee2 , nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CPR:4	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb1 monoamine transporter eeeee1  selectivities (BTCP, indatraline, GBR 12935, mazindol,  bbbbb2 nomifensine eeeee2 , and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CPR:4	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb1 monoamine transporter eeeee1  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and  bbbbb2 zimeldine eeeee2 ) either did not produce a rapid pressor response or produced only a small pressor response
CPR:4	At nonconvulsant doses, the  bbbbb1 sodium channel eeeee1  blockers  bbbbb2 acetylprocainamide eeeee2 , dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP
CPR:4	At nonconvulsant doses, the  bbbbb1 sodium channel eeeee1  blockers acetylprocainamide,  bbbbb2 dibucaine eeeee2 , dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP
CPR:4	At nonconvulsant doses, the  bbbbb1 sodium channel eeeee1  blockers acetylprocainamide, dibucaine,  bbbbb2 dyclonine eeeee2 , prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP
CPR:4	At nonconvulsant doses, the  bbbbb1 sodium channel eeeee1  blockers acetylprocainamide, dibucaine, dyclonine,  bbbbb2 prilocaine eeeee2 , proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP
CPR:4	At nonconvulsant doses, the  bbbbb1 sodium channel eeeee1  blockers acetylprocainamide, dibucaine, dyclonine, prilocaine,  bbbbb2 proparacaine eeeee2 , quinidine, and tetracaine produced a small pressor response or no increase in BP
CPR:4	At nonconvulsant doses, the  bbbbb1 sodium channel eeeee1  blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine,  bbbbb2 quinidine eeeee2 , and tetracaine produced a small pressor response or no increase in BP
CPR:4	At nonconvulsant doses, the  bbbbb1 sodium channel eeeee1  blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and  bbbbb2 tetracaine eeeee2  produced a small pressor response or no increase in BP
CPR:4	The  bbbbb1 sodium channel eeeee1 -blocking action of  bbbbb2 cocaine eeeee2  per se does not appear to be involved in the rapid pressor response to cocaine
CPR:6	Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the  bbbbb1 dopamine receptor eeeee1  antagonist,  bbbbb2 SCH 23390 eeeee2 
CPR:10	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the  bbbbb1 levocabastine eeeee1 -insensitive  bbbbb2 neurotensin NT1 receptors eeeee2  (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CPR:2	In conclusion, these findings indicate that  bbbbb1 [3H]SR 142948A eeeee1  is a new potent antagonist radioligand which recognizes with high affinity both  bbbbb2 neurotensin NT1 eeeee2  and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.
CPR:2	In conclusion, these findings indicate that  bbbbb1 [3H]SR 142948A eeeee1  is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and  bbbbb2 NT2 receptors eeeee2  and represents thus an excellent tool to study neurotensin receptors in the rat brain.
CPR:2	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that  bbbbb1 [3H]SR 142948A eeeee1  bound with similar affinities to both the levocabastine-insensitive  bbbbb2 neurotensin NT1 receptors eeeee2  (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CPR:2	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that  bbbbb1 [3H]SR 142948A eeeee1  bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive  bbbbb2 neurotensin NT2 receptors eeeee2  (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CPR:2	In conclusion, these findings indicate that  bbbbb1 [3H]SR 142948A eeeee1  is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and NT2 receptors and represents thus an excellent tool to study  bbbbb2 neurotensin receptors eeeee2  in the rat brain.
CPR:2	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned  bbbbb1 levocabastine eeeee1 -sensitive  bbbbb2 neurotensin NT2 receptors eeeee2  (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CPR:6	In conclusion, these findings indicate that  bbbbb1 [3H]SR 142948A eeeee1  is a new potent antagonist radioligand which recognizes with high affinity both  bbbbb2 neurotensin NT1 eeeee2  and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.
CPR:6	In conclusion, these findings indicate that  bbbbb1 [3H]SR 142948A eeeee1  is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and  bbbbb2 NT2 receptors eeeee2  and represents thus an excellent tool to study neurotensin receptors in the rat brain.
CPR:6	The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of  bbbbb1 neurotensin receptors eeeee1 ,  bbbbb2 [3H]SR 142948A eeeee2  (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain
CPR:6	The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of  bbbbb1 neurotensin receptors eeeee1 , [3H]SR 142948A ( bbbbb2 2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride eeeee2 ), in the rat brain
CPR:6	Characterization of binding sites of a new  bbbbb1 neurotensin receptor eeeee1  antagonist,  bbbbb2 [3H]SR 142948A eeeee2 , in the rat brain
CPR:6	Saturation and competition studies in the presence or absence of the  bbbbb1 histamine H1 receptor eeeee1  antagonist,  bbbbb2 levocabastine eeeee2 , revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CPR:2	The  bbbbb1 retinoid eeeee1  action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors  bbbbb2 RAR beta eeeee2  and RAR gamma
CPR:2	The  bbbbb1 retinoid eeeee1  action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and  bbbbb2 RAR gamma eeeee2 
CPR:2	The  bbbbb1 retinoid eeeee1  action of adapalene are mediated by the  bbbbb2 ligand-activated gene transcription factors eeeee2  retinoic acid receptors RAR beta and RAR gamma
CPR:2	The retinoid action of  bbbbb1 adapalene eeeee1  are mediated by the ligand-activated gene transcription factors retinoic acid receptors  bbbbb2 RAR beta eeeee2  and RAR gamma
CPR:2	The retinoid action of  bbbbb1 adapalene eeeee1  are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and  bbbbb2 RAR gamma eeeee2 
CPR:2	The retinoid action of  bbbbb1 adapalene eeeee1  are mediated by the  bbbbb2 ligand-activated gene transcription factors eeeee2  retinoic acid receptors RAR beta and RAR gamma
CPR:2	Intrinsic, gating-independent  bbbbb1 DHP receptor eeeee1  binding affinity differences must be invoked to explain the isoform-specific sensitivity of the  bbbbb2 DHP eeeee2  block.
CPR:2	We expressed cardiac or  bbbbb1 smooth muscle alpha1C eeeee1  subunits in combination with beta2a and alpha2/delta subunits in human embryonic kidney cells, and used 2 mM  bbbbb2 Ca2+ eeeee2  as the permeant ion
CPR:4	Isoform-specific inhibition of  bbbbb1 L-type calcium channels eeeee1  by  bbbbb2 dihydropyridines eeeee2  is independent of isoform-specific gating properties
CPR:4	 bbbbb1 Dihydropyridines eeeee1  (DHPs) block  bbbbb2 L-type Ca2+ channels eeeee2  more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state
CPR:4	We thus conclude that the more potent  bbbbb1 nisoldipine eeeee1  inhibition of smooth muscle versus  bbbbb2 cardiac L-type Ca2+ channels eeeee2  is not attributable to differences in channel inactivation or activation
CPR:4	 bbbbb1 Nisoldipine eeeee1  (a DHP antagonist) blocks the  bbbbb2 smooth muscle channel eeeee2  more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels
CPR:4	Nisoldipine (a  bbbbb1 DHP eeeee1  antagonist) blocks the  bbbbb2 smooth muscle channel eeeee2  more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels
CPR:4	Dihydropyridines ( bbbbb1 DHPs eeeee1 ) block  bbbbb2 L-type Ca2+ channels eeeee2  more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state
CPR:9	 bbbbb1 Methylenetetrahydrofolate reductase eeeee1  deficiency impairs  bbbbb2 methyltetrahydrofolate eeeee2  synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis
CPR:9	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of  bbbbb1 methionine synthase eeeee1  (CblE/G) are associated with defective  bbbbb2 methyl cobalamin eeeee2  synthesis
CPR:9	These results suggest that  bbbbb1 Cat3 eeeee1  compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity  bbbbb2 arginine eeeee2  transport.
CPR:9	The majority of  bbbbb1 L-Arg eeeee1  transport is mediated by  bbbbb2 System y+ eeeee2 , although several other carriers have been kinetically defined
CPR:9	 bbbbb1 System y+ eeeee1  cationic  bbbbb2 amino acid eeeee2  transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3
CPR:9	System y+ cationic  bbbbb1 amino acid eeeee1  transport is mediated by proteins encoded by a family of genes,  bbbbb2 Cat1 eeeee2 , Cat2, and Cat3
CPR:9	System y+ cationic  bbbbb1 amino acid eeeee1  transport is mediated by proteins encoded by a family of genes, Cat1,  bbbbb2 Cat2 eeeee2 , and Cat3
CPR:9	System y+ cationic  bbbbb1 amino acid eeeee1  transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and  bbbbb2 Cat3 eeeee2 
CPR:9	However, the apparent affinity for  bbbbb1 lysine eeeee1  transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of  bbbbb2 Cat3 eeeee2 -mediated transport
CPR:9	Increased  bbbbb1 Cat3 eeeee1 -mediated cationic  bbbbb2 amino acid eeeee2  transport functionally compensates in Cat1 knockout cell lines
CPR:3	 bbbbb1 Lintitript eeeee1  markedly increased postprandial plasma  bbbbb2 CCK eeeee2  release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo
CPR:4	 bbbbb1 Lintitript eeeee1  markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial  bbbbb2 PP eeeee2  levels (P<0.01) as compared to placebo
CPR:6	The study demonstrates for the first time the marked gastrokinetic properties of the new  bbbbb1 CCK-A receptor eeeee1  antagonist  bbbbb2 lintitript eeeee2  in humans.
CPR:6	We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent  bbbbb1 CCK-A receptor eeeee1  antagonist  bbbbb2 lintitript eeeee2 
CPR:6	Effect of  bbbbb1 lintitript eeeee1 , a new  bbbbb2 CCK-A receptor eeeee2  antagonist, on gastric emptying of a solid-liquid meal in humans
CPR:2	In addition, the betaAR-mediated inhibition of  bbbbb1 IFN-gamma eeeee1 , GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular  bbbbb2 cyclic adenosine monophosphate eeeee2  (cAMP) levels
CPR:2	In addition, the betaAR-mediated inhibition of IFN-gamma,  bbbbb1 GM-CSF eeeee1 , and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular  bbbbb2 cyclic adenosine monophosphate eeeee2  (cAMP) levels
CPR:2	In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and  bbbbb1 IL-3 eeeee1  mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular  bbbbb2 cyclic adenosine monophosphate eeeee2  (cAMP) levels
CPR:2	In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and  bbbbb1 GM-CSF eeeee1  protein secretion were related to the accumulation of intracellular  bbbbb2 cyclic adenosine monophosphate eeeee2  (cAMP) levels
CPR:2	In addition, the betaAR-mediated inhibition of  bbbbb1 IFN-gamma eeeee1 , GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ( bbbbb2 cAMP eeeee2 ) levels
CPR:2	In addition, the betaAR-mediated inhibition of IFN-gamma,  bbbbb1 GM-CSF eeeee1 , and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ( bbbbb2 cAMP eeeee2 ) levels
CPR:2	In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and  bbbbb1 IL-3 eeeee1  mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ( bbbbb2 cAMP eeeee2 ) levels
CPR:2	In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and  bbbbb1 GM-CSF eeeee1  protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ( bbbbb2 cAMP eeeee2 ) levels
CPR:2	In addition, the  bbbbb1 betaAR eeeee1 -mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular  bbbbb2 cyclic adenosine monophosphate eeeee2  (cAMP) levels
CPR:2	In addition, the  bbbbb1 betaAR eeeee1 -mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ( bbbbb2 cAMP eeeee2 ) levels
CPR:2	 bbbbb1 Concanavalin A eeeee1  (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist  bbbbb2 isoproterenol eeeee2  and by the selective beta2AR agonist fenoterol
CPR:2	Concanavalin A ( bbbbb1 Con A eeeee1 )-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist  bbbbb2 isoproterenol eeeee2  and by the selective beta2AR agonist fenoterol
CPR:2	 bbbbb1 Concanavalin A eeeee1  (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist  bbbbb2 fenoterol eeeee2 
CPR:2	Concanavalin A ( bbbbb1 Con A eeeee1 )-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist  bbbbb2 fenoterol eeeee2 
CPR:3	The observed inhibition on  bbbbb1 IFN-gamma eeeee1 , GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist  bbbbb2 ICI 118,551 eeeee2  (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist
CPR:3	The observed inhibition on IFN-gamma,  bbbbb1 GM-CSF eeeee1 , and IL-3 mRNA was blocked by the selective beta2AR antagonist  bbbbb2 ICI 118,551 eeeee2  (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist
CPR:3	The observed inhibition on IFN-gamma, GM-CSF, and  bbbbb1 IL-3 eeeee1  mRNA was blocked by the selective beta2AR antagonist  bbbbb2 ICI 118,551 eeeee2  (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist
CPR:3	The observed inhibition on  bbbbb1 IFN-gamma eeeee1 , GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by  bbbbb2 timolol eeeee2  (10(-6) M), a nonselective antagonist
CPR:3	The observed inhibition on IFN-gamma,  bbbbb1 GM-CSF eeeee1 , and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by  bbbbb2 timolol eeeee2  (10(-6) M), a nonselective antagonist
CPR:3	The observed inhibition on IFN-gamma, GM-CSF, and  bbbbb1 IL-3 eeeee1  mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by  bbbbb2 timolol eeeee2  (10(-6) M), a nonselective antagonist
CPR:3	Secretion of  bbbbb1 GM-CSF eeeee1  protein in the presence of increasing concentrations of  bbbbb2 isoproterenol eeeee2  followed a similar pattern as observed for GM-CSF mRNA
CPR:3	Secretion of GM-CSF protein in the presence of increasing concentrations of  bbbbb1 isoproterenol eeeee1  followed a similar pattern as observed for  bbbbb2 GM-CSF eeeee2  mRNA
CPR:4	Concanavalin A (Con A)-induced  bbbbb1 IFN-gamma eeeee1 , GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist  bbbbb2 isoproterenol eeeee2  and by the selective beta2AR agonist fenoterol
CPR:4	Concanavalin A (Con A)-induced IFN-gamma,  bbbbb1 GM-CSF eeeee1 , and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist  bbbbb2 isoproterenol eeeee2  and by the selective beta2AR agonist fenoterol
CPR:4	Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and  bbbbb1 IL-3 eeeee1  mRNAs are dose-dependently inhibited by the nonselective betaAR agonist  bbbbb2 isoproterenol eeeee2  and by the selective beta2AR agonist fenoterol
CPR:4	Concanavalin A (Con A)-induced  bbbbb1 IFN-gamma eeeee1 , GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist  bbbbb2 fenoterol eeeee2 
CPR:4	Concanavalin A (Con A)-induced IFN-gamma,  bbbbb1 GM-CSF eeeee1 , and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist  bbbbb2 fenoterol eeeee2 
CPR:4	Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and  bbbbb1 IL-3 eeeee1  mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist  bbbbb2 fenoterol eeeee2 
CPR:5	Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the  bbbbb1 beta3AR eeeee1  agonist  bbbbb2 BRL 37344 eeeee2  had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels
CPR:5	Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective  bbbbb1 betaAR eeeee1  agonist  bbbbb2 isoproterenol eeeee2  and by the selective beta2AR agonist fenoterol
CPR:5	Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective  bbbbb1 beta2AR eeeee1  agonist  bbbbb2 fenoterol eeeee2 
CPR:6	The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective  bbbbb1 beta2AR eeeee1  antagonist  bbbbb2 ICI 118,551 eeeee2  (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist
CPR:6	The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective  bbbbb1 beta2AR eeeee1  antagonist ICI 118,551 (10(-6) M) and by  bbbbb2 timolol eeeee2  (10(-6) M), a nonselective antagonist
CPR:6	The selective  bbbbb1 beta1AR eeeee1  antagonist  bbbbb2 atenolol eeeee2  (0.3 x 10(-6) M) did not have any effect
CPR:2	Only  bbbbb1 carbetocin eeeee1  bound to the renal  bbbbb2 vasopressin V2 receptor eeeee2  though the binding affinity was very low (61.3 +/- 14.6 nM).
CPR:2	Both  bbbbb1 carbetocin eeeee1 , carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial  bbbbb2 oxytocin receptor eeeee2  of a similar magnitude as oxytocin
CPR:2	Both carbetocin,  bbbbb1 carbetocin eeeee1  metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial  bbbbb2 oxytocin receptor eeeee2  of a similar magnitude as oxytocin
CPR:2	Both carbetocin, carbetocin metabolite I and  bbbbb1 carbetocin eeeee1  metabolite II displayed binding affinities to the myometrial  bbbbb2 oxytocin receptor eeeee2  of a similar magnitude as oxytocin
CPR:2	Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial  bbbbb1 oxytocin receptor eeeee1  of a similar magnitude as  bbbbb2 oxytocin eeeee2 
CPR:2	 bbbbb1 Oxytocin receptor eeeee1  binding and uterotonic activity of  bbbbb2 carbetocin eeeee2  and its metabolites following enzymatic degradation
CPR:4	All three compounds displayed antagonistic properties against  bbbbb1 oxytocin eeeee1  in vitro, with  bbbbb2 carbetocin eeeee2  being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81)
CPR:4	All three compounds displayed antagonistic properties against  bbbbb1 oxytocin eeeee1  in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and  bbbbb2 carbetocin eeeee2  metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81)
CPR:4	All three compounds displayed antagonistic properties against  bbbbb1 oxytocin eeeee1  in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than  bbbbb2 carbetocin eeeee2  metabolite I (pA2 = 7.81)
CPR:5	These results indicate that  bbbbb1 carbetocin eeeee1  is a partial agonist/antagonist to the  bbbbb2 oxytocin receptor eeeee2  while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists
CPR:6	These results indicate that  bbbbb1 carbetocin eeeee1  is a partial agonist/antagonist to the  bbbbb2 oxytocin receptor eeeee2  while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists
CPR:6	These results indicate that carbetocin is a partial agonist/antagonist to the  bbbbb1 oxytocin receptor eeeee1  while the two metabolites  bbbbb2 carbetocin eeeee2  metabolite I and carbetocin metabolite II are pure antagonists
CPR:6	These results indicate that carbetocin is a partial agonist/antagonist to the  bbbbb1 oxytocin receptor eeeee1  while the two metabolites carbetocin metabolite I and  bbbbb2 carbetocin eeeee2  metabolite II are pure antagonists
CPR:2	Crystallographic comparison with the structurally related  bbbbb1 rat tyrosine hydroxylase eeeee1  binary complex with the oxidized cofactor  bbbbb2 7,8-dihydrobiopterin eeeee2  revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4
CPR:2	Crystallographic comparison with the structurally related  bbbbb1 rat tyrosine hydroxylase eeeee1  binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the  bbbbb2 catechols eeeee2  and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4
CPR:4	Crystallographic analysis of the  bbbbb1 human phenylalanine hydroxylase catalytic domain eeeee1  with bound  bbbbb2 catechol eeeee2  inhibitors at 2.0 A resolution
CPR:4	The  bbbbb1 aromatic amino acid hydroxylases eeeee1  represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by  bbbbb2 catechol eeeee2  derivatives
CPR:4	Crystallographic comparison with the structurally related  bbbbb1 rat tyrosine hydroxylase eeeee1  binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the  bbbbb2 catechols eeeee2  versus BH4
CPR:4	Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of  bbbbb1 human phenylalanine hydroxylase eeeee1  (hPheOH), cocrystallized with various potent and well-known  bbbbb2 catechol eeeee2  inhibitors and refined at a resolution of 2.0 A
CPR:4	Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase ( bbbbb1 hPheOH eeeee1 ), cocrystallized with various potent and well-known  bbbbb2 catechol eeeee2  inhibitors and refined at a resolution of 2.0 A
CPR:8	Crystallographic comparison with the structurally related  bbbbb1 rat tyrosine hydroxylase eeeee1  binary complex with the oxidized cofactor  bbbbb2 7,8-dihydrobiopterin eeeee2  revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4
CPR:2	All GCs including the antagonistic compound  bbbbb1 RU486 eeeee1  efficiently reduced NF-kappaB-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the  bbbbb2 GR eeeee2  is sufficient for transrepression
CPR:4	All GCs including the antagonistic compound  bbbbb1 RU486 eeeee1  efficiently reduced  bbbbb2 NF-kappaB eeeee2 -mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression
CPR:10	Here, we report that MgATP and MgADP, but not the  bbbbb1 Mg eeeee1  salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to  bbbbb2 SUR1 eeeee2 
CPR:10	Here, we report that MgATP and MgADP, but not the Mg salt of  bbbbb1 gamma-thio-ATP eeeee1 , stabilize the binding of prebound 8-azido-[alpha-32P]ATP to  bbbbb2 SUR1 eeeee2 
CPR:10	Mutation in the  bbbbb1 Walker A and B motifs eeeee1  of NBF2 of SUR1 abolished this stabilizing effect of  bbbbb2 MgADP eeeee2 
CPR:10	Mutation in the Walker A and B motifs of  bbbbb1 NBF2 eeeee1  of SUR1 abolished this stabilizing effect of  bbbbb2 MgADP eeeee2 
CPR:10	Mutation in the Walker A and B motifs of NBF2 of  bbbbb1 SUR1 eeeee1  abolished this stabilizing effect of  bbbbb2 MgADP eeeee2 
CPR:2	The KATP channel is a heterooligomeric complex of SUR1 subunits of the  bbbbb1 ATP eeeee1 -binding-cassette superfamily with two  bbbbb2 nucleotide-binding folds eeeee2  (NBF1 and NBF2) and the pore-forming Kir6.2 subunits
CPR:2	The KATP channel is a heterooligomeric complex of SUR1 subunits of the  bbbbb1 ATP eeeee1 -binding-cassette superfamily with two nucleotide-binding folds ( bbbbb2 NBF1 eeeee2  and NBF2) and the pore-forming Kir6.2 subunits
CPR:2	The KATP channel is a heterooligomeric complex of SUR1 subunits of the  bbbbb1 ATP eeeee1 -binding-cassette superfamily with two nucleotide-binding folds (NBF1 and  bbbbb2 NBF2 eeeee2 ) and the pore-forming Kir6.2 subunits
CPR:2	Here, we report that MgATP and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound  bbbbb1 8-azido-[alpha-32P]ATP eeeee1  to  bbbbb2 SUR1 eeeee2 
CPR:2	These results suggest that  bbbbb1 SUR1 eeeee1  binds  bbbbb2 8-azido-ATP eeeee2  strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CPR:2	These results suggest that SUR1 binds  bbbbb1 8-azido-ATP eeeee1  strongly at  bbbbb2 NBF1 eeeee2  and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CPR:2	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that  bbbbb1 MgADP eeeee1 , either by direct binding to  bbbbb2 NBF2 eeeee2  or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CPR:2	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound  bbbbb1 8-azido-ATP eeeee1  binding at  bbbbb2 NBF1 eeeee2 
CPR:2	The  bbbbb1 sulfonylurea glibenclamide eeeee1  caused release of prebound 8-azido-[alpha-32P]ATP from  bbbbb2 SUR1 eeeee2  in the presence of MgADP or MgATP in a concentration-dependent manner
CPR:2	Cooperative binding of  bbbbb1 ATP eeeee1  and MgADP in the  bbbbb2 sulfonylurea receptor eeeee2  is modulated by glibenclamide
CPR:2	Cooperative binding of ATP and  bbbbb1 MgADP eeeee1  in the  bbbbb2 sulfonylurea receptor eeeee2  is modulated by glibenclamide
CPR:2	The sulfonylurea glibenclamide caused release of prebound  bbbbb1 8-azido-[alpha-32P]ATP eeeee1  from  bbbbb2 SUR1 eeeee2  in the presence of MgADP or MgATP in a concentration-dependent manner
CPR:2	This direct biochemical evidence of cooperative interaction in  bbbbb1 nucleotide eeeee1  binding of the two  bbbbb2 NBFs eeeee2  of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.
CPR:2	This direct biochemical evidence of cooperative interaction in  bbbbb1 nucleotide eeeee1  binding of the two NBFs of  bbbbb2 SUR1 eeeee2  suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.
CPR:2	This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that  bbbbb1 glibenclamide eeeee1  both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at  bbbbb2 NBF2 eeeee2 , causes ATP to be released from NBF1.
CPR:2	This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that  bbbbb1 glibenclamide eeeee1  both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from  bbbbb2 NBF1 eeeee2 .
CPR:2	This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of  bbbbb1 ATP eeeee1  and MgADP and, in cooperation with the MgADP bound at  bbbbb2 NBF2 eeeee2 , causes ATP to be released from NBF1.
CPR:2	This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and  bbbbb1 MgADP eeeee1  and, in cooperation with the MgADP bound at  bbbbb2 NBF2 eeeee2 , causes ATP to be released from NBF1.
CPR:2	This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the  bbbbb1 MgADP eeeee1  bound at  bbbbb2 NBF2 eeeee2 , causes ATP to be released from NBF1.
CPR:2	Although electrophysiological studies provide clues to the complex control of  bbbbb1 KATP channels eeeee1  by  bbbbb2 ATP eeeee2 , MgADP, and pharmacological agents, the molecular mechanism of KATP-channel regulation remains unclear
CPR:2	Although electrophysiological studies provide clues to the complex control of  bbbbb1 KATP channels eeeee1  by ATP,  bbbbb2 MgADP eeeee2 , and pharmacological agents, the molecular mechanism of KATP-channel regulation remains unclear
CPR:2	Here, we report that  bbbbb1 MgATP eeeee1  and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to  bbbbb2 SUR1 eeeee2 
CPR:2	Here, we report that MgATP and  bbbbb1 MgADP eeeee1 , but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to  bbbbb2 SUR1 eeeee2 
CPR:2	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound  bbbbb1 MgATP eeeee1  at NBF2, stabilizes prebound 8-azido-ATP binding at  bbbbb2 NBF1 eeeee2 
CPR:2	Cooperative binding of ATP and MgADP in the  bbbbb1 sulfonylurea receptor eeeee1  is modulated by  bbbbb2 glibenclamide eeeee2 
CPR:2	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from  bbbbb1 SUR1 eeeee1  in the presence of  bbbbb2 MgADP eeeee2  or MgATP in a concentration-dependent manner
CPR:2	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from  bbbbb1 SUR1 eeeee1  in the presence of MgADP or  bbbbb2 MgATP eeeee2  in a concentration-dependent manner
CPR:3	The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of  bbbbb1 glucose eeeee1 -induced  bbbbb2 insulin eeeee2  secretion
CPR:9	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound  bbbbb1 MgATP eeeee1  at  bbbbb2 NBF2 eeeee2 , stabilizes prebound 8-azido-ATP binding at NBF1